

Index

An *F* following a page reference indicates that the reference is to a figure; a *T* indicates that the reference is to a table.

A1555G mitochondrial mutation 16–7
Abbe–Estlander flap, lip reconstruction 2545–6, 2546 *F*
Abbreviated Performance with the Hearing Aid Benefit (APHAB), middle ear implants 3663–4
Abciximab 114
abdominal wall flaps 2876–83
abducent nerve (VI) 3918–22 anatomy 3918–9, 3918 *F*, 3919 *F*, 3920 *F*
central anatomy 3919
central mechanisms 3919–21
diplopia 3945
examination, eye movements 3710–1
fascicles 3919
meningiomas and 4009
vestibular schwannoma 3958–9
abducent nerve palsy 3918–9
tumour-induced 3922
vestibular schwannoma removal 3980
abducent nucleus 3919, 3920 *F*
ocular muscle innervation 3221
ABO blood groups 253–4, 254 *T*
antigens 253–4
incompatibility 260
inheritance 253–4
matching errors 253–4
Aboulker stent, laryngeal reconstruction 1157–8, 1158 *F*, 2279
abscess(es)
Bezold's 922, 922 *F*
cervical, children 1213, 1213 *F*
dental *see* dental abscess
oral mucosa 1827–8
orbital *see* orbital abscess
parapharyngeal *see* parapharyngeal abscess
periosteal 1087–8
peritonsillar *see* peritonsillar abscess (quinsy)

retropharyngeal *see* retropharyngeal abscess
salivary 724
septal 1076, 1572–3
subdural *see* subdural abscess
subperiosteal 3359
subperiosteal 1539, 1540
Absidia, fungal rhinosinusitis 217
absolute threshold, sound 3250, 3251 *F*
absorbent devices, saliva collection 1862
Acanthamoeba castellani 241–2
accelerated hyperfractionation 2755
Accent method, speech therapy 2219–20, 2225
accents, speech rhythm 2168
accessory devices, hearing 3666–72 communication aids 3667–8
current devices 3667–9 categories 3667 definitions 3666 elderly 3666 fitting strategy 3670–1 future developments 3669 hardwired systems 3667 induction loop systems 3668 infrared systems 3668 literature 3669 microphones 3667 nonauditory 3668 performance 3670 provision 3670 quality 3670 radio systems 3667, 3670 speech-to-noise ratio 3667 studies 3669 telephones 3668–9, 3669 text systems 3669 uses 3669 warning/alerting systems 3668 doorbells 3668 accessory meningeal artery 3907

accessory nerve (XI) damage
cancer surgery 2807 neck dissection complication 2744, 2807–8
surgical, medical negligence 2807–8
in jugular foramen 3901–3, 3903 *F* functional deficit, postoperative 4041 lesions 3937 skull base lesions 3946 surface anatomy 1741 accessory ostia 1330 Access to Health Records Act (1990) 602 accreditation, continuing medical education points 555–6 acetazolamide episodic ataxia 3804 Menière's disease 3799 migrainous vertigo 3803, 3803 *T* side effects 3799 spinocerebellar ataxias 3774 acetic acid, otitis externa 430 acetylcholine cilia, effects on 1361 nose, effects on 1364 pubertal rhinitis 1077 vestibular hair cells 3238 acetylcysteine otitis media with effusion 3392 ototoxicity prevention 3302 achalasia 2066 aetiology 1288 children 1288–90 incidence 1288 treatment 1289–90 clinical features 1288, 2066 diagnosis 1288–9, 2066

achalasia (*continued*)
 dysphagia 1288, 2032, 2066
 pathogenesis 1288
 radiological features 1288, 1289 *F*
 treatment 1289–90, 2066
 forceful dilatation 1289–90
 pharmacological 1289
 surgical 1290, 2066

aciclovir 209

Bell's palsy 210, 3886

herpes zoster 1700–1, 2005, 2079

herpes zoster oticus 434

juvenile-onset recurrent respiratory papillomatosis 1178–9

mouth ulceration, advanced head and neck cancer 2789

ototoxicity 240–1

Ramsey Hunt Syndrome 434

sudden sensorineural hearing loss 434

acid burns, pinna reconstruction 3035, 3037 *F*

'acid laryngitis' 2262

acid suppression therapy 1276

acinic cell carcinoma 2497

survival 2512–3

acinus, salivary glands 1852

secretions 1860–1

acne vulgaris, external nose 1715

acoustic admittance/compliance 3168–9

acoustic brainstem evoked response (ABR)

auditory neuropathy/
 dyssynchrony 3839–40, 3842, 3844 *F*
 children 3839–40
 latency-intensity studies 3843

detection 3842

multiple sclerosis 3846, 3847 *F*
 quinine administration 3850, 3850 *F*

acoustic impedance 3167–9

definition 713, 3168, 3288–9

middle ear 3288–9

ultrasound 712, 713

acoustic interface 713

acoustic neuroma (AN) *see* vestibular schwannoma (VS)

acoustic reflectometry, otitis media with effusion 889

acoustic reflexes, otitis media with effusion 941

acoustic rhinometry 1358, 1375

accuracy 1375

nasal blood flow measurement 1363

normal values 1375

rhinomanometry *vs.* 1375, 1376–7

septal pathology 1576, 1577 *F*

acoustics 3158

see also sound

acoustic shock 3552, 3552 *T*

acoustic signals, voice 2170

acoustic trauma

definition 3548

glutamate neuroexcitotoxicity 3604

hyperacusis 3596

tinnitus 3599

see also noise-induced hearing loss

acoustic voice measures *see* voice evaluation

acquired atresia, external ear 3346–50

aetiology 3347

bone-anchored hearing aids 3643

complications 3347–8

definition 3346

diagnosis 3346–7

epidemiology 3347

future research 3349

inflammation 3347

knowledge deficiencies 3349

management options 3348–9

medical 3348

membranous 3346, 3347 *F*

pathogenesis 3347

surgery 3349

natural history 3347–8

outcomes 3349

pathogenesis 3347

solid 3346, 3346 *F*, 3347 *F*

pathogenesis 3347

surgery 3348–9

with tympanoplasty 3349

surgery-induced 3347

acquired immune deficiency syndrome (AIDS) *see* HIV infection/AIDS

acquired immunity, nasal 1361–2

acral lentiginous melanoma 2401 *T*

acriflavin, respiratory scleroma 1463

acromegaly 309, 4100–1

clinical features 399, 399 *T*

diabetes mellitus (onset) 309

diagnosis 301, 309, 4101

pathophysiology 399

presentation 399, 4100–1

prevalence 399

treatment 301, 4101

medical 4101

no treatment 4101

surgical 4101, 4114

actinic keratoses

external nose 1705

squamous cell carcinoma, risk of 2398

Actinomyces 201

growth 201

Actinomyces bovis 2268

Actinomyces israelii 201

laryngeal infection 2268

nasal infection 1703–4

paediatric cervicofacial infections 1216

Actinomyces meyeri 201

Actinomyces odontolyticus 201

actinomycin D 38

actinomycosis 201

children 1216

laryngeal manifestations 2268

neck manifestations 1785, 1786 *F*

activated C protein, critical care 535–6

activated partial thromboplastin time (APTT) 280

activated partial thromboplastin time (APTT), lupus anticoagulant 281

active noise reduction 3554

acute bacterial rhinosinusitis (ABRS)

complications 1443

diagnosis 1442

pathogenesis 1440

prevalence 1443

acute confusional states, palliative care

patients 2797–8

causes 2797–8

clinical features 2797

treatment 2798, 2798 *T*

acute epiglottitis *see* epiglottitis, acute

acute exacerbations of chronic rhinosinusitis (AECRS) 1382, 1382 *T*, 1439–40

acute laryngotracheobronchitis (ALTB)

see croup

acute lymphoblastic leukaemia (ALL)

clinical presentation 274

investigations 274

treatment 274

acute myeloid leukaemia (AML)

clinical presentation 274

investigations 274

treatment 274

acute necrotizing ulcerative gingivitis (ANUG) 1819, 1819 *T*

cancrum oris 1822

clinical features 1819

gingival bleeding 1819

acute otitis media (AOM) 3385–7
 aetiopathology 914–6, 3385, 3386 *T*
 antibiotics 431, 917–8, 918–9, 3386
 bacterial 915, 915 *T*
 children 912–27, 3527–8
 acute episodes 917–8
 auditory functioning 921
 cumulative incidence 917
 diagnosis 913–4
 differential diagnosis 914
 environmental factors 916
 epidemiology 917, 3410–1, 3411 *T*
 facial paralysis 1056, 1056 *F*
 gastro-oesophageal reflux
 disease 1274
 incidence 917 *F*
 management 917–21
 medical prophylaxis 918–20
 natural history 921
 outcomes 921
 recurrent 913, 918–21
 signs 913–4
 speech development 921
 symptoms 913, 913 *T*
 chronic otitis media
 development 3408, 3410–1
 commensals, benign 920
 complications 921–5, 3386
 extracranial 921–3
 intracranial 923–5
 congenital atresia 981
 corticosteroids 423
 definition 912–3, 3385
 diagnosis 3385–6
 criteria 3386
 facial nerve paralysis 923, 3882, 3890
 genetics 916
 immune factors 916
 incidence 3385
 infection spread routes 915–6
 infective agents 211, 914–5
 investigations 914
 management 3386
 natural history 3386
 otalgia 3527–8
 outcomes research instruments 640
 risk factors 916
 alteration of 918
 surgery 918
 prophylactic 920–1
 syndromic associations 916
 tympanic membrane
 assessment 913–4, 914 *F*
 vaccination 211, 919–20
 Wegener's granulomatosis 1650

acute pain management plans 463
 acute parotitis of infancy 1243, 1243 *F*
 acute renal failure (ARF)
 causes 530, 531 *T*
 critical care patients 530
 acute respiratory distress syndrome,
 aspiration-related 2094–5
 acute rhinosinusitis (ARS)
 antibiotic treatment 438–9
 bacteriology 1441
 children 1080
 corticosteroid treatment 437
 definition 1382, 1382 *T*
 histopathology 1441
 microbiology 1441 *F*, 1442 *F*
 symptom duration 1439–40
 acute suppurative otogenic
 labyrinthitis 3692
 acute unilateral peripheral vestibulopathy
 see vestibular neuritis
 acycloguanosine *see* aciclovir
 adamantiades syndrome *see* Behçet's
 syndrome
 adaptation, vestibular hair cells 3231–2,
 3232 *F*, 3235, 3236 *F*, 3792
 active motor model 3233–4, 3233 *F*,
 3234 *F*
 calcium-dependent closure
 model 3233 *F*, 3234–5
 functions 3234
 as high-pass filter 3234
 process 3231
 adaptive immunity 133–4
 lymphocyte activation 133
 adaptive sleep drive 2306
 Adcortyl *see* triamcinolone
 Addison's disease
 adrenocorticotropin secretion 300
 clinical features 401
 adductor paralysis, larynx 2223
 adductor spasmotic dysphonia 2224
 adenine 3
 adeno-associated virus (AAV) gene
 therapy
 cystic fibrosis 25
 head and neck cancer 27–8
 adenocarcinoma(s)
 ceruminous 4070
 salivary glands 2500
 polymorphous low-grade 2500
 sinonasal 2420
 see also specific types/locations
 adenohypophysis 296–7, 307–8
 blood supply 297
 cell types 296
 embryology 295
 hormones 300–2, 307, 4098
 secretion 297, 308
 magnetic resonance imaging 305
 pars tuberalis 296
 structure 296, 307
 venous drainage 297
 adenoid(s) 1094–101, 2121–2
 anatomy 2108
 assessment 1096–7, 1096 *F*, 1097 *T*
 associated antibodies 2121
 blood supply 2121
 clinical examination 1096
 corticosteroids 422
 development 1094, 2121
 enlargement
 HIV patients 241
 obstructive sleep apnoea 1104,
 1105 *F*
 paediatric rhinosinusitis 1082
 history taking 1096
 immune function 1094–5, 2121
 infants 2121
 neoplasia 1096
 pathology associated 1095–6
 regrowth, post-adenoideectomy 1098
 adenoid cystic carcinoma (ACC)
 metastases, jugular foramen 4033–4
 otalgia 3528
 parotid gland 2503–4, 2504 *F*
 salivary glands 2498–500, 2502
 chemotherapy 2499
 histology 2498–9, 2498 *F*
 lung metastases 2498–9
 molecular biology 2496
 perineural spread 2499, 2499 *F*
 postoperative radiotherapy 2508
 radiological work-up 2499
 recurrence rates 2511
 surgery 2499
 survival 2512–3, 2515–6
 treatment 2499
 sinonasal 2420
 submandibular gland 2504–5
 adenoid cystic sarcoma, external
 auditory canal 4068 *F*, 4070
 adenoideectomy 1097
 acute otitis media 920–1, 1095
 airway management 500–1
 anaesthesia 500–1
 children 515–7
 maintenance 501
 recovery 501
 complications 903, 1097–8
 dental damage 1308

adenoidectomy (*continued*)
 extubation 501
 haemorrhage 1097–8, 1308
 indications 1095–6
 medical negligence 1308
 obstructive sleep apnoea 1095
 olfaction following 1096
 otitis media with effusion 902–3, 1095
 outcomes 902–3
 preoperative investigations 1097
 rhinosinusitis 1084
 speech, effects on 993
 syndromic craniosynostosis 1028
 techniques 902
 velopharyngeal insufficiency 1011
see also adenotonsillectomy
 adenolymphoma *see* Warthin's tumour
 adenoma(s)
 ceruminous 4069–70
 parathyroid *see* parathyroid adenoma
 parotid glands 723, 723 *F*
 pituitary *see* pituitary adenomas
 pleomorphic *see* pleomorphic adenoma
 thyroid 330, 719–20, 719 *F*
 toxic *see* toxic adenoma
 adenomatoid odontogenic tumour 1928
 adenosine deaminase (ADA)
 deficiency 175
 adenotonsillar hypertrophy
 paediatric anaesthesia 508–9
 sickle cell disease 271
 adenotonsillectomy
 acute otitis media 920–1
 analgesia, postoperative 515–6
 day stay 516–7
 Down's syndrome 1109
 haemorrhage 516
 nausea and vomiting 516
 obstructive sleep apnoea 1111
 outcome measures 1230–1
 paediatric anaesthesia 515
 sleep-disordered breathing 1109
 special needs children 787
 tonsillectomy alone *vs.* 1230
 variant Creutzfeldt–Jacob disease
 transmission risk 517, 626
see also adenoidectomy
 adenovirus(es) 205
 diseases caused 24
 gene therapy
 cystic fibrosis 24–5
 head and neck cancer 27
 skin flap survival 114

infection 27
 respiratory tract 205
 transmission 205
 viral characteristics 27
 adhesion molecule antagonists, multiple sclerosis 3772
 adhesion molecules
 allergic rhinitis 1391
 head and neck tumour markers 2384–5, 2386–90 *T*
 nasal polyposis 1552
see also individual types
 adhesive otitis media 3426
 adhesives
 endovascular embolization 733–4
 prostheses retention 2931–2
 adolescents, surgical scarring 3090
 adolescent transitional voice disorder
see puberphonia
 adrenal cortex stimulation 300
 adrenal disease 401
see also individual diseases/disorders
 adrenalectomy
 Cushing's disease 4102
 Nelson's syndrome induction 311
 adrenaline
 cilia, effects on 1361
 critical care 529–30
 food allergy 1431
 nasal vasculature 1365
 performance anxiety 2212–3
 reduction rhinoplasty 2952
 upper eyelid blepharoplasty 3057
 adrenocortical insufficiency *see* Addison's disease
 adrenocorticotropic hormone (ACTH) 300–1, 309–11
 circulating levels 300
 Cushing's syndrome screening 309
 deficiency tests 300
 ectopic production 401
 effects 300
 excess secretion 300
 half-life 300
 medullary thyroid carcinoma 401
 secretion control 300–1, 309
 circadian rhythms 308
 stress 300
 structure 309
 tumours secreting *see* Cushing's disease
 adrenocorticotropic hormone (ACTH) stimulation test 300

adrenocorticotropin (ACTH) *see* adrenocorticotropic hormone (ACTH)
 adult epiglottitis *see* epiglottitis, adult advancement flaps
 'bucket handle' 2821 *F*
 cervicofacial cheek 2837
 nasal reconstruction 3019
 Webster cheek 2547
 adverse drug reactions 414–5
 allergic (non-dose-related) 414–5
 dose-related 415
 drug interactions as cause 415
 long-term therapy 415
 pseudoallergic 414–5
 reporting 408
 aerobic Gram-negative bacilli *see* *Enterobacteriaceae*
 aerodynamic equivalent diameter (AED), occupational rhinitis 1416
 aerodynamic measures, voice evaluation 2171, 2181–3
Aeromonas hydrophila (medicinal leech), skin flap survival 115
 aesthesioneuroblastoma 2420–1
 aesthetics 2944–6
 beauty, concept of 2944–5
 definition 2943–4
 facial plastic surgery 2943–9
 facial proportion 2945–6
 historical aspects 2943–4
 afficates 2167, 2167 *T*
 aflatoxins, salivary glands tumours 2494
 agarose gel electrophoresis 61
 agarose gels, electrophoresis 5–6
 age-associated hearing loss (AAHL) 3542
see also age-related (sensorineural) hearing loss
 age effects, orbital anatomy 1679
 ageing/age-related changes
 auditory nerve fibre thresholds 3199–200
 cochlear duct 3540–1
 drug prescribing 415–6
 dysphagia aetiology 2034
 facial *see* ageing face
 olfactory dysfunction 1670, 1670 *F*
 olfactory epithelium 1328–9
 olfactory nerve 3914
 organ of Corti 3540–1, 3540 *F*
 parathyroid glands cells 373
 pharynx, neurological disorders 2076
 swallowing 1961
 tympanic membrane 3317

- vestibular hair cells 3239
 vocal folds 2205
 wound healing 94
 ageing face 3068–76
 biology 3069
 clinical evaluation 3070–1
 histological transformations 3069
 proportions 2946, 2947 *F*
 surgery
 complications 3074–5
 historical aspects 3068–9
 patient age and 3070
 techniques 3071–3
 see also individual techniques
- Agency for Health Care Policy and Research (AHCPR), dysphagia management review 2085
 age-related changes *see ageing/ age-related changes*
 Age-related sensorineural hearing impairment 3539–47
 aetiology 3543 *T*
 definition 3539
 diagnosis 3542, 3544
 environmental factors 3542
 examination 3544
 genetics 17, 3541–2
 history 3543–4
 investigations 3544
 management 3544–5
 pathology 3540–1, 3540 *F*, 3540 *T*, 3541 *F*
 prevalence 3543 *T*
 tinnitus 3599
 age-related typical audiograms (ARTA) 3560, 3561 *F*, 3562 *F*, 3563 *F*
 ageusia
 brainstem injury 1847
 definition 1842
 post-traumatic 1846
 agger nasi
 anatomy 1332
 development 1319
 nasofrontal recess obstruction 1507–8
 pneumatization 1332
 agonists (drugs) 411
 agoraphobia
 posturography 3736
 vestibular disorders and 3814–5
 vestibular rehabilitation 3816
 agranulocytosis
 antithyroid drugs 346
 mouth ulcers 1834
 pharyngeal symptoms 2015
Ahl gene, noise-induced hearing loss 3549
 Aid for Children with Tracheostomies (ACT) 1204
 AIDS *see HIV infection/AIDS*
 Aintree catheter 475–6, 476 *F*
 air, characteristic impedance 3165
 air–bone gap
 inactive mucosal chronic otitis media 3421
 measurement procedure 3461
 otitis media with effusion 889
 otosclerosis 3461
 surgical contraindication 3470
 surgical eligibility 3465
 air-conduction (AC) hearing aid, bone-anchored hearing aid *vs.* 3643 *T*, 3644–6
 air-conduction tests, otitis media with effusion 889
 air embolism
 skull base surgery 4136
 syndromic craniosynostosis surgery 1031
 tracheostomy 2301
 airflow
 nasal *see nasal airflow*
 voice evaluation 2181–2
 air pollutants
 occupational rhinitis 1419
 olfactory dysfunction 1673–4
 rhinitis 1383, 1411
 air pressure, voice evaluation 2182–3
 air travel, professional voice and 2212
 air volume, voice evaluation 2181
 airway(s)
 difficult *see difficult airways*
 nasopharyngeal 1109, 2289, 2289 *F*
 oral 2289, 2289 *F*
 patency 2308, 2308 *F*
 protection during swallowing 1955, 2217
 airway-clearing manouevres, children 1188, 1189 *F*
 airway disorders, gastro-oesophageal reflux and 1273
 airway endoscopy, children
 anaesthesia 517–9, 1120–2
 maintenance 1121–2
 cardiovascular monitoring 518
 diagnostic 517–8
 induction 1120–1
 intubation 1121
 jet ventilation 1121
 laryngeal mask 1121
 nonintubation technique 1121
 recovery phase 518
 sedative premedication 517
 stridor 1119–23, 1143
 airway management
 anticipated or known difficulties 494
 critical care, adult 533
 devices 467
 anaesthesia 492–5
 choice influencing factors 493–5
 surgical factors 494–5
 laser endoscopy 519–20
 neck trauma 1766–7
 paediatric anaesthesia 510–1
 paediatric surgery 519
 postoperative intensive care treatment 546
 postoperative pain 495
 special needs children 786
 tonsillectomy 515
 airway obstruction 2286–91, 477–83
 acute 477–8, 478 *F*
 adenoidectomy 1095
 adult epiglottitis 2250
 airway endoscopy procedures 517–8
 alternative airways 2289–91
 anaesthesia 493
 children 508–9
 assessment 2287–8
 capnograms 499 *F*
 children *see airway obstruction, children*
 chronic 478
 evaluation 478
 infectious mononucleosis 2253, 2254 *F*
 laryngopyocele 2256
 management 478–83, 2288–91
 acute laryngeal infections 1132–3
 medical 2288–9
 midtracheal obstruction 483
 noninvasive procedures 2288–9
 sleep-disordered breathing 1102
 stridor 478, 1117, 1118 *F*
 symptoms/signs 2286–7
 tracheostomy 2293
 children 1195, 1195 *T*
 turbulent gas flow 477–8
 airway obstruction, children
 acute
 emergency tracheostomy 1124
 humidification 1123
 management 1123–4
 medical management 1123
 oxygen therapy 1123

airway obstruction, children (*continued*)
 pharmacotherapy 1123
 surgery 1123–4
 symptoms 1117 *T*
 intensive care 543
 laryngeal causes 1115 *T*
 nasopharyngeal causes 1115 *T*
 symptoms 1116–7, 1117 *T*
 tracheal causes 1116 *T*
 airway oedema
 extubation 484
 respiratory sleep disorders 2309
 airway pressure, perioperative
 monitoring 498
 akinetic syndromes 3731
 ala 3006
 collapse 3010–1
 alar base reduction surgery 3091
 alar cartilage(s)
 anatomy 1325, 2960–1, 2995–6,
 2996 *F*
 asymmetry, post-nasal tip
 surgery 3004
 cleft lip and palate 1005, 1006 *F*
 nasal tip delivery 2998, 2998 *F*
 nasal valve collapse 3007
 retraction, post-nasal tip
 surgery 3004, 3092
 suture techniques 3001 *F*
 alar muscle paralysis, nasal valve
 collapse 3007
 albinism
 basal cell carcinoma 1705–6
 squamous cell carcinoma 2398
 Albright syndrome 1929
 albumin
 malnutrition assessment 95
 thyroid hormone binding 323
 alcohol
 epistaxis 1600
 head and neck cancer 2351–2
 beverage type 2352
 biological mechanisms 2352
 quality of life 2776
 hypopharyngeal cancer 2634
 laryngeal cancer 2348, 2351–2
 olfactory dysfunction 1664
 oral cavity tumours 2347–8, 2550,
 2550 *F*
 oropharyngeal tumours 2347–8
 rhinitis 1383
 upper aerodigestive tract
 tumours 2352
 alcohol-induced positional
 nystagmus 3701

Alexander's law 3712, 3712 *F*
 alginate
 fungating wounds 453, 2794
 gastro-oesophageal reflux 1276
 tissue scaffolds 123
 aliphatic amine N-oxides 51
 alkaline phosphatase, pregnancy 403
 alkylating agents 37
 alleles, recessive mutant expression 8–9
 allelic deletion 9
 allelotyping 8–9
 allergen(s) 145
 allergic rhinitis 145, 145 *T*
 avoidance *see* allergen avoidance
 early phase response 1390
 food allergy 1426–7
 indoor 1396
 inhaled 145 *T*
 late phase response 1390–2
 occupational exposure 1397
 sensitization 1388–90
see also individual allergens
 allergen avoidance 1396–7
 allergic rhinitis 1396–7
 occupational exposure 1397
 primary prevention 1396
 secondary prevention 1396–7
 allergen immunotherapy 1399–400
 allergic fungal rhinosinusitis 1454
 allergic occupational rhinitis 1421
 allergic rhinitis 421, 1399–400,
 1564–5
 children 1399
 contraindications 1400 *T*
 efficacy 1399
 indications 1399, 1400 *T*
 mechanisms 1400
 novel strategies 1400
 practical immunotherapy 1399–400
 seasonal hayfever 1399
 side effects 1399
 sublingual administration 1400
 allergen-specific IgE 159–60, 160 *F*, 169
 allergic fungal rhinosinusitis (AFRS)
 220–2, 1450 *T*, 1452–4, 1453 *F*
 aetiology 221, 1452–3
 clinical manifestations 221, 221 *F*,
 1470
 complications 222
 definition 220–1
 diagnosis 220, 221
 diagnostic criteria 1451 *T*, 1453,
 1453 *T*
 epidemiology 221
 immunotherapy 1454
 incidence 220
 management 221–2
 nasal polyposis 1550
 outcomes 222
 pathophysiology 1453
 surgical debridement 221
 treatment 1454
 'allergic mucin' *see* eosinophilic mucin
 allergic reactions *see* allergy/allergic
 reaction
 allergic rhinitis 1386–407
 aetiology 1388–92
 allergens 145, 145 *T*
 avoidance 1083, 1396–7
 sensitization 1388–9
 allergy diagnosis 1393–5
 asthma 158, 1387–8, 1388, 1402
 children 1080, 1401
 classification 1381, 1381 *T*, 1387 *F*
 clinical presentation 1392–3
 co-morbidities 1388
 contact endoscopy 764–5
 corticosteroids 419–20
 intranasal 420
 systemic 420, 1398–9
 topical 153, 421, 1398
 decongestants 1398
 definition 1386
 diagnosis 1082, 1393–5
 endoscopic appearance 764–5
 endothelial cells 1391
 environment and 1388
 eosinophils 1390–1
 epithelial cells 1391
 examination 1393
 family history 1387–8
 fibroblasts 1392
 food allergy and 1397
 genetics 20, 1387–8
 history taking 1393
 IgE-independent responses 1392
 immune response 1389 *F*
 immunotherapy *see* allergen
 immunotherapy
 intermittent (seasonal) 1381, 1381 *T*,
 1386
 knowledge deficiencies 1402
 mucus production 764–5
 nasal polyposis 1550
 neutrophils 1392
 olfactory dysfunction 1667–8
 pathophysiology 1388–92,
 1389 *F*
 early phase response 1390
 late phase response 1390–2

- sensitization 1388–90
 systemic activation 1392
 persistent (perennial) 1381, 1381 *T*,
 1392–3
 pregnancy 1401–2
 prevalence 1381, 1386–7, 1387 *F*
 quality of life 1388
 risk factors 1387–8
 surgery 1400
 treatment 1396–400
 antihistamines 1397–8
 environmental control 1396–7
 novel strategies 155
 pharmacotherapy 1397–9, 1397 *T*,
 1398 *F*
- Allergic Rhinitis and its impact on
 Asthma (ARIA) 1080, 1381, 1386,
 1387 *F*
- allergy/allergic reaction 144–66
 aetiology 144–6
 allergens 145
 asthma *see* asthma
 autoimmunity 141
 basophils 149
 blood tests 1394
 chronic laryngitis 2258–9
 dendrite cells 151–2
 diagnosis 160–1, 161 *F*, 1393–5
 effector cell recruitment 149
 environment and 145–6
 eosinophils 62, 149, 150 *F*
 epistaxis, children 1067
 food *see* food allergy
 genetics 144–5, 145 *T*
 geographical tongue 1826
 hygiene hypothesis 145–6
 hypersensitivity *see* hypersensitivity
 reactions
 inactive squamous chronic otitis
 media 3427
 mast cells 148–9
 mechanisms 146, 146 *F*
 nasal polyposis 1550
 otitis externa 3352
 otitis media with effusion 3389
 pathogenesis 146–52
 early/late phase response 146
 effector cells 148–52
 IgG 148
 sensory nerves 148
 penicillin-induced 230
 pollution 146
 rhinitis *see* allergic rhinitis
 rhinosinusitis 1440–1
 sulphonamide-induced 231
- systemic 1563
 T cells 149–51
 tests 158–61, 169–70
 see also individual tests
 treatment 152–5
 novel strategies 155–8
- alloplastic grafts 96
 augmentation rhinoplasty 2971
 allopurinol, skin flap survival 113
 all-trans retinoic acid (ATRA) 274
 allylamines 234
 alopecia
 cyclophosphamide-related 1652–3
 post-rhytidectomy 3075
 alpha 1-antichymotrypsin 2495–6
 α-antiplasmin 279
 Alport syndrome 813 *T*, 3683
 alprazolam 3617
 AlterImage 2947 *F*
Alternaria, fungal rhinosinusitis 217
 allergic 221, 1452–3
 noninvasive 219
 alternative lengthening of telomeres
 (ALT) 71
 alternative lengthening of telomeres
 (ALT)-associated promyelocytic
 leukaemia bodies 71
 alternative splicing 4, 15–6
 alternobaric facial palsy 3513–4
 alternobaric oxygen therapy, Menière's
 disease 3800
 alternobaric vertigo 3513
 aluminium acetate
 ear inflammation 430
 furunculosis 3324
 alveolar arch 1341
 alveolar bone 2907
 secondary grafting 1006, 1006 *F*
 alveolar cleft 1005–6
 alveolar consonants 2166–7, 2167 *T*
 alveolar nerves 3924
 Alzheimer's disease (AD), olfactory
 dysfunction 1669
 amalgam tattoos 1825, 1826 *F*
 amantadine 210, 232
 ambient pressure, otitic
 barotrauma 3500–2
 ambroxol *see* acetylcysteine
 amelanotic melanoma
 diagnosis delay 3093
 nasopharyngeal carcinoma 2455
 ameloblastic carcinoma 1938
 ameloblastic fibroma 1927–8
 ameloblastic fibro-odontoma
 1927–8
- ameloblastoma 1927–8, 1928 *F*
 epidemiology 1927
 incidence 1921
 malignant (metastasizing) 1938
 maxillary 1927
 types 1927
 variants 1927
 ameloblasts 799–800
 amelogenesis imperfecta 1817
 amenorrhoea, prolactinoma 4100
 American Academy of
 Otolaryngologists/ Head and Neck
 Surgeons (AAO HNS),
 tonsillectomy guidelines 1232
 American Academy of Otolaryngology–
 Head and Neck Surgery,
 rhinosinusitis classification
 system 1439, 1439 *T*
 American Head and Neck Society, data
 collection coordination 2375
 American Joint Committee on Cancer
 (AJCC), lymph node classification/
 staging 715, 715 *T*, 2360, 2363
 American Sleep Apnoea
 Association 1106
 American Society of Anesthesiologists,
 physical status grading 461 *T*
 American Society of Pediatric
 Otolaryngologists (ASPO),
 juvenile-onset recurrent respiratory
 papillomatosis staging 1176
 amethocaine gel (AMETOP), nasal
 fractures 1612–3
 AMETOP (amethocaine gel), nasal
 fractures 1612–3
 amifostine 2536
 aminoglycosides 232
 mechanism of action 232
 Menière's disease 3760, 3800
 nephrotoxicity 236
 ototoxicity 236, 3299 *T*, 3424,
 3567–70
 aetiopathology 3298–300, 3299 *F*,
 3567–9, 3568 *T*, 3676, 3764
 drug monitoring 3570
 genetic susceptibility 16–7,
 3568
 hearing loss, attribution to 3542,
 3572
 incidence 3300
 medical negligence 3831
 natural history 3569
 potentiators 3568
 prevention 3302
 recognition 3571–3

aminoglycosides (*continued*)
 relative toxicity 3568–9
 risk factors 3569–70
 side effects 232
 tympanic membrane perforation with
 discharge 937
 vertigo induction, children 1047–8
 vestibular hair cell transduction
 channel blockage 3239

aminopenicillins 230

amino precursor uptake
 decarboxylation (APUD)
 tumours 4030

amiodarone, goitre and 2668

amitriptyline
 midfacial segment pain 1727
 migrainous vertigo 3803 *T*, 3804
 motor neurone disease 2080
 neuropathic pain, advanced head and
 neck cancer 2785

sialorrhoea 2080

tension-type headache 1725

tinnitus 3617

amoxicillin
 acute otitis media 918, 920
 intermittent rhinosinusitis 437

amphotericin 233
 candidiasis 224
 fungal rhinosinusitis 218, 219,
 1455
 mycotic laryngitis 2254

nephrotoxicity 236
 resistance 224–5
 side effects 233

ampicillin
 hepatotoxicity 236
 infectious mononucleosis 1225

amplifiers, hearing aids 3631–2,
 3632

amplitude, sound 2165

amplitude distortion 3178

amplitude linearity 3178

amplitude perturbation
 (shimmer) 2165, 2179

amplitude reduction, tinnitus 3608

ampulla 3153–4

amputation 97
 ear 3028, 3032 *F*
 nose 2924–5

amputation neuroma 3685, 3685 *F*

amrinone 114

amyloidosis 190
 cranial nerves 2080

larynx 2266

macroglossia 1828

amyotrophic lateral sclerosis
 (ALS) 2079–80
see also motor neurone disease

anacusis, vestibular schwannoma
 3959

anaemia(s) 267–72
 clinical assessment 267–8
 critical care 535
 definition 267
 haemolytic *see* haemolytic anaemia
 history taking 268
 investigations 268, 268 *T*
 lead poisoning 269
 macrocytic 268 *T*, 269
 microcytic 268–9, 268 *T*
 nonmegaloblastic 269
 normocytic 268 *T*, 269–70
 radiotherapy 2756
see also individual types

anaemia of chronic disease
 (AoCD) 268–9, 268 *T*

anaerobes 200–1
 detection 200
see also individual species

anaesthesia 488–506
 agents 490–1
 balanced 489, 489 *F*
children see paediatric anaesthesia
 consent 462–3
 conservative parotidectomy 2483
 depth indices 500
 explanation of (to patient) 462–3
 fasting periods 465
 high frequency jet-ventilation
 2149

hypophysectomy 4106

induction 495–6
 inhalational 496
 intravenous 495
 post-airway securing 496
 rapid sequence 496

inhalational agents 491

intravenous agents 490–1

monitoring 496–500
 intraoperative 496–500

nasal endoscopy 1347

nasal fractures 1612–3, 1613

operative laryngoscopy 2148–9

paediatric imaging 1301–2

patient anxieties 463

phonosurgery 2236

premedication 489–90, 490 *T*

preoxygenation 495

principles 488–9

reaction tests 169

total intravenous tubeless 2149

vocal fold injection 2240

see also individual drugs; individual procedures

analgesia
 dying child 1261
 paediatric intensive care 544
 pain management, head and neck
 cancer 2785

analogue-to-digital conversion,
 averaging 3279

analysis accumulation, voice
 evaluation 2183

analytical studies *see* epidemiology

anaphylactic (type 1) drug
 reactions 414

anaphylatoxins 89

anaphylaxis
 antimicrobial-induced 236
 food allergy 1431
 latex allergy 1419
 penicillin-induced 230
 transfusion reactions 261

anastomotic stricture, oesophageal
 atresia repair 1286–7

androgenic drugs, laryngeal disorders
 and 2201

androgen receptors, juvenile
 angiofibroma 2437–8

androgens 302

anethole trithione 1909

aneurysmal bone cysts, jaw 1931

Angell James disectors 4110

anger, palliative care patients 2795–6,
 2796 *T*

angina
 Ludwig's 1807, 1902
New York Heart Association
 classification 458 *T*
 patient preparation, surgery 459

Anginosus-Milleri group,
 streptococci 198

angioedema, corticosteroids 421

angiofibroma(s)
juvenile see juvenile angiofibroma
 nasal involvement 1708
 nasopharyngeal 1297
 resection, historical aspects
 2439–40

tumour embolization 734, 734–5

angiogenesis 93
 dermal repair 93
 macrophages 93
 pericyte-endothelial cell
 interactions 93

- pro-angiogenic factors 44 *F*
 skin flaps 114
 thyroid cancer research 2698–9
 tumours 43
 angiogenesis inhibitors 43, 44 *F*
 as maintenance therapy 43
 angiography
 children 1300, 1300 *F*
 glomus tumours 3950 *F*
 hyperparathyroidism, primary 392
 jugular foramen tumours 4035
 juvenile angiofibroma 2438–9, 2440 *F*,
 3954
 meningioma 736
 paragangliomas 739, 3953
 temporal bone squamous cell
 carcinoma 4090
 vascular injury, neck 1772
 see also specific techniques
 angiomas tumour embolization
 734 *F*
 angioneurotic oedema 3951
 drug therapy 449
 angiooedema, acquired, oral
 swelling 1828
 angio-oedema, hereditary *see* hereditary
 angio-oedema (HANE)
 angiosarcoma, larynx 2604
 angiotensin converting enzyme (ACE),
 sarcoidosis 1648, 1711
 angiotensin-converting enzyme (ACE)
 inhibitors
 angio-oedema induction 1828
 rhinitis induction 1410
 taste abnormalities 1847
 angular cheilitis, oral mucosa 1827,
 1827 *F*, 1837 *T*
 nutritional deficiencies 1827
 treatment 1827
 angular displacement, cupula
 3212
 angular frequency 3159
 angular stomatitis *see* angular
 cheilitis
 angular vein 1325
 angular vestibuloocular reflex
 (aVOR) 3213
 animal laboratory workers,
 occupational rhinitis 1419
 ankyloglossia (tongue tie) 994
 Annexin-V 61
 annular ligament, ear
 otosclerosis 3456
 sound transmission 3182
 anodontia (dental aplasia) 1817
 anosmia
 atrophic rhinitis 1465
 corticosteroid treatment 421
 definition 1664
 nonallergic occupational
 rhinitis 1416–8
 post-traumatic 1846
 supportive measures 1671
 taste sensations 3929–30
 anotia 975 *F*, 976
 treatment 979–80
 antacids 1276, 2063
 antagonists (drug) 411
 anterior atlantoaxial ligament 2111
 anterior belly of digastric
 transfer 3084–5, 3084 *F*
 anterior clinoid process 298, 4120
 anterior commissure tendon
 2132–3
 anterior condylar canal 3899
 anterior cranial fossa (ACF)
 boundaries 4120
 meningioma, diagnostic failure
 4144
 surgical anatomy 4120,
 4122 *F*
 anterior craniofacial resection 4128–30,
 4128
 anterior cranial fossa floor
 exposure 4129
 contraindications 4129
 incisions 4129
 indications 4129
 pericranial flaps 4130
 procedure 4129–30
 sinonasal malignancy 2431–3, 2432 *F*,
 2433 *F*
 anterior cricoid decompression 2282
 anterior cricoid split 1162, 1162 *F*
 anaesthesia 521
 indications 1162
 anterior ethmoidal artery
 absence 1335
 anatomy 1334–5, 1574
 skull base 3897–8
 endoscopic sinus surgery 1598
 iatrogenic damage 1605
 epistaxis 1598
 ligation 1604
 anterior glottic webs
 acquired 1160, 2281
 aetiology 1160
 management 1160
 congenital 1137
 phonosurgery 2237
 anterior inferior cerebellar artery
 (AICA)
 loops, vestibular pathology 3701
 skull base surgery 4136
 vestibular schwannoma
 compression 3958–9
 anterior macula flava 2135
 anterior nasal artery 1335
 anterior olfactory nucleus (AON) 1367,
 1663
 anterior pituitary gland *see*
 adenohypophysis
 anterior septal angle 1326
 anterior skull base 3897–8
 intracranial contents 4121
 osteology 4120
 subcranial relationships 4121–2,
 4122 *F*
 surgical anatomy 4120–2
 surgical approaches 3898
 anterior superior alveolar (dental)
 artery 1798
 anterior superior alveolar nerve 1328,
 1338, 1341, 1802
 anterior superior dental (alveolar)
 artery 1798
 anterior superior dental (alveolar)
 nerve 1328, 1338, 1341, 1802
 anterior synostoses 1025
 anterior triangle, neck 1741–2, 1742 *T*
 muscular 1742
 anterior tympanic artery 3907
 anterolateral craniofacial
 resection 4130, 4131 *F*
 contraindications 4130
 indications 4130
 procedure 4130
 anterolateral thigh flap 2879–81
 advantages 2880
 anatomy 2879–80, 2880 *F*
 clinical applications 2881
 disadvantages 2880–1
 technical nuances 2881
 anteroventral cochlear nuclei
 (AVCN) 3140
 anthracyclines 38
 antiadrenergic drugs, skin flap
 survival 113
 antiangiogenic agents, radiotherapy
 and 51
 antibacterial spectrum 431, 432 *T*
 antibiotic-inactivating enzymes 235
 antibiotics 229–30
 acute otitis media 431, 917–8, 3386
 recurrent 918–9

- antibiotics (*continued*)
- acute rhinosinusitis 438–9
 - adult epiglottitis 2251
 - antibacterial spectrum 431, 432 *T*
 - cerebrospinal fluid
 - rhinorrhoea 1639–40 - chronic otitis media, active
 - mucosal 3424 - chronic rhinosinusitis 1470–1, 1471
 - contraindications 432
 - croup 2251
 - cytotoxic 38
 - deep neck space abscesses 1786
 - dosage 432
 - furunculosis 3324
 - hypophysectomy 4105, 4111
 - infectious mononucleosis 2253
 - interactions 441
 - jugular foramen lesions 4042
 - laryngeal trauma 2274
 - laryngitis, acute 2213
 - laryngology 448
 - malignant otitis externa 3339
 - mechanisms of action 431
 - otitis externa 3353
 - otitis media with effusion 895–6
 - otological disease 431
 - ototoxicity 3298–300, 3299 *T*
 - parenteral, malignant otitis
 - externa 3339 - persistent rhinosinusitis 439
 - pharyngitis 1222
 - precautions 432–3
 - radial neck dissection 2743
 - resistance
 - antibiotic-inactivating enzymes 235
 - binding site alterations 235 - retropharyngeal abscess,
 - children 2001 - rheumatic fever prevention 1985–6
 - rhinosinusitis 1543–4
 - side effects 433
 - sinusitis, HIV patients 242
 - sore throat 1984–5
 - surgical prophylaxis 448
 - taste abnormalities 1845
 - temporal bone fractures 3496
 - tonsillectomy 1237
 - upper airway obstruction 2288–9
 - see also individual drugs*
- antibodies 135–6
- classes 138, 138 *T*
 - deficiency 176–7
 - tests 168
 - functions 138
- monoclonal *see monoclonal antibodies (MAb)*
- structure 138
 - subclasses 138, 138 *T*
 - see also immunoglobulin(s); individual types*
- antibody-dependent cellular
- cytotoxicity (ADCC) 41, 140
 - nasopharyngeal carcinoma 2448
- anticancer drugs
- clinical response assessment 36
 - tumour products 36
 - tumour size 36
 - mechanisms 34–46
 - see also individual drugs*
- anticholinergics
- drooling 788–9
 - mechanism of action 3795
 - nonallergic rhinitis 1506
 - vestibular attacks, acute 3795
 - see also individual drugs*
- anticoagulants 282–3, 446–7
- bleeding management 283, 283 *T*
 - drug interactions 283
 - excessive 283, 283 *T*
 - mechanism of action 282, 447 *F*
 - perioperative management 282–3
 - surgery and 282–3
 - thrombophilia 289
 - thyrotoxicosis 347
 - see also individual drugs*
- anticonvulsants, trigeminal
- neuralgia 1830
- anti-D antibodies 254
- antidepressants
- globus 2040
 - tinnitus 3617
- anti-diuretic hormone (ADH)
- diabetes insipidus 308
 - effects 308
 - function 300
 - secretion 308
 - post-pituitary surgery 308
- antiemetics
- advanced head and neck cancer 2787
 - anaesthesia premedication 490 *T*
 - migrainous vertigo 3801
 - vestibular attacks 3794–5
 - see also individual drugs*
- antiepileptics, tinnitus 3617
- antifungals 233–4
- allergic fungal rhinosinusitis 222
 - candidiasis, cancer patients 2789
 - chronic rhinosinusitis 1472
 - invasive fungal rhinosinusitis 1454
- mycotic laryngitis 2254
- resistance 233
 - rhinological diseases 442
 - see also individual drugs*
- antigen(s)
- presentation, T cells 136–7, 136 *F*
 - recognition 134–7
 - B cells 135–6
- antigenic determinant 135
- antihistamines
- acute otitis media 918
 - allergic rhinitis 1397–8, 3392
 - allergy 152–3
 - drug interactions 411
 - food allergy 1431
 - nasal vasculature, effects on 1365, 1365 *T*
 - nausea and vomiting 2787–8
 - nonallergic rhinitis 1412
 - otitis media with effusion 3392
 - rhinosinusitis 440
 - children 1083
 - chronic 1472
 - vertigo 433
 - vestibular attacks, acute 3795–7
 - see also specific drugs*
- anti-HPA 1a 262
- anti-immunoglobulin E monoclonal antibody, allergic rhinitis 1565
- antileukotrienes 441–2
- allergic rhinitis 1399
 - chronic rhinosinusitis 1472
- antimalarials 1048
- antimetabolites 37–8
- cell cycle specificity 37
 - mechanism of action 37–8
- antimicrobials 228–37
- activity 229–34
 - concentration dependent
 - killing 1471 *F*
 - concentration-dependent
 - killing 1471
 - time dependent killing 1471 *F*
 - time-dependent killing 1471
- adverse effects 235–6
- cutaneous 236
 - gastrointestinal 236
 - haematological 236
 - liver toxicity 236
 - renal toxicity 236
- bacterial target sites 228–9, 229 *F*
- blood-brain barrier 228–9
- excretion routes 228–9
- pharmacokinetics 229–34
- resistance 228, 234–5

- altered penetration 235
binding site alterations 235
genetic mutation 234
multiresistant organisms 234
sensitivity testing 234–5
sepsis 534
surgical prophylaxis 228–9
therapeutic principles 228–9
see also individual drugs
- antimitotic agents, dacryocysto-rhinostomy 1695–6
- antimycotics, rhinosinusitis 441
- anti-neutrophil antibody (ANA) 167
- antineutrophil cytoplasmic antibody associated vasculitis 346
- antineutrophil cytoplasmic antibody test (ANCA) interpretation guide 171 *T*
vasculitis 171
- Wegener's granulomatosis 1649, 1649–50, 1651, 1652
- antioxidants, ototoxicity and intrinsic pathways 3300, 3301 *F*
prevention 3302
- antiphospholipid antibodies 290
- antiphospholipid syndrome 171
- α-antiplasmin 279
- antiplatelet agents, thrombocytosis 275–6
- antiplatelet antibodies 262
- antiproteases, nasal secretions 1360
- antipsychotics, palliative care patients 2795, 2798
- antireflux medication, laryngeal trauma 2274
- antiretroviral therapy (ART) 233 HIV salivary gland disease 1901
- antiseptics, tympanic membrane perforation 938
- antisialogogue anaesthesia 489
awake fibreoptic intubation 479–80
- antithrombin(s) 279, 279 *T* deficiency 290
- antithyroid drugs 346, 450–1 dose regimen 346
efficacy 347
Graves' disease 346–7
pretreatment 348
side effects 346 agranulocytosis 346
- antineutrophil cytoplasmic antibody associated vasculitis 346
- surgical preparations 349–51
see also specific drugs
- antituberculous drugs 3449, 3450 *T*
see also specific drugs
- antivascular agents haemorrhagic necrosis 51
radiotherapy and 51
- antivertigo drugs, migrainous vertigo 3801
- antivirals 209–10, 232–3 idiopathic sudden sensorineural hearing loss 1, 3584–8, 3589, 3589 *T*
- labial herpes 208
- otitis media with effusion 3392
- side effects 236
- target areas 209
see also individual drugs
- Antoni A pattern facial schwannomas 4078
- vestibular schwannoma 3957, 3960–1
- Antoni B pattern facial schwannomas 4078
- vestibular schwannoma 3957, 3960–1
- antral carcinomas 3927
- antral lavage 1490–2 anaesthesia 1491
complications 1492
contraindications 1491
indications 1490–1
surgical technique 1491–2, 1492 *F*
- antrum, imploding *see* imploding antrum syndrome
- anxiety globus 2039
head and neck cancer patients 2777
palliative care 2795, 2795 *T*
muscle tension dysphonia 2204
posturography 3736
professional voice 2212–3
salivary flow 1861
vestibular disorders 3814–5
- anxiety-related dizziness 3815 *F*
- anxiolysis, anaesthesia premedication 489, 490 *T*
- aortopexy, tracheomalacia 1287
- AP-1 2380
- 'apathetic hyperthyroidism' 339
- APECED (autoimmune polyendocrinopathy –candidiasis–ectodermal dystrophy) 180 *T*, 181
- aperiodic sound (noise) 2165
- Apert syndrome 1027, 1713, 2120 clinical features 1027
incidence 1021
nasopharyngeal airway 1109
- aphthae *see* recurrent aphthous stomatitis (RAS)
- aphthous ulcers, recurrent *see* recurrent aphthous stomatitis (RAS)
- apical jaw cysts 1922
- apicoposterior bronchus 2141
- Apligraf 126
- apnoea definition 2317–8
gastro-oesophageal reflux 1273
- apnoea/hypnoea index (AHI) 1106, 1106 *T*, 2319–20
- apnoea termination 2309
- apoptosis 56–65, 2383 biochemical changes 58
biochemical identification 60–1, 60 *T*
- cancer 62–3
- carcinogenesis 62
- caspase family 57, 2383
- cell cycle 58
- cell populations 57
- chemotherapy 63
- chromatin condensation 59, 60, 60 *F*
- congenital defects 61
- death receptors 57–8
- detection 60–1
- developmental processes 57
- disease states 61–2, 61 *T* congenital defects 61
non-neoplastic 61–2
- disruption, restorative gene therapy 29
- drug-induced 36
- executors 57
- extracellular signalling 57–8
- historical aspects 56, 59 *F*
- hypopharyngeal cancer 2636
- inhibition, ototoxicity prevention 3302
- intracellular signalling 58
- measurement 60–1
- mechanisms 36, 57–60, 57 *T* abnormalities 63
loss in malignancy 62–3
- mitochondrial pathways 58
- morphological changes 59–60, 59 *F*, detection 60–1, 60 *F*, 60 *T*
- nasal polyps 62
- necrosis *vs.* 57 *T*
- noise-induced hearing loss 3549
- nuclear changes 58

- apoptosis (*continued*)
 oligosomal fragmentation 58, 61
 ototoxicity 3300–1, 3301 *F*
 p53 58
 proteasome inhibition 44
 radiotherapy-induced 47, 63
 sensorineural deafness 61–2
 thyroid diseases 62
 tissue staining 60
 triggers 57, 57 *T*, 58 *T*
 tumour growth 57
 viral infection 61
 apoptotic bodies 59–60
 apoptotic index (AI)
 cancer 62–3
 cellular turnover 62
 radiotherapy 63
 apparent latency 3288
 apparent life-threatening events
 (ALTEs), gastro-oesophageal reflux 1273
 apple jelly nodules, sarcoidosis 189 *F*
 application specific integrated circuits
 (ASIC), ultrasound 713
 apprenticeship model, surgical training 552
 approximant consonants 2167, 2167 *T*
 aprotinin 283
 AQ4N 51
 arachnoid cysts
 aetiology 4013
 clinical presentation 4013
 CPA tumours 4013–4
 definition 4013
 diagnosis 4013, 4014 *F*
 epidemiology 4013
 pathology 4013
 treatment 4014, 4014 *F*
 arachnoid sheath, optic nerve 3914
 arch bars 1622–3, 1623 *F*
 arcuate eminence, middle fossa surgery 4019
 arcus marginalis 3051
 area under the curve (AUC), pharmacokinetics 410
 argon plasma coagulation
 tonsillectomy 1992
 argon plasma coagulator (APC)
 dissector 1992
 Argyll Robertson pupils 3916–7
 Arnold–Chiari malformation
 inner ear disorders 3683
 pharyngeal manifestations 2080
 treatment 2080
 vocal fold paralysis 1138
 Arnold's nerve 1751, 3527, 3910
 arousal, sleep-disordered breathing 1103
 arrhythmias, surgical preparation 459
 arsenical ototoxicity 3571
 Ars-Marquet procedure 946 *F*
 arterial leg ulcers 98
 wound dressings 102
 arterial spin tagging 677, 677 *F*
 arterial thrombosis
 antiphospholipid antibodies 290
 pathogenesis 288
 risk factors 289 *T*
 arterioles, nasal 1362
 arteriovenous fistulae 4145
 arteriovenous malformations (AVMs) 726
 articulation 992–3
 disorders 993
 artifact rejection 3279
 artificial larynx
 electronic 2230
 rehabilitation post-total laryngectomy 2227, 2228–30, 2228 *T*
 artificial saliva 449, 1912, 2788
 aryepiglottic folds 2133
 congenital disorders 1135
 development 2130
 aryepiglotticus 2136 *T*
 aryepiglottoplasty
 laryngomalacia 1136
 paediatric anaesthesia 520
 arytenoid cartilages 2133, 2133 *F*
 arytenoidectomy 1159
 arytenoid fixation and cricothyroid subluxation 2242–3
 arytenoid granuloma 1170 *F*, 2196–7, 2197 *F*, 2220–1
 aetiology 2196, 2220
 botulinum toxin injections 2238
 extra-oesophageal reflux 2196
 mitomycin C 2238
 phonosurgery 2238
 speech therapy 2221
 symptoms 2197
 treatment 2197
 arytenoid prolapse 1159
 arytenoid swelling 2130
 ASA difficult airway algorithm 472–3, 472 *F*
 Asai's technique, laryngeal prosthesis placement 2625
 ascending auditory pathway 3140–4, 3141 *F*
 ascending cervical artery 2113
 ascending (modified Hughson-Westlake) method, pure-tone audiometry 3263–4
 ascending palatine artery 2113, 3909
 ascending pharyngeal artery 1947, 1951, 2113
 aseptic technique, blood donation 260
 Ashe's forceps 1613, 1613 *F*
 aspartame allergy 1427
 aspergillosis *see* fungus ball
Aspergillus
 cervicofacial infections, children 1216
 fungus ball 1452
 otomycosis 213
 rhinosinusitis 217, 1381, 1452–3
 HIV-associated 241–2
see also individual organisms
Aspergillus flavus
 fungal rhinosinusitis 217, 1450 *T*
 otomycosis 213
Aspergillus fumigatus
 external ear infection, HIV-associated 240
 fungal rhinosinusitis 217, 219, 1450 *T*
 otomycosis 213
Aspergillus niger, otomycosis 213, 214 *F*, 3355 *F*
 aspiration 1277–8
 barium in videofluoroscopy 1967
 causes 1277
 chronic *see* intractable aspiration
 definition 1277, 2085, 2094
 diagnostic tests 1277–8
 dysphagia 2085
 neurological 2076
 intractable *see* intractable aspiration
 laryngeal stenosis 1154, 1155
 management 1278
 stridor 1117
 symptoms and signs 1277
 aspiration biopsy cytology (ABC) 1252–3
 aspiration pneumonia 1284, 2085
 aspirin
 chronic rhinosinusitis 1472–3
 nasal administration 1473
 oral administration 1473, 1473 *T*
 desensitization, nasal polyps 442
 epistaxis, recurrent 1604
 food allergy 1427
 migrainous vertigo 3801
 ototoxicity prevention and 3302
 patient preparation, surgery 460
 sensitivity 1472
 testing 1395

- side effects
 rhinorrhoea 1410
 tinnitus 3599–600
- spontaneous otoacoustic emissions 3603–4
- vocal fold haemorrhage induction 2213
- aspirin triad *see* Samter's triad
- assessment, outcomes research *see* outcomes research
- assistive listening devices (ALDS) 3864–5
- astemizole 1397–8
- asthma
 allergen associations 145, 145 *T*
 allergic rhinitis 158, 1387–8, 1388, 1402, 1561
 anti-immunoglobulin E monoclonal antibody 1565
 causative agents 1561
 Churg–Strauss syndrome 1653
 costs 1565
 diagnostic indicators 1395
 disease continuum 1565
 food allergy and 1428, 1429
 future research 1402
 genetic associations 145 *T*
 immunotherapy 1564–5
 interleukin-5 155–6
 molecular biology 1562
 nasal inflammation 1561–2
 bronchial inflammation *vs.* 1561–2
 nasal polyposis 1553
 bronchial hyperreactivity 1551
 incidence 1553
 omalizumab 1565
 oral drugs 1564
 paediatric anaesthesia 508
 quality of life 1564
 severity, rhinitis treatment 1565
 sinus involvement 1561–2, 1562
 therapeutic consequences 1564–5
 topical drugs 1564
 viral infection, nasal 1563
- astomia 1811–2
- astrocytomas 4015
- A stronger local voice* 574
- asymmetric crying facies 1055
- ataxia
 cerebellar *see* cerebellar ataxia
 children 1048–9
 ototoxicity-related 3569
 sensory 3778, 3780
- ataxia telangiectasia (AT) 179–80, 180 *T*
 ATM gene 58, 188
 radiotherapy dose response curves 48
- ataxic nystagmus, internuclear
 ophthalmoplegia 3715, 3716 *F*
- atelectasis 942, 942 *T*
- atenolol 3803–4
- ateriography, sinonasal
 malignancy 2426
- atlanto-axial instability 1308, 1308 *F*
- atlantoaxial subluxation
 adenoidectomy-related 1098
 nontraumatic 1236
- atlantooccipital joints 3899
- atlantooccipital movement 470
- atlas 2111
- ATM gene/protein 58, 179–80
- atopic eczema dermatitis syndrome (AEDC) 1424–5
- atopy 144, 145 *T*
- atresia
 acquired, external ear *see* acquired atresia, external ear
 congenital, external ear *see* aural atresia, congenital
 definition 3346
 oesophageal *see* oesophageal atresia
- atrial fibrillation (AF), thyrotoxicosis 339
- atrophic rhinitis 1383, 1411, 1465–6
 aetiology 1411, 1465
 clinical features 1411, 1465–6
 drug therapy 443
 investigations 1465–6
 pathology 1465
 primary 1383, 1411, 1465
 secondary 1411
 symptoms 1383
 treatment 1466
 medical 443, 1466
 surgical 1466
- atrophic vocal fold 2243, 2243 *F*
- atropine
 airway endoscopy procedures 517
 nasal vasculature, effects on 1365
 paediatric anaesthesia 509
- ATR protein 58
- attention deficit hyperactivity disorder (ADHD), speech disorders and 991–2
- attic cholesteatoma 950–1
- attico-antrostomy 3432
- atypical mole syndrome 2400
- atypical mycobacteria 201
- atypical naevi, external nose 1707
- audiology
 cholesteatoma 951–2
 chronic otitis media 3419
 otitis media with effusion 3391, 3391 *T*
- paediatric cochlear implantation 863
- skull base lesions 3946
- see also specific tests*
- audiometric scales 3171
- audiometry
 audiometric scales 3171
 auditory neuropathy/
 dyssynchrony 3841 *F*
- behavioural *see* behavioural audiology
- congenital ossicular abnormalities 871
- dizzy child 1042
- facial nerve tumours 4080
- Menière's disease 3757, 3758 *F*
- otitis media with effusion 889–90, 890, 3390, 3391, 3391 *T*
- psychoacoustic 3260–75
- pure-tone *see* pure-tone audiometry
- screening methods 3264–5
- speech *see* speech audiometry
- temporal bone squamous cell carcinoma 4090
- visual reinforcement *see* visual reinforcement audiometry (VRA)
- see also* sound
- audit, comparative 2376
- auditory brainstem implant, vestibular schwannoma 3976–7
- auditory brainstem responses (ABRs)
- auditory function monitoring 750, 751
- central auditory dysfunction 3860, 3860–1, 3861 *F*
- childhood deafness 848
- paediatric cochlear implantation 863
- skull base lesions 3946
- auditory canal, external *see* external auditory canal
- auditory cortex 3143–4
 projection to 3144, 3144 *F*
 response types 3144
 tinnitus 3602
- auditory cortical potentials *see* auditory long-latency evoked potentials (ALEPs)
- auditory dyssynchrony *see* auditory neuropathy/dyssynchrony

auditory event-related potentials (ERP),
tinnitus 3612–3
auditory evoked cortical magnetic fields
(AEF), tinnitus 3613
auditory-evoked potentials 3278–88
averaging 3279
central auditory dysfunction 3862
classification 3278–9
definition 3278–9
endogenous 3279
exogenous 3278–9
intraoperative monitoring 3292
methodological
considerations 3279–80
neurogenic 3278–88
recording system 3279
signal-to-noise ratio 3279
transient 3280
waveform analysis 3279–80, 3280 *F*
see also individual types

auditory filters 3246–9
asymmetric 3249
centre frequency 3248
characteristics 3247
definition 3245
excitation pattern 3249–50, 3250 *F*
masking patterns 3247
notched-noise shape determination
3248–9, 3248 *F*, 3249 *F*

auditory function monitoring 750
efficacy 751–2
preoperative hearing
requirements 750
techniques 751
auditory brainstem responses 750,
751
combined 751
direct cochlear nerve recording 751
electrocotchleography 751
otoacoustic emissions 751

auditory hallucinations 3595
central auditory dysfunction 3863–4
tinnitus *vs.* 3595

auditory language processing,
functional magnetic resonance
imaging 680, 680 *F*

auditory late evoked potentials (ALEPs)
see auditory long-latency evoked
potentials (ALEPs)

auditory long-latency evoked potentials
(ALEPs) 3285–7
children 3287

frequency-specific sensitivity
assessment 3291
generators 3287

mismatch negativity (MMN)
3286–7
N₂₀₀–P₃₀₀ complex 3287
N₄₀₀ 3287
negative peak (N₁) 3286–7
neuro-otological evaluation 3292
'oddball paradigm' 3287
P_{3a} 3287
P_{3b} 3287
P₃₀₀ 3287
schizophrenic patients 3292
positive peak P₁ 3286
processing negativity (negative
difference; N_d) 3286–7
recording 3285–6
vertex potential 3286
waveform 3286, 3287 *F*

auditory middle latency evoked
potentials (AMEPs) 3285
40 Hz 3286 *F*, 3288
frequency-specific sensitivity
assessment 3291
neuro-otological evaluation 3292
sampling rate 3285
waveform components 3285, 3286 *F*

auditory nerve (VIII)
activity recording, tinnitus 3612
afferent fibres 3136
arachnoid cysts 4013
auditory neuropathy/dyssynchrony
3837–8
CPA lipomas 4013
demyelination, multiple sclerosis 3846
electrical stimulation, auditory
neuropathy/dyssynchrony 3852
epidermoids (primary
cholesteatomas) 4011
fibres
activation 3195 *F*, 3197–8
best/characteristic frequency 3197
cochlea, nonlinear
interactions 3198–9
efferent 3138 *F*, 3139
frequency selectivity 3197–8
intensity responses 3198, 3198 *F*
phase locking 3197–8, 3197 *F*
responses 3197–200
pathological cochlea 3199–200
tuning characteristics 3197
type I 3849
type II 3849

glomus tumours
(paragangliomas) 4015

intraoperative monitoring 3292–3,
3293 *F*

meningiomas and 4009
organ of Corti innervation 3136
speech recognition post-cochlear
implants 3650
tuning curves 3177 *F*, 3190, 3191 *F*,
3197
cochlear damage 3199, 3199 *F*
width 3199–200
vestibular schwannoma
compression 3958–9

auditory nerve and brainstem evoked
potentials (ABEP) 3281–5
age-related changes 3284–5
amplitude ratios 3284 *T*
amplitude ratios 3284 *T*
audiometric measures 3283
auditory sensitivity indicators 3291
best clinical practice 3294
children 3284–5
frequency-specific stimuli 3291
gender 3285
generators 3283
high-frequency sensorineural hearing
loss 3291
interpeak latency difference
measures 3283, 3284 *T*
intraoperative monitoring 3292–3
IV–V complex 3283
neonatal hearing screening 3291
neuro-otological evaluation 3292
neuro-otologic measures 3283
nonpathologic factors affecting 3284
peak I 3281–3
peak II 3283
peak III 3283
peak IV 3283
peak latencies 3283, 3284 *T*
peak V 3281–3
peripheral hearing loss 3291
sampling rate 3281–3
stimulus intensity 3284, 3285 *F*
troughs 3281–3
V/I amplitude ratio 3292
waveform 3281–3, 3283 *F*

auditory nerve electrodes 3292–3,
3293 *F*

auditory neuropathy/
dyssynchrony 3839–45
amplification strategies 3851–2
axonal neuropathy and 3848–9
brainstem neuropathy *vs.* 3851
Charcot-Marie-Tooth type 1 3849
children 824, 3845–6
causes 3845–6
genetic risk factors 3846

- hearing screening
programmes 3846
perinatal risk factors 3845–6,
 3845 *T*
prevalence 3839–40, 3840 *T*, 3845
clinical presentation 3840–1
diagnosis 3842–5
diagnostic criteria 3842 *T*
differential diagnosis 3850–1
early language intervention 3851
hereditary sensory-motor
 neuropathy 3849–50
historical aspects 3839
impairment severity 3840, 3841 *F*
lesion site 3849–50
 axons 3849–50
 cell bodies 3849–50
 inner hair cell electromechanical
 transduction 3849
 myelin sheaths 3849–50
 olivocochlear feedback
 mechanisms 3850
neurological 3846–9
peripheral neuropathy and 3848–9
 incidence 3848
 nerve conduction studies 3848–9
psychophysical tests 3845
rehabilitation strategies 3851–2
speech 3840
speech recognition tests 3844
steady-state potentials 3843–4
temperature-sensitive hearing
 loss 3848–9
tests 3842–5, 3842 *T*
total communication strategy 3851
 see also hearing loss/impairment
auditory pathways 3265
 afferent 3601, 3602 *F*
 ascending 3140–4, 3141 *F*
 central masking 3265
 descending 3144–5
 efferent 3601, 3602 *F*
 future research areas 3145
 knowledge deficiencies 3145
 pure-tone audiometry errors 3265
auditory processing disorder
 (APD) 3857–8
Auditory Response Cradle devices 3290
auditory sensitivity, evoked
 physiological
 measurements 3276–97
 audiogram estimation 3291–2
 clinical utility 3290–3
 evoked potentials *see* auditory-evoked
 potentials
future research areas 3294
intraoperative monitoring 3292–3
knowledge deficiencies 3294
myogenic activity 3288–90
neonatal hearing screening 3290–1
neuro-otological evaluation 3292
otoacoustic emissions *see* otoacoustic
 emissions (OAEs)
 see also specific tests
auditory speech discrimination
 tests 841
auditory steady-state response (ASSR),
 central auditory dysfunction 3860
auditory system
 feedback mechanisms 3601, 3602 *F*
 modifier genes 817
 noise-induced cochlear lesion 3601
 see also ear(s)
auditory thalamocortical potentials *see*
 auditory middle latency evoked
 potentials (AMEPs)
auditory therapy (AT), children 3865
auditory tube 2113
augmentation rhinoplasty 2970–8
 ethnic variations 2970
 implant materials 2970–4
 semisynthetic 2973–4
 synthetic 2972 *T*, 2973–4
 infection 2971
 Wegner's granulomatosis 2976 *F*
augmentation tracheoplasty 1144
augmented reality 702, 702 *F*
aural atresia, congenital 975–80
 acute otitis media 981
 audiological investigations 981
 cholesteatoma 981
 classification 976–7, 977 *T*
 examination 980–1
 history 980–1
 imaging 981
 otological surveillance 981
 surgical candidacy scoring
 systems 977, 977 *T*
 surgical treatment 981–2
aural foreign bodies 3370–2, 3371 *F*
 children 1184–6
 management 1185–6
 presentation 1184–5, 1185 *F*
 clinical picture 3370
 complications 3371
 location 3371
 management/removal 1185–6,
 3370–1, 3371 *T*
 patient considerations 3371
 techniques 1185
pathology 3370
 types 1185, 3370–1
aural polyps
 active mucosal chronic otitis
 media 3397, 3425
 cholesteatoma 950
 removal 3425
 medical negligence 1307
aural toilet 3313–4
cholesteatoma 3432
chronic otitis media
 active mucosal 3424
 children 935, 936 *F*, 937
 inactive squamous 3428
malignant otitis externa 3338–9
microscopic 3314
otitis externa 3353
auricle *see* pinna
auricular cartilage grafts
 laryngeal reconstruction 1156
 septal perforations 1586–7
auricular implants 2908 *F*, 2909,
 2928
auriculotemporal nerve 3109, 3907–8,
 3925
 injury, taste abnormalities and 1846
europexy 973–4
autoantibodies
 autoimmune screen 170, 170 *T*
 thyroid disease, *in vitro* tests 328,
 328 *T*, 332, 335
autocannibalism 530–1
auto-CPAP machines 2321
autografts
 augmentation rhinoplasty 2971,
 2972
 surgical harvesting 2972–3
 tissue regeneration 75
autoimmune disease
 apoptosis 62
 chronic otitis media 3409
 inner ear 3680–1
 basophilic amorphous
 deposits 3680–1
 diagnosis 3754, 3758–9
 nonorgan specific 3680
 management 170–2
 otosclerosis 3459
autoimmune lymphocytic thyroiditis
 see Hashimoto's thyroiditis
autoimmune lymphoproliferative
 syndrome (ALPS) 180 *T*, 181
autoimmune polyendocrinopathy
 –candidiasis–ectodermal dystrophy
 (APECED) 180 *T*, 181

autoimmune thrombocytopenia *see*
 idiopathic thrombocytopenic
 purpura

autoimmune thyroiditis
 painless thyroiditis 352–3
 thyroid lymphoma aetiology 2675

autoimmune thyrotoxicosis *see* Grave's
 disease

autoimmunity 141

autoinflation, otitis media with
 effusion 896, 3392

autologous blood clots, as embolic
 agent 733

autologous grafts 96

automated auditory brainstem response
 (AABR) testing, newborns 826,
 848

automated otoacoustic emissions
 (AOAE)
 childhood deafness screening 848
 newborn hearing screening 826

automatic noninvasive blood pressure
 monitoring 497

autonomic nervous system
 nose 1358, 1363, 1363 *F*
 thyroid gland control 319

autonomy (ethical principle) 561–2, 582

autoradiography 6

autosomal dominant inheritance 18

autosomal dominant nonsyndromic
 sensorineural hearing
 impairment 3558–66, 852

associated hearing impairments
 3560–2

DFNA diagnosis 3562

gene linkage strategies 3559

recent developments 3559

terminology 3559–60

autosomal recessive hereditary hearing
 loss 852–3

autosomal recessive inheritance 18

autosome 3–4, 18

Avastin 43–4

Avellis's syndrome (of brainstem)
 3938

avian H5N1 influenza 205–6

awake extubation, difficult airways 484

awake fiberoptic intubation 479, 479 *F*
 periglottic/glottic obstruction 481
 premedication 479–80
 sedation 480
 supraglottic obstruction 479, 481

awake fiberoptic nasolaryngoscopy,
 juvenile-onset recurrent respiratory
 papillomatosis 1175–6

axial flaps 2845–6, 2848–53
 blood supply 2844 *F*, 2848, 2848 *F*
 distant 2827, 2853–4, 2854–65
 oral cavity tumours 2569
see also specific types

axis 2111

axolotl 72

axoneme 3228

axonotmesis 3873

axon reflexes, nasal 1364

azathioprine
 Sjögren syndrome 1913
 Wegener's granulomatosis
 treatment 1652–3

azelastine
 chronic rhinosinusitis 1471–2
 nonallergic rhinitis 1412
 otitis media with effusion 3392

3'azido3'deoxythymidine zidovudine
 (AZT) 233, 239, 240

azithromycin
 ototoxicity 3571
 syphilis 2008

azoles 233–4
 acute fulminant fungal
 rhinosinusitis 1455

babbling 2168

bacillary angiomatosis 247–8

Bacillus subtilis 1419

baclofen
 periodic alternating nystagmus
 3804

tinnitus 3606–7, 3617

bacteria
 anaerobes 200–1
 colonization 195
 definition 195
 Gram-negative 199–200
 Gram-positive 196–9
 microaerophilic 201
see also individual species

bacterial artificial chromosome
 (BAC) 5–6, 11

bacterial cell wall synthesis
 inhibitors 229

bacterial endocarditis, antibiotic
 prophylaxis 460

bacterial infection
 acute otitis media 915, 915 *T*
 blood transfusion 261
 chronic laryngitis 2258–9
 nasal 1700, 1703
 olfactory dysfunction 1673–4
 oral 1833

otitis externa 3352, 3352 *T*

pharyngitis 1982–3

wound healing 95

see also specific diseases

bacterial interference 195–6

bacterial labyrinthitis 3691–2,
 3691 *F*

active chronic otitis media 3436

causative microorganisms 3692,
 3692 *F*, 3693 *F*

clinical features 3692

histopathology 3692

management 3436–7

bacterial laryngotracheobronchitis *see*
 pseudomembranous croup

bacterial lysate preparations,
 rhinosinusitis 441

bacterial parotitis 1212

bacterial protein synthesis
 inhibitors 231–2

bacterial tracheitis *see*
 pseudomembranous croup

bacterial vaccines, rhinosinusitis 1084,
 1473

bacteriostatic agents 234

bacteriotherapy 195–6, 198

Bacteroides fragilis 200–1

bakers, occupational rhinitis 1418

'balaclava' ('onion peel') sensory
 deficit 3926

balance
 evaluation 3706–47
 dizzy child 1042
 otitis media with effusion 894

balanced anaesthesia 489, 489 *F*

balance disorders/disturbances
 active chronic otitis media 3436
 causes 3932–3
 children, vestibular symptoms 1041 *T*,
 1042

classification 3673–4

diagnostic flow chart, children 1043 *F*

examination 3710–36
 eye movements 3710–23
 neurofibromatosis 2 4000
 posturography 3732–6
 skull base lesions 3944
 symptoms 3706–10
 vestibulocochlear nerve 3932–3
see also vertigo

ballistic gene delivery 25

balloon dacryocystoplasty 1694

balloon dilation
 oesophageal strictures 2064, 2064 *F*

tracheal stenosis 1143–4

- balloon embolization 733
 balloon myotomy, achalasia 2066
 balloon occlusion test 2534,
 3951
 bar and clip arrangement, implant
 retention 2932, 2933 *F*
 Barany, Robert 3154
 Barany box 3317
 270 ‘barbecue’ manoeuvre 3813
 Barclay’s procedure 2283, 2283 *F*
 barium swallow 1967
 achalasia 1288, 1289 *F*, 2027 *F*
 congenital oesophageal
 stenosis 1287–8
 dysphagia 1967, 2026–8, 2027 *F*
 contraindications 2026–8
 laryngeal stenosis
 investigations 1151–2
 modified *see* videofluoroscopy
 oesophageal injuries 1771
 corrosive 1291, 1291 *F*
 paediatric imaging 1296
 pharyngeal pouch carcinoma 2048,
 2728
 sensitivity 1770–1
 Barnett v. Chelsea & Kensington
 Hospital (1968) 596–7
 baroreflex, vestibular system 3227–8
 barotitis media *see* middle ear
 barotrauma
 barotrauma *see* otitic barotrauma
 barotraumatic facial palsy 3513–4
 Barrett’s cancer 2067
 Barrett’s oesophagus 2065–6, 2065 *F*
 incidence 2065
 malignant transformation 2065,
 2065 *F*
 management 2065
 barrier membranes, guided tissue
 regeneration 2916, 2916 *F*
 Bartholin’s duct 1808
Bartonella henselae 1784
 basal cell(s)
 cochlea 3186
 olfactory neuroepithelium 1663 *F*
 globose (light) 1662
 horizontal (dark) 1662
 basal cell carcinoma (BCC) 2395–8,
 2396 *F*
 associated syndromes 2396
 genetic predisposition 2395–6
 head and neck 2395–8
 incomplete excision 2397–8
 Moh’s micrographic surgery 1706,
 2397
 nasal 1705–6
 morpheaform 1706, 1706 *F*
 nodular 1706, 1706 *F*, 2396
 pinna reconstruction 3028
 premalignant lesions 2396
 recurrence 2397–8
 risk factors 1705–6, 2395–6, 2396 *T*
 environmental exposure 2396
 skin type 1705–6, 2395–6
 superficial 1706, 2396–7
 treatment 1706, 2397
 destructive 2397
 medical 2397
 surgical 2397
 types 2396–7
 wound healing 92 *F*
 basal ganglia 2158–9
 disorders 3777–8
 base of tongue tumours *see* tongue base
 tumours
 base substitution 9–10, 16
 basilar aneurysms
 cerebellopontine angle lesions
 4014–5
 middle fossa surgery 4024
 basilar artery, aneurysm, CPA
 lesions 4014–5
 basilar membrane 3127, 3128 *F*
 frequency filtering 3189, 3191 *F*
 function 3139–40
 vibration
 amplitude, stimulus intensity
 and 3190–1, 3191 *F*, 3192 *F*
 frequency filtering 3189
 pathological cochlea 3199–200,
 3199 *F*
 basilar migraine 3771
 children 1044
 EEG changes 1044
 family history 1044
 genetic basis 1044
 treatment 1044
 video-nystagmography 1044
 basiocciput 2110, 3899
 basisphenoid 1944, 2110
 juvenile angioma 2443
 basophil(s)
 allergic response 149
 allergic rhinitis 1391
 basophil histamine release test 160
 ‘bat’ ear 970–1, 971 *F*, 973 *F*
 correction 971, 971 *F*
 postoperative haematoma 3033,
 3035 *F*, 3036 *F*
 bathing, otitis externa and 3352
 ‘battery’ (‘resistance modulation’)
 theory 3193–4
 Battle’s sign 3495
Bazooka 68
 B cell(s)
 activated, adaptive immunity
 133
 allergic rhinitis 1389
 antibodies 135–6
 disorders 175 *T*
 receptor 135
 tonsil immune function 1220
 B cell lymphoma
 Epstein-Barr infection 209
 Hashimoto’s thyroiditis and 331–2
 positron emission tomography
 694
 B cell receptor 135
Bcl-2
 apoptosis 56, 58
 salivary gland tumours 2495
 Beahrs’ triangle 2664–5, 2665 *F*
 beat frequency, cilia 1361
 ‘beats’ 3245–6
 beauty, concept of 2944–5
 Bechterew effect 3749
 beclomethasone 420
 allergic rhinitis, children 1401
 frontal sinus inflammation 1508
 bedside swallowing examination (BSE),
 dysphagia 2085
 behavioural audiology
 auditory neuropathy/
 dyssynchrony 3839–40
 central processing disorders 3851
 children 835
 ototoxicity management 3573
 behavioural observation audiology
 (BOA) 835
 Behçet’s syndrome 189, 1831
 clinical features 1831, 1832 *T*
 genetics 1831
 Bekesy-audiometry 3264
 ‘Belfast rules of thumb’ 955
 Bell’s palsy 3883–6
 aetiology 210, 1059, 3885, 3931
 children 1059
 incidence 1052
 diabetes mellitus 401–2
 diagnostic criteria 3883–4
 epidemiology 3885
 facial synkinesis 1845, 3931
 herpes simplex virus 210, 3885
 HIV patients 241
 hyperacusis 3596

Bell's palsy (*continued*)
 imaging 3881–2, 3883 *F*, 4081, 4081 *F*
 middle ear muscle reflexes 3183–4
 prognosis 3885–6
 sudden sensorineural hearing loss 3579
 taste impairment 1845, 3929–30
 treatment 210, 3886
 corticosteroids 424, 3886
 facial nerve decompression 4022
 bell stage, tooth development 1922–4
 bels 3174–5
 belt-type singing style 2212
 bendroflurazide, Menière's disease 3799, 3799 *T*
 Benedikt's syndrome 3921
 beneficence (ethical principle) 562, 582
 beneficence model of healthcare 650
 benign intracranial hypertension *see* otitic hydrocephalus
 benign migratory glossitis 1825–6, 1826 *F*
 benign necrotizing otitis externa 3332–5
 aetiology 3332–3
 clinical features 3333, 3334 *T*
 complications 3334
 definition 3332
 diagnosis 3333–4
 differential diagnosis 3333, 3334 *T*
 examination 3333
 history 3333
 investigations 3334
 management 3334
 natural history 3334
 necrotic bone 3333, 3333 *F*
 outcomes 3334
 pathology 3332
 tympanic membrane perforation 3333
 benign paroxysmal positional vertigo (BPPV) 3760–3, 3767
 aetiology 3760, 3760 *F*, 3772
 anterior semicircular canal (a-BPPV) 3809
 positional manoeuvres 3722
 treatment 3814
 basophilic deposits 3679, 3679 *F*, 3680 *F*
 childhood 1041, 1044
 clinical manifestations 3761
 cochlear implant-related 3654
 complications 3763, 3812
 definition 3760
 diagnosis 3761–2, 3809–10

differential diagnosis 3762
 epidemiology 3760–1
 horizontal semicircular canal (h-BPPV) 3809
 positional manoeuvres 3722
 treatment 3812–4, 3814
 imaging 3809–10
 management 3762–3
 nystagmus 3750, 3761
 otoconia detachment 3678–9
 outcomes 3763, 3812
 positional manoeuvres 3720, 3721 *F*
 posterior semicircular canal (p-BPPV) 3756–7, 3809
 positional manoeuvres 3721 *F*, 3722
 treatment 3810–2
 post-stapedectomy 3476
 post-traumatic 3497
 presentation 3709
 recurrence 3812
 repositioning manoeuvres/exercises 3809–14
 spontaneous resolution 3810
 subjective 3812
 surgery 3812–4
 symptom duration 3706
 vestibular neuritis 3760
 vestibular rehabilitation 3808, 3810–2
 head trauma 3812
 treatment efficacy 3812
 benign paroxysmal trigeminal neuralgia *see* trigeminal neuralgia
 benign skin lesions removal, medical negligence 3090
 Bentham, Jeremy 584
 benzalkonium chloride 429
 benzocaine 448
 benzodiazepine(s)
 acute confusional states 2798
 anxiety, palliative care 2795
 supraglottic obstruction 480
 temporomandibular disorder 3530
 tinnitus 3617
 benzodiazepine withdrawal syndrome 3596
 benzopyrines, salivary glands tumours 2494
 benzydamine
 acute pharyngitis 1984
 mouth ulcers 1830
 benzylpenicillin
 peritonsillar abscess 1997–8
 tonsillitis 1222
 Bernard–Soulier syndrome 288

Bernard–Webster flap 2547, 2547 *F*
 Bernouilli's principle 1145
 Bernoulli effect 2160
 Accent method of speech therapy 2219–20
 Bernoulli's equation 1357
 Berry's ligament division, thyroidectomy 2690, 2690 *F*
 beta-2-transferrin cerebrospinal rhinorrhoea diagnosis 1638
 perilymphatic fistulae 3510
 beta-adrenergic blockers, thyrotoxicosis 347
 pre iodine treatment 348
 β -lactam antibiotics 229 methicillin-resistant *Staphylococcus aureus* 196
 β -lactamases 235
 beta blockers migrainous vertigo 3803–4
 performance anxiety 2212–3
 betahistine contraindications 433
 Menière's disease 3799, 3799 *T*
 vertigo 433
 betamethasone chronic rhinosinusitis 1471
 croup 3165
 betel nut chewing 2560–1, 2560 *F*
 bethanechol radiotherapy-associated xerostomia 1909
 Sjögren syndrome 1912
 Betnovate leprosy 1464
 medical negligence 3831
 bevacizumab 43–4
 Bezold's abscess 922, 922 *F*
 β -haemolysis 197 *F*
 β -haemolytic streptococci 197
 bias critical appraisal 652, 659
 epidemiological research 624–5
 outcomes research 637
 bicellular reserve cell theory, salivary gland tumours 2503
 Bickerstaff's 'brainstem encephalitis' 3778
 bicoronal skin flap 2433 *F*
 bifid epiglottis 1137
 bilabial consonants 2166–7, 2167 *T*
 bilateral vestibular failure (BVF), vestibular rehabilitation 3808–9

- bilateral vestibulopathy 3764–6, 3767
 aetiology 3764
 children 1046
 clinical manifestations 3764–6
 complications 3766
 definition 3764
 diagnosis 3766
 differential diagnosis 3766
 management 3766
 outcomes 3766
- bile reflux
 gastric resection 2064
 measurement 2063, 2063 *F*
- bilirubin, auditory neuropathy/
 dyssynchrony 3845
- Bilitec probe, gastro-oesophageal
 reflux 2063
- Bill's bar 3120
- bilobed flap 2840, 2843
 nasal reconstruction 3019
- binary data, systematic reviews 663
- binaural interaction tests 3858–9
- Binder's syndrome 1713
- Bing test 3318–9
- bioactive glass
 bone repair 123, 124 *T*
 melt-derived 123
 sol-gel-derived 123–4
 tissue scaffolds 122 *F*, 123–4
- biofeedback (BF)
 dysphagia 2088
 tinnitus 3616
- biofilm
 chronic otitis media, childhood 931–2
 coagulase-negative staphylococci 196
 definition 1095
 otitis media with effusion 1095
- Bioglass 120, 123
- biomaterials 118–30
 bioactive 119
 biocompatibility 119–22
 definition 119
 bioinert 119
 biotolerant 119
 ceramics *see* ceramic biomaterials
 classification 119
 definition 118
 historical aspects 118
 immune responses 119
 metals *see* metal biomaterials
 polymers *see* polymers
 reconstructive middle ear surgery 118
 vascular surgery 121
- biomedical approach, medical
 consultations 559–60
- bioplastique 2240
Biopolaris 217, 221
- biopsy
 chronic laryngitis 2260
 epistaxis, children 1065
 facial nerve tumours 4081
 fungal rhinosinusitis 218
 head and neck tumours 1931
 children 1252–3
 laryngeal tumours 2608
 metastatic neck disease 2722
 nasal endoscopy 1350–1
 numbers required for diagnosis 755
 odontogenic keratocysts 1925
 olfactory dysfunction 1665
 oropharyngeal tumours 2584
 parathyroidectomy 393
 salivary gland tumours 2506
 sinonasal malignancy 2426
 temporal bone squamous cell
 carcinoma 4089
 tonsil 1238, 1989
 tuberculous otitis 3449
see also individual types
- bioreductive drugs 50–1
 antivascular effects 51
 efficiency 50
 tumour hypoxia 50
see also individual drugs
- Bipolaris* 1452–3
- Birbeck's granules 4075
- birch rhinitis 1428
- birefringence, polarization-sensitive
 OCT 756, 758
- bisphosphonates
 bone pain, head and neck cancer 2784
 hypercalcaemia 2794
 Paget's disease 3489
see also specific drugs
- bisyllabic words, speech
 audiotometry 3270, 3272
- bitemporal hemianopia, optic chiasm
 lesions 3915
- bitemporal superior quadrantanopia,
 pituitary tumours 312
- bites, traumatic ear loss 3028, 3030 *F*
- Bivona tubes 1199, 1201, 1201 *F*
- 'Black Book,' noise-induced hearing
 loss 3553
- black hairy tongue 1825
- blade implants 2904, 2905 *F*
- Blair, Vilray 2944
- Bland, Tony 588
- blastocyst 68–9
- Blastomyces dermatitidis* 2268
- blastomycosis 2268
- bleeding *see* haemorrhage
- bleeding disorders 280–8, 281 *T*
 assessment 280–1
 bleeding patterns 281
 drug history 281
 timing 280
 diagnostic tests 281–2
- inheritance patterns 280
- management algorithm 282 *F*
- spontaneous bleeding 280
- bleomycin 38
- blepharochalasis 3052
- blepharoplasty 3048–67
 applied anatomy 3048–53
 complications 3064–6, 3095
 cosmetic use 3064
 lower eyelid 3057–64
 examination 3058
 eyelid laxity assessment 3058
 history taking 3058
 preoperative evaluation 3058
 surgical approaches 3058–64
 surgical technique 3058–64
 medical negligence 3095–6
 medicolegal pitfalls 3066
 photographs, preoperative 3055
 postoperative care 3064
 postoperative haematoma 3095
 preoperative assessment 3095
 scar placement 3095–6
 suture removal 3064
 upper eyelid 3053–7, 3059 *F*
 anaesthesia 3057
 examination 3055–6
 eyelid laxity assessment 3055
 history taking 3054–5
 patient expectations 3055
 preoperative evaluation
 3054–6
 skin closure 3057
 skin crease marking 3056–7,
 3057 *F*
 surgical procedure 3057
 surgical technique 3056–7
 wound closure 3060
- blepharoptosis 3053, 3066
- blind eye
 consensual light reflex 3916
 direct light reaction 3916
- blinding, epidemiological research 621,
 629
- blindness
 embolic agents 3953
 post-blepharoplasty 3064–5

- blindness (*continued*)
 syndromic craniosynostosis
 surgery 1031
 Wegener's granulomatosis 1650
- blisters
 gingival 1819
 oral mucosa *see* oral mucosa
- 'blobogram' (Forrest plot) 664, 664 *F*
- Blom–Singer valve 2625, 2626 *F*, 2627
- blood
 investigations 267
 physiology 265
- blood-brain barrier
 antihistamines 1397–8
 antimicrobial agents 228–9
- blood cells
 formation 265–6
 red *see* red cell(s)
 white *see* white blood cells (WBC)
- blood components 255–60, 256 *F*, 258 *T*
 bacterial infection transmission
 prevention 260
 leukodepletion 260
see also individual components
- blood donation 260
 aseptic technique 260
 Creutzfeldt–Jacob disease 260
 grouping 260
 infection testing 260, 260 *T*, 284
 inherited platelet disorders 288
- blood flow 111–2
 critical closing pressure 112
 Doppler ultrasound *see* Doppler
 ultrasound
 humoral factors 112
 hyperthermia 112
 hypothermia 112
 laminar flow 111
 red blood cell orientation 112
 vasoconstriction 112
 vessel diameter 111
 vessel wall tension 112
 viscosity 112
- blood gas analysis, stridor 1119
- blood groups 253–5
ABO *see* ABO blood groups
 crossmatch 254
 elective surgery 255
 emergency surgery 255, 256 *F*
 plasma incubation 254
- Kell antigens 260
- red cell antibodies 254
- Rh *see* Rhesus (Rh) blood group
- screening *see* group and screen (G&S)
 test
- blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging 675
- contrast generation 678
- haemodynamic change
 mechanisms 677, 677 *F*
- magnetic flux 678
- neuronal activation and
 haemodynamic changes 677
- physiological basis 677–8
- blood pressure
 anaesthesia monitoring 497–8
 paediatric parameters 543 *T*
 sleep-disordered breathing 1103
- blood tests, deaf child 852
- blood transfusion 253–64
 adverse reactions *see* transfusion
 reactions
 alternatives 262–4
 autologous 262–3
 acute normovolaemic haemodilution 263
 cell salvage 263
 preoperative autologous deposit 262–3
- colloids 257
- critical care 535
- crystalloids 257
- fluid overload 262
- immunomodulatory effects 262
- massive 284
- maximum surgical blood ordering schedule 255, 255 *T*
- refusal, Jehovah's Witnesses 583, 586
- sickle cell disease 271
- sinus surgery 257
- syndromic craniosynostosis
 surgery 1030–1
- β thalassaemia 271–2
- blood vessels
 flow dynamics *see* blood flow
 formation *see* angiogenesis
 haemostasis 278
- 'blue mantle,' otosclerosis 3454–5
- Bluetooth-enabled hearing aids 3669
- blunt trauma, larynx 2272
- B lymphocytes *see* B cell(s)
- body image, post-laryngectomy 2624, 2630
- body motion sensing, neonatal hearing screening 3290
- body temperature
 anaesthesia monitoring 498
 children 512–3
- auditory nerve and brainstem evoked potentials 3285
- Boerhaave's syndrome 2070–1
- boils, nasal vestibule 1700
- Bolam test 596, 600, 2805
- Bolam v. Friern Hospital Management Committee (1957) 596, 2805
- BOLD fMRI *see* blood oxygenation level-dependent (BOLD)
 functional magnetic resonance imaging
- Bolitho v. City and Hackney Health Authority (1997) 596, 2805–6
- bolus control exercises 2089, 2089 *T*
- bolus escape 1975
- bolus formation 1954–7
- bolus grafting 2824
- bolus propulsion exercises 2089 *T*
- bone(s)
 hyperbaric oxygen, effects on 2911
- Paget's disease 3487
- resorption
 1,25-dihydroxyvitamin D₃ 375
 implant placement 2915
 meningiomas 4008
 parathyroid hormone 374
 vestibular schwannoma 3957–8
- skin grafts 2821
- tissue engineering 124
- tissue scaffolds 124
see also individual bones
- bone-anchored hearing aid (BAHA) 3642–8, 3640–1
- active chronic otitis media 3435
- advantages/disadvantages 3643 *T*
- audiological evaluation 985–6
- children 854, 854 *F*, 985–6
 age at implantation 985
 audiological criteria 985
 otological criteria 985
 patient selection 985
 surgery 985
- complications 3644
- components 3642 *F*, 3643 *F*
- congenital atresia 981–2
- congenital ossicular abnormalities 871
- definition 3642
- eligibility 3643–4
- indications 3642–3
- otitis externa 3354, 3643
- otosclerosis 3467
- outcomes 3644–7
- conductive impairment 3644–6, 3646
- generic 3646–7

- mixed impairment 3646
other aids *vs.* 3643 *T*, 3644–6, 3644, 3646
other otological procedures
vs. 3647
sensorineural impairment 3646
total impairment 3646
surgical technique 3644, 3645 *F*
vestibular schwannoma removal 3984
bone-anchored prosthesis, pinna
reconstruction 3044, 3045 *F*
bone collecting devices 2920, 2920 *F*
bone-conduction (BC) hearing
aids 3640–1
bone-anchored hearing aid *vs.* 3643 *T*, 3644
otitis media with effusion, childhood 903
bone conduction pure-tone
audiometry 3262
otitis media with effusion 889
bone distraction, implant
placement 2919, 2919 *F*
bone grafts
augmentation rhinoplasty 2972, 2973
implant placement 2917–8
bone graft substitutes 2917
bone marrow
antimicrobial-induced suppression 236
haemopoietic stem cells 72
lymphocyte development 133
mesenchymal stem cells 72
multipotent cell populations 72
neural regulation 70
bone marrow transplantation (BMT) 275
infection risk 275
bone morphogenic proteins (BMP)
stem cells 67, 70, 74
synthetic 2917
bone pain, cancer patients 2784
bone pins, intermaxillary 1623
bone repair 94
bioactive glasses 123, 124 *T*
hydroxycarbonate apatite 123
metal plates 119
remodelling 94
tissue engineering 124, 125 *F*
bone tumours, pituitary region 4104
bony labyrinth, development 3123, 3124 *T*
bony labyrinthectomy, vestibular schwannoma 3970, 3970 *F*
bony palate 1341 *F*
- bony pyramid, nose 2960–1
deviated nose 2990
external rhinoplasty 2963–4
border cells 3130, 3136
borderline leprosy, nasal 1464
Bordetella bronchiseptica 1465
Bordetella pertussis 200, 2252
boric acid
otitis externa 430
otomycosis 214
boron neutron capture therapy 2410
Borrelia 202
see also individual organisms
Borrelia burgdorferi 202
Borrelia vincentii 202
acute necrotizing ulcerative gingivitis 1819
bortezomib (Velcade) 44
Bosker implants 2904, 2905 *F*
bossa formation
medical negligence 3092
post-nasal tip surgery 3004
botryoid odontogenic cyst 1925
botulinum toxin
arytenoid granuloma 2197
blepharoplasty 3058
contraindications 449–50
cricopharyngeal muscle spasm 2098
drooling 789
frontalis 3078
granulomas 2238
hemifacial spasm, benign 3931
laryngeal dystonia 449
lower lip depressor weakness 3084
nonallergic rhinitis 1412
spasmodic dysphonia 641, 2203, 2224
spasmodic dystonia 449–50
vocal fold injection 2240
voice disorders 2195
botulism, dysphagia 2079
Boveri, Theodore 6
bovine spongiform encephalopathy (BSE) 1990
Bowen's disease 1705
'bow-hunter' syndrome
diagnosis 3769
management 3770
provoked vertigo 3767
stroke aetiology 3768, 3768 *F*
Bowman's glands 1662
Boyle-Davis gag 501, 501 *F*
Boyle's law 3500, 3501 *T*
brachiocephalic artery *see* innominate artery
brachycephaly 1022 *T*, 1025
- brachytherapy
lip cancer 2548
tongue cancer 2553–4, 2557
bracketing method, pure-tone audiometry 3263–4
bradykinin 89
brain-derived neurotrophic factor (BDNF) 3302
brainstem
hearing loss 3846–9
swallowing control 1959
vestibular schwannoma
compression 3958–9, 3958 *F*
symptoms 3959
brainstem haemorrhage
clinical manifestations 3769
management 3770
stroke aetiology 3768
brainstem infarction
clinical manifestations 3768–9
management 3770
stroke aetiology 3767
brainstem lesions
facial nerve damage 3930
Horner's syndrome 3937
taste abnormalities 1847
vestibular schwannoma
removal 3978–9
brainstem neuropathy, auditory
neuropathy/dyssynchrony *vs.* 3851
branchial abnormalities 1779–82
branchial apparatus, development 813–4, 814 *F*, 1779 *F*
branchial arch(es) 795–6, 1264, 1942
derivatives 795 *F*, 796 *T*, 1740 *T*, 1943 *F*, 1943 *T*
embryology 795–6, 813–4, 1264
fifth 1740, 1740 *T*
first 795, 796 *T*, 1739, 1740 *T*, 1943 *T*
ear development 3121–2, 3121 *T*
fistulae *see* first branchial arch
fistula
formation failures 3122
fourth 795–6, 796 *T*, 1740, 1740 *T*, 1943 *T*
abnormalities 1267–8, 1267 *F*, 1779, 1780 *F*
innervation 1942–3
mesoderm 2130
preauricular sinus *see* preauricular sinus
second 795, 796 *T*, 1739–40, 1740 *T*, 1943 *T*
ear development 3121–2, 3121 *T*

branchial arch(es) (*continued*)
 fistulae *see* second branchial arch
 fistula
 formation failures 3122
 sixth 795–6, 796 *T*, 1740, 1740 *T*,
 1943 *T*
 terminology 1264
 third 795, 796 *T*, 1267 *F*, 1740, 1740 *T*,
 1943 *T*
 abnormalities 1267–8, 1779
 branchial clefts 797, 814, 1942
 branchial cysts 798 *F*, 1758, 1759 *F*,
 1779–82, 1942–3
 differential diagnosis 1781
 management 1781
 nasopharyngeal 2119
 origin, theories of 1780–1
 otitis media with effusion 3389
 presentation 1781
 salivary glands 1882, 1883 *F*
 surgical removal 1781
 ultrasound examination 724, 725 *F*
 branchial fistulae 1264–71, 1779–80
 embryology 797, 1779
 first arch *see* first branchial arch fistula
 fourth arch 1779, 1780 *F*
 management 1779–80
 presentation 1779
 second arch *see* second branchial arch
 fistula
 surgery 1779–80, 1780 *F*
 third 1779
 branchial pouches 1741 *T*
 development 813–4
 lateral cervical cysts 1780
 bronchiogenic carcinoma 1781–2, 2728
 branchio-oto-renal syndrome 813 *T*,
 968, 1267
 Brandt-Daroff positional exercises 3810
 BrdUrd 50
 breaking bad news 554 *T*, 565, 2782–3,
 2783 *T*
 children 780
 WARN, PAUSE, CHECK (WPC) 2782
 breakpoint method, antimicrobial
 sensitivity testing 234, 235 *F*
 breast cancer
 Halstedian concept of treatment 2717
 pituitary involvement 4104
 breastfeeding
 allergic rhinitis 1396
 food allergy prevention 1426
 post-partum thyroiditis 359
 breathing, neck trauma and 1767
 breathing systems, paediatric 510

Bristol Royal Infirmary Inquiry 594
 British Association for Paediatric
 Otolaryngology (BAPO) 773,
 773 *F*
 British Association of Day Surgery
 (BADS), head and neck procedure
 recommendations 458
 British Association of Head and Neck
 Oncologists (BAHNO)
 comparative audit 2376
 data collection coordination 2375
 National Cancer Data Set 2376
 British Association of Otolaryngologists
 Head and Neck Surgeons
 (BAO-HNS), tonsillectomy
 guidelines 1231
 British Association of
 Otorhinolaryngologists
 (BAO-HNS), clinical governance
 guidance 574–5
 British Committee for Safety in
 Haematology guidelines
 2001 256–7
 blood loss estimation 256–7
 haemoglobin concentration
 estimations 257
 British Committee for Standards in
 Haematology splenectomy
 guidelines 276
 British National Study of Hearing,
 otosclerosis prevalence 3460,
 3460 *T*
 British sign language (BSL) 566
 broad nasal tip 3004
 bromhexine 1912
 bromocriptine 309
 bronchi
 anatomy 2140–4
 anomalous bifurcations 1147
 blood supply 2142
 circular muscle fibres 2142
 congenital disorders 1142–7
 cysts 1782
 congenital 1147
 development 2131
 foreign bodies 1188
 inflammation
 rhinitis 1562–4, 1563
 viral nasal infections 1563
 juvenile-onset recurrent respiratory
 papillomatosis 1179, 1180 *F*
 lymphatic drainage 2142
 main, right 2140 *F*, 2141
 mucous membrane 2142
 obstruction 478
 remodelling, rhinitis 1562
 segmental 2141
 small 2142
 structure 2141–2
 venous drainage 2142
 bronchial agenesis 1142
 bronchial arteries 2142
 bronchial challenge, rhinitis 1563
 bronchial hyperreactivity, rhinitis 1561
 bronchial stenosis 1142–4
 bronchial veins 2142
 bronchiolitis 205 *T*
 bronchitis, viral agents 205 *T*
 bronchoalveolar lavage
 aspiration evaluation, laryngeal
 stenosis 1154
 PICU 547
 bronchogenic carcinoma 685 *F*
 bronchogenic cysts 1147
 bronchography
 children 1296–7, 1298 *F*
 stridor 1119
 tracheal stenosis 1143, 1143 *F*
 bronchomalacia 1144–5
 bronchopulmonary lymph nodes 2142
 bronchopulmonary segments 2141
 bronchoscopy
 anaesthesia 503–4, 1152–3
 children 518–9
 flexible *see* flexible bronchoscopy
 laryngeal stenosis evaluation 1152–3,
 1153
 paediatric anaesthesia 519
 paediatric intensive care 547
 stridor 1122–3
 tracheomalacia 1122–3, 1145, 1145 *F*
 bronchus *see* bronchi
 brown hairy tongue 1825, 1825 *F*
 ‘brown tumours’ (osteitis fibrosa
 cystica) 390, 401
 brow ptosis 3049 *F*, 3054 *F*
 bilateral 3055–6, 3056 *F*
 surgical approaches 3055
 brucellosis 1216, 1784
 Brun’s nystagmus 3712–3, 3713 *F*
 Bryce’s sign 2255
 bubbles, decompression illness 3514–5
 buccal artery 1798
 buccal carcinoma 2560–1
 epidemiology 2560–1
 investigations 2561
 precancerous lesions 2560–1
 presentation 2560–1, 2560 *F*
 survival rates 2561 *T*
 treatment 2561

- buccal gland 1808
 buccal hemi-neglect syndrome 1847
 buccal–lingual–masticatory syndrome 3939
 buccal mucosa 1792–3
 reconstruction, forearm flap 2561, 2561 *F*, 2871
 buccal nerve 1795 *F*, 1800, 1801 *F*, 3907, 3925
 buccal space 1806
 buccal vein 1799
 buccinator muscle 1795, 1795 *F*, 2108–9
 innervation 1795, 1803
 bucconasal membrane 1315
 buccopharyngeal fascia 1947, 2108
 buccopharyngeal membrane 3120–1
 ‘bucket handle’ advancement flap 2821 *F*
 budesonide
 acute airway obstruction 1123
 allergic rhinitis, children 1401
 chronic rhinosinusitis 1470
 croup 1128–9
 nasal polyposis 1554 *F*, 1555 *F*
 nonallergic rhinitis 1412
 persistent rhinosinusitis 437
 bulbar palsy 3939
 differential diagnosis 3939
 dysphagia 2033
 motor neurone disease 2079–80
 signs/symptoms 3939
 speech 3939
 bulbar poliomyelitis 2078–9
 bulimia nervosa, salivary gland in 1908
 bulla ethmoidalis *see* ethmoidal bulla
 bulla frontalis (frontal cells) 1333, 1500, 1501 *F*
 Bullard fibrescope 473
 bullous myringitis 3326–7
 aetiology 3326
 definition 3326
 diagnosis 3326–7
 investigations 3327
 management 3327
 outcomes 3327
 pain 3326, 3527
 pathology 3326
 signs 3326
 symptoms 3326
 bullous pemphigoid 171
 Burkitt’s lymphoma 208, 1254
 burn(s)
 classification 96
 dressings 102
 first degree 96
 grafting techniques 96
 oral white lesions 1836
 pinna reconstruction 3032–3, 3033 *F*
 second degree 96
 third degree 96
 tissue engineering 94
 treatment 102
 burning mouth syndrome (BMS) 1829, 1829 *T*, 1848–9
 Burow’s triangle 2832, 2833 *F*
 bursa pharyngeal embryonalis (Thornwaldt’s bursa) 2122
 bursa pharyngeal embryonalis (Thornwaldt’s) cyst 1074, 2122
 Buscopan *see* hyoscine
 bushy cells 3140–1, 3142 *F*
 button batteries (as foreign bodies)
 ears 1185, 3371
 medical negligence 1310
 button therapy 2893
 bystander effect 28
 C1 esterase inhibitor deficiency *see* hereditary angio-oedema (HANE)
 C1q deficiency 178, 179 *T*
 C1r deficiency 178, 179 *T*
 C2 deficiency 178, 179 *T*
 C3 139
 deficiency 179
 C3 convertase 139
 C4 deficiency 178, 179 *T*
 C5 139
 cabergoline 309
 cacosmia (dysosmia) 1664, 1666–7
 cadaverine, malodorous malignant ulcers 2792
 cadaver tracheal homograft, tracheal stenosis 1144
 CADCAM models, implant osseointegration 2911–2
 cadherins 2384
Caenorhabditis elegans 56
 caffeine, migrainous vertigo 3801
 calcifediol 451
 calcification
 costal cartilage 3044–5
 lymph nodes 717
 meningiomas 4009
 vestibular schwannoma 3959–60
 calcifying epithelial odontogenic tumour, jaw 1928
 calcifying odontogenic cysts 1925–6
 calcimimetic drugs 393
 calcitonin 375, 388, 3489
 function 324
 half-life 388
 secretion 327, 375, 388
 calcitonin gene related peptide (CGRP) 388, 3238
 calcium
 biochemical analysis 379–80
 interpretation 380, 380 *T*
 methodology 379–80
 homeostasis 373, 375
 diurnal variation 380
 endocrinology 375 *F*
 parathyroid function and 379
 vitamin D role 451, 451 *F*
 intestinal transport 374
 metabolism 388
 reabsorption 374
 renal excretion 388
 salivary secretion 1860
 supplementation, post-parathyroidectomy 395
see also hypercalcaemia; hypocalcaemia
 calcium channel blockers
 migrainous vertigo 3804
 tinnitus 3617
 vestibular attacks, acute 3797
 calcium channel dysfunction
 outer hair cells 3605
 tinnitus 3605
 calcium sensing receptor (CaR) 388, 389
 calculi, salivary glands *see* sialolithiasis
 Caldwell–Luc procedure 1493–4
 anaesthesia 1493
 complications 1494
 contraindications 1493
 indications 1493
 medical negligence 1733
 modified 2917
 technique 1494, 1494 *F*
 callus formation, bone repair 94
 Calman–Hine Report (1995) 576
 Calman Report, surgical training 553
 caloric test 3154–5, 3241, 3727–9
 astronauts 3154
 canal paresis, unilateral 3727, 3728 *F*
 chronic otitis media 3419
 external auditory canal irrigation methods 3727
 labyrinthine stimulation 3750–1
 perverted nystagmus 3729
 posturography *vs.* 3733

caloric test (*continued*)
 response
 abnormalities 3727, 3727 *T*,
 3728 *F*
 mechanisms 3727
 skull base lesions 3946
 vestibular neuritis 3752, 3756 *F*
 vestibular schwannoma 3959
 VOR suppression 3728
 caloric vertigo 3506–11
 mild hearing loss 3509–10
 minimal hearing loss 3509
 moderate to severe hearing loss 3509
 calretinin 3237
 calvarial bone, augmentation
 rhinoplasty 2972
 camouflage technique, deviated
 nose 2989
 camptothecin 39
 Canadian beaver (*Castor Canadensis*),
 nasal cavity 1322 *F*
 canaliculodacryocystorhinostomy 1696
 canalis sinosus 1341, 1798
 ‘canalith jam’ 3812
 canalith repositioning procedure
 (CRP) 3810–2
 complications 3812
 gait instability, post treatment 3812
 outcomes 3812
 canal of Huguier 3110
 canalolithiasis 3678–80, 3760, 3761 *F*
 canalplasty, keratosis obturans 3344
 canal wall down mastoidectomy
 cholesteatoma 3432–3
 intact canal wall mastoidectomy
vs. 3433
 recurrence rates 3433
 labyrinthine fistulae 3437
 cancer
 apoptosis 62–3, 63 *T*
 outcomes 63
 apoptotic index 62–3
 head and neck *see* head and neck
 cancer
 prevention *see* cancer prevention
 ‘somatic mutation theory’ 2354
 stem cell theory of 69–70
see also individual types
 cancer antigen 15-3 (CA15-3) 1867
 cancer care
 multidisciplinary teamworking 576,
 576–7
 outcomes research 641
 standards 575
see also clinical governance

cancer data *see* data collection, head
 and neck cancer
 cancer pain 2783–8
 management 2782, 2785
 analgesics 2783, 2785
 WHO analgesic ladder 2785
see also specific drugs
 ‘total pain’ concept 2783
 types 2784–5, 2784 *T*
 cancer prevention 2345–6
 primary (risk avoidance) 2345
 secondary (screening) 2345
 benchmark 2345–6
 false positive tests 2345
 predictive value 2345, 2346 *T*
 cancer registration 2373
 cancrum oris (noma) 1822
Candida
 antifungal resistant 233
 cervicofacial infections, children 1216
 denture-related stomatitis 1826
 otomycosis 213
see also individual species
Candida albicans 223
 oral infection 1836
 otomycosis 213
 tracheo-oesophageal voice
 protheses 225
 xerostomia 1867
 candida-associated denture stomatitis
see denture-related stomatitis
Candida glabrata 223
 tracheo-oesophageal voice
 protheses 225
Candida krusei 223
 HIV associated infection 1826
 tracheo-oesophageal voice
 protheses 225
 candidal leukoplakia *see* candidiasis,
 hyperplastic
Candida parapsilosis 223
 otomycosis 213
Candida tropicalis 223
 otomycosis 213
 tracheo-oesophageal voice
 protheses 225
 candidiasis 223–5
 aetiology 223
 chronic atrophic *see* denture-related
 stomatitis
 chronic mucocutaneous 180 *T*, 181
 classification 223
 clinical manifestations 223–4
 complications 224–5
 definition 223
 diagnosis 224
 dysphagia 2031
 epidemiology 223
 gingival white patches 1820
 head and neck cancer, palliative
 care 2789
 HIV-associated infection 223, 2013
 oesophageal 244
 oral 242, 244 *T*
 treatment 224, 242
 hyperplastic 224
 advanced head and neck
 cancer 2789
 malignant transformation 224
 immunocompromised patients 223
 laryngeal *see* laryngeal candidiasis
 management 224
 oesophageal
 barium swallow appearance 2027 *F*
 HIV patients 243–4, 244–5
 symptoms 244–5
 oral 1836, 1837 *F*
 acute 1826
 acute pharyngitis 1983
 chronic 1836–7
 HIV-associated infection 242,
 244 *T*
 mouth ulcers 1833
 mucosal redness 1822, 1826
 types 1837 *T*
 white lesions 1836–7
 oropharyngeal 223–5
 outcomes 224–5
 pharyngeal 2011
 predisposing factors 2011 *T*
 pseudomembranous 223
 HIV patients 244 *T*
 treatment 224
 throat 223–5
 treatment 2011
 canine fossa 1340
 canines 1803
 deciduous 1804–5
 permanent 1803
 roots 1803
 caniniform teeth *see* canines
 canker sores *see* recurrent aphthous
 stomatitis (RAS)
 cannabis smoking, head and neck
 squamous cell carcinoma 2351–2
 Cannon’s disease (white-sponge
 naevus) 1824
 canonical bubbling phase, speech/
 language development 990–1
 canthal (palpebral) ligaments 1679

- CAPE V scheme 2175, 2175 *T*
 capillary bleeding, hypotensive anaesthesia 502
 capillary ectasias, vocal folds 2203
 capillary haemangiomas, nasal 1708
 capillary lymphangioma 1782
 capnograms 498, 499 *F*
 CAP RAST testing 1394–5
 capsaicin 148
 nonallergic noninfectious perennial rhinitis 1409
 capsogugine 1455
 capsulotomy techniques, tonsillectomy 1235
 capular flap 2873–6
 carbachol 1365
 carbamazepine
 glossopharyngeal neuralgia 2081, 3531–2
 hemifacial spasm, benign 3931
 tinnitus 3617
 trigeminal neuralgia 1830
 carbapenems 230
 carbimazole
 goitre aetiology 2668
 hypothyroidism 450
 mechanism of action 346
 side effects 346
 thyrotoxicosis 346
 carbogen 50
 carbon dioxide (CO₂) laser 743
 blepharoplasty 3058, 3059 *F*
 juvenile-onset recurrent respiratory papillomatosis 1176–7
 laryngeal stenosis 2278
 papillomas 2238
 pharyngeal pouch 2054, 2058, 2058 *T*
 Reinke's oedema 2265
 subglottic haemangioma 1140
 tympanic membrane fenestration, otitis media with effusion 3392–3
 carboplatin 37
 carcinoembryonic antigen 2495–6
 carcinogenesis, apoptosis and 62
 carcinogens, nasal malignancy 2418
 carcinoma, primary 2702
 carcinoma(s)
 acinic cell 2497
 ameloblastic 1938
 antral 3927
 branchiogenic 1781–2, 2728
 bronchogenic 685 *F*
 buccal *see* buccal carcinoma
 hard palate *see* hard palate carcinoma
 nasopharyngeal *see* nasopharyngeal carcinoma (NPC)
 oesophageal *see* oesophageal carcinoma
 parotid gland 723
 taste abnormalities 1845
 thyroid *see* thyroid cancer
 carcinoma ex pleomorphic adenoma, salivary glands 2500–1, 2502
 carcinoma *in situ*, larynx 2609, 2609 *F*
 cardiac dysrhythmia
 blepharoplasty complications 3065
 skull base surgery 4137
 cardiac index monitoring 529
 cardiac output, anaesthetic monitoring 500
 cardiac risk, clinical predictors 459 *T*
 cardiogenic embolism 3767
 cardiolipin antibodies 171
 cardiomyotomy, achalasia 1290
 cardiopulmonary resuscitation (CPR), palliative care patients 2798, 2799 *T*
 cardiospasm *see* achalasia
 cardiovascular disease
 obstructive sleep apnoea 2314
 patient preparation, surgery 458–60
 cardiovascular support, critical care patients 528–30
 children 543
 cardiovascular syncope 3732
 CaR gene 389
 mutations 389
 Carhart effect 3461
 Carhart notch 3185
 otosclerosis 3461–3, 3462 *F*
 mixed hearing impairment 3462–3, 3463 *F*
 sensorineural hearing impairment 3462–3, 3464 *F*
 total hearing impairment 3462–3, 3464 *F*
 carina 2140
 Carlson-Crittenden device, saliva collection 1862–3
 Carnegie stages, head and neck embryology 793 *T*
 carotiocavernous fistula, acute 3916
 carotid artery
 aneurysmal dilation 3927
 in cavernous sinus 299
 hypophysectomy and 4108
 injury, surgery-induced 2743, 2743–4
 permanent balloon occlusion, jugular foramen tumours 4035
 surface anatomy 1741
 carotid artery aneurysm, endovascular embolization 739
 carotid artery replacement 2727
 carotid artery resection
 head and neck cancer 696
 metastatic neck disease 2727
 salivary gland tumours 2514–5
 carotid artery stenosis, diagnostic delay 4144–5
 carotid body paragangliomas 2526, 2531 *F*
 imaging 725–6, 726 *F*, 2529–30
 management 2532
 surgical treatment 2532
 carotid canal 3116
 carotid plexus lesions, Horner's syndrome 3937
 carotid sheath 1743, 1757, 2110
 contents 2110 *T*
 parapharyngeal abscess 2000
 skull base 3901–3
 carotid space *see* carotid sheath
 carotid triangle, neck 1742
 caroverine 3618
 carpal tunnel syndrome 355
 Carpenter syndrome 1028
 'carpet tack' sign 1711–2
 Carpue, Joseph 110
 cartilage repair, tissue engineering 125
 cartilago triticea 2133–4
 case-control studies
 epidemiological research 627–8, 2344
 evidence-based medicine 655
 caspase(s) 57, 2383
 activation pathways 57
 caspase 3 57, 58
 caspase 8 57–8
 caspase 9 58
 caspase-activated DNase 58
 caspase inhibitors 3302
Castor Canadensis (Canadian beaver), nasal cavity 1322 *F*
 cat allergen avoidance 1397
 cataracts, neurofibromatosis 2 4000
 CATCH-22 180–1
 catch up saccades, unidirectional 3713
 catecholamine metabolite assessment, glomus tumours 4028
 beta-catenin mutations, juvenile angiofibroma 2438
 cathepsin-D 2637

- catheter angiography
skull base surgery 3949–51
indications 3949–50
risks 3951
stroke risk 3951
- catheters, endovascular 732–3
- cat scratch disease 1216, 1701, 1784
- cauliflower ear deformity 3373
- causality 2343–4
- caustic soda ingestion 1290
- caustic stricture, dysphagia 2034
- cautery, epistaxis 1065 *F*, 1066
- cavernous haemangioma
nasal neoplasms 1708
painful red eye 3916
- cavernous lymphangioma 1782
- cavernous sinus(es) 299, 3918 *F*
blood supply 299, 303
corrosion casts 299
drainage 299
magnetic resonance imaging 306
nervous relations 299
pituitary tumour extension 4100
hypophysectomy and 4110
sampling, Cushing's disease 4102
size 299
tumours 2426 *F*
- cavernous sinus syndrome 4027–8
- cavernous sinus thrombosis 1088
orbital 1540
symptoms 1540–2
treatment 1544
- Cavilon 100
- cavity wounds 101
- cavum conchae 3105–6
- Cawthorne–Cooksey exercises,
vestibular rehabilitation 3806,
3806 *T*
efficacy 3807
historical aspects 3805
- C cells *see* parafollicular (C) cells,
thyroid gland
- ced genes 56
- cefotaxime 230
- cefradine 230
- ceftazidime, malignant otitis
externa 3339
- ceftriaxone 230, 2008
- cell adhesion molecules *see* adhesion
molecules
- cell biology, molecular aberrations
8–10
- cell cycle 34–5, 35 *F*, 2380–1, 2381 *F*
apoptosis 58
arrest 10, 58
- DNA damage 58
p53 58
- control 2382
p53 role 2382, 2382 *F*
- growth phase (G1) 35, 35 *F*, 2381
- growth phase 2 (G2) 35, 35 *F*, 2381
- interphase 2381
- mitosis 35, 35 *F*, 2381
- restriction points/check points 58
- synthesis phase (S) 35, 35 *F*, 2381
- tumour biology 34–5
- cell cycle-nonspecific chemotherapy 37
- cell cycle-specific chemotherapy 37
- cell death 56–65
apoptosis *see* apoptosis
cell population regulation 57
mechanisms 36
necrosis *see* necrosis
ototoxicity 3300–1, 3301 *F*
prevention 3302
radiation-induced 47
types 57
- cell differentiation 16
ear development 815
- cell division, anticancer drugs 34
- cell-mediated drug reactions 414
- cell-mediated immunity (CMI),
nasopharyngeal carcinoma 2448
- cell membrane, apoptosis and 59–60
- cell migration, wound healing 89, 90
- cell receptors 2383–4
- cell salvage, autologous blood
transfusion 263
- cell senescence 10
- cell signalling 36
growth factors 36
transcription factors 36
- cell survival curves, radiotherapy 48
- cellular radiosensitivity 47–8
acute effects 47–8
late effects 47–8
- cellulitis
nasal infection 1700
orbital *see* orbital cellulitis,
rhinosinusitis complication
- perichondritis aetiology 3358
- peri-orbital 1087–8
- cemento-osseous dysplasia 1930
- Center for Epidemiologic Studies—
Depression scale, cochlear
implants assessment 3654–5
- central apnoea 492
- central auditory dysfunction
3857–69
aetiology 3858
- auditory brainstem responses 3860–1,
3861 *F*
- auditory evoked potentials 3862
- auditory hallucinations 3863–4
- auditory steady-state response 3860
- behavioural tests 3858–60
- central deafness 3863
- children, management 3864–6
- compressed speech test 3860
- definition 3857–8
- dichotic digit test 3859–60, 3859 *F*
- dichotic speech tests 3862
- electrophysiologic tests 3860–2
- frequency pattern sequences 3859
- interhemispheric lesions 3862–3
- masking level difference test 3860
- middle latency response 3861–2,
3861 *F*, 3862 *F*
- peripheral hearing loss 3864
- prevalence 3858
- central auditory nervous system
(CANS) 3857
- evaluation 3858
- peripheral hearing loss 3864
- central deafness
auditory hallucinations 3864
central auditory dysfunction 3863
- central hyperventilation
syndrome 1154–5
- central hypothyroidism 357
- central masking, pure-tone audiometry
and 3265
- central neck swellings, children 1211
- central nervous system (CNS)
damage, voice disorders and
2222–5
- pathways and processing, cochlear
implants 3650
- tumours, CPA impingement 4015
- central nystagmus, peripheral *vs.*
3724 *T*
- central papillary atrophy,
tongue 1826–7
- central pattern generators (CPGs),
swallowing 1959
- central processing disorders
(CAPD) 3851
- central scotoma 3914, 3914 *F*
- central venous pressure, anaesthesia
monitoring 500
- central vestibular disorders (CVD)
pharmacological treatment 3804–5,
3804 *T*
- vestibular rehabilitation 3809
- see also* vestibular diseases/disorders

- central vestibular pathways 3147, 3147 *F*
 Centre for Involvement 574
 Centres for Disease Control (CDC)
 HIV staging system 239
 Universal Blood and Body
 Precautions 239–40
 centromere 3–4
 centromere antibodies 170–1
 cephalic margin resection 2952
 cephalic trim 2952–4, 2953 *F*
 cephalometry, snoring 2329
 cephalosporins 229, 230
 adult epiglottitis 2251
 antibacterial spectrum 432 *T*
 cross-reactivity 230
 pharyngitis 1985, 1986
 rhinosinusitis 1543–4
 ceramic biomaterials 120
 applications 120
 bone tissue attachment 124 *T*
 glass 120
 tissue response 119
 tissue scaffolds 123, 124 *T*
 applications 120
 ceramic microphone 3169–70
 Ceravital 120
 c-erbB-2
 adenoid cystic carcinoma 2496
 saliva screening 1867
 cerebellar ataxia
 acquired 3775–6
 definition 3775–6
 acute-onset 3775
 children 1048
 dizzy child 1042
 episodic *see* episodic cerebellar
 ataxia
 hereditary *see* hereditary cerebellar
 ataxia
 insidious-onset 3775–6
 sporadic 3775–6
 definition 3775–6
 cerebellar disorders/lesions
 dysarthria 3940
 nystagmus 3922
 posturography 3735
 saccade abnormalities 3716
 stepping patterns 3731
 cerebellar haemorrhage
 clinical manifestations 3769
 management 3770
 stroke aetiology 3768
 cerebellar infarction
 clinical manifestations 3768–9
 diagnosis 3752, 3756 *F*
 management 3770
 stroke aetiology 3767
 cerebellar medulloblastoma 3848
 cerebellar syndromes
 aetiology 3775
 postural reflexes 3731
 cerebellar tumours 3776
 diagnosis 3776, 3776 *F*
 positional vertigo 3776
 cerebellopontine angle (CPA) 3932 *F*, 3942
 surgery
 auditory function monitoring 750
 facial nerve palsy induction 3880, 3889
 middle fossa 4021–2
 tumours *see* cerebellopontine angle
 (CPA) tumours
 cerebellopontine angle (CPA)
 syndrome 3932, 4007–8
 cerebellopontine angle (CPA)
 tumours 3776, 3777
 congenital rest lesions 4014
 CPA syndrome 4007–8
 diagnosis 3848
 enterogenous cysts 4014
 hearing loss 3943–4
 incidence 3943, 4007
 intraaxial tumours with CPA
 impingement 4015
 choroid plexus papillomas 4015
 primary CNS tumours 4015
 nonacoustic (non-vestibular
 schwannoma)
 current knowledge/future
 research 4016
 management 4007–17
 radiological characteristics 4008 *T*
 skull base origin 4015
 tumours originating in
 CPA 4008–15
 retrocochlear hearing loss 3848
 vestibular schwannoma *see* vestibular
 schwannoma (VS)
 see also specific sites/tumours
 cerebellum
 epidermoids 4011
 injury, vestibular schwannoma
 removal 3978
 meningiomas and 4009
 movement control 2158–9
 vestibular schwannoma
 expansion 3958–9, 3958 *F*
 symptoms 3959
 cerebral abscess
 acute otitis media 924–5, 925 *F*
 rhinosinusitis 1443, 1540
 cerebral air gas embolism
 (CAGE) 3519–20
 cerebral arteriosclerosis 3768
 cerebral cortex, sleep and 2306
 cerebral oedema
 radical neck dissection
 complications 2745
 syndromic craniosynostosis
 surgery 1031
 cerebral palsy
 drooling 788
 dysphagia management 2086
 obstructive sleep apnoea 1109
 postoperative complications 1110
 pharyngeal problems 2080
 cerebritis, vestibular schwannoma
 removal 3982
 cerebrospinal fluid (CSF)
 flow, arachnoid cysts and 4013
 otorrhoea, vestibular schwannoma
 removal 3981
 cerebrospinal fluid fistula
 syndromic craniosynostosis
 surgery 1031
 traumatic 3390
 vestibular schwannoma 3968–9
 cerebrospinal fluid ‘gusher,’ stapes
 surgery 3474–5
 cerebrospinal fluid leak
 encephalomeningocele 1035
 hypophysectomy
 complication 4112–3
 medical negligence 3830
 middle fossa surgery 4023
 nasal *see* cerebrospinal fluid
 rhinorrhoea
 post-craniofacial surgery 4132, 4132 *F*
 skull base surgery complication 4138
 vestibular schwannoma surgery 3981, 4138
 cerebrospinal fluid
 rhinorrhoea 1636–44
 aetiology 1636–7, 1637 *T*
 iatrogenic 1636–7, 1637 *F*, 1640 *F*
 definition 1636
 diagnosis 1637–41
 encephalocoele 1638, 1638 *F*
 head injury 1636–7, 1637 *F*
 imaging 1638, 1638 *F*, 1639 *F*
 laboratory investigations 1638
 intrathecal dyes/markers 1638–9,
 1639 *F*

cerebrospinal fluid rhinorrhoea
(continued)
 management 1637–41, 1639 *F*
 medical negligence 4144
 meningitis 1636, 1638, 1639–40
 nasal endoscopy 1351–2
 nasal fractures 1612
 perilymphatic fistulae 3510
 physiology 1636
 pituitary tumours 305, 4100
 surgery 1640–1, 1640 *F*, 1641
 temporal bone trauma 3496
 transsphenoidal meningoencephalocoeles 2116–7
 vestibular schwannoma
 removal 3981–2
 cerebrovascular accident, pseudobulbar palsy 3939
 cerumenolysis 431
 ceruminous adenocarcinoma 4070
 ceruminous adenoma 4069–70
 ceruminous glands 3107
 cervical abscess, children 1213, 1213 *F*
 cervical lymphadenopathy
 assessment 2719–20
 diagnosis 2703
 Epstein Barr virus 2703
 examination 2703
 genetics 2703–4
 imaging 2703, 2705 *F*
 irradiation 2706
 management 2702–10
 putative site 2706–7
 medical negligence 1310
 molecular analysis 2703–4
 nasopharyngeal carcinoma 2451, 2451 *F*
 panmucosal irradiation 2706–7
 positron emission tomography 2704, 2705 *F*
 recent advances 2707
 surgical management 2706
 tuberculosis 1783
 unknown primary carcinoma 2704–5
 cervical lymphatics 1746–9
 assessment 1759–62
 computed tomography 1760–1
 magnetic resonance imaging 1761–2
 normal measurements 1759
 palpation 1759
 positron emission tomography 1762
 radiological staging methods 1759

echogenic hilum 717–8
 image-based classification 1759
 jugular chain 1747
 levels 715, 715 *T*, 1748–9, 1748 *F*, 2363, 2363 *T*, 2712 *F*
 level I 1748
 level II 1748
 level III 1749
 level IV 1749
 level V 1749
 level VI 1749
 level VII 1749
 metastases 2714
 N stage definition 2363, 2363 *T*
 organ-specific drainage 2713–4
 palpation 716–7
 posterior nodes 1747–8
 primary tumour evaluation 2363
 submandibular 1747, 1799
 submental 1747, 1799
 tumour staging 2363–4, 2363 *T*
 ultrasound 715–8, 716 *F*, 1759–60
 calcified 717
 children 1297, 1297 *F*
 cystic 717, 717 *F*, 718 *F*
 echogenic hilum 717–8
 echogenicity 717
 FNAC and 716–7
 inflammatory nodes 716
 metastatic nodes 717 *T*, 716, 716 *F*
 prognostic value 716–7
 reactive nodes 715, 716 *F*
 shape 717
 size 717
 vascular pattern 718
 cervical lymphoma, children 1254
 cervical necrotizing fasciitis 1785, 1785 *F*
 cervical oesophagostomy, oesophageal atresia repair 1285
 cervical oesophagus tumours see oesophageal carcinoma
 cervical plexus 1752, 2739 *F*, 2740
 cutaneous branches 1752
 muscular branches 1752
 cervical sinus 1740, 1942–3
 lateral cysts see branchial cysts
 cervical spine
 atlantoaxial subluxation, adenoideectomy-related 1098
 fractures, intubation-induced 2289
 protection, neck trauma 1766–7

cervical sympathetic trunk 1752, 3936–7, 3936 *F*
 clinical involvement 3937–8
 lateral skull base 3903
 cervico-aural fistula *see first branchial arch fistula*
 cervicofacial cheek advancement flap 2837
 cervicofacial infections 1783–5
 children 1210–8
 assessment 1210, 1210–1
 bacterial 1213–4
 examination 1211–2
 fungal 1216
 head and neck examination 1212
 imaging 1212
 laboratory tests 1212
 lymphoma simulating conditions 1217
 microbiology 1214
 mycobacterial 1214–6
 nature of 1212
 noninfective inflammatory disorders 1216–7
 viral 1212–3
see also individual diseases
 cervicoocular reflex 3227
 ‘ceteris paribus’ principle, epidemiological research 617
 cetirizine hydrochloride 411
 cetuximab 43, 52, 2760
 cevimeline 1912
 Chagas disease 2032
 Chaissaignac’s triangle 2737
 Chaissaignac’s triangle clearance, radical neck dissection 2737–8
 chancre 1460–1
 channelopathies 3773
 characteristic impedance, air 3165
 charcoal dressings, fungating lesions 453
 Charcot–Leyden crystals 1654
 Charcot-Marie-Tooth disease
 auditory neuropathy/dyssynchrony 3849
 vertigo, children 1048
 CHARGE association 968, 1046, 1071, 3683
 CHARGE syndrome 1055
 Charles’s Law 3501 *T*
 CHART trial 2755
 cheek(s)
 anatomy 1792–3
 blood supply 1798

- development 798
 lymphatic drainage 1799
 mucous membrane 1792–3
 muscles 1795, 1795 *F*
 sensory innervation 1800–1
 swallowing 1954–5
 venous drainage 1799
see also entries beginning buccal
 cheek biting, (morsatio buccarum) 1836
 cheilitis glandularis 1915–6, 1916 *F*
 cheilosis 1827
 chemical agents
 basal cell carcinoma 2396
 olfactory dysfunction 1670, 1673–4
 chemical burns, oral 1836
 chemical labyrinthectomy 3567
 chemodectoma *see* glomus tumours
 chemogustometry 1844
 α -chemokine family 89
 chemoprevention 41
 chemoradiation 41
 chemoradiotherapy 2757
 cervical lymphadenopathy 2707
 meta-analyses 2757–8
 chemosensitization
 bystander effect 28
 head and neck cancer gene therapy 28
 p53 transfer 28
 chemosis, post-blepharoplasty 3066, 3066 *F*
 chemotactic factors 89, 89–90
 chemotherapy
 adjuvant 40
 head and neck sarcomas 1933–4
 adjuvant radiotherapy 51–2
 administration, cell cycle synchronization 37
 agents 452
 classification 37–40
 by mechanism 37–40
 phase-specific toxicity 37–40
 as radiosensitizers 52
 resistance 63
 site of action 452, 452 *F*
 see also individual agents
 apoptosis 63
 cell cycle-nonspecific 37
 cell cycle-specific 37
 combination 40
 concurrent chemoradiation 41
 drug dosing 36
 Ewing's family of tumours 1936
 future developments 41
 head and neck cancers 40
 drug choice 40
 rhabdomyosarcoma 1935
 single agent treatment 40
 head and neck sarcomas 1933–4
 treatment regimens 1934
 high-dose 41
 hypopharyngeal cancer 2649
 intraarterial 735
 laryngeal cancer 452
 mechanism of action 63
 nasal malignancy 2427
 nasopharyngeal carcinoma 2460
 neoadjuvant
 head and neck sarcomas 1934
 phase III trials 40
 oropharyngeal tumours 2591
 osteosarcoma 1936–7
 ototoxicity 3298–300
 phase-specific 37
 principles 34
 salivary gland tumours 2508
 strategies 40–1
 temporal bone squamous cell carcinoma 4094
 cherubism 1654–5, 1654 *F*, 1931
 chewing exercises 2089, 2089 *T*
 chewing gum, Sjögren syndrome 1912
 chewing tobacco, buccal carcinoma 2560
 Cheyne-Stokes respiration, obstructive sleep apnoea 2316–7
 Chiari malformations 3777, 3777 *F*
 children 1048
 chiasmatic sulcus, sphenoid bone 1338–9
 chief cells, parathyroid gland 316 *F*, 320, 373–4
 chilblains (pernirosis) 1715
 childbirth, laryngeal effort closure 2159
 childhood deafness 844–59
 aetiology 845–9
 acquired causes 847
 congenital causes 817–8, 845–7
 perinatal factors 845–6
 audiology 850
 clinical examination 18
 education 854–6
 epidemiology 844–5
 genetic causes 17, 845
 genetic counselling 852–3
 genetic screening 851–2
 imaging 850–1, 851 *F*
 inheritance patterns 18
 investigations 850–2, 850 *T*, 851 *T*
 newly diagnosed child 849–53
 reactions to diagnosis 849
 presentation 848–9
 delayed 848
 screening 851–2
 serology 851
 single-sided deafness 848
 support 853–6
 hearing aids 854
 rationale for intervention 853–4
 child protection issues 780
 children
 anaesthesia *see* paediatric anaesthesia
 consent issues 601
 deafness *see* childhood deafness
 drug prescribing 415
 hearing tests *see* hearing tests, children
 see also entries beginning paediatric; individual diseases
 Children's Respiratory Study 1561
 chimpanzee (*Pan troglodytes*), paranasal sinuses 1321 *F*
 chin down posture, dysphagia 707–8
 chitosan tissue scaffolds 123
 chlamydia 201–2
 definition 201
 diagnosis 202
 neonatal rhinitis 1076–7
 treatment 202
 see also individual species
Chlamydophila pneumoniae 202
Chlamydophila psittaci 201
Chlamydophila trachomatis 201
 chloramphenicol 231
 acute epiglottitis 1131
 chlorhexidine 448
 denture-related stomatitis 1826
 dysgeusias 1848–9
 epistaxis 1604
 children 1066
 mouth ulcers 1830
 mouthwashes 448
 chloride ions
 endolymph 3187 *T*
 nasal secretions 1360
 perilymph 3189 *T*
 chloroquine ototoxicity 3571
 chlorphenarimine 1397–8
 chlorpromazine 415
 chlorthalidone 3799, 3799 *T*
 choanae 2110
 primitive 1315
 choanal atresia 1070–2, 1071 *F*, 1320
 airway expansion 1071, 1072 *F*

choanal atresia (*continued*)
 bilateral 1071
 correction techniques 1071–2, 1072 *F*
 dysphagia aetiology 2029
 paediatric anaesthesia 514–5
 septum 1570
 choanal polyp 1554
 ‘choke vessels’ 114
 choking
 glossopharyngeal nerve lesions 3937
 obstructive sleep apnoea 1104
 recurrent laryngeal nerve lesions 3937
 cholesteatoma 3430–4
 aetiology 3411–2
 misplaced epithelium 3411–2
 squamous metaplasia 3411
 bone resorption 3399
 children 947–54
 acquired 948
 acquired vs. congenital 948
 anatomical features 949, 949 *F*, 949 *T*
 classification 947, 948 *T*
 congenital 947–8
 epidemiology 948–50, 949 *F*, 949 *T*
 iatrogenic 948
 investigation 951–2
 pathogenesis 947
 recurrence, prevention of 953–4, 953 *F*, 954 *F*
 residual, risk factors for 952–3, 952 *T*
 signs 950–1
 special needs 786
 symptoms 950, 950 *T*
 treatment 952–4, 952 *F*, 952 *T*
 congenital 947–8, 947 *F*, 3683
 congenital atresia 981
 definition 947
 diagnostic delay 1306–7
 examination 3431–2
 radiology 3431–2
 hearing in 3431
 inactive squamous chronic otitis media and 3428
 jugular foramen 4036 *F*
 medical negligence 1306–7, 3828–9
 negligent management 1307
 natural history 3430–1
 active disease progression 3431
 bone erosion 3431
 progression towards healing 3431
 otalgia 3527
 otoscopic diagnosis 3418, 3418 *F*, 3419 *F*

 pars tensa 3433
 pathology 3400–1, 3400 *F*
 post-stapes surgery 3477
 presentation 3413 *F*, 3431
 prevalence 949 *F*
 primary auditory canal *see* primary auditory canal cholesteatoma
 surgery 3432–4
 aims 3432
 complications 3434
 medical negligence 3829
 problem mastoid cavities 3434
 revision 3434
 see also epidermoids
 cholesterol cyst, petrous apex 4047
 drainage 4050–1, 4051 *F*
 cholesterol granuloma 1655
 active mucosal chronic otitis media 3399, 3399 *F*
 CPA involvement 4015
 definition 1655
 histology 1655
 imaging 1655
 treatment 1655
 choline salicylate gel 2785
 cholinesterase inhibitors 2077
 chondrectomy, perichondritis 3359–60
 chondritis, burnt ears 3032–3
 chondroblasts 94
 chondrocytes 75
 chondroethmoid junctions 2989
 chondroma(s)
 CPA involvement 4015
 larynx 2600 *T*
 chondromucosal grafts 2827
 chondroradionecrosis 3376
 chondrosarcoma(s)
 CPA involvement 3943, 4015
 head and neck 1937–8
 hyaline 4073
 larynx 2603, 2604
 mesenchymal 1937–8
 middle ear 4073
 petrous apex 4024 *F*
 radiosurgery 3996
 skull base 4125–6
 temporal bone 4050 *F*, 4073
 classification 4047, 4073
 development 4073
 grading system 4073
 incidence 4073
 management 4051
 symptoms 4047, 4073 *T*
 treatment 4073
 chondrotomy, posterior 1578, 1579 *F*
 chondrovomerine 2989
 chorda tympani 3116, 3905, 3928
 injury
 local anaesthetic injection 1847
 stapes surgery 3477
 taste abnormalities 1844, 1846
 temporal bone resection 4092
 chordoma(s)
 clivus 4126
 CPA involvement 4015
 cranial 4126
 dysphagia aetiology 2033
 head and neck tumours, childhood 1260
 pituitary 4104
 radiosurgery 3996
 skull base 4126
 temporal bone 4072–3
 classification 4072
 differential diagnosis 4073
 incidence 4047, 4072–3
 management 4051, 4052 *F*, 4073
 open cavity surgery 4052
 radiotherapy 4051–2
 recurrence 4047
 symptoms 4047
 choreiform syndromes 3939
 choroid plexus papillomas 4015
 Christmas disease *see* haemophilia B
 CHRN1, salivary gland tumours 2496
 chromatin condensation 59
 chromoblastomycosis 214
 chromophobe cells, pituitary gland 297
 chromosome(s) 3–4, 15, 2379, 2379 *F*
 chromosome 1b protooncogene 389
 mutation 389
 chromosome 6q 2496
 chromosome 22
 deletions 180–1, 180 *T*
 neurofibromatosis 2 3998–9
 chromosome breakage, craniofacial defects 792
 chromosome silencing 27
 chromosome spreads 2379 *F*
 chromosome Xp11 tumour suppressor gene 389
 chronic aspiration *see* intractable aspiration
 chronic atrophic candidiasis *see* denture-related stomatitis
 chronic autoimmune hypothyroidism *see* Hashimoto’s thyroiditis
 chronic granulomatous disease (CGD) 177 *T*, 178
 laryngeal manifestations 2266–8

- chronic lymphocytic leukaemia
(CLL) 275
- chronic myeloid leukaemia (CML)
275
- chronic myringitis *see* granular
myringitis
- chronic nasal obstruction
(CNO) 1591–2
- chronic nonpurulent otitis media *see*
otitis media with effusion (OME)
- chronic non-specific sialadenitis 1903
- chronic obstructive pulmonary disease
(COPD)
- hyperbaric oxygen 2910
 - nasal inflammation 1561–2
 - sinusal inflammation 1561–2
- chronic otitis media (COM) 3395–445
- active
 - definition 3396
 - hearing aids 3435
 - prevalence 3408
 - active mucosal (perforation with
otorrhoea) 3423–5
 - aural polyps 3397
 - bacteriology 3424
 - cholesterol granuloma 3399, 3399 *F*
 - diagnosis 3415 *F*, 3416, 3416 *F*,
examination 3424
 - granulation tissue 3397
 - hearing in 3423–4
 - management 3424
 - natural history 3423–4
 - pathology 3397–9, 3398 *F*
 - presentation 3424
 - progression with continuing
activity 3423
 - resorptive osteitis 3397–9, 3399 *F*
 - surgery 3425
 - topical mediation 3424
 - active squamous *see* cholesteatoma
 - activity, factors influencing 3410
 - aetiology 3408
 - environment 3409
 - racial factors 3409
 - arachnoid granulations 3402
 - assessment 3412
 - audiology 3419
 - bacteriology 3420
 - bone-anchored hearing aid 3643
 - children *see* chronic otitis media
(COM), children
 - classification 3396 *T*
 - complications 3435–8
 - classification 3435–6
 - extracranial 3435 *T*, 3436–7
 - incidence 3435, 3435 *T*
 - infection routes 3437
 - intracranial 3435 *T*, 3437–8
 - labyrinthine 3436
 - mortality from 3436
 - otogenic intracranial 3404, 3405 *F*
 - pathology 3402–4
 - petrositis 3404, 3404 *F*
 - definition 928–9, 3396
 - International Symposium on
Recent Advances in Otitis
Media 929
 - new classification 929, 931 *F*
 - World Health Organization 929
 - diagnosis 3412
 - endoscopy 3420
 - epidemiology 3408
 - facial nerve paralysis 3404, 3890
 - children 1056
 - imaging 3882
 - management 3437
 - genetics 3409
 - healed 3425–6
 - definition 3396
 - diagnosis 3406 *F*, 3413–4, 3414 *F*,
3415 *F*
 - dimeric membrane 3398 *F*, 3401
 - examination 3426
 - fibrocystic sclerosis 3401–2
 - fibro-osseous sclerosis 3400 *F*,
3401–2, 3401 *F*
 - hearing aids 3434–5
 - hearing in 3426
 - management 3426
 - natural history 3425–6
 - neo-osteogenesis 3401–2, 3402 *F*
 - pathology 3401–2
 - presentation 3426
 - prevalence 3408
 - progression 3425–6
 - progression towards activity 3426
 - surgery 3426
 - tympanosclerosis *see*
tympanosclerosis
 - hearing aids 3434–5
 - histology 930
 - history taking 3418
 - inactive
 - definition 3396
 - hearing aids 3434–5
 - prevalence 3408
 - inactive mucosal (dry
perforation) 3415 *F*
 - diagnosis 3414, 3415 *F*
 - examination 3421
 - myringoplasty 3421–2
 - natural history 3420–3
 - pathology 3397, 3397 *F*, 3398 *F*
 - presentation 3421
 - surgical management 3421–3
 - surgical objectives 3421
 - inactive squamous 3416–7, 3417 *F*,
3417 *F*, 3418 *F*, 3426
 - children 941–7, 941 *F*
 - cholesteatoma and 3411, 3428
 - definition 3426–7
 - examination 3427
 - pars flaccida retraction 3427
 - pars tensa retraction 3427
 - excision 946, 946 *F*, 946 *T*
 - long-term results 946 *F*, 947
 - hearing levels, retraction and
3430
 - management 3428–30
 - adults 3430
 - nasal disease management 3428
 - natural history 3427–8
 - pathology 3400, 3400 *F*
 - progression 3428
 - recurrence 3429
 - surgical treatments 3428
 - tympanic membrane
 - management 3428–9
 - ventilation tubes 3429
 - infection 3410, 3410 *T*
 - bone erosion 3402
 - congenital defects and 3402
 - spread routes 3402
 - labyrinthine fistulae 3402–3
 - labyrinthitis 3403–4
 - management 3420
 - corticosteroids 423
 - mucosal 3410–1
 - natural history 3420
 - otosclerosis 3461
 - otoscopy 3412, 3413–8
 - outcomes 3420
 - pathogenesis 930
 - pathology 3396, 3412–3
 - prevalence 3408, 3409 *T*
 - radiology 3419–20
 - resolution prevention 931–2
 - bacterial biofilm
 - colonization 931–2
 - repeated infection 931
 - surgery rates 3408
 - surgical pathology 3404–7
 - cartilaginous grafts 3405–6
 - creeping substitution, bone
formation 3405–6

chronic otitis media (COM) (*continued*)
 mastoidectomy cavities 3406–7,
 3406 *F*, 3407 *F*
 ossicular grafts 3405–6, 3405 *F*
 ossicular implants 3405–6, 3406 *F*
 tympanic membrane grafts 3404–5,
 3405 *F*
 symptoms 3418, 3419 *T*
 synonyms 3396 *T*
 tuberculous otitis 3448, 3448 *T*, 3449
 tympanomastoid surgery
 adhesion formation
 prevention 3407
 middle ear non-aeration 3407–8
 success, factors determining 3400 *F*,
 3401 *F*, 3402 *F*, 3407–8
 vestibular assessment 3419
 chronic otitis media (COM),
 children 928–64
 cholesteatoma *see* cholesteatoma
 complications 931 *F*
 ear discharge, profuse chronic 935
 inactive squamous, management
 3430
 ossicular erosion 931 *F*, 954–7
 classification 954–5
 epidemiology 954
 outcome measures 955
 pathology 954
 results 955–6, 956, 956 *F*, 956 *T*
 risk factors 955
 timing of intervention 956–7
 pars tensa atrophy 931 *F*, 941–7, 942 *F*
 classification 942–3
 definitions 942–3
 epidemiology 943, 943 *F*
 investigations 945
 management 945
 natural history 943–4, 943 *T*
 pathology 941–2
 signs 944–5
 surgical intervention 945–6
 symptoms 944
 tympanic membrane chronic
 perforation 931, 931 *F*, 932,
 932–41
 age 933, 934 *F*
 classification 932–3
 clinical examination 935
 clinical presentation 934–5
 definitions 932
 epidemiology 933
 investigation 936
 microbiology 934
 pathology 932

 risk factors 933–4
 treatment 936–41
 chronic renal failure (CRF), taste
 abnormalities 1848
 chronic rhinosinusitis (CRS)
 acute exacerbations 1382, 1382 *T*,
 1439–40
 allergen avoidance 1470
 antibiotics 1470–1
 antifungals 1472
 antihistamines 1472
 antileukotrienes 1472
 aspirin 1472–3
 bacteriology 1441
 causative agents 1381
 children 1080–2
 complications 1540
 computed tomography
 protocols 1479 *T*
 contact endoscopy 764
 corticosteroids 1470
 decongestants 1470
 definition 1382, 1382 *T*, 1440
 diagnosis 1442, 1469, 1474
 dietary management 1473
 enlarged turbinates 1591–2
 histopathology 1441
 immunotherapy 1473
 investigations 1469
 irritant avoidance 1470
 lateral nasal wall anomalies 1334
 long-term prophylaxis 1471–4
 medical management 1469–77
 surgery vs. 1470
 treatment aims 1470
 mucocoeles 1540
 nasal polyps 437–8
 postoperative treatment 438
 systemic steroid use 438
 topical steroid use 437–8
 nitric oxide donors 1473–4
 olfactory dysfunction 1666, 1667–8
 ostiomeatal complex drainage 1474
 paranasal sinus procedures 1482 *T*
 pathogenesis 1441
 predisposing factors 1469–70
 systemic diseases 1469
 prevalence 1381
 sinonasal malignancy 2418
 structural/anatomical
 abnormalities 1469
 symptoms 1469
 duration 1439–40
 without nasal polyps 437
 chronic sclerosing sialadenitis 1904

chronic suppurative otitis media
 (CSOM) 935 *F*
 children
 balance problems 1045–6
 cochlear implantation 865
 definition 929, 932
 epidemiology 933, 934 *F*
 risk factors 933 *T*
 temporal bone squamous cell
 carcinoma 4087
 see also chronic otitis media (COM)
 chronic vestibular insufficiency
 (Dandy's) syndrome 3749, 3750 *F*
 Churg–Strauss syndrome 189, 1653
 Chvostek's sign 401
 chylous fistula 2744
 chylous injury 1774
 cidofovir
 juvenile-onset recurrent respiratory
 papillomatosis 1178
 laryngeal papillomatosis,
 paediatric 1170
 mechanism of action 1178
 papillomas 2238
 cigarette smoking *see* smoking
 cilia
 larynx 763
 replacement by squamous
 epithelium 763
 nasal 764, 1360–1
 action 1361
 beat frequency 1361
 drugs, effects of 1361
 drying 1361
 microtubules 1360
 mucus flow 1361
 septal 1327
 structure 1327, 1327 *F*
 ultrastructure 1360, 1361 *F*
 nasopharynx 766
 cimetidine
 juvenile-onset recurrent respiratory
 papillomatosis 1179
 mucosal malignant melanoma 2410
 Cincinnati x-ray 1143
 cinnarizine
 Menière's disease 3800
 side effects 3797
 vestibular attacks, acute 3796 *T*, 3797
 ciprofloxacin
 dosage 432
 malignant otitis externa 3891
 respiratory scleroma 1463
 tympanic membrane perforation with
 discharge 937–8

- circadian rhythms 2306
 Circle of Willis, internal carotid artery test 3951
 circumvallate papillae 1794
 cisplatin
 adjuvant radiotherapy 52
 head and neck cancer 40
 inner hair cell function 3849
 mechanism of action 37
 mucosal malignant melanoma 2410
 nasopharyngeal carcinoma 2460
 neoadjuvant 40
 ototoxicity 3298–300, 3570–1
 aetiopathology 3570
 hearing loss attribution 3572
 incidence 3300
 natural history 3570
 oxidative stress and 3300–1,
 3301 *F*
 recognition 3571–3
 risk factors 3570–1
 salivary gland tumours,
 malignant 2508
 cisplatin ototoxicity 3677
 citrate phosphate dextrose (CPD) 255
 Civil Procedure Rules (1998) 598, 603,
 604
Cladosporium 221
 clarithromycin 231
 chronic rhinosinusitis 1471–2
 ototoxicity 3571
 class switching, immunoglobulins 148
 Claudius' cells 3127, 3128 *F*, 3130
 clavicular head 1745
 clavicular periosteal grafts 1156–7
 cleft lip *see* cleft lip and palate
 cleft lip and palate 996–1018
 airway and feeding 1002
 associated syndromes 1001 *T*
 bilateral 1005, 1005 *F*
 chronic otitis media 3409, 3428
 classification 996–7
 diagnosis 1001
 dysphagia 2030
 embryopathology 1320
 embryology 999, 1320, 1811–4
 environmental factors 1000
 epidemiology 997
 gender differences 997
 racial differences 997
 genetic factors 999–1000, 999 *T*
 Greenspan model 1000
 implant placement 2933–4, 2934 *F*
 labiomaxillary muscle function restoration 1005, 1006 *F*
 management 1001–10
 general principles 1002
 presurgical orthopaedics 1002–3
 secondary surgery 1010
 surgery expectations 1003
 timing of surgery 1004, 1004 *T*
 normal embryogenesis 998–9, 998 *F*
 otitis media 1003–4, 1010–3
 otitis media with effusion 903, 1010–3
 paediatric intensive care 546
 pars tensa retraction 3428
 Pierre Robin sequence 1000–1, 1001 *F*
 prenatal diagnosis 1001
 research outcomes 1002, 1002 *T*
 septum abnormalities 1570–1
 speech disorders 993
 syndromic 1000
 tympanic membrane disorders 934
 unilateral 1004, 1004 *F*, 1005 *F*
 epidemiology 997
 cleft lip nasal deformities, external
 rhinoplasty 2967, 2967 *F*
 bilateral deformity 2967
 incisions 2962
 unilateral deformity 2967 *F*
 cleft palate *see* cleft lip and palate
 click-evoked vestibular myogenic potentials (CEVMP) 3741–2
 click sound, Fourier analysis 3177 *F*,
 3178
 clindamycin 1471
Clinical Evidence 653
 clinical governance 568–80
 basis for 570–1, 571 *T*
 definition 569, 569–70
 implementation, barriers to 570,
 570 *T*
 integration of approaches 569 *F*
 medical negligence 598, 2803
 monitoring and inspecting 572–3
 multidisciplinary teamworking 568,
 576, 576–7
 patient involvement 574–5
 public involvement 574–5
 quality assurance 573–4
 standard setting 571–4
 support 575–6
 Clinical Governance Development Programme 575
 Clinical Governance Support Team (CGST) 654–5
 clinical heterogeneity 663
 clinical test of sensory integration and balance ('foam and dome'
 test) 3733–4, 3734 *F*
 clivus 298
 clofazimine 1464
 clonazepam
 diplopia 3804
 idiopathic downbeat nystagmus 3804
 tinnitus 3617
 cloning 19–20
Clostridium difficile 229
 clot formation
 bone repair 94
 disseminated intravascular coagulation 283–4
 inflammation 89
 clotrimazole 233, 430
 clover leaf skull (Kleeblattschädel anomaly) 1028
 cluster headache 1722, 1723 *F*
 c-myc, stem cell activation 67
 CO₂ laser *see* carbon dioxide (CO₂)
 laser
 coagulase-negative staphylococci 196–7
 coagulase test, staphylococci 196
 coagulation 279
 coagulation disorders 281 *T*
 acquired 282–4
 bleeding patterns 281
 inherited 284–6, 284 *T*
 symptoms 280
 see also individual disorders
 coagulation factors 279
 activated platelets 278
 fibrin formation 279
 see also individual factors
 coagulation inhibitors 279
 acquired 284
 coagulation tests 280
 epistaxis, children 1065
 sodium citrate 280
 co-amoxiclav 938
 cobalt-chromium implants 119
 coblation tonsillectomy 1235, 1992
 Coblator plasma field device 1097
 'Coca Cola' bottle sign 1680 *F*
 cocaine
 cilia, effects on 1361
 glossopharyngeal neuralgia 2081
 mouth ulcer induction 1835
 nasal surgery 442
 nasal vasculature, effects on 1365
 septal perforation 1582
 COCH (DFNA9) gene mutations 3238
 cochlea 3126–46, 3186–8
 auditory nerve fibres, nonlinear interactions 3198–9
 conditions 3537–8

- cochlea (*continued*)
 drug-induced ototoxicity 3298–300,
 3299 *T*
 fluid spaces 3186, 3186 *F*
 function
 otoacoustic emissions 3842
 petrous apex lesion management
 and 4050
 gross morphology 3126, 3127 *F*
 hair cells *see* cochlear hair cells
 hearing 3186–8
 electrical responses 3196–7,
 3196 *F*
 mechanics 3189–92
 impedance 3176, 3181
 implants *see* cochlear implants (CI)
 innervation, centrifugal 3200
 lesions
 neurophysiology 3606
 Pendred's syndrome 400
 serotonergic system 3607
 tinnitus 3606–7
 tonotopic reorganization 3607
 Mondini abnormality, CT
 imaging 1298 *F*
 ossification, meningitis-related 3652
 potassium ions 3186–7
 sharply sloping high frequency
 hearing loss 3850, 3850 *F*
 sound detection 3462, 3463 *F*
 conductive hearing
 impairment 3462
 ultrastructure 3127–32
 future research areas 3140
 knowledge deficiencies 3140
 vestibular schwannoma
 invasion 3959–60
 cochlear aqueduct
 bone conduction 3185
 vertigo, children 1046
 cochlear blood flow, noise-induced
 hearing loss 3549
 cochlear duct
 age-related changes 3540–1
 embryology 806–7, 807 *F*
 lateral wall cells 3130
 structure 3127–30, 3128 *F*
 cochlear echoes 3183, 3200–1, 3201 *F*
 cochlear endosteum,
 otosclerosis 3456–7
 cochlear fluids
 composition 3187–8
 electrical potential 3187–8
 impedance 3181
see also endolymph; perilymph
- cochlear hair cells
 calcium channel dysfunction,
 tinnitus 3605
 degeneration 20
 drug-induced tinnitus 3600
 drug/noise-induced
 ototoxicity 3298–300, 3299 *F*,
 3299 *T*
 incidence 3300
 molecular mechanisms 3300–1
see also ototoxicity
 electrical responses 3194–6
 inner *see* inner hair cells (IHC)
 innervation 3200
 outer *see* outer hair cells (OHC)
 regeneration
 deafness 818
 stem cell therapy 75
 resistance 3192–3
 stereocilia tip links 3192, 3193 *F*
 transduction 3192–4
 ion channels 3193–4, 3194 *F*
 shear forces 3192–3, 3193 *F*
 vertebrate similarities 3301
 cochlear implants (CI) 3649–59
 auditory neuropathy/
 dyssynchrony 3852
 electrically evoked compound
 action potential 3852, 3853 *F*
 candidature 3650–1
 audiological 3650–1
 imaging 3651
 medical 3651
 otological 3651
 psychological 3651
 central pathways and processing 3650
 children *see* paediatric cochlear
 implantation
 clinical outcomes/benefits 3654–6
 predictive factors 3655–6
 quality of life 3655, 3656
 complications 3654
 facial nerve stimulation 3654, 3655
 incidence 3652
 meningitis 3654
 vertigo 3654
 cost-effectiveness 3656
 deafness duration and 3655
 devices 3651–2, 3653 *T*
 failure 3654
 safety 3652
 functional magnetic resonance
 imaging 681
 glass ionomer cement fixation 120
 hearing aids *vs.* 3636
- medical negligence 1306
 middle fossa surgery 4023–4
 otological contraindications 3651
 ototoxicity-related hearing loss 3573
 rationale for 3649–50
 silicone elastomer 122
 speech processing strategies 3650
 surgical approaches 3652–4
 cochlea access 3652
 cochlear abnormalities 3652–4
 surgical outcomes 3652, 3654
 tinnitus 3614–5
Cochlear implants: Principles and practices 3656
 Cochlear Implant Study Group (CISG),
 UK 3656
 cochlear microphonics 3844 *T*
 auditory neuropathy/
 dyssynchrony 3840, 3843, 3844 *T*
 definition 3843
 transtympanic
 electrocochleogram 3843
 cochlear nerve
 auditory function monitoring *see*
 auditory function monitoring
 surgical damage 750
 vestibular schwannoma invasion 3957
 cochlear nucleus complex 3140–1,
 3142 *F*
 cochlear potentials 3280–1, 3282 *F*
 decompression 3516
 ear canal recordings 3281
 electrodes 3281, 3282 *F*
 intraoperative monitoring 3292–3
 invasive recording 3280–1
 noninvasive 3281
 surface recording 3281
 transtympanic 3280–1
 waveforms 3281, 3282 *F*
 cochlear travelling wave 3189,
 3190 *F*
 cochlear sensorineural hearing
 loss 3199, 3199 *F*
 components 3191–2
 cochleolabyrinthitis *see* bacterial
 labyrinthitis
 cochleosaccular abnormalities 811–2
 cochleosaccular deafness 811–2
 cochleostomy 3652, 3652–4
 cochleotopic gradient of
 susceptibility 3569
 cochleovestibular dysfunction,
 acute 3582
 Cochrane Central Register of
 Controlled Trials 646

Cochrane Collaboration 647–8, 647 *T*, 662
 Cochrane Database of Systematic Reviews 662
 Cochrane Library 662
 coded excitation, ultrasound advances 713
 codeine 2786
 codes of conduct 582
 codominant inheritance 18
 codon 3, 15
 coeliac disease 171
 cerebellar ataxia 3775
 salivary gland physiology 1866
 Cogan's syndrome 3680–1, 3757
 benign paroxysmal positioning vertigo
 aetiology 3760
 clinical manifestations 3754
 cognitive behavioural techniques (CBT), tinnitus 3614, 3616
 cognitive function
 pure-tone audiometry and 3265
 speech audiometry and 3273
 coherent, laser light 743
 cohort studies
 epidemiological research 627
 evidence-based medicine 655
 terminology 627
 coils, embolization 733
 coinheritance 11
 COL1A1 gene 3458
 cold dry air (CDA) challenge, idiopathic rhinitis 1409
 cold receptors, nasal 1364
 'cold steel' tonsillectomy 1232–3, 1233 *F*
 cold water exposure, exostosis and 3367
 anima studies 3367
 collagen(s)
 chemical modification 123
 as embolic agent 733
 hypertrophic scars 3090
 keloids 2891–2, 3090
 polarization-sensitive OCT 758
 remodelling, wound healing 93
 tissue scaffolds 123, 123 *F*
 clinical applications 123
 types 123
 collagen injections, vocal fold
 paralysis 450, 2240, 2245 *T*
 contraindications 450
 Collet–Sicard syndrome 2080 *T*, 3938
 collimated laser light 743

colloid goitre 331, 720
 colloids
 cardiovascular resuscitation 529
 transfusion 257
 colour-coded duplex ultrasonography (CCDU) 686–7
 colour-flow duplex Doppler (CFD), vascular neck injury 1772
 colour vision, thyroid eye disease 344
 columella 1325
 anatomy 2996
 retraction, surgical
 complication 3004, 3092
 revision rhinoplasty 2982
 short, management of 1005
 columella strut 2964 *F*
 columnar cells, septum 1327
 combination chemotherapy 40
 intraarterial 735
 combined approach tympanoplasty *see* intact canal wall mastoidectomy
 'Commission E' monographs, herbal medicines 408
 Commission for Healthcare Audit and Inspection 569
 Commission for Health Improvement (CHI) 569, 572
 Commission for Patient and Public Involvement in Health (CPPIH) 574
 Commission for Social Care Inspection (CSCI) 572
 Committee on Professional Performance 606
 Committee on Safety of Medicines (CSM) 408
 common canaliculus 1690
 obstruction 1696
 canaliculodacryocystorhinostomy 1696
 Lester–Jones tube insertion 1696
 common carotid artery 1749
 common cold (infectious rhinitis)
 causative agents 205 *T*
 children 1076
 corticosteroid treatment 421
 common variable immunodeficiency (CVI) 175 *T*, 176
 communication
 palliative care, head and neck cancer 2782–3, 2783 *T*
 skills 554 *T*
 surgeons *see* surgical training
 voice quality and 2170
 communication, medical
 consultations 559–67
 acquired hearing loss patients 566
 bad news *see* breaking bad news
 biomedical approach 559–60
 core skills 564–6
 dealing with loss 565–6
 eye contact 565
 hearing loss 566
 'heart-sink' patients 565
 jargon 562
 listening 564
 loss, dealing with 565–6
 medical negligence and 2804
 models/styles 559–60, 560 *F*, 563–4
 doctor-centred 559–60, 563 *F*
 nonverbal cues 564, 565
 paternalism 582
 patient-centred approach 559–60, 560–4
 compliance 562–3
 ethical framework 561–2
 Pendleton's model 563
 power issues 560–1
 seat/desk arrangements 564, 564 *F*
 training 554 *T*
 community effect 68
 Community Health Councils 574
 comparative audit 2376
 comparative genomic hybridization (CGH) 6–7
 compensatory turbinate hypertrophy 1590–1, 1591 *F*
 complaints
 communication skills 554 *T*
 medical negligence issues 2803–4
 complement 139
 activity tests 169
 alternative pathway 139, 139 *F*
 deficiencies 179
 cellular cytotoxicity 41
 classical pathway 139, 139 *F*
 deficiencies 178–9
 deficiencies 178–9
 mannan-binding lectin pathway 139 *F*
 nasal secretions 1360
 pathway levels, measuring of 169
 terminal pathway defects 179, 179 *T*
 complement-dependent opsonization, acute otitis media 916
 compliance
 communication, medical
 consultations 562–3
 definition 562

- composite cartilage grafts 2825
 nasal reconstruction 3022–3, 3024 *F*
 graft size 3018
- composite fibular flap, mandibular
 resection 2558–9, 2558 *F*, 2559 *F*
- composite mandibular defects 2886–7
 issues 2886–7
 options 2887, 2887 *T*
 problems 2887
- compound action potentials (CAP),
 auditory neuropathy/
 dyssynchrony 3844 *T*
- compound muscle action potentials
 (CMAP)
- facial nerve monitoring 748, 749
 outcome prediction 749–50
 facial nerve paralysis 3879
- compressed speech test, central
 auditory dysfunction 3860
- compression (descent)
 injuries 3503 *F*, 3504–6
 physiological consequences 3502–3
- compression inner ear barotrauma *see*
 inner ear barotrauma
- computed tomography (CT)
 adenoid cystic carcinoma 2499
 arachnoid cysts 4013
 cerebrospinal fluid rhinorrhoea 1638,
 1639 *F*
 cervical lymph node
 assessment 1760–1
 children 1297, 1298 *F*
 choanal atresia 1297
 cholesteatoma 3431–2, 3432 *T*
 chronic otitis media 3419, 3420 *T*
 false positive findings 3419–20
 chronic rhinosinusitis 1479 *T*, 1480 *F*
 cochlear implantation 863
 concha bullosa 1592
 craniosynostosis 1022, 1023 *F*
 dacryocystorhinostomy preoperative
 assessment 1691
 dysphagia 1967–8, 2028
 ectopic parathyroids 392
 encephalomeningocele 1035, 1035 *F*
 epidermoids 4011
 epiglottitis 2250
 external auditory canal exostosis 3367
 facial nerve 3881, 3883 *F*
 frontal sinus 1502
 frontal sinus osteoma 1502 *F*
 fungal rhinosinusitis
 acute fulminant 1455
 allergic 221, 1453–4, 1453 *F*
 chronic invasive 218
- invasive 218
 noninvasive 219–20
- fungus ball 1452, 1452 *F*
- glioma 1505 *F*
- glomus temporale tumour 4032
- head and neck sarcomas 1931
- hyperparathyroidism 392
- hypopharyngeal cancer 2643–4,
 2643 *F*
- hypothyroidism 336
- implant osseointegration 2911–2
- inverted papilloma 1503 *F*, 1523
- jugular foramen lesions 4029, 4042
- juvenile angioblastoma 2124, 2438–9,
 2439 *F*
- laryngeal stenosis 2279–80
- laryngeal trauma 2273
 3D scans 2273
- laryngeal tumours 2607, 2607 *F*
- laryngopyocele 2255, 2256 *F*
- larynx 1297
- lipomas 4013
- malignant otitis externa 3338
- meningiomas 736, 4009
- metastatic neck disease 2720
- mucocoeles 1533–4
 ethmoidal 1533 *F*, 1534 *F*
 frontal 1533 *F*, 1534 *F*
 sphenoid 1534 *F*
- mucosal malignant melanoma 2409,
 2411 *F*
- nasal endoscopy and 1344
 inflammatory diseases 1350, 1350 *F*
- nasal inflammation 1350, 1350 *F*
- nasal polypsis 1553, 1553 *T*
- nasopharyngeal carcinoma 2456–7,
 2457 *F*
- nasopharyngeal tuberculosis 2121
- neck 1755
- neck trauma 1769
- neurofibromatosis 2 4002
- nodular thyroid disease 333, 334, 361,
 362, 2677
- objective tinnitus 3601
- oesophageal carcinoma 2068, 2068 *F*
- olfactory dysfunction 1666
- orbital cellulitis 1542–3, 1545 *F*
- orbital floor fractures 1630–1, 1631 *F*
- otalgia 3534
- otosclerosis 3464
- Paget's disease 3488
- paragangliomas 736–9
- parapharyngeal space tumours 2525 *F*,
 2530
- parathyroid glands 384
- peritonsillar abscess 1997
- petrous apex chondrosarcoma 4049,
 4050 *F*
- petrous apex cysts 4047, 4048, 4048 *F*,
 4049 *F*
- petrous apex tumours 4048
- pituitary gland 306
- pituitary tumours 306
 craniopharyngioma 4103–4
 malignant 4104
 nonfunctioning adenomas 4103
 technological advances 307
- prolactinoma 305
- prosthetic reconstruction 2941
- retropharyngeal abscess 1223,
 1223 *F*
- rhinosinusitis 1442–3
- salivary gland calculi 1880, 1880 *F*
- salivary glands 1876–7, 1877 *F*
 advantages/disadvantages 1874 *T*
 artefacts 1876–7
 contrast media 1876–7
 indications 1890 *T*
 slice thickness 1876
- salivary gland tumours,
 malignant 1885, 2506–7, 2506 *F*
- sarcoidosis diagnosis 1648, 1649 *F*
- schwannomas
 facial nerve 4014
 trigeminal nerve 4014
 vestibular 3959
- sinus surgery 306
- skull base lesions 3947
- snoring 2329
- subperiosteal implants 2902–3
- surgical implications 551
- temporal bone fractures 3495,
 3495 *F*
- temporal bone tumours 4069, 4090,
 4090 *F*
- thyroid cancer 333
- thyroid eye disease 344
- thyroid gland 328
- tinnitus 3610
- tuberculous otitis 3449
- vestibular schwannoma 3959
- Wegener's granulomatosis 1651 *F*,
 1652, 1652 *F*
- computed tomography (CT)
- cisternography 1638
- computer-aided design, computer aided
 manufacture (CAD/CAM),
 subperiosteal implants 2902–3
- computer-assisted surgery (CAS),
 rhinosinusitis 1484

- computer assisted three-dimensional (3D) navigation systems, jugular foramen surgery 4034
- computerized dynamic posturography (CDP) systems 3733
- computer software, prosthetic reconstruction 2941
- concha bullosa 1334 *F*, 1335 *T*
- conchae *see* turbinates
- conchal cartilage grafting
- augmentation rhinoplasty 2973, 2974 *F*
 - nasal reconstruction 3023
 - pinna reconstruction 3033
 - saddle nose 2975–6
- conchal crest 1341
- condenser microphone 3169–70
- conditioned taste aversions, cancer treatment 1844
- conductive audiogram, otosclerosis 3827
- conductive hearing impairment 811–2
- active mucosal chronic otitis media 3423–4
 - bone-anchored hearing aids
 - bilateral 3646
 - unilateral 3644–6, 3646 - otitis media with effusion, childhood 892–3, 893 *T*
 - otosclerosis 3456, 3465–6
 - hearing aids 3467
 - post-stapes surgery 3475
 - tuberculous otitis 3448
- conduit devices, nervous tissue engineering 126
- condylar neck fractures 1622, 1624–5
- condylomas, oral 1828
- cones 3914
- The Confidential Enquiry into Perioperative Deaths (CEPOD) 478–9
- confidentiality 602
- data collection, head and neck cancer 2374
 - ethical issues 586–7, 589
 - medical negligence and 2805
 - see also* disclosure
- confounding 624–5
- confusional states, acute *see* acute confusional states
- congenital cytomegalovirus
- childhood deafness 846, 851
 - vertigo 1048
- congenital deafness 845–7
- drug therapy 818
 - genetic manipulation 817–8
- intervention timing 818
- prenatal tests 818
- congenital ear defects, paediatric anaesthesia 514
- congenital hypothyroidism (cretinism) 400
- clinical features 400, 2667
 - incidence 400
 - neonatal iodine deficiency 356
 - treatment 400
- congenital isolated stapes
- ankylosis 870 *T*, 871–2
- congenital nasal cysts 1073–4
- congenital nasal masses 1074–6
- congenital nystagmus 3725, 3725 *F*, 3922
- congenital oesophageal stenosis 1287–8
- clinical features 1287
 - diagnosis 1287–8
 - treatment 1288
- congenital ossicular abnormalities
- classification 869–70, 870 *T*
 - clinical presentation 871
 - definition 869
 - incidence 870–1
 - investigation 871
 - investigations 871
 - isolated non-stapes anomalies 870 *T*, 872
 - management 871–3
 - principles 871
- congenital permanent bilateral hearing loss 823–4
- risk factors 824
- congenital rubella syndrome (CRS) 846, 846 *F*
- congenital sideroblastic anaemia 269
- congenital stapes footplate fixation 872
- congenital subglottic stenosis 1139–40, 1139 *F*
- airway compromise 1139
 - diagnosis 1139
 - grading 1139–40
 - surgical options 1139
- congenital syphilis
- childhood deafness 846
 - infant 1462
 - nasal 1462, 1703
 - puberty 1462
 - treatment 1462
- congenital venous malformations, ultrasound examination 726
- Conidiobolus coronatus* 215
- conjunctivochalasis, post-blepharoplasty 3065
- conjugate gaze palsy 3920
- Connecting for Health* 570
- connective tissue diseases 1711–3
- ENA antibodies 170
 - see also* specific disorders
- connexin(s) 68
- definition 68
 - connexin 26 mutation 818
 - consensual light reflex, blind eye 3916
- consent
- anaesthesia 462–3
 - children 585–6
 - medical research 589
 - ethical issues 585–6
 - research participation 589
 - facial plastic surgery 3089
 - Jehovah's Witnesses 601
 - laryngoscopy 2147
 - medical negligence 600–1, 1732, 2806–7
 - tonsillectomy 1308
 - mental incapacity 601
 - paediatric consultation 780–1
 - postoperative bleeding and 1308
 - process 462
 - risk perception 563
 - surgery 461–2, 551–2
 - treatment refusal 586
- consent forms 462
- conservation neck dissection, N_{2c} disease 2726
- conservative parotidectomy
- cosmetic defects 2484
 - facial nerve identification 2485 *F*
 - informed consent 2483–4
 - procedure 2484–7
- consonant discrimination tests 841
- consonants 2166
- manner of articulation 2167
 - paired 2167
 - place of articulation 2166–7
- consonant–vowel sequences 2172–4
- constant domains/regions, antibodies 135
- constipation, palliative care
- patients 2791
 - management 2791, 2792 *T*
 - symptoms 2791
- constrictor muscles, pharynx 1947, 1947–9, 1948 *T*, 1949 *F*, 1955
- construct validity 635
- consultation communication *see* communication, medical consultations

consumerism
 consultation style 560, 560 *F*
 doctor-patient relationship 582

contact dermatitis
 external nose 1714–5, 1715
 food 1

contact endoscopy 762–8
 chronic laryngitis 2260–1
 current knowledge/future
 research 767

historical aspects 762

larynx 763–4
 abnormal appearance 763–4, 765
 normal appearance 763

method/technical details 763
 methylene blue staining 762–3, 763

microvascular changes 762–3, 764

nasal cavity 764–6
 abnormal appearance 764–6
 normal appearance 764
 utility 764

nasopharyngeal carcinoma 766–7

nasopharynx 766–7
 abnormal appearance 766–7
 normal appearance 766

oral cavity 767

utility 762–3, 767
 microvascular changes 762–3

contact granuloma *see* arytenoid granuloma

contact pachydermia *see* arytenoid granuloma

‘contact point pain’ 1723–4

contact quotient measurement, voice evaluation 2179

contact ulcer *see* arytenoid granuloma

contact urticaria 1

content validity 635

continuing professional development
see surgical training

continuous positive airway pressure (CPAP)
 acute airway obstruction 1124
 compliance and troubleshooting 2321
 masks 2320
 obstructive sleep apnoea 1108–9,
 1591, 2320–1

paediatric tonsillectomy 515

side effects 2321
 titration 2320–1
 treatment failure 2321

continuous renal replacement therapy (CRRT) 530

continuous-wave Doppler
 ultrasound 714

contralateral routing of signals (CROS)
 hearing aids 3640–1, 3646

contrast-enhanced CT (CE-CT)
 salivary gland tumours 1885
 sialadenitis, acute 1880, 1881 *F*

contrast swallow
 aspiration investigations 2096
 pharyngeal pouch 2044, 2045 *F*

conus elasicus 2134

convection, nasal 1356

Cooperative Study of Sickle Cell Disease 271

co-operative test, hearing 841

COOP-WONCA system, post-laryngectomy rehabilitation 2630

Copenhagen allergy study 1560–1

cophenolcaine(tm), epistaxis 1064

coping skills, head and neck cancer patients 2777

‘copper-beaten appearance,’ raised intracranial pressure 1023, 1024 *F*

coral, bone repair 124, 125 *F*

cordal polyposis *see* Reinke’s oedema

cordectomy 2613

Corlan *see* hydrocortisone

corneal abrasion prevention, post-blepharoplasty 3066

corneal irritation, post-blepharoplasty 3065

corneal protectors
 eyelid surgery 3095
 unilateral facial palsy 3079

corneal reflex 3923
 absence 3923
 skull base lesions 3946

corneal ulceration, thyroid eye disease 344

corniculate cartilages 2133

coronal approach, zygomatic complex fractures 1629 *T*

coronal synostosis 1025
 bilateral 1022 *T*, 1025
 genetic testing 1021
 surgery 1025–6
 unilateral 1022 *T*, 1025

coronavirus 205

coroners
 medical jurisprudence 602–3
 reportable deaths 602

cor pulmonale 1136

corpus callosum, central auditory dysfunction 3857–8, 3862

corpus luteum 302

cortical mastoidectomy
 active mucosal chronic otitis media 3425

vestibular schwannoma, translabyrinthine approach 3969–70, 3969 *F*

corticobulbar tract, phonation 2158

corticosteroids 418–28
 adenoids 422
 allergic rhinitis 419–20, 1398–9
 allergy 153
 angioedema 421
 anosmia 421
 Bell’s palsy 424, 3886
 chronic rhinosinusitis 1470
 cilia, effects on 1361
 critical care patients 536
 croup 422, 1128–9
 density 418
 ear drops 419
 enlarged turbinates 1592
 eosinophil apoptosis induction 62
 epiglottitis 422
 facial palsy 424
 hyposmia 421
 idiopathic rhinitis 420
 idiopathic sudden sensorineural hearing loss 1, 423, 3584–8,
 3585 *T*, 3589, 3589 *T*

infectious mononucleosis 422, 1225,
 2004

intramuscular depot-injection 419

intranasal 419
 children 420
 side effects 419

intravenous 418–9

jugular foramen lesions 4042

keloids 2893

laryngeal trauma 2274

Menière’s disease 423–4

mononucleosis 422

mucous membrane pemphigoid 1834

myasthenia gravis 2077

nasal function 1366

nasal polypsis 421, 437–8, 1470,
 1554–5, 1555
 adverse effects 1555

nasal airway patency 1554

recurrence 1554–5

responsiveness 1554

rhinitis symptoms 1554

safety 1555

sense of smell 1554

size reduction 1554, 1554 *F*

- obstructive sleep apnoea 1110
 oesophageal corrosive injury 1291
 olfactory dysfunction 1670–1
 oral 419
 otitis externa 422–3, 430
 otitis media
 acute 423
 chronic 423
 otitis media with effusion 423, 895
 pharmacodynamics 418
 pharmacokinetics 418–9
 pharyngitis 422
 pregnancy 420
 recurrent aphthous stomatitis 1830–1
 replacement after
 hypophysectomy 4111
 rhinitis medicamentosa 421
 rhinosinusitis 436–8
 sarcoidosis 424
 scar revision 2898–9
 sepsis 536
 side effects 419
 sinusitis 421
 Sjögren syndrome 1913
 sudden sensorineural hearing loss 434
 thyroid eye disease 345
 tonsillectomy 422
 topical
 allergy 153
 medical negligence 3831
 otitis media with effusion 895
 rhinosinusitis, paediatric 1083
 upper airway obstruction 2288
 vestibular attacks, acute 3797
 vestibular neuritis 3756
 Wegener's granulomatosis 424
see also individual corticosteroids
 corticotrophs, pituitary gland 297
 corticotropin releasing factor (CRF)
 test 310
 corticotropin-releasing hormone 300
 cortilymph 3189
Corynebacteria 195–6, 198–9
Corynebacterium diphtheriae 198–9,
 199 F, 1130, 2079, 2252
Corynebacterium ulcerans 198–9
 Coryzal syndrome 207
 cosmetics, scar revision 2899
 costal cartilage
 augmentation rhinoplasty 2972, 2973
 calcification 3044–5
 laryngotracheal reconstruction 521
 pinna reconstruction 3033–5, 3038 F
 harvesting 3036
 postoperative pain 3036
 Costen's syndrome 3530
 costochondral grafting, hemifacial
 microsomia 1033
 cotrimoxazole 1653
 Cottle and van Dishoeck nasal
 surgery 1577
 cough/coughing
 larynx in 2159, 2217
 pertussis 2252
 cough medicines 449
 over-the-counter preparations 449
 cough suppressants 449
 coup/contrecoup injury 1667
 cover/body theory 2160
 Cowden's disease 2671
 cow's milk allergy 1425, 1427
 Coxsackie virus, mouth ulcers 1833
 Cox's proportional hazards model
 hypopharyngeal cancer 2653–5
 mucosal malignant melanoma
 survival 2412–3, 2413
 salivary gland tumour survival
 2514
 crack cocaine, septal perforations 1582
 Crane principle, skin grafts 2821
 cranialization, frontal sinus 1518
 fractures 1507
 operative technique 1518
 postoperative complications 1518
 results 1518
 cranial nerve(s) 3911
 diabetic neuropathy 402
 group 1 3911–22
 group 2 3923–33
 group 3 3933–40
 lower
 skull base lesions 3945
 surgery-induced injury 4137
 neck trauma 1767
 otalgia 3527
 preservation, vestibular
 schwannoma 3992
 pretrematic branch 1052
 surgery-induced injury 4136–7
 meningioma surgery 4010–1
 see also individual nerves
 cranial nerve 0 (terminal nerve) 1662
 cranial nerve palsy
 isolated 4144
 lower, vestibular schwannoma
 removal 3980–1
 post-jugular foramen surgery 4041
 rabies 2079
 temporal bone resection
 complication 4094
 cranial neuropathies, vestibular
 schwannoma removal 3979–81
 cranial root injury, glossopharyngeal
 neuralgia 3531
 cranial sutures 1020
 craniectomy
 craniosynostosis 1024
 vestibular schwannoma 3974
 craniofacial and skull base
 surgery 4119–34
 approaches 4127–32
 complications 4132–3, 4132 F
 historical aspects 4120
 postoperative CSF leakage 4127
 results 4132–3
 surgical anatomy 4120–2
 surgical principles 4127
 surgical team 4120
 survival figures 4133, 4133 T
 see also individual techniques
 craniofacial anomalies 1019–39
 chronic otitis media 3409
 classification 1019–20
 future research areas 1037
 genetics 1021
 knowledge deficiencies 1037
 management 1019–39
 principles 1019
 multidisciplinary team 1020 T
 otitis media with effusion 903
 prenatal diagnosis 1021
 reconstruction 2926
 see also individual anomalies
 craniofacial bone repair, tissue
 engineering 124, 125 F
 scaffold types 124
 craniofacial clefts 799, 802 F,
 1035–6
 aetiology 1035
 classification 997, 1036
 clinical features 1036, 1036 F
 management 1036
 craniofacial resection, anterior *see*
 anterior craniofacial resection
 craniofacial resection (CFR)
 anterior *see* anterior craniofacial
 resection
 anterolateral *see* anterolateral
 craniofacial resection
 historical aspects 4120
 lateral, sinonasal malignancy
 2434
 type I 2431
 type II 2431–3
 type III 2433, 2433 F

craniofacial surgery
paediatric intensive care 546
skull base surgery and *see* craniofacial and skull base surgery
craniofrontonasal syndrome 1028
craniomandibular joint *see* temporomandibular joint (TMJ)
craniopharyngiomas 2033, 4103–4
craniosynostosis 1020–7
aetiology 1021
classification 1020
clinical assessment 1022, 1022 *T*
clinical consequences 1021–2
cranial volume 1021–2
definition 1020
differential diagnosis 1024
endoscopic treatment 1027
familial 1021
genetics 813 *T*, 1021
hydrocephalus 1023
imaging 1022, 1023 *F*
incidence 1021
nonsyndromic
aetiology 1021
definition 1020
incidence 1021
raised intracranial pressure 1023
single suture 1025–6
pathogenesis 1021–2
prenatal diagnosis 1021
primary 1020
raised intracranial pressure 1022–3, 1024 *F*
restenosis 1024, 1031
secondary 1020
surgical management 1024–5
indications 1024
timing 1024
surgical outcomes 1031
reoperation rates 1031, 1032 *T*
syndromic 1027–31
aetiology 1021
airway management 1028
correction 1029
definition 1020
feeding problems 1029
incidence 1021
management 1028
raised intracranial pressure 1023, 1029
surgical complications 1030–1
blood loss 1030–1
surgical procedures 1029

surgical timing 1029
visual complications 1028–9
types 1022 *T*
craniotomy
cerebrospinal fluid
rhinorrhoea 1636–7, 1640
extended/basal frontal
approach 4130–2
contraindications 4130–2
indications 4130
middle fossa 3449, 4020
vestibular schwannoma 3975
C-reactive protein (CRP) 168
creaky voice (vocal pulse register) 2161, 2162 *T*
creatine 380–1
crescentric advancement 2834, 2839 *F*
CREST syndrome 1712–3, 2031
cretinism *see* congenital hypothyroidism (cretinism)
Creutzfeldt–Jakob disease (CJD)
cerebellar ataxia 3775
variant *see* variant Creutzfeldt–Jakob disease (vCJD)
criatrical tracheal stenosis 2283
cribiform plate 3897, 4120
development 1318
Crib-o-gram 3290
cribroethmoid foramen 4120
cricoarytenoids 2136 *T*
cricoid cartilage 2133, 2133 *F*
development 2130
integrity, tracheostomy 2301
surface anatomy 1740
cricoidectomy, intractable aspiration
management
partial submucosal 2101
subperichondrial 2100, 2101 *F*
cricoid grafting, posterior glottic
stenosis 1161
cricoid hook, tracheostomy 2296
cricoid pressure, anaesthesia 496
cricoid ring, children 1151
cricopharyngeal myotomy
intractable aspiration 2098, 2099–100
neurological dysphagia 2081
pharyngeal pouch 2049, 2054, 2059
cricopharyngeal spasm
barium swallow appearance 2027 *F*
management 2097
cricopharyngeus 1947, 1948 *T*, 1955
innervation 1948 *T*, 1950
spasm, pharyngeal pouch
aetiology 2045–6
cricothyroid artery 2139

cricothyroid ligament 2134
cricothyroid membrane (CTM) 476
laryngeal trauma 2271–2
cricothyroid muscle 2136 *T*
muscle tension dysphonia 2204
paralysis, vagus nerve lesions 2223
pubertal changes 2205
cricothyroidotomy 2294
equipment 2294 *F*
neck trauma 1766–7
upper airway obstruction 2288, 2290–1
cricothyrotomy, difficult airways 477
cricotracheal ligament 2133–4
cricotracheal resection (CTR) 1163–4, 1163 *F*
cricovocal ligament 2134
cri-du-chat syndrome 1138
Crile (Y type) incision 2731–3
criminal law 607–9
crista ampullaris 3153–4, 3153 *F*
hair cells 3228
ototoxic drugs 3677 *F*
crista ethmoidalis 1598
crista galli 1318, 4120
criterion validity 635
critical appraisal skills 649–72
basic principles 651–2
bias 652, 659
diagnosis articles 654–8, 656 *T*, 668, 670 *F*
levels of evidence 649, 665–8, 666
question formation 650, 651–2, 652–4, 653 *F*
statistics 652
systematic reviews 649, 650, 661–5, 671 *F*
treatment articles 653, 658–61, 668, 671 *F*
validity 649–52, 654–5
value 649–50
worksheets 668, 669 *F*, 670 *F*, 671 *F*
critical bandwidth (CB) 3247
critical bandwidth for loudness summation 3251
critical care 526–41
activated C protein 535–6
airway management 533
cardiovascular support 528–30
children *see* paediatric intensive care
communication with relatives 536
definition 526–7
early goal-directed therapy 535
end of life issues 536–7
ENT, interface between 533–4

- evidence-based strategies 535–6
 fluid therapy 529, 532 *T*
 immunonutrition 532–3
 nutritional support 530–3, 532 *T*
 organ system support 527–33
 post-head/neck trauma 533
 post-surgery care 533
 renal support 528–30
 respiratory support 527–8
 severe sepsis 534–5
 investigations 534, 534–5
 treatment limitations 537
 critical closing pressure, blood vessels 112
 Crohn's disease
 dysphagia 2032
 oral manifestations 1828
 ulceration 1828, 1834
 salivary glands 1906
 Cronbach's alpha 636, 641
 cross-facial nerve graft 3080, 3080 *F*
 cross-sectional studies,
 epidemiology 626–7
 croup 1128–9, 2251
 causative agents 205 *T*, 1130, 2251
 clinical features 1128, 2251
 incidence 1128, 2251
 investigations 2251
 management 1128, 2251
 corticosteroids 422, 1128–9
 medical negligence 1309
 paediatric intensive care 545
 stridor 1128
 subglottic oedema 1128, 2251
 Crouzon syndrome 968, 1027, 1713,
 2120
 clinical features 1027
 distraction osteogenesis 1030 *F*
 incidence 1021, 1027
 nasopharyngeal airway 1109
 nasopharyngeal narrowing 2120
 cryoglobulinaemia 171
 cryoprecipitate 258 *T*, 259
 disseminated intravascular coagulation 259, 284
 cryosurgery, basal cell carcinoma 2397
 cryptococcal meningitis, HIV
 patients 247
 cryptococcosis 1703–4
Cryptococcus neoformans, HIV
 patients 247
 cryptotia (hidden ear) 973, 974 *F*
 crystal arthropathies 188
 crystalloid fluids 529
 crystalloids 257
- 'cued speech' 3851
 cuffed tracheostomy tubes 2298
 anaesthesia 492–3
 children 1201
 cuneiform cartilages 2133
 cup ears 973
 cupula
 biomechanics 3211
 deflection 3212
 deflection, head angular velocity 3212
 deviation 3154–5
 displacement 3212
 hair cell movement 3230
 function 3153–4
 hair cells 3228
 structure 3153–4
 cupulolithiasis 3678–80, 3760, 3761
 post-rotation manoeuvres 3814
 cupulometry 3740
 curare notch, capnograms 499 *F*
 curriculum development project,
 surgical training 553, 554 *T*, 555 *T*
- Curvularia*
 allergic fungal rhinosinusitis 221,
 1452–3
 fungal rhinosinusitis 217, 1450 *T*
- Cushing's disease 309–11, 4101–2
 causes 401
 Cushing's syndrome *vs.* 310–1
 diagnosis 4101
 medical management 4102
 pituitary adenomas 304
 pituitary hyperplasia 304
 presentation 4101
 tests 310–1
 postoperative period 312
 treatment options 4102
 medical treatment 4102
 radiotherapy 4102
 see also Cushing's syndrome
- Cushing's syndrome 309–11, 4101
 aetiology 310, 401
 Cushing's disease *vs.* 310–1
 diagnosis 309–10, 4101–2
 hypokalaemic alkalosis 310
 screening 309
 see also Cushing's disease
- cuspid teeth *see* canines
 cusplet of Carabelli 1804
 cutaneous axial median forehead
 flap 2846, 2848, 2844 *F*
 cutaneous cysts, nasal 1708–9
 cutaneous defect reconstructions 2887
 issues 2887
 options 2887
- cutaneous lesions, neurofibromatosis 2
 4001, 4001 *F*
 cuticular plate, stereocilia 3132–3,
 3132 *F*, 3133 *F*
 organization 3134
Cyamopsis tetragonoloba 1418
 cyclic adenosine 3', 5'-monophosphate (cAMP)
 salivary secretion 1859–60
 thyroid cancer 2670
 cyclical neutropenia 177 *T*, 178
 cyclin(s) 58
 cyclin A 2382
 cyclin D1 2382
 hypopharyngeal cancer 2636
 cyclizine
 motion sickness 3795
 nausea and vomiting, head and neck cancer 2787–8
 vestibular attacks, acute 3795,
 3796 *T*
- cyclo-oxygenase 2 (COX-2)
 inhibitors 41
- cyclophosphamide
 side effects 415, 1652–3
 Sjögren syndrome 1913
 Wegener's granulomatosis 1652–3
- cyfra 21-1 2386–90 *T*
- cyst(s)
 arachnoid *see* arachnoid cysts
 botryoid odontogenic 1925
 branchial *see* branchial cysts
 bronchial 1147, 1782
 bronchogenic 1147
 bursa pharyngeal embryonalis (Thornwaldt's) 1074, 2122
 CPA tumours 4014
 definition 1922
 dentigerous 1074, 1924, 1924 *F*
 dermoid *see* dermoid cyst
 dysontogenetic cysts 724
 frontal sinus *see* frontal sinus cysts
 gingival
 adults 1926
 of infancy 1926
 globulomaxillary 1320–1
 jaws *see* jaw cysts
 lateral cervical *see* branchial cysts
 lymph nodes 717, 717 *F*, 718 *F*
 lymphoepithelial 245–6, 245 *F*, 1914
 'machinery oil' 4103
 nasal 1073–4, 1708–9
 nasolabial (nasoalveolar) 1074,
 1320–1, 1926
 nasopalatine duct 1926 *F*

cyst(s) (*continued*)
 odontogenic *see* odontogenic cysts
 palatal, of infancy 1926
 parotid gland 1246, 1246 *F*
 periapical 1817
 petrous apex 4047, 4051 *F*
 radicular *see* radicular cyst
 Rathke's pouch 4103
 residual 1817, 1924
 saccular 1136–7, 1137 *F*
 simple (solitary) bone 1926–7
 thyroglossal duct *see* thyroglossal duct
 cysts
 tracheal, congenital cysts 1147
 ultrasound 724–5, 1297, 1297 *F*
 lymph nodes 717, 717 *F*, 718 *F*, 724
 ranulas 725
 ventricular 2201
 vestibular schwannoma 3960–1,
 3961 *F*
 vocal folds *see* vocal fold cysts
see also individual types
 cystic fibrosis (CF)
 bio-electric phenotype 24
 children 1081
 chloride channel defect 24
 diagnosis 1866
 gene therapy 24–6
 adeno-associated virus 25
 adenovirus vectors 24, 24–5
 animal models 24
 clinical trials 24
 intrapulmonary administration 24,
 25
in vitro studies 24
 lentivirus 25
 liposomes 25–6
 nasal model 24
 nasal mucosa 24
 nonviral vectors 24–5
 pulmonary toxicity 24–5
 vector-induced inflammation 25
 genetics 24
 nasal polyposis 1550
 histology 1550
 mucosal abnormalities 1550
 salivary glands 1866
 cystic fibrosis sinus disease, gene
 therapy 24
 cystic fibrosis transmembrane
 conductance regulator (CFTR) 24
 cystic hygroma 1782–3
 embryology 1269
 histology 1270 *F*, 1782
 investigation 726, 1270

management 1782–3
 natural history 1270
 presentation 1269–70, 1270 *F*, 1782
 treatment 1270
 cystic lesions, neck 1777–9
 lateral *see* branchial cysts
 cystic nodules, thyroid 363
 cystic vestibular schwannoma 3960–1,
 3961 *F*
Cystophora cristata (hooded seal),
 exostosis 3367
 cytochrome P-450 410–1
 cytogenetics 6–7
 tumours 6
 cytokines
 mucocoeles 1532
 nasal mucus 1361
 nasal polyposis 1552
 salivary gland tumours 2495
 stimulatory pathways, immune
 modulation 28
 cytomegalovirus (CMV)
 congenital *see* congenital
 cytomegalovirus
 HIV-associated infection 240–1
 oesophagitis 245
 pharyngeal infection 2004
 testing, donated blood 260
 cytosine 3
 cytoskeleton 2385
 cytosolic infectious agents 140
 cytotoxic agents
 adverse effects 40
 apoptosis 36
 ototoxicity 3677
 therapeutic limitations 40
 cytotoxic antibiotics 38
 cytotoxic drug reactions 414
 dacrocystogram 1691
 dacryocystitis 1689, 1690 *F*
 dacryocystorhinostomy (DCR) 1689–98
 antimitotic agents 1695–6
 children 1696
 complications 1695
 historical aspects 1689–90
 indications 1690–1
 operative techniques 1691–4
 balloon dacryocystoplasty 1694
 endonasal, conventional
 instruments 1692, 1692 *F*,
 1692 *T*, 1693 *F*
 endonasal laser *see* endonasal laser
 dacryocystorhinostomy
 (ELDCR)
 external 1691, 1692 *T*
 transcanicular 1689
 variations 1694–5
 post-surgical nasal endoscopy 1352
 preoperative assessment 1691
 inferior canalculus probing 1691,
 1691 *F*
 surgical anatomy 1690
 dacryoscintigraphy,
 pre-dacryocystorhinostomy 1691
 daily personal noise exposure level 3171
 dairy free diet, chronic
 rhinosinusitis 1473
 Dalton's Law 3501 *T*, 3516
 damages, medical negligence *see*
 medical negligence
 damper, hearing aids 3632
 damping, vibrations 3161
 Danazol, laryngeal enlargement 2201
 Dandy's (chronic vestibular
 insufficiency) syndrome 3749,
 3750 *F*
 Dandy's vein, surgical injury 3978
 Dandy–Walker syndrome 1823–4, 2080
 Danish Head and Neck Cancer Study
 Group (DAHANCA) 2754–5,
 2756
 dantron 2791
 dapson
 leprosy 1464
 relapsing polychondritis 3364
 'dark' cells, vestibular labyrinth 3155
 dark-skin, face lifts 3094
 Darwin's tubercle 972, 3105–6
 data collection, head and neck
 cancer 2372–7
 coding classifications 2374–5
 ICD-0-3 morphology 2374–5,
 2375 *T*
 ICD-10 tumour site 2374, 2374 *T*,
 2375 *T*
 operation and procedure 2375,
 2375 *T*
 comparative audit 2376
 computerized database structure 2374
 confidentiality 2374
 developmental stages 2373–4,
 2373 *F*
 methods, historical 2373
 minimum data set principles 2373
 National Cancer Data Set 2375–6,
 2376
 national coordination, value 2375
 national minimum data set 2375
 purpose 2372–3

Data for Head and Neck Oncology
 (DAHNO) audit service 572, 2376
 data protection, ethical issues 587, 589
 Data Protection Act (1984) 587
 Data Protection Act (1997) 602
 Data Protection Act (1998) 606
 daunorubicin 38
 daytime sleepiness assessment 2315
 DCIA-flaps, intra-oral
 reconstruction 2935, 2936 *F*
 DDAVP 308, 4112
 dead ear, cholesteatoma surgical
 complication 3434
 deaf child *see* childhood deafness
 deaf community 566
 deaf educational units 855
 deafness
 categorization 811
 children *see* childhood deafness
 genetic research 20
 animal models 20
 misdiagnosis 1306
 morphogenetic defects 811–2
 neuroepithelial 811–2
 nonsyndromic 811
 polygenic features 16
 single gene mutations 16
 sudden *see* idiopathic sudden
 sensorineural hearing loss
 (ISSNHL)
 tuberculous otitis 3447, 3447 *T*,
 3450 *T*
 types 811–2
 deaf schools 855
 death domain (DD) 58
 death receptor(s) (DR) 57–8
 death receptor 5 (DR5) 57
 decalcification, teeth 1816
 decibels (dB) 3174–5
 calculation 3174–5
 decibel scales 3170
 decibel sound pressure level (dB SPL)
 scale 3174
 decibels sensation level 3175
 Declaration of Helsinki 589
 decompression (ascent)
 injuries 3513–4
 physiological consequences 3503–4
 decompression illness 3514–6
 bubbles 3514–5
 inner ear 3516
 hyperbaric oxygen therapy 3515–6
 pathophysiology 3514–5
 peripheral vasoconstriction 3515
 tissue perfusion rates 3515

decongestants
 acute otitis media 918
 allergic rhinitis 1398
 chronic rhinosinusitis 1470
 otitis media with effusion 896
 rhinitis induction 1410
 rhinomanometry, normal nasal
 airflow effects 1374
 rhinosinusitis 439–40, 1543
 children 1083
 side effects 1398
 sinusitis, HIV patients 242
 deep auricular artery 3907
 deep bronchial veins 2142
 deep cervical fascia 1743, 2108
 deep layer/prevertebral fascia 1743,
 2109
 middle layer 1743, 2108
 pretracheal/ visceral layer 316–7,
 1743, 2108
 superficial/investing layer 1743, 2108
 deep circumflex iliac artery flap 2878–9
 advantages 2878
 anatomy 2878, 2878 *F*
 clinical applications 2879, 2879 *F*,
 2880 *F*
 disadvantages 2878–9
 oral cavity reconstruction 2571,
 2571 *F*
 technical nuances 2879
 deep inferior epigastric perforator
 flaps 2876–8, 2877 *F*
 advantages 2876
 anatomy 2876
 clinical applications 2877–8
 disadvantages 2877
 technical nuances 2877
 deep lingual artery 1799
 deep lingual vein 1793 *F*, 1799
 deep neck space abscesses 1785–6
 airway compromise 1786
 clinical features 1786
 investigations 1786
 management 1786
see also individual types
 deep petrosal nerve 3903, 3910,
 3928
 deep vein thrombosis (DVT)
 heparin 447
 perioperative management 289
 treatment 288
 defaecation, laryngeal effort
 closure 2159
 default consultation style 560, 560 *F*
 defence mechanisms 133–43

deferoxamine
 ototoxicity prevention and 3302
 skin flap survival 113
 deficiency glossitis 1828–9
 deformity
 surgery-induced 3091
 wound contraction 91
see also specific types
 degenerative vestibulopathy 3698,
 3699 *F*
 deglutition *see* swallowing
 degrees of freedom 3208
 dehiscent superior semicircular canal
 syndrome 1046–7
 dehydrated alcohol, skull base tumour
 embolization 3952
 dehydroepiandrosterone sulphate assay
 (DHA-S), salivary 1867
 Deiters' cell cup 3132 *F*
 Deiters' cells 3123, 3130, 3131 *F*, 3132 *F*,
 3136
 phalangeal process 3132 *F*, 3136
 Delaire-type repair, cleft lip and
 palate 1004, 1005 *F*
 deletions (DNA) 16
Delivering the NHS Plan 570–1
 Delphian node 2601
 deltopectoral flap 2853–4, 2854 *F*
 transfer planning 2854
 De Meester score 2063–4
 dementia, hyperparathyroidism and
 391
 demulcent cough preparations 449
 demyelination, auditory neuropathy/
 dyssynchrony 3848
 denasalization, consonants 2167
 dendritic cells
 allergic response 151–2
 nasal mucus 1361
 denervation, stem cell proliferation 70
 Denny's lines 1082, 1082 *F*
 dens, axis 2111
 dental abscess 1817
 bacterioids 1817
 children 1213, 1214 *F*
 diagnosis 1817
 discharge 1817
 drainage 1807
 granuloma formation 1817
 dental aplasia 1817
 dental bud 799–800
 dental caries 1816–7
 causative agents 1816
 decay progression 1816
 infection spread 1805

- dental caries (*continued*)
 otalgia 3529
 differential diagnosis 3529
 saliva and 1866
 Sjögren syndrome 1911, 1911 *F*
 dental consonants 2166–7, 2167 *T*
 dental disease
 benign 1816–39
 otalgia 3529
 dental lamina 1922–4
 dental pain 1721
 dental papilla 799–800
 dental plaque 1816
 dental prostheses
 ionomer cements 120
 taste abnormalities 1848
 dental trauma
 adenoidectomy-related 1098
 children 1633
 dentatorubral-pallidoluysian atrophy (DRPLA) 3773
 dentigerous cyst 1924, 1924 *F*
 nasal obstruction, children 1074
 dentinal pain 1816
 dentine 800–1
 dentinogenesis imperfecta 1818,
 1818 *F*
 denture granuloma 1828
 denture-induced candidiasis *see*
 denture-related stomatitis
 denture-induced hyperplasia 1828
 denture-related stomatitis 224, 1826
 complications 1826
 treatment 1826
 dentures
 angular cheilitis 1827
 modification 2912
 deontology 583
 deoxyribonucleic acid (DNA) *see* DNA
 (deoxyribonucleic acid)
 depression
 globus 2039
 head and neck cancer patients 2777,
 2796
 muscle tension dysphonia 2204
 salivary flow 1861
 smell appreciation disorders 3913–4
 tinnitus 3598, 3608
 vestibular disorders 3814–5
 depressor glabellae 1324
 depressor septi nasi muscle 1322–4
 De Quervain's thyroiditis *see* subacute
 thyroiditis
 dermabrasion 2898, 2899 *F*
 patient preparation 2898
 patient selection 2898
 re-epithelialization 2898
 Dermagraft 126
 dermal grafts 2826–7
 dermal sinus 1502–3
 dermatitis 186
 external nose 1714–5
 dermatitis artefacta 102
 dermatochalasis 3052–3, 3054 *F*, 3063 *F*
 genetic predisposition 3052–3
 pathophysiology 3052–3
 preoperative evaluation 3055
 visual defects 3055
 dermatofibromas, nasal 1708
 dermatomyositis 1712
 dysphagia 2031–2
 septal perforations 1584
 dermatophytosis 214
 dermatosis papula nigra 1709
 dermofat graft, Moebius
 syndrome 3086 *F*
 dermoid cyst
 CPA tumours 4014
 epidermoids *vs.* 4011
 formation theories 1320–1
 cranial theory 1320–1
 nasal 1320–1, 1502–3, 1708–9
 external rhinoplasty 2968
 nasolacrimal 1073–4, 1074 *F*
 nasopharyngeal 2119
 neck 1782
 oropharyngeal 2579–80
 surgical approaches 1074
 ultrasound 724
 descendens hypoglossi 1752
 descending auditory pathways 3144–5
 descending palatine artery 2113
 descending vestibular nuclei (MVN) 3220
 descent speed, middle ear
 barotrauma 3504
 descriptive epidemiology 2343
 descriptive studies, epidemiological
 research 624, 625–6, 2344
 desferrioxamine 271–2
 desloratadine 1402
 detectable change in frequency
 (DLF) 3252 *F*
 detergent manufacturers, occupational
 rhinitis 1419
 determinant odds ration 622
 determination, otic field 815
 deviated nose 2987–94
 aetiology 2987–8
 analysis 2989 *F*
 assessment 2988–9
 external rhinoplasty 2965–6, 2966 *F*
 facial asymmetries 2987
 fractures 2988
 management 2990–3
 midline, defining 2988
 post-natal trauma 2988
 septal abnormalities 2991–3, 2992 *F*
 surgical access 2990
 surgical correction 2989–90
 algorithm 2992 *F*
 lower third deviations 2991–3
 middle third deviations 2990–1
 outcomes 2988 *T*
 upper third deviations 2990
 three-dimensional laser facial
 scanning 2988
 without hump 2990, 2991 *F*
 deviated septum 1326–7, 3009
 caudal displacement 2991
 correction 2990–1, 2992 *F*
 epistaxis 1574
 children 1067
 Eustachian tube dysfunction 3506
 devils ear deformity 3075
 dexamethasone
 acute airway obstruction 1123
 chronic rhinosinusitis 1470
 croup 422, 1128–9
 dysphagia, cancer patients 2790–1
 idiopathic sudden sensorineural
 hearing loss 1, 3584, 3589 *T*
 laryngeal stenosis 1152
 liver capsule distension 2784
 Menière's disease 3800
 nausea and vomiting, cancer
 patients 2788
 pharyngitis 1984
 spasmodic croup 1129
 stridor 2795
 superior vena caval
 obstruction 2794–5
 tonsillectomy 1237
 tonsillitis 1222
 dexamethasone suppression test 310 *T*
 accuracy 310
 Cushing's syndrome 310
 Dexa-Rhinaspay Duo 440
 dextran
 idiopathic sudden sensorineural
 hearing loss 1, 3588, 3589 *T*
 skin flap survival 114
 dextrocardia, primary ciliary
 dyskinesia 1081
 DFNA9 3562

- DFNA11 gene/protein 20
 DFNB2 gene/protein 20
 diabetes insipidus
 aetiology 308, 312
 anti-diuretic hormone 308
 hypophysectomy complications 4112, 4113
 diabetes mellitus (DM) 401–2
 acromegaly 4100–1
 acute fulminant fungal rhinosinusitis 216
 auditory dysfunction 402
 Bell's palsy 401–2
 clinical manifestations 401
 Cushing's disease 4101
 implants 2910
 infection 402
 macrovascular manifestations 401
 malignant otitis externa 402, 3337
 microvascular disease 401
 ocular findings 401
 orbital infections 3916
 periodontitis 1818
 pituitary tumours 4100–1, 4101
 rhinosinusitis 1082
 taste abnormalities 1845–6
 type 1 401
 disease presentation 401
 prevalence 401
 type 2 401
 disease presentation 401
 prevalence 401
 taste abnormalities 1845–6
 vestibular end organ 402
 wound healing 95, 95 *F*
 diabetic nephropathy 402
 diabetic neuropathy 401–2, 2080
 diabetic retinopathy 401–2
 diabetic ulcers 102
 diabetic wounds 97
 diagnostic wax up/models,
 implants 2911, 2911 *F*
 3,4-diaminopyridine (3,4-DAP) 3804
 diamorphine, cancer pain
 management 2786, 2787 *T*
 diaphragm
 screening
 fluoroscopy 1296
 ultrasound 1297
 sleep 2307
 diaphragma sellae 298, 304
 diaphragm screening 1296
 diarrhoea, antimicrobial-induced 236
 'diaschisis'-type phenomenon 3793
 diathermy burns 1308
 diathermy tonsillectomy 1233–4, 1991
 diazepam 3796 *T*, 3797
 dichotic digit test
 central auditory dysfunction 3859–60, 3859 *F*
 peripheral hearing loss 3864
 dichotic speech tests 3270
 central auditory dysfunction 3858–9, 3862
 Diclofenac, formulation choice 410
 diclofenac, tonsillectomy 1993, 1994–5
 diet
 chronic rhinosinusitis 1473
 dysphagia management 2087–8
 hypopharyngeal cancer 2634
 laryngeal cancer 2348
 laryngeal trauma 2274
 migrainous vertigo 3800–1
 nasopharyngeal carcinoma 2346, 2354
 oral cavity cancer 2348
 oropharyngeal tumours 2348
 vitamin K deficiency 282
 voice disorders 2195
 differential amplifier 3279
 difficult airways 467–87
 definitions 467–8
 difficulty prediction 471–2
 emergency cricothyrotomy 476–7
 evaluation 468–70, 468 *T*, 472
 examination 469–70
 extubation 483–4
 failed ventilation 476–7
 follow-up 484–5
 gum elastic bougie 472–3, 473 *F*
 investigations 470
 laryngeal masks 473 *T*, 475–6
 management 467–87
 alternative techniques 473–5
 strategy 471 *T*, 472–3
 morbidity/mortality 485
 patient history 468–9
 preoperative assessment 2151
 prevalence 468
 recovery 483–4
 tumours 471
 difficult direct laryngoscopy 468, 471, 472
 difficult face mask ventilation
 definition 467
 prevalence 468
 difficult intubation
 definition 467
 prevalence 468
 difficult ventilation 468
 Difflam 1984
 diffraction, sound waves 3167, 3167 *F*
 diffuse goitre
 nontoxic 330
 toxic *see* Grave's disease
 diffuse hyperplastic laryngitis 2259 *F*
 diffuse infiltrated lymphocytosis syndrome (DILS) 1900
 diffuse Lewy body disease 3778
 diffuse oesophageal spasm 2066
 clinical features 2066
 diagnosis 2066, 2067 *F*
 dysphagia aetiology 2032
 manometry 2032
 treatment 2066
 diffusion-weighted imaging, salivary gland 1876
 digastric muscle 1746, 2135 *T*, 3910
 digastric ridge 3873
 Di George syndrome (anomaly) 180–1, 1267
 digital planning
 camera specification 2947–8
 facial plastic surgery 2943–9
 digital subtraction sialography 1877
 sialolithiasis 1880
 digital subtraction angiography (DSA),
 pituitary gland 306–7
 postoperative imaging 306–7
 dihaematoxoporphyrinether (DHE),
 juvenile-onset recurrent respiratory papillomatosis 1177
 dihydrocodeine
 advanced head and neck cancer 2786
 postoperative pain 463
 dihydroergotamine 3802–3
 dihydrofolate reductase inhibition,
 methotrexate 38
 2,3-dihydroxybenzoic acid 3302
 1,25-dihydroxyvitamin D₃
 (1,25-(OH)₂D₃)
 function 375
 synthesis 374
 diiodotyrosine (DIT) 322
 dilatation, achalasia 1289–90
 dilator naris anterior
 strengthening 3012
 dimenhydrinate
 migrainous vertigo 3801
 side effects 3795
 vestibular attacks, acute 3795, 3796 *T*
 dimethylsulfoxide (DMSO), skin flap survival 114

- dimethyl triazeno imidazole carboxamide (DTIC) 2410
- Dingman supraorbital approach, zygomatic complex fractures 1629 *T*, 1630
- diphenylhydramine 1397–8
- diphtheria 1130, 2252–3
aetiology 2252
clinical features 2252
complications 2253
infection site 2252
investigations 2253
larynx 1130, 2252–3
management 2253
pharyngeal manifestations 2079
prevalence 2252
strains 1130
symptoms 1130
transmission 2079
treatment 1130, 2079
- diphtheria toxin 198–9
- diphthong 2166
- diplacusis 3597
binaural 3597
Menière's disease 3597
monaural 3597
patient evaluation 3597
- diplophonia, subglottic cancer 2608–9
- diplopia
abducent nerve 3945
blepharoplasty-related 3066
orbital decompression-related 1683
- directive counselling, tinnitus 3614
- direct laryngoscopy
anaesthesia 2236
laryngeal trauma 2275
laryngeal tumours 2608
supraglottic obstruction 479
- direct light reaction, blind eye 3916
- disability (definition) 783
- disclosure
ethical issues 586
legal issues 602
see also confidentiality
- discoid lupus erythematosus (DLE) 1711, 1711–2
- discourse, voice analysis 2174
- disequilibrium, meningioma 4009
- dishonesty, medical negligence 2805
- disodium edetate 429
- displacement, sound waves 3174
- dissection tonsillectomy 1991–3
electrosurgery vs. harmonic scalpel 1992
- haemorrhage, control of 1991
techniques 1991
- disseminated intravascular coagulation (DIC) 283–4
causes 283–4
clinical manifestations 283–4
cryoprecipitate 259, 284
fresh frozen plasma 258, 284
laboratory tests 284
platelet transfusion 259, 284
treatment 284
- disseminating sclerosis 1724
- distortion product otoacoustic emissions (DPOAEs) 3278, 3278 *F*
auditory neuropathy/
dyssynchrony 3842
neonatal hearing screening 3291
presentation 3278
recording 3278
- distortion products 3597
- distraction osteogenesis
hemifacial microsomia 1033
syndromic craniosynostosis 1029–30,
1030 *F*
- distraction test, hearing 835–7
method 835–6, 836 *F*
no sound control trials 837
pitfalls 837 *T*
results 837
stimulus 836–7
frequency spectrum 836, 837 *F*
- diuresis
DDAVP treatment 308
post-hypophysectomy 308, 4112
- diuretics
chronic rhinosinusitis 1473
Menière's disease 3759, 3799
ototoxicity 3568 *T*, 3569–70, 3571,
3677
- diverticulae, oesophageal body 2072
- Divine Proportion 2944–5
- Diving Diseases Research Centre 3517–8
- Dix–Hallpike manoeuvre 3761, 3762–3,
3762 *F*
- Dix–Hallpike positional tests 3809–10
- dizziness 3706–7
children
assessment 1041–2
examination 1042
investigations 1042
chronic 3709–10, 3710 *T*
medical negligence 3829–30
neurofibromatosis 2 4000
nonvestibular causes 3707 *T*
- patient's description 3707
positional manoeuvres 3720–1
see also vertigo
- Dizziness Handicap Inventory (DHI) 640
- DNA (deoxyribonucleic acid) 3–5, 15–6
amplification 7
fragmentation techniques 5–8
function 3–5
identification techniques 5–8
radiation-induced damage 47
replication 4, 35 *F*
sequence variations 16
stability 5
structure 3–5, 15–6
- DNA analysis
craniofacial anomalies 1021
neurofibromatosis 2 3999
- DNA complexes, cancer treatment 26
- DNA fragmentation factor 58
- DNA helicase 4
- DNA ploidy, oral cancer 2552
- DNA polymerase 4
- DNA proofreading mechanism 4
- dobutamine 529–30
- docetaxel (taxotere) 39, 2761
- doctor-patient relationship
consumerism 582
ethical issues 581–2
- doctors, duties/responsibilities 582–3
- docosate, constipation 2791
- dog bite injury 2929 *F*
- doll's head manoeuvre 3718, 3719 *F*
eye movement observation 3718
vestibular ocular reflex testing 3718
- domains, outcomes research 634, 636
- domperidone 2787
- Do Not Resuscitate (DNR) orders 537
- dopamine
noise-induced tinnitus 3604–5
prolactin secretion control 300, 301
vestibular neurones 3794
- dopamine agonists, acromegaly 4101
- dopamine antagonists, vertigo 433
children 1049
- dopaminergic cells, stem cell therapy 75
- dopexamine 530
- Doppler effect 714
- Doppler equation 714
- Doppler shift frequency 714
- Doppler ultrasound
cervical lymph node assessment 1759
perfusion patterns 1760
- continuous-wave 714
- duplex scanners 714

facial reanimation 3082–3
 Grave's disease 335, 720–1, 721 *F*
 lymph nodes 718
 physics/basic principles 714
 pulsatility index 714
 pulsed-wave 714
 resistance index 714
 thyroid papillary cell carcinoma 719
 wound assessment 100
 dorsal cochlear nucleus (DCN) 3140
 dorsal humps, nasal
 deviated nose 2989, 2990, 2990 *F*
 en bloc reduction 2955, 2955 *F*
 dorsal lingual artery 1799
 dorsal lingual vein 1799
 dorsal onlay graft 2952 *F*
 dorsal reduction surgery 2954
 dorsum sellae 298
 dose response curves, radiotherapy 48
 double aortic arch 1146
 double blind placebo controlled food challenges (DBPCFC) 1, 1429
 double hearing *see* diplacusis
 double paddled radial free flap, buccal carcinoma 2561, 2561 *F*
 double stranded DNA (dsDNA) 7
 downbeat nystagmus, idiopathic 3804,
 3804 *T*
 Down syndrome
 adenoidectomy 1097, 1098
 adenotonsillectomy 1109
 characteristics 784 *F*, 2119–20
 ENT-related problems 784 *T*
 incidence 2119–20
 inner ear disorders 3683
 medical negligence 1308
 nasopharyngeal disorders 2119–20
 obstructive sleep apnoea 1109
 postoperative complications 1110
 olfactory dysfunction 1669
 tympanic membrane disorders 934
 doxorubicin
 mechanism of action 38
 salivary gland tumours 2508
 DP-gram 3278, 3278 *F*
 Dramamine *see* dimenhydrinate
 dreams 2305
Drechslera 221
 dressings 100–3
 burns 102
 malignant wounds 101, 2794
 see also individual types
 Driver and Vehicle Licensing Authority (DVLA), obstructive sleep apnoea 2322

drooling
 palliative care patients 2788–9, 2788 *T*
 salivary gland obstruction 789
 special needs children 788–9
 treatment 788–9, 2788–9
 upper airway obstruction 2287
 drop attacks 3758
 droperidol 3795–6
Drosophila neural stem cells 68
 drug(s)
 administration 407–17
 delivery methods 408–9
 adverse reactions *see* adverse drug reactions
 bioavailability 408, 410
 development 407–8
 dosing frequency 410, 410 *F*, 411 *F*
 dysphagia aetiology 2033–4
 elimination 411
 first pass effect 408
 formulation choice 410, 410 *F*
 half-life 410
 interactions 415
 metabolism 410–1
 monitoring *see* drug monitoring
 otology 429–35
 pharmacology 409–12
 potency 411–2, 412 *F*
 regulatory systems 408
 rhinology 436–45
 drug-induced conditions
 generalized oral mucosal
 hyperpigmentation 1825
 gingival pigmentation 1819
 gingival swelling 1820, 1821 *F*
 hearing loss 3298–300, 3299 *T*
 factors affecting 3301
 incidence 3300
 molecular mechanisms 3300–1
 pathology 3298–300, 3299 *F*
 prevention 3301–2
 see also ototoxicity
 mouth ulcers 1835
 olfactory dysfunction 1664,
 1673–4
 olfactory nerve damage 3913
 rhinitis 1383, 1410
 taste abnormalities 1847
 treatment 1848
 tinnitus 3599–600
 animal studies 3600
 tongue discolouration 1825
 vertigo, children 1047–8
 see also specific drugs/drug types
 drug licencing 408
 drug–light interval (drug uptake period), photodynamic therapy 746
 drug monitoring 412–4
 compliance 413
 factors affecting 413–4
 improvement methods 414
 methods 412–3
 microelectromechanical systems 413
 patient self-monitoring 412–3
 physical 412
 plasma concentration monitoring 413
 drug prescribing 415–6
 children 415
 elderly 415–6
 hepatic failure 416
 infants 415
 neonates 415
 pregnancy 415
 renal failure 416
 drug uptake period (drug–light interval), photodynamic therapy 746
 dry eye syndrome (keratoconjunctivitis sicca) 3065, 3095
 'drying spells' 1116–7
 dry mouth *see* xerostomia
 dry skin dressings 100
 dsDNA antibodies 170
 dual phase single tracer scintigraphy, parathyroid imaging 383–4
 Duchenne muscular dystrophy, stem cell therapy 73, 75–6
 dufourmental flap 2838–40, 2842 *F*
 'duplex theory,' sound localization 3255
 dural resection, nasopharyngeal surgery 4056
 'dural tail sign' 4009–10
 dural tears, syndromic craniosynostosis surgery 1031
 dura mater
 hypophysectomy 4110
 olfactory fossa 1335
 Dutch College of General Practitioners, acute otitis media diagnostic guidelines 3385–6
 dwarf gueron (*Miopithecus talapoin*) 1322 *F*
 dyazide 3799, 3799 *T*
 dyclonine 1848–9
 dye test, toxoplasmosis 2010
 Dynamic Gait Index (DGI) 3806

dynamic visual acuity
technique 3718, 3719 *F*
vestibular ocular reflex testing 3718–9

dynorphins, tinnitus 3604–5, 3607

dysacuses 3594–628
definition 3595
see also specific disorders

dysaesthesia, oral (burning mouth syndrome) 1829, 1829 *T*, 1848–9

dysarthria
cerebellar disorders 3940
definition 2192

dysarthrophonia 2192

dysgeusia 1843
physical examination 1843–4
treatment 1848–9

dyskeratosis, epithelial dysplasia 2221

dyskinetic syndromes 3939–40

dysmorphophobia, litigation
risk 3088–9

dysontogenetic cysts 724

dysosmia 1664, 1666–7

dysphagia 2025–36, 2084–93
aetiology 1964–5, 2029–35
ageing 2034
congenital 2029, 2029–30
foreign bodies 2034
head and neck cancer 2029
infectious 2030–1
inflammatory 2031–2
neoplastic 2032–3
tracheostomy-related 2035
traumatic 2030

bolus escape 1975

chronic laryngitis 2259

definition 1964–5, 2025, 2085

diagnosis 2085

drug-induced 2033–4, 2081

examination 2025–6

history 2025–6

iatrogenic 2080–1

incidence 2084

investigations 1964–80, 2026–9,
2027 *F*

good practice principles 1965
respiratory recordings 1976

laryngeal candidiasis 224

laryngectomy rehabilitation 2627–8

malignant, palliation 2069, 2070 *T*,
2071 *T*

intubation 2069

stenting 2069

management 2086
compensatory strategies 2086,
2086–8

dietary 2087–8

evidence-based 2084–5

postural techniques 2086–7

prosthetics 2088

rehabilitative therapy 2086,
2088–90, 2089 *T*, 2090 *T*

swallowing manoeuvres 2089–90,
2090 *T*

neurological 1975, 2033
assessment 2076

botulism 2079

feeding 2081

investigations 2076
management 2081–2

Parkinson's disease 2078

pharyngeal pouch 2034–5, 2044

prevalence 2084

stroke 2077

surgery-induced 2081

symptoms 1964–5

temporal bone squamous cell
carcinoma 4087

dysphasia 2192

dysphonia
child's voice assessment 1169
chronic laryngitis 2259
definition 2192
laryngeal amyloidosis 2266
nonorganic 2219–20
organic 2220–2
special needs children 787

temporal bone squamous cell
carcinoma 4087

vocal nodules 1169
see also individual types

dysphonia symptom index (DSI)
2184

dysplasia
Barrett's oesophagus 2065

epithelial 2221

fibrous *see* fibrous dysplasia

frontonasal 1036

laryngeal 763–4

oral, genetic analysis 11–2

round window 873

dysplastic naevus 2400

dyspnoea
grading 459 *T*

posterior glottic stenosis
1160–1

sarcoidosis 1648

stridor 1116–7

dysstereoacusis 3597
causes 3597

dysthyroid eye disease 331

Eagle's syndrome 2081

ear(s)
clinical examination 3311–20

collapsed 971

deformity, hemifacial
microsomia 1032–3

development 805–8, 813–7, 965–7,
3120–4

discharge *see* otorrhoea

external *see* external ear

foreign bodies *see* aural foreign
bodies

as frequency analyser 3245

HIV infection 240

incision placement 3312 *F*

inner *see* inner ear

middle *see* middle ear

missing
amputation of cancerous 3028–32,
3032 *F*

causes 3028–33

trauma 3028, 3029 *F*, 3030 *F*

mycotic diseases 213–4

outer *see* external ear

pain *see* otalgia

prominent *see* 'bat' ear

rheumatological diseases 184

temporal resolution 3254

see also entries beginning aural

earache *see* otalgia

Ear Buddies 974–5

eardrops 429

eardrum *see* tympanic membrane

early goal-directed therapy (EGDT),
critical care 535

earmoulds 3633–4

earmuffs 3554

ear piercing, perichondritis 625–6,
3033, 3034 *F*, 3358

earplugs 3554

ear preparations, topical 429–33
contraindications 430–1
inflammatory/infective
conditions 430–1

side effects 431

steroids 430

ear prosthesis, children 980, 983 *F*

ear protectors 3554

earshells 3633–4

ear sprays 430

ear surgery
anaesthesia 501–3
children 513–4
hypotensive 502–3

facial paralysis, childhood 1057–8

- special needs children 786
taste abnormalities 1847
see also individual procedures
ear swabs, chronic otitis media 936
ear syringing 3313, 3313 *F*
 medical negligence 3826–7
ear toilet *see aural toilet*
ear trauma 3491–525
 missing ear 3028, 3029 *F*, 3030 *F*
 types 3492–3, 3493 *T*
see also individual types
earwax
 genetics 3107
 production 3311–2, 3313 *F*
 removal 3311
 softening 3312–3
ebastine 1397–8
E-cadherin 2385, 2385 *F*
echinocandins 234
echocardiography, stridor 1119
'echoing' tinnitus 3604, 3605 *F*
ectodermal dysplasia, oral 1818
ectoturbinals 1321
ectropion
 anterior lamella shortening 3051
 post-blepharoplasty 3065, 3096
eczema, external nose 1714–5
eczema herpeticum 1700
edropontium 2077
education, deaf children 854–6
effectiveness analysis 823
effector cells, allergic response
 148–52
effect size, outcomes research 636
effortful swallow, dysphagia 2090,
 2090 *T*
EGFR
 inhibition 2760
 tumour associations 2384
EGFR receptor 2760
VIII nerve *see vestibulocochlear nerve*
 (VIII)
eight month IDT screen 828–9
Einstein's equivalence principle
 3210–1
ejection fraction 459
elderly
 drug prescribing 415–6
 rhinoplasty 3091
 toxic multinodular goitre 345
electrical impedance 3168
electrically evoked compound action
 potential (ECAP), auditory
 neuropathy/dysynchrony 3852,
 3853 *F*
electrical stimulation, tinnitus 3615 *T*,
 3618
'electric larynx' 2624–5
electrocardiogram (ECG), anaesthesia
 monitoring 496, 497 *F*
electrocautery
 paediatric epistaxis 1066
 tonsillectomy 1991
electrococleogram 3280–1
electrococleography 751, 3280–1
 Menière's disease 3758
 otosclerosis 3827
 paediatric cochlear implantation 863
 transtympanic
 cochlear microphonics 3843
 multiple sclerosis 3847
electrodes
 auditory nerve 3292–3, 3293 *F*
 facial nerve 749
electrodesiccation and curettage (EDC)
 basal cell carcinoma 2397
 squamous cell carcinoma 2399
electroencephalography (EEG), basilar
 migraine 1044
electroglossography 2171
electrogustometry 1844
electrolaryngography 2171, 2173 *F*,
 2176–7, 2178 *F*
electrolyte balance
 hypophysectomy and 4112
 newborn infant 544
 paediatric parameters 544 *T*
electromyographic (EMG) biofeedback
 training 2225
electromyography (EMG) 3288
 dysphagia 1977
 facial nerve 748, 3878–9, 3879–80
electroneurography (ENoG)
 facial nerve 3878–9, 3879, 3888,
 3946–7
 facial nerve tumours 4080–1
electronic resources, evidence-based
 medicine 646, 647 *T*
electron microscopy, apoptosis 60,
 60 *F*
electronystagmography (ENG) 3213
 facial nerve disorders 3879, 3880 *T*
 ototoxicity recognition 3573
 skull base lesions 3946
electrooculography (EOG) 3723
 analysis 3724
 routine 3724
 technique 3723–4
electroolfactogram (EOG) 1367
electrophoresis 5–6
electrophysiological monitoring
 748–54
auditory function *see auditory*
 function monitoring
current knowledge/future
 research 752
facial nerve *see facial nerve*
 monitoring
see also specific techniques
electroporation, head and neck
 cancer 26
XI nerve *see spinal accessory nerve (XI)*
Eltroxin (thyroxine sodium/
 levothyroxine sodium) 450
EMBASE 646, 647 *T*
embolic agents 733–4, 733 *T*
 balloons 733
 categorization 733
 coils 733
 liquid agents 733–4
 particles 733
 temporary vs. permanent 733
tumour embolization 734
 skull base tumours 3952
embolism, medical negligence 3831
embolization
 epistaxis 1604
 therapeutic *see interventional*
 neuroradiology (INR)
 tumours *see tumour embolization*
embryogenesis 68–9
 telomerase 71
embryonic disc 792, 793 *F*
embryonic fibroblasts 73
embryonic germ (EG) cells 73
embryonic human endothelial cells
 68
embryonic stem cells
 coculture 73
 differentiation control 73
 lineage-specific gene transduction 74
 origins 74
osteoblast generation 73
pluripotency 73
therapeutic uses 73–4
emergency cricothyrotomy 476–7
emergency tracheostomy
 acute airway obstruction 1124
 extubation 484, 484 *F*
 principles of 2151–2
 recovery 484
 tube placement confirmation 482–3
'eminence-based medicine' 646
emissary venous sphenoidal
 foramen 1339

EMLA, nasal fractures 1612–3
 emotionally-induced rhinitis 1383,
 1411
 emotional states, nasal
 vasoconstriction 1366
 emphysema, airway obstruction 2287
 ENA antibodies 170
 encephalitis, vestibular schwannoma
 removal 3982
 encephalocoele(s) 1034–5
 aetiology 1034–5
 cerebrospinal fluid rhinorrhoea 1638,
 1638 *F*
 classification 1035
 diagnosis 1035
 frontal sinus 1504
 frontoethmoidal 1503, 1505 *F*
 incidence 1034, 2116
 management 1035
 middle fossa surgery 4023
 nasal 1709
 children 1075
 endoscopy 1351–2, 1352 *F*
 nasopharyngeal 2119
 outcomes 1035
 surgery 1035, 1505
 transphenoidal 2116–7
 children 2116–7
 incidence 2116
 intrasphenoidal 2116–7
 treatment 2116–7
 true transphenoidal 2116–7
 encephalomeningocele *see*
 encephalocoele(s)
 end bulb of Held 3140–1, 3142 *F*
 endocarditis, antibiotic prophylaxis 460
 endochondral ossification 794–5
 endocochlear potential 3188, 3188 *F*,
 3230–1
 endocrine diseases/disorders
 head and neck
 manifestations 398–404
 pregnancy 402–3
 meningiomas 4008–9
 olfactory dysfunction 1670, 1673–4
 pituitary tumours 4099
 rhinosinusitis 1383
 voice disorders 2201
see also specific diseases/disorders
 endocrine glands 398–9;
see also individual glands
 end of life issues, critical care 536–7
 endolaryngeal stents, intractable
 aspiration management 2099,
 2100 *F*

endolymph
 absorption 3186–7
 composition 3130, 3187–8, 3187 *T*
 electric potential 3187–8, 3188 *F*
 electrolytes 3187–8, 3187 *T*
 forces acting upon 3211
 formation 3186–7
 vestibular hair cells 3230–1
 viscous drag 3195
 viscous forces 3211, 3212
 endolymphatic hydrops
 aetiology 3757
 auditory nerve fibre thresholds
 3200
 delayed 3696–7
 contralateral type 3697
 ipsilateral type 3696–7
 Menière's disease 3687 *F*, 3695, 3696 *F*
 endolymphatic potential (EP) 3130
 age-related hearing loss 3130
 endolymphatic sac
 endolymph homeostasis 3187
 labyrinth 3147–8, 3149 *F*
 surgery, Menière's disease 3759
 endolymphatic sac tumours
 (ELST) 3685–6, 3686 *F*, 4071–2,
 4071 *F*
 clinical features 4071
 differential diagnosis 4071
 histology 4071–2, 4071 *F*
 progression 4071
 treatment 4072
 von Hippel–Landau disease 4072
 endolymphatic space, cochlea 3186,
 3186 *F*
 endonasal dacryocystorhinostomy
 comparison with other
 techniques 1692 *T*, 1695
 conventional instruments 1692,
 1692 *F*, 1693 *F*
 laser *see* endonasal laser
 dacryocystorhinostomy
 (ELDCR)
 endonasal flaps, septal
 perforations 1587
 endonasal laser dacryocystorhinostomy
 (ELDCR)
 choice of laser 1694
 conventional endonasal
 dacryocystorhinostomy *vs.* 1695
 technique 1692 *T*, 1693 *F*, 1694,
 1694 *F*
 endonasal ligation of the
 sphenopalatine artery
 (ESPAL) 1603, 1603 *F*
 endoscopes
 contact endoscopy 763
 nasal endoscopy 1346–7
 endoscopic balloon dilation, tracheal
 stenosis 1143–4
 endoscopic brow lifts, frontalis
 paralysis 3078–9
 endoscopic laser surgery,
 hypopharyngeal cancer 2648
 endoscopic parathyroidectomy 395
 endoscopic sinus surgery (ESS) 1481–9
 anaesthesia 1482–3
 children 1495–6
 rhinosinusitis 1085, 1085 *T*
 complications 1485–6, 1485 *T*
 contraindications 1482
 demographic data 1488 *T*
 failure rates 1488, 1489 *F*, 1489 *T*
 follow-up assessment (after 5
 years) 1488 *T*
 image-guided 708, 709 *F*
 indications 1481–2
 medical negligence 1731, 1732–5
 postoperative management 1484–5,
 1485 *F*
 results 1486–9
 technique 1483–4, 1483 *F*
 endoscopic stapling, pharyngeal
 pouch 2049–50, 2052 *F*
 access problems 2052
 gun jamming 2053
 historical aspects 2049
 Hopkins telescope 2050–1, 2051 *F*,
 2053
 Negus pharyngoscope 2052, 2053 *F*
 outcome studies 2056, 2058 *T*
 postoperative care 2054
 septum division 2053
 tear prevention 2053
 tips and tricks 2052–4
 view maximization 2052
 Weerda distending
 diverticuloscope 2050–1, 2050 *F*,
 2051 *F*, 2058
 endoscopic surgery
 cerebrospinal fluid
 rhinorrhoea 1636–7, 1640,
 1640–1
 craniosynostosis 1027
 glottic cancer 2612, 2612 *F*
 laryngeal cancer 2612
en bloc 2599, 2612
 mucocoeles 1535
 pharyngeal pouch *see* pharyngeal
 pouch surgery

endoscopy
 achalasia 1288, 2066
 airway *see* airway endoscopy
 aspiration investigations 2096
 chronic otitis media 3420
 contact *see* contact endoscopy
 croup 2251
 dysphagia 1968–70
 frontal sinus 1501, 1508
 gastro-oesophageal reflux 1275–6,
 1276 *F*, 2063
 history 1479
 infectious mononucleosis 1784
 laryngeal stenosis 2281
 children 1152–3
 light 755
 medical negligence and 2807
 mucocoeles 1532
 nasal *see* nasal endoscopy
 oesophageal carcinoma 2067 *F*
 otalgia 3531
 paediatric consultation 777
 sleep *see* sleep nasendoscopy
 subglottic stenosis 2282
 see also specific techniques
 endosteal implants 2902 *T*, 2903–4,
 2903 *F*
 endothelial cells, allergic rhinitis 1391
 intercellular adhesion molecule 1
 expression 1391
 vascular cell adhesion molecule 1
 expression 1391
 endothelin-1 (ET-1), skin flaps 113
 tissue necrosis 113
 endotracheal intubation 2151, 2289
 children 511, 512 *F*
 contraindications 2289
 endotracheal tubes 511
 endovascular catheters 732–3
 microcatheters 732–3
 endovascular embolization 731–2
 balloons/coils 733
 dynamic testing and 735
 epistaxis 739
 plastics 733–4
 temporary *vs.* permanent 735
 see also interventional neuroradiology
 (INR)
 endovestibular potential 3230–1
 ‘end replication problem’ 2379
 end-stage liver disease 1848
 end-tidal
 anaesthetic agent concentration 498
 definition 498
 energy 3165

enlarged turbinates 1589–95
 chronic rhinitis 1591–2
 chronic rhinosinusitis 1591–2
 definition 1590
 management 1589–95
 medical treatment 1592
 ‘nasal cycle’ 1590
 sleep apnoea 1591
 snoring 1591
 surgery 1592–4
 children 1084–5
 complications 1592–3
 methods 1593 *T*
 procedures 1593 *T*
 reviews 1592–3
 submucosal resection 1593,
 1593 *F*
 enlarged vestibular aqueduct syndrome
 (EVAS) *see* large vestibular
 aqueduct syndrome (LVAS)
 enophthalmos, imploding antrum 1685
 ‘en plaque’ type meningiomas 4008
 ENT and Audiology Library, National
 Library for Health and Clinical
 Evidence 646, 647 *T*
 enteral nutrition (EN), critical care
 patients 531
 delivery method 532
 timing 532
 enteric reconstructions 2883–5
 free gastro-omental flap 2884–5
 free jejunal transfer 2883–4
Enterobacteriaceae 200
 chronic rhinosinusitis 1441
 granulomatosis 200
 prevalence 200
 see also individual species
 enterococci 198
 enteroviruses, oral infection 1833
 entomophthoramycosis 215
 aetiological agent 215
 clinical manifestations 215
 definition 215
 diagnosis 215
 epidemiology 215
 management 215
 enucleation, jaw cysts 1922
 environmental factors, genetic
 predisposition 16–7
 enzyme-linked immunosorbent assay
 (ELISA)
 allergy testing 1394–5
 heparin-induced thrombocytopaenia
 with thrombosis 287
 EORTC 22791 trial 2755
 EORTC QLQ-C30/H&N35 2770
 characteristics 2773, 2774 *T*
 development 2773
 outcomes research 641
 purposes 2774 *T*
 eosinophil(s) 274
 allergic fungal rhinosinusitis 220
 allergic response 149, 150 *F*
 allergic rhinitis 1390–1
 apoptosis 62
 allergic inflammation 62
 corticosteroid-induced 62
 cytokine release 1391
 nasal polyposis 1552, 1556
 eosinophilia 274 *T*
 eosinophilic fungal sinusitis *see* allergic
 fungal rhinosinusitis (AFRS)
 eosinophilic granuloma *see* Langerhan’s
 cell histiocytosis (LCH)
 eosinophilic mucin
 rhinosinusitis 220–1, 1453, 1472
 eosinophilic oesophagitis, laryngeal
 stenosis and 1156
 ependymomas 3776, 3776 *F*
 CPA impingement 4015
 neurofibromatosis 2 4000, 4002
 ephedrine
 adverse reactions 415
 pharmacodynamics 411
 rhinosinusitis 440, 1543
 epidemic parotitis *see* mumps
 epidemiology 615–32
 analytical studies 626–30, 2344–5, 2344
 case control (retrospective)
 studies 627–8, 2344
 cohort (longitudinal/prospective)
 studies 627, 2344
 cross-sectional studies 626–7
 causality 2343–4
 ‘ceteris paribus’ principle 617
 classical 616–7, 617–8
 clinical 617–8, 617
 components 618–24
 definition 616, 2343
 determinant-occurrence
 relationship 616, 617
 descriptive, definition of 2343
 descriptive studies 624, 625–6, 2344
 head and neck cancer 2343–50
 health services/public health 617–8
 incidence (of a disease) 2344
 interventional studies 2344, 2345
 observational studies 625–6
 prevalence definition 2344
 principles 616

epidemiology (*continued*)
 protocols 618–24
 randomized controlled trials *see*
 randomized controlled trials
 (RCTs)
 sinonal surgery 619–20
 study design 618–24, 619 *F*,
 2343–4
 bias and confounding 624–5
 blinding 621, 629
 choice of 624–30
 measurement of variables 620–1
 questions 618
 results analysis 621–3, 622 *F*,
 622 *T*
 size 623–4
 structure 619
 subject selection and
 recruitment 619–20
 tonsillectomy 615–6, 618, 622, 622 *T*,
 627–8
 epidermal growth factor receptor
 (EGFR) 42–3
 hypopharyngeal cancer 2636
 immunoglobulin G cetuximab 43
 monoclonal antibodies against 43
 signalling pathways 42–3, 42 *F*
 targeted small molecules 43
 targetted therapies 52
 epidermal growth factor receptor
 tyrosine kinase inhibitors
 (EGFR-TKI) 43
 epidermization 3400
 epidermolyticus verruciformis 2396
 epidermoids (primary cholesteatomas)
 aetiology 4011
 clinical presentation 4011
 CPA tumours 4007, 4011–2
 definition 4011
 diagnosis 4011
 arachnoid cysts *vs.* 4013
 dermoids *vs.* 4011
 MRI 4011, 4012 *F*
 epidemiology 4007, 4011
 mortality 4012
 nasal 1708–9
 pathology 4011
 petrous apex 4047, 4049 *F*
 clinical features 4047
 management 4050, 4051 *F*
 resection 4051
 recurrence rates 4012
 treatment 4012
 ultrasound 724
 vocal folds 2201–2, 2201 *F*

epidermolysis bullosa (EB)
 dysphagia 2032
 oral lesions 1823, 1824
 squamous cell carcinoma 2398
 epidural anaesthesia 463
 epiglottic flap closure 2099, 2100 *F*
 epiglottic petiole prolapse 1159–60
 epiglottic plication 2099–100, 2101 *F*
 epiglottis 2133
 bifid 1137
 development 2130
 innervation 2156
 laryngomalacia 1135
 optical coherence tomography 757,
 757 *F*
 pubertal changes 2205
 swallowing 1955, 1957–8, 2159
 epiglottitis
 acute 1130–2, 1131 *F*
 corticosteroids 422
 dysphagia 2030–1
 Hib infection 1131
 immunocompromised
 individuals 1131
 incidence 2250
 medical negligence 1309
 paediatric intensive care 545
 treatment 1131
 adult 2250–1
 clinical features 2250
 complications 2251
 dysphagia 2030–1
 examination 2250
 incidence 2250
 investigations 2250, 2250 *F*
 management 2250–1
 microbiology 2250
 paediatric *vs.* 2250
 epiglottopexy, intractable
 aspiration 2099, 2100 *F*
 epignathia, nasopharyngeal 2119
 epilepsy
 olfactory dysfunction 1669–70
 treatment 1671
 skull base surgery 4139
 taste abnormalities 1846
 epiphora
 children 1696
 definition 1689
 maxillary sinus carcinomas 2424
 nasolacrimal duct obstruction 1689
 orbital decompression-related
 1683–4
 post-blepharoplasty 3065
 treatment 3079
 epipodophyllotoxin derivatives 39–40
 epirubicin 38
 episodic cerebellar ataxia (EA) 3773–5
 aetiology 3773–4
 clinical manifestations 3774
 complications 3775
 definition 3773
 diagnosis 3774
 differential diagnosis 3774
 management 3774
 type 2 3804, 3804 *T*
 outcomes 3775
 epistat, facial fractures 1619–20, 1620 *F*
 epistaxis 1596–608
 anaesthesia 503
 anterior 1599–600
 assessment 1601
 children 1063–9, 1599
 acute bleed 1064
 aetiology 1063–4, 1064 *T*
 assessment 1064–5
 associated medical conditions 1067
 clinical guidelines 1067
 effects 1063
 management 1064–5
 management controversies 1065–7
 medical negligence 1310
 prevalence 1063
 recurrent 1064–5
 research, Naseptin efficacy 651,
 660 *T*
 seasonal variation 1063
 classification 1599–600, 1599 *T*
 definition 1596
 head injuries 1605
 lateral wall bleeding 1598
 management 1601–4, 1601 *F*
 direct therapies 1601–2
 indirect therapies 1602
 nasal fractures 1615
 newborns 1065
 posterior bleeding sites 1598 *F*,
 1599–600, 1602
 post-surgery 1605
 presentation 1599, 1599 *T*
 primary 1599, 1600–4
 aetiology 1600–1, 1600 *T*
 chronobiology 1600
 demography 1600
 secondary *vs.* 1599
 recurrent 1604
 resuscitation 1601
 secondary 1599, 1605–6
 primary *vs.* 1599
 secondary abnormalities 1574, 1583, 1601

- septal bleeding 1598
 septal surgery 1604
 surgical management
 1603–4
 embolization 1604
 ligation 1603–4
 septal surgery 1604
 trauma 1605
 tumours 1606
 vascular anatomy 1596–9
 epithelial cells
 allergic rhinitis 1391
 pleomorphic adenoma 2482
 epithelial dysplasia 2221
 epithelial hyperplasia 2221–2
 gastro–oesophageal reflux
 disease 2222
 speech therapy 2222
 epithelial retention cysts, chronic otitis
 media 3406–7
 epithelializing wounds, dressings 100
 epithelium
 contact endoscopy 762–3
 keratinized, oral cavity 767
 larynx 763
 wound healing 98
 see also specific types
 epitope 135
 Epley's repositioning manoeuvre
 benign paroxysmal positional
 vertigo 3762–3, 3762 *F*, 3810–2,
 3811 *F*
 complications/adverse effects 3812
 efficacy 3812
 modified, self-treatment 3812
 Epstein–Barr virus (EBV) 208
 facial nerve palsy 3887, 3887 *F*
 hairy oral leukoplakia 208–9
 infectious mononucleosis *see*
 infectious mononucleosis
 investigations 1984
 malignancy and 208–9
 nasopharyngeal carcinoma 2346,
 2353, 2447, 2448, 2456
 oral infection 1832–3
 salivary gland tumours 2494,
 2496
 undifferentiated carcinoma 2501
 X-linked lymphoproliferative
 syndrome 181
 Epstein–Barr virus-associated nuclear
 antigen (EBNA), nasopharyngeal
 carcinoma 2456
 epulides 1820
 epulis fissuratum 1828
- Epworth Sleepiness Scale (ESS) 2315 *T*,
 2327 *F*
 obstructive sleep apnoea 620–1,
 2315
 snoring 2326
 equilibrium, physiology of 3207–44
 Equitest 3733
 equivalent continuous sound level
 3171
 equivalent rectangular bandwidths
 (ERBs), auditory filter 3245
 normal (ERB_N) 3245
 calculation 3249
 erbium:yttrium-aluminium-garnet
 (Er:yAG) lasers, medical
 negligence 3096
 Erb's point 1751, 2738–9
 ergotamine 3803 *T*
 ergot drugs 3802–3
 erlotinib
 mechanism of action 43
 side effects 43
 as targetted therapy 52
 eruption cyst 1925
 erysipelas
 nasal infection 1700
 perichondritis 3358
 erythema multiforme (EM), oral
 manifestations 1835
 diagnosis 1835
 genetics 1835
 treatment 1835
 erythema nodosum 1710
 erythematous candidiasis 223–4
 erythrocyte sedimentation rate
 (ESR) 267
 raised 267
 rheumatological diseases 185
 subacute thyroiditis 351–2
 erythromycin 231
 allergic rhinitis 1397–8
 chronic rhinosinusitis 1471–2
 drug interactions 411, 433
 laryngitis, acute 2213
 nasal polyps 1471–2
 ototoxicity 3568 *T*, 3571
 pan-bronchiolitis 1471–2
 peritonsillar abscess 1997–8
 pertussis 2252
 erythroplasia, oral mucosa 1825–6
 erythropoiesis 266
 erythropoietin (EPO) 266
 normochromic/normocytic
 anaemia 270
Escherichia coli 200
- essential thrombocytopathy (ET) 275
 Esteem -Hearing Implant(tm) 3661
 etamsylate 2792–3
 etanidazole 2756
 ethambutol 1460
 ethanol *see* alcohol
 ether 491
 ethical issues 581–93
 communication, medical
 consultations 561–2
 confidentiality 586–7, 589
 consent and refusal 585–6
 data protection 587, 589
 disclosure 586
 doctor-patient relationship 581–2
 doctors' duties/responsibilities 582–3
 medical records 587, 589
 moral foundations 583–5
 consequence-based 584
 principle-based 583–4
 virtue-based 584–5
 patients' rights 582
 purpose 581
 research 588–9
 resource allocation 589–91
 treatment withholding/
 withdrawal 587–8
 ethical principles 582–3
 autonomy 561–2, 582
 beneficence 561–2, 562, 582
 justice 562
 nonmaleficence 561–2, 562, 582
 ethmoid air cell, development 803,
 805 *F*
 ethmoidal arteries
 anterior *see* anterior ethmoidal artery
 posterior *see* posterior ethmoidal
 artery
 ethmoidal artery ligation (EAL) 1604
 ethmoidal bulla
 anatomy 1333–4
 development 1319
 overpneumatized 1335 *T*
 third pass endoscopy 1348
 ethmoidal infundibulum 1318–9,
 1318 *F*, 1331–2, 1344–6
 atelectatic 1332
 bony defects 1331
 development 1318 *F*, 1319
 ethmoidal sinusitis
 complications 1540
 medical negligence 1735
 ethmoidal sulcus 1335
 ethmoidal turbinates 1319, 1319 *F*
 ethmoidal veins 1337–8

ethmoid bone 1334–5, 1336 *F*
 anterior skull base 3897
 development 1316–7, 1318
 ossification centres 1318
ethmoid complex
 posterior 1336–7
 cells 1336–7
 roof 1334–5
ethmoidectomy
 bilateral maxillary antral washout and 1087
intranasal *see* *intranasal ethmoidectomy*
 juvenile angiomyxoma 2441, 2441 *F*
 Patterson's approach 1678, 1683–4 modified 1679–80
transantral *see* *transantral ethmoidectomy*
ethmoid sinus
 blood supply 1338
 development 1319, 1319 *F*
 innervation 1338
 lymphatic drainage 1338
ethmoid sinus tumours
 presentation 2424–5
 spread patterns 2419, 2419 *F*
 staging 2423, 2424 *T*
 TNM classification 2367 *T*
ethmolacrimal cell 1331–2
ethmoturbinales 1321
ethnicity
augmentation rhinoplasty 2970
keloids 2892
nasal airflow resistance 1357–8
ethylene vinyl alcohol 733–4
European Agency for the Evaluation of Medicinal Products (EMEA) 408
European Community Respiratory Health Survey (ECRHS) 1564
European Convention on Human Rights 606–7
see also *Human Rights Act (1998)*
European Laryngological Society, glottic cancer classification 2607
European Organization for Research and Treatment of Cancer (EORTC)
laryngectomy rehabilitation assessment 2630
Quality of Life Questionnaire for Head and Neck Cancer *see* *EORTC QLQ-C30/H&N35*
Quality of Life Study Group 641
European Position Paper on Rhinosinusitis and Nasal Polyps 1469

EuroQol (EQ-5D) 639, 639–40
Eustachian cushion 2107
Eustachian locking 3502, 3503 *F*
Eustachian tube 1344–6, 1346 *F*
 acute otitis media 914–5, 915
 anatomy 3116–8, 3118 *F*, 3119 *F*
 bony part 3901
 cartilaginous part 3901
 decompression 3503–4
 dysfunction
chronic otitis media 3409
septal deviation 3506
 function tests, otitis media with effusion 888–9
 isthmus 3901
 lower end, opening 1944
 middle ear surgery and 3423
 muscles attached 3118
 obstruction
barotrauma-related 3390
otitis media with effusion 3389–90
 patulous, somatosounds 3600
 surgical approaches 4054–66
anterior approaches 4056–9
anterolateral approaches 4059–61
classification 4054–6
combined approaches 4062–5
facial translocation 4064–5, 4064 *F*
infratemporal approach type C 4061
lateral approaches 4061
maxillary swing technique 4059–61
preoperative assessment 4056
subtemporal-preauricular infratemporal fossa approach 4062–4
transcervical approach 4058–9
transmandibular approach 4058–9
transoral approaches 4056–8
transpalatine approaches 4056–8
euthyroid Graves'
ophthalmopathy 343–4
Evans blue dye test 2097
event-related potentials *see* *auditory-evoked potentials*
Evidence Based Medicine 650
evidence-based medicine (EBM) 645–8
application 647–8
case-control studies 655
cohort studies 655
critical appraisal *see* *critical appraisal skills*
current 646
definitions 645–7, 647
dysphagia management review 2085
electronic resources 646, 647 *T*
limitations 647
principles 647, 650–1
conscientiousness 645–6
explicitness 646
judiciousness 646
tonsillectomy 1229–32
Ewald's first law 3230
Ewing's family of tumours 1936
children 1259 *T*
management principles 1936
presentation 1936
prognosis 1936
staging 1936
survival rates 1936
exanthems, facial 1701
excision biopsy
cervical lymphadenopathy 2703
chronic laryngitis 2260, 2261 *F*
excretory duct, salivary glands 1852
exhaust fumes, occupational rhinitis 1419
exon(s) 4, 15–6, 2378–9
sequencing 19–20
exophthalmos (exorbitism)
Crouzon syndrome 1027
thyroid eye disease 344
exophytic lip cancer 2544 *F*
exostosis 1930
expansion phase, speech/language development 990–1
expectorant cough preparations 449
expert medical witnesses 603–5
clinical negligence 604
doctor as 604–5
expiration
nasal humidification 1356
swallowing 1960
vocal fold adduction 2159
expired PCO₂
anaesthesia monitoring 498
end-tidal 498
exposure keratitis 3079
expressive speech disorders 991, 992 *T*
Exserohilum 217
extended field-of-view, ultrasound advances 713
extended maxillectomy 2428
extended supraomohyoid neck dissection 2747, 2747 *T*, 2748 *F*
extended thyroid incision 2732 *F*
external auditory canal (EAC)
anatomy 3107–8, 3109 *F*
arterial supply 3108
auricular implant placement 2908

- bony erosion 3334 *T*
 clinical examination 3311
 development 966, 3122
 disorder classification 3321–2
 exophytic masses 4089, 4089 *F*
 exostosis 3366–9, 3367 *F*
 aetiology 3367
 cold water exposure 3367
 definition 3366, 3366 *F*
 diagnosis 3367
 epidemiology 3367
 management 3367–8
 natural history 3367
 outcomes 3367
 pathology 3366
 stenosis 3367
 surgery 3368
 glandular tumours 4069–70
 classification 4069
 progression 4068–9
 see also individual types
 hearing 3178
 HIV-associated lesions 240
 hypothyroidism 400
 Kaposi's sarcoma 240
 lacerations, foreign
 body-induced 3371
 mopping 3313–4, 3314 *F*
 occlusion 3035, 3037 *F*, 3311
 osteonecrosis *see* benign necrotizing
 otitis externa
 polyps, HIV-associated 240
 relationships 3108, 3108 *F*
 restoration 3035
 skin 3107
 external auditory meatus (EAM) *see*
 external auditory canal (EAC)
 external beam radiation
 lip cancer 2548
 pituitary tumours 4115
 external carotid artery 1749–50, 3904
 branches 1749–50, 1750 *T*
 course 1853–4
 epistaxis 1596–7
 territories 1597
 external carotid artery ligation
 (ECAL) 1604, 1750
 external ear
 abnormal folds 970, 970 *F*
 anatomy 3105–25
 atresia
 acquired *see* acquired atresia,
 external ear
 congenital, bone-anchored hearing
 aids 3642–3
 ‘bumps’ 972
 clefts 972, 973 *F*
 collapsed 971
 congenital deformities 965–89
 aetiology 967–8
 classification 975–6, 976 *T*
 epidemiology 967
 range of 968–75
 syndromic associations 967–8
 treatment 977–80
 embryology 808, 814, 3120–2
 extrinsic muscles 3106
 hearing 3178–9
 bone conduction 3185–6
 tympanic membrane pressure
 gains 3178–9
 hidden (cryptotia) 973, 974 *F*
 HIV 240
 mycotic diseases 214
 normal 967, 969 *F*
 otalgia 3527
 positional problems 973–4, 974 *F*
 sound localization 3179, 3179 *F*
 splintage 972 *F*, 974–5, 975 *F*
 external ear barotrauma 3504
 external ear squeeze 3504
 external fixation
 Le Fort 2 fractures 1627, 1627 *F*
 mandibular fractures 1623, 1624 *F*
 maxillary fractures 1627
 external jugular vein 1750
 external laryngeal nerve 3935
 external nares (nostrils) 1325–6
 HIV patients 248
 external nose
 anatomy 1322–41, 1323 *F*
 blood supply 1325
 cartilages 1324 *F*, 1325
 lower lateral *see* alar cartilage(s)
 upper 1325, 2960–1
 conditions of 1699–717
 see also specific disorders
 destructive lesions 1713
 development 1315
 innervation 1325
 inspection 1575, 1576 *F*
 lymphatic drainage 1325
 muscles 1322–4, 1323 *F*
 neoplasms 1704–10
 fibroadnexal tumours 1708
 melanocytic 1706–7
 vascular lesions 1708
 skin 1322
 venous drainage 1325
 external occipital crest 3899
 external palatine (paratonsillar)
 vein 1793
 external rhinoplasty 2959–69
 applications 2963–8
 bony pyramid 2963–4
 cleft lip nasal deformities 2967, 2967 *F*
 deviated nose 2965–6, 2966 *F*
 historical aspects 2959–60
 incisions 2961, 2962, 2963 *F*
 indications 2960, 2960 *T*
 middle nasal vault 2964
 nasal tip surgery 2964–5, 2965 *F*,
 2998–9, 2999 *F*
 principles 2961
 retrograde approach 2999
 revision surgery 2965
 septal access 2962
 soft tissue envelope dissection 2962,
 2963 *F*
 surgical anatomy 2960–1, 2961 *F*
 technique 2962–3
 tension nose 2966
 transcolumnellar incision
 closure 2962–3, 2963 *F*
 extracellular agents 137–40
 extracellular matrix (ECM) 89, 93
 cancer and 2385
 extracorporeal circuits (ECC) 287–8
 extracranial-intracranial bypass,
 jugular foramen surgery 4039,
 4040 *F*
 extradural abscess, acute otitis
 media 924
 extramedullary haemopoiesis 266
 extraocular muscles 3917
 extra-oral prostheses
 construction 2930–1
 stages 2931, 2931 *F*
 treatment planning 2925
 extrapyramidal disorders 3777–8, 3780
 see also specific disorders
 extrapyramidal syndromes 3939
 extrapyramidal system,
 phonation 2158–9
 extrauterine intrapartum treatment
 (EXIT) procedure 1137–8
 exuding wounds, dressings 101
 eye(s)
 scars 2896
 unilateral facial palsy 3079
 Wegener's granulomatosis 1650,
 1651 *F*
 see also entries beginning orbital
 ‘eyebags’ 3054 *F*
 orbital fat removal 3057

eyebrow, ideal position 3048, 3049 *F*
 eyebrow lifts 3078–9
 eyebrow ptosis, medial 3049
 eye contact, medical consultations 565
 eye cover test
 cranial nerve examination 3710–1
 latent nystagmus 3711
 spontaneous nystagmus 3711
 eye disease, dysthyroid 331
 eyelid(s)
 hollowing 3065
 lower *see* lower eyelid
 surgery *see* blepharoplasty
 upper *see* upper eyelid
 eyelid ptosis, Horner's syndrome 3937
 eyelid retraction, post-blepharoplasty 3053 *F*, 3065
 eyelid swelling, blepharochalasis 3053
 eye movements
 automatic 3921
 balance disorders
 examination 3710–23
 laboratory assessment 3723–30
 central control mechanisms 3919, 3920 *F*
 functional classes 3227 *T*
 optokinetic 3227 *T*
 rotationally induced 3216
 semicircular canal stimulation 3216, 3217 *F*, 3218 *F*, 3219 *F*, 3219 *T*
 torsional, control of 3216
 tracking 3921
 vertical, control of 3216
 voluntarily controlled 3919

face
 ageing *see* ageing face
 development 797–8, 1810–2, 1811 *F*
 gender differences 2945, 2945 *F*
 face lifts *see* rhytidectomy
 face masks, anaesthesia 492
 children 510
 facets 703, 704, 705 *F*
 face validity 635
 facial artery 1325
 facial artery myomucosal flap (FAMM) 2850–1
 facial assessment
 computer manipulation 2947, 2947 *F*
 digital imaging 2946–8
 facial baropareisis 3513–4
 facial bipartition, syndromic
 craniostenosis 1029

facial cleft(s)
 embryology 798–9, 1320, 1811–2
 types 801 *F*
 see also individual types
 facial colliculus 3929
 facial cosmetic units 2828, 2829 *F*
 facial defect(s)
 ablative surgery 2937 *F*
 acquired 2926
 traumatic burns injury 2926 *F*
 aetiology 2925–30
 congenital
 aetiology 2925
 decision to treat 2925
 psychological aspects 2927
 reconstruction delay 2927
 patient follow-up 2933
 facial defect reconstruction 2926–7
 auricular 2927–8
 bony defects 2926–7
 decision to not reconstruct 2926
 firearms injury 2937–8, 2937 *F*, 2938 *F*
 polymers 121
 prosthesis referral 2928
 sites 2927–30
 skeletal fixation 2926–7
 small soft tissue defects 2926–7
 surgical *vs.* prosthetic 2927 *T*
 facial injuries, children 1632–3
 anterior teeth 1633
 fronto-naso-ethmoid injuries 1633
 soft tissue injuries 1633
 facial nerve (VII) 3870–6, 3871 *F*, 3927–31, 3928 *F*
 anatomy 1052–4
 adults *vs.* children 1054 *T*
 anomalous course, middle ear 873, 874 *F*
 applied anatomy 4079–80
 blood supply 4080
 branches 3928
 patterns 1854, 1855 *F*
 central connections 3920 *F*, 3929
 cerebellopontine angle syndrome 3932
 clinical testing 3931
 composition 3870
 compression 3872
 cortical lesions 3930
 cutaneous fibres 3928–9
 disorders *see* facial nerve disorders
 electrophysiological monitoring *see* facial nerve monitoring
 embryology 966–7, 1052–4
 abnormalities 1053
 epidermoids 4011
 facial reanimation 3080
 function assessment 3946–7, 4080–1
 see also facial nerve monitoring
 imaging 3881
 injury, blepharoplasty 3066
 intracranial portion 3871
 intraparotid 1853–4, 1854–6, 1855 *F*
 intratemporal portion 3871
 jugular foramen surgery 4034, 4035–7
 conservative management 4037, 4037 *F*
 nerve transposition ear, canal wall up 4037–8, 4038 *F*
 transposition ear, canal wall down 4038, 4038 *F*
 labyrinthine segment 3871–2, 3882 *F*
 lateral skull base 3904
 management, tumour surgery 4082
 morphology 4079–80
 motor root 3871
 neurofibromatosis 2 4000, 4003
 neurological examination 3946
 otalgia 3527
 paediatric cochlear implantation 864
 parotid gland divisions 3873
 protection, branchial arch fistula surgery 1266
 recesses 3872, 3872 *F*
 rhytidectomy 3094
 salivary gland tumours surgery 2508–9
 schwannoma *see* facial schwannoma
 sensory fibres 3927–8
 skull base lesions 3945, 3946, 3946–7
 stapedius muscle 3870
 surgical anatomy 3870–3
 surgical repair 2509
 taste bud innervation 1841
 trauma *see* facial nerve injury/trama
 tympanic cavity 3112, 3114 *F*
 facial nerve canal 3111, 3112 *F*
 facial nerve disorders 3870–94, 3930–1
 classification 3835–6
 clinical evaluation 3876–83
 coexisting trigeminal nerve damage 3931
 history taking 3876
 imaging 3881–3
 inflammatory 3891
 investigations 3878–81
 management 3883–91
 viral diseases 3886–7
 middle ear infection complications 3890–1

- neuropathophysiology 3873–6,
3875 T
- physical examination 3876–8
- topodiagnostic evaluation 3878,
3878 T
- see also specific disorders/diseases*
- facial nerve injury/trauma 3887–90,
3931
- gunshot injury 3887–8, 3887 F
- iatrogenic 3889
- management 3887–90
- maxillofacial trauma 3887
- medical negligence 1307, 3827–8
- neonatal 3889–90, 3890 T
- petrous bone fractures 3931
- post-rhytidectomy 3074
- post-stapes surgery 3476
- salivary gland tumour surgery 2487,
2515
- surgery-induced 749, 750
- temporal bone trauma 3888,
3889 F
- vestibular schwannoma
removal 3979–80
- facial nerve (VII) injury/trauma, skull
base surgery 4137
- facial nerve monitoring
airway management 494–5
- chronic middle ear disease surgery
and 749
- development/history 748–9
- difficulties 750
- electrodes 749
- facial nerve paralysis 3878–81
children 1055, 1057
- intraoperative 3880–1, 3881 T
- medical negligence 3828
- nonotological procedures and 750
- outcome prediction 749–50
- techniques 749
evoked facial twitch 748
see also individual techniques
- facial nerve paralysis
acute otitis media 923, 3882, 3890
- bilateral 3085
reanimation 3085
- causes 1, 3078 T
- children 1052–62
acquired 1056–8
branchial cleft sinus and fistula
excision 1058
- congenital 1055
- diagnosis 1054–5
- ear surgery 1057–8
- electrophysiology 1055, 1057
- examination 1054
- history taking 1054
- iatrogenic 1057–8
- idiopathic 1059
- infections 1056–7
- investigations 1055
- neoplasms 1058
- parotid surgery 1058, 1058 F
- penetrating trauma 1057
- traumatic 1057–8
- cholesteatoma surgical
complication 3434
- chronic otitis media *see chronic otitis
media (COM)*
- congenital 1055, 3889–90
- decompression surgery 4022
- facial nerve tumours 4080
- grading 3876–8
- herpes zoster oticus 3380
- HIV infection 3887
- HIV patients 241
- idiopathic *see Bell's palsy*
- imaging 3881–3
- ipsilateral recurrent 3876
- jugular foramen lesions 4028
- management 3078–85
surgical 3079–80
- parotid gland tumours 2503–4
- rhytidectomy 3094–5
- skull base lesions 3945
- surgery-related 2808
- temporal bone fracture 3497–8
- temporal bone squamous cell
carcinoma 4088, 4094
- temporal bone trauma 3496
- tuberculous otitis 3448, 3448 T,
3450 T
- varicella zoster virus infection 3886
- facial nerve preservation, vestibular
nerve schwannoma 3688, 3688 F,
3689 F, 3690 F
- facial nerve stimulation, cochlear
implant-related 3654, 3655
- facial nerve surgery 4022
- facial nerve tumours 4078–85
decompression 3891
- epineurium 4079–80
- facial weakness 4080
- grafting technique 4082–3
- hearing loss 4080
- histology 4078–9
- imaging 3883, 3884 F
- investigations 4080–1
- malignant sheath tumours 4083
- management 3891
- middle fossa surgery 4022, 4022 F
- near-total tumour removal 4083
- patient counselling 4082
- patient selection 4081–2
- presentation 4080
- radiotherapy 4083
- surgery 4082–3
- tumour biology 4078–9
- tumour stripping 4083
- facial nucleus 1052–3, 3920 F, 3929
- facial pain
associations 1719
- atypical 1727, 1829
- clinical features 1829
- definitions 1829
- patient traits 1829
- treatment 1829
- background 1718–9
- characteristics 1719
- daily life, effects on 1719
- dental 1721
- diagnosis 1718–29
- duration 1719
- history taking 1719
- management 1718–29
- neuralgias 1724
- psychological aspects 1719
- radiation 1719
- relief 1719
- rhinological 1720–1
- sarcoidosis 1647–8
- skull base lesions 3944–5
- tumours 1724
- vascular 1722–4
- facial plastic surgery
aesthetics 2943–9
- bizarre requests 3089
- complications 3089
- digital planning 2943–9
- medical negligence 3088
aggressive and violent patients
3089
- complication management 3096
- computer enhanced images
2948
- consent issues 3089
- patient selection 3088–9
- objective 2948
- patient dissatisfaction, previous
surgery 3089
- patient expectations 2948
- preoperative cooling-off period 3089
- risks 3089
- see also specific procedures*
- facial prominences (processes) 1810–1

facial proportions 2945–6
 ageing 2946, 2947 *F*
 component widths 2946, 2946 *F*
 frontal view 2946
 horizontal planes 2946, 2946 *F*
 facial prostheses, retention
 methods 2931–2
 adhesive 2931–2
 mechanical/anatomical 2932
 see also individual prostheses
 facial rashes
 infective 1701
 nasal 1715
 rubella 1701
 facial reanimation 3077–87
 adjustments 3083–4
 congenital facial paralysis 1055
 excessive muscle bulk 3083–4
 future research areas 3086–7
 knowledge deficiencies 3086–7
 patient's age 3077, 3082 *F*
 results 3082, 3083 *F*
 facial reconstruction *see* facial defect
 reconstruction
 facial schwannoma 3883, 3884 *F*, 4014,
 4078
 MRI appearance 4079 *F*
 surgical decompression 4083
 tumour debulking 4083
 facial skeleton fractures 1618–35
 aetiology 1619
 children 1633
 frontal sinus 1632
 haemorrhage 1619–20
 intervention, timing of 1620
 management principles 1620
 mandible *see* mandibular fractures
 maxilla *see* maxillary fractures
 naso-orbito-ethmoid *see* naso-orbito-
 ethmoid (NOE) complex fractures
 orbital floor *see* orbital floor fractures
 primary care 1619–20
 initial survey 1619–20, 1619 *F*
 radiographic evaluation 1620
 soft tissue injuries 1632
 upper facial third 1632
 zygomatic complex *see* zygomatic
 complex fractures
 facial slings, unilateral facial
 palsy 3079–80
 facial synkinesis, Bell's palsy 1845, 3931
 facial translocation 4064–5, 4064 *F*
 facial trauma
 intubation 2289
 taste abnormalities 1846

facial vein 1325
 facial weakness
 conservative parotidectomy
 2483
 facial nerve damage 3930
 facial nerve tumours 4080
 facioacoustic crest 1052
 factor II (prothrombin) 279
 factor V 279
 factor V Leiden variant 290
 factor VIIa 279
 factor VIII
 haemophilia 285
 inhibition 284
 venous thrombosis 290
 factor X 279
 factor XI deficiency 281
 factor XIII 279
 deficiency 281
 Fahreus–Lindqvist affect 112
 failed ventilation 476–7
 Fallopian canal, facial nerve
 tumours 4079
 false cords 757, 2132
 falsetto voice, mutational *see*
 mutational falsetto voice
 falx cerebri 4121
 famciclovir 208, 232, 2079
 familial adenomatous polyposis
 juvenile angiomyomas 2438
 thyroid cancer 2671
 familial dysautonomia 1848
 familial facial paralysis 1055
 familial paragangliomas 2526–7
 Family Law Reform Act (1969), consent
 issues 601
 famotidine 2262
 farmers, occupational rhinitis 1418
 fascia bulbi 1679
 fascial grafts 2827
 Fas ligand (Fas-L) 57, 137
 fast Fourier transform (FFT), voice
 evaluation 2180
 fasting, preoperative 465
 children 509, 509 *T*
 fat atrophy
 facial ageing 3069
 steroid injections 2898–9
 fat grafts 2826–7
 fat injection, vocal fold paralysis 2239,
 2245 *T*
 fat necrosis, blepharoplasty 3066
 faucial pillar
 anterior 1944
 posterior 1944
 FDG-PET imaging 686
 best clinical practice 696–7
 cervical lymphadenopathy 2702,
 2704
 indications 696
 lymphoma 694, 694 *F*
 nononcological applications 696
 occult primary tumours 691–2, 695,
 696
 opharyngeal cancer 695 *F*
 parathyroid carcinoma 694
 principles 685 *F*
 pulmonary lesions 694, 695 *F*
 salivary gland tumours 694
 squamous cell carcinoma *see*
 squamous cell carcinoma
 (SCC)
 thyroid cancer 334, 692, 693 *F*, 695,
 696
 febrile nonhaemolytic transfusion
 reactions 261
 feeding problems, special needs
 children 786–7
 feed thickeners 1276
 fenestrated tracheostomy tubes 1199,
 2299
 fenestration procedures, historical
 aspects 3468
 fentanyl 2786–7
 ferritin 268
 'festoons' 3060–1, 3063 *F*
 fetomaternal haemorrhage, anti-D
 254
 FGFR1 mutation, Pfeiffer
 syndrome 1027
 FGFR2 mutation
 Apert syndrome 1027
 Pfeiffer syndrome 1027
 FGFR3-associated coronal synostosis
 syndrome (Muenke
 craniostenosis) 1027–8
 fibreoptic assisted techniques, difficult
 airways 475–6, 476 *F*
 fibreoptic bronchoscopy
 paediatric anaesthesia 519
 paediatric intensive care 547
 fibreoptic endoscopic evaluation of
 swallowing (FEES)
 aspiration 1277, 2096
 dysphagia investigations 1965, 1965 *T*,
 1968–70, 2028
 advantages 1968
 contraindications 1970
 equipment 1968
 limitations 1970

- procedure 1968, 1969 *F*
 risks 1970
 neurological dysphagia 2076
 fibreoptic endoscopic evaluation of swallowing with sensory testing (FEESST)
 aspiration 1277
 dysphagia 1968
 fibreoptic orotracheal intubation (FOI), supraglottic obstruction 481
 fibrillogenesis, dermabrasion 2898
 fibrin degradation 279
 formation 279
 inhibitors 279
 skin graft adherence 2821–2
 fibrin glue 263
 fibrinogen 279
 fibrinolysis 279, 280 *F*
 fibroadnexal tumours, nasal 1708
 fibroblast(s)
 allergic rhinitis 1392
 fibroplasia 91
 migration 91
 phenotypic alterations 91
 proliferation 89, 91
 stimulation responses 90
 wound healing 90, 91
 fibroblast growth factor (FGF)
 goitre 2668
 salivary gland tumours 2495
 fibroblast growth factor-2 (FGF-2)
 skin flap survival 114
 stem cell activation 67
 stem cell differentiation 68
 fibroblast theory, wound healing 92
 fibroelastic membrane 2132 *F*, 2134, 2134 *F*
 fibroma
 ameloblastic 1927–8
 ossifying *see* ossifying fibroma
 fibronectin 91
 fibro-osseous lesions
 nasal obstruction, children 1077
 skull base 4123
 fibroplasia proliferation 91
 fibrosarcoma
 childhood 1259 *T*
 larynx 2604
 fibrous adhesions, post-stapes surgery 3475
 fibrous atresia, external ear 3348
 fibrous dysplasia 1522–3
 clinical types 1522
 definition 1522–3
 differential diagnosis 1523
 incidence 1522
 location 1522–3
 nasal obstruction, children 1077, 1077 *F*
 optic nerve decompression 1523
 polyostotic 1929
 presentation 1929
 radiological appearance 1929, 1929 *F*
 skull base 4124
 proptosis 4125, 4125 *F*
 radiological features 4124–5
 surgery 1523
 symptoms 1522–3
 fibrous meningiomas 4008
 fibula free flap, oral cavity reconstruction 2571, 2572 *F*
 Vth cranial nerve *see* trigeminal nerve (V)
 filiform papillae 1794
 fine needle aspirate biopsy (FNAB), lymphoepithelial cyst 245–6
 fine needle aspiration cytology (FNAC) cervical lymphadenopathy 2703
 head and neck tumours, childhood 1252–3
 metastatic neck disease 2721
 nasopharyngeal carcinoma 2456
 nodular thyroid disease 361, 361 *F*
 limitations 361
 results 361, 362 *T*
 ultrasound-guided 361
 salivary gland tumours
 benign 2479–80, 2480 *F*
 malignant 1885, 1892 *F*, 2506
 temporal bone squamous cell carcinoma 4089
 thyroid cancer 333, 2698
 finger clubbing, Graves' disease 343
 firearms injuries, neck trauma 1767
 first branchial arch fistula 1264–6
 histology 1265, 1265 *F*
 investigation 1265, 1265 *F*
 presentation 1265, 1265 *F*
 treatment 1265–6, 1266 *F*
 first degree burns 96
 Ist nerve *see* olfactory nerve (I)
 first pass effect 408
 first primary interturbinal furrow 1332
 Fisch staging system, juvenile angiofibroma 2438–9, 2439 *T*, 2441
 Fisch technique 4020
 Fisch type B infratemporal fossa approach, petrous apex lesion resection 4051, 4052 *F*
 Fisch type C procedure, parapharyngeal space tumours 2533–4
 Fisch type D procedure, parapharyngeal space tumours 2533–4
 fish bone removal, oropharynx 1187–8
 fissural cysts 1926
 fistula(e)
 arteriovenous 4145
 branchial arch *see* branchial fistulae cerebrospinal fluid *see* cerebrospinal fluid fistula chylous 2744
 endovascular embolization 733
 frontal sinus *see* frontal sinus fistulae innominate artery 1203
 labyrinthine fistulae *see* labyrinthine fistulae malignant *see* palliative care, head and neck cancer nasal *see* nasal fistula(e) oro antral 1085 palatal 1010 perilymphatic *see* perilymphatic fistulae salivary 2484, 2515 thyroglossal duct *see* thyroglossal duct fistula tracheoarterial 2302 tracheocutaneous, persistent *see* tracheocutaneous fistula (TCF), persistent tracheo-oesophageal *see* tracheo-oesophageal fistula tracheostomy-induced 2302 fistula speech 2625 Fistula test chronic otitis media 3419 skull base lesions 3946 Fitness to Practise (FTP) panel 2803–4 fixation external *see* external fixation intermaxillary *see* intermaxillary fixation (IMF) internal *see* internal fixation ‘flamingo flush,’ otosclerosis 3460–1 flavour enhancers, olfactory dysfunction 1671 flexible bronchoscopy laryngeal stenosis 1153, 1161 posterior glottic stenosis 1161 flexible endoscopic evaluation of swallowing *see* fibreoptic endoscopic evaluation of swallowing (FEES)

- flexible endoscopy
oesophageal foreign bodies 1188
stridor 1120
upper airway obstruction 2289,
2290 *F*
- flexible intubating fibrescopes 473–4
- flexible laryngoscopy 2146–8, 2147 *F*
laryngomalacia 1136
- flexible nasendoscopy 2147
airway management 470
head and neck tumours,
childhood 1252, 1252 *F*
- flexible nasolaryngoscopy, chronic
laryngitis 2259
- flexible nasopharyngoscopy
laryngeal stenosis 1152, 1161
posterior glottic stenosis 1161
- floating mass transducer (FMT),
middle ear implants 3661
- floor of mouth carcinoma 2552–4,
2557–8
clinical presentation 2552
imaging 2552–3, 2557
investigation 2552–3
management 2557–8
presentation 2557, 2557 *F*
survival rates 2558, 2558 *T*
- floppy 360 Nissen fundoplication,
gastro-oesophageal reflux 2064
complications 2064
- flow cytometric analysis, apoptosis 60
- flow-directed microcatheters 732–3
- flow-volume loop, airway
management 470
- flucloxacillin 236
- fluconazole 233–4
candidiasis 224, 2789
entomophthoramycosis 215
mycotic laryngitis 2254
- flucytosine 234, 442
resistance 234
- fluency disorders 993–4
- fluent speech samples, voice
evaluation 2172, 2174 *T*
- fluid management
hypophysectomy and 4112
newborn infant 543–4
paediatric intensive care 543–4, 544 *T*
unwell child 544
- flunarizine
Menière's disease 3800
migrainous vertigo 3804
side effects 3797, 3804
tinnitus 3617
vestibular attacks, acute 3797
- flunisolide 1401
- fluorescein lumbar puncture
cerebrospinal fluid
rhinorrhoea 1638–9, 1639 *F*
complications 1639
- fluorescence-activated cell sorter
(FACS) 73–4
- fluorescence *in situ* hybridization
(FISH) 6
- fluorescent treponemal antibody (FTA),
syphilis 1461, 2008
- fluoride
otosclerosis treatment 434, 3466
tooth discolouration 1817
- fluorine-18
fluoroerythronitroimidazole
(FETNIM), head and neck cancer
imaging 696
- 2-[¹⁸F] fluoro-2-deoxy-D-glucose-
positron emission tomography *see*
FDG-PET imaging
- fluoromisonidazole (FMISO) 696
- fluoroquinolones 230–1
malignant otitis externa 3339
otitis externa 3354
pertussis 2252
tympanic membrane perforation with
discharge 937, 937–8
- fluoroscopy, children 1296–7
- fluorosis 1817
- 5-fluorouracil (5-FU)
adjuvant radiotherapy 52
basal cell carcinoma 2397
dacryocystorhinostomy 1695
mechanism of action 38, 39 *F*
neoadjuvant treatment 40
salivary gland tumours,
malignant 2508
- temporal bone squamous cell
carcinoma 4094
- flutamide 2441
- fluticasone propionate
allergic rhinitis 1398
children 1401
nasal polyps 1470
nonallergic rhinitis 1412
persistent rhinosinusitis 437
rhinosinusitis, children 1083
- flying, ear surgery and 3469, 3506
- FM systems, education of deaf
children 855, 855 *F*
- 'foam and dome' test 3733–4, 3734 *F*
- foam dressings, maxillectomy 2930,
2930 *F*
- focal bone marrow defect, jaw 1927
- focal dermal hypoplasia 1824
- focal otitic encephalitis, acute otitis
media 924
- foetal alcohol syndrome 968
- foetal goitre, thionamide-induced 347
- foetal haemoglobin 266–7
- foetal surgical procedures, deafness 818
- Fogarty embolectomy balloon catheter,
foreign body removal 1186
- folate deficiency 269
- Foley catheter, epistaxis 1603
- foliate papillae 1794
- foliate papillitis 1828
- folic acid
cleft lip and palate 1000
deficiency 269
encephalocoele 1034–5
- folic acid antagonists 38
- follicle stimulating hormone
(FSH) 301–2
circulating levels 301–2
effects 302
secretion 297, 302
structure 302
- follicular dendritic cell tumour,
parapharyngeal space 2527
- folliculostellate cells 297
- fontanelles 794
- fonticulus frontalis closure, dermoid
cyst 1073
- food, adverse reactions 1, 1424
- food additives
food allergy 1427
orofacial granulomatosis 1828
- food allergy 1, 1424–38, 1425 *F*
allergens 1426–7
avoidance 1397
nickel 1426
pollen cross-reacting foods 1426,
1426 *T*
- children 1397
- clinical trials 1
- cross-reactivity
clinical 1427
food items 1426 *T*
immunological 1427
- definitions 1424–5
- delayed reaction (type IV) 1424
- diagnosis 1397, 1427–9, 1428 *F*
case history 1427–8
diet 1429
- food additives 1427
- food challenge 1429
children 1429
respiratory symptoms 1, 1429

- investigations 1428–9
 pregnancy 1426
 prevalence 1427
 primary prevention 1426
 in infants 1426
 sensitization 1425–6
 infants 1425
 ingestion 1425
 inhalation 1425–6
 intrauterine 1425
 skin 1426
 skin prick tests 1394
 symptoms 1428, 1428 T
 tolerance 1427
 treatment 1431
 type I-mediated reaction 1424
 food aversion 1, 1424
 food intolerance 1424, 1425 F
 causes 1, 1424
 definition 1424
 rhinitis 1383
 symptoms 1428, 1428 T
 food poisoning 196
 food-processing workers, occupational
 rhinitis 1418
 foot drop 3731
 footplate 1326
 foramen caecum 314–5, 1794, 4120
 foramen diaphragmatis 298
 foramen lacerum 1339, 2111, 3900
 foramen magnum 3898, 3905 F
 foramen of Huscke 3124
 foramen of Vesalius 3899
 foramen ovale 1339, 4122
 foramen rotundum 1339, 4122,
 4123 F
 foramen spinosum 1339
 forced expiratory volume (FEV) 1375
 ‘forced prolonged position’ on healthy
 side 3812–3
 Fordyce spots (granules) 1792–3, 1824,
 1824 F
 forearm flap 2869–72
 advantages 2869
 anatomy 2869, 2870 F
 applications 2871–2
 buccal carcinoma 2561, 2561 F
 disadvantages 2869–70
 external skin 2871–2
 oral cavity reconstruction 2570,
 2570 F
 pinna reconstruction 3046 F
 technical nuances 2870–1
 tongue cancer 2555–6, 2556 F
 foregut 1942, 1942 F
 forehead flaps 2844, 2845–6, 2848–9,
 2849 F
 nasal reconstruction 3022, 3024 F
 foreign bodies
 children 1184–93
 aerodigestive tract 1184–93
 bronchial 1188
 larynx 546, 1188
 nose *see* nasal foreign bodies,
 children
 tracheo-bronchial tree 1188–91
 ear *see* aural foreign bodies
 ingested 1186–91
 management 1187–8
 inhaled 545–6
 paediatric anaesthesia 519
 removal 519
 oesophagus *see* oesophageal foreign
 bodies
 pharyngeal *see* pharyngeal foreign
 bodies
 ultrasound examination 727
 foreign speakers, speech rhythm 2168
 formal angiography, children 1300,
 1300 F
 formaldehyde, occupational
 rhinitis 1419
 formants 2166, 2179–80
 singer’s 2178 F, 2180, 2211
 fornix vestibuli 1793
 Forrest plot 664, 664 F
 ‘40 Hz response’ 3288
 Fos–Jun protooncogenes 2380
 fossa of Rosenmüller *see* pharyngeal
 recess (fossa of Rosenmüller)
 Foster–Kennedy syndrome 1668–9, 3915
 four alternative auditory feature
 (FAAF) test 841
 Fourier analysis 3176–8, 3176 F
 linear systems 3178
 nonperiodic sounds 3177–8, 3177 F
 periodic sounds 3177, 3177 F
 sinusoid waves 3176
 square waves 3176–7, 3177 F
 fourth branchial fistulae 1779, 1780 F
 IVth nerve *see* trochlear nerve (IV)
 fovea ethmoidales ossid frontalis 1328
 fractional cell kill hypothesis 36
 fractionated plasma products 260
 fractionation 48–9, 48 F
 accelerated 2754–5
 definition 48
 early reactions 2754
 fraction size 48
 late tissue reactions 2754
 modifications 49, 2754
 repopulation 2754
 simultaneous chemotherapy
 and 2758–9
 fracture(s)
 condylar neck 1622, 1624–5
 facial skeleton *see* facial skeleton
 fractures
 hyoid bone 2272
 mandible *see* mandibular fractures
 maxilla *see* maxillary fractures
 nasal *see* nasal fractures
 temporal bone *see* temporal bone
 fractures
 upper airway obstruction 2287
 zygomatic complex *see* zygomatic
 complex fractures
 fragment antigen binding (Fab)
 regions 138
 fragment crystallizable (Fc) region 138,
 139–40
 Framingham Heart Study, age-related
 hearing loss findings 3541–2
 Framingham Offspring Study,
 age-related hearing loss
 findings 3541–2
 framycetin 937–8
Francisella tularensis 1216
 Frankfort plane 2946, 2946 F
 Frazer’s test 3509
 free cartilage grafts, nasal
 reconstruction 3022
 free-electron lasers 743
 free-field speech testing 3317
 otitis media with effusion 887
 free flaps, head and neck
 reconstruction 2867–90
 abdominal wall and pelvis 2876–83
 classification 2867–8
 defect-based options 2885–7
 enteric reconstructions 2883–5
 flap types 2869–72
 forearm flap 2869–72
 lateral arm flap 2872
 free tissue transfer,
 considerations 2868–9
 flap failure management 2869
 perioperative management
 2868
 postoperative management
 2868
 recipient vessels 2868–9
 perforator flaps 2867–8, 2868 F
 scapular system 2873–6
 temporal bone 4093, 4094

- free gastro-mental flap 2884–5
advantages 2884
anatomy 2884, 2885 *F*
clinical applications 2884–5,
2885 *F*
disadvantages 2884
technical nuances 2884
free grafts 2819–20
free jejunal transfer 2883–4
advantages 2883
anatomy 2883
clinical applications 2884, 2884 *F*
disadvantages 2883
technical nuances 2883–4
free osseocutaneous fibular flap
2881–3
advantages 2881
anatomy 2881, 2882 *F*
clinical applications 2883,
2883 *F*
disadvantages 2881
technical nuances 2881–3
free radicals
compromised skin flaps 113
ototoxicity and 3300–1, 3301 *F*
free radical scavengers, ototoxicity
prevention 3302
free skin grafts 2820–5
Frenzel's glasses/lenses
Hallpike manoeuvre 3721
skull base lesions 3946
frequency discrimination 3252
centre frequency 3252, 3252 *F*
frequency pattern sequences, central
auditory dysfunction 3859
frequency resolution *see* frequency
selectivity
frequency response 3170
frequency selectivity
auditory filters 3246–9
auditory nerve fibres 3197–8
cochlear hearing loss 3256
critical bands 3246–9
definition 3245
excitation pattern 3249–50
loudness perception 3251–2
masking 3246–9
measurement 3245–50
audibility of partials in complex
sounds 3245–6, 3246 *F*
place coding 3197–8
tuning curves bandwidths 3198
frequency separation 3245–6
frequency threshold curves (FTCs) *see*
tuning curves
- fresh frozen plasma (FFP) 257–60,
258 *T*
ABO compatibility 258
characteristics 257–8
disseminated intravascular
coagulation 284
haemophilia 285–6
indications 258–9
liver disease 258, 282
Rh D-compatible 258
shelf life 257
vitamin K deficiency 258
Frey's syndrome 1846, 2484
post-parotidectomy 2484, 2484 *F*,
2515
taste abnormalities 1846
fricatives 2167, 2167 *T*
Friedreich's ataxia 3773, 3774
Frisch bacillus *see Klebsiella*
rhinoscleromatis
frontal bone 1340, 1340 *F*
development 1318
fusion 1318
orbital plate 3897
ossification 1318
pneumatization 1320
frontal bone osteomyelitis
rhinosinusitis 1545
sinusitis 1086
frontal bulla (cells) 1333, 1500, 1501 *F*
frontal cells (bulba) 1333, 1500, 1501 *F*
frontalis, unilateral facial
paralysis 3078–9
frontal lobes
in anterior cranial fossa 4121
eye movement disorders 3921
frontal lobe tumours, hyposmia 1668–9
frontal nerve 3923
frontal-orbital advancement and
remodelling (FOAR),
synostoses 1025–6, 1026 *F*
frontal plagiocephaly 1022 *T*, 1025
frontal pneumosinus dilatans 1519–20
aetiology 1519–20
associated conditions 1519
clinical symptoms 1519
definition 1519
differential diagnosis 1520
frontal sinus obliteration 1515, 1520
pathogenesis 1519–20
surgical therapy 1520
frontal recess 1332–3
development 1332
ostia 1332
shape/configuration 1332
- frontal rhinosinusitis
complications 1539
intracranial 1545
orbital cellulitis 1544–5, 1545 *F*
medical negligence 1735
orbital abscess 1544–5
frontal sinus 1500–30
absence 1340
accessory channels 1340
anatomy 1340, 1500
at birth 1320
blood supply 1340
clinical examination 1501
clinical pathology 1502–5
development 1320, 1500–1
disorders 1500
clinical diagnosis 1501–2
patient history 1501
drainage 1368, 1500
anatomical variation 1507–8
frontobasal malformations 1502–5,
1503 *T*
closure defects 1502
manifest malformations 1504,
1506 *T*
occult malformations 1504, 1506 *T*
histology 1340
imaging 1501–2
infection, medical negligence 1735
inflammatory diseases 1507–20
surgical therapy 1518–9
innervation 1340
inspection 1501
intersinus septum 1340
lymphatic drainage 1340
osteology 1340
oxygen tension 1368
palpation 1501
pathophysiological
considerations 1500–1
surgical approaches 1508–18
Fulda concept 1509, 1509–14
intra-extranasal 1514
nonresponsive inflammatory
disease 1518–9
see also individual techniques
surgical drainage 1507–8, 1510 *F*
classification 1509
endonasal median 1511–3
endoscopic four-hand
technique 1509
extended 1509–11
indications 1510 *T*
Lothrop procedure 1512
neo-ostium diameter 1509

- post-surgical packing 1512
 'rescue procedure' 1511, 1512 *F*
 results 1513–4, 1513 *F*
 simple 1509
 type I 1509
 type II 1509–11, 1511 *F*
 type III 1511–3, 1514 *F*
- trauma 1505–7
 variations 1320, 1340
- frontal sinus cysts 1502–5, 1504 *F*, 1506 *F*
 diagnosis 1504–5
 extradural 1502–3
 intradural 1502–3
 operative principles 1505
 prognosis 1505
- frontal sinus endonasal surgery
 improvements 1509
 osteomas 1522
 results 1513–4
 studies 1513
- frontal sinus fistulae 1502–5, 1504 *F*,
 1506 *F*
 diagnosis 1504–5
 operative principles 1505
 prognosis 1505
- frontal sinus fractures 1505–7, 1632
 dural lesion 1507
 dural reconstructive techniques 1507
 imaging 1506
 reconstruction 1507
 surgery 1506–7
- frontal sinus osteomas 1521–2
 definition 1521–2
 differential diagnosis 1522
 imaging 1502 *F*
 incidence 1522
 location 1521–2
 surgery
 indications 1522 *T*
 results 1522
 techniques 1522
 symptoms 1521–2
- frontal sinus rescue procedure 1511,
 1512 *F*
- frontal sinus trephination 1508
 medical negligence 1733
 operative principles 1508
- frontal sinus tumours 1520–4
 benign 1521–4
 imaging 1520–1
 malignant tumour resection 1524
 pneumatization 1521
 spread patterns 2419
 surgical approaches 1521
 surgical indications 1521, 1521 *F*
- frontal sinus wall osteoplasty,
 anterior 1520, 1520 *F*
- frontal (metopic) suture 1318
- frontal swallowing centre 1958–9
- frontoethmoidal encephaloceles 1503,
 1505 *F*
- frontoethmoidectomy, external 1508–9
 complications 1508–9
 operative principles 1508
 results 1508–9
- frontoethmoid suture 4121–2
- frontonasal dysplasia 1036
- frontonasal malformation 1036
- frontonasal process 1570
- frontonasal prominence 797, 1810–1
- frontonasal recess 1500
- frozen section biopsy,
 parathyroidectomy 393
- frusemide
 chronic rhinosinusitis 1473
 ototoxicity 3568, 3568 *T*, 3570
- Fryns syndrome 1713
- fucomucins, nasal mucus 1359
- Fukuda test, vestibular neuritis 3752
- full blood count (FBC) 267
 bleeding disorders 281
 mean corpuscular volume 267
 normal cell ranges 267 *T*
 rhinosinusitis complications 1543
- full thickness burns, dressings 102
- full-thickness skin grafts 2824–5
 with cartilage *see* composite cartilage
 grafts
 donor sites 2831 *F*
 healing 2825, 3093
- eyelid carcinoma 2826 *F*
- nasal reconstruction 3019
- pressure method 2827 *F*
 technique 2825, 2827 *F*
- Functional Assessment of Cancer
 Therapy-General/Head and Neck
 (FACT-G/H&N) 2773, 2774 *T*
- functional dysphonia *see* muscle
 tension dysphonia (MTD)
- functional hyposplenism 276
- functional magnetic resonance imaging
 (fMRI) 675–83
 analysis of imaging studies 678–9
 auditory system 679–80, 680 *F*
 brain activation patterns 679 *F*
 brain region relations 680–1
 cochlear implants 681
 illustrative applications 679–81
 image contrast generation 676–7
 imaging drug responses 681
- imaging plasticity 681
- individual voxels 679
- left hemispheric dominance 680,
 680 *F*
- MT activation 681
- neuroanatomical interpretation 679
- perfusion 677, 677 *F*
- practical details 678–9
- relaxation rate 676
- study designs 678
- see also* blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging
- functional voice disorders,
 children 1169–70
- fundamental frequency (F_0) 2173 *F*,
 2176, 2177–9, 2178 *F*, 3167
- parameters 2174 *T*, 2178
- range 2177–9
- reliability 2178
- speaking fundamental
 frequency 2177–8
- voice evaluation 2177–9
- fungal infection
 external nose 1703–4
- HIV patients
 cervical masses 247
 nasal manifestations 241–2
 paranasal sinuses 241–2, 241 *F*
 orofacial 1833, 1833 *T*
 tracheo-oesophageal voice prothesis
 valve failure 225
- see also specific diseases*
- fungal rhinosinusitis 1449–57
 acute fulminant 216, 1450 *T*,
 1454–5
 aetiology 217
 clinical features 217
 diagnosis 218, 1455
 epidemiology 217
 fatalities 1455
 immunocompromised
 patients 1454–5
 infection sites 1455
 symptoms 1455
 treatment 218, 1455
- allergic *see* allergic fungal
 rhinosinusitis (AFRS)
 classification 1450 *T*
 diagnostic criteria 1451 *T*
 fungus ball *see* fungus ball
 invasive 216–9, 1454–5
 active 216
 aetiology 217
 chronic 216–7, 1450 *T*, 1454

- fungal rhinosinusitis (*continued*)
 chronic granulomatous *see*
 paranasal granuloma
 clinical features 217–8, 1454
 complications 219
 definition 216–7
 diabetes mellitus 402
 diagnosis 218, 1451 *T*
 epidemiology 217
 granulomatous 1454
 imaging 1454, 1454 *F*
 indolent 1454, 1454 *F*
 management 218–9
 mouth ulcers 1833
 nongranulomatous 1454
 outcomes 219
 surgery 218–9, 219
 treatment 1454
 noninvasive 219–20, 1452–4
 aetiology 219
 clinical manifestations 219
 complications 220
 definition 219
 diagnosis 219–20
 epidemiology 219
 management 220
 outcomes 220
see also infectious rhinosinusitis;
individual conditions
- fungating wounds, management 101, 453
- fungi 213–27
see also individual species
- fungiform papillae 1794
- fungus ball 1450 *T*, 1452
 cultures 1452
 diagnosis 1451 *T*, 1452
 imaging 1452
 symptoms 1452
 treatment 1452
- furred tongue 1825
- furuncles, nasal vestibule 1700
- furunculosis 3323–5
 aetiology 3324
 definition 3323
 diagnosis 3323–4, 3323 *F*
 epidemiology 3324
 management 3324
 outcomes 3324
 recurrent 3324
- Fusarium* 217
- fusidic acid 231–2
- fusiform bacteria
 acute necrotizing ulcerative gingivitis 1819
 dental abscess 1817
- fusiform incisions, scar revision 2895, 2896 *F*
- Fusobacterium necrophorum* 200–1, 1214
- G1 phase, cell cycle 2381
- G2 phase, cell cycle 2381
- gabapentin
 acquired pendular nystagmus 3804–5
 herpes zoster 2005
 tinnitus 3617
- gain, definition 3212
- gait, clinical examination 3731–2, 3731 *T*, 3732 *F*
- gait disorders/disturbances
 acute unilateral vestibular deafferentation 3223
 elderly 3732
 neurological examination 3732
 ototoxicity-related 3569
 topographical classification 3730 *T*
- galactorhoea 4100
- Galen's anastomosis 2139
- gallium (Ga-67), malignant otitis externa 3338
- gallium arsenide lasers 743
- gamma-aminobutyric acid (GABA),
 vestibular neurochemistry 3794
- gamma-aminobutyric acid (GABA)
 analogues, tinnitus 3617
- gamma-aminobutyric acid (GABA)
 receptors, vestibular compensation 3793
- gamma knife stereotactic radiosurgery 3989–97
 concerns with 3992–3
 conformal plan 3990–1, 3990 *F*
 dose issues 3989–90, 3990 *F*
 knife components 3989–90
 limitations 3991
 malignant transformation 3993
 meningiomas 3993–4
 neurofibromatosis 2 3994–5
 patient treatment 3990–1, 3991 *F*
 pituitary tumours 4115
 principles 3989–90
 radiotherapy *vs.* 3989–90
 skull-base meningioma 3993–4, 3994 *T*
- vestibular schwannoma 3992–3, 3992 *T*
- Gammaplan 3990–1
- ganciclovir 28, 209, 232
- ganglion mother cells (GMC) 68
- gap detection, auditory neuropathy/dyssynchrony 3852
- gape 469, 470 *F*
- 'gap' theory 2767
- Gardner's syndrome 1708–9, 2671
- GαS, thyroid cancer 2670
- gas analysis, anaesthesia
 monitoring 498
- gas laws 3501 *T*
- gastric alkalinizers 490 *T*
- gastric transposition
 hypopharyngeal cancer 2655–6
 mortality 2656
- gastrointestinal disorders
 antimicrobial adverse effects 236
 oral manifestations 1834
- gastro-oesophageal reflux disease (GORD) 1272–81, 2062–5
- acute otitis media 1274
- airway disorders 1273
- airway management devices 493–4
- apnoeas 1273
- Barrett's cancer 2067
- cause 2062
- child's voice assessment 1169
- chronic laryngitis and *see* laryngitis, chronic
- chronic otitis media 3409
- clinical presentation 2063–4
- complications 2064–5
- contact endoscopy 763
- definition 1272
- dysphagia aetiology 2031
- epithelial hyperplasia 2222
- globus 2037, 2038
- investigation 1274–6, 1275 *F*, 1275 *T*, 2063
- laryngeal cancer 663, 664 *T*
- laryngeal stenosis 1154, 1155, 2276
- management 2063–4
- natural history 1272
- otitis media with effusion 1274
- otolaryngological
 manifestations 1273–4
- pathophysiology 1273
- pharyngeal pouch 2044, 2047
- post-oesophageal atresia repair 1287
- prevalence 2062
- rhinitis 1383
- rhinosinusitis 1274
- self-medication 2063
- spasmodic croup 1129
- stridor 1119

- surgery 2064
 indications 2064
 procedural choice 2066
- symptoms/signs 1273, 2063
 taste abnormalities 1848
 treatment 1276
- gastropharyngeal reflux 1272
- gastrostomy
 dysphagia, advanced head and neck cancer 2791
 intractable aspiration 2097
 oesophageal atresia repair 1285
 oesophageal corrosive injury 1291
- gastrulation 69
- GAX-collagen, vocal fold injection 2240
- gaze centres, midbrain 3921
- gaze-evoked nystagmus 3712–3, 3713 *F*
 degrees of 3712
 examination 3712–3
 laboratory assessment 3724–5
- gaze holding 3225–7
- gaze palsy, optokinetic nystagmus 3717
- gaze paretic nystagmus 3712–3, 3712 *F*
- gaze stabilization 3207
 testing 3208
- GDP, salivary secretion 1859
- gefitinib (Iressa, ZD1839) 43, 52
- gelatin microspheres, as embolic agent 733
- gelfoam, as embolic agent 733
 tumour embolization, skull base 3952
- gemcitabine 40
- gene(s)
 amplification 9
 definition 4, 15
 disease associations 11
 mapping methods 11
 environmental factors and 16–7
 expression 16, 2380
 disorders 3773
 identification 19
 hearing impairment 18
 inactivation 9–10
 interactions 16
 mapping 11, 19–20
 non-coding sequences 16
 positional cloning 19–20
 transcription problems 2379
 variant 16
- gene arrays 12, 67
- gene cloning 19–20
- gene gun 23, 25
- generalized lymphadenopathy *see* HIV lymphadenopathy
- General Medical Council (GMC) 573
 consent issues 2806
 medical negligence cases 2803
 performance and complaints 605
- gene therapy 23–33
 ballistic gene delivery 23, 25
 chromosome silencing 27
 clinical trials 23
cystic fibrosis see cystic fibrosis
 deafness 818
 head and neck cancer *see* head and neck cancer
 immune modulation 28
 liposomes 25
neurofibromatosis 2 4004
 vectors 23
- genetic code 15
- genetic counselling, childhood deafness 852–3
- genetic deafness 811
 mouse models 812–3
- genetic disorders
 cell biology 8–10
 stem cell therapy 73, 75–6
- genetic manipulation
 congenital deafness 817–8
 molecular otology 811–20
- genetic mutation 9
- genetics 15–22
 animal models 20
 deafness 17, 20
 childhood deafness 845
 future developments 21
 inheritance patterns 18–9
 research 20
 terminology 812 *T*
- genetic testing
 childhood deafness 851–2
craniosynostosis 1021
neurofibromatosis 4001, 4003, 4004
- gene transfer
 congenital deafness 817
 vectors 817
- genial tubercles 2908
- geniculate ganglion
 embryology 1052, 1053
 facial nerve tumours 4079
geniculate neuralgia surgery 3532
- geniculate neuralgia 3532
 aetiology 3532
 surgery 3532
- genioglossus 1796 *F*, 1797, 1797 *F*, 1956–7
- geniohyoid 1796, 1796 *F*, 1797 *F*, 2135 *T*
- genital warts, juvenile-onset recurrent respiratory papillomatosis 1175
- genome 3
 human 4
 mitochondrial 3, 4–5
 structure 2378–9
- genome scan 19–20
- genomic rearrangements 10
- gentamicin
 active mucosal chronic otitis media 3424
 malignant otitis externa 3339
 medical negligence 3831
Menière's disease 433, 3760, 3800
 ototoxicity 3299 *F*, 3568–9, 3676, 3677 *F*, 3800
 bilateral vestibulopathy
 aetiology 3764
 incidence 3300
- geographical tongue 1825–6, 1826 *F*
- geometric broken line closure (GBLC) 2896, 2897, 2898 *F*
- geometric primitives 704
- Gerlach's (tubal) tonsil 1094, 2108
- Gerstmann–Sträussler–Scheinker syndrome 3775
- giant cell granuloma 1654–5, 1930
 clinical features 1654 *F*, 1655
 definition 1654–5
 histology 1655
 imaging 1655
 treatment 1655
- 'giant cell reaction of bone' *see* giant cell granuloma
- 'giant cell reparative granuloma' *see* giant cell granuloma
- giant cell thyroiditis *see* subacute thyroiditis
- giant hairs 3676
- giant hairy naevus 2400
- giddiness *see* vertigo
- 'Gillick competence' 585–6, 601, 781
- Gillick v. West Norfolk and Wisbech Area Health Authority (1985) 601
- Gillies fan flap, lip cancer 2547, 2547 *F*
- Gillies principles, reconstructive surgery 2847
- Gillies procedure 3079
- Gillies temporal approach, zygomatic complex fractures 1629, 1629 *T*
- ginger, motion sickness 3797

gingivae 1791–2
 blood supply 1798
 innervation 1801–2, 1802 *T*
 lymphatic drainage 1799
 pigmentation 1819
 causes 1819, 1820 *T*
 racial 1820 *F*
 venous drainage 1799
 gingival cysts
 adults 1926
 of infancy 1926
 gingival disorders 1818–20
 bleeding 1818–9, 1819 *T*
 blisters 1819
 redness 1819–20
 causes 1819
 swelling 1820, 1821 *T*
 drug-induced 1820, 1821 *F*
 ulcers 1820
 white patches 1820, 1821 *T*
 gingivitis
 acute necrotizing ulcerative *see* acute
 necrotizing ulcerative gingivitis
 (ANUG)
 chronic
 gingival bleeding 1818–9, 1819 *T*
 gingival redness 1819
 HIV patients 243, 244 *T*
 Gingko biloba
 idiopathic sudden sensorineural
 hearing loss 1, 3589 *T*
 tinnitus 3618
GJB2 gene 15–6, 18, 20, 845, 851–2
 glandular fever *see* infectious
 mononucleosis
 glandular odontogenic cysts 1925
 Glanzmann's disease 288
 Glasgow Benefit Inventory (GBI) 639,
 639 *T*
 bone-anchored hearing aids 3647
 vestibular schwannoma
 removal 3984–5
 Glasgow Children's Benefit
 Inventory 895
 Glasgow coma scale (GCS)
 maxillofacial injuries 1620
 neck trauma 1766–7
 Glasgow Hearing Aid Benefit
 Profile 640
 bone-anchored hearing aids 3646
 glass ceramics 120
 synthetic tissue scaffolds 123
 tissue scaffolds 124 *T*
 glass ionomer cements (GIC) 120,
 121 *F*

glatiramer acetate 3772
Gleevec (imatinib mesylate) 44
 glenoid fossa reconstruction 4052
 glial cell-derived neurotrophic factor
 (GDNF) 2669, 3302
 glioma(s)
 CPA impingement 4015
 frontal sinus 1503, 1505 *F*
 nasal 1075, 1075 *F*, 1709
 nasopharyngeal 2119
 neurofibromatosis 2 4000, 4002
 pituitary region 4104
 global developmental delay, speech and
 language 992
 'global' type meningiomas 4008
 globulomaxillary cysts 1320–1
 globus 2037–42
 aetiology 2038–9
 behavioural control 2040
 clinical recommendations 2040
 clinical studies 2038
 definition 2037
 diagnosis 2039–40
 differential diagnosis 2039
 dysphagia 2026, 2035
 dysphagia aetiology 2026, 2035
 epidemiology 2037–8
 follow-up 2040–1
 gastro-oesophageal reflux 2038
 gender 2038
 historical aspects 2037
 history taking 2039
 incidence 2037
 management 2040
 patient examination 2039
 prognosis 2040–1
 psychogenic causes 2039
 radiology 2039–40
 symptom persistence 2040
 globus clinic 2040–1
 globus pharyngeus *see* globus
 globus pharyngis *see* globus
 glomeruli, olfactory bulb 1663
 glomerulonephritis
 antibiotic-induced 1985–6
 tonsillitis complications 1224
 glomus jugulare 4029–30
 tumours 2526, 2531
 carotid angiography 3950 *F*
 complete particle
 embolization 3954 *F*
 radiosurgery 3995
 surgery-induced injury
 2222–3
 glomus jugulotympanicum 4029–30
 glomus tumours (paragangliomas)
 anatomy/physiology 736, 738 *F*
 CPA involvement 4015
 carotid body *see* carotid body
 paragangliomas
 catecholamine metabolite
 assessment 4028
 chromaffin 4029–30
 clinical symptoms 736–9
 embolization 3953
 familial 2526–7
 hearing loss 3943–4
 histology 4029–30
 incidence 3943
 jugular foramen 4029–30, 4031 *F*,
 4032
 categorization 4029–30
 classification 4030, 4030 *T*
 embolization 4034
 incidence 4030
 localization 4029–30
 radiotherapy 4043
 resection 4039–40, 4041 *F*
 surgery, internal carotid artery
 management 4039
 symptoms 4028
 laryngeal 2600 *T*
 malignant 2526
 multiple 2526–7
 nonchromaffin 4029–30
 otoscopy 3945
 tumour embolization 734, 736–9,
 738 *F*, 739 *F*
 preoperative 3953
 ultrasound examination 725–6, 726 *F*
 vagal 2526, 2530
 vestibular nerve 3691
 glomus tympanicum 4029–30
 glomus vagale tumours 3953
 glossitis 1828–9, 1843–4
 glossodynia (burning mouth
 syndrome) 1829, 1829 *T*, 1848–9
 glossoepiglottic fold 2133
 glossopharyngeal-accessorius
 complex 2155–6
 glossopharyngeal nerve (IX) 1751,
 1797 *F*, 1803, 3933–4, 3933 *F*
 autonomic parasympathetic
 fibres 3933–4
 carotid branch 3933–4
 central processes 3933–4, 3934 *F*
 clinical disorders 3937–8
 clinical evaluation 3937–40
 in jugular foramen 3901, 3903 *F*
 motor nucleus 3933–4

- in neck 1751
 neuralgia 3531–2
 pharyngeal branches 1950, 2074
 skull base lesions 3946
 taste bud innervation 1841
 glossopharyngeal nerve block 480
 glossopharyngeal nerve injury/lesions
 taste abnormalities 1846–7
 taste sensation impairment 3937
 temporal bone resection
 complication 4094
 glossopharyngeal neuralgia
 (GPN) 1724, 2081, 3934
 aetiology 3531
 cranial root injury 3531
 incidence 2081
 medical management 3531–2
 oropharyngeal 3531
 otalgia 3531–2
 pain sensation 3919
 recurrence 2081
 surgery 3532
 symptoms 2081, 3531
 treatment 2081
 tympanic 3531
 glossopharyngeal nuclei 2075 *F*
 glossopyrosis (burning mouth
 syndrome) 1818 *T*, 1829, 1848–9
 glottal consonants 2167 *T*
 glottal fry (vocal pulse register) 2161,
 2162 *T*
 glottal insufficiency 2160
 glottal signal
 characteristics 2165
 frequency 2165
 modification 2165–6
 quality 2165
 glottal-to-noise excitation (GNE) 2181
 glottal volume velocity waveform 2182
 glottic cancer
 clinical presentations 2608
 diagnostic delays 2603
 endoscopic resection 2612, 2612 *F*
 haemoptysis 2608
 radiotherapy regimens 2610
 referred otalgia 2608
 spread 2601
 surgery vs. radiotherapy 2610, 2610 *T*
 TNM classification 2366 *T*
 treatment 2610
 glottic chink 1151
 glottic closure
 incomplete, phonation and 2160–1
 surgical, intractable
 aspiration 2101–2, 2101 *F*
- glottic irritability 481–2
 glottic obstruction 481–2
 anaesthesia depth 481
 glottic stenosis 2281–2
 posterior *see* posterior glottic stenosis
 glottic webs, anterior *see* anterior
 glottic webs
 glottis 2134–7
 anatomy 1135, 2132, 2132 *F*, 2134–7,
 2134 *F*
 children 1151
 congenital disorders 1137–9
 development 803–5, 2130
 laryngeal stenosis 2277
 laryngeal trauma 2272
 glucocorticoids
 allergic rhinitis 1398
 asthma 1564
 croup 1128–9
 Cushing's syndrome diagnosis 309
 excess *see* Cushing's syndrome
 jugular foramen meningioma 4042
 onset of action 1398
 rhinitis 1564
 rhinosinusitis 436–7
 side effects 1398
 vestibular compensation 3793
 wound healing inhibition 95
 gluconeogenesis, critical care
 patients 530–1
 glucose, newborn infant 544
 glucose tolerance test 301
 glue ear *see* otitis media with effusion
 (OME)
 glutamate
 noise-induced hearing loss 3549
 olfactory receptor neurons
 1662–3
 tinnitus 3604
 vestibular hair cells 3237, 3794
 glutamine, critical care patients 532
 glutathione 3302
 glycaemic control, critical care 535
 glycerine injection, vocal fold
 paralysis 2240, 2245 *T*
 glycopeptides 230
 glycoproteins
 acidic 1359
 nasal secretions 1359
 neutral 1359
 glycosaminoglycans (GAG)
 DFNA9 mutations 3238
 Graves' disease 343
 myxoedema 353
 tissue scaffolds 123
- goblet cells
 frontal sinus 1340
 maxillary sinus 1341
 nasal 1359, 1359 *F*
 nasal polyposis 1551
 otitis media with effusion 878
 septum 1327
 sphenoid sinus 1339
 goitre
 aetiology 2666–9
 growth factors 2668
 atrophic autoimmune thyroiditis 356
 classification 2666
 colloid 331, 720
 diffuse
 nontoxic 330
 toxic *see* Grave's disease
 foetal 347
 genetics 2667–8
 Hashimoto's thyroiditis 356
 hypothyroid 335
 iodine deficiency 356
 iodine-deficiency 2666–7
 iodine-sufficient 2667
 multinodular *see* multinodular goitre
 nodular
 with abnormal function 335
 with normal function 330–1
 ultrasound 719, 719 *F*
 prevalence 2666–7
 thyroid neoplasms 400
 thyrotoxicosis 339
 WHO definition 2666
 see also nodular thyroid disease
 goitrogens 2668
 Goldenhar syndrome 1033, 1055,
 3642–3
 golden ratio 2944, 2944 *F*
 Goldman tip technique 2951 *F*, 3001–2
 columella struts 3002, 3002 *F*
 incision 3001–2, 3001 *F*
 shortening 3003 *F*
 suture 3001–2, 3001 *F*
 underprojected nasal tip 3002
 vertical dome division 3001 *F*, 3002
 Goltz–Gorlin syndrome 1824
 gonadal diseases 402–3
 see also individual diseases
 gonadal dysgenesis *see* Turner's
 syndrome
 gonadotrophinoma 311, 4103
 gonadotrophs 297
 gonadotropin(s) 301–2
 circulating levels 301–2
 effects 302

- gonadotropin(s) (*continued*)
 pituitary gland 297
 puberty 301–2
 secretion 308
 control 302
 in women 302, 308
 structure 302
- gonadotropin-releasing hormone (GnRH) 300
 effects 302
- gonococci 199
- Good doctors, safer patients* 573, 575
- Good medical practice* 573, 574, 576, 2804
- Gore-Tex
 augmentation rhinoplasty 2971, 2974
 complication rates 2975 *T*
 facial surgery 121
- Gorlin's syndrome 1705–6, 2396
- Goundou 1703
- gp120 glycoprotein, HIV 238–9
- G-protein coupled receptors, olfaction 1367
- Gradenigo's syndrome 3119, 3918–9, 4046, 4047
- grafts
 alloplastic 96
 autologous 96
 failure, medical negligence 3093
 free 2819–20
 head and neck surgery 2819–46
 heterologous 96
 homologous 96
 skin *see* skin grafts
see also individual grafts
- Gram-negative bacteria 199–200
 aerobic *see* Enterobacteriaceae
see also individual species
- Gram-positive bacteria 196–9
see also individual species
- granular cell tumours, larynx 2600 *T*
- granular myringitis 3328–31
 aetiology 3328
 complications 3329
 definition 3328
 diagnosis 3329
 investigations 3329
 management 3329–30, 3330 *T*
 natural history 3329
 outcomes 3329
 pathology 3328
 post-tympanic membrane grafting 3328
 signs 3329, 3329 *F*
 symptoms 3328
- granulating wounds, dressings 101–2
- granulation tissue 90 *F*, 98
 composition 93
 formation 88, 89–90
 proliferation 91–3
 tracheostomy-induced 1203–4
- granulocyte-colony stimulating factor (G-CSF), effects on stem cells 69
- granulocyte-macrophage-colony stimulating factor (GM-CSF), effects on stem cells 69
- granulocytes 273
- granuloma(s)
 arytenoid *see* arytenoid granuloma
 cholesterol *see* cholesterol granuloma
 dental abscess 1817
 denture 1828
 giant cell *see* giant cell granuloma
 paranasal *see* paranasal granuloma
 vocal process *see* arytenoid granuloma
- granulomata formulation, vasculitides 187, 187 *F*
- granulomatous conditions, nasal *see* nasal granulomatous conditions
- granulomatous myringitis *see* granular myringitis
- granulomatous thyroiditis *see* subacute thyroiditis
- granulopoiesis 272–3
- Graves' disease 340–5
 acropachy 343
 associated conditions 343
 clinical manifestations 331, 343, 400
 dermopathy 343
 drug treatment 346–7
 combination 347
 efficacy 347
 extra thyroidal manifestations 343
 eye disease *see* thyroid eye disease
- genetics 342, 2668
- histology 343 *F*
- imaging 335
- incidence 340
- investigations 335
in vitro tests 328 *T*, 334–5
- multinodular goitre and 331, 335
- natural history 343
- pathogenesis 341–3
- post-partum thyroiditis 358
- pregnancy 359
 diagnosis 359
 symptoms 359
 treatment 359
- radioiodine therapy 347, 349
 dosage 349
 recurrent hyperthyroidism 349
- relapse 347
 prognostic factors 347
- risk factors 340
- surgery 351
- thyroid autoantibodies 343
- thyroid cancer association 2671
- treatment 343, 2670–1
- tremors 400–1
- vitiligo 343 *F*
see also hyperthyroidism
- gravitoinertial acceleration (GIA) 3211
- gray (Gy)
 accelerated hyperfractionation 2755
 accelerated radiotherapy 2754
 elimination 2754–5
 hyperfractionated radiotherapy 2755
- GRBAS scheme 2175, 2175 *T*, 2176
- greater auricular nerve 1853
- pleomorphic adenoma
 recurrence 2489
- greater cornua, hyoid bone 1740, 2132
- greater palatine artery 1328, 1799
- greater palatine nerve 1801, 1802 *T*
- greater petrosal nerve 1801, 3928
- greater superficial petrosal nerve 3910
 middle fossa surgery 4018–9, 4020
- greater wing, sphenoid 3899
- Greatest Happiness Principle (GHP) 584
- Greenspan model 1000
- 'grey baby' syndrome 231
- Griesinger's sign 924
- Grisel syndrome 1098, 1236
- griseofulvin 234
- grommets *see* ventilation tubes
- Groningen valve 2625, 2626 *F*, 2627
- Group A beta-haemolytic streptococci (GABHS)
- pharyngitis 1982–3
 antibiotic use 1984–5
 carrier state 1987
 clinical findings 1983
 complications following 1986–7
- diagnosis article appraisal 654, 656, 656 *T*
- features 1983
- incubation period 1982–3
- investigations 1984
- M-proteins 1982–3, 1983
- pathophysiology 1983
- prognosis 1987

- rapid antigen testing 1984
 throat culture 1984
 rheumatic fever 1986–7
 tonsillitis 1219–20, 1220–1, 1220 *F*
 group and screen (G&S) test 254
 elective surgery 255
 emergency surgery 255, 256 *F*
 fresh frozen plasma transfusion 258
 safe practice 255
 group A streptococci *see* streptococci,
 group A
 group C streptococci 197
 group G streptococci 197
 growth factors
 cell signalling 36
 goitre 2668
 overproduction 36
 stem cells 67, 71–2
 growth fraction 2381
 growth hormone (GH) 297, 301, 309
 adenoma secretion *see* acromegaly
 anterior pituitary secretion 4098
 circulating levels 301
 deficiency 309
 effects 301
 half-life 301
 insulin-like growth factor 1 301
 secretion control 301, 309
 fluctuations 308
 structure 309
 tests 301, 309
 growth hormone releasing hormone
 (GHRH) 300
 GSTM1 AB 2355
 GTP binding protein cell
 receptors 2384, 2384 *F*
 Guangdong tumour 2445
 guanine 3
 guanine nucleotide-binding regulatory
 protein (G protein), saliva 1859
 guar gum, occupational rhinitis 1418
 guided bone regeneration 2920, 2920 *F*
 guided tissue regeneration (GTR) 2916,
 2916 *F*
 Guillain–Barre syndrome
 facial nerve palsy 3887
 pharyngeal dysfunction 2078
 sensory ataxia 3778
 guillotine tonsillectomy 1232–3,
 1992–3
 gum elastic bougie, difficult
 airways 472–3, 473 *F*
 gumma 1461, 1461 *F*, 1703
 gunning splints, mandibular
 fractures 1623, 1624 *F*
- gunshot wounds
 facial nerve trauma 3887–8,
 3887 *F*
 transcervical 1766–7
 gustatory agnosia 1843
 gustatory auras 1846
 gustatory disorders *see* taste
 abnormalities
 gustatory lemniscus injury 1847
 gustatory mucosa, mouth 1795
 gustatory rhinitis 1383, 1411
 gustatory structures, central 1841–2
 citric acid recognition 1842
 gut-associated lymphoid tissue (GALT),
 pharynx 1951
 gyrus rectus 4121
- H1-antihistamines
 allergic rhinitis 1564
 asthma 1564
 H₂-receptor antagonists
 advanced head and neck
 cancer 2785–6
 juvenile-onset recurrent respiratory
 papillomatosis 1179
 reflux oesophagitis 452
 H5N1 influenza 205–6
 habituation
 tinnitus 3601–2, 3607–8
 vestibular compensation 3792
 hadrons 47
 haemangioblastoma, embolization
 734
 haemangioma, parotid 1247, 1247 *F*,
 1248 *F*
 haemangioma(s)
 geniculate ganglion 4081
 larynx 2600 *T*
 middle ear 4072
 differential diagnosis 4072
 nasal 1075–6, 1075 *F*, 1708
 oral 1823, 1823–4
 salivary glands 1247, 1247 *F*
 subglottic *see* subglottic haemangioma
 ultrasound examination 726
- haemangiopericytoma(s)
 children 1259 *T*
 epistaxis 1606
 middle ear 4072
 radiosurgery 3996
 sinonasal 2422–3
 tumour embolization 734–5
- haematocrit, polycythaemia 272
 haematological diseases, oral
 manifestations 1833–4
- haematoma 102
 post-rhytidectomy 3074
 post-vestibular schwannoma
 removal 3978
 septal *see* septal haematoma
 skull base surgery 4137–8
 subdermal 3092
 subdural 1031
 syndromic craniosynostosis surgery-
 induced 1031
 thyroidectomy complication 351
 treatment 102
 haematoma auris 3373–5, 3374 *F*
 aetiology 3373
 clinical picture 3373
 definition 3373
 diagnosis 3373
 management options 3374
 outcomes 3373
 pathogenesis 3373
 pathology 3373
 haemato-oncology 265–77
 haematorrhoea, skull base fracture 3496
 haematoxylin and eosin (H&E),
 apoptosis identification 60, 60 *F*
 haemin (X) 199
 haemodialysis (HD), critical care unit 530
 haemoglobin (Hb) 266–7
 2,3-diphosphoglycerate 267
 adult (HbA) 266–7
 anaemia 267
 blood oxygenation level-dependent
 fMRI 678
 critical care, adult 535
 erythropoiesis 266
 foetal 266–7
 oxygen delivery 267
 synthetic allosteric modifiers 51
 haemoglobin Barts (HbBarts) 271
 haemoglobin electrophoresis 271
 haemoglobinopathies 270
 haemoglobin S (HbSS) 270
 haemoglobin substitutes 263
 haemolytic anaemia 270
 causes 270
 investigations 270, 270 *T*
 haemolytic disease of the newborn 254
 haemolytic toxins 196
 haemolytic uraemic syndrome
 (HUS) 286–7
 diagnosis 286
 treatment 287
- haemophilia 285
 bleeding patterns 281, 285
 inheritance 280, 285

- haemophilia (*continued*)
 pre-surgery management 285
 blood tests 285 *T*
 elective surgery 285
 emergency surgery 285–6
- haemophilia A 284 *T*, 285
 inheritance 280, 285
- haemophilia B 284 *T*, 285
 inheritance 280, 285
- Haemophilus* 199–200
- Haemophilus influenzae* 199–200
 acute otitis media 915
 acute sinusitis 1080
 adult epiglottitis 2250
 nasal infection 1700
 nasopharynx 2121
 otitis media
 children 195–6
 HIV-associated infection 240
- rhinosinusitis 1441
 chronic 1471
 HIV-associated 241–2
- serology 199–200
- tonsil flora 1219–20
- vaccination 199–200, 919, 920
- Haemophilus influenzae type b*
 meningitis 924
- Haemophilus influenzae type b* vaccine
 (Hib vaccine) 199–200, 1131–2
- epiglottitis 1309, 2250
- haemopoiesis 265–6, 266 *F*
 children 265–6
 extramedullary 266
 foetal 265–6
 sites 265–6
- haemopoietic malignancies 274
- treatment 274
- haemopoietic stem cells 67, 72, 266,
 266 *F*
 classification 69
 erythropoietin 266
 lineage 266
 pluripotency 266
- haemoptysis, glottic cancer 2608
- haemorrhage
 facial skeleton fractures 1619–20
 gingival 1818–9, 1819 *T*
 hypophysectomy 4113
 hypotensive anaesthesia 502
 intracranial
 hypophysectomy
 complications 4113
 olfactory dysfunction 1667
 malignant ulcers/fistulae, palliative
 care 2792–4, 2793 *T*
- radical neck dissection
 complication 2743
 perioperative 2743
 postoperative 2743
- skull base surgery complication 4136
 arterial 4136
 venous 4136
- spontaneous 280
 haemophilia 285
 tonsil 1225
 vestibular system 3698–9
- tracheostomy 2301
 upper airway obstruction 2287
 vestibular schwannoma 3959–60
- haemorrhagic (solitary bone)
 cyst 1926–7
- haemorrhagic necrosis, antivascular
 agents 51
- haemosiderin 268
- haemostasis 278–92
 disorders 278–92
 laboratory tests 280
 mechanism 279 *F*
 neck trauma 1767
 tracheostomy 2301
- haemostatic clips 1603, 1603 *F*
- haemotympanum 3496
- 'haem pockets' 267
- haem synthesis 267
- Hageman factor 89
- hair cell(s)
 cochlear *see* cochlear hair cells
 duplex activity 3139
 function 3132–6
 supporting cells of 3130
 ultrastructure 3136
 ultrastructure 3132–6
 vestibular system *see* vestibular hair cells
- hairstyling, scar revision 2899
- hairy leukoplakia (HL) 1837, 1837 *F*
 Epstein–Barr infection 208–9
 HIV 208–9, 242, 244 *T*
- hairy polyp, nasopharynx 2119
- Haller cells 1334 *F*, 1335 *T*
- Hallpike manoeuvre
 benign paroxysmal positional
 vertigo 3721, 3721 *F*
 nystagmus 3722
- halogenated methyl-ethyl ethers 491
- halogenated pyrimidines, as
 radiosensitizer 50
- haloperidol, cancer patients
 acute confusional states 2798
 anxiety 2795
 nausea and vomiting 2788
- halothane
 endoscopy procedures 517,
 1121–2
- periglottic/glottic obstruction 481
- hamartomas, cerebellopontine
 angle 4014
- Hanafy lens 712
- hand, foot and mouth disease 2005
- handicap (definition) 783
- Hand–Schuller–Christian disease *see*
 Langerhan's cell histiocytosis
 (LCH)
- Hansen's disease *see* leprosy
- H antigen 253–4
- HAPEX implants 120, 120 *F*
- hard palate 1791–2, 1792 *F*
 blood supply 1799
 centres of ossification 1813
 repair 1006–7, 1007 *F*
 rugae 1791–2
 skeleton 1791
- hard palate carcinoma 2562–3, 2562 *F*
 investigations 2562
 outcome 2563, 2563 *T*
 presentation 2562
 treatment 2562–3
 partial lateral maxillectomy
 2562–3
- hard tissue repair 87–109
- hardwired systems, hearing
 impaired 3667
- Hardy dissectors, hypophysectomy 4110
- Hardy retractor, hypophysectomy 4106,
 4106 *F*
- 'harlequin eye,' craniosynostosis 1022
- harmonic oscillation 3158–9
- harmonics 3167
 spacing 3253
- harmonic scalpel dissection
 tonsillectomy 1992
- harmonics of the frequency 3177
- harmonics-to-noise ratio (HNR) 2165,
 2180–1, 2180 *T*
- Hashimoto's thyroiditis 355–6
 atrophic autoimmune thyroiditis 356
 goitre 356
 histology 331–2, 356, 356 *F*
 investigations
 radionuclide scan 336
 ultrasound examination 721
 in vitro investigations 332
- pathogenesis 356
 prevalence 355–6
 thyroid lymphoma 331–2, 336, 2671,
 2676–7

- 'Hashitoxicosis' 335
 Hasner's valve 1344–6, 1690
 hatchet flap 2869–70, 2871 *F*
 hayfever immunotherapy 1399
 HbH disease 271
 headache
 acute otitis media 924
 cluster 1722, 1723 *F*
 glomus tumours
 (paragangliomas) 4015
 intracranial procedure,
 following 4145
 nasopharyngeal carcinoma 2452
 pituitary tumours 4100
 skull base lesions 3944–5
 skull base surgery 4139
 tension-type 1724–5, 1725 *F*
 head and neck
 embryology 792–810
 Carnegie stages 793 *T*
 examination, skull base lesions 3945
 head and neck cancer
 aetiology 2351–8
 AIDS defining 2012–3
 chemotherapy/radiotherapy
 developments, hypoxic cell
 sensitization 2756–7
 children 1251–63
 assessment 1252–3
 biopsy 1252–3
 cardiac problems 1260
 cognitive and psychological
 problems 1261
 common types 1254–60
 dying child 1261
 effect on child 1253
 epidemiology 1251–2
 follow-up 1261
 growth 1260
 imaging 1253
 impact on family 1253
 long-term treatment
 sequelae 1260–1
 oncology services 1253
 otolaryngological
 manifestations 1260–1
 presentation 1252–3
 reproductive function 1260
 thyroid disorders 1260
 complications 2655
 data collection *see* data collection,
 head and neck cancer
 dysphagia management 2086, 2087–8
 epidemiology 2343–50
 principles 2343–6
 facial defect reconstruction
 2926
 FDG-PET imaging *see* FDG-PET
 imaging
 gene therapy 26–9
 adenoviruses 27, 29
 chemosensitization 28
 delivery 26
 immune modulation 28
 lentiviral vectors 27
 nonviral vectors 26–7
 p53 delivery 29
 plasmid DNA 26–7
 restorative 29
 retroviral vectors 27
 selective oncolytic virus 29
 strategies 28–9
 gene therapy-induced 27
 HIV infection 2012, 2012 *T*
 markers 2385
 metastatic *see* metastatic neck disease
 palliative care *see* palliative care, head
 and neck cancer
 photodynamic therapy 746
 prognostic indications 2378–94
 quality of life *see* quality of life
 radiotherapy 2753–65
 serum markers 2378–94, 2385
 see also individual types
 staging 2359–71
 aims 2359–60
 classification 2362
 component definitions 2360 *T*
 grouping 2361–2, 2361 *T*
 grouping limitations 2368–9
 histopathological grading 2361
 history 2360
 lip and oral cavity 2364
 method 2362–3
 N staging limitations 2368
 pathological classification 2364
 preoperative investigations 1984
 primary site evaluation 1984
 sites 2363–6
 see also individual head and neck
 regions
 TANIS score 2369
 T staging limitations 2367–8
 tumour-specific survival 2654 *F*
 see also specific cancers
 Head and Neck Radiotherapy
 Questionnaire (HNRQ) 2773,
 2774 *T*
 head and neck reconstruction
 historical perspective 2925
 prosthetic and surgical combined
 approach 2924–42
 case studies 2933–41
 extra-oral prostheses
 construction 2930–1
 future developments 2941–2
 historical perspective 2924–5
 patient assessment 2925
 patient follow-up 2932–3
 surgical resection planning 2925
 see also individual techniques
 head and neck sarcomas 1931–8
 aetiology 1931, 1933 *T*
 histological distribution 1931,
 1933 *T*
 imaging 1931
 inherited disease and 1931, 1933 *T*
 investigations 1931
 lymph node metastases 1931
 management principles 1931–4
 pathogenesis 1931
 relapse 1938
 treatment 1938
 risk factors 1931, 1933 *T*
 soft tissue *see* soft tissue sarcomas
 (STS)
 surgery 1933
 surveillance 1938
 systemic therapy 1933–4
 see also individual types
 head and neck squamous cell
 carcinoma (HNSCC)
 aetiology
 alcohol 2351–2
 diet 2353–4
 environment 2353
 familial predisposition 2354–6
 genetic disease 2354
 molecular/genetic progression
 model 2355 *F*, 2356
 occupation 2353–4
 tobacco 2351–2
 viruses 2352–3
 case-controlled study 2356
 chemotherapy 40
 GSTM1 AB 2355
 markers 2385, 2386–90 *T*, 2391 *T*
 radiotherapy, dose-response curves
 48
 head and neck surgery
 drug therapy 446–54
 grafts *see* grafts
 historical aspects 2813–8
 lasers *see* laser therapy
 local flaps *see* local flaps

- head and neck surgery (*continued*)
 medical negligence 2803–10
 diagnostic delay 2807
 operative problems 2807–9
 preoperative issues 2807
- head angular acceleration
 calculation 3212
 semicircular canal 3211
- head angular velocity 3212
- head eccentric rotation, otolith
 testing 3737
- head impulse test 3224–5, 3226 *F*,
 3719–20, 3719 *F*
- bilateral vestibulopathy 3764
- catch up saccades 3719–20
- unilateral peripheral vestibular
 deficits 3719–20
- vestibular neuritis 3752, 3753 *F*,
 3756–7, 3756 *F*, 3769–70
- vestibuloocular reflex 3224, 3719–20
- head injury/trauma
 benign paroxysmal positioning
 vertigo 3760
- cerebrospinal fluid
 rhinorrhoea 1636–7, 1637 *F*
- epistaxis 1605
- olfactory dysfunction 1667, 1668 *F*
- olfactory fasciculi lesions 3913
- taste abnormalities 1846
- temporal bone fractures 1057
- headlight intranasal surgery 1636–7
- head movement, eye movements and
 backwards tilt 3219 *F*
 pitch forwards 3218 *F*
 sideways tilt 3218 *F*
- head orientation 3208–10
 internal model 3210–1
 observation 3731
- head-out body plethysmograph,
 rhinomanometry 1373
- head-thrust test *see* head impulse test
- head trauma *see* head injury/trauma
- healthcare beneficence model 650
- Healthcare Commission
 clinical governance monitoring 572,
 572–3
 head and neck cancer audit 572
 performance and complaints 605
- Health Care Standards Unit
 (HCSU) 571
- health care workers, occupational
 rhinitis 1419
- health information, internet 574
- health-related quality of life (HRQoL)
 definition 634
- measures *see* outcomes research
 WHO definition 2767
see also quality of life
- Health Service Commissioner 605
- health service research,
 epidemiology 617–8
- Health Utilities Index (HUI) 637, 639,
 642
- hearing 3173–206
 bone conduction 3185–6
 cochlear fluid movement 3185
 external ear factors 3185–6
 inner ear factors 3185
 middle ear factors 3185
 clinical assessment 3317–9
 middle ear *see* middle ear
 physiological vs. behavioural
 assessment 3276
 physiology 3173–206
see also ear(s); sound
- hearing aids 3631–41
 adaptive arrays 3635
 adjustment 3637
 advanced signal processing
 schemes 3635
- age-related sensorineural hearing
 impairment 3544, 3545
- auditory neuropathy/dyssynchrony
 3851–2, 3852 *T*
 children 3852
- bilateral fitting 3639–40
- binaural considerations 3639–40
- Bluetooth-enabled 3669
- children 854, 3640
 evaluation 3640
- chronic otitis media 3434–5
 active 3435
 healed 3434–5
 inactive 3435
- communication training 3638
- comparisons 3643 *T*
- components 3632
- compression systems 3634–5
- counselling 3638
- coupler targets 3637
- coupling systems 3633–4
- electroacoustic performance 3633
- feedback oscillation 3635, 3637
- fine tuning 3637–8
- fitting, pure-tone audiometry 3267
- gain adjustment, tympanometric
 acoustic reflex
 measurement 3289
- loudness recruitment 3256
- maximum output 3636
- measurement 3633
- mechanism of action 3631
- multichannel compression 3634, 3637
- multimemory 3637
- otitis media with effusion 3393
 children 903
- otosclerosis 3467
- ototoxicity-related hearing loss 3573
- outcome assessment 3638–9
- patient assessment 3635–6
- prescribing 3636–7
 linear aids 3636
 nonlinear aids 3636
- problem solving 3637–8
- selection 3637
- self-report measures 3639
- signal-to-noise ratio 3634
- special needs children 786
- systems 3632–3
- tinnitus 3614–5
see also specific devices
- hearing dogs 3545
- Hearing Handicap Inventory for the
 Elderly (HHIE) 640
- hearing loss/impairment
 acquired
 aetiology 3298–300
 noise-related 3298
 permanent bilateral 824
 age-related (presbycusis) 3298
- animal models 3298, 3301–2, 3303
- auditory hallucinations 3864
- bone-anchored hearing aids 3646
- children
 diagnostic delay 1306
 early deprivation and plasticity 825
 medical negligence 1306
 prevalence 823–5
 risk factors 823–5
 temporary 825
 voice assessment 1169
- communication, medical
 consultations 566
- conductive, otitis media with
 effusion 3391
- definitions 3298
- devices *see* accessory devices
- diabetes mellitus 402
- drug-related *see* ototoxicity
- epidermoids 4011
- facial nerve tumours 4080
- frequency selectivity 3256
- genetics 17–8
- hair cell degeneration 20
- high frequencies 3257

HIV-associated 241
 hypothyroidism 400
 incidence 17
 loudness perception 3256
 loudness recruitment 3256
 management 3629–30
 masking 3256
measurement see audiometry
 meningioma 3943–4, 4009
 mixed, bone-anchored hearing aids 3646
 multiple sclerosis 3846–8
 neurofibromatosis 2 4000, 4003
 noise-related *see noise-induced hearing loss (NIHL)*
 otitis media with effusion 893
 ototoxic *see ototoxicity*
 Paget's disease 3487–8
 paraganglioma 3943–4
 perilymph fistulae 1047
 peripheral, central auditory dysfunction 3864
 pitch perception 3256
 post-meningitic 824
 postsurgical, medical negligence 3831
 prevention 3298–306
 antioxidants 3302
 cell death inhibitors 3302
 clinical outlook 3302–3
 limitations 3303
 neurotrophic factors 3302
 principles 3301
 retrocochlear *see retrocochlear hearing disorders*
 rheumatoid arthritis 186
 rheumatological diseases 184
 sensorineural *see sensorineuronal hearing loss (SNHL)*
 skull base lesions 3943–4
 sound localization 3257
 sound perception 3255–7
 stereocilia disruption 20
 temporal resolution 3256–7
 tinnitus 3598
 traumatic 824
 tympanic membrane perforations 939
 unilateral, vestibular schwannoma 3983–4
 vertigo, children 1042
 vestibular schwannoma 3837, 3943,
 3959, 4007–8
 resection, outcome prediction 749–50
see also deafness; specific causes; specific types

hearing monitoring,
 intraoperative 3292–3
 auditory/nonauditory structure differentiation 3293
 patient preparation 3293
 hearing rehabilitation, vestibular schwannoma 3984
 hearing tests, children 821–33,
 834–43
 costs 826
 definitions 821–3
 developmental age
 0–6 months 834–5
 6–18 months 835
 6–36 months 838
 2–5 years 839
 3 years onwards 840
 electrophysiological testing 834–5
 late identification 825–6
 linguistic age
 18–30 months 841
 30 months onwards 841
 6 years and over 841
 management 826
 newborns *see newborn hearing screening*
 outcomes 825
 parental wishes 826
 principles 821–3
 rationale 825–6
 school-entry screen 829
 special needs children 841
see also auditory sensitivity, evoked physiological measurements; specific tests
 hearing threshold
 definition 3261
 otitis media with effusion 889
 pure-tone audiometry 3260–1,
 3263–4
 heartburn 2063
 heart rate, children 543 *T*
 'heart-sink' patients 565
 heat exchange, nasal 1355–6
 heat moisture exchange devices 2628,
 2630 *F*
 heavy metal chemotherapy 37
 Heck's tumour 209 *T*
 Heerfordt's disease 3891
 Heimlich manoeuvre 2288
 children 1188, 1189 *F*
 helical rim, folded-over 971–2
Helicobacter pylori, gastro-oesophageal reflux 1274
 laryngeal manifestations 2262–3

helicotrema 3130
 Heliox
 airway obstruction 477–8, 2288
 stridor treatment 449
 tracheobronchial tree foreign bodies 1189
 helium-neon lasers 743
 helium-oxygen mixture *see Heliox*
 hemifacial microsomia 967–8,
 1032–3
 aetiology 1032
 classification 1032, 1032 *T*
 clinical features 1032–3, 1033 *F*
 diagnosis 1032–3
 management 1033
 timing 1033
 neuromuscular deficiencies 1032–3
 orthodontic treatment 1033
 surgery 1033
 hemifacial spasm, benign 3931
 hemitransfixion, septum 1578, 1578 *F*
 hemizygosity 8
 Henderson, John 473
 Hennebert sign 1046–7, 3763
 Henry's law 3501 *T*, 3514, 3516
 Hensen's body 3132 *F*, 3134
 Hensen's cells 3128 *F*, 3130–1
 heparin 446–7
 deep vein thrombosis 447
 mechanism of action 279, 282,
 447 *F*
 perioperative prophylaxis 290
 skin flap survival 114
 thrombophilia 289
 heparin-binding growth factors 67
 heparin-induced thrombocytopaenia (HIT) 260
 heparin-induced thrombocytopaenia with thrombosis (HITT) 287
 heparin sulphate proteoglycan (HSPG) 67
 hepatitis
 drug-induced 236
 salivary assay 1868
 hepatitis B surface antigen (HBsAg),
 salivary assay 1868
 hepatitis C virus, salivary gland infection 1901
 hepatocyte growth factor (HGF),
 thyroid cancer 2669–70
 hepatocyte proliferation 67
 heptanucleotide 5
 HER 2 oncogene 2384
 herbal medicine regulation 408
 Herceptin 44

- hereditary angio-oedema
 (HANE) 178–9, 179 T, 180 T
 airway obstruction 1824
 investigations 169
 oral manifestations 1824
- hereditary cerebellar ataxia 3773–5, 3779
 aetiology 3773–4
 children 1048
 clinical manifestations 3774
 complications 3775
 definition 3773
 diagnosis 3774
 differential diagnosis 3774
 management 3774
 outcomes 3775
- hereditary familial telangiectasia
 (HFT) 443
- hereditary haemorrhagic telangiectasia
 (HHT)
 epistaxis 1574, 1605–6, 1708
 children 1067
 nasal manifestations 1708
 oral manifestations 1823
 treatment 1605 F
- hereditary hearing loss 852
 autosomal dominant 852
 autosomal recessive 852–3
- hereditary sensory-motor neuropathy
 (HSMN), hearing loss and 3848,
 3849–50
- heritability, auditory function 17
- herpangina 1833, 2005
- herpes labialis 207–8, 1825
 HIV patients 242–3
 herpes simplex encephalitis 3913
 herpes simplex stomatitis 1832
 herpes simplex thymidine kinase
 (HSV-TK) 28
- herpes simplex virus (HSV) 207
 Bell's palsy 210, 3885
 children 2004
 drug resistance 208
 erythema multiforme 1835
 HIV patients
 dermatological manifestations 247
 inner ear infections 240–1
 laryngeal infection 244
 oesophagitis 245
 oral infections 242–3
 pharynx infections 244
 immunocompromised patients 208
 mouth ulcers
 advanced head and neck
 cancer 2789
 chronic 1832
- nasal infection 1700
 oral infection 207, 1832
 recurrent 1832
 pharyngeal infection 2004–5
 reactivation 207
 recurrent infections 207–8
 replication 207
 Steven–Johnson syndrome 2004
 treatment 208
 vaccines 208
 vestibular neuritis 3678, 3751
- herpes viruses 207–8
 head and neck cancer gene therapy 28
- herpes zoster ophthalmicus 3916,
 3916–7
- herpes zoster oticus 3379–82, 3380 F,
 3694, 3886
 AIDS patients 241, 247
 auricular pain 3380
 definition 3379
 diagnosis 3379–80
 facial palsy 3380, 3885, 3886 F, 3931
 histopathology 3694
 hyperacusis 3596
 management 434, 3380
 nomenclature 3379
 outcomes 3380
 pathology 3379
 symptoms 241, 3321
 taste abnormalities 1845
- herpes zoster virus
 facial nerve palsy 3886
 facial pain 1724
 mouth ulcers 1832
 advanced head and neck
 cancer 2789
 nasal infection 1700–1
 oral infection 1832
 pharyngeal infection 2005, 2079
 treatment 2005
- herpetic gingivostomatitis 207 F
- hertz 2165
- Heschl's gyrus 3863–4
- heterogeneity, clinical and
 statistical 663
- heterologous grafts 96
- heterosmia 1664
- heterozygotes 18
- Hetter incision 2731–3, 2732 F
- heuristics 563
- Hevea brasiliensis* 1419
- hiatus hernia
 barium swallow appearance 2027 F
 paediatric reflux 1273
 rolling 2062
- hiatus semilunaris 1332, 1333 F,
 1344–6
 third pass endoscopy 1348
- Hib vaccine *see Haemophilus influenzae type b vaccine (Hib vaccine)*
- high dependency unit
 definition 526–7
 staffing, structure and role 527
- high jugular bulb (HJB) 874
- highly active antiretroviral therapy
 (HAART) 2013
- high molecular weight compounds
 (HMWC), allergic occupational
 rhinitis 145, 1416, 1417 T
- high-pressure nervous
 syndrome 3512–3
- high resolution computed tomography
 (HRCT)
 cochlear implants assessment 3651
 facial nerve paralysis 3881
- high-resolution manometry (HRM)
 analysis 1971
 conventional manometry *vs.* 1971
 dysphagia investigations 1971–2
 sensor spacing 1974
- H-incision 2732 F
- hindbrain segmentation, inner ear
 development and 815
- HindII* 5
- HINT lists, speech audiometry 3270
- Hirudo medicinalis*, skin flaps 115
- histamine
 allergic response 1390
 allergic rhinitis 1561
 asthma 1561
 food intolerance 1424
 nasal polypsis 1552
 nasal vasculature, effects on 1365,
 1365 T
 nonallergic rhinitis 1409
 vestibular neurochemistry 3794
- histiocytosis X *see Langerhan's cell histiocytosis (LCH)*
- histopathological records, cancer data
 collection 2373
- Histoplasma capsulatum* 1216, 2267
- histoplasmosis
 cervicofacial infections,
 children 1216–7
 diagnosis 2267
 larynx 2267
 symptoms 2267
 throat 225
- HIV infection/AIDS 238–50
 antiretroviral resistance 2012

apoptosis 61
 birth rate 2011
 candidiasis 2011
 candidiasis, oral manifestations 1826
 CD4 receptor binding 238–9
 CD counts 239
 chemoprophylaxis 240
 children 2013
 chronic otitis media 3410
 dermatological manifestations 247–8
 epidemiological data 2011
 facial nerve paralysis 3887
 glycoproteins 238–9
 head and neck cancer 2012
 head manifestations 240–1, 2012 *T*
 AIDS defining 2012–3
 healthcare workers, acquired
 infection 2011–2
 intravenous drug users 2011
 larynx 243–4
 latency period 239
 mouth ulcers 1835
 nasal manifestations 241–2
 neck manifestations 246–7, 1784,
 2012 *T*
 AIDS defining 2012–3
 children 1213
 occupational exposure 239–40
 oesophagus 244–5
 olfactory dysfunction 1667
 opportunistic infections 239, 2013
 oral/oropharyngeal lesions 2013
 oral candidiasis 2013
 oral cavity 242–3, 2013
 oropharyngeal candidiasis 223
 oropharyngeal squamous cell
 carcinoma 2580
 otitis media with effusion 3389
 otologic manifestations 240–1
 external ear 240
 inner ear 240–1
 middle ear 240
 paranasal sinuses 241–2
 pharynx 243–4, 2011–4, 2012 *T*
 lymphoid tissue hyperplasia 2013
 neoplasms 2013–4
 post-exposure prophylaxis 2011–2
 primary infection 2013
 acute seroconversion illness 2013
 replication 238–9
 saliva assay 1868–9
 salivary glands, children 1246
 staging system 239
 symptoms 239
 syphilis 2007

therapy 239
 tuberculosis 1702, 2008
 viral structure 238–9
 HIV lymphadenopathy 247
 cervical 246, 1784
 diagnosis 247
 HIV salivary gland disease
 (HIV-SGD) 245–6, 1900–1, 1900 *T*
 children 1246
 imaging 1882, 1882 *F*
 parotid gland cyst 1246, 1246 *F*
 HLA *see* human leukocyte antigen
 (HLA)
 HMB45 monoclonal antibody, mucosal
 malignant melanoma 2408
 hMSH2, salivary gland tumours 2496
 hoarseness
 aetiology 2025–6
 assessment 2165
 definition 2165, 2192
 features 2184
 laryngitis 2196
 perceptual factors 2174
 upper airway obstruction 2287
 vocal fold cysts 2220
 hoarseness diagram 2184
 Hodgkin's disease *see* Hodgkin's
 lymphoma
 Hodgkin's lymphoma
 children 1254
 presentation 1254
 treatment 1254
 HIV-associated neck
 manifestations 246
 salivary glands 2501
 'holding strategy,' 'heart-sink'
 patients 565
 Holmes–Adie (myotonic) pupil 3917
 homeopathy
 otitis media with effusion 896
 vestibular compensation 3805
 homologous grafts 96
 augmentation rhinoplasty 2971
 homozygotes 18
 hooded seal (*Cystophora cristata*),
 exostosis 3367
 Hopkins rod endoscopes
 hypophysectomy 4106
 nasopharyngeal carcinoma 2454–5
 Hopkins rod telescope
 emergency tracheostomy 1124
 endoscopic sinus surgery 1483
 pharyngeal pouch surgery 2050–1,
 2051 *F*, 2053
 stridor investigations 1120, 1124 *F*

horizontal nystagmus 3219–20
 horizontal-T (Hetter) incision 2731–3,
 2732 *F*
 hormonal rhinitis 1383, 1410
 oestrogen 1410
 pregnancy 1410
 hormone assays, postoperative pituitary
 gland function 312
 hormones, effects on nasal
 vasculature 1365
 Horner syndrome
 causes 3937
 cerebellar infarction 3768
 congenital 3937
 external evidence 3936
 pupillary light reactions 3917
 skull base lesions 3946
 sweating loss 3936
 Hospice Movement 2771
 hot water irrigation, epistaxis 1602
 hourglass tumours 4126
 House, William 3968
 House-Brackmann's system
 facial function 3874–6, 3877, 3877 *T*,
 3979
 facial nerve tumours 4083
 house dust mite avoidance/
 reduction 1396
 children 1396
 'houseman's suture' 2736
 Howarth's elevators 1613, 1613 *F*
 Howarth's incision, external
 dacryocystorhinostomy 1691
 5-HT *see* serotonin
 HT3 antagonists, childhood
 vertigo 1049
 beta human chorionic gonadotropin
 (HCG) 359
 human embryonic stem cells (ES) 68
 Human Genome Mapping Project 10,
 11
 human immunodeficiency virus (HIV)
 see HIV infection/AIDS
 human leukocyte antigen (HLA)
 acute otitis media 916
 narcolepsy 2310
 nasopharyngeal carcinoma 2354,
 2446–7
 see also major histocompatibility
 complex (MHC)
 human papilloma virus (HPV) 209
 head and neck squamous cell
 carcinoma 2352–3
 hypopharyngeal cancer 2637–8
 inverted nasal papilloma 210

- human papilloma virus (HPV)
(continued)
 juvenile-onset recurrent respiratory papillomatosis 1174–5
 laryngeal papillomatosis 2221, 2599
 malignancy 208, 209, 209 *T*
 nasal infection 1701
 oral infection
 HIV-associated 243, 243 *F*
 mucosal disorders 1828
 respiratory papilloma 209
 temporal bone tumours 4068
- Human Rights Act (1998) 582, 590, 606–7
 confidentiality 602
 medical negligence 2806
 performance and complaints 605
- human telomerase reverse transcriptase (hTERT) 70–1
- human telomerase RNA (hTR) 70–1
- humidification, nose 1356
 water production 1356
- humps (nasal)
 removal techniques 2954–5
 saddle nose 2975, 2976 *F*
- Hunter's syndrome 468–9, 469 *F*
- Huntington's chorea 3939
- Hurler's syndrome 1048
- Hürthle cell tumours 2673 *T*, 2674
 FDG-PET imaging 694
- Hutchinson's incisors 1818
- Hutchinson's triad 847
- hyaline chondrosarcoma 4073
- hyaluronan, palatal shelf elevation 1814
- hybridization 6, 6 *F*, 12
- hydrocephalus
 craniosynostosis 1023
 normal-pressure 3778, 3780
 postural imbalance 3778
 skull base surgery 4139
 vestibular schwannoma and 3958–9
- hydrochlorothiazide 3799
- hydrocortisone
 active mucosal chronic otitis media 3424
 infected mouth ulcers, head and neck cancer 2789
 post-hypophysectomy 4111
 recurrent aphthous stomatitis 1830–1
- hydrogel dressings, malignant wounds 2794
- hydrogen peroxide mouthwash 448
- hydromorphone, cancer pain 2786
 doses 2787 *T*
- hydroxaminoacids, nasal mucus 1359
- hydroxyapatite (HA) implants 120, 2917
 composites 120, 120 *F*
 extrusion rates 120
 frontal sinus cranialization 1518
 historical aspects 118
 root form 2904
 subperiosteal 2903
 tympanoplasty 120
- hydroxycarbonate apatite (HCA) 123
- hydroxychloroquine 1913
- 1,25-hydroxycholecalciferol *see* vitamin D
- hydroxyethyl starch, idiopathic sudden sensorineural hearing loss 1, 3588
- hydroxyurea, jugular foramen meningioma 4042
- hydroxyzine 1397–8
- hygiene hypothesis 145–6, 1388
- Hynes pharyngoplasty 1011
- hyglossus 1797, 1797 *F*
- hyoid bone 2132, 2132 *F*
 cornua 1740, 2132
 fractures 2272
 surface anatomy 1740
 swallowing 1956–7
- hyoscine
 motion sickness 3795
 transdermal delivery 408–9
- periodic cancer pain 2784–5
- pharmacodynamics 411
- salivary leakage, head and neck cancer 2788–9
- vertigo 3795
- vestibular attacks, acute 3796 *T*
- xerostomia, palliative care 414
- hyperacusis 3595–6
 evaluation 3596
 music-related sound exposure 3596
 noise-induced hearing loss 3552
 pathophysiology 3596
 prevalence 3595–6
 symptoms 3595–6
 treatment 3596
- hyperbaric oxygen therapy
 bone matrix production 2911
 decompression illness 3515–6
 Eustachian tube obstruction 3390
- idiopathic sudden sensorineural hearing loss 1, 3584, 3589 *T*
- implant osseointegration 2910
- indications 3516 *T*
- malignant otitis externa 3339
- radiotherapy and 49–50
- secondary ear barotrauma 3519
- tinnitus 3584
- hyperbilirubinaemia
 auditory neuropathy/dyssynchrony 3845–6
 childhood deafness 845–6
- hypercalcaemia
 acute treatment 393
 biochemical analysis 379–80
 PTH assay 382, 382 *T*
 causes 380 *T*
 medical therapy 393
 palliative care, head and neck cancer 2794
- hypercarbia
 sleep apnoea 1105–6, 2309
 sleep-disordered breathing 1103
- hyperemesis gravidarum
 thyrotoxicosis 359
 transient hyperthyroidism 359
 β human chorionic gonadotropin 359
 thyroid stimulating hormone serum levels 359
- hyperexcitability 495
- hyperfractionated radiotherapy 2755
 simultaneous chemotherapy combination implications 2758–9
see also individual types
- hyperfractionation 49
 accelerated 2755
- hyperfunctional voice disorders 2225
- hyperglycaemia, critical care patients 535
- hyperglycexternal auditory canalia 3337
- hypergranulation tissue 101–2
- hyper IgE syndrome 180 *T*, 181
- hyperkalaemia 262
- hyperkeratosis 2221
- hypermagnesaemia
 biochemical analysis 381
 causes 381
- permethylation 8
- hypernasal speech (rhinolalia aperta) 993, 1366, 2166
- hyperosmia
 causes 1666–7
 definition 1664
 epilepsy 1669–70
- hyperostosis, meningiomas 4008, 4009
- hyperparathyroidism
 calcium levels 380 *T*
 clinical features 401
 genetics 388–9, 401

medical treatment 395
 multiple endocrine neoplasia 388
 oxyphil cells 373
 persistent 395
 phosphate levels 380, 381 *T*
 primary *see* primary
 hyperparathyroidism (pHPT)
 recurrent 395
 secondary 395–6
 renal transplantation 395
 surgery 392–3
 tertiary 389, 395–6
 ultrasound 722
 hyperphosphataemia 380, 381 *T*
 hyperprolactinaemia 301, 308
 hyperreflexia, thyrotoxicosis 339
 hypersalivation 3830
 hypersensitivity reactions 140–3, 142 *F*,
 147
 mechanisms 141–3, 142 *F*
 type I 141
 type II 141
 type III 141–2
 type IV 142
 hypersomnia, idiopathic 2310–1
 hypertension
 benign intracranial *see* otitic
 hydrocephalus
 cerebrospinal fluid rhinorrhoea 1641
 epistaxis 1600–1
 facial paralysis, childhood 1059
 patient preparation, surgery 459
 taste abnormalities 1840
 hyperthyroidism 323–4, 331
 aetiology/pathology 330
 apathetic 339
 causes 339 *T*
 definition 338
 pregnancy 358–9
 subclinical *see* subclinical
 hyperthyroidism
 thyroid cancer and 331
 transient of hypermesis
 gravidarum 359
 vocal manifestations 2201
 see also Graves' disease; thyrotoxicosis
 hypertrophic scars 2891–900
 classification 2891–2
 face lift complication 3095
 keloids *vs.* 2891–2
 medical negligence 3090–1
 steroid treatment 2898–9
 hyperventilation, capnograms 499 *F*
 hypoadrenalinism 357
 hypobranchial eminence 2130

hypocalcaemia
 biochemical analysis 379–80
 PTH assay 382, 382 *T*
 causes 380 *T*
 drug therapy 451
 large volume transfusion 262
 thyroidectomy-related 351, 2692
 hypocapnia, sleep 2307
 hypochlorite, denture-related
 stomatitis 1826, 1827
 hypocretin, narcolepsy 2310
 hypodermoclysis, palliative care 2800
 hypodontia (dental aplasia) 1817
 hypogeausia 1842
 hypoglossal facial anastomoses 3078
 hypoglossal nerve (XII) 1751–2, 1797 *F*,
 1803, 3933 *F*, 3934 *F*, 3936–7
 central connections 3934 *F*
 clinical disorders 3937–8
 clinical evaluation 3937–40
 fascicular fibres 3936
 functional deficit, post-jugular
 foramen surgery 4041
 in jugular foramen 3903, 3903 *F*
 motor fibres 3936
 in neck 1751–2
 rootlets 3936
 roots 3936
 skull base lesions 3946
 hypoglossal nerve lesions 3937
 submandibular gland tumours
 2488
 hypoglossal nerve palsy
 clival chordoma 4126
 submandibular gland
 tumours 2504–5
 hypogonadotropic hypogonadism
 (Kallmann's syndrome) 403, 813 *T*,
 1664, 1670
 hypokalaemic alkalosis 310
 hypomagnesaemia
 biochemical analysis 381
 causes 381, 381 *T*
 hyponasal speech (rhinolalia
 clausa) 993, 1366, 2166
 hypoparathyroidism
 calcium levels 380, 380 *T*
 Chvostek's sign 401
 magnesium levels 381
 thyroidectomy-related 2684 *T*
 hypopharyngeal cancer 2633–62
 aetiology 2634
 apoptosis 2636
 benign lesions 2635
 cell biology 2635–7
 chemotherapy 2649
 radiotherapy and 52
 complications 2655–6
 diagnosis 2643–5
 endoscopic assessment 2645 *T*
 endoscopic laser surgery 2648
 epidemiology 2634–5
 histology 2637–8, 2637 *F*
 imaging 2643–4
 incidence 2633–4
 investigations 2643–5
 locoregional spread 2638–42
 oesophagus 2639–40, 2640 *F*
 thyroid gland invasion 2640 *F*
 tracheal invasion 2639–40, 2640 *F*
 vocal fold palsy 2639
 lymph node metastases 2641,
 2642 *T*, 2652, 2654 *F*, 2655,
 2656
 molecular biology 2635–7
 non-squamous 2637 *T*
 piriform fossa *see* piriform fossa
 postcricoid region
 epidemiology 2634–5, 2639 *F*
 neck node metastases 2641
 vocal fold palsy 2639 *F*
 postoperative survival rates 624
 prognosis 2653–5, 2653 *F*, 2654 *F*
 quality of life issues 2775
 radiotherapy 2647–8, 2650
 chemotherapy and 52
 complications 2655
 recurrence 2652 *F*
 signs 2643–5
 staging 2645, 2646 *T*
 stomach transposition 2655–6
 surgery 2648, 2651
 symptomatology 2642–3, 2643 *T*
 TNM classification 2365 *T*
 treatment 2647, 2647 *T*
 combination protocols 2649–50
 failure patterns 2651–3
 neck irradiation 2651
 T-stage 2654 *F*
 tumour markers 2636
 see also oesophageal carcinoma
 hypopharyngeal diverticulum *see*
 pharyngeal pouch
 hypopharyngeal fibrolipomas 2635
 hypopharyngeal injury 1770
 hypopharyngeal leiomyomas 2635
 'hypopharyngeal suction pump' *see*
 upper oesophageal sphincter (UOS)
 hypopharynx 1944–5
 acquired stenosis 2635

hypopharynx (*continued*)
 anatomy 2638
 postcricoid region 2638
 subsites 2638 *T*
 lymphatic drainage 2714
 mucous membrane 1947
 otalgia 3530–1
 postcricoid region 1944–5
 structure 2365
 walls 1944–5
 hypophosphataemia 380, 381 *T*
 hypophosphataemic osteomalacia 382–3
 hypophyseal cleft 295
 hypophyseal veins 297
 hypophysectomy
 anaesthesia 4106
 biochemical investigations 4105
 complications 4110–1, 4113
 early postoperative 4113
 failure to cure 4113
 intracranial haemorrhage 4113
 intraoperative haemorrhage 4113
 late postoperative 4113
 nasal/sinus 4113
 contraindications 4104
 Cushing's disease 4102
 discharge after 4113
 diagnostic 4104
 equipment 4106, 4106 *F*, 4107 *F*, 4110,
 4111 *F*
 functioning adenomas
 acromegaly 4101, 4114
 Cushing's disease (ACTH
 excess) 4102, 4114
 prolactinomas 4100, 4114
 TSHomas 4102
 hospital discharge 4113
 indications 4104
 laboratory investigations 4105
 nasal instruments 4106, 4106 *F*
 nasal preparation 4105
 nonfunctioning adenomas 4103
 outcomes 4105, 4114–5
 Cushing's disease 4114
 functioning adenomas 4114
 nonfunctioning adenomas 4114
 patient information/consent 4104–5
 patient positioning 4106
 postoperative management 4111–3
 antibiotic cover 4111
 fluid balance and diabetes insipidus
 management 4112
 nasal pack 4112–3
 neurological assessment 4112
 steroid replacement 4111

preoperative investigations 4105
 biochemical 4105
 imaging 4105
 inferior petrosal sinus
 sampling 4105
 visual field assessment 4105
 preparation for surgery 4105–6
 revision surgery 4115
 specialization 4104, 4115
 surgical approaches 4106–8
 dual approach 4108
 transcranial approach 4108,
 4110 *F*
 transsphenoidal approaches *see*
 transsphenoidal
 hypophysectomy
 surgical learning curve 4115
 therapeutic 4104
 tumour management role 4104–13
 written information 4105
 hypophysiotropic neurones 307
 hypophysis cerebri *see* pituitary gland
 hypopigmentation, laser skin
 resurfacing 3096
 hypopituitarism 4103
 hyposmia
 corticosteroids 421
 epilepsy 1669–70
 frontal lobe tumours 1668–9
 nonallergic occupational
 rhinitis 1416–8
 hyposplenism, functional 276
 hypotensive anaesthesia, ear
 surgery 502–3, 502 *F*
 hypothalamic–pituitary–thyroid
 axis 321 *F*
 hypothalamus
 feedback mechanisms 398–9
 hormones 307
 pituitary gland, effects on 300, 307
 regulation 398–9
 synthesis 307
 see also individual hormones
 hypophysiotropic neurones 307
 nasal reflexes 1365
 physiology 300–2, 307
 target glands 398–9
 hypothermia, paediatric anaesthesia
 512
 hypothyroidism 353–8
 aetiology 330, 354 *T*, 355–7, 399–400
 central 357
 chronic autoimmune *see* Hashimoto's
 thyroiditis
 clinical features 355, 355 *T*
 congenital *see* congenital
 hypothyroidism (cretinism)
 drug-induced 354 *T*
 epidemiology 353–5
 goitre 335
 iatrogenic 356
 aetiology 356
 incidence 399–400
 investigations 331–2, 335–6
 radionuclide scans 336
 ultrasound examination 721
 in vitro tests 332, 335
 iodine deficiency 356–7
 nasal obstruction 1366
 neonatal 355
 otologic symptoms 400
 pathology 330
 pregnancy 359–60
 adverse effects 359
 treatment 360
 prevalence 353–5
 radioiodine-induced 348, 356, 415,
 2696
 radiotherapy-induced 356
 Reinke's oedema 2199
 rhinitis 400
 subclinical *see* subclinical
 hypothyroidism
 symptoms 355, 399–400
 taste abnormalities 1846
 thyroidectomy-induced 356
 treatment 357, 450–1
 tumour-induced 357
 vestibular symptoms 400
 vocal manifestations 400, 2201
 see also thyroid disease; specific causes
 hypoventilation
 capnograms 499 *F*
 sleep 2307
 hypovolaemic shock 257 *T*
 hypoxaemia
 sleep apnoea 2309
 stridor 1119
 hypoxia
 childhood deafness 845–6
 obstructive sleep apnoea 1105–6
 sleep-disordered breathing 1103
 hypoxic cells
 sensitizers 50
 tumours 49
 x-ray resistance 49
 hypoxic cell sensitization
 cellular hypoxia 2756
 head and neck cancer 2756–7
 research 2756

- ibuprofen 3801
 icatibant 1390
 idiopathic facial nerve paralysis (IFNP)
 see Bell's palsy
 idiopathic rhinitis *see* rhinitis,
 idiopathic
 idiopathic sudden sensorineural hearing
 loss (ISSNHL) 3577–93
 aetiology 3580–2
 definitions 3577, 3578, 3578 *T*
 diagnosis 3582–4, 3583 *T*
 epidemiology 3580–2
 incidence 3581, 3582
 bilateral 3582
 investigations 3579, 3583
 management 3584–9, 3585 *T*
 adverse events associated 3589,
 3589 *T*
 corticosteroids 423, 3585 *T*
 efficacy 3589
 evidence-based 3588–9
 protocol 3588
 randomized controlled trials 1
 outcomes 3584
 management effects 3584–9
 pathology 3580–2
 recovery 3584
 idiopathic thrombocytopenic
 purpura 286
 children 286
 epistaxis 1065
 treatment 286
 idiopathic trigeminal neuralgia *see*
 trigeminal neuralgia
 iliac crest bone grafts 2972
 image-guided surgery (IGS) 701–10
 clinical applications 708
 functional endoscopic surgery 709 *F*
 image data visualization 703–4
 image reconstruction 703
 volume averaging 703
 infrared light sensors 707, 708 *F*
 pixels and voxels 703
 registration 706
 slices, concepts of 703
 surface rendering 703–4
 surgical planning 704
 surgical simulation 704–5
 tracking 706–8, 708 *F*
 imaging
 airway management 470
 cerebrospinal fluid rhinorrhoea 1638,
 1638 *F*, 1639 *F*
 children 1295–304
 interventional procedures 1300
 modalities 1295 *T*
 patient preparation 1301–2, 1302 *T*
 radiation protection 1300–1, 1301 *T*
 cholesterol granuloma 1655
 cochlear implants candidature 3651
 giant cell granuloma 1655
 hypophysectomy 4105
 incidentalomas, pituitary
 tumours 4103
 laryngeal stenosis evaluation 1151–2
 medical negligence and 2807
 preoperative, purpose of 702
 recent advances 755
 T/NK cell lymphoma 1656
 Wegener's granulomatosis 1651 *F*,
 1652, 1652 *F*
 see also specific modalities
 imatinib mesylate 44
 imbalance, persistent in children 1048
 imidazoles 214, 233, 442
 imitative test of speech pattern contrast
 perception (IMSPAC) 841
 immittance 3289
 immortalized HEp-2 185
 immune complex disorders
 tonsillitis complications 1224
 see also specific disorders
 immune complex (type 3) drug
 reactions 414
 immune modulation
 cytokine stimulatory pathway 28
 head and neck cancer treatment 28
 multiple sclerosis 3772
 immune response
 extracellular infectious agents 137–40,
 138 *F*
 stages 134, 134 *F*
 vesicular infectious agents 137–40,
 138 *F*
 immune system
 adaptive 133–4
 evaluation 167–73
 immunological tests *see*
 immunological tests
 innate 133–4
 tonsils' role 1220
 immunization status, salivary
 assay 1869
 immunodeficiency
 childhood rhinosinusitis 1081
 chronic otitis media 3410
 combined 174–6
 diabetes mellitus 401
 investigations 167–9
 genetic studies 169
 immunoglobulins 168
 molecular studies 169
 see also individual tests
 pathogen associations 168 *T*
 primary 174–82
 B cell defects 175 *T*, 176
 complement deficiencies 178–9,
 179 *T*
 definition 174
 immunological tests 177 *T*
 phagocyte defects 177–8, 177 *T*
 syndromes 179–81, 180 *T*
 T cell defects 174–5, 175 *T*
 tests 168 *T*
 see also individual disease/disorders
 secondary 174
 immunoglobulin(s) 135–6
 acute otitis media 916, 920
 classes 138
 class switching 148
 immunodeficiency testing 168
 nasal secretions 1360, 1361–2, 1361
 in newborn infants 138
 structure 135 *F*, 138
 subclasses 138, 138 *T*
 deficiency 176–7
 testing 168
 surface 135
 see also antibodies; specific types
 immunoglobulin A (IgA)
 class comparisons 138
 coeliac disease 1866
 deficiency 175 *T*, 176
 HIV infection 1868–9
 mucosal secretions 138
 nasal secretions 1362
 spasmodic croup 1129
 immunoglobulin A₂ (IgA₂) 1361–2
 immunoglobulin A (IgA) subclass
 deficiency 1081
 immunoglobulin E (IgE)
 allergen-specific 159–60, 160 *F*
 in allergic reactions 144, 169, 1389
 total 159
 immunoglobulin G (IgG) subclass
 deficiency 1081
 immunoglobulin (Ig)-like adhesion
 molecules 2384
 immunoglobulin M (IgM) 138
 ABO blood groups 253–4
 immunoglobulin replacement therapy,
 chronic rhinosinusitis 1473
 immunohistochemistry
 p53 2382 *F*
 salivary gland tumours 2495

immunological tests 167–72
 allergy 169–70
 autoimmune disease 170–2
immunodeficiency *see*
 immunodeficiency
 lymphoproliferative disease 170–2, 172
 vasculitis 170–2
see also individual tests
 immunonutrition 532–3
 immunosuppression
 basal cell carcinoma 2396
 paediatric rhinosinusitis 1081–2
 relapsing polychondritis 3364
 transfusion-associated graft-versus-
 host disease 262

immunotherapy
 allergic rhinitis 1564–5
 allergy 153–5
 nasopharyngeal carcinoma 2467
 rhinosinusitis
 children 1083–4
 chronic 1473

impedance 3167, 3168 *T*
 sound 3173–4
 cochlea 3176, 3181
 different media 3175–6
 tympanic membrane 3178–9

impedance monitoring, facial
 reanimation 3081–2

impetigo, nasal 1700

implant bourne facial prostheses 2915

implanted hearing aids 3640–1

implant osseointegration
 absolute contraindications 2910
 CADCAM models 2911–2
 counselling 2911
 CT-3D imaging 2911–2
 diagnostic wax up/models 2911, 2911 *F*
 hyperbaric oxygen 2910
 irrigation and cooling of bone 2913
 local factors 2911
 maintenance 2915
 medical factors 2901
 mucoperiosteal flap access 2912–3
 patient assessment 2910–2
 planning 2910–2
 prophylactic antibiotics 2912
 radio-opaque markers 2912
 site, determination of 2912
 suitability 2910
 surgical tapping and threading of
 bone 2913–4
 surgical techniques 2912–5
 advanced 2915–7
 surgical template 2912–3

implant-retained extra-oral
 prostheses 2933 *T*
 implant retention 2932
 abutment type selection 2932
 bar and clip arrangement 2932, 2933 *F*
 magnets 2932

implant salvage 2920–1

imploding antrum syndrome 1685–6
 complications 1686
 CT imaging 1685–6, 1686 *F*
 idiopathic 1685–6
 secondary 1685–6
 surgical techniques 1685–6

‘impulsive’ rotational test *see* velocity
 step test

impulsive sounds, middle ear
 reflexes 3183–4

incidence (of a disease) 823, 2344

incidentaloma(s)
 pituitary gland 4099, 4103
 thyroid gland 363

incident pain 2785

incisiform teeth *see* incisors

incision wounds 97

incisive artery 1798

incisive papilla 1791–2

incisivus labii inferioris 1798

incisivus labii superioris 1798

incisors 1803
 deciduous 1804–5
 permanent 1803
 roots 1803

incisura jugularis 4026–7

incremental yield 823

incus 3115, 3115 *F*
 displacement, stapes surgery–
 induced 3474
 repositioning 3493

Indian technique, nasal
 reconstruction 3015–6

indinavir 233, 239

indole-3-carbinol 1179

indoloquinone EO9 50–1

inducible nitric oxide synthase (iNOS)
 primary ciliary dyskinesia 1081
 skin flap survival 113

induction loop systems 3668

industrial dusts, olfactory
 dysfunction 1673–4

indwelling prostheses, orbital 2928

indwelling tracheostomy, laryngeal
 stenosis 2277

infant(s)
 drug prescribing 415
 haemopoiesis 265–6

infant distraction test (IDT) 825–6, 848
 eight month 828–9

infection(s)
 adenoidectomy-related 1098
 bacterial *see* bacterial infection
 chronic otitis media 3410, 3410 *T*
 dental caries 1805
 diabetes mellitus 402
 dysphagia 2030–1
 fungal *see* fungal infection
 inactive squamous chronic otitis
 media 3427

intracranial, vestibular schwannoma
 removal 3982

jugular foramen 4034

malignant ulcers and fistulae 2792

maternal, childhood deafness
 and 846–7

mycobacterial *see* mycobacterial
 infections

nasal *see* nasal infections

neck 1783–5

neurological pharyngeal
 disease 2078–9

otitis media with effusion 3389

painful red eye 3916

petrous apex 4047

pinna reconstruction 3033

sinonasal malignancy 2347

skull base surgery 4138

syndromic craniosynostosis
 surgery 1031

taste abnormalities 1844–5

β thalassaemias 271–2

vestibular schwannoma surgery 3982

viral *see* viral infection

voice disorders 2219

wound healing 95, 98–9

wounds, dressings for 101

see also specific infections

infections
 cervicofacial *see* cervicofacial
 infections
 salivary gland diseases/
 disorders 1899–900, 1899 *T*

infectious mononucleosis 2002–4, 2253
 acute upper airway obstruction 2004

cervical lymphadenopathy 1213,
 1783–4, 2703

clinical features 208, 1225 *F*, 2002–3,
 2253, 2254 *F*

facial rash 1701

complications 2253

diagnosis 2003–4

dysphagia aetiology 2030

- epidemiology 2002
 facial nerve palsy 3887, 3887 *F*
 investigations 2003–4, 2253
 management 1784, 2253
 systemic manifestations 2003, 2003 *T*
 tonsils 208, 1213, 1225, 1783–4
 transmission 2002, 2253
 treatment 208, 422, 2004
see also Epstein–Barr virus (EBV)
- infectious rhinitis (common cold) *see*
 common cold (infectious rhinitis)
 infectious rhinosinusitis 1381–2, 1382 *T*
 acute *see* acute rhinosinusitis (ARS)
 chronic *see* chronic rhinosinusitis
 (CRS)
 clinical forms 1382, 1382 *T*
 recurrent acute *see* recurrent acute
 rhinosinusitis (RARS)
see also fungal rhinosinusitis
- inferior alveolar (dental) artery 1795 *F*,
 1798, 3907
 inferior alveolar (dental) nerve 1795 *F*,
 1801 *F*, 1802, 3907–8, 3925–6
 injury, odontogenic keratocyst
 treatment 1925
 inferior alveolar vein 1799
 inferior canaliculus 1690
 probing,
 dacryocystorhinostomy 1691 *F*
 inferior cantholysis, orbital
 haemorrhage 3065
 inferior circular sinus of Winslow 299
 inferior colliculus 3142–3, 3143 *F*
 auditory neuropathy 3849
 central nucleus 3142–3
 function 3142–3
 lesions 3921
 sound pattern recognition 3143
 inferior constrictor, pharynx 1947,
 1948 *T*, 1949 *F*
 lateral relations 1947–9
 inferior constrictor strain swallow,
 globus 2038
 inferior dental (alveolar) artery 1795 *F*,
 1798, 3907
 inferior dental nerve *see* inferior
 alveolar nerve
 inferior hypophyseal arteries 297
 inferior labial vein 1799
 inferior laryngeal artery 317, 2139
 inferior laryngeal nerve 1949–50, 3935
 inferior laryngeal veins 2140
 inferior meatal antrostomy 1492–3
 anaesthesia 1492
 complications 1493
 indications 1492
 rhinosinusitis, children 1084
 surgical technique 1492–3, 1493 *F*
- inferior meatus 1329
 inferior nuchal line 3899
 inferior oblique muscle 3053 *F*
 inferior petrosal sinus 3909
 inferior petrosal sinus sampling
 (IPSS) 310–1
 Cushing's disease 310–1
 hypophysectomy 4105
 inferior thyroid artery 317, 372
 inferior thyroid veins 317–8, 372–3
 inferior tracheobronchial lymph
 nodes 2142
 inferior turbinate
 anatomy 1329–30, 1329 *F*, 1344–6,
 1346 *F*, 1589
 blood supply, surgical anatomy 1599
 congestion state 1589, 1590 *F*
 reduction, chronic nasal
 obstruction 1592
 infertility, prolactinoma 4100
 inflammation 140–3
 acquired atresia, external ear 3347
 acute response 88
 dysphagia 2031–2
 early 89
 healing stages 98
 late 89–90
 nasal polyposis 1552
 wound healing 88–90, 98
 inflammatory disease/disorders
 facial nerve disorders 3891
 gingival hyperplasia, pregnancy 403
 paranasal 1344–6
 nasal endoscopy 1349–50, 1349 *F*
 saddle nose deformity 2976
 inflammatory lymphadenopathy,
 children 1210, 1211 *T*
 inflammatory response
 acute 88
 embolic agents 733
 influenza
 aetiology 205, 205 *T*
 complications 205–6
 pandemic 205
 at risk groups 205–6
 influenza A treatment 210, 232
 influenza neuraminidase
 inhibitors 209–10, 232–3
see also individual drugs
 influenza vaccination 205–6
 acute otitis media 211, 919
 influenza virus 205–6, 206 *F*
- informed consent 585
 categories 2806
 genetic testing 1021
 medical negligence 2806
see also consent
 infraglottis 803–5
 infrahyoid muscles 2134, 2135 *T*
 infraorbital artery 1798–9
 infraorbital foramen 1340
 infraorbital nerve 1800, 1801 *F*
 infrared light sensors, image-guided
 surgery 707
 infrared oculography 3723
 infrared systems, hearing impaired
 user 3668
 infratemporal fossa 3905–8, 3905 *F*,
 3906 *F*
 boundaries 3905
 contents 3905
 otalgia 3528
 infundibular cells 1331–2
 infundibular entrance, third pass
 endoscopy 1348
 infundibulotomy 1483
 infundibulum, pituitary gland 295
 blood supply 297
 magnetic resonance imaging 305
 inhalational agents, anaesthesia 491,
 496
 inheritance, genetic 18–9
 codominance 18
 dominant 18, 18–9
 heterozygote 18
 homozygote 18
 maternal 18
 recessive 18, 18–9
 inherited immunodeficiency *see*
 immunodeficiency, primary
 inhibin 302
 innate immune system 133–4
 pattern-recognition molecules 133
 inner ear
 congenital disorders 3683
 deafness, pathology 811–2, 966
 development 3122–3
 distortion products 3198–9, 3201
 embryology 806–7
 HIV manifestations 240–1
 otalgia 3528–9
 trauma 3681–2
 vascular anomalies 3701
 inner ear barotrauma 3507
 differential diagnosis 3508 *T*
 hyperbaric oxygen treatment,
 secondary to 3519

- inner ear barotrauma (*continued*)
 inner ear haemorrhage 3507
 pathoaeiology 3502–3, 3503 *F*
 inner ear decompression illness 3517–8
 clinical signs 3518
 co-existing symptoms 3517 *T*
 diagnosis 3517, 3518 *T*
 differential diagnosis 3508 *T*
 investigations 3518
 treatment 3518
- inner hair cells (IHC) 3130, 3131 *F*
 auditory neuropathy/
 dyssynchrony 3849
 cell body 3135–6, 3135 *F*
 depolarization 3136
 electrical potential 3194–5, 3195 *F*
 electrical responses 3194–5, 3195 *F*
 electromechanical transduction 3849
 function 3135–6
 innervation 3136, 3849
 stereocilia 3135, 3135 *F*
 lateral links 3135
 rootlets 3135
 tip links 3135, 3135 *F*
 transduction 3135
 synaptic pole 3136
 tinnitus 3605
 ultrastructure 3135–6, 3135 *F*
- inner sulcus 3127
- innominate artery
 aberrant 1146
 paediatric tracheostomy 1203,
 1203 *F*
 rupture, surgery-related 2808
- innominate artery fistula 1203
- innominate foramen 3899
- inosine-5-monophosphate
 dehydrogenase 209
- 1,4,5-inositol triphosphate (IP₃),
 salivary secretion 1859
- inotropes, critical care patients 529–30
- Inscutible* 68
- insects, removal from ears 1185–6,
 3370
- insertion, DNA mutation 16
- insertional mutagenesis, gene
 therapy 29
- insertional plaque (plate), vestibular
 hair cells 3228, 3234 *F*
- myosin I β 3234
- in situ* end labelling (ISEL) 61
- in situ* hybridization 6 *F*, 2383
- inspiration
 nasal humidification 1356
 post-swallowing 1960
- inspired anaesthetic agent
 concentration 498
- inspired oxygen fraction (F_iO₂),
 anaesthesia monitoring 498
- inspired PCO₂, anaesthesia
 monitoring 498
- insula, swallowing 1959
- insulin-induced hypoglycaemia
 adrenocorticotropin testing 300
 growth hormone deficiency test 301
- insulin infusion, critical care
 patients 535
- insulin-like growth factor I (IGF-1)
 acromegaly 4101
 circulating levels 301, 309
 see also growth hormone (GH)
- insulin-like growth factor II (IGF-2),
 juvenile angiomyxoma 2437–8
- insulin tolerance test, Cushing's
 syndrome 310
- intact canal wall mastoidectomy,
 cholesteatoma 3433
 canal wall down mastoidectomy
 vs. 3433
- integrins 2384
 head and neck cancer markers 2384
 metastatic spread 36
- intensity (definition) 3165
- intensity modulated radiotherapy
 (IMRT) 2759–60, 2760 *F*
 cervical lymphadenopathy 2707
- nasopharyngeal carcinoma,
 children 1258
 oropharyngeal tumours 2585
 xerostomia 1909
- intensive care
 admission indications 526
 definition 526–7
 medical responsibility 527
 patient management 527
 staffing, structure and role 527
 see also paediatric intensive care
- intention-to-treat analysis 629, 659
 drug trials 413
- interarytenoid adhesion 1161–2
- intercavernous venous sinuses 299
- intercellular adhesion molecule 1
 (ICAM-1), allergic rhinitis 1391
- interferon (IFN) 209
 basal cell carcinoma 2397
 mucosal malignant melanoma 2410
- interferon alpha 209
 juvenile-onset recurrent respiratory
 papillomatosis 1178
 Sjögren syndrome 1912–3
- interferon alpha-2a 1141
- interferon beta, multiple sclerosis 3772
- interferon-gamma 137
- interforaminal atrophy 2919–20
- interforaminal implant placement
 2919
- Intergroup Rhabdomyosarcoma Study
 (IRS) 4074, 4074 *T*
- Interim Orders Committee (IOC) 606
- interleukin(s), tumour markers
 2388 *T*
- interleukin-1 (IL-1), stem cells and 69
- interleukin-3 (IL-3), stem cells and 69
- interleukin-5 (IL-5)
 asthma 155–6
 nasal polyposis 1552
- intermaxillary fixation (IMF)
 arch bars 1622–3, 1623 *F*
 complications/problems 1621, 1621 *F*
 incomplete dental arch 1622–3
 intact dental arch 1622
 mandibular fractures 1621 *F*, 1622
 maxillary fractures 1627
- intermediate olfactory striae 3912–3
- intermittent rhinosinusitis *see acute*
 rhinosinusitis (ARS)
- internal auditory canal (meatus)
 anatomy 3119–20, 3121 *F*
 facial nerve anatomy 3871
- fundus dilation 872
- middle fossa surgery 4018
- skeletonization, translabyrinthine
 vestibular schwannoma
 removal 3970–1, 3971 *F*
- stapes surgery 3474–5
- internal carotid artery (ICA) 1749–50,
 3901, 3902 *F*, 3909
- aberrant
 middle ear 874
 nasopharynx 2120, 2120 *F*, 2121 *F*
- balloon occlusion 3949, 3952 *F*
- epistaxis 1597
- jugular foramen surgery 4034, 4039
 extracranial-intracranial
 bypass 4039, 4040 *F*
- petrous apex cholesterol cyst 4050–1
- skull base tumours 4056
- temporal bone tumours 4068–9
- internal carotid artery test 3951
- internal carotid territories,
 epistaxis 1597
- internal ear *see* inner ear
- internal fixation
 mandibular fractures 1624–5, 1624,
 1624 *F*

- maxilla
fracture repair 1627
orbital access 1627, 1628 *T*
- internal jugular vein 1750, 3901, 3902 *F*
lymph nodes, association with 1747
relations 1750, 1750 *T*
- internal laryngeal nerve 1803
- internal maxillary artery ligation,
epistaxis 1603–4
embolization *vs.* 739
- internal suspension, maxilla 1627
- internal suspension, maxillary
fractures 1627
- International Association for the Study
of Pain, pain definition 3526
- International Classification of Disease
(ICD)
morphology codes 2374–5, 2375 *T*
tumour site codes 2374 *T*, 2375 *T*
- International Classification of Diseases
for Oncology (ICD-O) 2362
- International Classification of Sleep
Disorders 2307
- International Journal of Pediatric
Otolaryngology 773
- international normalized ratio
(INR) 280, 447
- International Study of Asthma and
Allergies in Childhood
(ISAAC) 1080, 1386
- International Symposium on Recent
Advances in Otitis Media 1978 929
- International Symposium on Recent
Advances in Otitis Media 1999 929
- International Union Against Cancer
(UICC)
laryngeal tumour staging 2603–7
TNM staging system 2360
- International Union Against Cancer
(UICC), salivary gland
staging 2507 *T*
- International Union Against Cancer
(uicc)/American Joint Committee
on Cancer (AJCC), Hart stage
grouping 2360
- internet 574
- internuclear lesions, eye movement
defects 3922
- internuclear ophthalmoplegia (INO)
ataxic nystagmus 3715, 3716 *F*
causes 3715
- interphase, cell cycle 2381
- interventional neuroradiology
(INR) 731–41
applications 732, 734–5
- dynamic testing and 735
epistaxis management 739
large artery occlusion 735
complications 734, 736, 739
current knowledge/future
research 740
- definition 731
- equipment/agents used 732–4,
733 *T*
embolization materials *see* embolic
agents
- endovascular catheters 732–3
- temporary *vs.* permanent
agents 733
- indications 732, 732 *T*
clinical/anatomical factors 732
- mechanism of action 733
- preoperative treatment planning
and 732
- risk/benefit analysis 732
- tumour embolization *see* tumour
embolization
see also specific techniques/applications
- intonation 2174
- intraarterial chemotherapy 735
- intracapsular partial tonsillectomy
1993
- intracerebral abscess, children 1089
- intracochlear vector delivery 817
- intracranial abscess
active chronic otitis media 3437
management 3438
sinusitis, children 1088–9
- intracranial ischaemia, olfactory
dysfunction 1667
- intracranial pressure (ICP), raised
barotrauma 3500–2
craniosynostosis 1022–3, 1024 *F*
diagnosis 1023
incidence 1023
syndromic 1029
- intractable aspiration 2094–104
causes 2095
conservative management 2096–7
definition 2094
investigations 2096
pathophysiology 2094–5
surgical management 2097–103,
2098 *T*
endolaryngeal stents 2099, 2100 *F*
vocal fold medialization
techniques 2097–8
symptoms and signs 2095–6
- intrajugular processes 4026–7
- intralabyrinthine schwannoma 3685
- intraluminal impedance testing, gastro-
oesophageal reflux 1275
- intranasal ethmoidectomy 1494–5
complications 1495
contraindications 1495
indications 1494
surgical technique 1495
- intraoral prostheses
healing times 2914
insertion 2913 *F*
nasal reconstruction 2928
progressive loading 2914
types 2915
- intraorbital nerve injury,
blepharoplasty 3066
- intraparotid lymph nodes 1853–4,
1856
- intrapharyngeal space 1807
- intraspheoid sinus septae 300
- intrathecal dyes/markers, cerebrospinal
fluid rhinorrhoea 1638–9, 1639 *F*
- intrathoracic obstruction, stridor 1118,
1118 *F*
- intrathyroidal parathyroid glands 722
- intravenous drug users (IDUs), HIV
infection/AIDS 2011
- intrinsic factor (IF) 269
- intrinsic sleep drive 2306
- introns 4, 15–6
- intubating laryngeal mask airway
(ILMA) 474–5, 475 *F*
- intubation
awake fibreoptic *see* awake fibreoptic
intubation
- cervical spine fractures 2289
- cricoid ring damage 1151
- difficult 467, 468
- endoscopy 1121
- endotracheal *see* endotracheal
intubation
- facial trauma, severe 2289
- failed, upper airway
obstruction 2151–2
- laryngeal endoscopy 2151–2
- laryngeal infections, acute 1132–3
- laryngeal reconstruction 1158
- laryngeal trauma 2289
- malignant dysphagia palliation
2069
- prolonged, otitis media with
effusion 3390
- tonsillectomy 515, 515 *F*
- tracheal *see* tracheal intubation
- vocal injuries, children 1170, 1170 *F*,
1171 *F*

- intubation granuloma *see* arytenoid granuloma
- invasive aspergillosis 217 *F*
mycotic laryngitis 2254
- invasive monitoring of blood pressure (IBP), perioperative 497–8
- inverted papilloma
middle ear 4072–4
sinonasal 1523–4
clinical symptoms 1523
definition 1523
endoscopic resection 1350–1, 1351 *F*
human papilloma virus 209 *T*, 210
imaging 1503 *F*, 1523
incidence 1523
pathogenesis 1523
recurrence 1523
results/statistics 1524
site of origin 1523
surgery 1523–4
surgical indications 1523–4
- involuntary manslaughter 607–8
- iodide mumps 1906–7
- iodine
daily requirements 356–7
metabolism 321
thyroid cancer aetiology 2671
thyroid gland physiology 321, 321–2
thyrotoxicosis 451
- iodine, radioactive *see* radioiodine therapy
- iodine-131 *see* radioiodine
- iodine deficiency
dietary factors 356
goitre 345, 356
hypothyroidism 354 *T*, 356–7
neonatal cretinism 356
- iodothyronine deiodinase
isoenzymes 323, 324 *T*
- ionizing radiation 47
basal cell carcinoma 2396
- ionomer cements 120
- ions, nasal secretions 1360
- iontophoresis, perichondritis 3360
- Iowa Oral Performance Instrument (IOPI), dysphagia 2088
- ipratropium bromide
allergic rhinitis 1398
nonallergic rhinitis 1412
pharmacodynamics 411
rhinosinusitis 442
- ipsilateral coronoidectomy, trismus reduction 2915
- Iressa (gefitinib, ZD1839) 43, 52
- irinotecan 39
- iron
daily requirements 268
overload, transfusion reaction 262
supplementation 268
tongue staining 1825
- iron chelation, β thalassaemia 271–2
- iron-deficiency anaemia (IDA) 268, 268 *T*
- irritant-induced rhinitis 1383
- Isaacs Report (2003) 574
- isobaric gas counterdiffusion 3512–3
- isomasking curves, tinnitus 3612
- isoniazid
hepatotoxicity 236
nasal tuberculosis 1460
- isoprenaline 1365
- isoretinoxin 2609
- isosorbide dinitrate 1289
- Isshiki thyroplasty type I 2097
- isthmus nasi 1589
- Itard, Jean-Marie Gaspard 3607, 3615–6
- itraconazole 233–4
candidiasis 224
entomophthoramycosis 215
fungal rhinosinusitis 218
histoplasmosis 225
mycotic laryngitis 2254
paracoccidioidomycosis 225
- IUDR 50
- Jackson, Chevalier 771–2, 772 *F*
- Jackson's syndrome 2080 *T*, 3938
- Jacobson's nerve (tympanic nerve) 1751, 3116, 3527, 3910
- Jacobson's organ (vomeronasal organ) 1316–7, 1321, 1368, 1662, 1819
- Jadad score, randomized controlled trials 650
- Jansen's disease 389
- jaw(s)
lower
blood supply 1798
venous drainage 1799
lower, development 798, 1811–2
receding, airway management 469, 469 *F*
swallowing 1954–5
upper
adjunctive implant techniques 2917
blood supply 1798
- development 1811–2, 1812 *F*
venous drainage 1799
- jaw cysts 1921–41
classification 1921–2, 1923 *T*
enucleation 1922
formation mechanisms 1922
management principles 1922
large cysts 1922
marsupialization 1922
nonodontogenic
fissural (epithelium lined) 1926
pseudo bone cysts (nonepithelium lined) 1926–7
observation 1922
odontogenic *see* odontogenic cysts
- jaw jerk test 3926
- jaw slide 469–70
- jaw tumours 1921–41
benign 1927–31
giant cell lesions 1930–1
malignant 1931–9
mesenchymal 1928–9
metastatic 1939
nonodontogenic 1929–30
odontogenic 1923 *T*, 1927–8
tumour-like lesions 1927–8
see also individual types
- Jehovah's Witnesses
blood transfusion refusal 583, 586
consent issues 601
- jejunal loop procedure, hypopharyngeal cancer 2655
- jelly nystagmus 3922
- jerk nystagmus 3711 *F*, 3712 *F*, 3725
CNS lesions 3712 *F*, 3725
peripheral vestibular lesions 3712 *F*, 3725
- Jervell and Lange-Neilsen syndrome 813 *T*
- jet lag, professional voice 2212
- jet ventilation, endoscopy 1121
- jitter (pitch perturbation) 2165, 2179
- Jobson-Horne probe 3008–9, 3009 *F*
- Jod Basedow phenomenon (effect) 345, 2667
- John Hopkins/University of Miami programme, vestibular exercises 3807, 3807 *T*
- Joint Committee on Continuing Professional Development 556
- Joint Committee on Infant Hearing guidelines 3291
- Joll's triangle 2664, 2664 *F*
- Joseph reduction rhinoplasty 2950
- josithromycin 1471–2

jugular bulb 3909
 anatomy 4027
 disorders 4034
 high 4034
 injury, vestibular schwannoma
 removal 3977–8
 jugular foramen surgery 4038–9
 petrous apex cyst drainage 4050
 jugular bulb diverticulum 4034, 4035 *F*
 4036 *F*
 jugular bulb skeletonization, vestibular schwannoma 3970
 jugular chain 1747
 jugular foramen 3901, 3903 *F*, 3933 *F*
 4026–7, 4027 *F*, 4028 *F*
 jugular foramen lesions 4026–45
 diagnosis 4028–9
 glomus tumours *see* glomus tumours
 history 4028
 imaging 4029
 infectious conditions 4034
 symptoms 4028
 metastatic lesions 4033–4
 nonsurgical management 4041–3
 medical therapy 4042
 radiotherapy 4042–3
 stereotactic radiosurgery 4043
 ‘wait-and-see’ policy 4042
 palliation 4042–3
 pathology 4029–34
 neoplasia 4029–34
 physical examination 4028
 progression 4042
 surgical management 4034–41
 approaches 4039, 4039 *T*
 facial nerve conservation 4037
 internal carotid artery
 management 4039
 postoperative management 4041
 preoperative embolization
 4034–5
 rehabilitation 4041
 sigmoid-jugular complex
 management 4038–9
 transtemporal approach 4035–9,
 4037 *F*
 tumour resection 4039–41
 symptomatology 4027–8
 jugular foramen syndrome 2222–3,
 2528
 jugular lymph nodes 1747
 jugular veins
 external 1750
 internal *see* internal jugular vein
 thyroid cancer 2691

jugulodigastric lymph nodes 1800,
 2713
 jugulo-omohyoid lymph nodes 1800,
 2713
 jugum sphenoidale 4120
 Jun and Fos (ATF)
 protooncogenes 2380
 junctional epithelium, mouth 1795
 junctional scotoma 3915
 jun kinase inhibition 3302
 jurisprudence *see* medical jurisprudence
 Just-Follow-Conversion (JFC) 3271
 justice (ethical principle) 562
 juvenile angiomyxoma 2437–44
 assessment 2438–9
 blood loss 2440
 chemotherapy, preoperative 2441
 classification systems 2123 *T*, 2438–9,
 2439 *T*, 2440 *T*
 complications 2442–3
 nasal crusting 2443
 diagnosis 2124
 embolization 734, 734–5, 2440,
 3954
 epistaxis 1606
 expansion 2124
 familial adenomatous polyposis 2438
 histology 2122
 incidence 2122
 pathogenesis 2437–8
 presentation 2122, 2438
 radiotherapy 2442
 recurrence 2124, 2442–3
 sites of involvement 2122
 surgical resection 2124, 2441–2
 endoscopic endonasal
 technique 2441, 2441 *F*, 2442 *F*
 open approaches 2442
 skull base approach 2442
 treatment 2439–40
 juvenile-onset recurrent respiratory papillomatosis (JORRP) 1174–83
 clinical presentation 1175
 cold steel surgery 1176
 diagnosis 1175–6, 1176 *F*
 epidemiology 1175
 human papilloma virus 1174–5, 1175
 malignant disease 1180
 natural history 1179
 staging 1176
 susceptibility factors 1175
 tracheobronchial disease 1179
 treatment 1176–9
 adjuvant therapy 1177–9
 surgical 1176–7
 juvenile ossifying fibroma 1929–30
 juvenile recurrent parotitis 1904
 Kadish staging, nasal
 malignancy 2425 *F*, 2425 *T*
 Kallmann’s syndrome
 (hypogonadotropic
 hypogonadism) 403, 813 *T*, 1664,
 1670
 kanamycin, auditory nerve fibre tuning
 curves 3199, 3199 *F*
 Kant, Immanuel 583–4, 2943–4
 Kaposi’s sarcoma
 children 1259 *T*
 external ear 240
 larynx 244, 2604
 nasal 241, 1707–8
 neck 246
 oral 243, 243 *F*, 244 *T*, 2013–4
 pharynx 244
 skin lesions 248
 Karapandzic flap, lip
 reconstruction 2546, 2547 *F*
 Kartagener’s syndrome *see* primary
 ciliary dyskinesia (PCD)
 Kawasaki syndrome 1217
 Kay swallowing workstation 2089
 Kearns-Sayre syndrome (KSS) 813 *T*
 keels, laryngeal stenosis 2278
 Keen (intraoral) approach, zygomatic
 complex fractures 1629 *T*, 1630
 keloids 2891–900
 button/pressure therapy 2893
 classification 2891–2
 genetics 2892
 hypertrophic scars *vs.* 2891–2
 laser excision 2893
 medical negligence 3090–1
 molecular biology 2892–5
 radiation therapy 2893–4
 surgery and 2894–5
 recurrence rate 2893
 steroids 2898–9
 intralesional 2893
 surgery 2893
 radiation therapy and 2894–5
 steroids and 2893, 2894 *F*
 treatment 2892–5, 3090
 keratinocytes, wound healing 90–1, 90 *F*
 keratoacanthoma 1704–5, 1704 *F*
 keratoconjunctivitis sicca (dry eye
 syndrome) 3065
 keratocysts 1922
 keratosis
 with cellular atypia 2221

keratosis (*continued*)
 laryngeal 763
 nasal cavity 764

keratosis obturans 3342–5, 3344 *F*
 aetiology 3343, 3343 *T*
 definition 3342
 diagnosis 3343–4
 differential diagnosis 3334 *T*
 epidemiology 3343
 management 3343 *T*, 3344
 natural history/complications 3344
 pathology 3342, 3343 *T*
 primary auditory canal cholesteatoma
 vs. 3343 *T*
 symptoms 3332, 3343 *T*
 types 3343

‘keratosis tympanicum’ 3343

Kernahan and Stark classification, facial clefts 801 *F*, 996, 997 *F*

ketoconazole 233
 allergic rhinitis 1397–8
 candidiasis 224, 2789
 entomophthoramycosis 215
 histoplasmosis 225
 mycotic laryngitis 2254
 paracoccidioidomycosis 225

Ki-67
 hypopharyngeal cancer 2636
 salivary gland tumours 2495

kidney(s)
 antimicrobial-induced toxicity 236
 calcium reabsorption 374, 375
 Wegener’s granulomatosis 1650

Kiesselbach’s area 1572 *F*, 1574

Kiesselbach’s plexus 1328

Kikuchi’s disease (subacute necrotizing lymphadenitis) 1217, 1784–5

killer activating receptors (KAR) 140

killer inhibitory receptors (KIR) 140

Killian, Gustav 771–2

Killian’s dehiscence 1947, 2043, 2046 *F*
 pharyngeal pouch aetiology 2045,
 2045–6

Killian’s infundibulum 1500

Kimmelstiel–Wilson disease 402

King–Kopetsky syndrome (obscure auditory dysfunction) 3273

kinins 1390

kinocilium 3150 *F*, 3153 *F*, 3228, 3229 *F*

Kinyoun stain 3449

Kirschner (K) wires, nasal fracture reduction 1614

Kit oncogene 2384

Klebsiella ozaenae 1383, 1465

Klebsiella pneumoniae 2250

Klebsiella rhinoscleromatis 200
 infectious rhinosinusitis 1381
 respiratory scleroma 1462–3
 rhinoscleroma 2122, 2268

Kleeblattschädel anomaly (clover leaf skull) 1028

Klippel–Feil syndrome 2080

Klippel–Trenaunay–Weber syndrome 1708

Knudson’s ‘two hit’ hypothesis 8

koilocytes, laryngeal 764

Koplik’s spots 1701, 1837

Korsakoff’s psychosis 3775

Krien’s coding, cleft lip and palate 996

KTP laser
 adenoidectomy 1097
 juvenile-onset recurrent respiratory papillomatosis 1177

Kundin gauge 100

Kuttner tumour 1904

Kveim test 1648, 1711

labial gland 1808

labial mucosa 1793

labial veins 1799

labiodental consonants 2166–7, 2167 *T*

labiomandibulotomy
 oral cavity tumours 2566–7, 2566 *F*
 tongue base carcinoma 2554–5

labour, oxytocin 308

labyrinth, vestibular *see* vestibular labyrinth

labyrinthectomy
 ‘chemical’ 3567
 vestibular compensation 3793

labyrinthine fistulae
 active chronic otitis media 3436
 cholesteatoma 3431–2, 3432 *T*
 chronic otitis media 3402–3
 histology 3402–3, 3403 *F*
 management 3437

labyrinthine infarction 3768
 aetiology 3753–4

labyrinthine ischaemia 3768

labyrinthine tears 3507

labyrinthitis
 acute otitis media 923
 acute suppurative otogenic 3692
 bacterial *see* bacterial labyrinthitis
 chronic otitis media 3403–4
 sensorineural hearing loss 3403–4
 serous 3403
 suppurative 923, 3403, 3403 *F*
 viral *see* viral labyrinthitis

labyrinthitis obliterans, imaging 3651

labyrinthitis ossificans, cochlear implants assessment 3651

labyrinths 3897
 lesions, optokinetic nystagmus 3717
 orientation 3209, 3209 *F*

lacrimal bone 1690

lacrimal canal 1341

lacrimal cell 1690

lacrimal drainage system 1690

lacrimal fossa 1690

lacrimal gland prolapse 3049, 3050 *F*

lacrimal nerve 3923

lacrimal notch 1340–1

lacrimal sac 1690

β-lactamase inhibitors 230

lactase, occupational rhinitis 1419

lactation
 oxytocin 308
 prolactin 301, 308
 radioiodine contraindication 348

lactic dehydrogenase (LDH) 1255

Lactobacilli 1816

lactoferrin
 nasal secretions 1360
 saliva 1866

lactulose 2791

lagophthalmos 3048–9, 3049 *F*, 3096
 post-blepharoplasty 3066

LAHSHAL, cleft lip and palate classification 996, 997 *F*

lambdoid synostosis 1026–7
 positional plagioccephaly vs. 1026 *F*

lamina cribrosa 1334–5

lamotrigine 3617

lamuvidine 233
 resistance 235

Langenbeck flap 1006–7, 1007 *F*

Langerhan’s cell histiocytosis (LCH) 1653–4
 clinical features 1653–4
 definition 1653
 histology 1654
 imaging 1654
 temporal bone 4075
 incidence 4075
 prognosis 4075
 radiological appearance 4075
 symptoms 4075
 treatment 1654

Langerhan’s cells 1654, 4075
 allergy 1388–9

Langerhans’ granulomatosis *see* Langerhan’s cell histiocytosis (LCH)

Langer’s lines 2829–30

language development 990–1
 otitis media with effusion 621, 893–4
 stages 990–1, 991 *F*
 ventilation tubes 899

language disorders, children 990–5

lanreotide 4101

lansoprazole
 cancer pain management 2785–6
 gastro-oesophageal reflux 2063
 laryngitis, chronic 2263

Laplace's law 112

large cannula cricothyrotomy, difficult airways 477

large vestibular aqueduct syndrome (LVAS) 851, 3683–5
 associated conditions 3684–5
 children 1046
 Mondini malformation 3684

laryngeal airway resistance, consonant–vowel sequences 2172

laryngeal arteries 317, 2139

laryngeal atresia 1137–8

laryngeal candidiasis 2267
 clinical features 224, 2254, 2267
 immunocompromised patient 2268
 treatment 224, 2267

laryngeal carcinoma
 adenosquamous 2604
 human papilloma virus 209 *T*

laryngeal carcinoma *in situ* 2609, 2609 *F*

laryngeal cartilage trauma 2272

laryngeal chondroma 2600 *T*

laryngeal clefts 1141–2, 1141 *F*
 associated abnormalities 1141
 dysphagia 2030
 gastro-oesophageal reflux 1273
 mortality 1142
 paediatric anaesthesia 520–1
 severity 1141–2
 stridor 1141–2
 suspension microlaryngoscopy 1142
 tracheo-oesophageal fistula 1141
 treatment approaches 1142

laryngeal cysts 1136–7
 paediatric anaesthesia 520

laryngeal diphtheria 1130, 2252–3

laryngeal disorders
 androgenic drug-induced 2201
 drug therapy 446–54
 inflammatory 2196
 symptoms 2196
 special needs children 787
see also individual diseases/disorders

laryngeal dysplasia 763–4
 laryngeal framework surgery 2241–3, 2245 *T*
 arytenoid fixation 2242–3
 cartilage suture 2242–3, 2243 *F*
 cricothyroid subluxation 2242–3
 developments 2242–3
 materials 2241–2
 patient selection 2241
 prosthesis 2241–2, 2242 *F*
 techniques 2241–2
 thyroid cartilage window 2241–2, 2242 *F*
 voice disorders 2196

laryngeal infections, acute 2248–57
 children 1127–34
 airway management 1132–3
 clinical features 2248–9
see also individual infections

laryngeal inlet, swallowing 1955, 1957

laryngeal keel 1160

laryngeal keratosis 763

laryngeal leiomyoma 2600 *T*

laryngeal leiomyosarcoma 2604

laryngeal leukoplakia 763, 2218

laryngeal lymphoma 2602

laryngeal mask (LM)
 difficult airways 475–6, 475 *T*
 endoscopy 1121
 intubation via 475–6
 professional voice surgery 2213

laryngeal mask airway (LMA) 492, 492 *F*
 paediatric anaesthesia 510, 510 *T*, 511 *F*
 tonsillectomy 515

laryngeal mechanoreceptors 2156–8, 2159
 articular 2158
 myotatic 2158
 subglottic mucosal 2156

laryngeal microdebrider 2278

laryngeal nerve(s)
 external 3935
 inferior 1949–50, 3935
 internal 1803
 nonrecurrent 318
 recurrent *see recurrent laryngeal nerve (RLN)*
 superior *see superior laryngeal nerve (SLN)*

laryngeal papilloma/
 papillomatosis 2221, 2599, 2600 *T*
 children 1170

contact endoscopy 764
 human papilloma virus 209 *T*

laryngeal polyps 2265–6
see also vocal fold polyps

laryngeal prominence 2132

laryngeal reconstruction, children *see laryngotracheal reconstruction, children*

laryngeal sarcomatoid carcinoma 2604

laryngeal skeletal injuries 2272

laryngeal squamous cell carcinoma
 Department of Veterans Affairs Cooperative studies 2611
 tobacco implications 2351–2

laryngeal stenosis 2271–85
 assessment 2279
 children 1150–66
 anatomical considerations 1151
 aspiration evaluation 1154
 evaluation 1151–5
 examination 1151
 gastrointestinal evaluation 1154
 history taking 1151
 imaging 1151–2
 presurgical considerations 1155
 treatment 1155–64
 chronic 2276–83
 aetiology 2276, 2277 *T*
 classification 2281–3, 2281 *T*
 pathological considerations 2277
 treatment 2277–81, 2281 *T*
 classification 1152, 1153 *T*, 2281–3
 eosinophilic oesophagitis 1156
 examination 2279
 gastro-oesophageal reflux 1154, 1155
 imaging 2279–80
 investigations 2279–81
 paracoccidioidomycosis 225
 post-intubation 2293–4
 scar tissue formation 2277
 treatment
 children 1155–64
laryngeal reconstruction see laryngotracheal reconstruction
 medical 1155–6, 2278
 resection techniques 2277–8
 tracheotomy 1156, 1159

laryngeal stents
 laryngeal stenosis 2278–9
 laryngeal trauma 2275
see also individual types

laryngeal surgery 2234
 paediatric intensive care 546–7
 voice-related *see phonosurgery*

laryngeal trauma 2271–85
 assessment 2272–3
 classification 2271, 2274 *T*
 epidemiology 2271
 examination 2273
 follow-up 2275–6
 fracture repair 2275, 2275 *F*
 gender and 2271
 glottic competence 2272
 impact velocity 2271
 high 2272
 low 2272
 incidence 2271
 injury biomechanics 2271–2
 intubation 2289
 investigations 2273
 medical management 2273–4
 open operative intervention 2275
 paediatric intensive care 544
 pathological consequences 2272
 prognostic indicators 2273
 stents 2275
 surgical management 2274–6
 treatment principles 2272–3, 2273
 laryngeal tumours 2598–622
 age 2348
 benign 2599
 uncommon 2599, 2600 *T*
 biopsy 2608
 clinical guidelines 2603–7
 clinical presentations 2608–9
 combined chemotherapy and
 radiotherapy 52
 contact endoscopy 764, 765
 diagnosis 2603–9
 diagnostic delays 2603
 endoscopic resection 2612, 2612 *F*,
 2613 *F*
 endoscopy 2608
 FDG-PET imaging 688 *F*, 690 *F*
 follow-up 2618
 gastro-oesophageal reflux disease 663,
 664 *T*
 gender 2218, 2348
 incidence 2348
 malignant 2600–3
 uncommon 2602–3, 2604
 mucosal melanoma 2407
 neck management 2615–7
 open surgical tracheostomy 2295–6
 pathology 2599–603, 2612 *F*
 quality of life issues 650, 2772, 2775,
 2777
 radical neck dissection 2743
 radiology 2607–8

rehabilitation 2598, 2617–8
 post-treatment, early stage
 disease 2617–8
 pretreatment planning 2617
 risk factors 2348, 2349 *T*, 2603
 occupation 2348
 salivary gland type 2600 *T*, 2604
 spread 2601–2, 2602 *T*
 stage N0 neck treatment 2615–7,
 2724
 stage T3/T4
 chemotherapy 2611–2
 choice of treatment 2610–2
 operative treatment 2610–1,
 2614 *F*
 quality of life studies 2611
 radiotherapy 2611
 staging 2603–7
 surgery 2612–5
 voice preserving 2614
 TNM classification 2366, 2366 *T*
 upper respiratory tract
 management 2151
 viral implications 2348
 voice rehabilitation, postoperative *see*
 voice rehabilitation, post-
 laryngectomy
 see also individual tumours
 laryngeal ulcers, syphilis 2267
 laryngeal veins 2140
 laryngeal ventricle 2134
 laryngeal vestibule 803–5
 laryngeal voice 2228 *T*
 laryngeal webs
 anterior glottic *see* anterior glottic
 webs
 congenital 1137, 1138 *F*
 speech therapy 2222
 laryngectomy 2615, 2616
 airway during surgery 505
 anaesthesia 504–5
 dysphagia 2086
 intractable aspiration 2099
 laryngeal tumours 2615, 2616
 narrow field 2099, 2099 *F*
 preoperative patient state 505
 prophylactic antibiotics 448
 quality of life issues 2630, 2771
 rehabilitation 2623–32, 2618, 2618 *F*
 aims 2623–4
 body image issues 2624, 2630
 psychosocial 2630
 swallowing problems 2627–8
 voice *see* voice rehabilitation, post-
 laryngectomy

tracheal intubation 505
 see also specific techniques
 laryngismus stridulus 1129
 laryngitis
 ‘acid’ 2262
 acute 2249, 2249 *F*
 aetiology 2219
 bacterial superinfection 2249
 causes 2249
 clinical features 2249, 2249 *F*
 examination 2249
 management 2249
 pathophysiology 2249
 professional voice 2249
 residual dysfunction 2249
 speech therapy 2219
 chronic *see* laryngitis, chronic
 contact endoscopy 763
 definition 2196
 diagnosis 2196
 mycotic *see* mycotic laryngitis
 spasmodic 1129
 symptoms 2196
 treatment 2196
 laryngitis, chronic 2258–70
 24 hour pH monitoring
 2263
 aetiology 2258–9
 allergy 2258–9
 assessment 2259–61
 biopsies 2260
 operative 2260–1
 outpatients 2259–60
 bacterial infection 2258–9
 clinical presentation 2259
 definition 2258–9
 diagnostic inaccuracy 2260
 gastro-oesophageal reflux 2258–9,
 2262
 lifestyle modifications 2263
 pathophysiology 2262
 treatment 2262, 2264 *F*
 voice therapy 2263
 grading systems 2260, 2260 *T*, 2261–2,
 2262 *T*
 Helicobacter pylori 2262–3
 histological features 2261–2
 immunocompromised 2268
 inflammatory process 2258
 intralaryngeal abnormalities
 2259–60
 malignant transformation 2261–2,
 2264
 microlaryngeal specimen
 processing 2261, 2261 *F*

- nonspecific 2262–4
 aetiology 2262
 symptoms 2262
 treatment 2262
 occupational exposures 2258–9
 oesophagitis 2263
 proton pump inhibitors 2263
 radiation-induced 2268
 treatment 2268
 smoking 2258–9, 2268
 smoking cessation 2264
 speech therapy 2219, 2263
 symptoms 2219, 2259
 treatment algorithm 2264 *F*
laryngocoeles 1136–7
 classification 1136–7
 diagnosis 1137
 ultrasound 724
laryngofissure, posterior glottic
 stenosis 1161
laryngomalacia 1135–6, 1136 *F*
 cor pulmonale 1136
 diagnosis 1136
 dysphagia 2030
 gastro-oesophageal reflux 1273
 paediatric anaesthesia 520
 stridor 1116, 1135
 treatment 1136
laryngopathia premenstrualis 2212–3
laryngopharyngeal reflux (LPR)
 globus 2038–9
 laryngeal carcinogenesis 2348, 2354
 upper GI diseases 2263
 voice disorders 2219
laryngopharynx, in swallowing 1958
laryngoplasty
 intractable aspiration 2099–100,
 2101 *F*
 medialization 2242 *T*
laryngopycoele 2255–6
 clinical features 2255, 2255 *F*, 2256 *F*
 definition 2255
 investigation 2255
 management 2256
 surgery 2256, 2256 *F*
 Valsalva manoeuvre 2255, 2255 *F*
laryngoscopy 2146
 anaesthesia 503
 blade designs 473
 child's voice assessment 1169
 difficult direct 468, 471, 472
 endoscopic 2146
 contact 2150
 difficult airway 2150–1
 flexible 2146–8, 2147 *F*
 rigid 2149–50, 2149 *F*, 2150 *F*
 ultrasonography 2150
indirect 2146
operative 2148–9
 anaesthetic considerations 2148–9
 paediatric anaesthesia 511
laryngospasm, fibreoptic endoscopic
 evaluation of swallowing 1970
laryngostroboscopy 2172
laryngotomy, posterior glottic
 stenosis 1161
laryngotracheal reconstruction,
 children 1156–9
 aims 1154–5
 anaesthesia 521
 complications 1165
 contraindications 1165
 cricothoracal resection 1163–4,
 1163 *F*
 decannulation problems 1154–5
 extubation 1159
 grafts 1163
 anterior cartilage 1162, 1163
 expansion cartilage 1157 *F*
 materials 1156–7
 posterior cartilage 1163
laryngeal webs 1137
 presurgical considerations 1155
 revision surgery 1165
 single-stage 1158–9
 stents 1157–8, 1158 *F*
laryngotracheal separation, intractable
 aspiration 2102–3, 2102 *F*
laryngotracheal stenosis
 paediatric anaesthesia 521
 post-intubation 2293–4
laryngotracheobronchitis (LTB) see
 croup
laryngotracheobronchoscopy
 (LTB) 1120, 1121 *F*
laryngotracheoesophageal clefts 1141–2
laryngo-tracheo-oesophageal clefts,
 gastro-oesophageal reflux 1273
larynx 2130–44
 anatomy 1135–42, 2131–40, 2132 *F*
 adult *vs.* child 1167, 1168 *F*, 1168 *T*,
 2131–2
 children 1151
 sites/subsites 2366
 arterial supply 2137 *F*, 2139
 assessment, post-anaesthesia 1123
 congenital disorders 1135–42
 contact endoscopy 763–4
 abnormal appearance 763–4, 765
 normal appearance 763
' descent' 2045
 divisions 2132, 2132 *F*
 effort closure 2159
 'electric' 2624–5
 embryology 803–5, 1167–8, 2130–1,
 2131 *F*
 evolution 2130
 examination, mirror use 2193
 foreign bodies, children 546, 1188
 framework 2132–3
 functions 2159–61, 2217
 fungal infections *see* mycotic laryngitis
 growth 1167–8, 2131–2
 HIV associated lesions 243–4
 infantile 2131–2
 innervation 2137 *F*, 2139, 2155–9,
 2157 *F*
 Kaposi's sarcoma 244
 ligaments 2133–4
 extrinsic 2132 *F*, 2133–4
 intrinsic 2134
 lymphatic drainage 2140, 2713–4
 medical negligence issues 2808
 membranes 2133–4
 mucous membranes 2137–8
 muscles 2134
 extrinsic 2134, 2135 *T*, 2159
 intrinsic 2134, 2136 *T*, 2137 *F*,
 2138 *F*, 2159
 neoplastic lesions 2197–203
 paediatric consultation 778–9
 physiology 2155–63
 pseudocysts 2199
 relations 2139 *F*
 rheumatological diseases 184
 sound production 2217
 spaces around 1950
 spaces within 2138
 structural lesions 2197–203
 diagnosis 2198 *T*
 swallowing 1955, 1957, 2159
 topical anaesthesia, airway endoscopy
 procedures 518
 tuberculosis 2266, 2267 *F*
 ultrasound imaging 1297, 2150
 vasculature 2139–40
 venous drainage 2140
 visual assessment
 mirror use 2193
 voice evaluation 2171, 2181
 Wegener's granulomatosis 1651
laser(s) 743
 dacryocystorhinostomy 1692 *T*,
 1693 *F*, 1694, 1694 *F*
 solid state 743

- laser-assisted uvulopalatoplasty 2330
 postoperative care 2332
 success rate 2332–3
- laser capture microdissection (LCM) 7–8
- laser scanning, image guided surgery 706, 707 *F*
- laser skin resurfacing
 medical negligence 3096
 postoperative infection 3096
- laser stapedotomy minus prosthesis (STAMP) procedure 3472
- laser supraglottoplasty, obstructive sleep apnoea 1109, 1110 *F*
- laser surgery
 airway management 494
 children 519–21, 520 *F*
 anaesthesia 503–5
 keloids 2893
 vocal folds 2236
- laser therapy 742–7
 applications 745
 delivery devices 743–5, 744 *F*
 articulated arm 743
 fibreoptic fibre 744
 micromanipulators 744
 robotized scanners 745
 sharp tip 744
see also individual devices
- history 742
- laser–tissue interaction 745
- output patterns 743
 ‘active laser medium’ 743
 continuous wave 743
 pulsed 743
 Q-switch 743
- photoablative reactions 743
- photodynamic therapy *see* photodynamic therapy
 principles 742–3
 safety 745
 skin flap 115
 tissue interaction 743
- laser tonsillectomy 1235, 1991, 1992
- laser vapourization
 arytenoid granuloma 2197
 glottic cancer 2610, 2610 *F*
- Lashley cups, saliva collection 1862–3, 1863 *F*
- latent interval 2344
- latent nystagmus 3711
- lateral arm flap 2872
 advantages 2872
 anatomy 2873 *F*
 clinical applications 2872
- disadvantages 2872
 technical nuances 2872
- lateral bone cyst 1927, 1927 *F*
- lateral bulge (torus lateralis) *see* nose, lateral wall
- lateral canthal angle 3048
- lateral canthal tightening suture 3060, 3061 *F*
- lateral canthotomy, orbital haemorrhage 3065
- lateral canthus rounding 3065
- lateral cervical cysts *see* branchial cysts
- lateral cricoarytenoid 2136 *T*
- lateral crural onlay graft 3010, 3010 *F*, 3012 *F*
- lateral crural spanning graft 3009 *F*, 3010, 3010 *F*
- lateral crural steal, underprojected nasal tip 3003
- lateral crus
 anatomy 2996
 collapse 3011 *F*
 nasal tip surgery 2964
 tripod mechanism 2996, 2997 *F*
- lateral efferent system 3145
- lateral flap pharyngoplasty 1012 *F*
- lateral gaze centres, pons 3921
- lateral lemniscus 3142
- lateral ligament of the thyroid (suspensory ligament of Berry) 316–7
- lateral medullary swallowing centre 1959
- lateral nasal process 1811
- lateral neck swellings, children 1211
- lateral neck triangle 1743
- lateral olfactory striae 3912–3
- lateral olfactory nucleus 3141–2, 3141 *F*
- lateral olivocochlear system 3200
 function testing 3200
- lateral osteotomy 2955–6, 2956 *F*
- lateral periodontal cyst 1925
- lateral pharyngeal space *see* parapharyngeal space (PPS)
- lateral pterygoid muscle 1339, 1809–10, 2112–3, 3905, 3907 *F*
- lateral pterygoid plate 2111, 3900
- lateral rectus 3221
- lateral rhinotomy
 nasal malignancy 2428, 2428 *F*
 nasopharyngeal carcinoma 2462
- lateral skull base 3899–909
 arteries 3902 *F*
 articular area 3905
 auditory area 3904–5
- infratemporal fossa *see* infratemporal fossa
- muscles
 deep 3904, 3904 *F*
 superficial 3907 *F*
 superficial to 3907 *F*, 3910
 nerves 3903 *F*
 neurovascular area 3898 *F*, 3901–4
 pharyngeal area 3900–1
 subdivision 3898 *F*, 3900–9
 surgical approach 3910
 tubal area 3898 *F*, 3901
 veins 3902 *F*
- lateral superior olive 3138 *F*, 3145
- lateral utility incision 2732 *F*
- lateral venous sinus thrombophlebitis, chronic otitis media 3437–8
- lateral venous sinus thrombosis, chronic otitis media 3437–8
 management 3438
- lateral vestibular nuclei (LVN) 3220
- lateral vestibular tract 3227
- latex allergy 1419
 patient preparation, surgery 464–5
 latissimus dorsi flaps 2858–61, 2859 *F*, 2860 *F*, 2862 *F*, 2863 *F*
- laxatives 2791
- lazy ‘S’ incision, superficial
- parotidectomy 2478 *F*, 2484–5
- lead poisoning 269
- ‘leak test’ 1132
- leeches 115
- Lee Silverman Voice Program 2225
- Le Fort 1 fractures 1625, 1626 *F*
 management 1627
- Le Fort 1 osteotomy, nasopharyngeal carcinoma 2463
- Le Fort 2 fractures 1625, 1626 *F*
 external fixation 1627, 1627 *F*
- Le Fort 3 fractures 1625, 1626 *F*
- Le Fort 3 osteotomy, syndromic craniosynostosis 1029
- left anterior-right posterior (LARP) plane 3209
 eye movements 3217 *F*
- left main bronchus 2140 *F*, 2141
- leg ulcers 97–8
 arterial 98, 102
 venous 97, 102
- leg weakness assessment 3732
- leiomyoma
 hypopharyngeal 2635
 laryngeal 2600 *T*
- leiomyosarcoma, laryngeal 2604
- leishmaniasis 1703–4

- Lemierre's syndrome 1214, 1223–4, 1224 *F*, 2002
- lentigo maligna 2400 *F*, 2401 *T*
- lentigo melanoma 1707
- lentivirus gene therapy
- cystic fibrosis 25
 - head and neck cancer 27
- Leonard button 1622, 1622 *F*
- lepromatous leprosy, nasal 1464, 1703
- leprosy 1463–4, 2010
- disease parameters 1463–4
 - epidemiology 1463
 - laryngeal 2267
 - nasal 1463–4
 - clinical features 1464
 - diagnosis 1464
 - treatment 1464
 - pharyngeal 2010
 - transmission 1464
 - treatment 1464
- Leser–Trelat sign 1709
- lesser cornua, hyoid bone 2132
- lesser palatine artery 1799
- lesser palatine nerve 1801
- lesser petrosal nerve 3933–4
- superficial 3908
- Lester–Jones tube insertion 1696
- Lethal discs large* 68
- Lethal giant larvae* 68
- Letterer–Siwe disease *see* Langerhan's cell histiocytosis (LCH)
- leukaemia(s)
- acute 274–5
 - pharyngeal symptoms 2015
 - chronic 275
 - dysphagia 2033
 - vestibular labyrinth 3686, 3687 *F*
 - see also individual types*
- leukaemia-inhibitory factor (LIF) 73
- leukaemoid reaction 273
- leukocyte(s)
- digestive 139–40
 - inflammatory 139–40
 - mycobacterial defects 177 *T*, 178
 - nasal mucus 1362
- leukocyte adhesion defects
- (LAD) 177 *T*, 178
- leukoerythroblastic blood film 273
- leukophaenias, mouth ulcers 1834
- leukoplakia
- epithelial dysplasia 2221
 - gingival white patches 1820
 - laryngeal
- contact endoscopy 763
- prevalence, gender effects 2218
- oral cavity tumours 2551, 2551 *F*
- leukotriene receptor antagonists (LTRAs), rhinosinusitis 1083
- leukotrienes, allergic response 1390
- Levant frame 1627, 1627 *F*
- levator aponeurosis 3050, 3051 *F*
- levator labii superioris alaequeae naso 1324
- 'levator of the thyroid gland' 316
- levator palatini muscle 1007–8, 1009 *F*, 1946 *T*, 2112, 3909
- Eustachian tube 3118
 - soft palate repair 1009
- levocetirizine 1397–8, 1402
- levodopa 2078
- levomepromazine, palliative care
- patients
 - acute confusional states 2798
 - anxiety 2795
 - nausea and vomiting 2788
- levothyroxine sodium (thyroxine sodium, Eltroxin) 450
- liberatory manoeuvres
- benign paroxysmal positional vertigo 3814
 - contraindications 3814
- lichen planus (LP), oral 1836, 1836 *F*
- lidocaine
- airway endoscopy 518
 - endoscopic sinus surgery 1482
 - nasal vasculature, effects on 1365
 - ototoxicity 3677
 - reduction rhinoplasty 2952
 - side effects 3618
 - sprays 448
 - supraglottic obstruction 480, 481 *F*
 - tinnitus 3602, 3603 *F*, 3609, 3618
- lifestyle modifications
- migrainous vertigo 3800–1
 - voice disorders 2195
- ligation, DNA fragments 5
- 'light amplification' 742
- lighted stylets, intubation 475
- light endoscopy 755
- light microscopy, apoptosis 60
- lignocaine *see* lidocaine
- likelihood ratios 656, 657
- nomograms 657, 657 *F*
- Likert scale 636
- Glasgow Benefit Inventory 639
- Limberg flap 2841 *F*
- limen nasi 1325
- Lindsay–Hemenway syndrome 3699–700
- linea alba 1792–3
- linear acceleration tests 3737–42
- devices 3737, 3738 *F*, 3739 *F*
 - otolith testing 3737
- linear predictive coding (LPC) 2180
- linear vertigo 3706–7
- linear vestibuloocular reflex (IVOR) 3213
- lingual artery 1797 *F*, 1799
- lingual erythema migrans 1825–6, 1826 *F*
- lingual frenum 1793
- lingual glands 1808
- parasympathetic innervation 1801 *F*, 1803
- lingual mandibular salivary gland defect 1927, 1927 *F*
- lingual nerve 1795 *F*, 1796 *F*, 1797 *F*, 1801, 1801 *F*, 1802–3, 3907–8, 3925
- lingual nerve injury
- salivary gland tumour surgery 2515
 - submandibular gland tumours 2488
- lingual pressure recording, dysphagia 1977
- lingual thyroid 314–5, 1268–9, 1824
- carcinoma 2579
 - imaging 1824
 - investigation 1269, 1269 *F*
 - presentation 1269, 1269 *F*
 - symptoms 1824
 - treatment 1269
- lingual tonsil 1794
- linguistic skills, speech audiometry and 3273
- lingula 298
- lingular bronchus 2141
- lining mucosa, mouth 1795
- linkage analysis 11
- cleft lip and palate 999–1000, 1000 *T*
 - late-onset hearing loss 17
 - neurofibromatosis 2 3998–9
- liothyronine sodium (Tertroxin) 450
- lip(s) 1793
- blood supply 1798
 - cancer *see* lip cancer
 - development 1811–2, 1812 *F*
 - anomalies 1811–2
 - lymphatic drainage 1799
 - mucous membrane 1793
 - muscles 1798
 - sensory innervation 1800–1

- lip(s) (*continued*)
 swallowing 1954–5
 venous drainage 1799
- lip cancer 2543–9
 clinical characteristics 2543–4
 distribution 2544 *F*
 epidemiology 2543
 investigations 2544
 occurrence 2550 *T*
 survival rates 2549, 2549 *T*
 TNM staging 2364, 2364 *T*, 2544,
 2544 *T*
 treatment 2544–9
 choice of 2544
 defect repair 2544
 lower lip *see* lower lip
 reconstruction
 neck dissection 2548
 upper lip 2547–8
 tumour types 2543
- lipids, nasal secretions 1360
- lipodermal grafts, facial
 reanimation 3083–4
- α -lipoic acid 3302
- lipoma(s)
 clinical presentation 4013
 CPA tumours 4012–3
 definition 4012–3
 diagnosis 4013, 4013 *F*
 epidemiology 4013
 laryngeal 2600 *T*
 malignant transformation 4013
 pathology 4012–3
 treatment 4013
 ultrasound 725, 725 *F*
- lipoproteins 323
- liposarcoma, larynx 2604
- liposomes, cystic fibrosis gene
 therapy 25
- liposuction, rhytidectomy 3073–4,
 3094
- lip repair, cleft lip and palate 1003
- lip shave and mucosal
 advancement 2544–5
- liquid lasers 743
- listening, medical consultation 564
- lithium, as goitrogen 2668
- lithotripsy, sialolithiasis 1905
- Little's area 1599–600
- liver, antimicrobial-induced toxicity 236
- liver disease
 fresh frozen plasma 258
 haemostatic disorders 282
 treatment 282
- liver failure, drug prescribing 416
- Ljubljana classification, laryngeal
 lesions 2261–2
- lobules, salivary glands 1852
- local anaesthesia
 nasal fractures 1612–3
 nasal vasculature, effects on 1365
 sprays 448
 vocal fold injection 2240
- local flaps
 advancement 2832
 head and neck surgery 2827–46,
 2831 *F*
 planning considerations 2828–46
- Local Involvement Networks
 (LINKs) 574
- local research ethics committees
 (LRECs) 588–9
- local sialogogues, saliva collection 1862
- 'locus of control,' head and neck
 cancer 2770
- LOD score 11
- Loefflerella mallei* 1381
- lofepramine 2796
- loft register (falsetto) 2161, 2162 *T*
- logatoms, speech audiometry 3269,
 3272
- Lombard effect 2212
- longitudinal muscles, tongue
 inferior 1798
 superior 1798
- long stay ventilation tubes *see* T-tubes
- long-term average spectrum
 (LTAS) 2180, 3270–1
- longus capitis 1746, 2112
- longus capitis anterior 1746
- longus capitis lateralis 1746
- longus colli 1746
- loop diuretics, ototoxicity 3568 *T*,
 3569–70, 3571, 3677
- lop ears 972, 972 *F*
- loratadine
 allergic rhinitis 1399
 chronic rhinosinusitis 1472
- lorazepam
 acute confusional states 2798
 anxiety 2795
 vertigo 3795–6
- loss of heterozygosity (LOH) 8–9,
 9 *F*
- loudness
 bandwidth increases 3251–2
 calculation 3251
 scaling 3251
 units 3251
 voice perception 2174
- loudness discomfort levels (LDL)
 hyperacusis 3596
 noise-induced hearing loss 3553
- loudness perception 3250–2
 absolute threshold 3250, 3251 *F*
 cochlear hearing loss 3256
 equal-loudness contours 3250–1,
 3251 *F*
 frequency selectivity 3251–2
- loudness recruitment
 cochlear hearing loss 3256
 hearing aids 3256
- loud noise discomfort, post-stapes
 surgery 3477
- low dose unfractionated heparin
 (LDUH) 463
- low energy helium-neon laser
 irradiation, skin flaps 115
- Löwenstein–Jensen media 1459–60
- lower eyelid
 anatomy 3051–3, 3052 *F*
see also blepharoplasty
 fat compartments 3051–2, 3053 *F*
 fat herniation 3055
 retractors 3053 *F*
 skin crease 3051
 unilateral facial palsy 3079
- lower jaw *see* jaw(s)
- lower jugular lymph nodes 1747
- lower lip depressor weakness 3084 *F*
 botulinum toxin injections 3084
 correction 3084
 treatment 3084–5
- lower lip reconstruction 2545–7,
 2545 *F*
Abbe-Estlander flap 2545–6,
 2546 *F*
- defect involving less than one
 third 2545
- defect involving more than
 two-thirds 2546–7
- defect involving one-to-two
 thirds 2545–6
- Karapandzic flap 2546, 2547 *F*
- lower lobe bronchus
 left 2141
 right 2141
- lower oesophageal sphincter, gastro-
 oesophageal reflux 2062
- lower respiratory tract, relationship
 with upper tract 1560–8
- epidemiological evidence 1560–1
- low molecular weight compounds
 (LMWC), allergic occupational
 rhinitis 145, 1416, 1417 *T*

- low molecular weight heparin (LMWH)
deep vein thrombosis 288
prophylaxis 447
mechanism of action 282
pulmonary embolism 288
venous thromboembolism
prophylaxis 463
low (residue) pitch 3252–3
low tidal volume ventilation, critical care patients 535
lozenges 448
Ludwig's angina 1807, 1902
lumbar drainage
jugular foramen tumour
resection 4041
nasopharynx surgery 4056
lumbar puncture, fluorescein *see* fluorescein lumbar puncture
Lund and Mackay staging system, rhinosinusitis 1490 *T*
radiologic staging 1489 *T*
surgery score 1490 *T*
lung(s)
development 2131
hilum 2144, 2144 *F*
innervation 2142
pharyngeal pouch-related complications 2044
Wegener's granulomatosis 1650
lung buds 2131
lung cancer, pituitary involvement 4104
lung hyperinflation, bronchial obstruction 1188, 1190 *F*
lupus anticoagulant 290
lupus erythematosus 1711–2
discoid 1711, 1711–2
dsDNA antibodies 170
oral manifestations 1836
systemic *see* systemic lupus erythematosus (SLE)
lupus pernio 1645, 1647 *F*, 1648 *F*, 1710, 1710 *F*
see also sarcoidosis
lupus vulgaris
basal cell carcinoma *vs.* 1703
nasal 1458–9, 1459 *F*, 1702–3, 1702 *F*
squamous cell carcinoma *vs.* 1703
Lushka's tonsil *see* adenoid
luteinizing hormone (LH) 301–2
circulating levels 301–2
effects 302
secretion 297, 302
structure 302
women 302
Lyell's disease 1700
Lyme disease 1056, 3891
lymphadenopathy
cervical *see* cervical lymphadenopathy
HIV *see* HIV lymphadenopathy
rheumatological diseases 185
ultrasound examination 715, 716 *F*
lymphangioma(s) 1137, 1269–71, 1782–3
embryology 1269
macrocystic lesions *see* cystic hygroma management 1782–3
microcystic disease 1137, 1269, 1270
oral 1824
presentation 1782
ultrasound examination 726
lymph node(s)
cervical *see* cervical lymphatics
cystic transformation 1781
ultrasound examination 717, 717 *F*, 718 *F*, 724
enlargement *see* lymphadenopathy
neck *see* cervical lymphatics
surgical identification 371 *T*
lymphocyte(s)
activation 133–4
development 133
nasal polyposis 1552
lymphocyte phenotyping 168
lymphocyte proliferation test 168–9
lymphocytic carcinoma, larynx 2604
lymphocytosis 274, 274 *T*
lymphoepithelial carcinoma, larynx 2604
lymphoepithelial cyst 245–6, 245 *F*, 1914
lymphoepithelioma, oropharyngeal 2580
lymphoma(s)
B cell *see* B cell lymphoma
Burkitt's 208, 1254
children 1254
CPA involvement 4015
cranial nerve neuropathies 2080
dysphagia aetiology 2033
FDG-PET imaging 694, 694 *F*
Hodgkin's *see* Hodgkin's lymphoma
non-Hodgkin's *see* non-Hodgkin's lymphoma (NHL)
olfactory dysfunction 1668–9
reticuloendothelial 275
salivary glands 2501, 2503
thyroid *see* thyroid lymphoma
T/NK cell *see* T/NK cell lymphoma
tonsils 1226
ultrasound 1759–60
vestibular labyrinth 3687
lymphopenia 274
lymphoproliferative disease 172
immunoglobulin level analysis 172
paraprotein levels 172
phenotyping 172
lymphoscintigraphy, oral cancer 2565
Lynch–Howarth frontoethmoidectomy medical negligence 1733
mucocoeles 1535
orbital cellulitis 1544–5
lysine aspirin 1473
lysogenic bacteriophage 198–9
lysozyme nasal secretions 1360
saliva 1866
Sjögren syndrome 1865
Mabthera (ritiximab) 44
MacEwens triangle 3119
'machinery oil cysts' 4103
Macintosh curved blade 473
MacNaughton Jones, Henry 3594
macrocytic anaemias 268 *T*, 269
macroglossia 1828
macrolide antibiotics 231
activity spectrum 231
mechanism of action 1471–2, 1472 *T*
side effects 231
macrophage(s)
nasal mucus 1362
wound healing 89–90
macrophage-colony stimulating factor (M-CSF) 69
macrostomia 1811–2
macrotia 972–3, 974 *F*
macular hair cells 3150 *F*, 3228–30,
3230 *F*
macula sacculi 3151–2, 3152 *F*
macula utriculi 3151–2, 3152 *F*
macule 1699–700
Maffucci's syndrome 1708
magnesium biochemical analysis 381, 381 *T*
parathyroid function and 379
see also hypomagnesaemia;
hypomagnesaemia
magnesium-ATP, skin flap survival 113
magnetic-activated cell sorter (MACS) 73–4
magnetically retained prosthesis, orbital 2936, 2936 *F*
'magnetic feet' 3731

magnetic resonance angiography (MRA)
children 1299
glomus temporale tumour 4032
jugular foramen glomus
tumours 4029
skull base lesions 3947
thyroid cancer 2691
magnetic resonance imaging (MRI)
adenohypophysis 305
arachnoid cysts 4013, 4014 *F*
cavernous sinuses 306
cerebrospinal fluid rhinorrhoea 1638
cervical lymph node
assessment 1761–2
children 1298–9, 1299 *F*, 1302 *F*
cholesteatoma 3432
chronic otitis media 3419
cochlear implants assessment 3651
contrast, forms of 676 *F*
craniopharyngioma 4103–4
Cushing's disease 4102
cystic hygroma 1298, 1299 *F*, 1782–3
dysphagia 1967–8, 2028
epidermoids 4011, 4012 *F*
facial nerve 3881, 3883 *F*
facial nerve schwannomas 4014
facial paralysis, children 1055
frontal sinus 1502
fungal rhinosinusitis 218
acute fulminant 1455
invasive 1454 *F*
glomus temporale tumour 4032
hyperparathyroidism 392
hypopharyngeal cancer 2643–4
hypothyroidism 336
infundibulum, pituitary gland 305
intralabyrinthine schwannoma 3685
inverted papilloma 1503 *F*, 1523
jugular foramen lesions 4029, 4031 *F*
4042
juvenile angiofibroma 2438–9, 2439 *F*
large vestibular aqueduct
syndrome 3683–4, 3684 *F*
laryngeal trauma 2273
laryngeal tumours 2607, 2607 *F*
laryngopyocoele 2255
lipomas 4013, 4013 *F*
meningiomas 736, 4009–10, 4009 *F*
4010 *F*
mucocoeles 1533–4, 1534 *F*, 1535 *F*
mucosal malignant melanoma 2409
multiple sclerosis 3846, 3847–8,
3847 *F*
'nasal cycle' 1590

nasopharyngeal carcinoma 2456–7,
2457 *F*
nasopharyngeal tuberculosis 2121
neck 1755–6
benign tumours 1782–3
metastatic disease 2721
neurofibromatosis 2 3962, 3963
neurohypophysis 305
nodular thyroid disease 333, 334, 362
objective tinnitus 3601
olfactory dysfunction 1666
open bore scanners 307
optic chiasm 306
oral cavity tumours 2552–3, 2553,
2553 *F*
orbital cellulitis 1542–3
otitis media with effusion 3390
paragangliomas 736–9
parapharyngeal space tumours 2530
parathyroid glands 384
parotid gland pleomorphic
adenoma 1882, 1885 *F*, 1886
petrous apex lesions
chondrosarcoma 4049, 4050 *F*
chordoma 4049
cysts 4048, 4048 *F*, 4049 *F*
pituitary gland 304 *F*, 305–7
pituitary macroadenomas 306
pituitary microadenomas 305, 306
pituitary tumours 305–7
contrast use 306
malignant 4104
nonfunctioning adenomas 4103
T1-weighted images 305
T2-weighted images 305, 306
pleomorphic salivary adenoma
1299 *F*
Rathke's pouch cysts 4103
respiratory scleroma 1463
rhinosinusitis 1442–3, 1480
salivary glands 1875–6
advantages/disadvantages 1874 *T*
children 1886, 1893 *F*, 1894 *F*
contraindications 1876
dental artefacts 1876, 1876 *F*
fat suppression techniques 1875,
1875 *F*
gadolinium contrast 1875, 1875 *F*,
1876 *F*
indications 1890 *T*
salivary gland tumours
benign 1884
extension 1884, 1890
malignant 1884, 1887, 1889 *F*,
1892 *F*, 1895 *F*, 2506–7
sinonasal malignancy 2425–6
skull base lesions 3947
snoring 2328–9
sphenoid sinus 305 *F*, 306
temporal bone tumours 4069,
4090
temporomandibular disorder 3530
thyroid cancer 333, 2677, 2677 *F*,
2678 *F*
thyroid eye disease 344
thyroid gland 328
thyroid stimulating hormone
secreting adenomas 311
tinnitus 3610
trigeminal nerve schwannomas
4014
vestibular neuritis 3752
vestibular schwannomas 1298, 3544,
3687–8, 3959
Wegener's granulomatosis 1652
magnetic resonance proton
spectroscopy, salivary glands 1876
magnetic resonance sialography (MRS)
conventional sialography vs. 1879
indications 1890 *T*
salivary glands 1876
sialolithiasis 1879
magnetic stimulation, tinnitus 3615 *T*,
3618
magnets
foreign body removal 1186
implant retention 2932
magnitude estimation test 3251
magnitude production test 3251
mainstream education, deaf
children 855
major histocompatibility complex
(MHC) 136
antigen presentation 136
class I molecules 136
class II molecules 136, 137
allergic response 149–50
hypopharyngeal cancer 2637
see also human leukocyte antigen
(HLA)
malar augmentation, medical
negligence 3095
malaria 208
malignancy
hyperparathyroidism 401
telomerase activity 10
virus-associated 208–9
see also tumour(s)
malignant fistulae *see* palliative care,
head and neck cancer

- malignant histiocytoma, larynx 2604
 malignant melanoma 2399–402, 2399 *F*
 acral lentiginous 2401 *T*
 CPA lesions 4015
 distant disease 2402
 ear amputation 3028, 3032 *F*
 environmental exposure 2400
 family history 2400
 genetic predisposition 2400
 incidence 2406–7
 laryngeal 2604
 local disease 2401–2
 mucosal *see* mucosal malignant melanoma
 nasal 1706, 1707, 1707 *F*
 parotid metastases 2501–2
 pinna reconstruction 3032 *F*
 prognostic factors 2400
 recurrence 2402
 regional disease 2402
 risk factors 2396 *T*, 2400
 sinonasal 2422
 staging 2401 *T*
 syndromes 2400
 treatment 2401
 types 2400–1
 malignant odontogenic tumours (MOT) 1938
 malignant otitis externa 3336–41
 bacteriology 3337
 clinical features 3334 *T*, 3337–8
 complications 3338
 definition 3336
 diabetes mellitus 402, 3337
 diagnosis 3337–8, 3337 *F*
 differential diagnosis 3334 *T*
 facial nerve paralysis 3890 *F*, 3891
 management 3338–9
 treatment comparisons 3339
 nomenclature 3336
 outcomes 3338
 pathology 3336–7
 predisposing factors 3337
 radiology 3338
 staging 3336, 3337 *T*
 surgery 3339
 malignant teratoma 1259
 malignant wounds, dressings 101
 Maliniak, Jacques 2944
 mallampati 470
 malleostapedotomy 3479–80
 malleus
 anatomy 3114–5, 3115 *F*
 denuded, tuberculous otitis 3447,
 3448 *T*, 3450 *T*
- head fixation, otosclerosis 3474
 lateral process 3114–5
 otoscopic examination 3315–6
 malnutrition
 albumin levels 95
 indicators 95
 rhinosinusitis, paediatric 1082
 wound healing 94
 malodorous wounds 101
 malonyldialdehyde 113
 Maltz, Maxwell 2944
 mammosomatotrophs 297
 mammotrophs 297
 Manchester picture test 841
 mandible
 development 1739
 elevation, swallowing 1956–7
 osseointegration 2908
 surface anatomy 1740
 tumours *see* mandibular tumours
 mandibular advancement splints (MAS)
 children 1109
 snoring 2333
 mandibular cleft 1811–2
 mandibular condyle
 fractures 1622, 1624–5
 temporomandibular joint 1809
 mandibular fractures 1621–5
 closed reduction techniques 1622–3
 incomplete dental arch 1622–3
 intact dental arch 1622
 displacement 1621–2
 external fixation 1623, 1624 *F*
 internal fixation 1624–5
 principles 1624, 1624 *F*
 signs/symptoms 1622
 surgical anatomy 1621–2, 1621 *F*
 mandibular nerve (V_3) 1750–1, 1802,
 1802 *T*, 3924–7, 3925 *F*
 anterior division 3907, 3925
 damage, tumour-induced 3927
 in infratemporal fossa 1801 *F*, 3903 *F*,
 3907–8
 posterior division 3907–8, 3925
 mandibular prominences 798, 1810–1
 mandibular protrusion, airway
 management 469–70
 mandibular reconstruction
 fibula free flap 2571, 2572 *F*
 oral cavity tumours 2569–70
 mandibular resection 2558–9, 2559 *F*,
 2939–40, 2939 *F*
 rim 2559
 mandibular swing, nasopharyngeal carcinoma 2463
- mandibular tumours 2558–9
 imaging 2558
 management 2558–9
 mandibular nerve damage 3927
 presentation 2558
 rim resection 2559
 segmental resection 2558–9, 2559 *F*
 survival rates 2559 *T*
 treatment outcome 2559
 mandibulofacial dysostosis *see* Treacher Collins syndrome
 mandibulotomy 2586, 2587
 lateral 2586–7
 parapharyngeal space tumours 2533
 segmental resection 2588
 zigzag-stepped technique 2587–8
 mandrill (*Mandrillus sphinx*), paranasal sinuses 1321 *F*
 mannan-binding lectin (MBL)
 pathway 139 *F*
 mannitol, ototoxicity prevention 3302
 mannose binding lectin deficiency 1081
 manofluoroscopy 1972–5
 advantages 1972
 analysis 1975, 1975 *F*, 1976 *F*
 calibration 1975
 contraindications 1975
 equipment 1972–4, 1973 *F*
 methodology 1974–5, 1974 *F*
 procedure 1972–4
 manometry
 analysis 1975, 1975 *F*
 diffuse oesophageal spasm 2067 *F*
 dysphagia investigations 1965, 1965 *T*,
 1970–5, 2028
 disadvantages 1971 *T*
 high-resolution 1971–2
 measurement problems 1971 *T*
 oesophageal 1970
 pharyngeal 1970–1
 gastro-oesophageal reflux 2063
 interpretation 1975
 nasal *see* rhinomanometry
 sensor spacing 1973–4, 1973 *F*
 with videofluoroscopy *see* manofluoroscopy
 manslaughter, involuntary 607–8
 Manteaux test 1460
 Marcain, blepharoplasty 3057, 3059
 Marcus–Gunn pupil reaction 3916
 marginal cells, stria vascularis 3186
 marginal mandibular nerve of facial nerve 1750–1
 surface anatomy 1741
 maribavir 2004

marsupialization
 jaw cysts 1922
 odontogenic keratocysts 1925
 masking 3246–9
 cochlear hearing loss 3256
 definition 3246
 excitation pattern 3247 *F*, 3249
 narrow frequency range 3247, 3247 *F*
 sinusoidal tone 3247
 tinnitus 3612
 white noise 3247
 masking level difference (MLD) test,
 central auditory dysfunction 3860
 masseter muscle 3910
 wasting 3926
 massive transfusion 284
 Masson's tumour 2527
 mast cells
 allergic response 148–9
 degranulation, allergic rhinitis 1390,
 1392
 function 140, 140–1
 nasal polyposis 1552
 mastication 1956
 Parkinson's disease 3939
 masticator space 1757, 2110, 2110 *T*,
 2523
 tumours 2530
 masticatory mucosa 767, 1794–5
 mastoid air cell system 3118–9, 3120 *F*
 mastoid cavities, paediatric cochlear
 implantation 865
 mastoidectomy
 facial nerve palsy 923
 otitis media with effusion 3393
 paediatric anaesthesia 514
 tuberculous otitis 3449, 3450 *T*
 see also individual types
 mastoiditis, acute
 acute otitis media 922–3, 922 *F*
 AID patients 240
 differential diagnosis 923
 investigations 923
 organisms 923
 otalgia 3528
 symptoms 922–3
 mastoid obliteration,
 cholesteatoma 3434
 mastoid pneumatization
 middle ear barotrauma 3504
 otitis media with effusion 3390
 mastoid process 1053–4
 embryology 1053–4
 surface anatomy 1740

mastoid stimulation, ocular tilt
 reaction 3751
 mastoid surgery
 facial nerve palsy 3889
 medical negligence 1307
 mastoid vent, percutaneous 3393
 mastoid vibration 3812
 maternal genital warts, juvenile-onset
 recurrent respiratory papillomatosis 1175
 maternal infection, childhood
 deafness 846–7
 maternal inheritance 18
 maternally inherited diabetes and
 deafness (MIDD) 813 *T*
 matrix disruption enzymes 2387 *T*
 matrix-metalloproteases (MMP)
 hypopharyngeal cancer 2637
 maxilla 1340–1, 1340 *F*, 1341 *F*
 adjunctive implant techniques 2917
 body 1340
 development 1317
 grafting 2918
 ossification centres 1317
 processes 1340
 maxillary alveolectomy 2560
 maxillary antral washout, paediatric
 rhinosinusitis 1084
 maxillary artery 1798
 epistaxis 1574
 in infratemporal fossa 3902 *F*, 3906–7
 in nose 1363
 parts 2113, 3907
 maxillary cyst 799, 802 *F*
 maxillary fractures 1625–7
 emergency treatment 1627
 fixation 1627
 management 1627
 reduction 1627
 signs/symptoms 1625 *F*, 1626–7,
 1626 *F*
 surgical anatomy 1625–6
 maxillary hiatus 1330, 1341
 maxillary nerve (V_2) 3923–4, 3924 *F*
 branches 3923
 nasal 1325
 damage, tumour-induced 3927
 maxillary prominences (processes) 798,
 799 *F*, 1315, 1810–1
 maxillary prostheses 2907–8, 2934 *F*
 maxillary resection 2925, 2929
 maxillary rhinosinusitis 1540
 maxillary sinus 1340–1
 barotrauma 1369
 blood supply 1341

comparative anatomy 1321–2
 development 803, 805 *F*, 1318–9,
 1318 *F*
 drainage 1368
 enlargement 1318–9
 growth 1318–9
 histology 1341
 innervation 1341
 lymphatic drainage 1341
 noninvasive fungal rhinosinusitis 219
 osteology 1340–1
 oxygen tension 1368
 pressure changes 1369
 relations 1341
 size 1318–9
 maxillary sinus ostium 1332
 maxillary sinus tap, acute bacterial
 rhinosinusitis 1442
 maxillary sinus tumours
 epiphora 2424
 patterns of spread 2419
 staging 2421, 2424 *T*
 TNM classification 2367 *T*
 maxillary swing technique 4059–61,
 4060 *F*
 nasopharyngeal carcinoma 2463
 maxillary tuberosity 1341
 implant placement 2907
 maxillary tumours
 quality of life issues 2771
 surgery 2427–8
 maxillary veins 3907
 maxillectomy 2429–30
 case study 2933, 2934 *F*, 2936–7
 extended 2428
 lateral rhinotomy approach 2431,
 2431 *F*
 osteomies 2429, 2430 *F*
 otitis media with effusion 3390
 partial 2428
 hard palate carcinoma 2562–3
 prosthetic reconstruction 2930
 rehabilitation 2429–30
 resection completion 2429
 sinonasal malignancy 2429–30
 soft-tissue approach 2429, 2430 *F*
 total 2428
 maxillofacial surgery, 3D
 imaging 702–3
 maxillofacial trauma, facial nerve
 injury 3887
 maximal stimulation test (MST), facial
 nerve 3878–9, 3879 *T*
 maximum phonation time (MPT)
 2182

- maximum speech recognition score 3271
- maximum surgical blood ordering schedule (MSBOS) 255, 255 *T*
- Mayfield clamp fixation 4056
- McCormick toy test 841
- McCoy blades 473, 474 *F*
- McCune–Albright syndrome 1522
- McFee incision 2731–3, 2732 *F*
- McGill Pain Questionnaire 641
- McKenzie, Morrel 771
- McLaughlin's lateral tarsorrhaphy 3079
- mean airflow rate (MFR) 2181–2
- mean arterial blood pressure (MABP), hypotensive anaesthesia 502
- mean corpuscular volume (MCV) 267 anaemia 268, 268 *T*
- measles 206–7 childhood deafness 847 chronic otitis media 3410 complications 206–7 otosclerosis 3458–9 symptoms 206–7, 847, 847 *F*, 1701 vaccination 206–7
- measles–mumps–rubella (MMR) vaccine 206, 1243
- mechanical impedance 3288–9
- mechanical ventilation indications 528 weaning from 528
- mechanical wounds 97
- mechanoreceptors laryngeal *see* laryngeal mechanoreceptors oral cavity 1959
- Meckel's cartilage 1739
- meclizine 3801
- medial crura strut, underprojected nasal tip 3002
- medial crus 2996 *F* anatomy 2960–1 buckled, correction of 2962 incisions 3002 tripod mechanism 2996
- medial edge epithelium (MEE) 998
- medial efferent system 3145
- medial geniculate nuclei 3143–4 divisions 3143–4
- medicalization laryngoplasty 2242 *T*
- medicalization thyroplasty 1171
- medial medullary swallowing centre 1959
- medial nasal process 1811
- medial nucleus of the trapezoid body 3141–2
- medial olfactory striae 3912–3
- medial olfactory nucleus 3141–2, 3141 *F*
- medial olivocochlear reflex 3850
- medial olivocochlear system 3200 tinnitus 3606
- medial pterygoid muscle 1339, 2113, 3905, 3907 *F*
- medial pterygoid plate 2111, 3899–900
- medial rectus 3221
- medial vestibular nuclei (MVN) 3220 acute unilateral vestibular deafferentation 3222 neuron recovery 3224, 3225 *F* type 1 neurons 3220 type 2 neurons 3220 vestibular compensation 3793
- median cleft 1811–2
- median clefts, true 997
- median rhomboid glossitis 1826–7
- median thyrohyoid ligament 2133–4
- median thyroid anlage 314–5, 316 *F*
- mediastinitis parapharyngeal abscess 2000 peritonsillar abscess 1998 retropharyngeal abscess 2002
- Medical Advisory Committee, medical negligence cases 2803
- medical consultations children *see* paediatric consultation communication *see* communication, medical consultations seat/desk arrangements 564 *F*
- medical ethics *see* ethical issues
- medical jargon 562
- medical jurisprudence 594–612 assault and battery 595, 609 definitions 600 confidentiality *see* confidentiality consent *see* consent coroner's role 602–3 criminal law 607–9 European Convention on Human Rights 606–7 expert medical witnesses 603–5, 604, 604–5 Human Rights Act 2806 negligence *see* medical negligence patient's rights 609 performance and complaints 605–6 tort 595
- medically unexplained symptom (MUS) atypical facial pain 1829 burning mouth syndrome 1829
- medical negligence 595–600 Bolam test 596, 600, 2805 care standard ascertainment 595–6, 2805–7 Bolitho 2805–6 Sidaway 2806 causation 595, 596 clinical governance and 598, 2803 clinical situations 2804–5 communication issues 2804 note keeping and 2804 confidentiality breaches 2805 consent issues 600–1, 2806–7 criminal standard of proof 2804 damages 594, 595, 597–8 general 597–8 punitive 609 special 598 definition 595 dishonesty issues 2805 expert medical witnesses 604 facial plastic surgery *see* facial plastic surgery funding of claims 600 head and neck surgery *see* head and neck surgery Human Rights Act 2806 otology *see* otology paediatric otorhinolaryngology *see* paediatric otorhinolaryngology practitioners' health issues 2805 proof 596–7 protocol for claims 598–600 recklessness 2806 relationships 2805 rhinology *see* rhinology skull base surgery 4142–8 tort 595 trials 599–600
- Medical Outcome Study Short-Form 36-Item Health Survey (SF-36) *see* SF-36
- medical practitioners' health, medical negligence and 2805
- medical records, ethical issues 587, 589
- medical witnesses, expert *see* expert medical witnesses medicinal leech (*Aeromonas hydrophila*), skin flap survival 115
- MEDLINE 646, 647 *T*
- Medpore 121 augmentation rhinoplasty 2973–4 nasal reconstruction 121
- medulla, swallowing control 1959
- medullary swallowing centres 1959

medullary thyroid carcinoma
(MTC) 331, 2673 *T*, 2674–5
children 1256
ectopic adrenocorticotropin
production 401
genetic studies/screening 2687
imaging 720, 720 *F*, 2678 *F*
long-term follow-up 2697
Ret mutations 2669, 2671, 2687
serum calcitonin levels 361
treatment 2686–7
medulloblastomas 4015
megaloblast 269
megaloblastic anaemias 269
megavoltage external radiotherapy
(ERT), nasopharyngeal
carcinoma 2459–60, 2460 *F*
Meige's syndrome (oromandibular
syndrome) 3939–40
meiosis 2379
melanin, tinnitus 3598
melanocyte-stimulating hormone 4098
melanocytic lesions, external
nose 1706–7
melanocytic naevi, external
nose 1706–7
melanoma, malignant *see* malignant
melanoma
melanotic macule, oral mucosa 1823
melatonin 2306
Melkersson-Rosenthal syndrome 3876,
3876 *F*
children 1059
facial nerve decompression
surgery 4022
memantine 3804–5
membrane attack complex (MAC) 139
membranous labyrinth,
embryology 806, 807 *F*, 3122,
3123 *F*
membranous laryngotracheobronchitis
see pseudomembranous croup
memory loss, hyperparathyroidism 391
MEN-1 (MENIN) gene 389
MEN-2A 389, 2526
MEN-2B 389
MEN-2B syndrome 2526–7
MEN-2 gene *see* RET protooncogene
(cRET, MEN-2)
Mendelian pattern of inheritance 18,
18–9
Mendelsohn manoeuvre 2081, 2090,
2090 *T*
Meniere-like symptoms, DFNA9
mutations 3238

Menière's disease 3695–6, 3757–60
aetiology 3757
aminoglycoside ototoxicity 3567,
3568–9, 3676
benign paroxysmal positioning
vertigo 3760
children 1046, 1049
clinical manifestations 3695, 3709,
3757–8, 3758 *F*
complications 3760
definition 3757
diagnosis 3754, 3756, 3758, 3758 *F*,
3759 *F*, 3771
diet 3798
differential diagnosis 3758–9
diplocausis 3597
drug therapy 423–4, 3798–800,
3799 *T*
histopathology 3695–6, 3696 *F*,
3697 *F*
hyperacusis 3596
immunological suppression 3800
management 433, 434, 3759–60
medical negligence 3830
motion intolerance 3707–8
otalgia 3528
outcomes 3760
stapes surgery contraindication 3469
sudden sensorineural hearing
loss 3579
symptoms
duration 3706
severity and stress 3798
tinnitus 3599
treatment 3798–800, 3798 *F*
vestibular rehabilitation 3808
vestibuloocular reflex 3239, 3239 *F*
meningococcele 1351–2
meningeal artery
accessory 3907
middle 3907
MENIN gene 389
meningioma, sphenoid 1685
meningioma(s) 4008–11
abducent nerve 4009
aetiology 4008–9
anatomy/physiology 735–6
vascular supply 736, 737 *F*
calcification 4009
classification 735–6, 4008
clinical presentation 736, 3943–4,
4009
collision tumours 4002
CPA tumours 4007, 4008–11
definition 4008
diagnosis 4009–10, 4009 *F*, 4010 *F*
embolization 3954–5
'en plaque' type 4008
epidemiology 4007, 4008–9
extracranial 4126
failure to diagnose 4144
fibrous 4008
gamma knife stereotactic
radiosurgery 3993–4
hearing loss 3943–4
incidence 4032–3
intracranial 4126
jugular foramen 4032–3
intraoperative haemorrhage 4035
medical therapy 4042
radiotherapy 4043
resection 4039–40, 4041 *F*
tumour extension 4033
malignant transformation 4032–3
meningotheiomatos 4008
mortality 4010
neurofibromatosis 1 4008–9
neurofibromatosis 2 4000, 4002,
4008–9
olfactory groove 3954–5, 4144
orbital 3915
parapharyngeal space 2527
pathology 4008
petrous apex 4047–8
posterior fossa 4144
postural imbalance associated 3776
recurrence rates 4010
skull base 1684, 4126
transitional 4008
treatment 4010–1
tumour embolization 734, 735–6,
737 *F*
vestibular imbalance 3777
vestibular nerve 3690–1
WHO classification 4032–3, 4033 *T*
meningitis
abducent nerve damage 3918–9
active chronic otitis media 3437
management 3438
acute otitis media 924
cerebrospinal fluid rhinorrhoea 1636,
1638, 1639–40, 4144
childhood deafness 847
cochlear implantation 3654
children 864–5
cochlear implants candidature 3651
hearing loss 824
hearing loss, genetic disposition 16–7
hypophysectomy complication 4113
medical negligence 1306, 3830–1

- mumps 1900
pituitary tumours 305
post-stapes surgery 3477
sinusitis, children 1088
vestibular schwannoma removal 3982
meningococci 199
meningocoele
 frontal sinus malformations 1504
 nasal, children 1075
 resection 1505
meningoencephaloceles *see*
 encephalocele(s)
meningotheiomatous
 meningioma 4008
menstruation, vocal fold
 oedema 2212–3
mental artery 1798
Mental Health Act Commission 572–3
mentally incapacity, consent issues 601
mental nerve 1801 *F*, 1802
menthol 1377, 1377 *F*
mentoplasty, medical negligence 3095
6-mercaptopurine (6MP) 38
merlin (NF2 protein;
 schwannomin) 3999
Mersilene 121
meso-tetra (hydroxyphenyl) chlorin
 (mTHPC), juvenile-onset recurrent
 respiratory papillomatosis 1177
messenger RNA (mRNA) 4, 15, 2378–9
meta-analyses *see* systematic reviews
metabolic disorders, olfactory
 dysfunction 1673–4
metabolic rate, sleep 2307
metabolic syndrome
 associated disorders 391
 hyperparathyroidism 391
 obstructive sleep apnoea 2314–5
 premature death 391
metaiodobenzylguanidine (MIBG)
 neuroblastoma imaging 1258
 thyroid nodule imaging 2676–7
metal biomaterials 119
 advantages 119
 applications 119
 biocompatibility 119
 disadvantages 119
 properties 119
 tissue response 119
 see also individual metals
metallothionein 2495–6
metastasis 2716–7
 molecular detection methods
 2715–6
 skip 2715
 spread 36
 integrins 36
 surgery 2716
 see also individual tumours
metastatic neck disease 2711–52
 assessment 2719–20
 biopsy 2722
 clinical examination 2720–2
 clinical staging 2719–20, 2720 *T*
 current system criticisms 2719
 difficult neck 2727
 arterial tree invasion
 assessment 2727
 imaging 2727
 distant metastases predictors 2719
 evolution of 2712–3
 extracapsular nodal spread 2718
 treatment 2718
 future research areas 2750
 host factors 2712
 knowledge deficiencies 2750
 literature assessment 2711–2
 bias 2711–2
 locoregional control 2716
 lymph node levels 2712, 2712 *F*
 macrometastases 2718
 metastatic process 2716–7
 micrometastases 2718
 molecular detection methods 2715–6
 natural history 2712–3
 untreated neck 2713, 2722
 occult nodal disease 2717–8
 treatment 2724
 pathology 2721–2
 report standardization 2721–2
 physical examination sensitivity 2720
 postoperative radiotherapy,
 extracapsular nodal spread 2718
 primary tumour site prediction 2712,
 2713 *T*
 prognosis
 extracapsular nodal spread 2718
 N_{2c} disease 2726
 nodal features 2719
 recurrence 2718
 retropharyngeal nodes 2718–9
 survival 2718
 systemic tumour burden
 index 2715–6
 treatment *see* metastatic neck disease
 treatment
 tumour biology 2714–9
 bloodbourne metastases 2715
 cell destruction in lymph
 nodes 2715
 extranodal extension 2714
 growth patterns 2714
 malignant embolus 2714
 premetastatic lesions 2714
 secondary metastases 2714
 skip metastases 2715
 tumour vascularization 2715
metastatic neck disease
 treatment 2722–7
 bilateral and contralateral nodes
 (N_{2c}) 2726
 chemoradiation 2730
 quality of life 2730
 controversies 2722
 interval contralateral
 lymphadenopathy 2726
 large (greater than 3 cm and less than
 6 cm nodes) 2726
 massive nodes (greater than 6 cm;
 N3) 2727
 multiple unilateral nodes (N2b)
 2726
 neck dissection *see* neck dissection
 occult metastases 2724
 patient with no palpable node
 (N0) 2723, 2725 *T*
 delayed treatment 2723–4
 elective neck investigations 2725
 elective neck irradiation 2724–5,
 2725 *T*
 elective surgery 2723–4, 2725 *T*
 ‘wait and see’ policy 2723–4, 2725
 quality of life 2730–1
 chemoradiation 2730
 elective surgery *vs.* irradiation, N0
 neck 2730
 node positive disease 2730
 postoperative radiotherapy 2730
 psychosocial issues 2731
 surgical extent 2730
 radiotherapy 2728–9
 clinically N[–] neck 2729
 clinically positive neck 2729
 elective, post-surgery 2729
 quality of life 2730
 recurrent disease 2729
 surgery and 2729
 salvage surgery 2728
 single palpable metastasis, unilateral,
 less than 3 cm diameter
 (N1) 2725–6
 conservation neck surgery 2725–6
 radial neck dissection 2725–6
 radiotherapy 2726
 metastatic potential 2716

methacholine tests
 allergic rhinitis 1561
 asthma 1561
 idiopathic rhinitis 1409
methadone, cancer pain
 management 2787
methicillin-resistant *Staphylococcus aureus* (MRSA) 196
 otitis externa 3352
 skin grafts 2821–2
 treatment 442–3
D-methionine, ototoxicity
 prevention 3302
methotrexate
 head and neck cancer 40
 lupus pernio 1711
 mechanism of action 37, 38, 38 *F*
 Sjögren syndrome 1913
(2-methoxyisobutyl-isonitirile)
 technetium-99m (MIBI), thyroid
 cancer imaging 334, 694
methylation 10
methylcellulose solutions 2788
methylene blue staining, contact
 endoscopy 762–3, 763
methylprednisolone
 idiopathic sudden sensorineural
 hearing loss 1, 3584
 vestibular neuritis 3756
methysergide 3803 *T*, 3804
metoclopramide
 migrainous vertigo 3801
 nausea and vomiting 2787
 vestibular attacks, acute 3796 *T*,
 3797
Met oncogene 2384
metopic synostosis
 (trigonocephaly) 1022 *T*, 1025–6
metronidazole 231, 431
 anaerobe detection 200
 interactions 433
 malignant ulcers/fistulae, cancer
 patients 2792
 mechanisms of action 431
 as radiosensitizer 50
 rhinosinusitis 1543–4
 side effects 231
metyrapone, Cushing's disease 4102
metyrapone stimulation test 300,
 310
MHC *see* major histocompatibility
 complex (MHC)
microadenomas, pituitary gland *see*
 pituitary microadenomas
microaerophilic bacteria 201

microbial cultures
 fungus ball 1452
 nasal endoscopy and 1349–50, 1349 *F*
microbubble contrast agents 714
microbubbles, decompression
 injuries 3515
microcalcifications, papillary thyroid
 carcinoma 719
microcatheters 732–3
 tumour embolization, skull
 base 3951–2
micrococci 196
microcolposcopist, chronic
 laryngitis 2260–1
microcytic anaemias 268–9, 268 *T*
microdebrider
 adenoidectomy 1097
 juvenile-onset recurrent respiratory
 papillomatosis 1176, 1177 *F*
 phonosurgery 2236
microelectromechanical systems
 (MEMS) 413
microfibrillar collagen, as embolic
 agent 733
microflora
 nasopharynx 195–6, 196 *T*, 2121
 normal 195–6
 tonsils 1219–20
microimmunofluorescence,
 Chlamydiae 202
microlaryngoscopy 2234–8
 aims 2195
 anaesthesia 503
 direct laryngoscopy *vs.* 2236
 exposure 2235–6
 history 2234–5
 instrumentation 2235
 laryngeal clefts 1142
 laryngeal tumours 2608
 pathology 2236–8
 surgical anatomy 2235
 tubes 2148, 2150
 voice evaluation 2181
microlaryngotracheobronchoscopy
 (MLTB) 1121 *F*, 1122
microorganisms 195–203
 host risk factors 195–6
 see also individual species
microphones 3169–70
 voice evaluation 2176
microsatellite markers 8–9
microsatellite repeats 4
microstomia 1811–2
microtia 967, 967–8, 975–80
 bilateral 2927
classification 975–6
conchal type 975, 976 *F*
prosthetic reconstruction 2928
surgical reconstruction 978
treatment 979–80
unilateral 2927
microtubules, cilia 1360
microvascular flap reconstruction 110
microvascular free tissue transfer, oral
 cavity tumours 2569
microvilli
 olfactory neuroepithelium 1662,
 1663 *F*
 septal columnar cells 1327
 taste buds 1841
Miculicz disease 1914
Miculicz syndrome 1914
midazolam
 cancer patients
 acute confusional states 2798
 bleeding malignant ulcers and
 fistulae 2792–3
 paediatric anaesthesia 509
midbrain gaze centres 3921
midbrain lesions, eye movement
 defects 3921
middle clinoid process 298
middle constrictor, pharynx 1947–9,
 1948 *T*
middle ear
 acoustic impedance 3288–9
 anatomy 3105–25, 3117 *F*
 blood supply 3118 *T*
 compartments 3116, 3117 *F*
 congenital abnormalities 869–76
 management 965–89
 nonossicular 873–4
 ossicular *see* congenital ossicular
 abnormalities
 development 3105–25, 807–8, 814–5,
 966, 3120–2
 folds 3116, 3117 *F*
 glandular tumours 4070–2
 see also individual types
 hearing/sound transmission 3179–86
 bone conduction 3185
 damaged ear 3184–5
 high frequencies 3182–3
 impedance transformer
 action 3181–2
 low frequencies 3182
 mode of vibration 3179–81
 muscles, influence of 3183–4
 transfer function 3182–3, 3182 *F*
 transformer action loss 3184–5

HIV infection 240
 mucosa 3116
 otosclerosis 3456
 muscles
 myogenic somatosounds 3600
 reflexes 3183
 otalgia 3527–8
 differential diagnosis 3528
 relationships 3114 *F*
 surgery *see* middle ear surgery
 type I malformations 808
 see also tympanic membrane
 middle ear adenoma 4070–1
 middle ear barotrauma 3504–6
 differential diagnosis 3508 *T*
 hyperbaric oxygen treatment-related 3519
 mucosal oedema development 3505
 prevention 3505–6, 3506
 treatment 3505
 tympanic membrane 3505, 3505 *T*
 middle ear cleft 3108–20
 middle ear effusion
 acute otitis media 921
 rheumatological diseases 184
 middle ear haemangiopericytoma 4072
 middle ear implants 3660–5
 coupling mechanism 3661
 current devices 3661
 device development 3660–1
 future devices 3661–2
 history 3660–1
 mode of transmission 3661
 patient selection 3662
 results 3663–4
 middle ear infection, facial nerve
 damage 3931
 middle ear squeeze *see* middle ear barotrauma
 middle ear surgery
 diving, postoperative 3506
 facial nerve palsy 3889
 flying, postoperative 3506
 paediatric anaesthesia 514
 reconstructive 982–4
 anterior approach 983–4
 ceramic biomaterials 120
 complications 984
 historical aspects 118
 modified approach 984
 preoperative considerations 982–3
 transmastoid approach 984
 see also individual procedures

middle fossa craniotomy, tuberculous
 otitis 3449
 middle fossa-petrosectomy
 extension 4021
 middle fossa surgery 4018–25
 apex lesions 4024
 basilar aneurysms 4024
 cerebellopontine angle
 surgery 4021–2
 cerebrospinal fluid leaks 4023
 clinical applications 4021–4, 4021 *T*
 closure 4021
 cochlear implantation 4023–4
 craniotomy 4020
 encephalocoele
 (meningoencephalocoele) 4023
 facial nerve tumours 4022, 4022 *F*
 historical perspective 4018
 incision 4019–20
 informed consent 4024
 internal auditory canal 4021–2
 exposure completion 4020–1
 lateral end 4020
 medial end 4020
 landmarks 4018–9, 4019 *F*
 medial approach 4019
 middle fossa floor 4022–4
 exposure 4020
 patient position 4019
 petroclival lesions 4024
 petrous apicectomy 4024
 superior semicircular canal dehiscence
 syndrome 4023
 surgical anatomy 4018–9
 surgical technique 4018–21
 tegmen defect repair 4023, 4023 *F*
 transtemporal middle fossa
 approach 4019
 vestibular neurectomy 4021–2
 middle jugular lymph nodes 1747
 middle latency response (MLR),
 central auditory dysfunction 3860, 3861–2, 3861 *F*, 3862 *F*
 middle lobe bronchus, right 2141
 middle meatus 1330–1
 pathophysiology 1501
 rhinosinusitis 1442
 middle meningeal artery 3907
 middle nasal vault, external
 rhinoplasty 2964
 middle pitch, note production 2160–1
 middle superior alveolar (dental)
 artery 1798
 middle superior alveolar (dental)
 nerve 1341, 1802
 middle superior dental (alveolar)
 artery 1798
 middle superior dental (alveolar)
 nerve 1341, 1802
 middle thyroid veins 317–8, 372–3
 middle turbinate
 doubled 1332
 osteomeatal complex 1592
 paradoxical 1335 *F*, 1335 *T*
 rhinosinusitis 1592
 midfacial degloving
 juvenile angiofibroma 2442, 2442 *F*
 maxillary tumours 2428, 2429 *F*
 nasopharyngeal carcinoma 2463
 septal perforations 1587
 midfacial segment pain 1725–7, 1726 *F*
 midline flap pharyngoplasty 1011,
 1012 *F*
 midtracheal obstruction 483
 migraine 1722, 1722 *F*
 basilar *see* basilar migraine
 olfactory dysfunction 1669–70
 treatment 1671
 taste abnormalities 1848
 migraine-related vestibulopathy (MRV)
 see migrainous vertigo
 migrainous vertigo 3770–2, 3779
 aetiology 3770
 children 1049
 clinical manifestations 3771
 complications 3771–2
 definition 3770
 diagnosis 3754, 3762, 3771, 3800,
 3802 *F*, 3802 *T*
 dietary modifications 3800–1
 differential diagnosis 3771
 lifestyle modifications 3800–1
 management 3771
 outcomes 3771–2
 over-the-counter medications 3801
 pathogenesis 3801 *F*
 treatment 3800–4, 3803 *T*
 prophylactic 3803–4
 symptomatic/abortive 3801–3
 vestibular rehabilitation 3808
 migratory glossitis, benign 1825–6,
 1826 *F*
 Mikulicz cells 1462–3
 milia 1709
 ‘milk nasendoscopy’ *see* fibrooptic
 endoscopic evaluation of
 swallowing (FEES)
 Millard rotation, cleft lip and
 palate 1004, 1004 *F*
 Miller Fisher syndrome 3778

minimal bactericidal concentration 234
 minimal inhibitory concentration
 (MIC) 234, 1471
 minimum audible field 3250, 3251 *F*
 minimum audible pressure
 (MAP) 3250
 mini-Penning orthopaedic fixator 1623,
 1624 *F*
 minitracheostomy 2294
 commercial kits 2294, 2294 *F*
Miopithecus talapoin (dwarf
 guerou) 1322 *F*
 mirror ear (*polyotia*) 969, 970 *F*
 misonidazole 2756
 misopristol 3618
 mitochondria, apoptosis 58
 mitochondrial DNA (mtDNA) 4–5,
 18
 mitochondrial encephalopathy, lactic
 acidosis and stroke-like episodes
 (*MELAS*) 813 *T*
 mitochondrial genome 3, 4–5
 A1555G mutation 16–7
 aminoglycoside-induced hearing
 loss 16–7
 deafness-associated mutations 16–7,
 18, 853
 inheritance 18
 mitomycin C (MMC) 50–1
 arytenoid granuloma 2238
 choanal atresia 1072
 dacryocystorhinostomy 1695
 laryngeal stenosis 2278
 mechanism of action 38
 toxicity 50–1
 mitosis 35, 35 *F*, 2379, 2381
 mitotic spindle poisons 38–9
 mitoxantrone 3772–3
 mitral cells 1663, 3912
 ‘mixed rhinitis’ 1408–9
 mizolastine 1397–8
 MMR vaccine 206, 1243
 sensorineural hearing loss 211
 mobile phones, salivary gland
 tumours 2476
 Mobius syndrome 1055, 3085, 3086 *F*
 modal register 2161, 2162 *T*
Modernising medical careers 553
 modified Hughson-Westlake
 (ascending) method, pure-tone
 audiometry 3263–4
 modified neck dissection, medical
 negligence 2808
 modified radical mastoidectomy,
 cholesteatoma 3432

modified radical neck dissection 2564 *F*,
 2746–7
 complications 2749
 contraindications 2733
 indications 2746
 operative technique 2746–7
 accessory nerve
 preservation 2746–7
 internal jugular vein
 preservation 2747
 sternomastoid muscle
 preservation 2746–7
 postoperative management 2749
 single palpable metastasis, unilateral,
 less than 3 cm diameter
 (N1) 2725–6
 type 1 2745 *T*, 2746, 2746 *F*
 indications 2745 *T*, 2746
 type 2 2745 *T*, 2746, 2746 *F*
 indications 2745 *T*, 2746
 type 3 2745 *T*, 2746, 2746 *F*
 indications 2745 *T*, 2746
 modifier genes 16
 auditory system 817
 modulation transfer function, auditory
 neuropathy/dyssynchrony
 3852
 Moebius syndrome
 facial reanimation 3085, 3086 *F*
 muscle graft 3080–1
 Moffatt’s solution 1680–1
 endoscopic sinus surgery 1482–3
 Moh’s micrographic surgery
 basal cell carcinoma 2397
 nasal 1706
 medical negligence 3093
 postoperative nasal
 reconstruction 3017, 3021 *F*,
 3023 *F*, 3024 *F*
 molariform teeth *see* molars; premolars
 molars 1803
 cusps 1804
 deciduous 1804–5
 roots 1804–5
 permanent 1804
 roots 1804
 molecular biology 3–14
 future research areas 11–3
 knowledge deficiencies 11–3
 methods 5–8
 molecular cytogenetics 6–7
 molecular displacement, sound 3173
 molecular otology 811–20, 813 *T*
 molluscum contagiosum 247, 1701,
 1701 *F*

molluscum sebaceum 1704–5, 1704 *F*
 mometasone 437, 1398, 1401
 monaural low-redundancy speech
 tests 3858–9
 Mondini deformity 851 *F*, 1298 *F*
 monobactams 229, 230
 monobloc procedures, syndromic
 craniosynostosis 1029
 monochromatic 743
 monoclonal antibodies (MAb) 41, 52
 antibody-dependent cellular
 cytotoxicity 41
 epidermal growth factor receptor 43
 ideal target properties 41
 mechanism of action 41
 murine 41
 skin flap survival 114
 sources 41
 vascular endothelial growth factor
 receptor 43–4
 monocytes
 differentiation 89–90
 wound healing 89
 moniodotyrosine (MIT) 321
 secretion 322–3
 mononeuropathy, neurofibromatosis
 2 4000
 monophosphoryl lipid A (MPL) 157–8
 monosodium glutamate allergy
 1427
 monospot test
 Epstein–Barr virus 1225, 1984
 lymphocytosis 274
 monosyllabic words, speech
 audiometry 3270, 3272
 Montgomery stent, laryngeal
 stenosis 2279, 2280 *F*
 mood disorders, tinnitus 3608
 Moon’s molars 1818
 morality *see* ethical issues
Moraxella catarrhalis 199
 acute laryngitis 2249
 HIV-associated otitis media 240
 nasopharynx 2121
 rhinosinusitis 1441
 acute 1080
 chronic 1471
 HIV-associated 241–2
 vaccination 919, 920
 Morel-Fatio springs 3079
 Moro response 1040–1
 morphine
 acute pain management 463
 cancer pain management 2786
 doses 2787 *T*

- morphoeic basal cell carcinoma 2397
 morphogenetic deafness 811–2
 morsicatio buccarum (cheek biting) 1836
 mosaicism, neurofibromatosis 2 3999, 4001
 motion sickness 3239–40, 3707–8 children 1044
 DFNA9 gene mutations 3238
 passive forms of motion 3211
 transdermal hyoscine 408–9
 vestibular system anatomical differences 3209–10
 motor cortex, swallowing 1958
 motor delay, hearing tests and 841
 motor neurone disease 2079–80 diagnosis 2079–80
 dysphagia 2033
 pharyngeal symptoms 2079–80
 pseudobulbar palsy 3939 treatment 2080
 motor tinnitus 3606
 moulding helmets, posterior skull deformity 1026–7
 mouth anatomy 1791–815 development 799–802, 802 F dry *see* xerostomia floor 1793, 1793 F, 1796 F blood supply 1799 carcinoma *see* floor of mouth carcinoma muscles 1795–6, 1796 F sensory innervation 1795 F, 1801, 1801 F, 1802–3 oral mucosa 1794–5 primitive *see* stomodeum tissue spaces 1805–7, 1807 F *see also* oral cavity mouth breathing, sleep-disordered breathing 1104 mouth ulcers 1823, 1830–2 causes 1822, 1822 T, 1830 Crohn's disease 1828, 1834 drug-induced 1835 fungal infections 1833 haematological diseases 1833–4 head and neck cancer, palliative care 2788 T, 2789 HIV 1835 infected 2788 T, 2789 inherited disorders 1824 local aetiology 1830 malignant neoplasms 1832 pemphigus 1834 F syphilis 1833 tuberculosis 1833 mouthwashes 448 movement detection otolith organs 3210–1 semicircular canals 3211 vestibular system 3210–3 Movicol (polyethylene glycol) 2791 M-proteins 1982–3, 1983 MRSA *see* methicillin-resistant *Staphylococcus aureus* (MRSA) MT activation, functional magnetic resonance imaging 681 MUC2 gene 1359 MUC5AC gene 1359 mucin genes 1359 acute otitis media 916 mucinous adenocarcinoma, salivary glands 2500 survival 2512–3 mucins, nasal mucus 1359 mucocoeles 1531–8 aetiology 1531–2, 1532 T affected sites 1531, 1531 T bone dynamics 1532, 1533 F children 1537 frontoethmoid 1086 sinusitis 1086 chronic rhinosinusitis 1540 clinical features 1532–3 definition 1531 differential diagnosis 1533–4 ethmoidal 1533 F, 1534 F external frontoethmoidectomy complication 1508–9 fibrous dysplasia 1522–3 frontal 1533 F, 1534 F glandular tissue cystic degeneration 1532 histology 1532, 1532 F imaging 1533–4 immune factors 1532 maxillary sinus 1532–3, 1535 F nasolacrimal 1689, 1690 F, 1691 oral blisters 1822, 1825 pathogenesis 1531, 1532 F retention 1915 salivary glands 1915, 1915 F sphenoid 1532–3, 1534 F surgery 1535 complications 1535, 1536 T guidelines 1519 recurrence rates 1535, 1536 T results 1535, 1535 T, 1536 T treatment 1535 mucoepidermoid carcinoma larynx 2604 salivary gland 2497–8, 2498 F children 1249 F treatment 2498 mucolytics otitis media with effusion 896 rhinosinusitis 440 mucoperichondrium trauma 1573, 1573 F mucopolysaccharides, otosclerosis 3459 mucopolysaccharidosis 468–9, 469 F mucopus, olfactory dysfunction 1664–5 mucopyocoeles 1506 *Mucorales*, fungal rhinosinusitis 217, 1450 T mucormycosis 218 mucosa contact endoscopy 762–3 middle ear 3116 nasal *see* nasal mucosa nasopharynx 1947, 2108 oral *see* oral mucosa vocal folds 2193–4 mucosa-associated lymphoid tissue (MALT) tumour, Sjögren syndrome 1911, 1911 F mucosal barrier injury *see* mucositis mucosal bridge, vocal folds 2201–3, 2202 F mucosal flap repair, septal perforations 1586, 1586 F mucosal malignant melanoma 2406–16 aetiology 2409 biology 2409 complications 2413 diagnosis 2408, 2408 F host factors 2407–8, 2408 T incidence 2406–7 metastasis 2410–1, 2411 F presentation 2407, 2407 F recurrence 2410–1, 2411 F site 2407, 2408 T staging 2409 survival 2411–3 Cox's proportional hazards model 2412–3, 2413 melanotic *vs.* amelanotic 2412, 2412 F observed 2411–2, 2412 F treatment effects 2412, 2412 F tumour-specific 2411–2, 2412 F treatment 2409–10 tumour factors 2407–8, 2408 T types 2407

mucosal pain, advanced head and neck cancer 2785
 mucosal wave, vocal folds 2193
 mucositis 1835
 causes 1835
 clinical features 1835
 diagnosis 1835
 oral manifestations 1835
 palliative care, head and neck cancer 2789
 treatment 1835
 mucous cysts 1074
 mucous glands
 larynx 2137–8
 nasal cavity 764
 mucous membrane pemphigoid (MMP), oral 1834, 1834 *F*
 mucus, nasal *see* nasal mucus
 mucus retention cyst, vocal folds 2201, 2201 *F*
 Muenke craniostenosis (FGFR3-associated coronal synostosis syndrome) 1027–8
 Muir–Torre syndrome 1704–5
 mulberry molars 1818
 Müller, Johannes 3594
 multicentre regional ethics committees (MRECs) 588–9
 Multidimensional Voice Program (MDVP) 2184, 2184 *T*
 multidisciplinary audit 568
 multidisciplinary teamworking
 cancer care 576, 576–7
 clinical governance 568, 576, 576–7
 craniofacial anomalies 1020 *T*
 multidrug resistant (MDRTB)
 tuberculosis 1460
 multifluor FISH (M-FISH) 6
 multimemory hearing aids
 3637
 multinodular goitre 331
 Grave's disease and 331
 imaging studies 334
 nontoxic 360–1
 thyrotoxicosis 341
 tracheal compression 363
 treatment 362
 physical examination 361
 prevalence 360–1
 symptoms 361
 tracheal compression 363
 treatment 363
 treatment-induced
 hypothyroidism 363

multiple endocrine neoplasia (MEN)
 children 1256
 genetics 401
 hyperparathyroidism 388, 401
 thyroid cancer aetiology 2671, 2674–5, 2687
 medullary cell carcinoma 331, 720
 multiple myeloma, larynx 2604
 multiple papillomatosis 209 *T*
 multiple sclerosis (MS) 3772–3, 3779
 acoustic brainstem evoked responses 3846
 aetiology 3772
 clinical manifestations 3772
 complications 3773
 definition 3772
 diagnosis 3772, 3773 *F*
 differential diagnosis 3772
 dysphagia 2033, 2078
 gaze defects 3922
 hearing loss 3846–8
 magnetic resonance imaging 3846, 3847–8, 3847 *F*
 management 3772–3
 olfactory dysfunction 1669
 treatment 1671
 outcomes 3773
 taste abnormalities 1847
 treatment 2078
 vertigo 3754, 3773
 voice disorders 2222
 multiple step saccades, saccadic hypometria 3715
 multiple systems atrophy (MSA) 3775
 mumps 206, 1212
 children 1243
 deafness 847
 complications 206
 meningitis 1900
 salivary gland involvement 1243, 1900
 symptoms 206
 vaccination 206, 1243
 vestibular system 3694
 mupirocin 442–3
 murine oncogenic retroviruses, gene therapy 27
 muscle biopsy, neonatal facial paralysis 1055
 muscle grafts
 facial reanimation 3080–2
 choice of muscle 3080–1
 complications 3082–4

first stage 3080
 results 3082, 3082 *T*, 3083 *F*
 second stage 3080–2
 lower lip depressor weakness 3085
 muscle nerve pedicle reinnervation, laryngeal 2244
 muscle-only axial distant flaps 2854–5
 muscles of facial expression
 innervation 3928–9
 lips 1798
 muscle stem cells 74
 muscle tension dysphonia (MTD) 2203–5, 2204 *F*
 aetiology 2204
 clinical manifestations 2203–4
 contact quotient measurement 2179
 disorder hypotheses 2204
 symptoms 2204
 treatment 2195, 2204
 see also individual types
 muscular tension, tinnitus 3616
 musculoperiosteal flap, translabyrinthine vestibular schwannoma surgery 3969
 Mustarde pinnaplasty technique, medical negligence 3092
 mutation
 causative 19–20
 ‘crossing over’ 19–20
 definition 16
 DNA rearrangement 16
 mitochondrial 18
 neurofibromatosis 2 3999
 nonsyndromic deafness 18
 screening 19–20
 syndromic deafness 18
 types 9–10
 X-linked 18
 mutational falsetto voice 2204–5, 2226
 speech therapy 2226
 mutuality, consultation style 560, 560 *F*
 myasthenia gravis
 acetyl choline receptor antibodies 172
 bulbar type 3939
 causes 2077
 dysphagia aetiology 2033
 hyperacusis 3596
 pharyngeal dysfunction 2077
 symptoms 2077
 thymoma 172
 treatment 2077
 mycetomas *see* fungus ball
 mycobacteria 201
 atypical 201
 see also individual species

- mycobacterial infections
neck, children 1214–6
salivary glands, children 1244–5
- Mycobacterium avium* complex (MAC) 247
- Mycobacterium avium intracellulare* 201
- Mycobacterium bovis* 201
- Mycobacterium kansasii* 201
- Mycobacterium leprae* 1463, 2010
infectious rhinosinusitis 1381
nasal infection 1381, 1463, 1703
- Mycobacterium malmoense* 201
- Mycobacterium scrofulaceum* 201
- Mycobacterium tuberculosis* 201, 201 *F*
cervical swellings 1214–5
detection 201
HIV-associated cervical masses 246–7
infectious rhinosinusitis 1381
nasal tuberculosis 1458
rifampicin resistance testing 235
specimen handling precautions 201
- mycophenolate mofetil 1653
- mycoplasma(s) 201
cell structure 201
see also individual species
- Mycoplasma orale* 201
- Mycoplasma pneumoniae* 201
bullous myringitis 3326
erythema multiforme 1835
otitis media 201
pneumonia 201
- Mycoplasma salivarum* 201
- mycotic diseases
ear 213–4
nose 215–6
paranasal sinuses 216–22
throat 223–5
tracheo-oesophageal voice protheses 225
- mycotic laryngitis 2254
aetiology 2254
clinical features 2254
immunocompromised patients 2254
investigations 2254
management 2254
predisposing factors 2254
recurrent infection 2254
- myelin sheaths, auditory neuropathy/dyssynchrony 3849–50
- myelodysplastic syndrome (MDS) 269
- myelogenous carcinoma, larynx 2604
- myeloperoxidase, skin flap survival 113–4
- Myer-Cotton grading system, laryngotracheal stenosis 1139, 1152, 1153 *T*, 1160–1
- mylohyoid muscle 1795–6, 1796 *F*, 1803, 2135 *T*
- mylohyoid nerve 1803, 3907–8
- mylohyoid ridge, mandible implants 2908
- MYO7A gene mutations 15–6, 20
- myocardial ischaemia, surgical preparations 459
- myocarditis, diphtheria and 2253
- myoclonic epilepsy and ragged red fibres (MERRF) 813 *T*
- myocutaneous axial distant flaps 2854–5, 2855 *F*, 2855 *T*
- myoepithelioma 2483
- myofascial pain advanced head and neck cancer 2784
facial 1721
- myofibroblasts 91
- myofibroblast theory 91–2
- myogenic somatosounds 3600
- myopathy dysphagia 2077
hypothyroidism 355
- myosin, vestibular hair cells 3234 abnormalities 3238
- myosin I β 3234
- myosin-V 3238
- myosin VI 3238
- myosin VII 3238
- myosin VIIA gene mutations 3238
- myotonic dystrophy 2076–7
- myringitis bullosa haemorrhagica *see* bullous myringitis
- myringitis granulosa *see* granular myringitis
- myringoplasty active mucosal chronic otitis media 3425
complications 3422
inactive mucosal chronic otitis media 3421–2
hearing outcomes 3422, 3422 *T*
revision 3422
- procedure 3421
- tympanic membrane take rate 3421–2, 3422 *T*
- myringotomy acute mastoiditis 923
acute otitis media 918
cerebrospinal fluid fistula 3390
otitis media with effusion 3391, 3392
paediatric anaesthesia 513–4
- myringotomy with aspiration, otitis media with effusion 896
- myxoedema
definition 353
glycosaminoglycans 353
Graves' disease 344 *F*
hypothyroidism 355
sensorineural hearing loss 400
- myxoedema coma 350 *T*
'myxoedema madness' 355
- myxoid chondrosarcoma 4073
- myxoma, odontogenic 1928–9
- N₁ potential, cochlea 3196, 3281
- N₂ potential, cochlea 3196, 3281
- naevi
dysplastic 2400
external nose 1706–7
melanocytic 1706–7
oral mucosa 1823
Spitz 1707
- naevoid basal cell carcinoma syndrome 1705–6
- naevus flammeus 1708
- naftidrofuryl, idiopathic sudden sensorineural hearing loss 1, 3588
- Na⁺-K⁺-2Cl cotransporter, saliva secretion 1860
- nalidixic acid 230–1
- Nanog* 68–9
- narcolepsy 2310
- narcotic analgesia, obstructive sleep apnoea 1110
- Narcy test 1122
- narrow field laryngectomy, intractable aspiration 2099, 2099 *F*
- nasal agenesis 1073, 1320
- nasal airflow 1357–8
expiration 1357, 1357 *F*
inspiration 1357, 1357 *F*
measurement 1372–9, 2146
best clinical practice 1378
current knowledge/future research 1378
subjective 1376–7, 1377 *F*
see also individual techniques
- menthol, effects on sensation 1377, 1377 *F*
- normal 1374–5
- peak 1375
- resistance 1357–8
- septum, role of 1570, 1571 *F*
- nasal allergen challenge 1395
measurements 1395
occupational rhinitis 1420–1

- nasal amputation 2924–5
 nasalance 1375–6
 nasal balloon inflation,
 barotrauma 3506
 nasal bones 1324, 1324 *F*, 1325 *F*
 nasal bridge implants 2907
 nasal cavity
 anatomy 1325–6, 1344–6, 1944 *F*
 comparative 1321–2, 1321 *F*,
 1322 *F*
 floor 1325–6
 roof 1326
 anomalies 1346
 development 803, 1315, 1316 *F*,
 1811 *F*
 diffuser effect 1589
 drainage 1344–6, 1346 *F*
 endoscopy *see* nasal endoscopy
 function 1661
 lymphatic drainage 2713
 synechiae 1344–6, 1346 *F*
 tumours *see* sinonasal malignancy
 variations 1325–6
 vascular supply 1599 *F*
 see also nose
 nasal conduction 1356
 nasal consonants 2167, 2167 *T*
 nasal cycle 1358, 1376
 children 1358
 enlarged turbinates 1590
 mucosal swelling 1590
 olfactory sensitivity 1661–2
 nasal cysts 1073–4, 1708–9
 nasal defects
 aetiology 3016 *T*
 reconstruction *see* nasal
 reconstruction
 nasal diseases/disorders
 olfactory dysfunction 1667–8
 otalgia 3530
 see also individual diseases
 nasal dorsum
 autologous cartilage grafts 2972,
 2973 *T*
 deviation 2983 *F*
 irregularities 2982, 2983 *F*
 over-resection 2970
 reduction 2951 *F*
 sagging 2984 *F*
 nasal douching
 allergic rhinitis 1399
 chronic rhinosinusitis 1470
 nasal encephalocele
 (meningoencephalocele)
 1709
- nasal endoscopy 1344–54
 adenoid assessment 1096, 1096 *F*
 airway management 470
 anatomical aspects 1344–6
 anomalies 1346
 previously operated patients 1346,
 1346 *F*
 cancer surveillance 1351
 cleaning guidelines 2147
 clinical uses 1349–53
 complications 1347
 contact *see* contact endoscopy
 CT and 1344, 1350
 current knowledge/future
 research 1353
 epistaxis 1352–3, 1602, 1602 *F*
 equipment 1346–7
 historical aspects 1344
 infection control 2147
 inflammatory disease 1349–50
 CT and 1350, 1350 *F*
 cultures 1349–50, 1349 *F*
 differential diagnosis 1349 *F*, 1351 *F*
 postoperative care and
 evaluation 1350
 prognosis 1350
 midfacial segment pain 1727
 nasopharyngeal carcinoma 3391
 neoplastic disease 1350–1, 1351 *F*
 olfactory dysfunction 1664–5
 ophthalmologic procedures 1352,
 1353 *F*
 patient positioning 1347
 polyposis 1551, 1553, 1553 *T*
 rhinosinusitis 1442
 role 1344
 septal perforations 1583
 sinusitis 1720, 1720 *F*
 skull base lesions 1351–2, 1352 *F*
 technique 1347–8
 blue light endoscopy 1351–2,
 1352 *F*
 first pass 1347–8
 fluorescein endoscopy 1351–2,
 1352 *F*
 preparation 1347
 second pass 1348, 1348 *F*
 third pass 1348, 1348 *F*
 trauma due to 1347
 visualization 1347
 nasal fistula(e) 1502–5, 1504 *F*, 1506 *F*
 diagnosis 1504–5
 operative principles 1505
 prognosis 1505
 nasal folds 1315, 1316 *F*
- nasal fontanelle, anterior 1330
 nasal foreign bodies, children 1186
 epistaxis 1065
 management 1186
 medical negligence 1309–10
 presentation 1076, 1186, 1186 *F*
 nasal fossa 1321
 nasal fractures 1609–17
 aetiology 1609
 classification 1609–11
 class 1 1610, 1610 *F*
 class 2 1610–1, 1611 *F*
 class 3 *see* naso-orbito-ethmoid
 (NOE) complex fractures
 clinical presentation 1611–2
 complications 1614–5
 poor cosmetic result 1614–5
 septal 1615
 deformity, extent of 1610
 epidemiology 1609
 examination 1611–2
 history taking 1611
 injury, nature of 1609–10
 investigations 1612
 children 1296
 medical negligence 1310, 1730
 pathophysiology 1609–11, 1610 *F*,
 1611 *F*
 patterns 1610–1
 reduction methods 1613–4
 instruments 1613, 1613 *F*, 1614 *F*
 surgical indications 1612
 treatment 1612–4
 anaesthesia 1612–3
 septal management 1614
 nasal glands, contact endoscopy 764
 nasal glioma 1709
 children 1075, 1075 *F*
 nasal granulomatous
 conditions 1645–59, 1646 *T*
 definition 1645
 primary vasculitis 1646 *T*
 see also specific disorders
 nasal haemangioma 1075–6, 1075 *F*, 1708
 nasal implants 2971
 magnetic retention 2910 *F*, 2935 *F*
 nasal bridge 2907
 osseointegration 2909–10
 placement, ablative surgery and 2928
 polymer 121
 synthetic 2971
 nasal infections
 acute 1700–2
 bacterial 1700
 viral 1700–1

- bacterial 1700
 chronic 1458–68, 1702–4
 endoscopy 1349–50, 1349 *F*
lupus vulgaris 1702–3, 1702 *F*
 protozoal 1703–4
 viral 1700–1
see also specific conditions
- nasal inflammation
 asthma 1561–2
 chronic obstructive pulmonary disease 1561–2, 1562
 endoscopy *see* nasal endoscopy
 nonallergic, noninfectious 1382–3
 polyposis 1552
 rhinitis 1563
 nasal inlet restriction 3007
 nasal inspiratory flow rate (NIPF),
 occupational rhinitis 1420–1
 nasalis muscle 1322–4
 strengthening 3012
 nasal masses, congenital 1074–6
 nasal mastocytosis, nonallergic rhinitis
 vs. 1411
 nasal meatus
 inferior 1344–6
 first pass endoscopy 1347
 middle 1344–6, 1345 *F*
 second pass endoscopy 1348
 third pass endoscopy 1348, 1348 *F*
 superior 1344–6
 nasal mucosa
 allergic rhinitis 1393
 oestrogens, effects on 402–3
 olfactory dysfunction
 assessment 1664–5
 dryness 1667–8
 pregnancy-related changes 402–3
 surgical preparation 442
 nasal mucus
 composition 1359
 elasticity 1359–60
 odourant-binding proteins 1662
 rheology 1359–60
 surface cells 1362
 viscosity 1359–60
 measurement 1360
 nasal mycoses, epistaxis 1065
 nasal neoplasms *see* sinonasal malignancy
 nasal obstruction
 ACE inhibitor-induced 1410
 atrophic rhinitis 1465
 children 1070–8
 acquired disorders 1071 *T*, 1076–7
 congenital disorders 1070–6, 1071 *T*
- examination 1070
 fibro-osseous disease 1077
 foreign bodies 1076
 nasal masses 1074–6
 osseocartilagenous septal deformity 1076
 physiological rhinitis 1076–7
 septal haematoma/abscess 1076
 severity 1070
 skeletal anomalies 1070–3
 systemic diseases 1071 *T*
 chronic rhinitis 1591
 continuous positive airway pressure 1591
 HIV patients 241
 hypothyroidism 1366
 nasal cysts 1073–4
 nasal fractures 1612, 1615
 newborns 1070
 pregnancy 402–3
 septal pathology 1575
 septoplasty indication 1576–7
see also nasal polyposis
- nasal packing
 epistaxis 1602
 children 1064
 posterior 1603
 hypophysectomy 4112–3
- nasal papillae 764
 nasal pits 1811
 nasal placode 1315, 1811
 nasal polypectomy 1555–6
 medical negligence 1733
- nasal polyposis 1549–59
 aetiology 1550–1
 allergic fungal rhinosinusitis 221
 associated diseases 1550–1, 1550 *T*
 characteristics 1549
 children 1550
 clinical presentation 1552–3
 definition 1549
 diagnosis 1553–4, 1553 *T*
 differential diagnosis 1553–4
 epidemiology 1550
 epithelium 1551
 defects 1551
 inflammatory role 1551
 type 1551
 formation sites 1551
 genetic factors 1470
 goblet cells 1551
 imaging 1553
 inflammation 1552
 innervation 1551
 pathogenesis 1551–2
- pathology 1551–2
 prevalence 1550
 recurrence 1550
 staging 1553–4
 submucosal glands 1552
 surgery 1555–6
 treatment 421, 437–8, 1554–6,
 1556
 vascularity 1552
see also nasal polyps
- nasal polyps
 anterior cranial fossa
 meningioma 4144
 aspirin desensitization 442
 endoscopy
 contact endoscopy 765
 CT vs. 1350, 1350 *F*
 eosinophil apoptosis 62
 olfactory dysfunction 1661
 persistent rhinosinusitis and
 systemic steroid treatment 438
 topical steroid treatment 438
 unilateral 1383–4
see also nasal polyposis
- nasal reconstruction 3015–27
 aesthetic subunits 3016, 3017 *F*
 anatomy 3016
 composite cartilage grafts 3022–3
 distant pedicled flaps 3021–2
 dorsal nasal flap 3019
 excision 3018
 fixture placement 2928
 flap design 3019
 healing by secondary intention
 3018
 historical aspects 110, 3015–6
 local flaps 3019
 malignancy 3017
 midline forehead flap 3022
 nasolabial flap 3020, 3021 *F*
 osseointegration, midface region 2928
 paramedian forehead flap 3022
 physiology 3017–8
 graft healing 3017
 pinna, free sandwich graft 3022
 polymer implants 121
 primary closure 3018
 principles 3016–7
 prosthetic 2928
 regional pedicled flaps 3021–2
 septal flaps 3020–1
 skin flaps, historical aspects 110
 skin grafts 3019
 techniques 3018–23, 3018 *T*
 vascular bud growth 3017–8

nasal reflexes 1364–5
 axon reflexes 1364
 central control 1365
 cutaneous stimulation 1365
 stimulus-induced 1364
 nasal resistance, airflow 1357–8
 infants 1357–8
 racial differences 1357–8
 snoring 1591
 nasal resonance, speech 2166
 nasal sac 1315, 1316 *F*
 nasal secretions 1359
 granules 1359, 1359 *F*
 mucus *see* nasal mucus
 proteins 1360
 nasal septum *see* septum
 nasal speech (rhinolalia) 993
 nasal spine 2996
 nasal splints
 septal perforations aetiology 1584–5
 septal stabilization 1580
 nasal sprays
 epistaxis, paediatric 1065
 septal perforations aetiology 1584–5
 snoring 2329
 nasal surgery
 anaesthesia 503
 children 514–7
 cleft lip and palate 1003
 paediatric intensive care 546
see also individual procedures
 nasal tickle 1665
 nasal tip
 anatomy 2995–7, 2996 *F*
 deviations 2993
 skin 2995
 supporting mechanisms 2996–7
 nasal tip surgery 2964–5, 2995–3005
 cartilage-splitting incisions 2997,
 2997 *F*
 cephalic cartilage excision 2999,
 2999 *F*, 3000 *F*
 complications 3004
 defining procedures 2999–3000
 incisions 3000
 external rhinoplasty 2964–5, 2965 *F*,
 2998–9, 2999 *F*
 overprojecting tip 3000–2
 interrupted strip 3002
 suturing techniques 3000
 tip delivery approach 2997–8, 2998 *F*
 incision 2997–8, 2998 *F*, 3000
 tripod complex 2964, 2965 *F*
 underprojected tip 3002–4
 methods of increasing 3002

nasal trauma, medical
 negligence 1310–1
 nasal tumours *see* sinonasal malignancy
 nasal turbinates *see* turbinates
 nasal valve 1358, 1589, 3006–7
 nasal valve collapse 3006–14
 cartilaginous abnormalities 3007
 causes 3007 *T*
 diagnosis 3008–9
 lateral 3010
 pathology 3007–8
 physiology 3007
 primary valve 3007, 3008 *F*
 secondary valve 3007
 transmucosal separation 3007
 treatment options 3009–12
 nasal valve stenosis 3012, 3012 *F*
 nasal valve suspension 3012
 nasal vestibulitis 1064, 1064 *F*, 1186,
 1186 *F*
 nasendoscopy *see* nasal endoscopy
 Naseptin 651, 660 *T*
 nasoalveolar (nasolabial) cyst 1074,
 1320–1, 1926
 nasociliary nerve 1328, 3923
 nasogastric tubes
 dysphagia management, cancer
 patients 2791
 intractable aspiration 2097
 nasogastric tube syndrome 2635
 nasolabial angle
 anatomy 2995–7
 nasal tip rotation 3004
 skin 2995
 nasolabial (nasoalveolar) cyst 1074,
 1320–1, 1926
 nasolabial flaps 2830, 2840, 2849–50,
 2851 *F*
 nasal reconstruction 3020, 3021 *F*
 nasolabial muscle repair, cleft lip 1003,
 1003 *F*
 nasolacrimal duct 1690
 cysts 1074
 development 1315
 obstruction
 aetiology 1689
 children 1696
 incidence 1689
 surgery *see* dacryocystorhinostomy
 (DCR)
 opening 1329, 1344–6
 nasolacrimal mucocoele 1689, 1690 *F*,
 1691
 nasometry 1375–6
 nasooccipital acceleration 3214 *F*
 naso-orbito-ethmoid (NOE) complex
 fractures 1611, 1631–2
 classification 1611, 1631, 1631 *T*
 definition 1631
 management 1632
 signs/symptoms 1631–2, 1632 *F*
 nasopalatine duct cyst 1926, 1926 *F*
 nasopalatine nerve 1328, 1801, 1801 *F*,
 1802 *T*
 nasopharyngeal airway 2289, 2289 *F*
 obstructive sleep apnoea 1109
 nasopharyngeal angiofibroma 1297
 nasopharyngeal branchial cysts
 2119
 nasopharyngeal carcinoma
 (NPC) 2445–74
 aetiology 2446–8
 age-related 2346
 amelanotic melanoma 2455
 biopsy 2455, 2455 *F*
 cervical lymphadenopathy 716, 2451,
 2451 *F*
 chemotherapy 2460
 children 1257–8
 clinical features 2450–2
 diagnosis 2452–8, 2453 *F*
 diagnostic delays 2455–6
 differential diagnosis 2455
 dysphagia 2033
 environmental carcinogens 2447–8
 epidemiology 2445–6, 2446 *F*
 Epstein–Barr virus 208, 2346, 2353,
 2447, 2448, 2456
 examination 2453–5
 follow-up 2460–1
 fossa of Rosenmüller 2454–5,
 2454 *F*
 genetics 2346, 2446–7
 headache 2452
 histological classification 2449–50,
 2451 *F*
 history 2453
 HLA associations 2354, 2446–7
 imaging 2456–8, 2457 *F*
 immunochemistry 2456
 immunology 2448
 cell-mediated immunity 2448
 immunotherapy 2467
 incidence 2346
 infiltrative type 2449, 2450 *F*
 investigations 2456–8
 metastases, parapharyngeal space
 tumours 2527, 2536
 N stage definition 2364, 2364 *T*
 orbital disease 2452 *F*

otitis media with effusion 3388–9,
3389
pathogenesis 2448
pathology 2448–9, 2450 *F*, 2451 *F*
photodynamic therapy 2467
pituitary involvement 4104
prognosis 2464
radiotherapy 2459–60, 2460 *F*
complications 2464–7, 2465 *F*,
risk factors
 diet 2346, 2354
 infection 2346
 occupation 2346
 tobacco 2346
salvage treatment 2461–4, 2461–2
 anterior approaches 2462–3
 disseminated disease 2464
 inferior approaches 2463
 lateral approach 2463
 local failures 2461–2
 local persistence 2461–2
 local recurrence 2462
 regional failure 2462
 simultaneous local/regional
 failure 2464
surgery 2462
transnasal transmaxillary
 approach 2462
transpalatal approach 2463
serology 2448, 2456
staging 2458
 AJCC classification 2459 *T*
 Ho classification 2458, 2459 *T*
 TNM 2362 *T*, 2365 *T*
treatment 2458–64
 primary 2459–61
trismus 2452
undifferentiated 2451 *F*
Yankauer nasopharyngeal
 speculum 2455
nasopharyngeal dermoid 2119
nasopharyngeal swabs, acute otitis
 media 914
nasopharyngeal tonsil *see* adenoid(s)
nasopharyngeal tumours
 carcinoma *see* nasopharyngeal
 carcinoma (NPC)
 ontogenetic 2119
 trigeminal nerve damage 3927
 WHO classification 2449 *T*
nasopharyngoscopy
 flexible *see* flexible
 nasopharyngoscopy
nasopharyngeal carcinoma 2454,
2454 *F*

nasopharynx
 anatomy 2107–15, 1344–6, 1944,
 2365
 arterial supply 2113
 benign conditions 2116–29
 acquired 2121–2
 acquired cystic 2122
 neoplastic lesions 2122–4
 tortuous vessels 2120, 2120 *F*,
 2121 *F*
 biopsy 2455, 2455 *F*
 blood clot, adenoidectomy-related
 1098
 blood vessels 2113
 bones 2110–1
 communication 2107
 congenital conditions 2116–20
 form deficits 2119–20
 contact endoscopy 766–7
 abnormal appearance 766–7
 normal appearance 766
 epithelium 2108
 examination 2453–5
 fascial relations 2108–10
 cervical fascia layers 2109 *F*, 2110–1
 cervical fascial spaces 2109–10,
 2109 *F*, 2110 *T*
 floor 2107
 inferior wall 1944
 innervation 2114
 lateral wall 2107, 2108 *F*
 muscles 2112 *F*
 lymphatic drainage 2108, 2113–4,
 2713
 microflora 195–6, 196 *T*, 2121
 mucosa 1947, 2108
 muscles 2111–3
 masticator 2112–3
 palatal 2112, 2112 *F*
 pharyngeal 2111–2
 prevertebral 2112
 muscular layer 2108
 posterior wall 1944, 2107
 roof 2107
 submucosa 2108
 surgery, paediatric anaesthesia 514–7
 surgical approaches 4054–66
 anterior approaches 4056–9
 anterolateral approaches 4059–61
 classification 4054–6
 combined approaches 4062–5
 facial translocation 4064–5, 4064 *F*
 infratemporal approach type C 4061
 lateral approaches 4061
 preoperative assessment 4056

subtemporal-preauricular
 infratemporal fossa
 approach 4062–4
transcervical approach 4058–9
transmandibular approach 4058–9
transoral approaches 4056–8
 transpalatine approaches 4056–8
venous drainage 2113
wall layers 2108
nasopulmonary reflexes 1364
nasotracheal intubation 1132–3
naso-turbinal *see* agger nasi
natalizumab 3772
natal teeth 1817
National Anonymous Tonsil Archive
 (NATA) 1238
National Cancer Data Set, head and
 neck cancer data
 collection 2375–6, 2376
National Clinical Assessment Authority
 (NCAA) 605
National Clinical Assessment Service
 (NCAS) 572
National Clinical Audit Support
 Programme (NCASP), head and
 neck cancer audit 572
National Commission for Care
 Standards 2803
National Confidential Enquiry into
 Perioperative Deaths
 (NCE-POD) 2049, 2058–9
paediatric anaesthesia 507
National Health Service (NHS)
 accessory devices, hearing
 impaired 3670
Centre for Involvement 574
Community Health Councils
 574
 performance ratings 572
National Institute for Health and
 Clinical Excellence (NICE) 588
 patient preparation for surgery
 guidelines 461, 461 *T*, 462 *T*
 quality assurance 571, 572
 tonsillectomy guidelines 1235
National Institute on Deafness and
 Other Communication Disorders
 (NIDCD) 3701
National Laryngectomee
 Association 2623
National Library for Health and
 Clinical Evidence, ENT and
 Audiology Library 646, 647 *T*
national minimum data set
 (NMDS) 2375

National Patient Safety Agency (NPSA) 573, 605
 National Prospective Tonsillectomy Audit (NPTA) 1231, 1232, 1234 *T*
 National Reporting and Learning System (NRLS) 573
 National Screening Committee 822
 National Service Frameworks, standards delivery 571
 National Study of Hearing, tinnitus epidemiology 3597–8
 National Temporal Bone Registry, Menière's disease 3696
 naturalism 583
 nausea and vomiting
 palliative care, head and neck cancer 2787–8, 2787 *T*
 vertigo, children 1042
 n-butyl-2-cyanoacrylate (NBCA)
 endovascular embolization 733–4
 paragangliomas 3953
 skull base tumour embolization 3952
 Nd:yAG laser, juvenile-onset recurrent respiratory papillomatosis 1176–7
 near total laryngectomy, laryngeal tumours 2614
 near-total laryngectomy 2614
 nebulization, supraglottic obstruction 480
 neck
 benign disease 1777–88
 dissection 2728
 investigation 1777
 blood vessels 1749–50
 cutaneous 2734 *F*
 cross-sectional anatomy 1756–9
 cystic lesions 1777–9
 development 1739–40
 examination 1754–65
 children 779
 history taking 1754
 reliability 1755
 fascia 1743, 1744 *F*, 2108–9, 2109 *F*
 deep *see* deep cervical fascia
 superficial 1743, 2108
 HIV patients 246–7, 1784
 children 1213
 imaging 1754–65
 HIV patients 247
 techniques 1755–6
 see also individual techniques
 infections *see* cervicofacial infections
 Kaposi's sarcoma 246
 lymphadenopathy *see* cervical lymphadenopathy

lymphatics *see* cervical lymphatics
 muscles 1745–6
 nerves 1750–2
 palpation 1754–5
 reliability 1755
 root of *see* root of the neck
 surface anatomy 1745
 surgical anatomy 1739–53
 triangles 1741–3, 1742 *F*
 tumours, benign 1782–3, 1783 *T*
 zones 1768
 neck dissection 2731–49
 accessory nerve damage 2807
 contraindications 2727–8
 elective 2723–4
 arguments against 2723
 arguments for 2723
 incision 2731–3, 2732 *F*
 'less than five level,' N1 disease 2726
 lip cancer 2548
 oral cavity tumours 2564–5
 staging 2564–5
 patient positioning 2731
 preoperative preparations 2731
 radical *see* radical neck dissection
 salivary gland tumours 2510
 salvage surgery 2728
 selective *see* selective neck dissection
 sternomastoid muscle removal 2726
 tracheostomy 2731
 tumour recurrence rates 2726, 2728
 types 2731
 see also metastatic neck disease
 neck lymphadenopathy *see* cervical lymphadenopathy
 neck masses, medical negligence 1310
 neck spaces 1743–5, 2109–10, 2109 *F*,
 2110 *T*
 abscesses *see* deep neck space abscesses
 midline 2109
 see also individual spaces
 neck swelling 1777–88
 benign 1739
 children
 assessment 1210
 examination 1211–2
 nature of 1212
 sites of 1211–2
 examination 1754
 neck trauma 1766–76
 active observation 1769
 aetiological classification 1768
 airway protection 1766–7
 breathing 1767
 cervical spine protection 1766–7
 circulation 1767
 emergency surgery indications 1769
 exploration
 mandatory 1768–9
 mandatory *vs.* selective 1768–9
 principles 1774
 selective 1769, 1770 *F*
 history 1767–8
 investigations 1769
 management, selective
 conservative 1769 *T*
 neurological injury 1774
 perfusion 1767
 primary survey 1766–7
 adjuncts to 1767
 secondary survey 1767–8
 treatment delay 1771
 vascular injury 1772
 venous injuries 1773–4
 zones of neck 1768, 1768 *F*
 neck tumours, benign 1782–3, 1783 *T*
 necrobacillosis 200–1
 necrosis 36, 57, 57 *T*
 apoptosis *vs.* 57 *T*
 noise-induced hearing loss 3549
 necrotic bone, benign necrotizing otitis externa 3333, 3333 *F*
 necrotic tissue healing 98
 necrotic wounds, dressings 101
 necrotizing external otitis *see* malignant otitis externa
 necrotizing fasciitis
 neck 1785, 1785 *F*
 parapharyngeal abscess 2000
 necrotizing otitis externa *see* malignant otitis externa
 necrotizing sialadenitis, subacute 1915
 necrotizing sialometaplasia 1915
 needle aspiration of pus, peritonsillar abscess 1997
 needle cricothyrotomy 476–7
 needle stick injuries 239–40
 negligence (definition) 1305
 Negus pharyngoscope 2052, 2053 *F*
Neisseria 199
 see also individual species
Neisseria gonorrhoeae 199
Neisseria lactamica 199
Neisseria meningitidis 199
 adult epiglottitis 2250
 associated diseases 199
 vaccine 199
Neisseria sicca 199
 nelfinavir 239
 Nelson's syndrome 300, 311, 4102, 4115

- Neo-Mercazole (carbimazole)
see carbimazole
- neomycin 232
- active mucosal chronic otitis
 - media 3424
 - chronic rhinosinusitis 1471
 - ototoxicity 3239
- neonatal hearing screening *see* newborn hearing screening
- neonatal intensive care unit (NICU), deafness and 845–6
- neonatal necrotizing tracheobronchitis *see* pseudomembranous croup
- neonatal rhinitis 1076–7
- neonatal teeth 1817
- neonate(s)
- drug prescribing 415
 - facial nerve injury 3889–90, 3890 *T*
- neoplasia/neoplasms
- adenoid 1096
 - dysphagia aetiology 2032–3
 - facial paralysis, childhood 1058
 - HIV associated
 - cervical 246
 - nasal 241 - jugular foramen 4029–34
 - mouth ulcers 1832
 - multiple endocrine *see* multiple endocrine neoplasia (MEN)
 - nasal *see* sinonasal malignancy
 - nodular thyroid disease 361
 - oral mucosa 1823
 - salivary glands, children 1248
 - tonsils 1225, 1226
 - tumourigenesis mechanisms 8
 - vestibular labyrinth *see* vestibular labyrinth
 - vestibular nerve 3687–91
- nephrotoxicity, antimicrobial-induced 236
- nerve(s)
- demyelination 3848, 3848 *F*
 - epaptic transmission 3848–9
 - tissue engineering 126
- nerve excitability test (NET), facial nerve 3878–9, 3879 *T*
- nerve-muscle pedicle graft, vocal folds 2196
- nerve of the pterygoid canal 3910, 3924, 3928
- nerve of Wristsberg 3871
- nerve sheath tumour *see* schwannoma(s)
- nerve to stapedius 3928
- nerve transfer, facial nerve repair 2509
- nervus intermedius 3871
- geniculate neuralgia surgery 3532
 - vestibular schwannoma removal 3980
- nervus spinosus 3907
- nervus terminalis 1662
- netilmicin 3676
- neural crest cells
- ear development 815
 - facial development 1810–1
- neural dyssynchrony *see* auditory neuropathy/dyssynchrony
- neuralgia(s)
- facial pain 1724
 - geniculate 3532
 - glossopharyngeal *see* glossopharyngeal neuralgia (GPN)
 - otalgia 3531–3
 - postherpetic 1724
 - post-herpetic 2079
 - Sluder's 1723–4
 - sphenopalatine ganglion 1723
 - trigeminal *see* trigeminal neuralgia (TN)
- neural response telemetry (NRT),
- auditory neuropathy/dyssynchrony 3852
- neural stem cells 67
- differentiation 68
 - nervous tissue regeneration 75
- neural synchrony disorders 3849
- neurapraxia 3873
- neurectomy, special needs children 789
- neurilemoma *see* schwannoma(s)
- neurinoma *see* schwannoma(s)
- neuroanatomy 3911–41
- neuroblastoma 1258, 1258 *F*
- olfactory 2420–1
- neurodegenerative diseases, olfactory dysfunction 1669, 1673–4
- neuroendocrine carcinoma, larynx 2604
- neuroepithelial deafness 811–2
- neurofibroma(s)
- larynx 2600 *T*
 - neurofibromatosis 2527, 4002
 - orbital 3915
 - parapharyngeal space 2527
 - ultrasound examination 726
- neurofibromatosis 3688–90
- history 3998
 - incidence 2527
 - molecular analysis 12
 - pontine tumours 3922
 - type 2 (NF2) *see* neurofibromatosis 2 (NF2)
- neurofibromatosis 1 (NF1) 3689, 3998
- meningiomas 4008–9
- soft tissue sarcomas 1931
- type 2 *vs.* 4001
- neurofibromatosis 2 (NF2) 3998–4006, 3689–90
- adults 4000
 - aetiology 3689–90
 - childhood presentation 4000
 - clinical management 4002–3
 - risk assessment 4003, 4003 *F*
 - clinical manifestations 3690, 3945, 4000–1, 4000 *T*
 - adult *vs.* paediatric presentation 4000
 - cutaneous/subcutaneous 4001, 4001 *F*
 - neuropathies 4000
 - ophthalmic 4000
 - clinical outcomes 4003
 - current knowledge/future research 4004
 - diagnosis/differential diagnosis 4000–1
 - criteria 4001
 - NF1 *vs.* 4001
 - diagnostic delay 4143
 - epidemiology 3999–4000
 - birth incidence *vs.* diagnostic prevalence 3999
 - gene therapy 4004
 - genotype–phenotype correlation 3999, 4000
 - histopathology 3690
 - historical aspects 3998
 - imaging 4001
 - molecular genetics and NF2 gene 3998–9
 - diagnosis and screening 4001, 4003, 4004
 - maternal gene effects 4000
 - mosicism 3999, 4001
 - penetrance 4000
 - neurofibromas 4002
 - neuroradiology 4002
 - NF2 protein (merlin; schwannomin) 3999
 - pathology 4000 *T*, 4002
 - radiosurgery 3994–5
 - malignant transformation 3993, 3995
 - screening 4003–4
 - two hit theory of tumourigenesis 3995
 - vestibular schwannoma 3957, 3998, 4000, 4002, 4003
 - radiosurgery 3994–5
 - neurofibrosarcoma 1259 *T*

neurogenic stem cells *see* neural stem cells
 neurogenic tumours
 neurofibroma *see* neurofibroma(s)
 parapharyngeal space 2525–6
 schwannoma *see* schwannoma(s)
 ultrasound 726
 neurohormones, hypothalamic *see* hypothalamus
 neurohypophysis 297, 308
 associated nerves 297
 embryology 295
 hormones 297, 300, 308
 see also individual hormones
 magnetic resonance imaging 305
 children 305
 neurosecretory phospholipid granules 305
 neurolabyrinthitis *see* vestibular neuritis
 neurological gait disorders, balance problems and 3707
 neuroma *see* schwannoma(s)
 neuromuscular blockage 494–5
 airway management 494
 intravenous induction 495
 monitoring 500
 paediatric anaesthesia 513
 neuronavigation, skull base tumours 4056
 neuropathic pain, advanced head and neck cancer 2785
 neuropathy
 auditory *see* auditory neuropathy/dyssynchrony
 diabetic 401–2, 2080
 neurofibromatosis 2 4000
 neuropeptides, thyroid gland 319
 neuropeptide Y (NPY) 1364
 neuroplasticity, paediatric cochlear implantation 861–2
 neuroradiology
 CPA tumours 4007
 interventional *see* interventional neuroradiology (INR)
 neurofibromatosis 2 4002
 see also individual modalities; specific indications
 neurorrhaphy, facial nerve repair 2509
 neuroticism, globus 2039
 neurotmesis 3873
 neurotransmitters
 auditory nerve fibres 3197
 inner hair cells, auditory neuropathy/dyssynchrony 3849

nasal 1364
 parasympathetic 1364
 olfactory receptor cells 1662–3
 sleep patterns 2306
 see also individual transmitters
 neurotrophic factors, ototoxicity prevention 3302
 neurotrophism 70
 neurulation 69, 792–3, 793 F
 neutropenia 273
 causes 273 T
 cyclical 177 T, 178
 severe congenital 177 T, 178
 neutrophil(s) 89, 273
 allergic rhinitis 1392
 wound healing 89
 neutrophilia 273
 newborn
 ear splintage 975
 fluid management 543–4
 nasopharyngeal bacterial colonization 195
 newborn hearing screening 826–8, 848, 3290–1
 acoustic brainstem evoked responses 3846
 ‘at risk’ screening 827
 auditory neuropathy/dyssynchrony 3846
 cost-effectiveness 828
 costs 826
 cut-off level 827
 evoked physiological measurements 3290–1
 ‘family friendliness’ 828
 models 827
 otoacoustic emissions 3846
 performance 827–8
 principles 3290
 programme sensitivity 828
 quality assurance 828, 828 T
 Newborn Hearing Screening Programme 824, 848
 Newton’s first law 3210
 Newton’s second law 3210
 New York Heart Association (NYHA) angina classification 458 T
 NF2 gene 3998, 3998–9
 diagnosis and screening 4001, 4003
 maternal gene effects 4000
 mosaicism 3999
 nonpenetrance 4000
 NF2 protein (merlin; schwannomin) 3999
 The NHS Plan 570–1

nickel
 food allergy 1426
 sinonasal malignancy 2418
 nicorandil 1835
 nicotinamide, as radiosensitizer 50
 nicotinamide adenine dinucleotide 199
 nicotinic α -9-cholinergic receptor 3606
 nifedipine
 achalasia 1289
 skin flap survival 113
 nimodipine 3617, 3797
 nimorazole 50, 2756
 IXth nerve *see* glossopharyngeal nerve (IX)
 Nissen fundoplication 2262
 nitric oxide
 chronic rhinosinusitis 1473–4
 haemostasis inhibition 278
 nitric oxide donors, chronic rhinosinusitis 1473–4
 nitric oxide synthase
 salivary gland tumours 2495
 skin flap survival 113
 nitro blue tetrazolium test 169
 nitrogen, decompression illness 3515
 nitroglycerin (GTN) 113
 nitroimidazole 50, 2756
 nitrous oxide anaesthesia, ear surgery 502
 children 513–4, 514
 N-methyl-D-aspartate (NMDA) receptor, tinnitus 3600
Nocardia species 1785
 nodular melanoma 2401 T
 nodular thyroid disease 330, 360–3
 adenomatous 330, 719–20, 719 F
 aetiology 360, 360 T
 antibody status 361
 cystic nodules 363
 cystic vs. solid 330
 differential diagnosis 721–4
 epidemiology 360
 Grave’s disease and 331, 335
 investigation 361–2, 361 F
 in vitro investigations 332
 malignant 360, 360 T, 362, 2669, 2676 T
 see also thyroid cancer
 medical management 362–3
 multinodular goitre 360–1
 prevalence 360
 radioiodine therapy 349, 362–3
 serum calcitonin 361

- solitary nodules 2668–9, 2668 *F*
 imaging 335
 nontoxic, management 363
 toxic 331, 335, 363
- surgery 351
- thyroid functioning tests 361
- thyroid peroxidase antibodies 361
- ultrasound scanning 362, 718
- nodule(s)
 definition 1699–700
thyroid see nodular thyroid disease
vocal folds see vocal nodules
- noise 2165
see also sound
 noise exposure levels 3171
 measurement 3171
- noise generators, tinnitus 3615–6
 treatment length 3616
- noise immission level 3171
- noise-induced hearing loss (NIHL) 3548–57
 audiometry findings 3550 *F*
 claims 3554–5
 definition 3548–9
 diagnosis 3551, 3553
 equal energy principle 3171
 examination 3552–3
 history 3551–2
 incidence 3300
 light microscopy findings 3550 *F*
 loudness discomfort levels 3553
 management 3553
 non-specific 3554
 specific 3554
 mechanism 3300–1, 3301 *F*
 medicolegal aspects 3553
 pathology 3549–51
 apoptosis 3549
 metabolic mechanisms 3549
 necrosis 3549
 predisposing factors 3549–51
 structural mechanisms 3549
 prevention 3301–2, 3553–4
 report writing 3553
 social issues 3552
 temporal threshold shifts 3298
 tinnitus 3599, 3601
- noise levels, communication abilities 3552 *T*
- noise ratios 2180–1
- noma (cancrum oris) 1822
- Nomarski technique 3239
- nomograms, likelihood ratios 657 *F*
- nonallergic noninfectious perennial rhinitis (NANIPER) *see rhinitis, idiopathic*
- nonallergic rhinitis 1408–14
 diagnosis 1412
 differential diagnosis 1411
 food-induced 1383, 1411
 pathophysiology 1409
 perennial 1408–14
 pollution 1411
 surgery 1412
 symptoms 1408
 therapy 1412
 nonconventional 1412
 types 1409–11
- nonallergic rhinitis with eosinophilia syndrome (NARES) 1382–3, 1410–1
 prevalence 1411
 Samter's triad 1411
- nonauditory devices 3668
- non-coding sequences, genes 16
- non-Hodgkin's lymphoma (NHL)
 adenoid 1096
 children 1254–5
 diagnosis 1255
 prognosis 1255
 staging 1255
 treatment 1255
 FDG-PET imaging 694, 694 *F*
- HIV patients
 nasal obstruction 241
 neck 246, 246 *F*
 oral 243
- larynx 2604
- oropharynx 2580
- pinna 3359
- salivary glands 2501
- thyroid 720
- tonsil 2580, 2581 *F*
- nonimmunological contact urticaria (NICU) 1424–5
- noninsulin dependent diabetes mellitus (NIDDM) *see diabetes mellitus, type 2*
- noninvasive blood pressure monitoring 497
- nonmaleficence (ethical principle) 562, 582
- nonmegaloblastic anaemia 269
- non-nucleoside analogues 239
- non-nucleoside reverse transcriptase inhibitors 233
- nonopioids
 cancer pain management 2785–6
see also specific drugs
- nonrapid eye movement sleep (non-REM) 2305
 airway activity 2308–9
 neural activity 2306–7
- nonrecurrent laryngeal nerve 318
- nonrespiratory sleep disorders 2310–1
- nonsense mutation 9–10
- nonspecific immunity, nasal 1361
- nonsteroidal antiinflammatory drugs (NSAIDs)
 adenotonsillectomy 515–6
 adverse effects
 epistaxis 1600
 mouth ulcers 1835
 platelet dysfunction 287
- anaesthesia premedication 490 *T*
- dosage, children 516 *T*
- epistaxis 1600
- intolerance, nasal polyposis 1553
- pain management, advanced head and neck cancer 2785–6
- pharyngitis, acute 1984
- tonsillectomy 1993
- nonsyndromic autosomal dominant inherited hearing impairment 3559 *T*, 3560 *T*
- nonsyndromic autosomal recessive inherited hearing impairment 3559 *T*
- nonsyndromic cleft lip 999
- nonsyndromic deafness classification 811
 genetic mutations 18
- nonsyndromic recessive auditory neuropathy (NSRAN) 3846
- nonsyndromic X-linked inherited hearing impairment 3559 *T*
- nontuberculous mycobacteria (NTM) 1214–5, 1215 *F*, 1244
- Noonan syndrome 968
- noradrenaline critical care patients 529–30
 nasal vasculature 1364, 1365
 vestibular neurochemistry 3794
- 'no reflow phenomenon' 113
- normalized noise energy (NNE), voice evaluation 2181
- normochromic anaemia 269
 preoperative management 270
- normocytic anaemias 268 *T*, 269–70
 preoperative management 270
- Norie syndrome 813 *T*
- Northern blotting 6

North of England and Scotland Study
on Tonsillectomy and
Adenoideectomy in Children
(NESSTAC) 1231

nortriptyline
migrainous vertigo 3804
side effects 3804
tinnitus 3617

nose
absent 1073, 1320
anatomy 1315–43, 1661–3
comparative 1321–2
cosmetic 2928
sense of smell and 1661–2,
1661 F
subunits 2960–1, 2961 F

anthropoid 1321

arteries 1362

autonomic nervous system 1363,
1363 F

motor nerves 1363
sensory nerves 1363

bones 1324, 1324 F, 1325 F

comparative anatomy 1321–2

development 803, 1315–21, 1316 F
anomalies 1320–1

deviated *see* deviated nose

examination, children 778, 779 F

external *see* external nose

HIV infection 241–2

humidification 1356

hypophysectomy and 4105, 4113

immunology 1361–2, 1362 T
acquired immunity 1361–2
nonspecific immunity 1361

innervation 1362–5

lateral wall
anatomy 1329–38, 1329 F
blood supply 1337–8, 1337 F
bony structures 1330 F
clefts 1332
histology 1337
innervation 1338, 1338 F
lymphatic drainage 1338
middle meatus 1330–1, 1330 F
spaces 1332
variations 1334, 1334 F, 1335 F,
1335 T
venous drainage 1337–8

lower airway protection
chemical 1358–61
mechanical 1358–61

lymphatic drainage 2418

mycotic diseases 215–6

neural systems 1662

neuroepithelium *see* olfactory
(neuro)epithelium

neurotransmitters 1364

physiology 1355–71, 1356 T, 1661–3
current knowledge
deficiencies 1369
future research 1369

respiration 1355

retronal airflow 1661

rheumatological diseases 184–5

vasculature 1362–5, 1596–7
drugs acting on 1365–6, 1365 T
flow measurement 1363
flow variations 1363
microanatomy 1362–3, 1362 F,
1363 F
venous drainage 1597

voice production 1366

*see also entries beginning nasal; entries
beginning olfactory; olfaction;
specific components*

nosebleed *see* epistaxis

nostrils *see* external nares (nostrils)

Nothnagel's syndrome 3921

notifiable diseases, ethics 587

Nottingham Health Profile 637, 638–9

NPL tables, noise-induced hearing
loss 3553

N-ras mutation 2409

nuclear medicine
children 1299–300, 1300 F
parathyroid gland
assessment 1299–300, 1300 F
see also specific techniques

nuclear membrane 2379–80

nucleic acid synthesis inhibitors 230–1

nucleoside analogues 232
3'azido2'deoxythymidine
zidovudine 239

HIV 239
mechanism of action 239
side effects 232, 233, 239

nucleoside reverse transcriptase
inhibitors 233

nucleotide deletion 9–10

nucleotide insertion 9–10

nucleus ambiguus 2155, 3935
pharyngeal innervation 2075
swallowing 1959

nucleus of the tractus solitarius 3935

nucleus prepositus hypoglossus, gaze
holding 3225–7

nucleus raphe interpositus lesions
3715

nucleus retroambigualis (NRA) 2158

nucleus tractus solitarius (NTS)
injury 1847
taste 1841–2, 1843 F

Numb 68

number-letter combination speech
testing 3317

numbers needed to treat (NNT) 652,
660
calculation 661, 665

nutcracker oesophagus 2032, 2066

nutritional disorders, olfactory
dysfunction 1673–4

nutritional status
assessment 94–5
wound healing 94–5

nutritional support, critical care
patients 530–3

Nyquist sampling theorem
2179–80

nystagmus 3213, 3922
acute unilateral vestibular
deafferentation 3219–20

benign paroxysmal positioning
vertigo 3750, 3761

benign paroxysmal vertigo of
childhood 1044

congenital 3725, 3725 F, 3922

definition 3213

left 3213, 3215 F

Menière's disease 3757

recording 3213

semicircular canal 3749, 3749–50

skull base lesions 3946

superior semicircular canal
dehiscence 3763

vestibular disorders 3791

vestibular neuritis 3752

waveforms 3725
see also individual types

nystagmus quick phase 3227 T

nystatin 233
candidiasis 224, 2789

otomycosis 214

obesity
airway management 494
obstructive sleep apnoea 2308,
2314, 2315

obesity hypoventilation
syndrome 2313–4

oblique arytenoids 2136 T

obliterated cochlea, paediatric cochlear
implantation 865

obscure auditory dysfunction
(King-Kopetsky syndrome) 3273

- observational studies,
epidemiology 625–6
- observer bias 2344
- obstructive ‘awake’ apnoea 1106
- obstructive emphysema, foreign
bodies 1188, 1190 *F*
- obstructive sleep apnoea (OSA) 2307–9
age and 2308
anaesthesia 492
children 1102–13
adenoids 1104, 1105 *F*
anaesthesia 509, 515
clinical examination 1104–5
craniofacial disproportion 1104
imaging 1107–8, 1108 *F*
investigations 1105–8
postoperative complications 1110
prevalence 1103
recommendations for
investigations 1106 *T*, 1108
risk factors 1103, 1103 *T*
special needs 787, 788 *F*
surgery 1109–10
symptoms 1104
tonsillar involvement 1226
tonsillectomy, biopsy
purposes 1990
treatment 1108–10
- clinical examination 2315
- daytime sleepiness assessment 2315
- definitions 1102–3, 1103
- diagnosis 2315–20
criteria 2319–20
- Down’s syndrome 1109
- driving 2322
- enlarged turbinates 1591
- epidemiology 1102–3, 2314–5
- follow-up 2322
- gender 2308
- home multichannel testing 2316–8,
2319 *F*
- investigations, choice of 2318–9
- legal issues 2322
- long-term consequences 2310 *F*
- long-term postoperative follow-up 1110–1
- medical conditions associated
with 2314–5
- medical management 2313–24,
1108–9
- morbidity 1103
- nasal obstruction 2331
- nasal surgery 2331
- nasopharyngeal airway 1109
- obesity 2308
- obstruction sites 2307, 2308 *F*
- occasional procedures 2331–2,
2331 *T*
- oxygen saturation levels 2331
- pathogenesis 2308–9
- pharyngoplasty 1011–3
- post-intervention sleep study 1111
- risk factors 2314–5
- sleep position 2309
- snoring vs. 2327–8
- symptoms 2313, 2315
- tonic muscle activity 2308–9
- upper airway shape 2309
- upper airway size 2308
- vascular overperfusion 2309
- obstructive sleep apnoea/hypopnoea
(OSAH) *see* obstructive sleep
apnoea (OSA)
- obturation, septal perforations 1585
- obturator 2915
- occipital area 3898
- occipital bone 3898
squamous part 3899
- occipital condyle 3899
- occipital plagiocephaly 1024, 1026
- occupational asthma 1415, 1561
- occupational rhinitis (OR) 1415–23,
1382
- air pollution 1419
- allergic 1382, 1416
causative agents 1416, 1417 *T*
IgE mechanism 1416
- causes 1382, 1416
- definition 1415
- diagnosis 1420–1
- examination 1420
- exposure response 1420
- high risk occupations 1418–9
- history taking 1420–1
- immunotherapy 1421
- investigations 1420–1
- latency period 1416
- management 1421
- medical therapy 1421
- nonallergic (irritant) 1382, 1410,
1416–8
causative agents 1416–8, 1418 *T*
corrosive reactions 1416–8
neurogenic inflammation 1416
- olfactory disorders 1416–8
- symptoms 1410, 1416
- triggers 1410
- pathogenesis 1416–8
- prevalence 1415–6
- prevention 1421
- risk factors 1416
- symptoms 1420
- octave confusion, tinnitus 3612
- octopus cells 3141
- octreotide 4101
- ocular motility
blepharoplasty, upper eyelid 3055
frontoethmoidectomy 1509
- ocular tilt reaction
labyrinth destruction 3749
mastoid stimulation 3751
vestibular neuritis 3752, 3754 *F*
- oculoauriculovertebral dysplasia 1033,
1055, 3642–3
- oculocardiac reflex 3065
- oculography 3723–30
indications 3723, 3723 *T*
techniques 3723–4
visually guided eye movements 3726
- oculogyric crisis, postencephalic
Parkinson’s disease 3921
- oculomotor nerve (III) 3917
anatomy 3917, 3918 *F*, 3919 *F*, 3920 *F*
central anatomy 3917, 3920 *F*
central mechanisms 3919–21
examination 3710–1
fascicles 3917
frontal sinus fractures 1507
inferior ramus 3917
lesions
pituitary tumour extension 4100
pupillary 3916–7, 3917
- pupillary fibres 3917
superior ramus 3917
- oculomotor nucleus 3917, 3920 *F*
- odds ratio 663–4
- epidemiological research 622, 622 *T*,
628
- systematic reviews 663–4
- odonto-ameloblastoma 1927–8
- odontoblasts 799–800
- odontoclasts 1804–5
- odontogenic abscess *see* dental abscess
- odontogenic cysts 1922–6
botryoid 1925
calcifying 1925–6
definition 1921
development 1922
glandular 1925
- odontogenic keratocysts 1924–5
diagnosis 1925
incidence 1924–5
presentation 1925
squamous cell cancer 1938–9
treatment 1925

odontogenic myxoma 1928–9
 odontogenic tumours
 adenomatoid 1928
 benign 1923 *T*
 classification 1923 *T*
 incidence 1921
 malignant 1923 *T*
 see also individual types
 odontoid 2111
 odontomes 1929
 odourant-binding proteins 1662
 odours
 classification 1368
 nervous inhibition 3913
 O'Dwyer, Joseph 772
 odynophagia
 advanced head and neck cancer 2790
 chronic laryngitis 2259
 dysphagia-related 2025–6
 odynophonia, chronic laryngitis 2259
 oedema
 angioneurotic *see angioneurotic oedema*
 cerebral *see cerebral oedema*
 chronic, vocal folds *see Reinke's oedema*
 Graves' disease 343
 nasal polyposis 1552
 post-blepharoplasty 3064
 subglottic 1128, 1129, 2251
 uvula 2006
 oedematous wounds, wound
 dressings 101
 oesophageal atresia 1282–7
 associated anomalies 1283, 1283 *T*
 VACTERL complex 1283–4
 diagnosis 1284, 1284 *F*, 1285 *F*
 prenatal 1284
 dysphagia 2030
 embryology 801–2
 gastro-oesophageal reflux 1287
 incidence 1283
 management 1284–5
 mortality 1283, 1283 *T*
 pathogenesis 1283, 1943–4
 prognosis 1285
 respiratory infection 1287
 surgical repair 1284–5, 1286 *F*
 anastomotic leaks 1285
 complications 1285–7
 results 1285
 types 801–2, 805 *F*, 1283, 1283 *T*
 see also tracheo-oesophageal fistula
 oesophageal biopsy, laryngeal
 stenosis 1154

oesophageal body diverticulae 2072
 oesophageal carcinoma 2067–9
 aetiology 2633–4
 anatomical subsites 2638 *T*
 barium swallow appearance 2027 *F*
 cell biology 2635–7
 cervical node metastases 2641
 cervical tumours 2640
 endoscopic appearance 2067 *F*
 genetic alterations 2635
 histology 2637–8
 imaging 2068 *F*
 incidence 2067
 molecular biology 2635–7
 mucosal melanoma 2407
 multimodal therapy 2069, 2069 *T*
 oesophageal perforation 2071
 palliation 2069, 2070 *T*, 2071 *T*
 staging 2068, 2068 *F*, 2643 *T*, 2646 *T*
 surgery 2067, 2068 *T*, 2069 *T*
 total pharyngolaryngooesophagectomy 2649
 see also hypopharyngeal cancer
 oesophageal diseases 2062–73
 children 1282–94
 inflammatory, HIV patients 243–4
 oesophageal foreign bodies
 children 1187, 1187 *F*
 medical negligence 1310, 1310 *F*
 dysphagia aetiology 2034
 oesophageal injuries 1770–1
 complications 1771
 diagnostic accuracy 1770–1
 exploration, need for 1771
 surgical technique 1771
 treatment delay 1771
 oesophageal manometry
 achalasia 1288–9, 1289 *F*, 1290 *F*
 snoring 2328
 oesophageal motility disorders 2066
 dysphagia 2032
 globus 2038–9
 see also specific disorders
 oesophageal motility studies
 achalasia diagnosis 1290 *F*
 normal findings 1289 *F*
 oesophageal perforation 2070–1
 diagnosis 2026–8
 high 2071
 management 2071
 mid/lower perforation 2071
 oesophageal cancer 2071
 spontaneous (Boerhaave's syndrome) 2070–1
 surgery 2071
 oesophageal pH monitoring,
 dysphagia 1976–7, 2028–9
 oesophageal speech 2228, 2228 *T*, 2624
 definition 2227
 pharyngo-oesophageal segment 2227
 oesophageal sphincters 1951–2
 oesophageal stenosis, congenital
 see congenital oesophageal stenosis
 oesophageal strictures 2064
 oesophageal ulcers
 cytomegalovirus 245
 gastro-oesophageal reflux 2064
 idiopathic, HIV patients 245
 oesophagectomy 2068 *T*
 oesophagitis, laryngeal disorders
 and 2263
 oesophagogastroduodenoscopy,
 laryngeal stenosis 1154
 oesophagoscopy
 candidiasis 2031
 gastro-oesophageal reflux disease 2031
 hypopharyngeal cancer 2644–5
 laryngeal trauma 2275
 oesophageal injuries 1770–1
 oesophagotracheal septum 2130
 oesophagus
 anatomy 1951–2
 blood supply 1952
 constrictions 1951
 corrosive injury 1290–1
 clinical presentation 1290, 1291 *F*
 diagnosis 1290–1, 1291 *F*
 pathophysiology 1290
 treatment 1291
 embryology 801–2, 1282, 1943–4,
 2131 *F*
 epithelium 1951
 external adventitia 1952
 foreign bodies
 medical negligence 1310, 1310 *F*
 paediatric 1187, 1187 *F*
 HIV manifestations 244–5
 innervation 1952
 sympathetic 1952
 lymphatic drainage 1952
 muscular coat 1951–2
 mucosalis mucosa 1951
 pain 1952
 relations 1952
 submucosa 1951
 swallowing 1955, 1958
 transit times 1956
 vasculature 1952

- venous drainage 1952
wall 1951–2
- oestrogen(s)**
hormonal rhinitis 1410
lactation 301
nasal mucosa, effects on 402–3, 1366
animal studies 403
- oestrogen therapy, juvenile**
angiofibroma 2441
- off-frequency listening** 3248
- Office Population and Censuses (OPCS)** 2375, 2375 *T*
- off-vertical axis rotation (OVAR)** 3737, 3739 *F*
- ofloxacin** 938
- OFU** 51
- OK 432** 1270
- olanzepine** 2798
- older people** *see* elderly
- olfaction** 1366–8
adaptation 1367
ageing 1368
cross adaptations 1367
discrimination 1367
disorders *see* olfactory disorders/
dysfunction
eating 1368
higher brain centres 1367
nervous pathways 1367
odour classification 1368
paranasal sinus development 1369
post-adenoidectomy 1096
receptors 1367
sexual behaviour 1368
stimulus 1367
testing 1366
threshold 1367
trigeminal input 1367
see also nose
- olfactory agnosia**
causes 1666–7
definition 1664
- olfactory area** 1366–7
- olfactory auras** 1669–70
- olfactory bulb** 1329, 1367, 1663
glomeruli 1663
stem cells 70
- olfactory cilia** 3911–2
- olfactory cleft** 3911–2
- olfactory disorders/**
dysfunction 1660–76, 1366 *T*
age-related 1670, 1670 *F*
causes 1666–70
chemical agent exposure 1670, 1673–4
classification 1664
- clinical evaluation 1664–6
conductive/transport
impairments 1666
treatment 1670–1
- diminished ‘taste’ 1660
- endocrine disorders 1670, 1673–4
- epilepsy 1669–70
- future research areas 1672
- head trauma 1667, 1668 *F*
- history taking 1664
- imaging 1666
- knowledge deficiencies 1672
- mass lesions 1668–9
- medicolegal issues 1660–1, 1671
- nasal lesions 1673–4
- nasal passage inspection 1664–5
- neurodegenerative diseases 1669,
1673–4
- neurological evaluation 1665
- physical examination 1664–5
- prevalence 1660
- prognosis 1671
- quality of life issues 1660
- quantitative testing 1665–6
- sensorineural impairment 1666
treatment 1671
- supportive measures 1671
- surgery 1670–1
- treatment 1670–1
- tumours 1668–9, 1673–4
- olfactory ensheathing cells** 74
therapeutic uses 74
- olfactory (neuro)epithelium** 1662–3,
3911–2
- biopsy, olfactory dysfunction 1665
cell types 1662, 1663 *F*
lateral nasal wall 1337
location 1661
metaplasia 1662
nasal cavity 1326
neural transduction 1662–3
septum 1327, 1327 *F*
age-related changes 1328–9
nerve fibres 1328–9
supporting cells 1662, 1663 *F*
ultrastructure 1662, 1663 *F*
- olfactory event-related potentials (OREP)** 1666
- olfactory fasciculi** 3912
traumatic lesions 3913
- olfactory fila** 1662–3
injury 1667
- olfactory fossa** 1335
- olfactory glomeruli** 1367
- olfactory groove meningiomas** 3954–5
diagnostic failure 4144
olfactory nerve damage 3913
- olfactory hallucinations**
(phantosmia) 1664, 1666–7,
3913–4
- olfactory nerve (I)** 3911–4
age-related changes 3914
anatomy 3911–3, 3912 *F*
applied 3913–4
injury, skull base surgery 4136
- olfaction** 1662
physiology 3913
applies 3913–4
pigmentation 3911–2
- olfactory neuroblastoma (OAN)** 2420–1
- olfactory pit** 1315
- olfactory placode** 1315, 1811
- olfactory receptor cells** 1366–7, 1662,
1663 *F*, 3911–2
axons 1662–3, 3912
neurotransmitters 1662–3
renewal 74
septal 1327
signal transduction 1662–3
viral conduits 1663
- olfactory reference syndrome** 1666–7
- olfactory striae** 1329
- olfactory system**
central projections 1663
renewal 74–5
- olfactory testing**
quantitative 1665–6
unilateral 1666
- olfactory tracts** 1329, 3912
- oligonucleotide-mediated mismatch**
ligation assay, metastases
detection 2715
- oligosomal fragmentation, apoptosis** 58
- olivocochlear bundle** 3200
feedback mechanisms 3145, 3850
noise damage protection 3200
- olivocochlear feedback loop** 3145
- olivocochlear suppression test**
(OAE) 3606
- OM6**, outcomes research 640
- omalizumab** 1565
- ombudsman** 605
- omega-3 fatty acids, critical care**
patients 532–3
- OMENS classification, hemifacial**
microsomia 1032, 1032 *T*
- omeprazole**
chronic laryngitis 2262
globus 2040

omohyoid 1746
 oncocytoma
 larynx 2600 *T*
 salivary glands 2483
 oncogenes 36, 2380
 viral 208
 oncogenic transformation 9–10
 ondansetron
 nausea and vomiting 2788
 tonsillectomy 1237
 vestibular attacks, acute 3797
 ‘onion peel’ (*‘balaclava’*) sensory deficit 3926
 onlay graft 2918
 anterior maxillary deficiency 2919,
 2919 *F*
 posterior maxillary ridge 2917
 underprojected nasal tip 3003
 Online Mendelian Inheritance in Man (OMIM) 18
 Onodi cells (sphenoethmoidal cells) 1336–7, 1678
 ONYX-015 12–3, 29
 open rhinoplasty *see* external rhinoplasty
 open surgical tracheostomy 2295–7
 complication rate 2297
 incision 2295, 2296 *F*
 closing 2297
 percutaneous *vs.* 2297–8
 procedure 2295
 thyroid isthmus division 2295, 2296 *F*
 tracheal exposure 2295, 2296 *F*
 tracheal lumen opening 2295–6,
 2297 *F*
 tracheal stenosis 2295–6
 tube choice 2295
 ophthalmic disorders
 neurofibromatosis 2 4000
 pituitary tumours 4099, 4100
 ophthalmic examination,
 blepharoplasty 3055
 ophthalmic nerve (V_1) 3918 *F*, 3919 *F*,
 3923
 branches 1325, 3923
 damage 3927
 ophthalmologic procedures, nasal
 endoscopy 1352, 1353 *F*
 ophthalmopathy
 Graves’ disease 343, 400, 400 *F*
 see also thyroid eye disease
 ophthalmoplegia, Graves’ disease 400
 ophthalmoscopy, vestibular ocular
 reflex testing 3719, 3719 *F*
 opiates 489–90

opioids
 cancer pain management 2786,
 2786–7
 doses 2787 *T*
 periodic pain 2784–5
 see also specific drugs
 ‘opportunistic adherence,’ chronic otitis media 3410
 opthalmopathy, radioiodine
 treatment 349
 optical coherence tomography (OCT) 755–61
 adjuncts 759
 polarization-sensitive OCT 756,
 757–9
 current knowledge/future
 research 760
 laryngeal imaging: preliminary
 results 757, 757 *F*, 758 *F*
 basement membrane integrity 757
 principles 756–7
 image representation 757
 Michelson interferometer 756–7,
 756 *F*
 ultrasound analogy 756
 resolution 755–6
 utility/potential advantages of 756,
 759
 vocal folds 757, 758 *F*, 759 *F*
 optical grabbing forceps 1190 *F*,
 1191
 optic canal 4122
 lesions, visual disturbances 3915
 optic chiasm
 bitemporal hemianopia 3915
 hypophysectomy 4110–1, 4112 *F*
 magnetic resonance imaging 306
 pituitary tumour expansion 4099
 optic foramen 3914
 optic ganglion 3934
 optic nerve (II) 3914–7
 anatomy 3914, 3914 *F*
 damage
 orbital lesions 3914
 skull base surgery 4136
 hypophysectomy and 4108, 4110–1,
 4112 *F*
 myelinated fibres 3914
 papillomacular fibres 3914
 screening tests 3946
 sheaths 3914
 optic nerve decompression 1684–5
 complications 1685
 diagnostic nasal endoscopy 1352
 indications 1684
 surgical techniques 1684–5
 endoscopic 1685
 external 1685
 results 1685
 optic nerve sheath tumours 4000
 optic placode 1811
 optokinetic eye movement 3227 *T*
 optokinetic (after) nystagmus (OKN) 3214–5
 brainstem lesions 3717, 3718 *F*
 clinical examination/
 investigation 3716–7
 hand held drum method 3717,
 3717 *F*
 magazine/newspaper use 3717,
 3717 *F*
 direction 3717
 directional preponderance 3726
 dizzy child 1042
 laboratory assessment 3712 *F*, 3726
 neuroanatomy 3717
 optokinetic reflex 3214–5
 oral airway 2289, 2289 *F*
 oral allergy syndrome (OAS) 1428,
 1828
 birch rhinitis 1428
 sensitization 1425–6
 oral cavity
 anatomy 1758
 arterial supply 1798–9
 contact endoscopy 767
 development 1810–1, 1811 *F*
 HIV manifestations 242–3
 innervation 1800–3
 motor 1803
 sensory 1800–3
 lymphatic drainage 1799–800, 2713
 mechanoreceptors 1959
 medical negligence issues 2809
 muscles 1795–8, 1800 *T*
 rheumatological diseases 184
 swallowing 1954–5
 vascular supply 1798–803
 venous drainage 1799
 Wegener’s granulomatosis 1650
 see also mouth
 oral cavity reconstruction 2568–72,
 2885–6
 deep circumflex iliac artery flap 2571,
 2571 *F*
 distant pedicled flaps 2569
 fibula free flap 2571
 flaps 2885–6
 issues/potential problems 2885–6,
 2886

forearm flap 2871, 2871 *F*, 2872 *F*
 local flaps 2569
 mandibular reconstruction 2569–70
 microvascular free tissue transfer 2569
 options 2886, 2886 *T*
 osseointegration 2572
 osteoradionecrosis 2572, 2572 *F*
 primary closure 2568–9
 prostheses 2929–30
 quality of life issues 2776
 scapular free flap 2570–1, 2571 *F*
 split skin grafts 2569
 vascularized bone grafts 2572
 oral cavity squamous cell carcinoma,
 stage N0 neck treatment 2724
 oral cavity tumours 2543–76
 clinical presentation 2551
 diet 2550
 epidemiology 2549–50
 incidence 2347
 infection 2348
 lymph node groups 2565
 management 2929
 neck dissection 2564–5
 radical 2743
 staging 2564–5
 nodal staging 2564, 2564 *T*
 nutrition 2550
 occupation 2348
 occurrence 2550 *T*
 oral hygiene 2348, 2551
 pathology 2551
 premalignant conditions 2551
 reconstruction *see* oral cavity
 reconstruction
 resection, visor flap approach 2567,
 2567 *F*
 risk factors 2349 *T*, 2550–1
 second primary tumours 2550
 sentinel nodes 2565
 sites 2549 *T*
 smoking 2347–8
 surgical approaches 2566–8
 labiomandibulotomy 2566–7, 2566 *F*
 peroral 2566
 TNM classification 2364, 2364 *T*,
 2551, 2551 *T*
 viruses 2551
 oral condylomas 1828
 oral contraceptives
 rhinitis induction 1410
 venous thromboembolism 290
 oral disease
 benign 1816–39
 otalgia 3530–1

oral dysaesthesia (burning mouth
 syndrome) 1818 *T*, 1829, 1848–9
 oral hairy leukoplakia (OHL) 2012 *T*,
 2013
 oral hygiene, oral cavity tumours 2348,
 2551
 oral implants
 anatomical considerations 2907–10
 bone volume 2907
 classification 2902–4, 2902 *T*
 inflammation 2907
 local anaesthetic 2912
 overloading 2907
 see also individual implants
 oral mucosa 1794–5
 blisters 1822
 acquired 1825
 causes 1821 *T*, 1822
 inherited disorders 1823
 contact endoscopy 767
 morphological variation 767
 pigmentation 1822
 acquired lesions 1825
 hyperpigmentation *see* oral mucosal
 hyperpigmentation
 inherited conditions 1823
 oral mucosal disorders 1822–3
 acquired 1825–8
 ulcers 1830
 inherited 1823–4
 redness 1822–3
 acquired 1825–7
 inherited conditions 1823–4
 swelling 1823
 acquired 1827–8, 1827 *T*
 inherited disorders 1824
 white patches 1821 *T*, 1823
 acquired 1835–7
 inherited conditions 1824
 yellow lesions 1824
 oral mucosal hyperpigmentation 1825
 generalized 1825
 causes 1820 *T*, 1825
 drug-induced 1825
 localized lesions 1825
 oral/nasal airflow ratio 2182
 oral pain 1828–37
 oral papillomas 209 *T*, 1828
 oral petechiae 1822
 oral resonance, speech 2166
 oral soreness 1828–37
 oral (viridans) streptococci 195–6, 198
 oral thrush *see* candidiasis, oral
 oral trauma, taste abnormalities 1846
 oral ulcers *see* mouth ulcers
 oral vestibule 1793
 Orasure 1862
 orbicularis muscle 3050, 3051
 ptosis 3060
 orbicularis muscle flap 3061 *F*, 3062 *F*
 orbicularis oris 1803
 orbit
 anatomy 1677–9, 1678 *F*, 4121–2,
 4122 *F*
 age effects 1679
 boundaries 4121–2
 inferior wall 1678
 lateral wall 1679
 medial wall 1677–8
 periorbital 1679
 superior wall 1678
 contents 3919 *F*
 infection classification 1087 *T*
 radiological evaluation 1679
 orbital abscess 1540
 drainage 1544–5
 frontal rhinosinusitis 1544–5
 sinusitis, children 1087–8
 orbital apex
 decompression 1684–5
 indications 1684
 portals 4122
 orbital apex syndrome 217–8
 orbital blowouts, nasal endoscopic
 repair 1352
 orbital cellulitis, rhinosinusitis
 complication 1540–2
 CT imaging 1297
 disease stages 1540, 1541
 ethmoid sinus 1540
 examination 1542, 1545 *F*
 management 1546 *F*
 radiological investigations 1542–3
 surgery 1544–5
 treatment 1544
 visual problems 1540–2
 without abscess 1540
 orbital decompression 1679–84
 complications 1683–4
 indications 1679, 1680
 nasal endoscopy 1352
 orbital haemorrhage 3065
 preoperative assessment 1680, 1680 *F*
 radiological evaluation 1679
 surgical anatomy 1677–9, 1678 *F*
 surgical techniques 1680–2
 endoscopic 1680–3, 1682 *F*
 results 1682–3, 1682 *F*, 1683 *F*
 three-wall, minimal incision
 1681–2, 1682–3, 1683 *F*

- orbital exenteration
case study 2936–7
nasal malignancy 2434
orbital fat
advancement 3059, 3060 *F*
atrophy 3049
removal 3057
orbital floor fractures 1630–1
imaging 1630–1, 1631 *F*
management 1631
signs/symptoms 1630
orbital foramina 3918 *F*
orbital haemorrhage, post-
blepharoplasty 3064, 3064–5
orbital implants
magnetic positioning 2909 *F*, 2929 *F*
osseointegration 2909
orbital plate, frontal bone 3897
orbital prosthesis 2928–9
magnetically retained 2936 *F*
surgery requiring 2929 *T*
orbital pseudotumour 3916
orbital reconstruction 2928–9, 2938 *F*
case study 2938
sinuses 2929
orbital roof fractures, frontal sinus
trauma 1507
orbital roof meningiomas 3954–5
orbital septum
anatomy 3051
fat bulging 3054 *F*
skin-muscle flap dissection 3059,
3059 *F*
orbital tumours
benign 3916
malignant 3916
metastatic 3916
optic nerve damage 3915
orbitofrontal cortex
olfactory projections 1663
taste 1842
orbitomaxillary free bone flap 4065
orchitis 1900
organ of Corti 3123
age-related changes 3540–1, 3540 *F*
as amplifier 3131
cellular architecture 3128 *F*, 3130–2,
3131 *F*
development 806–7
fluid in, ionic concentrations
3189–97
function 3126, 3130–2, 3139–40
innervation 3136–9, 3138 *F*
travelling waves, effects of 3131
organ replacement, stem cells 75
organ-specific autoimmune inner ear
disease 3680
organ system support, critical
care 527–33
oro antral fistula 1085
orofacial defects, prosthetic
rehabilitation 2929
orofacial granulomatosis (OFG)
1828
oromandibular syndrome (Meige's
syndrome) 3939–40
oronasal cavity skin grafts 2824
oronasal membranes 1811, 1811 *F*
oropharyngeal aspiration *see* aspiration
oropharyngeal dysphagia *see* dysphagia
oropharyngeal isthmus 1792 *F*, 1793
oropharyngeal manometry *see*
manometry
oropharyngeal membrane 1811
oropharyngeal squamous cell
carcinoma 2580
aetiology 2580
epidemiology 2580
HIV implications 2580
oropharyngeal tumours 2577–97
benign 2579–80
biopsy 2584
chemotherapy 2591
clinical presentation 2579
complications 2591
distant metastases 2591
follow-up 2592
imaging 695 *F*, 2584
incidence 2347
malignant 2580–1
mandibular nerve damage 3927
metastatic disease 2581
neck management 2588, 2590–1
organ-preserving approaches
2591
pathology 2579–81
patient evaluation 2583–4
physical examination 2583
radiotherapy 2585
recurrence 2592
risk factors 2347–8
infection 2348
occupation 2348
oral cavity hygiene 2348
smoking 2347–8
surgery 2585–8
radical neck dissection 2743
transmandibular
approaches 2586–8, 2587
transoral approaches 2586, 2586 *F*
transoral/transcervical combined
approach 2586
transpharyngeal approaches 2586
symptoms 2583
TNM classification 2365 *T*, 2581–2,
2581 *T*, 2582 *T*
treatment
factors affecting choice 2584–5
functional outcome 2591–2
options 2585–8
policy 2584–5
sequelae 2591–2
see also individual tumours
oropharynx
anatomy 1792 *F*, 1793–4, 1944,
2364–5, 2577–9, 2578 *F*
blood supply 2579
embryology 801–2, 803 *F*
fascial spaces 2579
innervation 2578
lymphatic drainage 2579, 2713
mucous membrane 1947
otalgia 3530–1
relations 1950 *F*
swallowing 1957
tumours *see* oropharyngeal tumours
walls 1944, 2577
oropharynx reconstruction, forearm
flaps 2871
orthodontic treatment, hemifacial
microsomia 1033
orthopaedic surgery, 3D imaging 702–3
orthopantomogram (OPG)
mandibular ossifying fibroma 1930 *F*
oral cavity tumours 2553
orthostatic intolerance 3227–8
orthostatic tremor
postural imbalance syndrome 3779,
3780
posturography 3735–6, 3735 *F*
'oscillating veins,' skin flap 111
oscillation
harmonic (sinusoidal) 3158–9, 3159,
3159 *F*
mechanical systems 3161, 3161 *F*
vibrations *vs.* 3158–9
oscillopsia
causes 3708, 3708 *T*
labyrinth destruction 3749
ototoxicity-related 3569
paroxysmal 3708
symptoms 3708
oseltamivir 209–10
Osler–Weber–Rendu disease 739, 1574,
1823

- osmophobia 1664, 1669–70
 osseocartilagenous septal deformity, children 1076
 osseointegration 2901–23
 adjunctive implant techniques 2917–20
 extra oral implant sites 2908–9
 healing, final stages 2906
 history and background 2901–2
 implant salvage 2920–1
 implant- tissue interface 2906–7
 inductive materials 2917
 mandible 2908
 maxilla 2907–8
 metal selection 2904–6
 molecular level 2906
 neighbouring tissue, effects on 2906
 oral cavity reconstruction 2572
 percutaneous implants 2941
 process 2904–6
 progressive loading 2914
 surface characteristics 2904–6
 surgical salvage, bone loss 2920
 time before loading 2914–5
 titanium implants 119
 ossicle dislocation 3681–2, 3681 *F*
 development 966
 ossicles
 axis of rotation 3180, 3180 *F*
 congenital abnormalities
see congenital ossicular abnormalities
 development 814–5
 lever action 3181
 ligaments 3180
 mode of movement 3181
 vibration 3180
see also individual bones
 ossicular chain fixation 3289
 ossicular chain reconstruction 954
 ossicular chain trauma 3492
 associated injuries 3492–3
 surgical management 3493
 results 3493, 3494 *T*
 types 3493
 ossicular grafts, chronic otitis media 3405–6, 3405 *F*
 ossicular implants, chronic otitis media 3405–6, 3406 *F*
 ossicular replacement prostheses
 extrusion rates 119
 HAPEX 120, 120 *F*
 historical aspects 118
 hydroxyapatite devices 120
 polymers 121
 titanium 119
 ossiculoplasty
 cholesteatoma 3433–4
 inactive mucosal chronic otitis media 3422
 outcomes 3422
 medical negligence 3829
 ossifying fibroma
 juvenile 1929–30
 mandible 1929, 1930 *F*
 skull base 4124, 4124 *F*
 osteitis deformans *see* Paget's disease
 osteitis fibrosa cystica ('brown tumours') 390, 401
 ostelamivir 209–10, 232–3
 osteoarthritis 186
 osteoblasts
 activation 94
 bone repair 94
 osseointegration
 biocompatibility 2906, 2906 *F*
 osteoconduction 2917
 osteodistraction, hard palate carcinoma 2563
 osteogenesis imperfecta 3474
 type 1 3458
 osteoinductive materials 2917
 osteolysis, mucocoeles 1532
 osteoma(s)
 frontal sinus *see* frontal sinus
 osteomas
 jaw 1930
 mandibular 1930
 middle ear 4072
 skull base 4123
 osteomyelitis
 frontal *see* frontal bone osteomyelitis
 medical negligence 1735
 sinusitis, children 1086
 osteoplastic bone flap procedure,
 frontal sinus 1514–8, 1515
 complications 1516–7
 indications 1514
 limitations 1517–8
 results 1517–8
 sinus obliteration 1516–7
 technique 1515–7
 osteoporosis
 hyperparathyroidism 390
 implants 2910
 PTH assay 382–3
 subclinical hyperthyroidism 353
 thyrotoxicosis 400–1
 osteoradionecrosis, oral cavity reconstruction 2572, 2572 *F*
 osteosarcoma
 craniofacial 1936–7
 grading 1936
 management 1936–7
 presentation 1936, 1937 *F*
 subtypes 1936
 survival rates 1936
 larynx 2604
 pituitary region 4104
 osteosclerosis, tinnitus 3598
 osteotomy
 complications 3091
 deviated nose 2965–6, 2990, 2991 *F*
 dorsal humps 2955
 lateral 2955–6, 2956 *F*
 Le Fort 1 2463
 Le Fort 3 1029
 rhinoplasty 3091
 ostia, accessory 1330
 ostiomeatal complex 1344–6
 otalgia 3526–36
 acute 3527
 autonomic innervation and 3533–4
 bullous myringitis 3326, 3527
 children 3527–8
 deep temporal bone 3528
 definition 3526
 dental disease 3529
 diagnosis 3534
 external ear disease 3527
 geniculate neuralgia 3532
 hypopharyngeal disease 3530–1
 inner ear disease 3528–9
 middle ear disease 3527–8
 differential diagnosis 3528
 nasal disease 3530
 neuralgias 3531–3
 neuroanatomy 3527
 occult malignancy 3530–1
 oropharyngeal disease 3530–1
 post-tonsillectomy 3530, 3530 *F*
 skull base lesions 3527, 3944–5
 special needs children 786
 stylohyoid syndrome 3533
 temporomandibular joint dysfunction 3529–30
 tuberculous otitis 3447, 3447 *T*, 3450 *T*
 otic cup 815
 otic disc (placode) 806, 806 *F*, 815, 3122, 3123 *F*
 otic ganglion 3908

otic pit 806, 806 *F*, 3122, 3123 *F*
 otic placode (disc) 806, 806 *F*, 815,
 3122, 3123 *F*
 otic vesicle *see* otocyst
 otitic barotrauma 3499
 cerebral air gas embolism
 3519–20
 clinical features 3504–6
 definition 3499
 diving, postoperative 3506
 Eustachian tube dysfunction 3506
 flying, postoperative 3506
 historical perspective 3500
 hyperbaric oxygen therapy, secondary
 to 3519
 inner ear *see* inner ear barotrauma
 maxillary sinus 1369
 middle ear *see* middle ear barotrauma
 otitis media with effusion 3390
 pressure/volume relationships 3495 *F*,
 3500–4, 3502 *F*
 septal deviation 3506
 stable depth injuries 3512–3
 otitic hydrocephalus
 active chronic otitis media 3438
 management 3438
 acute otitis media 925
 cerebrospinal fluid rhinorrhoea
 1641
 otitis, tuberculous *see* tuberculous otitis
 otitis externa 3351–7
 aetiology 3352
 allergic reactions 3352
 benign necrotizing *see* benign
 necrotizing otitis externa
 classification 3351
 complications 3352–3
 definition 3321, 3351
 diagnosis 3352
 epidemiology 3352
 fungal *see* otomycosis
 with granulations *see* granular
 myringitis
 HIV patients 240
 malignant *see* malignant otitis externa
 management 422–3, 3353–4
 systemic antibiotics 3353
 topical medication 3353
 treatment comparisons 3354–5,
 3354 *T*
 outcomes 3352–3
 pathology 3352
 predisposing factors 3351 *T*
 recurrence prevention 3353–4
 symptoms/signs 3352, 3353 *F*

otitis externa granulosa *see* granular
 myringitis
 otitis media
 acute *see* acute otitis media (AOM)
 adhesive 3426
 chronic *see* chronic otitis media
 (COM)
 chronic suppurative *see* chronic
 suppurative otitis media
 (CSOM)
 classification 930 *T*
 cleft lip and palate 1010–3
 HIV patients 240
 secretory *see* otitis media with effusion
 (OME)
 otitis media with effusion
 (OME) 3388–94
 adenoidectomy 902–3, 1095
 aetiology 3388–9
 autoinflation 3392
 biofilm infection 1095
 children *see* otitis media with effusion
 (OME), childhood
 chronic otitis media
 development 3408
 clinical presentation 3390
 complications 3391
 definition 877–8, 3388
 diagnosis 3390–1
 audiology 3391, 3391 *T*
 clinical 3390–1
 radiology 3390
 surgery 3391
 hearing aids 3393
 management 3391–3
 medical 423, 3392
 surgical 3392–3
 nasopharyngeal pathology 2464–5,
 3391
 outcomes research instruments 640
 pathology 3389–90
 prevalence 3388
 surgery-induced 3390
 Wegener's granulomatosis 1650
 otitis media with effusion (OME),
 childhood 877–911
 acute otitis media 881
 age-related 880–1
 allergy 879
 bacteriology 878, 879 *T*
 behavioural problems 894
 cleft palate 1010
 cognition 894
 congenital atresia 981
 contact with other children 882, 882 *T*

craniofacial abnormalities 879
 definition 877–8
 diagnosis 884–91
 hearing assessment 890–1
 ideal strategy 890
 reference gold standard 884
 tools 885–90
 effusion characteristics 878
 epidemiology 880–4
 clinical applicability of
 evidence 884
 episode duration/recurrence
 children over three 883
 children under three 882–3, 883 *F*
 Eustachian tube dysfunction 878–9
 fluid level 886 *F*
 gastro-oesophageal reflux 880, 1274
 gender 882
 hearing loss
 parental perception of 884, 884 *F*
 temporary 825
 hereditability 882
 histology 878, 878 *F*, 879 *F*
 history 884–5
 language development measurement
 621
 management 895–903
 counselling 895
 hearing tactics 895
 medical 895–6
 surgery 896–903
 natural history 891–2
 otoscopy 885–7, 885 *F*
 air bubbles 886 *F*
 malleus handle retraction 885,
 885 *F*
 tympanic membrane
 discolouration 885 *F*, 886 *F*
 outcomes 891–5, 892 *T*
 parental smoking association 626,
 882
 pathology 878–80
 preschool surveillance 830
 prevalence 880–1, 880 *F*, 881 *T*
 race 882
 risk factors 881, 882
 for persistence 883–4
 seasonal 881
 vertigo 1045–6
 otoacoustic emissions (OAEs) 3276–8,
 3842, 3844 *T*
 ambient noise reduction 3277
 auditory function monitoring 751
 auditory neuropathy/dyssynchrony
 3840, 3844 *T*

- contralateral suppression 3843
 hearing aid status 3852 *T*
 infants 3840
 classification 3276–7
 definition 3276–7
 detection 3277
 frequency analysis 3291
 neonatal hearing screening 3291
 pathological factors affecting 3290
 recording 3276–7
 separation from other signals 3277
 stimulus 3843
 tinnitus 3605 *F*, 3610, 3611 *F*
 types 3276–7
see also individual types
 otoconia 3210, 3228–30
 benign paroxysmal positioning vertigo 3760, 3760 *F*, 3762–3
 embryology 807
 otocyst 806, 806 *F*, 814–5, 815, 815 *F*, 3122, 3123 *F*
 otoferlin (OTOF) gene 3846
 otogenic brain abscess, chronic otitis media 3436
 otogenic sepsis, chronic otitis media 3437
 otolithic crises, Menière's disease 3758
 otolithic membrane 3210
 otolith-ocular reflexes 3737
 otolith organs
 hair cells 3228–30, 3230 *F*
 linear acceleration detection 3210
 tilt differentiation 3210–1, 3210 *F*
 loss, vestibuloocular reflex and 3223
 movement detection 3210–1
 orientation 3210
 orthostatic tolerance 3227–8
see also saccule; utricle
 otolith testing 3737–42
 difficulties in 3737
 movement artefacts 3737
 Otologic(tm) middle ear
 transducer 3661
 otology
 drug therapy 429–35
 ear drops 429
 ear wax removal 431–3
 topical preparations *see ear preparations, topical*
 image-guided surgery 708
 medical negligence 3826–34
 cholesteatoma 3828–9
 dizziness 3829–30
 ear syringing 3826–7
 hearing loss 3830–1
 iatrogenic facial nerve damage 3827–8
 Menière's disease 3830
 ossiculoplasty 3829
 otosclerosis 3827
 sudden sensorineural deafness 3829
see also specific diseases/conditions
 otomycosis 213–4, 3355
 aetiological agents 213
 clinical findings 214, 3355, 3355 *F*
 complications 214
 definition 213
 diagnosis 214
 epidemiology 213–4
 management 214, 3355
 outcomes 214
 otorhinolaryngology, paediatric *see paediatric otorhinolaryngology*
 otorrhoea
 active chronic otitis media 3436
 active mucosal chronic otitis media 3424
 cholesteatoma 3431
 medical negligence 4144
 retropharyngeal abscess 2002
 skull base lesions 3944
 tuberculous otitis 3446, 3447, 3447 *T*, 3450 *T*
 tympanic membrane perforation and 936–41
 ventilation tube insertion 900, 900 *T*
 otosclerosis 3453–85
 aetiology 3458
 biochemistry 3459
 chronic otitis media 3461
 clinical
 definition 3454
 incidence 3460, 3460 *T*
 cochlear
 definition 3454
 diagnosis 3465
 clinical otosclerosis and 3465
 conductive impairment
 absence 3465
 pathology 3457
 cochlear implantation 3480, 3655
 assessment 3480
 pitfalls 3480 *T*
 conductive hearing
 impairment 3465–6
 hearing aids 3467
 definitions 3454
 diagnosis 3460
 histological 3461
 surgical 3455 *F*, 3461, 3471
 genetic predisposition 3458
 hearing aids 3467
 as rescue treatment 3467
 surgery and 3467
 histologic
 definition 3454, 3458
 incidence 3459–60
 histopathology 3454–5, 3455 *F*
 history 3463
 incidence 3459
 management, fluoride 434, 3466
 medical negligence 3827
 natural history 3465
 pathology 3454–8
 conductive hearing loss 3456
 lesion distribution 3456
 sensorineural hearing loss 3456–7
 temporal bone 3456
 vestibular symptoms 3457–8
 pure-tone audiometry 3461, 3462 *F*
 radiology 3464
 surgery 3468
 age and 3469
 audiological eligibility 3464–5
 children 3469
 contra-indications 3469
 hearing outcomes 3477–80
 historical perspectives 3468
 leisure activities 3469
 occupation and 3469
 postoperative
 complications 3475–7
 second side 3469–70, 3470 *F*
 techniques 3470–3
 unilateral 3469
 type II collagen autoimmunity 3459
 otosclerotic foci 3454–5
 otoscopy 3314–7
 active *vs.* inactive ear 3413, 3414 *F*
 attic, wide view 3314 *F*
 bulous myringitis 3326, 3327 *F*
 chronic otitis media 3412, 3413–8
 closed pneumatic 3314 *F*
 ear position 3312 *F*
 external auditory canal 3314–5
 healed chronic otitis media 3426
 open mastoid cavities 3413, 3413 *F*, 3414 *F*
 otitis media with effusion 884, 885–7, 885 *F*, 886–7, 887 *T*, 890, 3390–1, 3391 *T*
 otosclerosis 3460–1
 pathological sites 3412–3, 3412 *F*, 3413 *F*
 principles 3314

otoscopy (*continued*)
 simulated, otitis media with effusion 886
 skull base lesions 3945
 structured 3315–6
 temporal bone fractures 3495, 3495 *F*
 tuberculous otitis 3447, 3448 *T*
 video 887

otosyphilis 3694–5
 clinical picture 3694–5
 histopathology 3695, 3695 *F*
 HIV patients 240–1

ototoxicity 3567–76, 3676–7
 aetiology 3298–300, 3299 *T*, 3568 *T*, 3676
 animal models 3298, 3301–2, 3303
 cochleotopic gradient of susceptibility 3569
 hearing loss, attribution to 3572
 HIV patients 240–1
 incidence 3300
 management 3571–3
 medical negligence 3831
 pathology 3300–1, 3301 *F*
 prevention 3301–2, 3571
 antioxidants 3302
 reactive oxygen species 3300–1, 3301 *F*
 recognition 3571–3
 vestibular monitoring 3573

risk factors 3300
 tinnitus 3599–600
 treatment 3573
 vestibular monitoring 3573
see also specific drugs/drug types

Otovent balloons 896
 outcome odds ration 622
 outcomes research 633–44
 assessment 634–7, 634 *T*
 acceptability 637
 appropriateness 634–5
 feasibility 637
 interpretability 637
 precision/sensitivity 636–7
 reliability 635–6
 responsiveness to change 636
 validity 635

bias 637
 definition 634
 domains 634, 636
 future development 642
 instruments 637, 638 *T*
 choice of 641–2
 condition-specific 640–1
 dimension-specific 641

disease-specific 640–1
 generic 637–40, 642
 site-specific 641
see also specific instruments
 odds ratio *see odds ratio*
 quality of life 2770
 sinonasal disease 641
 value 634

outer hair cells (OHC) 3130, 3131 *F*, 3132 *F*
 apical surface 3132, 3132 *F*
 calcium channel dysfunction, tinnitus 3605
 cell bodies 3132–3, 3132 *F*, 3134
 drug-induced tinnitus 3600
 efferent inputs 3145
 electrical responses 3195–6
 electromotility 3134
 function 3132–5
 innervation 3138 *F*, 3139
 input-output function 3195 *F*, 3196
 mitochondria 3134
 nucleus 3134
 otoacoustic emissions 3842
 plasma membrane fluidity 3549
 stereocilia 3132, 3132 *F*, 3133 *F*
 actin filaments 3132–3, 3133 *F*
 contact region 3133
 deflection 3133–4
 mechanical amplification 3134
 membranes 3133–4
 rootlets 3132–3, 3133 *F*
 tip links 3133, 3133 *F*
 ultrastructure 3132–5

oval window 3126
 anatomy 3110–1
 bone conduction 3185
 congenital aplasia 873
 rupture 3497

overnight oximetry, obstructive sleep apnoea 2316

overnight polysomnography 2318

overshortened noses 2982–5, 2984 *F*, 2985 *F*
 grafts 2985 *F*

over-the-wire microcatheters 732–3

overtones 3167

Overview and Scrutiny Committees (OSC) 574

ovulation 302

oxaliplatin 37

oxazolidinones 232
 methicillin resistant *Staphylococcus aureus* 232

oxidative stress
 cellular responses 3301
 ototoxicity 3300–1, 3301 *F*

oxycodone, cancer pain
 management 2786, 2787 *T*

oxygen, upper airway obstruction 2288

oxygen desaturation index (ODI) 2316, 2316 *F*, 2317 *F*

oxygen ‘dips,’ obstructive sleep apnoea 2316, 2316 *F*, 2317 *F*, 2318 *F*

oxygen saturation levels
 critical care, adults 528
 obstructive sleep apnoea 2331

oxymetazoline 439, 3505–6

oxyphil cells 373

oxyphilic adenoma 2483

oxytocin
 effects 300, 308
 secretion 308

ozaena 1411

P1 artificial chromosomes (PAC) 11

p53
 apoptosis 58
 cell cycle control 58, 2382
 exons 2378–9

head and neck squamous cell carcinoma 29, 2386 *T*

hypopharyngeal cancer 2635–6

immunohistochemistry 2382 *F*

mechanisms 2382 *F*

mutations 58

oesophageal cancer 2635–6

squamous cell carcinoma 58

thyroid cancer 2670

p53 transfer, chemosensitization 28

pacemakers, surgical preparation 459

pachydermia oralis (white-sponge naevus) 1824

paclitaxel (taxol) 39, 2761

paediatric anaesthesia 507–25
 adenoidectomy 515–7
 airway endoscopy procedures 517–9
 airway surgery 519
 anaesthetist’s role 507
 breathing systems 510
 day case surgery 508
 ear surgery 513–4
 equipment 510–3
 airway management 510–1
 foreign body removal 519
 heat conservation 512–3
 induction 513
 inhalational induction 513

- laryngotracheal reconstruction 521
 laryngotracheal stenosis 521
 laser endoscopy 519
 nasal surgery 514–7
 nasopharyngeal surgery 514–7
 parental presence 513
 pharyngeal surgery 514–7
 physical examination 508
 physiological monitoring 513
 premedication 509
 preoperative assessment 508–9
 preoperative fasting 509, 509 *T*
 psychological preparation 508
 respiratory assessment 508–9
 sedative premedication 509
 techniques 510–3
 tonsillectomy 515–7
 tracheostomy 521
 tube sizing 511
 vascular access 511–2
 paediatric cochlear implantation 860–8
 adolescents 866
 anaesthesia 514
 assessment 863
 audiological tests 863
 auditory neuropathy/
 dyssynchrony 3852
 aural rehabilitation 866
 bilateral 866
 candidacy 866
 post-lingual 862–3
 chronic suppurative otitis media
 865
 cochlear anatomical
 abnormalities 865
 current status 860–1
 devices 861
 failures 865
 implantation 861, 861 *F*
 microphone 861
 history 860
 management controversies 866
 medical assessment 863
 MRI following 866
 neurodevelopmental issues 863
 obliterated cochlea 865
 older children 866
 open mastoid cavities 865
 ossification 865
 perilingual deafness 861
 post-meningitic patients 863
 postoperative habilitation 865
 prelingual deafness 861–2
 preoperative counselling 864
 quality of life measures 866–7
 special surgical circumstances 865
 surgery 864–5
 complications 864–5
 technique 864
 timing 861–3
 early 862
 paediatric consultation 776–82
 breaking bad news 780
 child protection issues 780
 clinic requirements 777
 rooms 777
 ‘special’ clinics 777
 waiting area 777
 consent 780–1
 competence 780–1
 parental responsibility 781
 consultation preparation 777
 decision to seek advice 776
 endoscopy 777
 examination 778
 functional problems 780
 history 778
 management plan 779–80
 otoscopy 778
 outcome documentation 780
 prescribing for children 780
 paediatric intensive care 542–8
 admission issues 543 *T*
 analgesia 544
 anatomical/physiological
 considerations 542–3, 543 *T*
 bronchoscopy 547
 ENT emergencies 544–6
 evaluation 543
 fluid management 543–4
 major surgery 546–7
 trauma 544
 upper airway obstruction 544–5
 paediatric intensive care unit
 (PICU) 774
 paediatric otolaryngologists 774
 general 774–5
 special children 774
 special hospitals 774
 specialist 774–5
 ‘special problems’ 774
 training 775
 paediatric otorhinolaryngology 771–5
 disease spectrum 773
 history 771–3
 medical negligence 1305–12
 acute epiglottitis 1309
 adenoidectomy 1308
 atlanto-axial instability 1308
 cholesteatoma 1306–7
 epistaxis 1310
 establishing damages 1306
 foreign bodies 1309–10
 hearing disorders 1306
 nasal trauma 1310–1
 neck masses 1310
 negligence causation 1306
 stapes, congenital fixation 1307
 tonsillectomy 1308
 tracheostomy 1309
 scope of practice 773
 service development 774
 societies 773
 paediatric reflux 1273
 paediatric special needs *see* special
 needs children
 paediatric tonsillectomy 1229–41
 anaesthesia 515–7, 1236–7
 at risk children 1235–6
 analgesia 1237
 antibiotics 1237
 antiemetic drugs 1237
 blood loss 1232–3
 complications
 late 1236
 perioperative 1236
 current practice 1231
 day-case surgery 1237
 dental damage 1308
 education, effect on 1232
 efficacy 1229–31
 evidence-based medicine 1229–32
 guidelines 1231–2
 haemorrhage 1236, 1308
 health economics 1232
 indications 1232
 infection 1236
 morbidity 1235–6
 mortality 1235–6
 nonsurgical alternatives 1237–8
 pain 1235
 perioperative management
 1236–7
 psychosocial morbidity 1235
 rates 1988
 recurrent sore throat 1988
 sociocultural factors 1231
 steroid therapy 1237
 techniques 1232–5
 capsulotomy 1235
 dissection 1232–3, 1233 *F*
 haemorrhage rates 1234 *T*
 ultrasonic 1235
 variant Creutzfeldt-Jacob
 disease 1231, 1238

- Paget's disease 3486–90, 188–9
 aetiology 3486–7
 bone changes 3487
 complications 3489
 definition 3486
 diagnosis 3488
 epidemiology 3486
 hearing loss 3487–8
 imaging 188–9, 189 *F*, 3488
 laboratory investigations 3488
 management 3488–9
 indications 3488, 3488 *T*
 medical 3489
 outcomes 3489
 pathophysiology 3487–8
 symptoms/signs 3487–8
 tinnitus 3487
 vestibular disturbance 3488
- Paget's seed and soil hypothesis 2714
- pain
 cancer *see* cancer pain
 ear *see* otalgia
 facial *see* facial pain
 neurophysiology 3526–7
 oesophageal 1952
 oral 1828–37
 otalgia 3526–7
 trigeminal neuralgia 1829–30, 3927
- painful teeth 1721
- painless thyroiditis 352–3
- palatal consonants 2166–7, 2167 *T*
- palatal cysts of infancy 1926
- palatal fistula 1010
- palatal lift 2088
- palatal muscles, myogenic
 somatosounds 3600
- palatal myoclonus 2078
- palatal processes 1315–6
 fusion 1315–6, 1812–3
- palatal shelf 1812, 1813 *F*
 elevation 1814
 fusion 1814
- palatal snoring surgery 2333 *T*
- palate
 anatomy 1791–2
 damage, surgery-related 2809
 development 798–9, 800 *F*, 1315–7
 1316 *F*, 1317 *F*, 1812–4, 1813 *F*
 anomalies 1320, 1813–4, 1814
 muscles 1813
 hard *see* hard palate
 minor salivary gland tumours 2505,
 2505 *F*
 primitive 1315–6
 sensory innervation 1800–1, 1801 *F*
- soft *see* soft palate
 vagal nerve lesions 3937
- palate repair s0150 1012 *F*
- palatine aponeurosis 1792, 1945,
 1945 *F*, 3908–9
- palatine arteries
 ascending 2113, 3909
 descending 2113
 greater 1328, 1799
 lesser 1799
- palatine bone 2111
- palatine canal 1799
- palatine glands 1808
- palatine process 1341
- palatine raphe 1791–2
- palatine sensation testing 3937
- palatine tonsil *see* tonsil(s)
- palatoglossal arch 1793
- palatoglossal folds 1944
- palatoglossal glands 1808
- palatoglossus 1797, 1946 *T*, 2112
- palatopharyngeal arch 1793
- palatopharyngeal fold 1944
- palatopharyngeal sphincter *see*
 velopharyngeal sphincter
- palatopharyngeus 1007–8, 1009 *F*,
 1946 *T*, 1949 *F*, 2112, 2135 *T*
 soft palate repair 1009
- palliative care, head and neck
 cancer 2781–802
 breaking bad news 2782–3, 2783 *T*
 children 1261
 definition 2782
 dysphagia 2789–91, 2790 *T*
 examination 2790
 management 2790–1
 hypercalcaemia 2794
 malignant ulcers and fistulae 2788 *T*
 2789, 2791–4
 bleeding 2792–4, 2793 *T*
 dressings 2794
 infection and odour 2792
 management 2793 *T*
 nausea and vomiting 2787–8, 2787 *T*
 oral problems 2788–9, 2788 *T*
 candidiasis 2789
 mucositis 2789
 salivary leakage 2788–9, 2788 *T*
 ulceration 2788 *T*, 2789
 xerostomia 2788
 pain *see* cancer pain
 psychological problems 2795–8
 acute confusional states 2797–8,
 2798 *T*
 anger 2795–6, 2796 *T*
- anxiety 2795, 2795 *T*
- withdrawal 2796–7, 2797 *T*
- sinonasal malignancy 2427
- stridor 2795
- superior vena caval
 obstruction 2794–5
- terminal phase 2798–800
- resuscitation issues 2798, 2799 *T*
- Pallister-Hall syndrome 1137
- palpebral fissures, blepharoplasty 3058
- palpebral (canthal) ligaments 1679
- pamidronate 2794
- pancreatic islet cell disease *see* diabetes mellitus
- pancreatic polypeptide, nose 1364
- pancytopenia 273, 273 *T*
- panic attacks 3709
- panic disorder, vestibular disorders
 and 3814–5
- panniculus carnosus* 91
- panthographic expansion 2832
- pantoprazole 2263
- Pan troglodytes* (chimpanzee), paranasal sinuses 1321 *F*
- papaverine-induced skin reactivity 1409
- papillae, tongue 1794, 1841, 1841 *F*
 see also individual types
- papillary adenocarcinomas, nasal 2420
- papillary cystadenocarcinoma 2500
- papillary cystadenoma lymphomatous
 see Warthin's tumour
- papillary thyroid cancer (PTC) 331,
 2672–4, 2673 *T*
- cervical nodal metastases 1761
- children 2693
- cystic nodes 1761
- cytological appearance 2679 *F*
- extent 2673 *T*
- genetics 2669, 2670
- histopathological features 2674 *F*
- imaging 2677 *F*, 2678 *F*
- microcalcifications 719
- nodal metastases 1761
- prognostic variables 2682 *T*
- treatment 2685
- ultrasound examination 719, 720 *F*
- papilloma(s)
 CO₂ laser excision 2238
 inverted *see* inverted papilloma
 laryngeal 764, 2600 *T*
 laser plume 2236
 oral 1828
 phonosurgery 2238, 2239
 respiratory 209
 sinonasal 11–2

- papule 1699–700
 parabrachial nucleus 3816
 paracetamol
 anaesthetic premedication 490 *T*
 children 509
 dosage, children 516 *T*
 head and neck cancer pain 2785–6
 migrainous vertigo 3801
 pharyngitis, acute 1984
 tonsillectomy 1993
 paracoccidioidomycosis 225
 paracrine signalling, embryonic
 myogenesis 68
 paracusis 3596–7
 Paradise study 1230
 paradoxical embolism, brainstem/
 cerebellar infarction 3756 *F*, 3767
 parafollicular (C) cells, thyroid
 gland 324, 327
 embryology 315, 368
 function 324
 microscopic anatomy 320, 320 *F*
 paragangliomas *see* glomus tumours
 (paragangliomas)
 paraglottic space 2137 *F*, 2138, 2139 *F*
 parainfluenza virus (PIV) 207
 parainfluenza virus vaccination, acute
 otitis media 919
 paramedian forehead flap, nasal
 reconstruction 3022, 3024 *F*
 paramedian mandibulotomy 2566 *F*
 paramedian pontine reticular
 formation, saccade
 abnormalities 3715
 parameningeal sarcoma 2527
 paramyxovirus antigens, Paget's
 disease 3486
 paranasal bones, development 1317–21
 paranasal granuloma 217
 clinical features 218
 epidemiology 217
 management 219
 nasal tuberculosis 1459, 1460 *F*
 outcomes 219
 treatment 219
 paranasal sinuses
 anatomy 1315–43
 comparative 1321–2
 asthma 1562
 development 803, 1315–21, 1368
 anomalies 1320–1
 olfaction 1369
 drainage 1368
 endoscopy *see* nasal endoscopy
 functions 1369
 granulomatous conditions 1646 *T*
 HIV infection 241–2
 hypophysectomy complications 4113
 infections
 chronic 1458–68
 orbital involvement 3916
 inflammatory disease 1344–6,
 1349–50, 1349 *F*
 lymphatic drainage 2418, 2713
 malignancy *see* sinonasal malignancy
 mucosa 1368
 mycotic diseases 216–22
 nonallergic, noninfectious
 inflammation 1382–3
 olfactory dysfunction 1667–8
 ostium size 1369
 oxygen tension 1368
 physiology 1368–9
 pneumatization 1519
 pressure changes 1369
 see also individual sinuses
 paranasal sinus inflammation
 asthma 1561–2
 chronic obstructive pulmonary
 disease 1561–2
 paranasal sinus surgery
 anaesthesia 503
 blood transfusion 257
 complications 1485 *T*
 training issues 551
 paraneoplastic cerebellar
 degeneration 3775
 paraneoplastic pemphigus (PNP) 1834
 parapharyngeal abscess 1223,
 1998–2000
 bacteriology 1999
 clinical features 1999
 complications 2000
 carotid sheath vessel
 thrombosis 2000
 mediastinitis 2000
 necrotizing fasciitis 2000
 CT imaging 1223 *F*
 differential diagnosis 1999
 dysphagia 2031, 2031 *F*
 epidemiology 1999
 investigation 1999
 treatment 1999–2000
 needle aspiration 2000
 surgical abscess
 drainage 1999–2000
 parapharyngeal space (PPS) 1744,
 1745 *F*, 1756, 1806–7, 1950, 1950 *F*,
 2110, 2110 *T*, 2523, 2523 *F*, 2579,
 3908–9
 poststyloid compartment 2523, 2579
 prestyloid compartment 2523, 2579,
 3905 *F*, 3906 *F*, 3908–9, 3909 *F*
 retrostyloid compartment 3909
 parapharyngeal space (PPS)
 tumours 2522–42
 angiography 2531, 2531 *F*
 carotid body paraganglioma 2525–6,
 2525 *F*
 chemotherapy 2534
 diagnosis 2529–32
 fine needle aspiration
 cytology 2529–30
 histopathology 2524–7
 imaging 2530–1
 investigations 2529–32
 masticator space 2530
 metastases 2527–8
 nasopharyngeal carcinoma 2527
 neck 2535
 neurofibromas 2527
 patterns of failure 2535–6
 prognosis 2535–6
 radiotherapy 2534
 rare forms 2527
 salivary gland 2525
 schwannomas 2527
 spread 2524–7
 adjacent to PPS 2528
 within PPS 2528
 staging 2529–32, 2531–2
 surgical treatment 2532–4
 definitive 2532–4
 extended transmandibular
 approach 2533
 transcervical approach 2533
 transparotid approach 2533
 see also individual procedures
 survival 2535–6, 2535 *F*
 symptomatology 2528–9, 2529 *T*
 syncope 2529
 treatment 2532–5
 complications 2536
 trismus 2528–9
 xerostomia 2536
 paras accessoria 1853
 parascapular flap 2873–6
 parasitosis 1216
 epistaxis 1065
 parasympathetic nervous system
 nose 1363
 thyroid gland control 319
 parasympathomimetics 1365, 1365 *T*
 parathyroid adenoma 390
 histology 390

- parathyroid adenoma (*continued*)
 hyperparathyroidism 401
 investigations 391
 MEN-1 gene 389
 ultrasound 722, 722 *F*
 parathyroid adenoma-1 (PRAD-1)
 gene 388
 parathyroid carcinoma 390
 FDG-PET imaging 694
 parathyroidectomy 393
 approach 373
 benefits 392–3
 bilateral neck exploration 393
 complications 395
 conventional 393
 endoscopic 395
 hyperparathyroidism 393–5, 396
 inferior gland location 394
 mediastinal exploration 394
 mediastinotomy and 394
 minimally invasive 383, 384
 persistent hyperparathyroidism 395
 preoperative imaging 383, 384
 radio-guided 395
 recurrent hyperparathyroidism 395
 results 395
 cure rate 395
 scan-directed minimally invasive
 open 394
 sternal split 372
 superior gland 393–4, 394 *F*
 surgical criteria 393
 video-assisted 395
 parathyroid glands 367–78
 anatomy 369–73, 387, 2665–6,
 2665 *F*
 macroscopic 369–71
 microscopic 319–21
 bilobed 369–70
 biochemistry 379–81
 blood supply 372
 calcium sensing receptor 388
 cells 373
 age-related changes 373
see also individual cell types
 descent 368, 370 *F*
 development 367–9, 368 *F*, 387
 disease 401
see also individual diseases
 dysfunction 387–97
 ectopic 370 *F*, 371
 blood supply 372
 imaging 392
 fat lobules *vs.* 370–1, 371 *T*
 function, normal 379
 function testing 379–86
 methods 379
 hyperplasia 390
 imaging 383–4, 722, 1299–300
 best clinical practice 385
 indications 384
 infarction 372
 inferior (parathyroid III)
 anatomical location 371
 development 367–8, 387
 maldescendent 372
 surgical location 394
 undescended 394
 injury, post-thyroidectomy 351
 innervation 373
 intrathyroidal 722
 ‘kissing pair’ 369–70
 location 370 *F*, 371–2
 asymmetrical 372
 variations 368, 371
 number of 369
 physiology 373–5, 388
 PTH *see* parathyroid hormone
 (PTH)
 removal (parathyroidectomy) *see*
 parathyroidectomy
 shape 369–71
 size 369
 superior (parathyroid IV)
 anatomical location 371
 development 368, 387
 migration 368
 surgical location 393–4, 394 *F*
 supernumerary 369
 surgical identification 370, 371 *T*
 venous drainage 372–3
 weight 369
 parathyroid hormone (PTH) 373–4,
 388
 action 374
 active form 388
 biochemistry 382–3
 in clinical practice 382–3
 intraoperative, gamma probe
 localization 384
 therapeutic strategies and 382
 bone, effects on 388
 end organ resistance 383
 half-life 388
 hypercalcaemia 382, 382 *T*
 hyperparathyroidism 389
 hypocalcaemia 374, 382, 382 *T*
 kidney, effects on 388
 metabolism 374
 pseudohypoparathyroidism 383
 regulation 374
 secretion 373–4, 388, 389
 structure 373–4
 parathyroid hormone receptors
 (PTH) 388
 parathyroid hormone-related protein
 (PTHRP) 375, 388
 parathyroid hyperplasia 390
 paratracheal nodes 2143
 Pare, Ambroise 2924–5
 ‘parent’s kiss’ 1186
 parietal lobe lesions, eye movement
 defects 3921
 Parinaud’s syndrome 3921
 Parkinsonian syndromes, gait 3731
 Parkinson’s disease 3939
 aetiology 2078
 arm swing loss 3731
 balance problems 3778
 dysphagia 2033, 2078
 mastication 3939
 olfactory dysfunction 1669
 postencephalitic, oculogyric
 crisis 3921
 posturography 3735–6
 sialorrhoea 3939
 speech 3939
 stem cell therapy 75
 symptoms 2078
 voice problems 2222, 2224–5
 Lee Silverman Voice Program
 2225
 parosmia (dysosmia) 1664, 1666–7
 parotid duct 1807–8, 1854
 imaging 1871–2, 1872 *F*, 1873 *F*
 ligation, drooling 789
 parotidectomy 4091
 conservative *see* conservative
 parotidectomy
 superficial 2484–6, 2485 *F*
 parotid gland(s) 1853–4
 accessory 1871–2
 anatomy 1807–8, 1853–4, 1853 *F*
 autonomic nerve supply 1855, 1856
 benign tumours 2475
 blood supply 1856
 capsule 1854
 embryogenesis 1852
 fascia 1854
 HIV patients 245, 245 *F*
 imaging 1871
 children 1297
 ultrasound 722–3, 723 *F*, 724
 inflammation 724
 innervation 1807–8, 1856

- lymphatic drainage 1856
 saliva collection 1862–3
 salivary flow rates 1807
 surgery, facial paralysis and 2808,
 3880–1, 3889
 children 1058, 1058 *F*
 swelling, children 1212
 venous drainage 1856
 parotid gland cysts, HIV
 infection 1246, 1246 *F*
 parotid gland tumours 2503–4, 2504 *F*,
 2525 *F*
 adenoid cystic carcinoma 2503–4,
 2504 *F*
 best clinical practice 2505–6
 deep lobe 1758 *F*, 2528
 surgical treatment 2532
 imaging 723, 723 *F*, 1883
 malignant 2503–4
 metastatic disease 2501–2
 molecular biology 2496
 mucoepidermoid carcinoma 2503–4,
 2504 *F*
 parapharyngeal space 2524–5, 2524 *F*
 presentation 2476–7, 2477 *F*
 sites 1854
 surgery 2483–7, 2503–4
 transpharyngeal approach 2486–7,
 2487
 symptoms 2503–4
 treatment 2483–7
 parotid haemangioma 1247, 1247 *F*,
 1248 *F*
 parotid space 1757, 1758 *F*, 1806, 2110,
 2110 *T*, 3905 *F*, 3908, 3908 *F*
 parotitis
 acute *see* mumps
 bacterial 1212
 paroxysmal hemicrania 1723
 pars flaccida 3108
 otoscopy 3315–6, 3315 *F*
 retractions 3417 *F*
 examination 3427
 stage one 3417, 3418 *F*
 stage two 3417, 3418 *F*
 stage three 3417, 3418 *F*
 stage four 3418 *F*
 stage four 3417
 pars intermedia, pituitary gland 295
 pars tensa
 anatomy 3108
 atrophy, childhood 901, 931 *F*, 941–7,
 942 *F*
 classification 942–3
 definitions 942–3
 epidemiology 943
 investigations 945
 management 945
 natural history 943–4, 943 *T*
 pathology 941–2
 signs 944–5
 surgical intervention 945–6
 symptoms 944
 ventilation tubes 892
 chalk patch 3315–6, 3316 *F*
 cholesteatoma 3433
 examination 3315–6, 3315 *F*
 retractions
 children 901
 examination 3427
 management 945
 otoscopic diagnosis 3416–7,
 3417 *F*
 skin 3107
 subdivisions 3412–3, 3412 *F*, 3413 *F*
 pars tuberalis 296
 partial anosmia 1664
 partial chromosome deletions 792
 partial cricotracheal resection
 (PCTR) 1139, 2282, 2282 *F*
 partial laryngectomy, laryngeal
 tumours 2612–5
 complications 2615
 vertical procedures 2613
 partial ossicular replacement prosthesis
 (PORP)
 ear reconstruction 983–4
 HDPE implants 121
 Soundbridge device and 3662
 partial submucosal cricoideectomy,
 intractable aspiration 2101
 particulate embolic agents 733
 parvalbumin 3237
 Passavant's ridge 2111–2
Pasteurella multocida 1465
 pastilles 448
 paternalism
 consultation style 560, 560 *F*, 562, 563,
 582
 ethical issues 586
 evidence-based medicine
 influence 562
 Paterson-Brown Kelly syndrome 2353
 pathologic reflux (definition) 1272
 pathology services, medical
 negligence 2807
 patient administration systems, cancer
 data collection 2373
 Patient Advice and Liaison Services
 (PALS) 574
 patient-based outcomes research *see*
 outcomes research
 patient controlled analgesia (PCA) 463
 patient information
 medical negligence 3089
 nasal endoscopy 1347
 patient preparation, surgery 457–66
 ambulatory case suitability 457–8
 cardiovascular disease 458–60,
 459 *T*
 communication, loss 464
 consent 461–2
 day case suitability 457 *T*
 explanations 461–2
 hypertension 459
 latex allergy 464–5
 medications 465
 National Institute for Clinical
 Excellence guidelines 461, 461 *T*,
 462 *T*
 nutrition 464
 on day of surgery 465
 oral intake 465
 pathway 457–8
 postoperative care planning 464–5
 preoperative assessment/tests 458–60,
 460–1
 previous problems 458
 risk indices 459
 special requirements 464
 theatre planning 464–5
 patient recall, information 563
 Patient's Charter 582, 590
 patient's rights 582, 609
 pattern-recognition molecules 133
 pattern recognition tests, central
 auditory dysfunction 3858–9
 Patterson–Brown–Kelly
 syndrome 2027 *F*, 2031, 2634–5
 PDGFR, tumour marker 2384
 peak inspiratory flow (PIFR) 1375
 peak nasal flow 1375
 peak velocity, sound 3174
 pectoralis major flap 2855–8, 2856 *F*,
 2858 *F*
 modifications 2857
 technique 2851–3, 2856–8
 pectoralis minor
 facial reanimation 3080–1, 3081 *F*
 insertion 3081–2, 3081 *F*
 pedicled flaps, head and neck
 surgery 2847–66
 advantages/disadvantages 2848 *T*
 axial flaps *see* axial flaps
 Gillies principles 2847

pedicled flaps, head and neck surgery
(continued)
 types 2847–8
see also individual types
 pedigree analysis 18–9
 peduncular infarct, vestibular schwannoma 3977, 3977 *F*
 Pegasus project 2626, 2627–8, 2630
 peg-shaped teeth 1817, 1818 *F*
 pegvisomant 4101
 pelvis flaps 2876–83
 pemphigoid dysphagia 2032
 nasal 1715
 pemphigus 171
 oral manifestations 1834–5, 1834 *F*
 pemphigus vulgaris (PV) 1834
 pencil tip sign, croup 1128, 1128 *F*
 Pendleton's model, doctor–patient relationship 563
 Pendred's syndrome 330, 400, 813 *T*, 849, 2667–8
 pendular nystagmus 3725, 3725 *F*
 treatment 3804–5, 3804 *T*
 pendulum model, semicircular canal 3211
 penetrating wounds, laryngeal 2271–2
 penicillin(s) 229–30
 absorption 229–30
 allergic reactions 230
 indications 230
 mechanisms of action 431
 natural 230
 parapharyngeal abscess 1999
 penicillinase-resistant 230
 pharyngitis 1985
 resistance 230, 235
 rheumatic heart disease prevention 1986
 side effects 230
 syphilis 1462, 2008
 penicillinase-resistant penicillins 230
 pentoxifyllin 1, 3588
 peptic granuloma *see* arytenoid granuloma
 percentage irregularity score, voice evaluation 2179
 perceptual tests, vestibular function 3737–40
 perceptual voice evaluation 2171, 2174–6, 2175 *T*
 harmonics-to-noise ratio and 2181
 perchlorate discharge test 1299–300, 1300 *F*

percutaneous endoscopic gastrostomy 2097
 percutaneous endoscopic jejunostomy 2097
 percutaneous fluoroscopic gastrostomy (PFG), dysphagia 2791
 percutaneous tracheostomy 2295 complications 2295
 rate 2297
 dilatational technique 2295
 open surgical *vs.* 2297–8
 time intubated 2293–4
 percutaneous tumour embolization 734–5
 perennial intrinsic rhinitis *see* nonallergic rhinitis with eosinophilia syndrome (NARES)
 perennial nonallergic noninfectious rhinitis *see* rhinitis, idiopathic perfluorocarbons (PFC) 263 performance test, hearing 839–40 method 839–40, 840 *F*
 stimulus 840 *F*
 perfusion functional magnetic resonance imaging 677, 677 *F*
 perfusion monitoring 529 periapical abscess *see* dental abscess periapical cyst 1817 periapical osseous (cemental) dysplasia 1930 periaqueductal grey matter (PAG), phonation 2158 perichondritis external ear 3358–61, 3359 *F* aetiology 3358 classification 3358 complications 3359 definition 3358 diagnosis 3359 differential diagnosis 3359 management 3359–60 pathology 3358–9 prevention 3359 trauma-induced 3358 treatment resistant cases 3359–60 tracheostomy 2302 perichondrium, tracheal cartilage 2141–2 pericoronitis 1805, 1821 pericyte–endothelial cell interactions, angiogenesis 93 periglottic obstruction 481–2 anaesthesia depth 481 peri-implant infections 2920

peri-implant mucosal inflammation 2920 *F*
 peri-implant sulcus 2906–7
 perilabyrinthitis 923
 perilingual deafness, cochlear implantation 861 perilymph absorption 3187 composition 3188–9, 3189 *T* electric potential 3188–9 formation 3187 perilymphatic fistulae children 1047 audiograms 1047 congenital 874 diagnosis 1047, 3764 post-stapes surgery 3476 traumatic 3507–10 children 1047 diagnosis 3507–8 differential diagnosis 3508, 3508 *T* investigations 3509 management 3507–8 surgery 3510–1 symptom onset 3508 treatment options 3509 tympanic membrane examination 3508 perilymphatic space, cochlea 3186, 3186 *F*
 perinatal anoxia, bilirubin encephalopathy 3845–6 perinatal trauma, facial paralysis 1057 periodic alternating nystagmus 3804, 3804 *T*
 periodic complex tones 3246 periodic limb movement disorder (PLMD) 2310 periodic pain, cancer 2784–5 periodic sound analysis 3252–3 periodic sound signal 2165 periodontal breakdown 1819 periodontal disorders 1820–2 periodontitis accelerated 1819 chronic 1819 *T*, 1820, 1821 *F* management 1821 tooth loosening 1820 HIV patients 243 periolytic nuclei 3141–2 perioral flare reaction 1424–5 periorbital cellulitis 1087–8 periosteal abscess, childhood sinusitis 1087–8

- periosteal stem cells 74
 periosteal tunnel creation, deviated nose 2990
 peripheral nerve disease
 sensory ataxia 3778, 3780
 see also specific disorders
 peripheral nerve fibres, degrees of injury 3873–4, 3874 *F*
 peripheral nerve stimulator 494–5, 495 *F*
 peripheral neuropathy
 auditory neuropathy/dyssynchrony and 3848–9
 diabetes mellitus 402
 posturography 3735
 peripheral nystagmus, central *vs.* 3724 *T*
 peristalsis
 disordered, post-oesophageal atresia repair 1287
 pharynx 1958
 peristomal granulations, tracheostomy-induced 1203
 peritonsillar abscess (quinsy) 1222–3, 1996–8
 abscess tonsillectomy 1998
 bacteriology 1996–7
 clinical features 1222, 1222 *F*, 1997
 complications 1998
 differential diagnosis 1997
 dysphagia 2030, 2030 *F*
 epidemiology 1996
 investigation 1997
 management 1989
 outpatient management 1997–8
 tonsillectomy 1222–3, 1998
 treatment 1997–8
 children 1997–8
 knife drainage 1998
 needle aspiration 1998
 peritonsillar space 1744, 1807
 perivertebral space 1758
 permanent balloon occlusion
 internal carotid artery 3951, 3952 *F*
 stroke risk 3951
 permanent childhood hearing impairment (PCHI)
 causes 845–9, 845 *T*
 epidemiology 844–5
 illness, due to 849
 meningitis 847
 presentation 848–9
 see also childhood deafness
 permanent threshold shift (PTS) 3298, 3548
 permanent tracheostomy 2293
 pernicious anaemia 269
 perniosis (chilblains) 1715
 perpendicular plate, ethmoid bone 3897
 per protocol analysis 629
 persistent acute otitis media 913
 persistent generalized lymphadenopathy
 see HIV lymphadenopathy
 persistent rhinosinusitis (PRS) *see*
 chronic rhinosinusitis (CRS)
 persistent stapedial artery (PSA) 873, 873 *F*, 3473–4
 persistent vegetative state (PVS) 588
 personal databases, cancer data collection 2373
 person-centred counselling, tinnitus 3614
 pertechnetate ($^{99m}\text{TcO}_4^-$), salivary gland uptake 1878
 pertussis (whooping cough) 2252
 causative organism 200
 clinical features 2252
 incidence 2252
 investigations 2252
 management 2252
 pathophysiology 2252
 vaccination 2252
 pertussis toxin 200
 perverted nystagmus 3729
 pes anserinus minor 1325
 petechiae, oral 1822
 petroclival lesions 3690 *F*
 middle fossa surgery 4024
 petroleum jelly, epistaxis 1066
 petromastoid 3124
 petrosal bone, vestibular schwannoma invasion 3959–60
 petrosal vein injury, surgical 3978
 petrosectomy
 petrous apex lesions 4051
 temporal bone post-resection reconstruction 4093
 petrositis, chronic otitis media 923, 3404, 3404 *F*
 petrosphenoccipital suture of Gruber 4026–7
 petrosquamous fissure 3900
 petrotympanic fissure 3900
 petrotympanic fissure of Glaser 3904
 petrous apex
 anatomy 4046–7, 4046 *F*
 cysts 4047, 4051 *F*
 erosion, otalgia 3528
 infection 4047
 lesions 4046–53
 complications 4052
 investigations 4048–9
 management 4050–2
 resection 4051–2
 pneumatization 4046–7
 surgical approaches 4050–2
 tumours 4047–8
 resection 4051
 petrous apex chondrosarcoma 4024, 4024 *F*
 petrous apex mucosal cyst 4047, 4051 *F*
 petrous apicectomy 4024
 Peutz–Jegher's syndrome 1823
 Pfeifer's classification, cleft lip/palate 996, 997 *F*
 Pfeiffer syndrome 813 *T*, 1027
 Pfu polymerase 7
 Phadiatop test 1394
 phaeochromocytomas 2526–7, 2671
 phage-clone technique, metastases detection 2715
 phagocyte disorders 177–8, 177 *T*
 see also individual disorders
 phagocytosis 139–40
 phagocytosis and killing test 169
 phalangeal cells 3130
 inner 3136
 outer *see* Deiters' cells
 phantogeusia 1843
 phantom taste, chorda tympani nerve injury 1844
 phantom tooth pain 1721
 phantosmia 1664, 1666–7, 3913–4
 pharmacodynamics 409, 411–2
 corticosteroids 418
 dose-related adverse reactions 415
 pharmacogenetics 409, 412
 pharmacokinetics 409, 409–10, 409 *F*
 antimicrobials 229–34
 dose-related adverse reactions 415
 pharyngeal arches *see* branchial arch(es)
 pharyngeal area, lateral skull base 3900–1
 pharyngeal clefts 797, 813–4, 1942
 pharyngeal diverticulum 797
 pharyngeal foreign bodies
 children 1187
 dysphagia aetiology 2034
 pharyngeal hypophysis 2117–9
 pharyngeal infection(s) 1981–2024
 acute *see* pharyngitis, acute
 blood diseases 2015
 chronic
 nonspecific 2006–7
 specific 2007–15

pharyngeal infection(s) (*continued*)
 lymphoid tissue hyperplasia 2013
 viral 2002–5
see also specific infection/disease
 pharyngeal injuries 1770
 pharyngeal mucosal space
 (PMS) 1756–7, 1757 *F*, 2109,
 2110 *T*
 pharyngeal neoplasms 2013–4
 pharyngeal nerve 2156, 2157 *F*
 pharyngeal pituitary 295
 pharyngeal plexus
 nervous 1947, 1950, 2075, 2114, 2156
 venous 1951
 pharyngeal pouch 2043–61
 aetiology 2045–7, 2046 *F*
 cricopharyngeus muscle
 spasm 2046
 incoordination theories 2046–7
 Killian's dehiscence 2045–6, 2046 *F*
 definition 2043
 diagnosis 2026, 2027 *F*, 2044
 differential diagnosis 2044
 dysphagia 2034, 2034–5, 2044
 incidence 2043–4
 management 2048
 pathology 2047–8
 regurgitation 2044
 surgery *see* pharyngeal pouch surgery
 symptoms 2044, 2044 *F*
 pharyngeal pouch (embryonic) 796–7,
 797 *F*, 1942
 derivatives 796 *T*, 1943 *T*
 first 1943 *T*
 fourth 368, 1943 *T*
 second 1943 *T*
 third 367–8, 1943 *T*
 pharyngeal pouch carcinoma 2047–8,
 2728
 barium studies 2048, 2728
 post-surgery 2048, 2058
 pharyngeal pouch surgery 2048
 access problems 2050, 2050 *F*, 2052,
 2053 *F*
 CO₂ laser technique 2054, 2058, 2058 *T*
 cricopharyngeal myotomy
 procedure 2049, 2054, 2059
 endoscopic *see* endoscopic stapling,
 pharyngeal pouch
 historical aspects 2048–9
 outcome studies 2055–9, 2056, 2058 *T*
 postoperative care 2054
 pouch excision 2054–5, 2055–8, 2056,
 2058 *T*
 pouch inversion 2055–8, 2055, 2056

pharyngeal recess (fossa of
 Rosenmüller) 1094, 1944, 3900–1
 nasopharyngeal carcinoma 2454–5,
 2454 *F*, 3900–1
 pharyngeal reconstruction 2886
 issues 2886
 options 2886
 problems 2886
 pharyngeal resection, hypopharyngeal
 cancer 2648
 pharyngeal space, swallowing 1957
 pharyngeal stenosis 2014
 causes 2014 *T*
 surgery-related 2809
 treatment 2014
 pharyngeal tubercle 3899
 pharyngeal tumours
 barium swallow appearance 2027 *F*
 posterior wall 2589–90
 radical neck dissection 2743
 staging 2364–5
 pharyngitis, acute 1982–7
 aetiology 1982–3
 antibiotics 1984–5
 cross infection prevention 1986
 recurrent infections 1985
 suppurative complication
 prevention 1986
 symptom relief 1986
 USA choice 1986
 bacterial pathogens 1982–3
see also Group A beta-haemolytic
 streptococci (GABHS)
 carrier state 1987
 children 1982–3
 clinical findings 1983–4
 complications 1986–7
 corticosteroids 422, 1984
 definition 1982
 differential diagnosis 1984
 dysphagia 2030
 epidemiology 1982
 hospital admission 1986
 investigations 1984
 pathophysiology 1983
 prognosis 1987
 treatment 1984–6
 costs 1982
 viral 205 *T*, 1983
 pharyngobasilar fascia 1947, 2111,
 2111 *F*, 2112 *F*, 3898 *F*, 3900,
 3901
 pharyngocutaneous fistula repair 2862 *F*
 pharyngolaryngectomy, hypopharyngeal
 cancer 2648–9
 pharyngolaryngooesophagectomy (total)
 hypopharyngeal cancer 2649
 oesophageal cancer 2649
 pharyngomaxillary space *see*
 parapharyngeal space
 pharyngo-oesophageal (PE)
 segment 2227
 pharyngoplasty
 complications 1011–3
 velopharyngeal insufficiency 1011,
 1012 *F*
 pharyngoscopy
 dysphagia investigations 2028
 globus 2039–40
 pharyngeal injuries 1770
 pharyngotomy, hypopharyngeal
 stenosis 2635
 pharyngotonsillitis, infectious
 mononucleosis 1225
 pharynx 1942–53
 anatomy 1944–51, 1944 *F*
 blood supply 1951
 embryology 1942–3
 HIV associated lesions 243–4
 hypopharynx *see* hypopharynx
 innervation 1950–1, 2074–5, 2075 *F*
 afferent fibres 2074–5
 Kaposi's sarcoma 244
 lymphatic drainage 1951
 lymphoid tissue 1951
 muscles 1945 *F*, 1946 *T*, 1947, 1948 *T*,
 1949 *F*, 1950, 1955
 nasopharynx *see* nasopharynx
 neurodevelopmental disorders 2080–1
 neurological disease/
 disorders 2074–83
 ageing 2076
 causes 2077 *T*
 clinical presentation 2076, 2077 *T*
 cranial nerve neuropathies 2080,
 2080 *T*
 demyelinating disorders 2078
 incidence 2075
 management 2081–2
 movement disorders 2077 *T*, 2078
 myogenic disorders 2076–8, 2077 *T*
 patient examination 2076
 patient history 2076
 peripheral nerve lesions 2080
 physiology 2075–6
 stroke 2077–8
 surgery 2081
 systemic infection 2077 *T*, 2078–9
see also dysphagia; specific disorders
 oropharynx *see* oropharynx

- paediatric consultation 778–9
 peristasis 1958
 relations 1947–50
 structure piercing 1949–50
 rheumatological diseases 184
 swallowing 1955
 vasculature 1951
 venous drainage 1951
 vesicular/bullous eruptions 2005
 wall 1947, 1955
 buccopharyngeal fascia 1947
 mucous membrane 1947
 pharyngobasilar fascia 1947
- phase (definition) 3212
 phase angle 3160, 3160 *F*
 phase coherence 3288
 phase dispersion optical coherence tomography 759
 phase-specific chemotherapy 37
 ‘phenomenon of the missing fundamental’ 3252–3
- phenothiazines
 dysphagia 2789–90
 salivary flow 1861
 vertigo, children 1049
 vestibular attacks, acute 3795
- phenotype 18–9
 phenylephrine, effects on cilia 1361
 phenytoin
 adverse reactions 415
 glossopharyngeal neuralgia 3531–2
- pheromones 1368
 Phi 2944, 2944 *F*, 2945
 philtrum 1793
 pH monitoring
 gastrointestinal evaluation, laryngeal stenosis 1154
 globus pharyngeus 2038
 phon 3250–1
 phonation 992–3, 2170–1
 biomechanics 2159–61
 vibratory cycle 2160–1
 voice initiation 2160
 involuntary 2158
 neuroanatomy 2158–9
 prephonatory inspiratory phase 2160
 reflex control 2159
 vegetative 2158
 see also speech; vocal fold(s); voice
- phonation quotient 2182
 phonation stage, speech and language development 990–1
 phonation threshold pressure 2160, 2182
 phonemes 3267
- phonetograms 2179
 phonosurgery 2234–47, 2195–6
 anaesthesia 2236
 anterior webs 2237
 best clinical practice 2238–9
 electrode pacing 2196
 granulomas 2238
 intracordal cysts 2237
 laryngeal framework 2196
 laryngeal injection 2195
 laser, microsurgical instrumentation, vs. 2236
 microdebrider 2236
 microlaryngoscopic *see* microlaryngoscopy
 nerve-muscle pedicle graft 2196
 nodules 2236–7
 papillomas 2238
 pathology 2236–8
 polyps 2237
 professional voice 2213
 Reinke’s oedema 2237, 2239
 reinnervation 2196, 2244, 2245 *T*
 laryngeal neuromuscular physiology 2244
 surgical techniques 2234
 ventilation 2236
 vocal sulcus 2238
 voice rest 2236
- phosphate homeostasis
 biochemical analysis 380–1, 381 *T*
 creatinine clearance 380–1
 parathyroid function and 379
 renal tubular absorption and 380
- phospholipase C, saliva 1860
 photoablative reactions, laser therapy 743
 photoageing 3069
 photochemical reactions, laser therapy 743
- photodynamic therapy (PDT) 745–6
 clinical reports 746
 drug uptake period (drug–light interval) 746
 head and neck cancer 746
 juvenile-onset recurrent respiratory papillomatosis 1177
 lip cancer 2548–9, 2548 *F*
 nasopharyngeal carcinoma 2467
 photosensitizer 745–6
 principles 745–6
 singlet oxygen 745–6
- photographs, facial assessment 2946–7
 photons 47, 742
- photosensitivity, antimicrobial-induced 236
 photosensitizer 745–6
 pH probe study, stridor 1119
 phrenic nerve 1752
 physiologic reflux 1272
 pial sheath, optic nerve 3914
 Pierre Robin sequence 1000–1, 1001 *F*, 1109, 2151
 pig bronchus 1147
 pigmented basal cell carcinoma 2397
 pillar cells 3130, 3131 *F*, 3136, 3137 *F*
 inner 3131 *F*, 3136
 microtubular bundles 3136
 outer 3131 *F*, 3136
 pillars of the fauces 1793
 pilocarpine
 nasal vasculature, effects on 1365
 salivary gland stimulation 1862
 Sjögren syndrome 1912
 taste abnormalities 1848
 xerostomia 414, 1908–9
- pinch grafts 2825
 pinch test 2829–30
 pineal tumours 3921
 pink noise therapy, hyperacusis 3596
 pinna
 anatomy 3105–6, 3105 *F*, 3312 *F*
 clinical examination 3311
 congenital abnormalities 3643
 development 808, 808 *F*, 965–6, 3122
 disorders, classification 3321–2
 grafting, augmentation
 rhinoplasty 2973
 infant 808 *F*
 Kaposi’s sarcoma 240
 keloid removal 2893
 non-Hodgkin’s lymphoma 3359
 perichondritis *see* perichondritis, external ear
 reconstruction *see* pinna reconstruction
 removal, temporal bone squamous cell carcinoma 4091–2, 4092
 sensory innervation 3106, 3106 *T*
 sound localization 3179, 3255
- pinna carcinoma 2501–2
 pinnoplasty
 cartilage scoring technique 3092
 haemostasis 3092
 medical negligence 3092
 Mustarde technique 3092
- pinna reconstruction 3028–47
 autogenous *vs.* prosthetic 3045
 bone-anchored prosthesis 3044

pinna reconstruction (*continued*)
 burns 3032–3, 3033 *F*
 cancer resection 3028–32
 case study 2940
 complications 3033, 3044–5
 costal cartilage 3029 *F*, 3030 *F*
 framework assembly 3035–9, 3038 *F*
 bilateral ear loss 3035–6
 free flaps 3044
 hair problems 3045
 implant retention 2932
 infection 3033, 3044
 local flaps 3039–40, 3040 *F*
 projection 3039 *F*
 radiotherapy 3045
 release 3039
 scalp dissection 3044
 silicone drains 3039
 skin cover 3039, 3039–44
 skin loss 3044
 smoking and 3044
 squamous cell carcinoma 2926 *F*
 suture extrusion 3045, 3047 *F*
 techniques 3033–44
 temporoparietal fascia 3042–4
 tissue expanders 3031 *F*, 3040–1,
 3041 *F*
 piperazines 3795
 piribedil 3604–5
 piriform cortex 1663
 piriform fossa 1945, 2638
 cancer/carcinoma 2639 *F*, 2644 *F*
 complications 2655
 cricoarytenoid joint
 invasion 2638–9, 2639 *F*
 epidemiology 2634–5
 neck node metastases 2641
 pitch 2165
 changes, children 1168
 definition 3252
 disorders 2226–7
 see also specific disorders
 harmonic spacing 3253
 range, paralinguistic features 2168
 sound wave frequency 3175
 vocal 2217
 voice perception 2174
 pitch perception 3252–3
 cochlear hearing loss 3256
 complex tones 3252–3, 3253 *F*
 place theory 3252
 pure tones 3252
 temporal theory 3252
 pitch perturbation ('jitter') 2165, 2179
 pitch registers *see* vocal registers

Pittsburgh algorithm 888, 889 *T*
 Pittsburgh staging, temporal bone
 squamous cell carcinoma 4090–1,
 4091 *T*, 4095, 4095 *T*
 pituitary adenomas 399 *F*
 acromegaly 399
 appearance 4110
 asymptomatic 304
 biochemical investigations 308–12
 extension pathways 399
 functioning 304, 4098, 4099, 4100–3
 follow-up 4113
 tests 312
 haemorrhage 4100
 incidence 304
 malignant transformation 4104
 mesadenomas 4099
 nonfunctioning 308, 311–2, 4099,
 4103, 4113
 children 311
 follow-up scans 4103, 4113
 identification 311
 tumour locations 399
 see also specific types
 pituitary apoplexy 4100
 pituitary fossa
 anterior wall 299, 303
 boundaries 303
 floor 303
 lining 298
 relations 299, 299–300
 lateral 299, 303
 posterior 299
 superior 299, 304
 tumour expansion 4099
 pituitary gland
 anatomy 295–302, 296 *F*
 imaging-related 303–4
 anterior *see* adenohypophysis
 blood supply 297, 297 *F*, 307
 capsule 297
 development 295, 296 *F*, 2117–9,
 2118 *F*
 disease 399
 function tests 303–13
 postoperative 312
 hypothalamic hormones,
 effects of 300
 imaging 303–13
 related anatomy 303–4
 normal appearance 4110
 pharyngeal 295, 2117–9
 physiology 300–2
 functional test-related 307–8
 posterior *see* neurohypophysis
 Rathke's pouch cysts 4103
 tumours *see* pituitary tumours
 venous drainage 297, 307
 pituitary gland macroadenomas 4099
 pituitary infarction 4100
 pituitary macroadenoma 304–5, 304 *F*
 biochemical investigations 308
 definition 304–5
 haemorrhage 305, 305 *F*
 imaging 306
 post-surgical imaging 306
 visual field assessment 312
 pituitary microadenomas 304, 4099
 definition 304
 digital subtraction angiography 306–7
 endocrine assessment 306–7
 pituitary stalk *see* infundibulum,
 pituitary gland
 pituitary tumours
 adenomas *see* pituitary adenomas
 chordomas 4104
 classification 4098–9
 functional 4098–9
 histological 4098
 size 4099
 clinical features 4099–103
 endocrine effects 4099
 infarction 4100
 visual defects 4099
 craniopharyngiomas 4103–4
 current knowledge/future
 research 4116
 epidemiology 4099
 gliomas 4104
 imaging 304–5
 extrinsic abnormalities 304–5,
 304 *F*
 intrinsic abnormalities 304, 304 *F*
 lateral extension 304 *F*, 305
 post-surgical 306–7
 superior extension 304, 304 *F*, 305 *F*
 technological advances 307
 malignant 4104
 management 4098–118
 adrenal resection 4102
 recurrence after 4113
 surgical resection *see*
 hypophysectomy
 see also specific treatments
 Rathke's pouch cysts 4103
 secondary (metastatic) 4104
 space-occupying effects 4099–100
 inferior expansion 4100
 lateral expansion 4100
 superior expansion 4099–100

- visual field assessment 312
see also specific sites/tumours
- pityriasis versicolour 1715
- Pityrosporum ovale* 1715
- pivot principle 2832–40
 local flaps 2827–8
 transposition flaps 2834–40, 2840 *F*
- pizotifen 3803 *T*, 3804
- placebos 629, 658–9
 research use, ethics 589
- place coding, frequency
 selectivity 3197–8
- place theory, pitch perception 3252
- placodal competence 815
- plain radiography
 adult epiglottitis 2250, 2250 *F*
 airway management 470
 aspiration 2096
 bronchial stenosis 1143
 children 1296
 craniosynostosis 1022, 1023 *F*
 croup 1128, 1128 *F*
 dysphagia 2028
 epidermoids 4011
 frontal sinus 1501
 head and neck sarcoma follow-up
 1938
 juvenile angiofibroma 2438–9, 2438 *F*
 laryngeal trauma 2273
 mandibular tumours 2558
 meningiomas 4009
 nasal fractures 1612
 nasopalatine duct cyst 1926
 neck trauma 1767
 obstructive sleep apnoea 1107–8,
 1108 *F*
 oesophageal atresia 1284 *F*, 1285 *F*,
 1288
 Paget's disease 3488
 raised intracranial pressure, 'copper-beaten' appearance 1024 *F*
 rhinosinusitis 1442
 salivary glands 1877–8
 malignant tumours 2506–7
 sarcoidosis 1649 *F*, 1711
 thyroid nodule evaluation 2676–8
 tuberculous otitis 3449
 Wegener's granulomatosis 1649 *F*
- plaque
 accumulation, oral implants 2906–7
 definition 1699–700
- plasma cell dyscrasias 275
- plasmacytomas
 extramedullary 275
 pituitary region 4104
- plasma imbibition, nasal
 reconstruction 3017
- plasma products, fractionated 260
- plasma viscosity 267
- plasmid DNA 26
- plasmin 279
- plasminogen 279
- plasminogen activator inhibitor type 1 (PAI-1) 279
- plasticity, vestibular compensation 3792
- PlastiPore 121
- plateau-seeking method, pure-tone audiometry 3264
- platelet(s)
 adhesion 278
 aggregation 278
 thrombotic
 thrombocytopaenia 286
- antibody sensitization 287
- collection 259
- disorders *see platelet disorders*
- haemostasis 278
- lifespan 278
- sequestration 278
- storage 259
- platelet count 280
 heparin monitoring 447
 normal range 280
- platelet-derived growth factor (PDGF) 89
- platelet disorders 275–6, 281 *T*
 acquired 286–8
 bleeding patterns 281
 diagnostic tests 281–2
 increased consumption/destruction 286–7
 inherited 288
 treatment 288
 reduced production 287
 treatment 287
- platelet dysfunction 287–8
 drug-induced 287
 extracorporeal circuit -induced 287–8
 renal failure 288
- platelet factor 4 (PF4) 89
- platelet plug 278
- platelet-rich plasma (PRP) 2920
- platelet transfusion 259–60
 complications 262
 contraindications 259–60
 cross-reactivity 262
 disseminated intravascular coagulation 259, 284
 indications 259
 liver disease 282
- reduced platelet production 287
- sepsis 259
- surgical prophylaxis 259
- thrombocytopaenia 259
- platinum agents, chemotherapeutic 37
- platysma flap 2865, 2865 *F*
- platysmaplasty 3070–1
- play therapy 1301
- pleasure calculus 584
- pleomorphic adenoma
 external auditory canal 4070
 salivary glands *see pleomorphic salivary adenoma*
- salivary adenoma (PSA)
 protein 2503
- pleomorphic salivary adenoma (PSA) 2480–2
 capsule 2481
 cartilage 2482
 categorization 2481
 cells 2482
 children 1248, 1248 *F*
 clinical features 2481, 2481 *F*
 epidemiology 2476
 fine needle cytology 2480 *F*
 historical aspects 2480–1, 2481 *F*
 imaging 723, 723 *F*, 1882, 1885 *F*, 1886
 recurrent lesions 1883
 postoperative follow-up 2490
 presentation 2477 *F*, 2478 *F*
 recurrent 2482, 2482 *F*, 2489–90
 management 2489–90
 revision parotidectomy 2489–90,
 2490 *F*
 stroma 2481–2
- plica fimbriata 1794
- plicatic acid 1419
- plosion noise 2167
- plosives 2167, 2167 *T*
- Plummer's disease *see toxic adenoma*
- Plummer–Vincent syndrome 2027 *F*, 2031, 2634–5
- plunging ranula 1246
- pluripotency, stem cells 68
- pneumatic dilatation, achalasia 1289–90
- pneumocephalus 4139
- pneumococcal meningitis 197–8
- pneumococci 197–8
- pneumococcus vaccination 3654
- Pneumocystis carinii*, HIV patients
 external ear infections 240
 neck manifestations 246
- pneumolarynx 2230
- pneumomediastinum, paediatric tracheostomy 1202–3

- pneumonia
 aspiration 1284, 2085
 viral agents 205 *T*
- pneumoparotitis 1908
- pneumosialadenitis 1908
- pneumotachograph 2181
- pneumothorax
 paediatric tracheostomy 1202–3
 radical neck dissection
 complications 2744
- Pneumovax 1084
- Poiseuilles' law 111, 3007
- polarization-sensitive optical coherence tomography (PS-OCT) 757–9
 advantages/potential applications 758
 principles 756, 758
 vocal folds 758, 759 *F*
- poliomyelitis
 aetiology 2078–9
 pharyngeal dysfunction 2078–9
- pollens
 avoidance 1397
 oral allergy syndrome 1428
 seasonal rhinitis 1396
- pollution, rhinitis and 1383
 allergic 1388
 nonallergic 1411
- pollybeak deformity 2982, 2983 *F*
 medical negligence 3092
 post-nasal tip surgery 3004
 predisposing factors 2982 *F*
- polyacrylamide gels, electrophoresis 5–6
- polyamide mesh, augmentation
 rhinoplasty 2973–4
- polychondritis
 relapsing *see* relapsing polychondritis
 septal perforations 1584
- polyclonal antibodies, Paget's disease 3486
- polycythaemia 272
 absolute 272
 causes 272 *T*
 investigations 272
 relative 272
- polycythaemia rubra vera (PRV) 272
- polydioxanone tissue scaffolds 123
- polyenes 233, 442
- Polyethylene glycol (Movicol) 2791
- polyglutamine expansion
 disorders 3773, 3775
- polyglycolide (PGA) tissue scaffolds 123
- polygons 703, 704, 705 *F*
- polyhydramnios, oesophageal atresia 1284
- polylactide-coglycolide (PLG) tissue scaffolds 123
- polylactide (PLA) tissue scaffolds 123
- polymerase chain reaction (PCR) 7–8, 7 *F*
 chlamydiae detection 202
 parainfluenza virus 207
 respiratory tract viral infections 204–5
- polymerization 4
- polymers 121–2
 advantages 121
 disadvantages 121
 extrusion rates 121
 nasal reconstruction 121
 nervous tissue engineering 126
 synthetic 121
 tissue response 119
 tissue scaffolds 123
see also individual types
- polymorphic marker 19–20
- polymorphism 16
- polymorph leukocytes 185
- polymorphonuclear leukocytes *see* neutrophil(s)
- polymyositis 186
- polyneuropathy, neurofibromatosis 2 4000
- polyotia (mirror ear) 969, 970 *F*
- polypectomy
 cerebrospinal fluid rhinorrhoea
 aetiology 1636–7
 'medical,' nasal polyposis 1555, 1556
 medical negligence 1307, 1733
- polypeptide synthesis 4
- polypoid corditis *see* Reinke's oedema
- polypoid degeneration *see* Reinke's oedema
- polypoid hypertrophy *see* Reinke's oedema
- polypoid vocal cord *see* Reinke's oedema
- polyps/polyposis
 aural *see* aural polyps
 choanal 1554
 frontal sinus 1519
 hairy, nasopharynx 2119
 laryngeal 2265–6
 nasal *see* nasal polyps
 vocal folds *see* Reinke's oedema; vocal fold polyps
- polysomnography
 obstructive sleep apnoea 1106, 2318, 2327
 sleep disorders, children 1104
- snoring 2327
- special needs children 787
- polytetrafluoroethylene (PTFE)
 augmentation rhinoplasty 2974
 facial reconstruction 121
 vascular surgery 121
- poly(ethylmethacrylate)/tetrahydrofurfuryl methacrylate (PEMA/THFMA) 125
- polyurethane foam dressings 2794
- polyvinyl alcohol (PVA) 733, 3952
- pons, vascular syndromes 3922
- pontine cistern, vestibular schwannoma expansion 3958–9, 3958 *F*, 3959
- pontine disorders 3922
- pontine lesions 3922
- pontine tegmentum injury 1847
- pores, tongue 3929
- porokeratosis 2398
- 'port-wine stains' 1708
- positional cloning 11, 19–20
- positional manoeuvres, balance disorders 3720–3, 3721 *F*
- positional plagiocephaly 1026
- lambdoid synostosis *vs.* 1026 *F*
- positional vertigo
 cerebellar tumours 3776
 presentation 3709
 recurrent 3781
 repositioning manoeuvres/exercises 3809–14
 treatment 3809–14
- position vestibular phases (PVP)
 neurones 3215
- positive intrathoracic pressure 528
- positive predictive value (PPV), difficult airways 471
- positron emission tomography (PET) 684–700
- brain imaging 675
- cervical lymph node assessment 1762, 1763 *F*
- citric acid recognition studies 1842
- 2-[¹⁸F] fluoro-2-deoxy-D-glucose-positron emission tomography *see* FDG-PET imaging
- [15-0]H₂O 696
- hyperparathyroidism 392
 recurrent 392
- hypopharyngeal cancer 2644
- laryngeal tumours 2607–8
- nasopharyngeal carcinoma 2457–8

- neck 1756
 metastatic disease 2721
 oral cavity tumours 2553
 paragangliomas 4029
 principles 684–6, 685 *F*
 standardized uptake value 684–6
 skull base lesions 3947
 thyroid cancer recurrence
 detection 2697
 tinnitus 3602, 3603 *F*
 post-auricular microphones 3661
 post-auricular muscle,
 electromyographic
 recording 3289–90
 postauricular scars, chronic otitis media
 assessment 3412
 posterior alveolar (dental) artery 1798
 posterior auricular nerve 3928
 posterior chondrotomy 1578, 1579 *F*
 posterior condylar canal 3899
 posterior cranial fossa, vestibular
 schwannoma surgery 3971
 posterior cricoarytenoid 2136 *T*
 posterior dental (alveolar) artery 1798
 posterior ethmoidal artery 1574, 3897–8
 ligation, epistaxis 1604
 posterior fossa malformations 3777,
 3777 *F*, 3780
 posterior fossa syndrome 2222–3
 posterior fossa tumours 3776–7,
 3779–80
 definition 3776–7
 diagnostic failure 4144
see also specific tumours
 posterior glottal chink 2160–1
 posterior glottic stenosis 2281–2
 aetiology 1160
 children 1160–1
 classification 2281
 management 1161, 2282
 posterior nasal fontanelle 1330
 posterior nasal packs, epistaxis 1603
 posterior pituitary gland *see*
 neurohypophysis
 posterior skull deformity 1026–7
 surgery 1026
 posterior superior alveolar (dental)
 nerve 1341, 1801–2
 posterior superior dental (alveolar)
 nerve 1341, 1801–2
 posterior synostotic plagiocephaly,
 true 1022 *T*
 posterior triangle 1742–3, 1743 *T*
 lymph nodes 1747–8
 swellings, children 1212
 posteroverentral cochlear nuclei
 (PVCN) 3140
 post-exposure tinnitus 3552
 post-functional endoscopic sinus
 surgery (FESS) 1350
 postherpetic neuralgia 1724, 2079
 post-intervention sleep study 1111
 postnasal packing, adenoidectomy 1097
 post-nasal space carcinoma, medical
 negligence 1731
 post-partum thyroiditis 358–9
 Graves' disease 358
 histology 358
 iodine uptake 359
 management 359
 post-post nystagmus 3213–4
 post-rotational nystagmus 3729
 postseptal orbital cellulitis 1540
 poststyloid parapharyngeal space *see*
 carotid sheath
 post-transcriptional processing *see*
 splicing
 post-transfusion purpura (PTP) 262,
 287
 clinical manifestations 287
 diagnosis 287
 treatment 287
 post-translational modification 4, 10
 post-traumatic vertigo 1045
 post-trematic nerve 3120–1
 postural balance examination 3730–2
 clinical 3730–2, 3731 *T*
 postural control
 ankle strategy 3733
 hip strategy 3733
 postural imbalance syndrome 3748,
 3781
 aetiology 3773, 3776
 cerebellar ataxias 3775
 hydrocephalus 3778
 orthostatic tremor 3779, 3780
 posterior fossa malformations
 3777
 vestibular schwannoma 3776
 postural reflexes, examination 3731
 postural techniques, dysphagia 2086–7
 posturography 3732–6
 caloric test *vs.* 3733
 clinical usefulness 3736
 dynamic 3732–3
 neurological disorders 3735–6
 peripheral vestibular
 disorders 3733–5, 3734 *F*
 bilateral 3734–5
 psychological unsteadiness 3736
 psychophysiological
 unsteadiness 3736
 static 3732–3
 vestibular rehabilitation 3736
 Poswillo hook 1629 *T*, 1630
 potassium
 cochlea 3186–7
 endolymph 3187–8, 3187 *T*
 perilymph 3189 *T*
 potassium channels
 cochlear hair cells 3193–4, 3194 *F*
 mutations, hearing loss and 3186–7
 potassium hydroxide, otomycosis 214
 potassium iodide
 entomophthoramycosis 215
 thyroidectomy 349–51
 potential doubling times (*T_{pot}*),
 tumours 57
 Pott's puffy tumour *see* subperiosteal
 abscess (Pott's puffy tumour)
POU3F4 gene mutations 16
 power 3162
 definition 3165
 powered microdebrider, juvenile-onset
 recurrent respiratory
 papillomatosis 1176
 power issues, medical
 consultations 560–1
 PRAD-1 (parathyroid adenoma-1)
 gene 388
 Prandtl number 1356
 pRB 2382–3, 2383 *F*
 preaponeurotic orbital fat 3050, 3050 *F*
 preauricular sinus 970, 970 *F*, 1267–8
 embryology 1267
 presentation 1267
 treatment 1267–8
 preauricular type D approach 4061
 precedence effect
 reflections 3255
 sound localization 3255
 precentral gyrus 2158
 predictive value 823
 prednisolone
 Bell's palsy 210
 idiopathic sudden sensorineural
 hearing loss management 3589 *T*
 nasal polypsis 1555
 oesophageal corrosive injury 1291
 Sjögren syndrome 1913
 Wegener's granulomatosis 1652–3
 prednisone
 allergic fungal rhinosinusitis 1454
 Bell's palsy 424
 Menière's disease 3800

preepiglottic space 2132 *F*, 2133, 2138
 pregnancy
 allergic rhinitis 1401–2
 consent issues 601
 dietary restriction 1426
 drug prescribing 415
 food allergy prevention 1426
 Graves' disease *see* Graves' disease
 head and neck complaints 402–3
 hyperthyroidism 358–9
 transient 359
 hypothyroidism 359–60
 adverse effects 359
 child defects 359–60
 treatment 360
 inflammatory gingival
 hyperplasia 403
 nasal mucosal changes 402–3
 alkaline phosphatase 403
 succinic dehydrogenase 403
 nasal obstruction 402–3
 post-partum thyroiditis
 see also post-partum thyroiditis
 prolactin 301, 308
 radioiodine contraindication 348
 rhinitis 1410
 rhinorrhoea 402–3
 thyroid disease 358–60
 thyroxine therapy 357
 ‘pregnancy tumour’ gingival 403
 Preliminary Proceedings Committee
 (PPC) 606
 prelingual deafness 566
 paediatric cochlear
 implantation 861–2
 premature neonates
 auditory nerve and brainstem evoked
 potentials 3284–5
 bilirubin encephalopathy 3845–6
 tracheostomy 1195
 premaxilla
 development 803
 ossification centres 1317
 premolars 1803, 1803–4
 roots 1803–4
 prenatal diagnosis, craniofacial
 anomalies 1021
 preoperative autologous deposit
 (PAD) 262–3
 Preoperative Transfusion Study, sickle
 cell disease 271
 preperiosteal dissection 3060–1
 prephonatory inspiratory phase 2160
 prephonatory tuning 2159
 pre-proPTH 373–4

presbyacusis/presbycusis *see* age-related
 (sensorineural) hearing loss
 presbydysphagia 2034
 presbylaryngis 2205
 presbyosmia 1664
 presbyphagia 1961
 preseptal cellulitis, orbital 1540
 pressed (strained) voice 2165
 pressure therapy, keloids 2893
 pressure ulcers 95 *F*, 97
 classification 97, 98 *F*
 dressing 100, 102
 prestin 3134
 presyncopal dizziness 3709
 pretracheal (visceral) fascia 316–7,
 1743, 2108
 pretracheal space 1745
 tracheostomy tube displacement
 2301
 prevalence, (definition) 823, 2344
 prevertebral fascia 1743, 2109
 prevertebral muscles 1746
 prevertebral space 1745, 2110, 2110 *T*
 primary auditory canal
 cholesteatoma 3342–5
 aetiology 3343, 3343 *T*
 clinical symptoms/findings 3334 *T*,
 3343 *T*
 definition 3342
 diagnosis 3343–4
 differential diagnosis 3334 *T*
 epidemiology 3343
 keratosis obturans *vs.* 3343 *T*
 management options 3343 *T*, 3344
 natural history/complications 3344
 pathology 3342, 3343 *T*
 primary ciliary dyskinesia (PCD)
 chronic rhinosinusitis 1381–2
 nasal polyposis 1551
 paediatric 1081
 primary endpoint 629–30
 primary gingivo-periosteoplasty
 (GPP) 1006
 primary hyperparathyroidism
 (pHPT) 389–95
 biochemical investigations 391
 clinical features 390–1
 gastrointestinal 391
 musculoskeletal 390
 psychological 391
 renal 391
 diagnosis 390
 familial/hereditary 390
 incidence 390
 gender differences 390
 investigations 391–2
 localization studies 391–2
 management 393–5
 metabolic syndrome 391
 nonfamilial/sporadic 390
 osteoporosis 390
 pathology 390
 Sestamibi scintiscan 391
 surgery
 asymptomatic patients 393
 indications 392–3
 strategies 393–5
 symptomatic patients 392–3
 see also parathyroideectomy
 venous sampling 392
 primary immunodeficiency *see*
 immunodeficiency, primary
 primary lateral sclerosis (PLS) 2079–80
 primary olfactory cortex 1367, 3912–3
 primary ossification, skull 794
 primary palate 803
 primary taste cortex 1842
 primitive articulation stage, speech/
 language development 990–1
 principle-based morality 583–4
 principle cells 316 *F*, 320, 373–4
 principiplism 561
 prion protein PrP 1238
 prions
 blood transfusion 260
 variant Creutzfeld–Jakob disease 1990
 proboscis lateralis 1320
 procaine 1, 3588
 procaspase 8 58
 procaspase 9 58
 procerus muscle 1324
 processus cochleariformis 3111–2, 3115
 prochlorperazine
 acute labyrinthine attack 408–9
 dysphagia aetiology 2789–90
 vertigo 433
 vestibular attacks, acute 3795, 3796 *T*
 vestibular neuritis 408–9
 professional codes of conduct 582
 Professional Conduct Committee
 (PCC) 606
 professional voice 2211–5
 acute illness 2213
 classification 2211
 confidence (in diagnosis) 2213
 demands 2212
 professional versatility 2212
 disorders, prevalence 2217–8
 environment 2212
 Lombard effect 2212

- formants 2178 *F*, 2180, 2211
 frequency patterns 2211
 humidity 2212
 laryngitis, acute 2249
 lifestyle 2212
 microphone placement 2212
 performance anxiety 2212–3
 personality 2211–2
 supralaryngeal constriction 2211–2
 travel 2212
 upper respiratory tract infection 2213
 vocal abuse 2211–2
 vocal physiology 2211–3
 vocal tract configuration 2211–2
 vocal tract surgery 2213
 progesterone
 respiratory sleep disorders 2308–9
 salivary assay 1867
 programme sensitivity 822–3
 progressive (solitary) bone cyst 1926–7
 progressive bulbar palsy (PBP) 2079–80
 progressive hearing loss,
 childhood 848–9
 progressive supranuclear palsy
 (PSP) 3777–8
 progressive systemic sclerosis *see*
 scleroderma
 prokinetics
 anaesthesia premedication 490 *T*
 gastro-oesophageal reflux 1276
 prolactin 301, 308–9
 circulating levels 301, 308
 effects 301, 308
 half-life 301
 lactation 301, 308
 pituitary adenomas 308
 pregnancy 301, 308
 secretion 297
 control 301, 308
 drugs, effects on 301
 structure 308
 prolactinoma 308–9, 4100
 diagnosis 4100
 presentation 4100
 treatment 309, 4100
 medical 4100
 radiotherapy 4100
 surgical 4100, 4114
 proliferating cell nuclear antigen (PCNA),
 salivary gland tumours 2495
 promethazine
 migrainous vertigo 3801
 vestibular attacks, acute 3795, 3796 *T*
 proof puncture 1734
 pro-opiomelanocorticotropin 297
 propagation velocity 712
 propanolol
 migrainous vertigo 3803–4, 3803 *T*
 pre-thyroidectomy 349–51
 side effects 3803–4
 thyrotoxicosis 347
 Proplast 121
 propofol
 anaesthesia 490–1
 supraglottic obstruction 480
 propranolol, effects on cilia 1361
 proPTH 373–4
 proptosis
 Graves' disease 400
 juvenile angiofibroma 2122
 skull base fibrous dysplasia 4125,
 4125 *F*
 propylthiouracil (PTU) 346
 prospective studies 2344
Prospero 68
 prostacyclin analogues, idiopathic
 sudden sensorineural hearing
 loss 1, 3588
 prostacyclin IG_2 , compromised skin
 flaps 113
 prostaglandin analogues 3618
 prostaglandin D2 1390
 prostaglandin-E1 113
 prostaglandin E2 1289
 prostaglandin I₂ 278
 prostheses
 children, optimum age for 2927
 construction 2930–1, 2930 *F*,
 2931 *F*
 decision to use 2925
 dysphagia management 2088
 failure, coagulase-negative
 staphylococci-induced 196–7
 nasal 2909
 osseointegration *see* osseointegration
 placement during ablative
 surgery 2930–1
 retention options 2930, 2931–2
 soft-tissue examination 2930
 see also individual types
 prosthetic heart valves, surgical
 preparation 460
 prosthetic nose 2909
 protease inhibitors 233, 239
 proteasome 44
 proteasome inhibitors 44
 protein(s)
 nasal secretions 1360
 synthesis 35 *F*
 protein C 279
 protein C deficiency 290
 warfarin 282
 'protein C pathway' 279
 protein S 279
 protein S deficiency 290
 warfarin 282
 proteoglycans 2384
 osseointegration 2906
 proteomics 10
 prothrombin (factor II) 279
 prothrombin complex concentrate
 (PCC)
 liver disease 258
 warfarin reversal 258, 283
 prothrombin time (PT) 280
 anticoagulant monitoring 447
 proton pump inhibitors (PPIs)
 Barrett's oesophagus 2065
 gastro-oesophageal reflux 452, 1276,
 2063, 2262
 laryngitis and 2263
 head and neck cancer pain 2785–6
 reflux oesophagitis 452
 protooncogenes 36
 protoporphyrin 269
 protozoal infection, nasal 1703–4
 provocation testing 160
 provoked vertigo syndrome 3748
 aetiology 3776
 'bow-hunter' syndrome 3767
 posterior fossa malformations
 3777
 subclavian steal syndrome 3767
 Provox valve 2625, 2626 *F*, 2627
 pruritus, otomycosis 214
 psammoma bodies 4008
 pseudoallergic drug reactions 414–5
 pseudoaneurysms, neck 1772, 1773 *F*,
 1774 *F*
 pseudobulbar palsy 3939
 dysphagia 2033
 pharyngeal manifestations 2077
 stroke 2077
 voice disorders 2222
 pseudo-conjunctivitis 3079
 pseudocroup 1129
 pseudocysts
 larynx 2199
 tonsil 2005–6
 vocal folds 2199
 pseudoephedrine 3505–6
 pseudo-Foster-Kennedy
 syndrome 1668–9
 pseudohump 2952, 2984 *F*
 pseudohypoparathyroidism 383

- pseudomembranous croup 1129–30
 diagnosis 1129, 1130 *F*
 paediatric intensive care 545
- Pseudomonas* 200
 chronic otitis media 3410
 HIV-associated otitis media 240
see also individual species
- Pseudomonas aeruginosa* 200
 chronic rhinosinusitis 1471
 cystic fibrosis 1081
 diabetes mellitus 402
 HIV-associated ear infection 240
 malignant otitis externa 3337, 3337–8
 otitis externa 3352
 diabetes mellitus 402
 perichondritis 3358, 3359
 skin grafts 2821–2
 tympanic membrane perforation 934
- pseudomyxoma *see* Reinke's oedema
- pseudomyxomatous laryngitis *see* Reinke's oedema
- pseudoptosis 3055
- pseudotumour, orbital 3916
- pseudowhisper 2624
- psoriasis, tonsillitis-related 1224
- psychiatric disorders, olfactory dysfunction 1669, 1673–4, 3913–4
- psychoacoustic audiometry 3260–75
 definition 3260
 pure-tone audiometry *see* pure-tone audiometry
 tinnitus 3612
- psychoacoustic tuning curves (PTC) 3267
- psychogenic vertigo, children 1045
- psycholinguistic ability testing, auditory neuropathy/dyssynchrony 3839–40
- psychological disorders, tinnitus 3607
- psychological issues
 cochlear implants candidature 3651
 laryngectomy rehabilitation 2630
 palliative care *see* palliative care, head and neck cancer
 pure-tone audiometry errors 3265
 quality of life, head and neck cancer 2777
 speech audiometry errors 3273
- psychological profiling, tinnitus 3613
- psychological tuning curves (PTCs) 3247
 determination 3247–8, 3248 *F*
 interpretation assumptions 3248
- psychosocial issues
 childhood deafness 849
- metastatic neck disease
 treatment 2731
 post-laryngectomy 2630
- psychotherapy, tinnitus 3615 *T*, 3616
- psychotropic drugs, taste abnormalities and 1847
- pterygoid fossa 2111
- pterygoid fovea 1809
- pterygoid hamulus 1792
- pterygoid plates, implant placement 2919
- pterygoid plexus, venous 2113, 3902 *F*, 3907
 communicating veins 3907
- pterygoid process, sphenoid bone 1339, 2111
- pterygoid testing 3926
- pterygomandibular raphe 1792–3, 1795, 1810
- pterygomandibular space 1806
- pterygomaxillary fissure 2111
- pterygomaxillary space *see* parapharyngeal space (PPS)
- pterygopalatine fossa 2111
- pterygopalatine ganglion 3924
- pterygopalatine plexus, nervous 1801, 1801 *F*, 1950–1
- pterygopharyngeal space *see* parapharyngeal space
- PTH-receptor gene 389
 mutation 389
- puberphonia 2204–5, 2226
 clinical manifestations 2205
 speech therapy 2226
 treatment 2205
- pubertal rhinitis 1077
- puberty, voice changes 1169–70, 2204–5
- Public Health Act (1984) 587
- public health research, epidemiology 617–8
- pulmonary artery catheter (PAC) 529
- pulmonary artery sling 1147, 1147 *F*
- pulmonary artery wedge pressure, perioperative monitoring 500
- pulmonary embolism
 capnograms 499 *F*
 treatment 288
- pulmonary function tests
 laryngeal stenosis 2280
 stridor 1119
- pulmonary plexus, nervous 2142
- pulmonary toxicity, cystic fibrosis gene therapy 24–5
- pulmonary ventilation, bronchoscopy 503
- pulpitis 1816
- pulsatile tinnitus 3944
 aetiology 3944 *T*, 4028
 arteriovenous fistulae 4145
 diagnosis delay 4144–5
 glomus tumours 4015
- pulsatility index (PI) 714
- pulsed carbon dioxide lasers
 basal cell carcinoma 2397
 medical negligence 3096
- pulsed-dye laser, juvenile-onset recurrent respiratory papillomatosis 1176–7
- pulsed-wave Doppler ultrasound 714
- pulse oximetry
 anaesthesia monitoring 496–7
 obstructive sleep apnoea 1105–6
- pulse plethysmography 497
- pulse register, vocal 2161, 2162 *T*
- pulse transit time, sleep-disordered breathing 1103
- punctum 1690
- pupillary abnormalities 3916–7
- pupillary escape phenomenon 3916
- pupilloconstriction, Horner's syndrome 3937
- pure-tone audiometry 3260–7
 active mucosal chronic otitis media 3424
 auditory neuropathy/dyssynchrony 3842–3, 3843 *F*
- bone conduction 3262
 children 840
 chronic otitis media
 healed 3426
 inactive mucosal 3421
 clinical applications 3266–7
 complete audiograms 3266–7
 confounding factors/errors 3265–6
 bone conduction 3262
 methodological 3265
 physical/acoustical 3265–6
 physiological 3265
 psychological 3265
- equipment 3261–2
 attenuator 3262, 3269
 bone vibrator 3262, 3265–6
 calibration/verification 3263, 3266
 earphones 3262, 3268
 principles/design 3261, 3261 *F*
 speech audiometry and 3268, 3269
 tone pulses 3261–2
 granular myringitis 3329
 hearing threshold 3260–1, 3263–4
 jugular foramen lesions 4028

masking 3262–3, 3264
noise-induced hearing loss 3552
objective tinnitus 3601
otosclerosis 3461, 3462 *F*
pars tensa retraction 945
purpose/role 3261
quinine administration 3850, 3850 *F*
screening audiometry 3264–5
skull base lesions 3946
test environment 3263
 ambient sound levels 3263, 3263 *T*,
 3266
test method 3263–4
 loudness scaling 3267
 problems 3265
 screening 3265
 special tests 3267
 tracking method 3264
 verbal instruction 3265
test reliability 3266
 averaging 3266, 3267 *F*
 quantification (test-retest
 differences) 3266, 3266 *F*
 see also speech audiometry
purine analogues 38
purpura
 oral pigmentation 1825
 post-transfusion *see* post-transfusion
 purpura (PTP)
‘pushing exercises,’ vocal fold
 paralysis 2223
putrescine, malodorous malignant
 ulcers 2792
‘*p*-value’ 623
pyocoele, chronic rhinosinusitis 1540
pyogenic granuloma 1708
pyogenic streptococci 197
pyorrhoea, chronic periodontitis 1821
pyostomatitis vegetans 1834
pyramidal tracts, phonation 2158–9
pyrazinamide 1460
pyridostygmine 1912
pyriform aperture 1324–5
 stenosis 1072–3, 1073 *F*
pyrimidine analogues 38
‘Q_{10dB}’ 3198
quality adjusted life year (QALY),
 cochlear implants 866
quality assurance *see* clinical
 governance
quality of life
 asthma 1564
 cancer patients *see* quality of life, head
 and neck cancer

cochlear implants 3655, 3656
 children 866–7
 concepts 2767–71
 definition 2767–8
 ‘gap’ theory 2767
 head and neck cancer 2766–80
 alcohol consumption 2776
 attitude changes 2771
 characteristics 2767 *T*, 2768–70
 coping skills 2777
 cultural, religious and spiritual
 factors 2769, 2777
 demographic characteristics
 2776–8
 disease site/stage impact 2775
 historical developments
 2771–2
 instruments 2771–2
 measurement 2772
 methodological issues 2770–1
 performance status 2778
 premorbidity patient
 characteristics 2776
 psychological factors 2777
 sexual functioning 2777
 social support 2777–8
 terminology 2771–2
 time impact 2769–70, 2775
 tobacco 2776
 treatment effects 2775–6
laryngectomy rehabilitation 2630
measurement 2767–71
 multidimensional 2769
 problems associated 2767
 subjectivity 2768–9
metastatic neck disease
 treatment 2730–1
otitis media with effusion 894–5
outcomes research 2770
prosthetic reconstruction 2933
rhinitis 1564
ventilation tubes 899
vestibular schwannoma
 removal 3984–5
voice evaluation measures 2171, 2183,
 2183 *T*
Quality of Life Instrument for Head and
 Neck Cancer (QL-H&N) 2774 *T*
Quality of Life Questionnaire for
 Advanced Head and Neck Cancer
 (QLQ) 2774 *T*
Quality of Life - Radiation Therapy
 Instrument Head and Neck
 Module (QL-RTI/HN) 2774 *T*
quantitative trait loci (QTL) 16

questionnaires
 head and neck cancer quality of
 life 2773–4, 2774 *T*
 development guidelines 2773
 generic vs. diagnosis-specific 2770–1
 methodological issues 2770–1
 self-administered 2768
 terminology 2773 *T*
 septal perforations assessment 1583,
 1584 *F*
 voice and quality of life 2183, 2183 *T*
 see also specific types
quinine
 ototoxicity 3571, 3850 *F*
 tinnitus induction 3599–600
quinolone antibiotics 230–1
 active mucosal chronic otitis
 media 3424
 adverse effects 230–1
 mechanism of action 230–1
quinsy *see* peritonsillar abscess (quinsy)
Quorum statement 650
rabies 2079
rabies encephalomyelitis 2079
radiation
 cell survival curves 48–9
 DNA damage induction 41
 dose response curves, acute *vs.* late-
 reacting tissues 48
 exposure *see* fractionation
 in nose 1356
 protection, paediatric
 imaging 1300–1, 1301 *T*
 temporal bone tumour
 induction 4068, 4087
radiation mucositis, HIV patients 243,
 244 *T*
radiation therapy *see* radiotherapy
Radiation Therapy Oncology
 Group 2755
 anaemia 2756
radiation thyroiditis 348, 362–3
radical neck dissection 2733–42
 accessory nerve identification 2738–9
 carotid sheath opening 2736
 cervical plexus identification 2739 *F*,
 2740
 Chaisson's triangle
 clearance 2737–8
 closure 2742
 suture placement 2734
 combined procedures 2742
 complications 2743
 accessory nerve division 2744

radical neck dissection (*continued*)
 carotid artery rupture
 2743–4
 cerebral oedema 2745
 chylous fistula 2744
 haemorrhage 2743
 local 2743
 nerve injury 2744–5
 pneumothorax 2744
 wound infection 2743
 contraindications 2733
 corners of consternation 2734
 digastric muscle retraction 2740–1,
 2740 F
 drains 2742
 extended 2745
 indications 2745
 facial nerve preservation 2735
 flap raising 2733–5, 2735 F
 hypoglossal nerve
 identification 2740–1,
 2741 F
 incisions 2732 F, 2733–4, 2735
 indications 2733
 internal jugular vein
 bleeding 2736–7, 2743
 ligation 2736, 2736 F
 lower end 2735–7, 2738 F
 tears 2736–7
 upper end, division of 2740–2,
 2740 F, 2741 F
 lingual nerve identification 2742
 marginal mandibular nerve
 preservation 2735, 2735 F
 modified *see* modified radical neck
 dissection
 mylohyoid muscle retraction 2742
 nasopharyngeal carcinoma 2464
 occipital artery ligation 2741
 omohyoid division 2737–8
 phrenic nerve identification 2737–8
 platysma muscle 2734
 posterior triangle dissection 2738–40,
 2739 F
 single palpable metastasis, unilateral,
 less than 3 cm diameter
 (N1) 2725–6
 sternomastoid muscle division 2736,
 2736 F, 2740
 submandibular triangle
 dissection 2742, 2742 F
 supraclavicular dissection 2737–8,
 2738 F
 venae nervi hypoglossi
 comitantes 2740–1, 2741 F

radicular cyst 1922, 1924
 eggshell cracking sign 1924
 radiographic appearance 1924, 1924 F
 radioactive iodine (^{131}I) *see* radioiodine
 therapy
 radioallergosorbent test (RAST) 1394–5
 allergic fungal rhinosinusitis 1453–4
 allergy diagnosis 159–60, 1394–5
 food allergy 1429
 occupational rhinitis 1420
 skin prick test *vs.* 1393 T
 radiofrequency ablation,
 snoring 2331–2
 radiofrequency tissue volume
 reduction, snoring 2330
 device types 2330
 success rates 2333
 radiofrequency tonsillotomy 1235,
 1991, 1991–2
 radio-guided parathyroidectomy 395
 radioiodine therapy
 administration 347
 adverse reactions 415
 antithyroid medication
 pretreatment 348
 contraindications 348
 dosage 347–8
 efficacy 347–8
 elderly 348
 follicular destruction 348
 follow-up 348–9
 Graves' disease 349
 hyperthyroidism 347–9,
 347–8
 hypothyroidism induction 356
 multinodular goitre 362–3
 nontoxic 363
 nodular thyroid disease 349, 362–3
 side effects 362–3
 ophthalmopathy 349
 safety 348
 children 348
 side effects 347, 348
 thyroid cancer 2693–6, 2694, 2694 F,
 2695 F
 thyroid gland studies 321–2
 thyrotoxicosis 346 T
 transient hypothyroidism 356
 radioisotope salivary function
 tests 1863, 1864 F
 radionuclide scans
 gastro-oesophageal reflux 1274
 Graves' disease 335
 hypothyroidism 336
 metastatic neck disease 2721

parathyroid glands
 dual isotope subtraction scans 383
 dual phase single tracer
 scintigraphy 383–4
 intraoperative PTH assay with
 gamma probe localization 384
 tracer choice 383
 parathyroid imaging 383
 skull base lesions 3947
 thyroglossal cysts 1778
 thyroid gland imaging 328, 329 T
 developmental disorders 332
 nodular/malignant
 disorders 333–4, 335
 parathyroid imaging and 383–4
 thyroiditis 335
 thyrotoxicosis 335
 see also positron emission tomography
 (PET)
 radiosensitizers 49–50
 antiangiogenic agents 51
 apparent sensitizers 50
 enhancement ratio 50
 glutathione depletion 50
 mechanisms of action 50
 true sensitizers 50
 radiosurgery
 glomus juglare tumours 3995
 jugular foramen lesions 4043
 neurofibromatosis 2 3994–5
 vascular malignant tumours 3996
 see also gamma knife stereotactic
 radiosurgery
 radio systems, hearing impaired
 user 3667
 radiotherapy 47–55
 accelerated treatments 49
 acromegaly 4101
 adjuvant chemotherapy 51–2
 clinical trials 52
 complication incidence 51–2
 meta-analysis 51–2
 advances in 2759–61
 adverse effects
 apoptosis-related 63
 salivary gland dysfunction 1908–9
 taste abnormalities 1845
 apoptosis 47, 63
 basal cell carcinoma 2397
 benign skin disease 2894–5
 bioreductive drugs 50–1
 cell replication 63
 cellular radiosensitivity 47–8
 Cushing's disease 4102
 definition 47

- DNA damage 47
 dosage 48
 dose response curves 48, 48 *F*
 endolymphatic sac tumours 4072
fractionation *see* fractionation
 head and neck cancer 2753–65
 head and neck
 rhabdomyosarcoma 1935
 head and neck sarcomas 1933
 hyperfractionated 2755
 hypopharyngeal cancer 2647–8
 hypothyroidism induction 356
 implant osseointegration 2910–1
 jugular foramen lesions 4042–3
 juvenile angioma 2442
 keloids 2893–4
 lip cancer 2548
 meningiomas 4008–9
 mucosal malignant melanoma
 2410
 nonfunctioning adenomas 4103
 oropharyngeal tumours 2585
 otitis media with effusion 3389
 perichondritis 3360
 peripheral lymphocyte count 2716–7
 pinna reconstruction 3045
 pituitary tumours 4115
 adverse effects 4115
 nonfunctioning adenomas 4103
 prolactinomas 4100
 radiosensitizers *see* radiosensitizers
 salivary gland tumours 2507–8, 2510
 skin grafts 2821
 skull base chondrosarcoma 4126
 soft tissue sarcomas 1936
 subglottic haemangioma 1140
 targetted therapies 52–3
 temporal bone chordoma 4073
 temporal bone squamous cell
 carcinoma 4094
 thermal wounds 96, 96 *F*
 thyroid cancer
 aetiology 2670–1
 treatment *see* thyroid cancer
 thyroid eye disease 345
 treatment interruptions 49
 TSHomas 4102
 Radix graft, septal cartilage 2952 *F*
 Radkowski staging system, juvenile
 angiomas 2438–9, 2440 *T*
 RADPLAT 735
 RAE tube 493 *F*
 ramp test 3213
 Ramsay Hunt syndrome *see* herpes
 zoster oticus
 Ramsay–Hunt syndrome (herpes zoster
 oticus) *see* herpes zoster oticus
 Rand device 2624–5
 randomized controlled trials
 (RCTs) 628–30
 critical appraisal worksheets 668,
 669 *F*, 670 *F*, 671 *F*
 ethical issues 589
 Jadad score 650
 methodology 650
 questions 653 *F*
 otitis media 649
 placebo control 658–9
 see also evidence-based medicine
 random pattern flaps 2828
 blood supply 2828, 2844 *F*
 design 2828
 technique 2828 *F*
 random transposition flaps 2840
 ranitidine 2785–6
 ranula(s) 1246
 imaging 725, 1882, 1884 *F*
 Rao v. the GMC (2003) 2804
 rapid antigen testing (RAT)
 pharyngitis 1984
 tonsillitis 1221
 rapid eye movement sleep (REM) 2305
 airway activity 2308–9
 narcolepsy 2310
 neural activity 2306–7
 sleep-disordered breathing 1103
 rapid sequence induction,
 anaesthesia 496
 RAS genes, thyroid cancer 2669
 Rathke's pouch 295, 2117–9, 2118 *F*
 cysts 4103
 embryology 803
 remnants 295, 2117–9
 Ravussin style cricothyrotomy
 cannula 477 *F*
 RB gene 389
 RBH scheme 2175, 2175 *T*
 RD4 receptor 57
 reactionary haemorrhage, post-
 tonsillectomy 1994–5
 reactive lymphadenopathy 1252
 reactive oxygen species (ROS),
 ototoxicity 3300–1, 3301 *F*
 reactive synaptogenesis, vestibular
 compensation 3793
 reactive upper airways dysfunction
 syndrome (RUDS) 1416
 Read codes 464–5
 read text, voice analysis 2172–4
 real-ear aided gain (REAG) 3633
 real-ear insertion gain (REIG) 3633
 real ear to coupler difference
 (RECD) 3633
 rebreathing, capnograms 499 *F*
 receding jaw, airway management 469,
 469 *F*
 receivers, hearing aids 3632
 receptive language disorders 991, 992 *T*
 receptive language skills 991
 receptor cells
 olfactory *see* olfactory receptor cells
 taste buds 3929
 receptor tyrosine kinase (RTK) 2383–4
 recessive mutant alleles 8–9, 9 *F*
 recessus terminalis 1331
 recklessness, medical negligence 2806
 recombinant erythropoietin (rEpo) 263
 recreational drugs, septal perforation
 and 1582
 rectus abdominus flaps 2876–8
 advantages 2876
 anatomy 2876, 2876 *F*
 clinical applications 2877–8
 disadvantages 2877
 technical nuances 2877, 2877–8
 rectus capitus posterior major 3899
 rectus capitus posterior minor 3899
 rectus palsy, cavernous sinus
 tumour 2426 *F*
 recurrent acute rhinosinusitis
 (RARS) 1382 *T*
 definition 1382
 symptom duration 1439–40
 recurrent aphthous stomatitis
 (RAS) 1830–1, 1831 *F*
 aetiology 1830
 AIDS patients 242, 244 *T*
 clinical features 242, 1831 *T*
 diagnosis 1830–1
 differential diagnosis 1830
 nutritional deficiencies 1830
 systemic factors 1831 *T*
 treatment 242, 1830–1
 types 1830
 ulceration 1830, 1830 *F*
 recurrent laryngeal nerve (RLN) 318,
 320 *F*, 1751, 2157 *F*, 3935
 development 2130–1, 2131 *F*
 distribution 1949–50, 2156, 2156 *F*,
 2157 *F*, 2664–5, 2665 *F*
 identification 318
 left 2139, 2156
 lesions 3937
 relations 2665 *F*
 right 2139, 2156

recurrent laryngeal nerve (RLN)
(continued)
 terminal branches 318
 thyroid surgery 2664–5, 2665 *F*
 tracheal innervation 2142
 recurrent laryngeal nerve injury/palsy
 dysphagia 2033
 left nerve 2156
 medical negligence 2808
 thyroidectomy-related 351, 2692
 recurrent parotitis of childhood 1903
 recurrent respiratory papillomatosis
 (RRP) 2599
juvenile *see* juvenile-onset recurrent
 respiratory papillomatosis
 red cell(s) 266–72
 abnormalities 270
 antibodies 254
 erythropoiesis 266
 fragmentation 270
 life span 266
 nucleated 266
 storage 255
 red cell transfusion 255–6, 258 *T*
 acute blood loss 256–7
 alternatives 262–4
 British Committee for Safety in
 Haematology guidelines
 2001 256–7
 haemoglobin concentration
 estimations 257
 indications 255–6
 patient assessment 255
 premature cell destruction 262
 preoperative preparation 255
 red eye, painful
 differential diagnosis 3915–6
 infective causes 3916
 inflammatory causes 3915–6
 neoplastic causes 3916
 vascular causes 3916
 ‘red man’ syndrome 230
 reduction glottoplasty, Reinke’s
 oedema 2200
 reduction rhinoplasty 2950–8
 aims 2950–1
 complication avoidance 2952–7
 contraindications 2951–2
 future directions 2957
 indications 2950–1
 outcome assessment 2957
 techniques 2952–7
 re-epithelialization, wound
 healing 90–1, 90 *F*
 refeeding syndrome 532

reference standard 655
 reflexes, nasal *see* nasal reflexes
 reflux oesophagitis 451–2
 Refsum’s disease 1048
 regional accents, speech rhythm 2168
 regional taste testing 1844
 rehabilitation
 dysphagia 2086, 2088–90, 2089 *T*,
 2090 *T*
post-laryngectomy see laryngectomy
 Reichart’s cartilage 1739–40
 reinforcement tympanoplasty 946
 Reinke’s oedema 2199–200, 2221,
 2264–5, 2265 *F*
 aetiology 2199, 2265
 definition 2199
 grading system 2200, 2200 *T*
 histology 2199
 malignant transformation 2265
 menstruation 2212–3
 phonosurgery 2200, 2237, 2239,
 2265
 postoperative complications 2200
 prevalence 2200
 speech therapy 2221
 symptoms 2200
 treatment 2200, 2265
 vocal fold appearance 2199 *F*, 2200,
 2265
 voice analysis 2178–9, 2179
 Reinke’s space 2134–5, 2221
 Reinke’s oedema 596, 2221
 Reissner’s membrane 3127–30, 3129 *F*
 rupture 3507
 relapsing acute parotitis 1243–4, 1244 *F*
 imaging 1244, 1244 *F*
 surgery 1244
 relapsing polychondritis 3362–5, 190
 aetiology 3362
 definition 3362
 diagnosis 3362–4
 diagnostic criteria 3363
 differential diagnosis 3364
 larynx 2266
 management options 3364
 nasal 1713
 noncartilaginous structures 3363
 outcomes 3364
 pathology 3362
 symptoms 3359
 relative loudness method 3318, 3318 *F*
 relative risk 660–1
 relatives, critically ill patients 536
 relaxed skin tension lines
 (RSTL) 2832 *F*
 scar revision 2891, 2895
 skin grafts 2829–30
 reliability, outcomes research 635–6
 religion, cancer patient’s quality of
 life 2777
 religious morality 583
see also ethical issues
 remifentanil
 awake intubation 480
 supraglottic obstruction 480
 tracheal intubation 494–5
 remodelling
 bone repair 94
 wound healing 93–4, 98–9
 collagen 93
 renal bone disease 382
 renal failure
 drug prescribing 416
 parathyroidectomy 395
 platelet dysfunction 288
 renal lithiasis 391
 renal replacement therapy, critical care
 patients 530
 renal stones 391
 renal support, critical care patients
 530
 renal transplantation,
 hyperparathyroidism 395
 Rendu-Osler-Weber disease *see*
 hereditary haemorrhagic
 telangiectasia (HHT)
 reparative granuloma, post-stapes
 surgery 3476–7
 repetitive apnoea 2316–7, 2319 *F*
 repetitive low-frequency transcranial
 magnetic stimulation (rTMS),
 tinnitus 3618
 Reporting Systems on Vestibular
 Schwannomas 3959, 3980
 Repose tongue base suspension
 suture 2331–2
 research
 consent 589
 epidemiological *see* epidemiology
 ethical issues 588–9
 outcome measures *see* outcomes
 research
 voluntariness 589
see also evidence-based medicine
 research fraud 2805
 research hypothesis 623
 residual cyst 1817, 1924
 residual inhibition 3612
 tinnitus 3612
 residue pitch 3252–3

- resistance exercises, dysphagia 2088, 2089 *T*
- resistance index (RI) 714
- 'resistance modulation' (battery) theory 3193–4
- resistant acute otitis media 913
- resonance 992–3, 3167
- resonance frequency 3162
- resorptive osteitis, chronic otitis media 954, 3397–9, 3399 *F*
- resource allocation ethical issues 589–91 levels 590–1
- respiration dysphagia investigations 1976 nose in 1355 swallowing and 1959–61, 1960 *F*
- respiratory arrest, adult epiglottitis 2251
- respiratory centre, sleep 2306–7
- respiratory disease, surgical preparation 460
- respiratory distress, acute epiglottitis 1130
- Respiratory Disturbance Index (RDI) 2331
- special needs children 787
- respiratory epithelial cysts 4014
- respiratory epithelium frontal sinus 1340 lateral nasal wall 1337 septum 1327, 1327 *F*
- respiratory gases 3515 *T*
- respiratory monitoring, airway endoscopy 518
- respiratory papilloma 209
- respiratory rate, children 543, 543 *T*
- respiratory scleroma (rhinoscleroma) 1462–3 clinical features 1463 diagnosis 1463 epidemiology 1462 histology 1462–3 infection stages 1463, 2268 laryngeal 2268 nasal 1462–3, 1703 nasopharyngeal 2122 pathology 1462–3 treatment 1463
- respiratory sleep disorders 2307–9
- respiratory support, relatives 527–8
- respiratory syncytial virus (RSV) 207 acute otitis media 915 symptoms 207 vaccination 919
- respiratory tract viral infections 204–7, 205 *T*
- children 1212
- diagnosis 204–5
- incidence 204
- pathogenesis 204 host-cell interaction 204
- serology 204–5
- respiratory-type epithelium larynx 2137
- nasopharynx 2108
- response time (RT), speech audiometry 3272
- resting strain, vestibular hair cells 3236 *F*
- restless legs syndrome (RLS) 2310
- restlessness, airway obstruction 2287
- restorative gene therapy 29
- restriction endonucleases 5, 5 *F*
- resuscitation critical care, adult 534 palliative care patients 2798, 2799 *T*
- retention cysts, nasopharyngeal 2122
- reticular activating system, sleep 2306
- reticular dysgenesis 175
- reticulocytes 266
- reticuloendothelial lymphoma 275
- reticuloendothelial malignancies, cytogenetic analysis 6
- retinacular ligament 1810
- retinoblastoma, genetics 8
- retinoblastoma gene 2382–3 exons 2378–9 hypopharyngeal cancer 2636 pocket protein family 2382–3
- 13 *cis*-retinoic acid dermabrasion 2898
- retinoids, chemoprevention 41
- retinopathy, diabetic 401–2
- RET protooncogene (cRET, MEN-2) 389, 2384 mutations 389 thyroid cancer 2669, 2671, 2687
- retraction pocket see chronic otitis media (COM), inactive squamous
- retrobulbar haematoma, post-blepharoplasty 3064–5
- retrobulbar haemorrhage, post-blepharoplasty 3059–60
- retrobulbar neuritis, acute 3916
- retrobullar recess 1333–4
- retrocochlear hearing disorders 3837–56 causes 3837, 3839 acquired 3839 *T* congenital 3838 *T* genetic 3838 *T*
- cerebellopontine angle tumours 3848 classification 3835–6 definition 3837
- Paget's disease 3487–8 speech audiometry 3273
- retromandibular vein 1853–4, 3904
- retro-orbicularis orbital fat (ROOF), descent 3049
- retropharyngeal abscess 2000–2 bacteriology 2000–1 children 1213–4, 1214 *F*, 1223, 2001 surgical drainage 2001
- clinical features 1786, 2001 complications 2002 differential diagnosis 2001 epidemiology 2000 investigations 471 *F*, 2001 children 2001 surgical drainage 2001 treatment 2001–2
- retropharyngeal lymph nodes lateral (nodes of Rouviere) 2113 medial 2113 metastatic neck disease 2718–9 evaluation 2719
- retropharyngeal space 1744–5, 1745 *F*, 1757–8, 1806–7, 1950, 1950 *F*, 2109, 2110 *T*, 2579 anterior compartment 2109–10 posterior compartment 2109–10
- retrospective studies 2344–5
- retrovirus gene therapy head and neck cancer 27 biosafety 27 insertional mutagenesis 29
- retrovirus replication 27
- reversed ear 3504 reverse ear squeeze 3504
- reverse genetic cloning technique 11 reverse transcriptase inhibitors 233 reverse triiodothyronine (rT₃) 321, 323 Revised European American Lymphoma (REAL) 1254
- revision rhinoplasty 2979–86 classification 2980, 2981 *T* deformity frequency 2980, 2981 *T* external approach 2965 prevention, factors affecting 2980–1 revision rates 2980, 2980 *T* surgical procedures 2979 treatment strategies 2982–5
- Reynell development language scales 621
- Reynolds number 1357
- rhabdomyoma, larynx 2600 *T*, 2604

rhabdomyosarcoma (RMS) 1934–8
 children 1255–6, 1256 *F*
 assessment 1255–6
 presentation 1255
 prognosis 1256
 staging 1255–6, 1256 *T*
 treatment and prognosis 1256
 ear 4074
 classification 4074, 4074 *T*
 diagnosis 4074
 site of origin 4074
 symptoms 4074 *T*
 treatment 4074
 types 4074
 epistaxis, children 1065, 1065 *F*
 management principles 1934–5
 outcomes 1935
 presentation 1934
 prognosis 1934 *T*
 skull base 3943
 staging 1934, 1934 *T*, 1935 *T*
 rhagades 1827
 Rhesus (Rh) blood group 254, 254 *T*
 fetomaternal haemorrhage 254
 rheumatic fever
 prevention, antibiotics 1985
 tonsillitis complications 1224
 rheumatoid arthritis 185–6
 dysphagia aetiology 2032
 rheumatoid factor 170
 serological tests 185
 rheumatoid factor 170
 rheumatological diseases 183–92
 aphthous ulceration 184
 diagnostic paradigms 187 *T*
 drugs 190
 ENT manifestations 183, 184 *T*
 imaging 185
 inflammatory diseases and
 infections 189
 investigations 185
 overlap syndromes 189
 symptoms and signs 184–5
see also specific diseases
 rhinectomy 2933, 2934
 rhinitis
 aetiology 1561
 allergic *see* allergic rhinitis
 asthma link 158, 1560–1
 disease continuum 1565
 atrophic *see* atrophic rhinitis
 bronchial challenge 1563
 bronchial inflammation 1562–4
 bronchial remodelling 1562
 definition 1380–1

drug-induced 1383, 1410
 emotional 1383, 1411
 food-induced 1383, 1429
 gastro-oesophageal reflux 1383
 hypothyroidism 400
 idiopathic 1383, 1409–10
 aetiology 1409–10
 corticosteroids 420
 diagnostic tools 1409
 neonatal 1076
 pathophysiology 1409
 symptoms 1409–10
 irritants 1383
 ‘mixed’ 1408–9
 molecular biology 1562
 oral drugs 1564
 topical drugs 1564
 treatment, asthma severity and 1565
 treatment costs 1565
see also rhinosinusitis; specific conditions
 rhinitis medicamentosa
 assessment 1376
 corticosteroid treatment 421
 decongestant-induced 1383, 1398, 1410
 rhinitis sicca 1466
‘rhinobasis’ 1505–6
 rhinocerebral mucormycosis *see* fungal rhinosinusitis, invasive
 rhinofrontal sinuseptotomy (RFS) 1514
 results 1514
 technique 1514
 rhinolalia (nasal speech) 993
 rhinolalia aperta (hypernasal speech) 993, 1366, 2166
 rhinolalia clausa (hyponasal speech) 993, 1366, 2166
 rhinolith 1186
 rhinological pain
 post-surgical 1721
 post-traumatic 1721
 sinusitis 1720–1
 rhinology
 drug therapy 436–45
 antibiotics 438–9
 antifungal agents 442
 immune response improving 441
 see also individual drugs
 image-guided surgery 708
 medical negligence 1730–6
 consent 1732
 conservative treatment, failure to consider 1732
 conservative treatment, inadequate 1735
 histological investigations 1731–2
 incompetent surgical technique 1732–4
 intraoperative monitoring 1734–5
 postoperative monitoring 1735
 pre-referral care,
 inadequate 1730–1
 presurgical management,
 inadequate 1731
 radiological investigations 1731
 tumour recurrence 1734
 tumour resection 1734
 video use in theatre 1733
 rhinomanometry 1358, 1358 *F*, 1372–5
 active 1373
 anterior 1373
 posterior 1373, 1373 *F*
 definition 1372–3
 disadvantages 1376–7
 ethnic differences 1374
 head-out body plethysmograph 1373
 normal nasal airflow 1374–5
 age effects 1374
 decongestant effects 1374
 passive 1373
 septal pathology 1576, 1577 *F*
 rhinometry, acoustic *see* acoustic rhinometry
 rhinophyma 1714, 1714 *F*
 medical negligence 3096
 rhinoplasty
 augmentation *see* augmentation rhinoplasty
 enlarged turbinates 1590
 external *see* external rhinoplasty
 infections 3091
 medical negligence 3091–2
 nasal fractures 1614
 nasal valve collapse 3007
 open *see* external rhinoplasty
 patient expectations 3091
 postoperative concerns 3091
 postoperative deformities 2979–80
 postoperative nasal obstruction 1590
 postoperative oedema 3091
 reduction *see* reduction rhinoplasty
 revision *see* revision rhinoplasty
 revision rate 3091
 septal perforations 1587
 rhinorrhoea
 aspirin-induced 1410
 cerebrospinal fluid *see* cerebrospinal fluid rhinorrhoea
 pregnancy 402–3

- skull base lesions 1351–2
watery, nasal fractures 1611
- rhinoscleroma* *see* respiratory scleroma (rhinoscleroma)
- rhinoscopy**
adenoids 1096
frontal sinus 1501
nasal polyposis 1553
- rhinosinusitis** 1439–48
acute *see* acute rhinosinusitis (ARS)
adenoidectomy 1096
allergy 1440–1
antimicrobial resistance 1441–2
children 1079–93, 1495–6
acute sinusitis 1080
complications 1085–9, 1086 *T*
diagnosis 1082
epidemiology 1080
examination 1082
immunotherapy 1083–4
inflammation pattern 1079
intracerebral abscesses 1089
investigations 1082–3
orbital complications 1086–8, 1088 *F*
pharmacotherapy 1083
predisposing factors 1079
prevalence 1443, 1444
radiology 1082–3
subdural infection 1088, 1088–9
surgery 1084–5
treatment 1083–4
viral rhinitis 1080
- chronic** *see* chronic rhinosinusitis (CRS)
classification 1380–5, 1380 *T*, 1439, 1439 *T*
complications *see* rhinosinusitis complications
definitions 1439–40
diagnosis 1442–3, 1478–80
differential diagnosis 1380–5, 1381 *T*
economic impacts 1444–7
endoscopy 1479
enlarged turbinates 1591–2
frontal *see* frontal rhinosinusitis
fungal *see* fungal rhinosinusitis
gastro-oesophageal reflux 1274
hormones, effects of 1383
inflammatory response 1440–1
intermittent *see* acute rhinosinusitis (ARS)
investigations 1384 *T*
microbiology 1441, 1441 *F*, 1442 *F*
nasal polyposis 1552–3
- natural history 1443
obstructive sleep apnoea 1104
parasympathetic nervous system blockers 442
pathophysiology 1440–2
environmental factors 1440
persistent *see* chronic rhinosinusitis (CRS)
prevalence 1443–4
quality of life 1444–7
radiology 1479–80
recurrent acute *see* recurrent acute rhinosinusitis (RARS)
saline irrigation 441
signs/symptoms 1440 *T*
staging system 1489 *T*, 1490 *T*
surgical management 1478–99
computed tomography 1479 *T*, 1480 *F*
historical aspects 1480–1
magnetic resonance imaging 1480
procedures 1481–95, 1482 *T*
results 1486–9
see also individual procedures
symptoms 1469
treatment
antibiotics 438–9
antihistamines 440
antimycotics 441
corticosteroids 436–8
costs 1444
decongestants 439–40
mucolytics 440
sodium cromoglicate 440
- rhinosinusitis complications** 1539–48, 1541 *T*
acute 1539–40
chronic 1540
classification 1539–40
clinical presentation 1540–2
definitions 1539
distant 1540
haematological investigation 1543
intracranial 1542
examination 1542
imaging 1543
incidence 1542
morbidity 1546
mortality rate 1546
prognosis 1546
surgery 1545
symptoms 1542
investigations 1542–3
local 1539–40
- medical management 1543–5
orbital 1541
imaging 1542–3
prognosis 1546
see also orbital cellulitis
prognosis 1546
surgery 1544–5
- Rhinosinusitis Disability Index** (RSDI) 1444–7, 1445
- Rhinosinusitis Outcome Measure** (RSOM-31) 641
- rhinosporidiosis** 215–6
aetiological agents 215
clinical manifestations 216
definition 215
diagnosis 216
epidemiology 215–6
nasal infection 1703–4
outcomes/complications 216
treatment 216
- Rhinosporidium seeberi* 215
- rhinostereometry** 1376
- rhinovirus** 205
- Rhizmucor* 217
- Rhizopus arrhizus* 217
- Rhomberg's test**, skull base lesions 3946
- rhomboid flap** 2838–40, 2841 *F*
- rhombomeres** 814
- rhytidectomy**
anaesthesia 3071, 3094
complications 3074–5
contraindications 3070
facial skeletal structure 3070
haematoma 3094
historical aspects 3068–9
incision design 3071
incision placement 3094
lobule incision 3071–2
long flap technique 3069
medical negligence 3093–5
medications 3070
nerve damage 3074
patient selection 3070
physical examination 3070
platysmaplasty and submental liposuction 3073–4
post-auricular incision 3072 *F*
postoperative complications 3094
post-tragal closure 3072, 3073 *F*
post-tragal incision 3071, 3071 *F*
preoperative assessment 3094
sensory changes 3094–5
short flap technique 3069
skin flap elevation 3069

rhytidectomy (*continued*)
 superficial musculo-aponeurotic system incision 3072, 3072 *F*
 surgical technique 3071–3
 ribavirin 210
 juvenile-onset recurrent respiratory papillomatosis 1178
 ribbon synapse 3136
 ribonucleic acid (RNA) *see* RNA (ribonucleic acid)
 ribosomal RNA 2379–80
 ridge expanders 2915–6
 Riedel's operation, frontal sinus fractures 1506–7
 rifampicin
 atrophic rhinitis 1466
 hepatotoxicity 236
 leprosy 1464
 respiratory scleroma 1463
 tuberculosis 1460
 rifamycins 231
 right anterior-left posterior (RALP) plane 3209
 eye movements 3217 *F*
 right main bronchus 2140 *F*, 2141
 rigid bronchoscopy
 anaesthesia 504, 504 *F*
 low tracheal obstruction 483
 paediatric intensive care 547
 ventilation 483, 483 *F*
 rigid endoscopy
 laryngeal stenosis 1152
 oesophageal foreign bodies 1188
 tracheo-bronchial foreign bodies 1190
 rigid fibrescopes 473
 rigid Hopkins rod system, laryngoscopy 2146
 rigid laryngobronchoscopy, obstructive sleep apnoea 1107
 rigid laryngoscopy 2149–50, 2149 *F*, 2150 *F*
 child's voice assessment 1169
 chronic laryngitis 2259–60
 Riley-Day syndrome 1288
 riluzole 2080
 rimantidine 210
 rima olfactoria 1344–6
 rim incision
 external rhinoplasty 2999, 2999 *F*
 nasal tip delivery 2997–8, 2998 *F*
 Rinatec *see* ipratropium bromide
 Ring, Adair, Eluyn (RAE) tube 511, 512 *F*
 Rinne tuning fork test 3318

Rion partially implantable hearing aid (PIHA) 3662
 risedronate 3489
 risk indices, surgery 459
 risk perception, surgery-related 563
 rituximab (Mabthera) 44
 ritonavir 233, 239
 rizatriptan 1049
 RNA (ribonucleic acid) 4
 HIV virus 238–9
 ribosomal 2379–80
 RNA polymerase 4
 Robin complex 1000–1
 Rochester study, thyroid cancer 2670
 rods 3914
 rods of Corti *see* pillar cells
 Rogers v Whitaker 1732
 rolling hiatal hernia 2062
 roll test 3809–10
 Romberg's sign 3778
 Romberg test 3731
 ROM (oral) exercises 2088, 2089 *T*
 root form implants 2903–4
 root mean square (RMS) values 3162, 3174
 root of the neck
 anatomy 2737 *F*
 radical neck dissection 2737
 surface anatomy 1741
 root sheath of Hertwig 1922–4
 rosacea 1714
 Rosai Dorfman disease (sinus histiocytosis) 1217
 rostrum, sphenoid bone 1339
 rotational movements, semicircular canals 3211
 rotational tests
 ototoxicity recognition 3573
 vestibuloocular reflex 3728 *F*, 3729–30
 rotational vertigo
 patient's description 3707
 presentation 3709
 rotation flaps 2832–4, 2835 *F*, 2836 *F*
 nasal reconstruction 3019
 round window
 anatomy 3111, 3126
 bone conduction 3185
 congenital aplasia 873
 dysplasia 873
 otosclerosis 3456, 3457 *F*
 total obliteration 3471
 rupture 3497
 roxithromycin 1471–2
 Royal College of Anaesthetists, paediatric NSAIDs use guidelines 516

Royal College of Surgeons, tonsillectomy surgical mortality audit 1235–6
 RSR13 51
 RTOG ETA (RTOG 85-27) trial 2756
 rubella 1701
 Russel bodies, respiratory scleroma 1462–3
 Rye classification, Hodgkin's lymphoma 1254
 S100 protein, mucosal malignant melanoma 2408
 saccades 3921
 balance disorders 3714–6
 corrective 3715
 examination 3714–6
 accuracy 3715
 conjugacy 3715–6
 techniques 3714, 3714 *F*
 function 3227 *T*
 medial longitudinal fasciculus lesions 3715
 oculographic recording 3715 *F*, 3716 *F*, 3726
 velocity
 examination 3714–5
 neurodegenerative disease 3712 *F*, 3714–5, 3715 *F*
 saccadic hypermetria 3715, 3716 *F*
 saccadic hypometria 3715, 3715 *F*
 sacular cysts 1136–7, 1137 *F*
 saccule 3151–2, 3151 *F*
 endolymphatic potential 3230–1
 orientation 3210
 vestibular hair cells 3228–30
see also otolith organs
 saccule of the larynx 2134
 saccus decompression surgery, medical negligence 3830
 saddle nose deformity 2970, 2971 *F*
 aetiology 2970, 2971 *T*
 antibiotic prophylaxis 2974
 management 2974–7
 medical negligence 1733, 3091–2
 nasal fractures 1615
 splinting 2974
 surgery 2974, 2976 *F*
 augmentation 2974
 graft fixation 2974
 graft preparation 2974
 traumatic 2970
 Saethre–Chotzen syndrome 1028
 sagittal synostosis *see* scaphocephaly

- salicylates
ototoxicity 3568 *T*, 3571
prevention and 3302
tinnitus induction 3599–600
- salicylic acid ototoxicity 3677
- saline-adenine-glucose-mannitol (SAGM) medium 255
- saline irrigation, rhinosinusitis 441
- saliva
antibacterial substances in 1866–7
artificial 449, 1912, 2788
collection 1861–3
drainage methods 1862
method comparison 1863
mixed whole saliva 1862
parotid gland 1862–3
stimuli 1862
submandibular gland 1863
composition 1865 *T*
inorganic ion concentration changes 1866 *T*
peptides 1842 *T*
proteins 1842 *T*
variables affecting 1865 *T*, 1866 *T*
- diagnostic assays 1867–9
drug monitoring 1868, 1868 *T*
hormone monitoring 1867–8
malignancy screening 1867
microbial antigens and antibodies 1868–9
- discolouration, drug-induced 1907
- flow rates 1807
factors affecting 1861
- functions 1859 *T*
in taste 1841, 1842 *T*
- secretion 1858–61
autonomic control 1858–9
mechanisms 1859–60
- salivary calculi *see* sialolithiasis
- salivary cysts, congenital 1242
- salivary fistula 2484, 2515
- salivary gland(s)
absence 1242, 1899
agenesis 1242, 1899
anatomy 1852–7, 1807–8
microscopic 1852
aplasia 1242, 1899
drug-induced pain 1906 *T*, 1907
- ectopic 1243
- embryology 799, 1852
- excretory duct 1852
- HIV patients 245–6, 1882
- imaging 1871–97, 722–4
children 1886–7
normal anatomy 1871–2, 1872 *F*, 1873 *F*
techniques 1872–8
see also individual techniques
- major 1852
- minor 1792, 1808, 1852
- physiology 1858–70
primary fluid secretion 1860–1
- secretory cells 1852
- surgery
anaesthesia 503
operation and procedure codes 2375 *T*
see also individual glands
- salivary gland diseases/disorders
children 1242–50
granulomatous 1244–7
inflammatory 1243–4
congenital 1242–3, 1899
- drug-associated 1906–7, 1906 *T*
swelling 1906–7, 1906 *T*
ductal anomalies 1242
- infections 1899–900, 1899 *T*
non-neoplastic 1898–920, 1899 *T*
imaging 1878–82
- radiotherapy-associated dysfunction 1908–9
- rheumatological diseases 184
- stones *see* sialolithiasis
see also specific diseases/disorders
- salivary gland lymphoma 2501, 2503
- salivary gland tumours
benign 2475–92
aetiology 2476
assessment 2478–80
children 1248
distribution 2475–6, 2476 *T*
epidemiology 2475–6
fine needle aspiration cytology 2479–80
histopathology 2480–3
imaging 1882–4, 2478–9, 2478 *T*
malignancy risks 2476
- molecular mechanisms 2476
- presentation 2476–8
- recurrent 2478, 2478 *F*
- secondary malignancies 2476
- treatment 2483–90
- children 1247–9
benign 1248
imaging 1886
investigation 1249
malignant 1248–9
- management 1249
- medical negligence 1310
- neoplasms 1248
vasoformative lesions 1247
- HIV-associated 245
- imaging 723, 723 *F*, 1882–5
- malignant *see* salivary gland tumours, malignant
- minor glands 2505, 2505 *F*
recurrence rates 2511, 2511 *F*, 2512 *F*
survival 2512–3, 2513 *F*
in oropharynx 2580–1
- parapharyngeal space 2525, 2530, 2536
- TNM classification 2366, 2368 *T*
- salivary gland tumours, malignant 2493–521
- cell biology 2494–6
- chemotherapy 2508
- children 1248–9
- classification 2496–502
- diagnosis 2506–7
- epidemiology 2494
- histogenesis 2503
- histology 2496–502
- imaging 1884–5, 1889 *F*
- incidence 2494
- investigations 2506–7
- metastatic disease 2501–2, 2503
- molecular biology 2494–6
- neck treatment 2510
- radiotherapy 2507–8
postoperative 2507–8
- recurrence rates 2511, 2511 *F*, 2512 *F*
- squamous cell carcinoma 2501
- staging 2507 *T*
- surgery 2508–9
complications 2515
- facial nerve 2508–9
- middle ear sacrifice 2508–9, 2509 *F*
- survival 2511–4, 2512 *F*
by histology 2512–3, 2513 *F*
- major glands 2512–3, 2512 *F*, 2513 *F*
- minor glands 2512–3, 2512 *F*, 2513 *F*, 2514 *F*
- treatment 2507–10
complications 2514–5
- undifferentiated carcinoma 2501
- see also individual glands; individual tumours*
- salpingopharyngeal fold 1944, 2107
- salpingopharyngeus 1945 *F*, 1948 *T*, 2112, 2135 *T*, 3118, 3901

salted fish, nasopharyngeal carcinoma risk 2346, 2354
 Samter's triad 1472
 frontal sinus surgery 1519
 NARES 1411
 nasal polyposis 1550
 Sanders injector 476–7, 477 *F*, 504, 504 *F*
 'sandpaper rash' 1983
 saquinavir 233, 239
 sarcoidosis 189–90, 1645–9
 aetiology 1646–7
 apple jelly nodules 189 *F*
 cervicofacial infections,
 children 1210–1
 clinical features 1647–8, 1647 *F*, 1648 *F*
 corticosteroids 424
 diagnosis 1648
 dysphagia aetiology 2032
 extrapulmonary organ involvement 1647 *T*
 facial nerve disorders 3891
 granulomata 187 *F*
 histology 1647
 Kveim test 1648, 1711
 laryngeal 2267
 nasal 1645, 1647–8, 1647 *F*, 1648 *F*, 1649 *F*, 1710–1, 1710 *F*
 symptoms 1647 *T*
 nodes involved 1759–60
 oral/perioral lesions 1828
 prevalence 1645
 pulmonary infiltrates 1649 *F*
 salivary glands 1906
 children 1245
 treatment 1648–9
 sarcoma(s), soft tissue *see* soft tissue sarcomas (STS)
 sarcomatoid carcinoma, larynx 2604
 satellite cells 69, 71
 Satisfaction with Life Areas scale,
 cochlear implants 3654–5
 Satyr ear deformity 3075
 saw-tooth nystagmus *see* jerk
 nystagmus
 scala media 3127, 3128 *F*
 scala tympani 3127, 3128 *F*
 access, cochlear implant surgery 3652
 scala vestibular 3127, 3128 *F*
 'scalded skin syndrome' 1700
 scalds, dressings 102
 scalene muscles 1746
 scalenus anterior 1746
 scalenus medius 1746

scalp flaps 2848–9, 2850 *F*
 scalp recorded electric responses 3280
 scan-directed minimally invasive open parathyroidectomy 394
 scaphocephaly 794, 794 *F*, 1022 *T*, 1025
 clinical features 1025, 1025 *F*
 incidence 1021, 1025
 surgery 1025
 scapular flap systems 2873–6
 anatomy 2873–4, 2874 *F*
 clinical applications 2875–6, 2875 *F*
 disadvantages 2874–5
 oral cavity reconstruction 2570–1
 technical nuances 2875
 S-carboxymethyl cysteine 3392
 scar camouflage 2895, 2895 *F*
 scarlet fever 1222
 Scarpa's ganglion 3148–9
 otosclerosis 3457–8
 vestibular compensation 3793
 vestibular neuritis 3678
 scar revision 2895–9
 adjunctive procedures 2899
 excision 2895, 2896 *F*
 expansion with 2895–6
 serial 2895–6
 indications 2895, 2895 *F*
 irregularization 2896–7
 techniques 2895–9
 tissue expansion 2896
 scars/scarring 87, 93
 benign skin lesions 3090
 chronic otitis media assessment 3412
 ear 3311, 3312 *F*
 chronic otitis media assessment 3412
 final appearance, influencing factors 2891
 tensile strength 93, 99, 99 *F*
 Schaumann bodies 1647
 Schilling test 269
 Schirmer test 3878 *F*, 3878 *T*
 schizophrenia 1669
 Schneiderian papillomas 2420
 Schobinger incision 2731–3, 2732 *F*
 school-entry screen, hearing loss 829
 schwannoma(s)
 collision tumours 4002
 CPA tumours 4014
 facial nerve *see* facial schwannoma
 jugular foramen 4030–1
 affected nerves 4030
 classification 4030, 4030 *T*, 4031 *T*
 histology 4031
 resection 4039–40, 4041 *F*
 site of origin 4030
 stereotactic radiosurgery 4043
 laryngeal, benign 2600 *T*
 lower cranial nerves 4014
 malignant transformation 4002
 nasopharyngeal 2124
 neurofibromatosis type 2 4000, 4002, 4003
 parapharyngeal space 2527
 trigeminal nerve *see* trigeminal nerve (V)
 tumour embolization 734
 ultrasound examination 726
 vestibular *see* vestibular schwannoma (VS)
 schwannomin (NF2 protein; merlin) 3999
 Schwartz-Bartter syndrome 2529
 Schwartz sign 3460–1
 scintigraphy
 dysphagia 1977
 frontal sinus 1502
 Graves' disease 340 *T*, 341
 jugular foramen infections 4029
 nodular thyroid disease 361–2
 salivary glands 1878, 1878 *F*, 1879 *F*
 advantages/disadvantages 1874 *T*, 1878
 children 1299–300
 function tests 1864 *F*
 indications 1890 *T*
 subacute thyroiditis 352
 thyroid neoplasia 361–2
 thyroid nodule evaluation 2676
 thyrotoxicosis 340, 340 *T*, 341
 Scl-70 antibodies 170–1
 scleral search coils 3723
 scleroderma 170–1, 186
 dysphagia 2031
 nasal 1712
 oesophageal 2066
 scleroma 2010
 respiratory *see* respiratory scleroma
 sclerosants
 endovascular embolization 733–4
 lymphangioma 1782–3
 sclerotherapy, cystic hygroma 1270
 scopolamine *see* hyoscine
 scotoma 3915
 Scottish Intercollegiate Guideline Network (SIGN), tonsillectomy recommendations 1230–1, 1996
 Scottish Tonsillectomy Audit 1231

- screening
 definition 821–2
 principles 822
- screening audiometry 3264–5
- screening programmes, coverage of 822
- screen negative result 822
- screen positive result 822
- screen sensitivity 822–3
- scrofuloderma infection 1702
- scrotal tongue 1825–6
- scuba diving, ear surgery and 3469,
 3506
- sea sickness 3240
- seasonal rhinitis, pollens 1396
- sebaceous glands, external auditory
 canal 3107
- seborrhoeic dermatitis
 HIV-associated 247
 external ear 240
 treatment 240
 nasal 1715
- seborrhoeic keratoses 1709
- secondary olfactory cortex 3912–3
- second branchial arch fistula 797,
 1266–7, 1779
- investigation 1266
- presentation 1266, 1266 *F*
- surgical removal 799 *F*, 1266–7,
 1779–80, 1780 *F*
- treatment 1266–7, 1267 *F*
- second degree burns 96
- second law of Newton 3210
- IIInd nerve *see* optic nerve (II)
- secretory otitis media (SOM) *see* otitis
 media with effusion (OME)
- sedation
 acute laryngeal infections 1128
 awake fibreoptic intubation 480
 paediatric imaging 1301–2, 1302 *T*
 paediatric intensive care 544
 see also anaesthesia
- segmental bronchi 2141
- seizures
 childhood disorders 1045
 vestibular schwannoma removal 3979
- selectins 2384
 allergic rhinitis 1391
- selective glutamate receptor antagonist,
 tinnitus 3617–8
- selective immunoglobulin
 immunodeficiency 175 *T*, 176–7
- selective neck dissection 2747–9,
 2747 *T*, 2748 *F*
- anterior compartment (level
 VI) 2747 *T*, 2748, 2748 *F*, 2749
- complications 2749
- incisions 2732 *F*
- indications 2747–9, 2747 *T*
- lateral 2747, 2747 *T*, 2748 *F*, 2749
- level VII 2748–9, 2749
- N1 disease 2726
- operative technique 2749
- posteriorlateral 2747–8, 2747 *T*, 2748 *F*,
 2749
- postoperative management 2749
- selective oncolytic virus, head and neck
 cancer treatment 29
- selective serotonin reuptake inhibitors
 (SSRIs)
 migrainous vertigo 3804
- tinnitus 3617
 vestibular attacks, acute 3798
- selective toxicity 235–6
- selenium 321
- self organizing maps, voice
 evaluation 2184
- sella spine 298
- sella turcica 298–300, 298 *F*
 content 298
 dural reflections 298–9
 landmarks 298
- semicircular canal(s)
 anatomical design 3211, 3211 *F*
 embryology 807, 816, 816 *F*
 forces acting upon 3211
 hair cells 3228, 3230 *F*
 head-impulse test 3224
 mean resting discharge 3237
 mechanical stimulation 3749–50
 movement detection 3211
 antagonistic responses 3215
 biomechanics 3211–3, 3213 *F*
 rotational 3211
 nystagmus 3749, 3749–50
 sinusoidal rotations, response
 to 3213 *F*
 stimulation 3215–20
 anterior canal, eye movements
 and 3217–9, 3217 *F*, 3218 *F*
 eye movements 3216, 3217 *F*,
 3218 *F*, 3219 *F*, 3219 *T*
 horizontal canals 3215
 posterior canal 3217–9, 3217 *F*,
 3218 *F*, 3219 *F*
 vertical canals 3215
semi-conservative replication 4
- semi-implantable middle ear
 electromagnetic hearing device
 (SIMEHD) 3661–2
- semispinalis capitis 3899
- semi-vowels 2167, 2167 *T*
- Semont's liberatory manoeuvre
 benign paroxysmal positional
 vertigo 3810, 3810 *F*
- complications/adverse effects 3812
- efficacy 3812
- senile keratosis *see* actinic keratosis
- sensation levels (SLs), temporal
 resolution assessment 3256
- 'sense of coherence' 2770
- senses, reliance on 3240 *T*
- sensitivity 822–3
- sensorineural hearing loss
 (SNHL) 3577–8
 active chronic otitis media 3436
- age-related *see* age-related
 (sensorineural) hearing loss
- aminoglycoside ototoxicity 3569
- apoptosis 61–2
- autosomal dominant nonsyndromic
 see autosomal dominant
 nonsyndromic sensorineural
 hearing impairment
- bone-anchored hearing aids 3646
- children 848
- definition 811–2
- desferrioxamine-induced 271–2
- glomus temporale tumour 4031 *F*, 4032
- idiopathic 3579–80
- idiopathic sudden *see* idiopathic
 sudden sensorineural hearing
 loss (ISSNHL)
- labyrinthitis 3403–4
- midfrequency 3562
- molecular analysis 12
- myxoedema 400
- otitis media with effusion 893, 3391
- otosclerosis 3456–7
- ototoxicity-related 3542
- petrous apex surgery 4052
- post-stapes surgery 3475–6
- recruitment 3199–200
- speech audiometry 3267
- sudden *see* sudden sensorineural
 hearing loss (SSNHL)
- tinnitus 3599
- tuberculous otitis 3448
- vestibular schwannoma 3943, 4143
- viral aetiology 210–1
- sensory ataxia 3778, 3780
 stepping patterns 3731
- sensory hair derangement, ototoxic
 drugs 3676, 3677 *F*
- sensory nerve monitoring, skull base
 surgery 4145

sensory organization test 3733
 sensory organs, origin of 816
 sensory tinnitus 3606
 sentences, speech audiometry 3270
 sentinel lymph node biopsy (SLNB)
 malignant melanoma 2402
 metastatic neck disease 2722
 oral cavity tumours 2565
 sepsis
 antimicrobial treatment 534
 critical care patients 534–5
 haemodynamic manipulations 534
 leukaemoid reaction 273
 nucleated red cells 266
 post-blood transfusion 262
 post-splenectomy 276
 severe 534
 Staphylococcus aureus 196
 septal abscess 1572–3
 children 1076
 septal cartilage grafts, alar collapse 3010
 septal deformities 1574–5
 compensatory turbinate
 hypertrophy 1590–1, 1591 *F*
 deviated nose 2987, 2989
 epistaxis 1601
 mucosal turbinate
 hypertrophy 1590–1
 septal deviation *see* deviated septum
 septal flaps, nasal
 reconstruction 3020–1
 septal fractures 1573, 1614
 septal haematoma 1572, 1615
 children 1076, 1311 *F*
 medical negligence 1311
 nasal fractures 1612, 1615
 septal abscess 1572–3
 septal luxation, newborn 1574
 septal perforation questionnaires 1583,
 1584 *F*
 septal perforations 1582–8, 1573–4
 aetiology 1582, 1583 *T*
 cautery and 1066, 1066 *F*
 clinical assessment 1583, 1584 *F*
 definition 1582
 epistaxis, children 1066
 investigations 1584
 management 1585
 nonsurgical 1585
 medical negligence 1733–4
 nasal fracture complication 1615
 obturation 1585
 prevalence 1582, 1584–5
 prevention 1585
 saddle nose deformity 1615

 surgery-induced 1573–4, 1584–5
 surgical enlargement 1585
 surgical repair 1574, 1586–7, 1586 *F*
 external rhinoplasty 2967–8
 symptoms 1574, 1582–3
 septal tubercle (intumescence) 1328,
 1328 *F*
 septal tunnels 1578, 1579 *F*
 septicaemia, rhinosinusitis 1540
 septoplasty
 access 1578
 cerebrospinal fluid rhinorrhoea
 aetiology 1636–7
 compensatory turbinate
 hypertrophy 1590–1
 indications 1576–7
 maxilla-premaxilla approach 1578
 open approach technique 1577,
 1578 *F*
 reconstruction 1579
 septal stabilization 1580
 supratip depression 3092
 turbines surgery and 1590–1
 septorhinoplasty
 aims 2979
 medical negligence 3091–2
 patient expectations 3091
 post-nasal fracture 1614
 septum 1569–81
 anatomy 1326–9, 1344–6, 1345 *F*
 anterior 1326
 augmentation rhinoplasty 2972
 bleeding disorders 1574
 blood supply 1328, 1328 *F*, 1570,
 1572 *F*
 bones 1326, 1326 *F*
 reshaping 1579
 cartilage 1326, 1326 *F*
 development 1316–7
 harvesting 2972, 2975–6
 reshaping 1579
 deflections 1326–7
 development 803, 1315–7, 1569–70
 surrounding structures 1570–1,
 1572 *F*
 developmental disorders 1570–1
 deviated *see* deviated septum
 growth 1569–70, 1570 *F*
 histology 1327–8, 1327 *F*
 inferior 1326
 innervation 1328–9, 1329 *F*
 investigations 1576
 lymphatic drainage 1329
 mucosa 1327
 trauma 1573
 nasal function 1570
 ossification 1316–7, 1570
 pathology 1570–5
 correction 1578
 diagnosis 1575–6
 removal 1578–9
 symptoms/signs 1575
 systemic disorders 1575, 1575 *T*
 posterior 1326
 sinusoid system 1328
 stem cells 75
 superior 1326
 tip shortening 3004, 3004 *F*
 trauma 1569–72
 vascular disorders 1574
 venous drainage 1328
 Serenocem 120, 121 *F*
 Serious Hazards of Transfusion (SHOT)
 reporting scheme, ABO
 incompatibility 261
 seromucinous glands
 maxillary sinus 1341
 septum 1327
 serotonin
 tinnitus 3608
 vestibular neurochemistry 3794
 serotonin agonists, migraine 1722
 serous glands of Von Ebner 1808
 serous labyrinthitis 923, 3692
 serous otitis media *see* otitis media
 with effusion (OME)
 Servox 2624–5
 sesamoid cartilage 1325
 sestamibi
 parathyroid imaging 383, 384
 primary hyperparathyroidism 391
 VIIth nerve *see* facial nerve (VII)
 severe combined immunodeficiency
 (SCID) 174–5, 175 *T*
 gene therapy 23, 27
 severe congenital neutropenia
 (SCN) 177 *T*, 178
 sevoflurane
 endoscopy 1121–2
 periglottic/glottic obstruction 481
 tracheostomy 482
 sex hormones, effects on nasal
 mucosa 1366
 sexual behaviour, olfaction and 1368
 sexual functioning, cancer patients 2777
 SF-6D 638
 SF-36 634–5, 637, 638, 638 *T*, 639–40,
 642
 shaker-1 mice, Usher syndrome
 model 3238

- Shaker manoeuvre 2090, 2090 *T*
 sham surgery 3830
 shared airways 494
 Sheehan's syndrome 4100
 shield graft
 cleft lip nasal deformities 2967, 2967 *F*
 nasal tip surgery 2965, 2965 *F*
 underprojected tip 3003–4
 Shiley tubes 1199
 shimmer (amplitude)
 perturbation) 2165, 2179
 shingles, pharyngeal
 manifestations 2079
 Shipman, Harold 594, 602
 Shipman Inquiry 2804
 shock 528
 short message service (SMS) 3669
 short Synachthen test 312
 short tandem repeat polymorphisms
 (STRP) 8–9
 shoulder syndrome 2744
 Shprintzen syndrome 1139
 sialadenitis, imaging 724, 1880
 sialagogues 1862
 sialochemistry 1863–7
 antibacterial substances 1866–7
 diseased states 1864–6, 1866 *T*
 normal 1863
 sialography 1877
 acute suppurative sialadenitis 1902
 advantages/disadvantages 1874 *T*,
 1877
 contraindications 1877
 indications 1890 *T*
 magnetic resonance sialography
 vs. 1879
 paediatric imaging 1297
 relapsing acute parotitis 1244, 1244 *F*
 sialolithiasis 1879
 sialolithiasis 1904–5
 children 1246–7
 clinical features 1904–5
 imaging 1878–80
 investigations 1905
 treatment 1905
 ultrasound 723, 723 *F*, 724 *F*, 1879,
 1880 *F*
 sialoliths 1904–5
 sialomucins, nasal mucus 1359
 sialorrhoea 1914
 Parkinson's disease 3939
 sialosis 1907–8, 1907 *F*
 Sicca syndrome 1245
 sick building syndrome (SBS) 1420
 sickle cell(s) 270
 sickle cell disease 270
 adenotonsillar hypertrophy 271
 blood transfusion, iron overload 262
 perioperative management 271
 surgical complications 271
 sickle solubility test 271
 sickling disorders 270–1
 blood transfusion 271
 clinical manifestations 270
 investigations 271
 Sickness Impact Profile (SIP) 638
 Sidaway v. Board of Governors of the
 Bethlem Royal Hospital and the
 Maudsley Hospital (1985) 600,
 2806
 side-lying tests 3809–10
 sigmoid-jugular complex 4027
 surgical management 4037 *F*, 4038–9,
 4038 *F*
 thrombosis 4027–8
 venous drainage 4027
 sigmoid sinus thrombosis, acute otitis
 media 924
 signal accumulation, voice
 evaluation 2183
 signal filtering, hearing aids 3632
 signal-to-noise ratio
 averaging 3279
 signal enhancement 3279
 speech audiometry 3270, 3271
 voice evaluation 2181
 sign bilingualism 855–6
 sign language
 deaf children 855–6
 forms 566
 visual-spatial axis 566
 Silastic 121
 dorsal nasal implants 2973
 maxillary resection 2930
 Silastic sheet (Swiss roll),
 laryngotracheoplasty 2279
 silent reflux 1272
 silent sinus syndrome 1345 *F*
 silent substitution 9–10
 silent thyroiditis 352–3
 silicone implants 121
 advantages for use 122
 augmentation rhinoplasty 2971
 complications 121
 dorsal nasal 2975 *T*
 intracochlear electrodes 122
 paralysed vocal folds 121–2
 silicone injection, vocal fold
 paralysis 2240, 2245 *T*
 silicone sheeting, keloids 2892–3
 silver nitrate cautery
 epistaxis, children 1065–6, 1065 *F*
 medical negligence 1310
 silver splints, mandibular
 fractures 1623, 1623 *F*
 silver staining nucleolar organizer
 regions (AgNOR) 2494–5
 simple (solitary) bone cyst 1926–7
 simple sequence length polymorphisms
 (SSLP) 8–9
 simple snoring 1102–3
 sine function 3159, 3159 *F*
 singer's formants 2178 *F*, 2180, 2211
 single photon emission computed
 tomography (SPECT)
 malignant otitis externa 3338
 parathyroid glands 384
 skull base lesions 3947
 singlet oxygen 745–6
 sinonasal malignancy 2417–36
 aetiology 2418
 biopsy 1350–1, 2426
 clinical evaluation 2425–6
 endoscopy 1350–1, 2425, 2426 *F*
 postoperative surveillance 1351
 resection 1350–1, 1351 *F*
 site of origin and surgical
 planning 1350–1, 1351 *F*
 visualization 1350–1
 epidemiology 2347, 2417–8
 epistaxis 1606
 genetic analysis 11–2
 imaging 2425–6, 2426 *F*, 2427 *F*
 incidence 2347
 medical negligence 1731
 olfactory dysfunction 1668–9, 1673–4
 presentation 2424–5
 prognosis 2417, 2434, 2434 *T*
 risk factors 2347
 occupation 2347
 social class 2347
 spread patterns 2418–20, 2419 *F*
 distant metastases 2420
 local invasion 2418–9, 2419 *T*
 regional spread 2419–20
 staging 2417, 2420, 2424 *T*, 2425 *T*
 surgical anatomy 2418
 surgical pathology 2420–3
 TNM classification 2366, 2367 *T*
 treatment 2417, 2427–31
 contraindications 2427
 maxillary tumours 2427–8
 principles 2427
 surgical approaches 2428–9
 see also specific types/locations

Sino-Nasal Outcome Test (SNOT-20) 620–1, 641
 sinonal papilloma 11–2
 sinonal surgery, epidemiological research 619–20
 sinonal undifferentiated carcinoma (SNUC) 2422
 sinus(es), paranasal *see* paranasal sinuses
 sinuscopy *see* nasal endoscopy
 sinus grafting 2917, 2918 *F*
 sinus histiocytosis (Rosai Dorfman disease) 1217
 sinusitis corticosteroids 421
 facial pain 1720–1
 children 1720–1
 frontal sinus, iatrogenic 1519
 HIV patients 241–2
 antibiotic treatment 242
 endoscopy 242
 imaging 306, 1720
 otitis media with effusion 3389
 referral delay 1730–1
see also rhinosinusitis
 sinus mycetoma *see* fungus ball
 sinusoidal rotation test 3728 *F*, 3729–30
 sinusoidal tone masking 3247
 sinus tympani 3112–4, 3113 *F*
 Sipple syndrome *see* multiple endocrine neoplasia (MEN)
 Sir Harold Gillies' fifteenth principles 112
 Sistrunk's operation 2686
 VIIth nerve *see* abducent nerve (VI)
 68kD protein 3680
 Sjögren syndrome 186, 1909–13
 children 1245
 classification 1910 *T*
 dental carries 1911, 1911 *F*
 diagnosis 1863, 1864–5
 dietary supplementation 1913
 drug induced 1906 *T*
 dysphagia aetiology 2032
 electrostimulation 1913
 investigation 1911
 salivary gland imaging 724, 1882
 salivary gland lymphoma 2501
 treatment 1912–3
 skeletal muscle denervation 70
 skew deviation, thalamic nuclei lesions 3921
 skier's nose 1411
Skills for the new millennium 552

skin antimicrobial side effects 236
 HIV patients 247–8
 nasal 1322
 rheumatological diseases 183–4
 stretching properties 2829
 tissue engineering 126
 wound dressings 100
 skin biopsy, wound healing 97
 skin cancer, head and neck 2395–405
 diagnostic delays 3092–3
 medical negligence 3092–3
 risk factors 2396 *T*
see also individual types
 skin care, wound dressings 102
 skin diseases, oral manifestations 1834–5
 skin eruptions, high-pressure nervous syndrome 3512
 skin flap(s) 110–7
 blood flow 111–2
 animal models 113
 distribution control 112
 fluid mechanics 111
 microcirculation 112
 vessel diameter 111
 viscosity 112
 'choke vessels' 111
 compromised 112–4
 appearance 112–3
 extrinsic factors 112–3
 intrinsic factors 113–4
 physical interventions 114–5
 definition 110
 design 111
 length to width ratio 111
 facial skin transfer 2829–30
 historical aspects 110–1
 nasal reconstruction 110
 laser treatment 115
 leeches 115
 medical negligence 3093
 musculocutaneous blood supply 111
 necrosis, rhytidectomy 3094
 'no reflow phenomenon' 113
 oscillating veins 111
 physiology 110–7
 'retiform anastomoses' 111
 surgical delay 114–5
 'choke vessels' 114
 tissue expansion 115
 survival angiogenesis 114
 combined therapy 114
 drug treatment 113
 gene therapy 114
 monoclonal antibodies 114
 surgically induced neutrophil recruitment 113–4
 vascular endothelial growth factor 114
 sympathetic innervation 112
 vasospasm 113
 vessel wall tension 112
see also individual types
 skin grafts adherence 2820, 2821–2
 application 2823
 bleeding, excessive 2823
 constituents 2820 *F*
 crusting 3093
 donor sites 2822, 2991 *F*
 head and neck 2825
 dressings 2823
 free 2820–5
 full thickness *see* full-thickness skin grafts
 harvesting 2820
 instrumentation required 2822
 medical negligence 3093
 movement prevention 2823
 nasal reconstruction 2928, 3019
 pressure methods 2823
 reconstruction ladder 2824, 2825 *F*
 secondary 2823–4
 granulations 2823
 infections 2824
 split thickness *see* split thickness skin grafts
 technique 2822–3
 timing 2823
see also specific types/areas
 skin necrosis splint-induced 3091
 warfarin-induced 282
 skin prick tests (SPT) 158–9, 159 *F*, 169, 1393–4
 allergic fungal rhinosinusitis 1453–4
 allergic rhinitis 1082, 1087 *F*, 1393–4
 food allergy 1394, 1428–9
 method 1394
 occupational rhinitis 1420
 patient exclusion 1394
 RAST vs. 1393 *T*
 rationale 1393–4
 sensitivity 1394
 specificity 1394
 skin regeneration, stem cell therapy 75
 skin tag, ear 967, 969, 969 *F*

skin types
 malignant melanoma 2400
 squamous cell carcinoma 2398

skip metastases 2715

ski-slope deformity 3091–2

skull
 embryology 794–5, 2117 *F*
 expansion, Paget's disease 3489
 normal growth 1020

skull base
 anatomy 3897–910, 3942
see also specific components
 anterior *see* anterior skull base
 boundaries 3897
 defects/lesions *see* skull base defects/
 lesions
 imaging 4123
 lateral *see* lateral skull base
 middle 4122, 4123 *F*
 posterior 3898–9
 structures within 3909–10
 surgery *see* skull base surgery
 tomography 3897, 3898 *F*

skull base defects/lesions
 audiology 3946
 common 3943 *T*
 current knowledge/future
 research 3948
 epidemiology 3943
 evaluation 3942–8
 examination 3945–6
 head and neck 3945
 neurological 3945–6
 vestibular 3946
 facial function tests 3946–7
 family history 3945
 hearing loss 3943–4
 investigations 3946–7
 medical history 3945
 radiology 3947
 symptoms 3942–3, 3943–5
 lower cranial nerves 3945
 neurological 3944–5
 ophthalmic 3945
 see also specific symptoms
 tumours *see* skull base tumours
 vestibular function tests 3946
see also specific lesions

skull base fractures
 cerebrospinal fluid
 rhinorrhoea 1636–7, 1637 *F*
 inner ear trauma 3681–2

skull base meningioma 1684, 3994 *T*

skull base osteomyelitis *see* malignant
 otitis externa

skull base surgery
 catheter angiography 3949–51
 complications 4135–41, 4137–9
 cardiac dysrhythmia 4137
 epilepsy 4139
 haematoma 4137–8
 headaches 4139
 hydrocephalus 4139
 infection 4138
 intraoperative 4136–7
 pneumocephalus 4139
 postoperative 4145
 vascular 4136
 consent 4146
 craniofacial surgery and *see*
 craniofacial and skull base
 surgery
 image-guided surgery 708, 708 *F*
 internal carotid artery test 3951
 medical negligence 4142–8
 monitoring 4145
 tumours embolization *see* tumour
 embolization, skull base
 vascular assessment and
 management 3949–56
 vascular management 3949–56

skull base tumours 4123–7
 dysphagia aetiology 2033
 extracranial lesions 4123
 hereditary syndromes 3945,
 3945–6
 incidence 3943
 intracranial 4123, 4126–7
 benign 4126–7
 pathology 4123–7
 primary lesions 4123–6
 benign 4123–5
 malignant 4125–6
 surgery 4127–32
 follow-up 4127
 principles 4127
 recurrence 4127
 symptoms 3943–4
 vascular assessment 3949
see also individual types

sleep
 definition 2305
 optimal duration 2306
 phases 2305
 physiology 2305–12
 respiration, effects on 2306–7,
 2306 *F*
 efferent output 2307

sleep clinics, special needs
 children 787–8

sleep-disordered breathing 2313–4
 adenotonsillectomy 1109
 arousal 1103
 home monitoring 2316–7
 mechanism 1103–4
 physiological effects 1103–4
 termination 1103–4
 upper airway obstruction 1102
see also obstructive sleep apnoea
 (OSA)

sleep disorders 2305–12
 full polysomnography 1104
 nonrespiratory 2310–1
 respiratory 2307–9
see also individual disorders

sleep nasendoscopy
 children 1106–7
 treatment options 1109–10
 grading 1106, 1107 *F*, 2328 *T*
 snoring 2328, 2328 *T*

sleep studies
 obstructive sleep apnoea 1105–6
 paediatric laryngeal stenosis 1154–5
 slide tracheoplasty, tracheal
 stenosis 1144
 'slipping clutch phenomenon' 3731
 slough 99 *F*
 post-rhytidectomy 3075
 wound dressings 101
 wound healing 98

Sluder's neuralgia 1723–4

small cannula cricothyrotomy 476–7

small cavity mastoidectomy,
 cholesteatoma 3432

smell *see* olfaction

smell abnormalities/disturbances *see*
 olfactory disorders/dysfunction

Smell Identification Test(tm) *see*
 University of Pennsylvania Smell
 Identification Test (UPSIT)

smell threshold tests 1666

smoke (artificial), professional voice
 and 2212

'smoker's larynx' *see* Reinke's oedema

smoking
 allergic rhinitis 1386–7, 1396
 candidiasis 223
 chronic laryngitis 2258–9
 radiation-induced 2268

Graves' disease 340

hypopharyngeal cancer 2634

implant osseointegration 2910

laryngeal cancer 2348

laryngeal changes 763

occupational rhinitis 1416

- smoking (*continued*)
olfactory dysfunction 1664, 1670
oral cavity tumours 2550, 2550 *F*
otitis media with effusion 626, 882,
 883–4
pinna reconstruction 3044
Reinke's oedema 2265
rhytidectomy 3070, 3094
sinonasal malignancy 2418
taste abnormalities 1848
thyroid eye disease 340
voice disorders 2195
see also tobacco
- smoking cessation, chronic
laryngitis 2264
- smooth pursuit eye movements 3227 *T*
balance disorders 3713–4
brainstem lesions 3713
examination 3713–4
global abnormalities 3714
laboratory assessment 3726
pandirectional 3714
saccadic tracking 3713, 3713 *F*
- sneezing 1364
- SnNOut mnemonic 656
- SNOMED CT (Standard Nomenclature of Medicine and Clinical Terms) 2375
- snoring
aggravating factors 2325–6
clinical presentation 2326
definitions 2307, 2325–6
enlarged turbinates 1591
epidemiology 2325–6
examination 2326
full polysomnography 2327
history 2326
nasal obstruction 2331
nasal resistance 1591
nonsurgical treatments 2333
obstructive sleep apnoea 1104, 2327–8
obstructive sleep apnoea *vs.* 2327–8
preoperative investigations 2326–9
severity 2327–9
simple 1102–3
site identification 2328–9
surgical management 2325–40
 complications 2332
 indications 2329
 occasional procedures 2331–2,
 2331 *T*
 outcomes 2332–3
 postoperative care 2332
 techniques 2329–32
upper airway wall vibration 2307, 2325
- snuffles 1462
treatment 1462
- societies, paediatric
otorhinolaryngology 773
- Society for Biomaterials 118
- sodium
endolymph 3187–8, 3187 *T*
nasal secretions 1360
perilymph 3189 *T*
restriction, Menière's disease 3759
- sodium bicarbonate, ear wax
removal 431
- sodium chloride testing, regional taste deficits 1844
- sodium citrate, coagulation tests 280
- sodium cromoglicate
allergic rhinitis 1398
rhinosinusitis 440
children 1083
- sodium fluoride, otosclerosis 434
- sodium iodide (Na^+/I^-)
symporter 321–2
- sodium metabisulphite 429
- sodium thiosulphate, ototoxicity
prevention 3302
- Softband hearing aid
childhood deafness 854, 854 *F*
otitis media with effusion,
childhood 903
- soft palate
anatomy 1007–9, 1009 *F*, 1792,
1792 *F*, 1945–7
development 1812–3
function 1007–9, 1009 *F*
innervation 1947
lymphatic drainage 1947
muscles 1945 *F*, 1946 *T*
paralysis, diphtheria 2253
repair 1008 *F*, 1009–10
structure 1945
swallowing 1954–5, 1956
- tumours 2589
- vasculature 1799, 1947
- soft tissue
facial injuries (level 3) 1632
pain, cancer patients 2784
transcutaneous electrical nerve stimulation 2784
- soft tissue flap mobilization 2920
- soft tissue neoplasms, ultrasound 725–7
- soft tissue sarcomas (STS)
adult type 1935–6
anatomical sites 1935, 1935 *T*
lymph node metastases 1935
- management 1935–6
resection 1935–6
children 1259, 1259 *T*, 1260 *F*
classification 1932 *T*
- solar keratosis *see* actinic keratosis
- solid state lasers 743
- solid tumours, Halstedian concept of treatment 2717
- solitary bone cyst 1926–7
- solutions 448–9
- somatic mutation 135
- 'somatic mutation theory' of cancer 2354
- somatic nuclear transfer/cloning 74
- somatosensory system
disturbances 3240 *T*
- somatosounds 3600–1
aetiopathophysiology 3600–1
myogenic 3600
vascular 3600
- somatostatin 300
- somatostatin analogues,
acromegaly 301, 4101
- somatotrophin *see* growth hormone
- somatotrophs 296
- sonoplast device, diathermy
vs. 2330 *T*
- sone 3251
- sonography *see* ultrasound
- sore throat, acute onset *see* pharyngitis, acute
- sound 3158–72
absolute threshold 3250, 3251 *F*
acoustic admittance/
compliance 3168–9
acoustic impedance 712, 713, 3165,
3167–9
acoustic radiation 3162
analysis 3173–8
intensity 3165, 3173–5
definition 3174
superior olivary complex 3142
voice evaluation 2177
- measuring 3169–71
audiometric scales 3171
decibel scales 3170
microphones 3169–70
noise exposure 3171
sound level meters 3170
weighting 3170–1
see also audiotometry
- 'particles' 3162
- perception 3245–59
frequency selectivity *see* frequency selectivity

- hearing impairment 3255–7
 loudness *see* loudness perception
 reflection 711, 3175–6
see also ultrasound
 resonance 3167
 vibration 3158–62
 adding (superposition) 3165–7
 forced vibrations 3161
 resonance frequency 3162
see also vibration(s)
 voiced 2170
 waves *see* sound waves
see also noise
 sound desensitization, hyperacusis 3596
 sound energy density 3165
 sound-evoked vestibulocollic reflex 3741
 sound exposure level 3171
 sound field 3162, 3163, 3164
 sound localization 3255
 binaural cues 3255
 cochlear hearing loss 3257
 ‘duplex theory’ 3255
 external ear 3179, 3179 *F*, 3255
 sound source elevation 3179
 high frequency sound 3255
 intensity differences 3255
 phase differences 3255
 precedence effect 3255
 superior olivary complex 3141–2
 sound ‘particles’ 3162
 sound power level 3170
 sound pressure 3162, 3168, 3169–70
 sound pressure level (SPL) 2177,
 3173
 sound production disorders 992–4
 sound retraining programme,
 hyperacusis 3596
 Soundtec Direct Drive Hearing System
 (DDHS) 3661
 sound waves 712, 3162–5
 diffraction 3167, 3167 *F*
 Fourier analysis *see* Fourier analysis
 frequency 3175
 sensation and 3175
 velocity 3175
 wavelength 3175
 interference patterns 3166–7
 longitudinal waves 3163
 medium density effects 3163
 nodes/antinodes 3166–7, 3166 *F*
 plane progressive 3164
 pressure 3162, 3168, 3169–70, 3173–5,
 3174 *F*
 propagation 3163, 3175–6
- attenuation by distance 3175
 transmission between different media 3175–6
 sound field 3162, 3163
 far field 3164
 near field 3164
 objects within 3164
 speed 3164
 standing waves 3166–7, 3166 *F*
 transmission 3173, 3174 *F*
 wavefront 3164
 distance and 3175
 wavelength constant (*k*) 3164
 Southern blotting 6
 space and motion discomfort *see* visual vertigo
 spasmodic croup 1129
 spasmodic dysphonia 2203, 2224, 3940
 diagnosis 2203
 treatment 641, 2203, 2224
 types 2203
 spasmodic dystonia 449–50
 spasmodic laryngitis 1129
 spasticity, stepping patterns 3731
 spatial coding
 definition 3235
 vestibular hair cells 3235
 spatial compounding, ultrasound
 advances 713
 spatula test 778, 779 *F*
 speaking fundamental frequency
 (SFF) 2177–8, 2178 *F*
 special care baby unit (SCBU) 774
 specialist registrars, training issues 553
 special needs children 783–91
 clinical environment 783–4
 communication and rapport 784–5
 drooling 788–9
 ear and hearing 785–6
 ethical issues 785
 hearing assessment 785, 841
 prognosis 785
 terminology 783
 upper aerodigestive tract 786–8
 specification, otic field 815
 specificity (definition) 823
 specific language impairment (SLI) 991
 spectacle-retained prostheses 2932,
 2932 *F*, 2934, 2936 *F*
 spectrograms, voice analysis 2178 *F*,
 2179–80
 spectroscopic optical coherence tomography 759
 speech
 bulbar palsy 3939
- development 990–1
 otitis media with effusion 893–4
 stages 991 *F*
 ventilation tubes 899
 dynamic range 3267
 fundamentals of 2166–7
 nasalalance assessment
 (nasometry) 1375–6
 paralinguistic features 2167–8
 Parkinson’s disease 3939
 phonemes 3267
 production 2164–9, 992–3
 disorders 992–4
 organic factors 2164–5
 phonetic factors 2164–5
 sound source characteristics 2165
 quality 2165
 rate, paralinguistic features 2168
 rhythm 2168
 voice evaluation 2172–4, 2173 *F*
 consonant–vowel sequences 2172–4
 fluent speech 2172, 2174 *T*
 percentage irregularity score 2179
see also voice
 speech and language therapists
 (SLT) 990
 speech audiometry 3267–73
 audiovisual aspects 3269, 3271–2
 background noise 3270–1
 applications 3273
 frequency spectrum 3270–1
 signal-to-noise ratio 3270, 3271
 unmodulated random noise 3271
 bisyllabic words 3270, 3272
 bone-conduction hearing aid
 assessment 3644
 clinical applications 3273
 complexity 3267–8, 3273
 confounding factors/error 3272–3
 cognitive 3273
 psychological/linguistic 3273
 statistical 3272, 3272 *F*
 diagnostic power 3270
 equipment 3268–9
 calibration/reliability 3269
 masking 3268, 3270
 monosyllabic test words 3270,
 3272
 psychometric function curve 3268,
 3268 *F*
 reference data 3273
 scoring 3272
 skull base lesions 3946
 sound field audiometry 3269
 speech level 3269

speech audiometry (*continued*)
 terminology/definitions 3268, 3269, 3271
 test environment 3269
 ambient noise levels 3269
 test material 3269–70
 connected/continuous speech 3270, 3271
 dialogue 3272
 dichotic speech 3270
 logatoms 3269, 3272
 sentences 3270
 test method 3271–2
see also pure-tone audiometry
 speech delay 992
 speech discrimination
 cochlear implants, children 863
 definition 3268
 speech disorders, children 990–5
 adenoids and 993
 classification 991–2, 992 T
 expressive 991, 992 T
 presentation 991–2
 tonsils and 993
 speech intelligibility 3268
 speech intelligibility rating (SIR) 3271
 speech reception threshold (SRT), central auditory dysfunction 3859
 speech recognition
 auditory neuropathy 3844
 definition 3268
 maximum score 3271
 scores 3564 F
 sigmoid curve of 3268, 3268 F
 threshold level 3271, 3273
 Speech Studio Programme 2177–8
 speech therapy 2216–33, 2195
 Accent method 2219–20, 2225
 aims 2195, 2218
 efficacy 2218, 2219–20
 hyperfunctional voice disorders 2225
 laryngitis 2219
 acute 2219
 chronic 2219, 2264
 radiation-induced 2268
 neurologically-based voice disorders 2222–5
 nonorganic voice disorders 2219–20
 organic voice disorders
 (benign) 2220–2
 outcomes, goal-based 2218
 pitch disorders 2226–7
 psychogenic voice disorders 2225–6
 techniques 2195
 velopharyngeal insufficiency 1011

vocal fold cysts 2202
 vocal hygiene techniques 2220
 speech-to-noise (S/N) ratio 3667
 speech-tracking 3271–2
 S phase, cell cycle 2381
 sphenoethmoidal cells (Onodi cells) 1336–7, 1678
 sphenoethmoidal recess 1337, 1344–6
 second pass endoscopy 1348
 sphenoid bone 1338–9, 1339 F
 in anterior cranial fossa 4120, 4122 F
 at birth 1318
 body 1338–9
 development 1318
 fusion 1318
 lateral skull base 3899–900
 nasopharynx 2110
 plates 1338–9
 pneumatization 1319–20
 premature ossification 1320
 pterygoid process 2111
 sella turcica *see* sella turcica
 wings 1338–9
 sphenoid meningioma 1685
 sphenoid os, endoscopy 1348
 sphenoid sinus
 anatomy 1338–9
 associated structures 4108
 asymmetry 1319–20
 blood supply 1339
 development 1319–20
 drainage 1368
 histology 1339
 innervation 1339
 intrasphenoid sinus septae 300
 lymphatic drainage 1339
 magnetic resonance imaging 305 F, 306
 opening 1339
 osteology 1338–9
 pituitary tumours 4100
 hypophysectomy 4106, 4106 F, 4108–11, 4108 F
 pneumatization 299–300, 1320 F, 1339
 prominences 1339
 rhinosinusitis 219, 220 F, 1540
 tumours, patterns of spread 2419, 2420 F
 sphenomandibular ligament 1810, 3908
 sphenooccipital junction 794–5
 sphenopalatine artery 1328, 1337
 endonasal ligation 1598, 1603, 1603 F
 epistaxis 1597
 embolization 739
 sphenopalatine foramen 1337, 1598, 3897–8
 sphenopalatine ganglion 2111
 sphenopalatine ganglion neuralgia 1723
 spherical cells 3140–1, 3142 F
 spinal accessory nerve (XI) 1751, 3933 F, 3934 F, 3935
 central connections 3934 F
 clinical disorders 3937–8
 clinical evaluation 3937–40
 cranial part 1751, 3935
 rootlets 3935
 spinal root 3935
 vascular lesions 3935
 spinal epidural abscess 2002
 spindle naevi, nasal 1707
 spindle poisons 38–9
 SPIN lists, speech audiometry 3270
 spinocerebellar ataxias (SCA) 3773
 aetiology 3773
 clinical manifestations 3774
 diagnosis 3774
 management 3774
 spin-spin time, functional magnetic resonance imaging 676
 spiral ganglion neurons 3136, 3138 F
 action potentials 3137–9
 speech recognition, post-cochlear implants 3650, 3655
 threshold frequencies 3139
 type I 3136
 type II 3138 F, 3139
 spiral ligament ‘hyalinization’, otosclerosis 3455 F, 3456–7
 spiral limbus, longitudinal ridge 3127
 spirochetes 202
 spirometry
 aerodynamic voice measures 2181
 nasal airway measurement 1376
 spitting, saliva collection 1862
 Spitz naevi, nasal 1707
 splenectomy 276
 sepsis 276
 thrombocytopenia 287
 vaccinations 276
 splenomegaly, thrombocytopenia 287
 splicing 4
 alternative 4, 15–6
 split thickness skin grafts 97, 2820–3
 adherence 2820
 buccal carcinoma 2561
 depth, effect of 2820
 donor site healing 3093
 lifespan 2820
 nasal reconstruction 3019

- surfaces that take well 2821
 'take' requirements 2820
 technique 2823 *F*
 spondylarthropathy 186
 spontaneous nystagmus
 acute unilateral vestibular
 deafferentation 3222–3
 balance disorders 3711–2
 convergence absence 3711
 dynamic visual acuity 3718
 examination 3711–2
 central lesions 3711–2, 3711 *F*, 3712 *F*
 peripheral vestibular lesions 3711,
 3711 *F*
 laboratory assessment 3724–5, 3725 *F*
 visual suppression 3724–5
 waveforms 3711, 3711 *F*
- spontaneous otoacoustic emissions
 (SOAE), tinnitus 3600–1, 3603–4
 auditory disinhibition 3604
 external sound interaction 3604
- spontaneous ventilation, airway
 endoscopy 518
- spontaneous vertigo syndrome 3748
 aetiology 3767, 3773
 presentation, post-first attack 3781
 presentation during attack 3780
 recurrent 3781
- sporadic acute otitis media 913
 sporotrichosis 214
 SpPIn mnemonic 655
 spreader grafts 3009 *F*, 3010 *F*, 3011
 middle nasal vault 2964, 2964 *F*
- squamotympanic fissure 3900
 squamous bone development 3124
 squamous cell carcinoma
 (SCC) 2398–9, 2398 *F*
 AIDS patients 246
 children 1259
 comparative genomic
 hybridization 6–7
 destructive treatment 2399
 environmental exposure 2398
 external auditory canal 3945
 FDG-PET imaging 686–91
 post-cricoid 686 *F*
 post-treatment neck
 assessment 690–1
 primary disease 686–7, 686 *F*
 recurrent/residual disease 687–90,
 690 *F*, 691 *F*
 staging 686–7
 subclinical disease 688 *F*, 689 *F*
 synchronous malignancies 687
 genetic predisposition 2398
- histopathological grading 2361
 ICD-0-3 morphology codes 2374–5,
 2375 *T*
 laryngeal 2600–2, 2601 *F*, 2608 *F*
 epidemiology 2602
 management 2609–18
 lip 2543
 lupus vulgaris *vs.* 1703
 metastasis 2399
 cervical lymphadenopathy 2703
 nasal 1705, 1705 *F*, 2420
 differential diagnosis 1705
 odontogenic keratocysts 1938–9
 p53 mutations 58
 paranasal sinuses 2420
 perineural spread 2399
 poorly differentiated tumour 2399
 premalignant conditions 2398
 recurrence 2399
 risk factors 2398
 salivary glands 2501, 2503
 recurrence rates 2511
 survival 2512–3
 salivary gland tumours,
 malignant 2501
 syndromes 2398
 temporal bone *see* temporal bone
 squamous cell carcinoma
 tonsils 1226
 treatment 2589
 tracheal 2602
 treatment 2398–9
 types 2398
- squamous cell carcinoma antigen
 2386 *T*
- squamous epithelium
 larynx 763
 replacement of ciliated
 epithelium 763
 nasal cavity 764
 nasopharynx 766
- squamous odontogenic tumour,
 jaw 1928
- Stafne's bone cyst 1927, 1927 *F*
- stage grouping, tumours 2361–2, 2361 *T*
- Stahl's bar deformity 970, 970 *F*
- stainless steel implants 119
- stance
 acute unilateral vestibular
 deafferentation 3223
 'bouncy' 3731
 observation 3731
 'tremulous' 3731
- standardized incidence ratio (SIR)
 cancer
- lung 2634
 oral cavity 2634
 pharynx 2634
 standardized uptake value (SUV),
 positron emission
 tomography 684–6, 1756
- Standard Nomenclature of Medicine
 and Clinical Terms (SNOMED
 CT) 2375
- Standards for better health 578
- stapedectomy
 bilateral audiogram 3827
 historical aspects 3468
 partial 3471–2
 postoperative sensorineural hearing
 damage 3475–6
 procedure 3472, 3473 *F*
 stapedotomy *vs.* 3477–8, 3478 *T*
 tympanosclerosis 3423
- stapedial tendon, ossified 872
- stapedius 3115
 acoustic reflex 3183, 3289
 facial nerve disorders 3870
 hearing 3183
- stapedius reflex thresholds, auditory
 neuropathy/dyssynchrony 3844
- stapedius tendon preservation 3479
- stapedotomy
 consent issues 600, 601
 hearing outcomes 3478–9
 equipment comparison 3478–9
 stapedectomy *vs.* 3477–8,
 3478 *T*
 medical negligence 1307
 postoperative sensorineural hearing
 damage 3475–6
 procedure 3471–2, 3472 *F*
 prosthesis selection 3471–2
- stapes
 anatomy 3115, 3115 *F*
 crus 3115
 footplate *see* stapes footplate
 mode of movement 3181
- stapes ankylosis
 associated deformities 872
 isolated 870 *T*, 871–2
- stapes footplate
 congenital fixation
 medical negligence 1307
 surgery 872
- floating 3474
 otosclerosis 3456
 'rice grain' 3474
- surgery, perioperative hazards
 3474–5

stapes mobilization 3472
 historical aspects 3468
 tympanosclerosis 3423

stapes piston *see* total ossicular replacement prosthesis (TORP)

stapes prostheses, historical aspects 3468

stapes surgery
 anaesthesia 3470–1
 general 3471
 local 3471

contraindications 3468–70

exposure 3471

hearing outcomes 3477–80
 connective tissue seals 3479
 prosthesis type 3479
 stapedius tendon preservation 3479
 technique comparisons 3477–9

incisions 3471

medical prophylaxis 3470

perioperative hazards 3473–5
 anatomical 3473–4
 comorbidities 3474
 ossicular problems 3474
 stapes footplate 3474–5
 surgical approach 3473

postoperative complications 3475–7
 incus necrosis 3475

prosthesis displacement 3475

revision 3473, 3479–80
 clinical indications 3473 *T*
 laser use 3479

sound transmission mechanism
 restoration 3471

suprastructure fixation 872

techniques 3470–3

tinnitus outcome 3480

tympanic membrane perforation 3473
see also individual procedures

staphylococci 196
 chronic rhinosinusitis 1441
 coagulase-negative 196–7
 coagulase test 196
 Gram stain 196
 growth conditions 196
 HIV-associated otitis media 240
 morphology 196
see also individual species

Staphylococcus aureus 196–7
 adult epiglottitis 2250
 blood agar cultures 196
 coagulase test 196
 facial infection 1700
 food poisoning 196
 furunculosis 3324

HIV-associated infection
 dermatological manifestations 248
 pinna 240

host-cell adhesion 196

infections caused 196

methicillin-resistant *see* methicillin-resistant *Staphylococcus aureus* (MRSA)

nasal infection 1700

perichondritis 3358

prevalence 196

rhinosinusitis
 chronic 1441, 1471
 HIV patients 241–2

sepsis 196

tonsil flora 1219–20

toxic shock syndrome 196

virulence factors 196

Staphylococcus epidermidis 196

Staphylococcus pneumoniae 1700

statistical heterogeneity 663

steady-state evoked potentials
 (SSEP) 3287–8

auditory neuropathy/
 dyssynchrony 3843–4

steady state responses (SSRs) 3280,
 3287–8

40 Hz AMEPs 3286 *F*, 3288

amplitude fluctuations 3288

frequency-specific sensitivity
 assessment 3291–2

neonatal hearing screening 3291

transient evoked potentials *vs.* 3288

Steele–Richardson syndrome 3939

steeple sign 1128, 1128 *F*

stem cell(s) 66–84
 activation
 adult tissue 67
 nerves and 70
 tissue repair 67

apoptosis 67–8

asymmetric division 67, 67–8

carcinogenetic potential 69–70

coculture 68

connexin expression 68

deafness treatment 818

differentiation 67, 67–8
 community effect 68
 specificity 68

embryonic development 68–9

embryonic origins 71

growth factors
 effects of 69
 production 71–2

growth signals, response to 69

haemopoietic *see* haemopoietic stem cells
 hierarchies 68–9

migration 71

mucosal malignant melanoma
 aetiology 2409

multipotency 69

neural *see* neural stem cells

niches 67

olfactory system 74–5

organ replacement 75

pluripotency 70

proliferation 67

properties 67, 76

purification 73–4

telomerase activity 70–1

therapeutic uses 66, 72–3
 embryonic stem cells 73–4
 genetic disorders 73, 75–6
 regeneration support 74–6

tissue/organ regeneration 69,
 72

adult teeth 75

cartilage 75

cochlear hair cells 75

mechanisms 72

neural stem cells 75
 skin 75

therapeutic intervention 72

tissue-specific committed 69

stem cell factor (SCF) 69

stem cell theory of cancer 69–70

Stemetil *see* prochlorperazine

Stemple's 'Voice Function Exercise Programme' 2225

Stenson's organ 1325–6

stent(s)

laryngotracheal reconstruction,
 children 1157–8, 1158 *F*

malignant dysphagia 2069

tracheobronchial 2279
see also individual types

step initiation impairment 3731

'stepping on the spot test' *see* Unterberger test

stereocilia

cochlear hair cells 3130, 3131 *F*, 3192
 tip links 3192, 3193 *F*

hearing impairment 20

membranes

ion channels 3133–4

transduction 3133–4

vestibular hair cells 3228, 3229 *F*
 tip links 3228, 3229 *F*

see also individual cell types

- stereotactic amygdalotomy, epilepsy-related olfactory dysfunction 1671
- sternal head 1745
- sternocleidomastoid 1745
- surface anatomy 1741
 - weakness, spinal accessory nerve lesions 3935
- sternohyoid 2135 *T*
- sternomastoid 3910
- vestibular-evoked myogenic potential 3751
- sternomastoid flap 2861–3, 2864 *F*
- sternothyroid 2135 *T*
- sternothyrolaryngeal triangle 2664, 2664 *F*
- steroids *see* corticosteroids
- stertor
- definition 1114
 - obstructive sleep apnoea 1104
- Stevens–Johnson syndrome 236, 2004, 2033–4
- Steven’s power law 3251–2
- STI 571, chronic myeloid leukaemia 275
- Stickler syndrome 813 *T*, 968
- ‘stimulated emission’ 742
- stimulus frequency otoacoustic emissions (SFOAEs) 3276–7
- Stokes method 234, 235 *F*
- stomatococci 196
- stomodeum 799, 799 *F*, 802 *F*, 1810–1, 1942, 1942 *F*
- pituitary gland development 295
- Stool, Sylvan 772
- Storz scopes 518, 518 *F*
- ‘stove-pipe’ microtrachea 1144
- strained (pressed) voice 2165
- strap muscles 1746
- ‘strawberry skin’ 1647–8, 1647 *F*
- streptococci 197–8
- Anginosus–Milleri group 198
 - classification 197
 - group A beta-haemolytic streptococci (GABHS) *see* Group A beta-haemolytic streptococci (GABHS)
 - group C 197
 - group G 197
 - morphology 197
 - oral (viridans) 195–6, 198
 - pyogenic 197
 - related species 197
 - see also individual species*
- streptococci, group A 197
- adult epiglottitis 2250
 - diseases caused 197
 - haemolysins 197
 - serotypes 197
- Streptococcus agalactiae* 197
- Streptococcus anginosus* 198
- Streptococcus constellatus* 198
- Streptococcus intermedius* 198
- Streptococcus milleri* 198
- Streptococcus pneumoniae* 197–8, 197 *F*
- acute otitis media 924
 - adult epiglottitis 2250
 - diseases caused 197–8
 - α-haemolysis 197–8, 198 *F*
 - HIV-associated otitis media 240
 - morphology 197–8
 - nasopharynx 2121
 - otitis-prone children 195–6
 - penicillin-resistant 197–8
 - prevention 197–8
 - rhinosinusitis 1441
 - acute 1080
 - chronic 1471
 - HIV-associated 241–2
 - sensitivity 197–8
 - vaccination 197–8, 919
- Streptococcus pyogenes* 197, 197 *F*
- diseases caused 197
 - facial infection 1700
 - nasal infection 1700
 - otitis-prone children 195–6
 - skin grafts 2821–2
- Streptococcus viridans* 1471
- streptogramins 232
- streptokinase 283
- streptomycin 232
- ototoxicity 3239, 3569, 3676
 - respiratory scleroma 1463
- stress
- adrenocorticotrophic hormone secretion 300
 - Menière’s disease 3798
 - tinnitus 3604 *F*, 3607
- stretch receptors, carotid artery 1749
- stria vascularis 3129 *F*, 3130, 3186
- stridor 1114–26, 2286–7
- acute laryngeal infections 1127, 2248–9
 - assessment 1115–23
 - associated features 1116–7, 1117 *T*, 1118
 - biphasic 1118, 2286
 - bronchoscopy 1122–3
 - characteristic sounds 1118
 - children 1114–26
 - examination 1118
 - feeding history 1117
- history 1116–7
- intensive care 544–5
- management 1114–5
- perinatal history 1116
- definition 1114
- differential diagnosis 1115 *T*, 1116 *T*, 1127
- endoscopy 1119–23
- expiratory 478, 2286
- extrathoracic obstruction 1118, 1118 *F*
- head and neck cancer palliative care 2795
- imaging 1119
 - inspiratory 2286
 - investigations, pre-endoscopy 1119
 - laryngeal cleft 1141–2
 - laryngeal stenosis 1151
 - laryngomalacia 1135
 - management 449
 - patterns 1116
 - periglottic/glottic obstruction 481–2
 - posterior glottic stenosis 1160–1
 - special needs children 787
 - tracheobronchomalacia 1145
 - tracheomalacia 1145
 - striola, saccule 3230
 - strip craniectomies, craniosynostosis 1027
 - strobovidéolaryngoscopy *see* videolaryngostroboscopy
 - stroke 3767–70, 3779
 - aetiology 3767–8, 3768 *F*
 - clinical manifestations 3768–9
 - complications 3770
 - definition 3767
 - diagnosis 2078, 3769
 - differential diagnosis 3769–70
 - dysphagia aetiology 2033
 - dysphagia management 2086
 - management 3770
 - neurological disorders, pharynx 2077–8
 - symptoms 2077
 - outcomes 3770
 - postoperative
 - carotid angiography 3951
 - permanent balloon occlusion 3951
 - prevention by endovascular embolization 735
 - sleep apnoeas 2314
 - taste abnormalities 1847, 1848 *F*
 - stroke volume, hypotensive anaesthesia 502
 - stromal cell-derived factor 1 α 71

stromal cells, bone marrow 266
 Sturge–Weber syndrome 1708
 stuttering 993–4
 Stycar test 841
 styloglossus 1797, 1797 *F*, 3904
 stylohyoid 1956–7, 2135 *T*, 3904
 stylohyoid ligament 3904
 stylohyoid syndrome 3533
 investigation 3533, 3533 *F*
 otalgia 3533
 presentation 3533
 surgery 3533
 styloid apparatus 3904
 styloid process, temporal bone 3900
 development 3124
 stylomandibular ligament 1810, 3904
 stylomastoid foramen 3904
 stylopharyngeus 1945 *F*, 1948 *T*, 1949 *F*,
 1950, 2135 *T*, 3904
 subacute necrotizing lymphadenitis
 (Kikuchi’s disease) 1217, 1784–5
 subacute necrotizing sialadenitis 1915
 subacute thyroiditis 331, 351–2, 352 *F*,
 720, 721
 disease course 352 *F*
 follicular destruction 352
 histology 352
 hypothyroidism 352
 imaging 335, 352, 721
 symptoms 351–2
 tests 351–2
 transient thyrotoxicosis 331
 treatment 352
 viral aetiology 352
 subarachnoid space 3914
 subcarinal lymph nodes 2143
 subclavian steal syndrome
 diagnosis 3769
 management 3770
 provoked vertigo aetiology 3767
 stroke aetiology 3768
 subclavian triangle, neck 1743
 subclinical hyperthyroidism 345, 353
 complications 353
 diagnosis 353
 treatment 353
 subclinical hypothyroidism 357–8
 aetiology 358
 autoimmune disease 358
 definition 357–8
 management 358
 pregnancy 359–60
 prevalence 357–8
 thyroid peroxidase antibodies 358
 subcupular meshwork 3228–30

subdermal haematoma, post-
 septoplasty 3092
 subdural abscess
 acute otitis media 924
 chronic otitis media 3404, 3405 *F*,
 3437, 3438
 subdural haematoma, syndromic
 craniosynostosis surgery 1031
 subdural space, optic nerve 3914
 subepithelial immune bullous diseases,
 oral manifestations 1834
 subepithelial tissue imaging
 limitations/problems 755
 OCT *see* optical coherence
 tomography (OCT)
 subglottic allergic oedema 1129
 subglottic cancer
 clinical presentations 2608–9
 laryngectomy 2602
 spread 2602, 2602 *T*
 TNM classification 2367 *T*
 subglottic haemangioma 1140–1,
 1140 *F*
 CO₂ laser vaporization 1140
 interferon alpha-2a 1141
 intralesional steroid injection 1141
 radiotherapy 1140
 submucosal excision 1141
 systemic steroids 1140
 tracheostomy 1140
 subglottic obstruction 483
 subglottic oedema
 acute 1129
 croup 1128, 2251
 subglottic pressure 2182
 subglottic reconstruction 1162–4
 repair techniques 1162–4
 see also individual procedures
 subglottic stenosis 2282
 acquired 1150
 acute laryngeal infections 1132
 congenital 1150
 gastro-oesophageal reflux 1273
 intubation 1170
 nasotracheal intubation-induced 1132
 surgery 1162–4
 subglottis
 anatomy 1135, 2132
 children 1151
 congenital disorders 1139–42
 subjective postural vertical 3738 *F*,
 3741
 subjective vertical testing 3737–40
 subjective visual horizontal (SVH)
 test 3752, 3754 *F*

subjective visual vertical (SVV) 3740–1,
 3741 *F*
 central vestibular lesions 3741
 hemisphere lesions 3741
 peripheral vestibular lesions 3741
 sublingual artery 1799
 sublingual ducts 1808
 sublingual folds 1793, 1808
 sublingual glands 1856–7
 anatomy 1793 *F*, 1808, 1856–7
 blood supply 1856–7
 embryogenesis 1852
 excretory ducts 1808
 imaging 1873 *F*
 innervation 1856–7
 salivary flow rates 1807
 tumours 2505
 sublingual immunotherapy (SLIT),
 allergic rhinitis 1084
 sublingual papilla 1793, 1793 *F*
 sublingual space 1758, 1796 *F*, 1806
 sublingual vein 1799
 submandibular duct 1796 *F*, 1797 *F*,
 1808, 1856
 ligation 789
 transposition, drooling 789
 submandibular ganglion 1808, 3929
 submandibular glands 1856
 anatomy 1796 *F*, 1808, 1856
 blood supply 1856
 capsule 1856
 embryogenesis 1852
 imaging 722–3, 1872, 1873 *F*
 calculi 723, 723 *F*, 724 *F*
 children 1297
 innervation 1801 *F*, 1808, 1856
 lymphatic drainage 1856
 resection 2487–9, 2489 *F*
 saliva collection 1863
 salivary flow rates 1807
 surfaces 1808, 1856
 swelling, children 1212
 venous drainage 1856
 submandibular gland tumours 2504–5
 adenoid cystic carcinoma 2504–5
 benign
 epidemiology 2475, 2476 *T*
 presentation 2477–8, 2477 *F*
 mucoepidermoid carcinoma 2504–5
 treatment 2487–9, 2489 *F*
 submandibular lymph nodes 1747, 1799
 submandibular space 1744, 1758–9,
 1805
 submandibular triangle, neck 1742,
 2742 *F*

- submasseteric spaces 1806
 submental island flaps 2850, 2852 *F*
 submental lymphatics 1747, 1799
 submental tissue space 1743, 1805
 submental triangle, neck 1741
 submersion reflex 1364
 submucosal glands, nasal
 polyposis 1552
 submucosal implants 2902, 2902 *T*
 submucosal resection (SMR) 1577
 epistaxis 1604
 medical negligence 1734
 septal perforation 1573–4
 see also septoplasty
 submucous cleft 1814
 suborbicularis oculi fat (SOOF) 3052
 lifting 3060–1, 3062 *F*
 subperichondrial abscess 3359
 subperichondrial cricoectomy,
 intractable aspiration 2100, 2101 *F*
 subperiosteal abscess (Pott's puffy
 tumour)
 frontal rhinosinusitis 1539
 children 1086
 orbital cellulitis 1540
 subperiosteal dissection 3060–1, 3062 *F*
 subperiosteal implants 2902–3, 2902 *T*
 substance P
 nose 1364
 type II vestibular hair cells 3237
 subtectorial space 3189–97
 subtotal glossectomy defects,
 reconstruction 2556, 2556 *F*
 subtotal laryngectomy, laryngeal
 tumours 2614
 subventricular zone (SVZ), stem
 cells 67
 succinic dehydrogenase, pregnancy 403
 succinyl choline 412
 suck-swallow exercise 2089 *T*
 sucralphate, malignant ulcers 2792–3
 suction, saliva collection 1862
 sudden sensorineural hearing loss
 (SSNHL) 3578–9, 3579–80
 active chronic otitis media 3436
 categorization 3580 *T*
 causes, postulated 3579 *T*, 3580 *T*,
 3582
 definitions 3578 *T*
 idiopathic *see* idiopathic sudden
 sensorineural hearing loss
 (ISSNHL)
 management 434
 sulcus terminalis 1794
 sulcus vergeture 2202, 2202 *F*, 2203
 sulcus vocalis 2202, 2202 *F*
 sulphamethoxazole-trimethoprim 1463
 sulphasalazine 1913
 sulphatide, skin flap survival 114
 sulphonamides 231
 allergic reactions 231
 resistance 235
 sumatriptan 3801–2, 3803 *T*
 summatting potential 3196, 3281
 sun exposure
 basal cell carcinoma 1705–6, 2395–6,
 2396
 lip cancer 2543
 squamous cell carcinoma 2398
 Superbass HC220 body-level aid 3642
 superficial musculo-aponeurotic system
 (SMAS) 3069, 3073 *F*, 3094
 superficial spreading melanoma 2401 *T*
 superglue, foreign body removal
 ear 1185
 nose 1186
 superior alveolar (dental) nerve 1801–2
 superior canaliculi 1690
 superior constrictor, pharynx 1945 *F*,
 1948 *T*, 1949 *F*, 2108–9, 2111
 lateral relations 1947–9, 1950 *F*
 superior dental (alveolar) nerve 1801–2
 superior flap pharyngoplasty 1012 *F*
 superior hiatus semilunaris 1332,
 1333 *F*
 superior hypophyseal arteries 297, 307
 superior labial vein 1799
 superior laryngeal artery 2139
 superior laryngeal nerve (SLN) 318,
 319 *F*, 2139, 2156, 2157 *F*, 2664,
 2664 *F*, 3935
 external branch 318–9, 2156, 2664,
 2664 *F*
 internal branch 2156
 local anaesthesia 2139
 superior laryngeal nerve block 480
 superior laryngeal veins 2140
 superior meatus 1335–6
 superior nuchal line 3898 *F*, 3899
 superior oblique muscle 3899
 superior olfactory complex 3141–2,
 3141 *F*
 sound localization 3141–2
 superior olivocochlear system 3602 *F*,
 3606
 superior parathyroid artery 317
 superior semicircular canal dehiscence
 (SCD) 3682–3, 3763–4
 aetiology 3682–3, 3763
 clinical manifestations 3682, 3763
 complications 3764
 definition 3763
 diagnosis 3763–4, 3765 *F*, 3766 *F*
 differential diagnosis 3764
 management 3764
 outcomes 3764
 superior semicircular canal dehiscence
 syndrome
 click-evoked vestibular myogenic
 potentials 3742
 middle fossa surgery 4023
 superior temporal quadrantanopia,
 pituitary tumours 304
 superior thyroid artery 317, 317 *F*, 372
 superior thyroid veins 317–8, 372–3
 superior tracheobronchial lymph
 nodes 2143
 superior vena caval obstruction
 (SVCO), tumours 2794–5
 superior vestibular nerve 3871, 3871 *F*
 superior vestibular nuclei (SVN) 3220
 supermarket syndrome *see* visual
 vertigo
 superoxide dismutase, skin flap
 survival 113
 super-supraglottic swallow, dysphagia
 management 2090, 2090 *T*
 suppurative labyrinthitis 923, 3403,
 3403 *F*
 suppurative meningogenic
 labyrinthitis 3692
 suppurative parotitis *see* suppurative
 sialadenitis, acute
 suppurative sialadenitis, acute 1901–2
 causative organisms 1902
 children 1243
 clinical features 1901–2, 1901 *F*
 complications 1902
 therapy 1902
 suppurative stomatitis
 glandularis 1915–6, 1916 *F*
 suprabullar recess 1333–4
 supracrlicoid laryngectomy with
 cricohyoidopexy 2614
 supraglottic airway devices (SAD)
 492
 supraglottic laryngectomy 504, 2613,
 2614 *F*
 supraglottic obstruction 479–81
 nerve blocks 480
 spontaneous respiration 481
 topical anaesthesia 480
 supraglottic stenosis 2281
 children 1159
 supraglottic swallow 2090, 2090 *T*

supraglottic tumours 2601–2
 clinical presentations 2608
 diagnostic delays 2603
 risk factors 2603
 spread 2602 *T*
 TNM classification 2366 *T*
 treatment 2610
supraglottis 1135, 2132
 congenital disorders 1135–7
 lymphatic drainage 2713–4
supraglottitis *see* epiglottitis
suprahyoid muscles 2135 *T*
supralaryngeal constriction, professional voice 2211–2
supraomohyoid neck dissection 2564,
 2564 *F*, 2738 *F*, 2747, 2747 *T*
 extended 2747, 2747 *T*, 2748 *F*
N1 disease 2726
 technique 2749
supraorbital nerve 3923
supraparamagnetic iron oxide (SPIO) 1761–2, 1762 *F*
Supraskin 100
suprasternal retraction, airway obstruction 2287
suprastomal granulation, tracheostomy-induced 1203–4
 removal 1204
supratrochlear nerve 3923
supreme turbinate 1336
sural nerve, facial reanimation 3080
surface electromyography (sEMG), dysphagia 1977
surface immunoglobulin (sIg) 135
surgical ciliated cysts 1926
surgical cricothyrotomy 477
surgical decompression, facial schwannoma 4083
surgical emphysema, tracheostomy-induced 2301–2
 children 1202–3
surgical negligence *see* medical negligence
surgical training 551–8
 appraisal and revalidation
 guidelines 556–8
 clinical care 556–7
 future directions 558
 working with colleagues 557–8
 communication skills 551–2, 553
 appraisal and revalidation
 guidelines 557
 continuing professional development 554–6
 accreditation 555–6
 applications review 556 *T*

categories 555, 556 *T*
 participation 556 *T*
 requirements 555, 556 *T*
 system review 556
 historic perspective 551, 552–3
UK 552–3
 apprenticeship model 552
Calman Report 553
 current 553
 curriculum development
 project 553, 554 *T*, 555 *T*
 future 553
 historic perspective 552–3
surveillance
 definition 821
 hearing loss 829–30
suspensions 448–9
suspensory ligament of Berry (lateral ligament of the thyroid) 316–7
suspensory ligament of Lockwood 1679
sustained vowels, voice evaluation 2172
sutectomy 1024
suture marks, litigation and 3090
sutures
 care of 102–3
 fibre scaffolds 124
swabs, retained during adenoidectomy 1098
swallow apnoea 1957, 1960, 1960 *F*
swallowing 1954–63, 2075
 age-related changes 1961
 airway protection 1955
 sphincteric mechanisms 1955
 disorders *see* dysphagia
 expiration 1960
 future research 1961
 glossopharyngeal nerve lesions 3937
 kinematics 1967
 knowledge deficiencies 1961
 multiple, post-bolus 1958
 neural control 1958–9
 feedback regulation 1958
 oesophageal phase 1958–9
 reflex activity 1958
 voluntary control 1958
 oesophageal phase 1958, 2076
 oral phase 1956–7, 2075, 2159
 preparatory 1956
 proper 1956–7
 pharyngeal phase 1957–8, 2075,
 2159
 neural control 1958–9
 reflex 1956
 physiology 1954–63, 1964
 post-oesophageal atresia repair 1287

respiration and 1959–61, 1960 *F*
 continuous *vs.* single swallows 1961
 monitoring problems 1960
 phase 1960
 research problems 1960
 sequence of events 1956–8, 1956 *F*
 timing 1956
 structures involved 1954–5, 1955 *F*
 thyroid movements 316–7
 videofluoroscopy 2076
swallowing manoeuvres, dysphagia 2089–90, 2090 *T*
sway platforms 3732–3
Swedish nose 1197–8, 1198 *F*
swimming
 chronic otitis media 936, 937
 otitis media with effusion 901–2
Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) 1386–7
Sydenham's chorea 3939
sympathetic nervous system
 nasal innervation 1363
 parathyroid gland innervation 318–9
 skin flap innervation 112
 thyroid gland innervation 319
sympathetic neurotransmitters, nose and 1364
sympathetic ophthalmitis 1732
sympathomimetics, effects on nasal vasculature 1365, 1365 *T*
synaptic ribbons, inner hair cells 3136
syncope, parapharyngeal space tumours 2529
syndrome of inappropriate antidiuretic hormone (SIADH), pituitary surgery-induced 308, 4112
syndromic cleft lip 1000
syndromic deafness
 definition 811
 genetic causes 18, 845
synechiae, nasal cavity 1344–6, 1346 *F*
synkinesis, Bell's palsy 1845, 3931
synostoses
 anterior 1025
 coronal *see* coronal synostosis
 lambdoid *see* lambdoid synostosis
 metopic 1022 *T*, 1025–6
 sagittal *see* scaphocephaly
 surgery 1025–6, 1026 *F*
synovial sarcoma
 children 1259 *T*
 larynx 2604
synthetic nasal implants 2971
synthetic oxygen carriers 263–4

- syphilis
 children 1216
 congenital *see* congenital syphilis
 dental defects 1818
 diagnosis 2008
 hereditary *see* congenital syphilis
 HIV infection/AIDS 2007
 laryngeal 2267
 mouth ulcers 1833
 nasal 1460–2, 1703
 clinical features 1460–2
 pharyngeal 2007–8
 primary 2007
 diagnosis 1461
 nasal manifestations 1460–1
 secondary 2007
 diagnosis 1461
 nasal 1461, 1703
 serological tests 2008
 sudden sensorineural hearing loss 3582
 tertiary 2007
 diagnosis 1461–2
 nasal manifestations 1461–2,
 1461 *F*
 symptoms 1461
 tonsil 1225
 treatment 1462, 2008
see also *Treponema pallidum*
 syphilis enzyme immunoassay 202
 syringing *see* ear syringing
 syringobulbia 2080
 syringomyelia 2080
 syrups 448–9
 systematic reviews
 binary data 663
 critical appraisal 649, 650, 661–5,
 671 *F*
 see also evidence-based medicine
 odds ratio 663–4
 Quorom statement 650
 sources 662
 validity 662–3
 systemic inflammatory response syndrome (SIRS) 534–5
 systemic lupus erythematosus (SLE) 186, 1712
 diagnosis 1712
 dysphagia 2031
 malar rash 1712, 1712 *F*
 nasal 188, 1712
 septal perforations 1584
 thrombotic thrombocytopaenia 286
 systemic sclerosis 1712–3
- T1 root lesions, Horner's syndrome 3937
 T2 relaxation time 676
 'T3 toxicosis' 340
 T₄-binding prealbumin 323
 tabetic gait 3731
 tachypnoea
 capnograms 499 *F*
 stridor 1116–7
 tamoxifen 4042
 TANIS score 2369
 tannins, taste thresholds 1841
 Tapia's syndrome 3938
 Taprosten 1, 3588
 Taq polymerase 7
 target controlled infusion (TCI) devices 480
 TARGET study
 adenoidectomy 897, 1095
 otitis media with effusion 825, 890
 ventilation tubes 897
 targeted therapies
 cancer treatment 52–3
 epidermal growth factor receptor 52
 monoclonal antibodies 52
 tyrosine kinase receptor 52
 tarsus, lower eyelid 3051
 tartrazine 1427
 taste
 anatomical structures 1841–2
 central pathways 3929
 mechanisms 3929–30
 peripheral pathways 3929–30, 3930 *F*
 physiology 1841–2
 saliva, role in 1841
 taste abnormalities 1840–51
 associated conditions 1843
 causes 1844–8
 classification 1842–3
 clinical assessment 1843–4
 clinical presentation 1840
 diabetes 1845–6
 epilepsy 1846
 glossopharyngeal nerve lesions 3937
 hypertension 1840
 hypothyroidism 1846
 iatrogenic causes 1846–7
 imaging 1843–4
 management 1848–9
 medication-induced 1847
 patient examination 1843–4
 patient history 1843
 perception alteration 1843
 post-stapes surgery 3477
 prevalence 1840
- quantitative testing 1844
 regional taste deficits 1844
 spontaneous resolution 1848
 stroke 1847, 1848 *F*
 trauma-induced 1846
 treatment 1848–9
 taste buds 1841, 3929, 3930 *F*
 anatomy 1841
 innervation 1841, 3929
 life span 3929
 location 1841
 maintenance, saliva 1841
 receptor cells 3929
 replacement 70
 ultrastructural appearance 1841
 taste pit 1841
 taste pore 1841
 taste-salivary reflex, Bell's palsy 1845
 taxanes 52, 2760–1
 taxoids 39
 head and neck cancer 40
 mechanism of action 39
 taxol (paclitaxel) 39, 2761
 taxotere (docetaxel) 39, 2761
 T cell(s)
 allergic response 149–51
 allergic rhinitis 1391
 antigen presentation 136–7, 136 *F*
 disorders 175 *T*
 nasal mucus 1361
 TCOF1 gene mutations 1034
 T cytotoxic (Tc) cells 136
 apoptosis 137
 TdT-mediated nick end labelling (TUNEL) 61
 tear film assessment,
 blepharoplasty 3055
 tearing, excessive *see* epiphora
^{99m}technetium-based radionuclide scans
 cervical lymph node metastases 1762
 malignant otitis externa 3338, 3338 *F*
 parathyroid imaging 383
 thyroid cancer 334, 694
 tectorial membrane 3127, 3128 *F*
 teeth 1803–5
 blood supply 1798
 decalcification 1816
 decay *see* dental caries
 deciduous 1804–5
 chronology 1805, 1805 *T*
 development 75, 799–801, 1922, 1924 *F*
 discoloration 1817, 1818 *F*, 1818 *T*
 diseases *see* dental disease
 disorders 1816–7
 eruption 1805, 1806 *F*, 1807 *F*

- teeth (*continued*)
 eruption disorders 1817–8
 premature eruption 1817
 retarded eruption 1817
 extractions, taste
 abnormalities 1846–7
 innervation 1801–2, 1802 *T*
 loosening 1818, 1819 *T*, 1820–1
 periodontitis 1820
 loss, maxillary arch changes
 2907–8
 lymphatic drainage 1799
 malformation 1817, 1818 *F*
 maxillary rhinosinusitis 1540
 missing 1817
 natal 1817
 neonatal 1817
 peg-shaped 1817, 1818 *F*
 permanent 1803–4, 1804 *F*
 chronology 1805, 1806 *T*
 premature loss 1818, 1819 *T*
 replacement, osseointegration
 2905
 supernumerary 1817
 tissue regeneration 75
 venous drainage 1799
see also entries beginning dental; individual types
 teething 1817
 Teflon 121
 vocal fold paralysis 121–2, 2239,
 2245 *T*
 tegmen defects, middle fossa
 surgery 4023, 4023 *F*
 tecoplanin 230
 telangiectasia
 gingival bleeding 1819 *T*
 gingival redness 1820
 oral mucosal redness 1822
 telephones, hearing impaired
 user 3668–9
 amplified handset 3668
 fixed, problems of 3668
 text 3669
 video 3668
 telomerase 10
 embryogenesis 71
 oral cavity tumours 10
 oral leukoplakia 10
 stem cells 70–1
 telomeres 3–4, 2379
 temazepam 2795
 temperature, anaesthesia
 monitoring 498
 temporal arteritis 1723
 temporal bone 3900
 autoimmune inner ear disease 3680
 child 1054 *F*
 CPA lesions originating from 4015
 development 808, 3124
 imaging, cholesteatoma 951, 951 *T*
 imaging, cochlear implants
 assessment 3651
 lateral skull base 3900
 necrosis and sequestration *see benign*
 necrotizing otitis externa
 neonatal 1053 *F*
 osseointegration 2908–9
 otalgia 3528
 Paget's disease 3487
 parts 3900
 petromastoid 3900
 petrous portion 2110
 osteoradionecrosis 3376, 3377 *F*
 resorption, vestibular
 schwannoma 3957–8
 squamous 3900
 studies 3701
 tuberculosis *see* tuberculous otitis
 vertigo, children 1046
 temporal bone fractures
 external auditory canal
 lacerations 3496
 facial nerve palsy 3497–8
 children 1057
 imaging 3882–3, 3883 *F*
 labyrinth injury 3497
 longitudinal 1057
 ossicular disruption 3496–7
 prophylactic antibiotics 3496
 radiology 3495
 taste abnormalities 1846
 tympanic membrane perforation
 3496
 vestibular labyrinth damage 3681–2,
 3682 *F*
 vestibular vascular injury 3699
 temporal bone
 osteoradionecrosis 3376–8
 aetiology 3376
 clinical picture 3377, 3377 *F*
 definition 3376
 diagnosis 3377
 diffuse necrosis 3378
 incidence 3376
 localized necrosis 3377–8
 management options 3377
 natural history 3377
 outcomes 3377
 pathogenesis 3376
 pathology 3377
 risk reduction techniques 3376
 temporal bone resection
 en bloc 4093 *F*
 efficacy 4091
 survival rate 4091, 4095
 extended 4092–3
 lateral 4093 *F*
 post-resectional
 reconstruction 4093–4
 free flaps 4093, 4094
 patient history 4093
 pedicled flaps 4093
 surgical criteria 4093
 techniques 4093
 temporal bone squamous cell
 carcinoma 4086–97
 aetiological theories 4087
 audiometry 4090
 chemotherapy 4094
 clinical features 4087–8
 diagnosis 4088–90
 differential diagnosis 4089
 epidemiology 4086–7
 examination 4089
 histology 4089, 4089 *F*
 historical aspects 4086
 history 4088, 4089 *T*
 imaging 4090
 investigations 4088–90
 metastases 4087, 4091
 palliative care 4095
 prognosis 4095–6, 4095 *F*
 carotid involvement 4095–6
 cerebral involvement 4095
 dural involvement 4095
 surgical margins 4095
 tumour differentiation 4095
 quality of life 4096
 radiation-induced 4068, 4087–8
 radiotherapy 4094
 spread 4087, 4088 *F*
 staging 4090–1, 4090 *T*, 4091 *T*
 surgical anatomy 4087–8
 surgical management
 complications 4094
 neck 4091
 postoperative appearance 4094 *F*
 primary site 4091–2
 survival rates 4095
 treatment 4091–5
 outcomes 4095–6
 temporal bone trauma 3494
 cerebrospinal fluid leak 3498
 classification 3494

- clinical features 3494–5
definition 3494
diagnosis 3494–6
epidemiology 3494
facial nerve involvement 3496, 3888,
 3889 *F*
hearing assessment 3495
investigations 3495–6
management 3496–8
vestibular assessment 3495–6
- temporal bone tumours 4067–77
 children 4074–5
 chronic suppurative otitis media 4068
 classification 4070 *T*
 clinical evaluation 4068–9
 genetic 4067–8
 head and neck examination 3945
 investigation 4069
 management 4069–74
 presentation 4068–9
 progression 4068–9
 radiation-induced 4068
 risk factors 4067–8
 secondary tumours 4073–4
 clinical presentation 4074
 prognosis 4074
 sites of origin 4074 *T*
 treatment 4074
 staging 4069
 vestibular schwannoma 3962–3
 resorption 3957–8
 see also individual types
- temporal coding 3197 *F*, 3235
temporal gaps
 cochlear hearing loss 3256
 detection experiments 3254
 thresholds 3254
- temporalis fascia grafts (TGF) 983
temporalis muscle 3910
temporal lobe injury, vestibular
 schwannoma removal 3979
temporal modulation transfer function
 (TMTF) 3254, 3254 *F*
 cochlear hearing loss 3257
- temporal paragangliomas, diagnostic
 delay 4145
- temporal resolution, ear 3254
 assessment 3254, 3256
 cochlear hearing loss 3256–7
 sensation levels 3256
- temporal theory, pitch perception
 3252
- temporary threshold shift (TTS) 3298,
 3548
- temporary tracheostomy 2292–3
- temporomandibular disorder (TMD)
 clinical features 3529
 comorbidity 3530
 Costen's syndrome 3530
 management 3530
- temporomandibular joint
 (TMJ) 1808–10, 1809 *F*
 articular disc (meniscus) 1809–10
 attachments 1809
 central (intermediate) zone
 1809
 retrodisclal tissue 1809
 bones 1808–9
 condylar cartilage 1810
 facial pain 1721
 innervation 1810
 joint capsule 1809
 ligaments 1810
 accessory 1810
 movements 1808–9
 otalgia 3529–30
 rheumatological diseases 184
 somatosounds 3600
 synovial fluid 1809
 synovial membrane 1809
 vascular supply 1810
- temporomandibular (lateral)
 ligament 1810
- temporoparietal fascia
 flaps 2851–3, 2852 *F*, 2853 *F*
 hair problems 3045
 pinna reconstruction 3042–4, 3043
- temporoparietal fascial flaps 2851–3,
 2852 *F*, 2853 *F*
- Tenon's capsule 1679
- Tensilon test, myasthenia gravis 2077
- tension nose
 definition 2966
 external rhinoplasty 2966
- tension pneumothorax 1767
 paediatric tracheostomy 1201
- tension-type headache 1724–5,
 1725 *F*
- tensor palati 1946 *T*, 2112, 2112 *F*,
 3908–9
 Eustachian tube 3118
 sleep 2308–9
- tensor tympani
 anatomy 3115
 development 3122
 hearing 3183
 myogenic somatosounds 3600
 reflex arc 3183
- X nerve *see* vagus nerve (X)
- tentorium cerebelli 298–9
- teratoma(s)
 airway compromise 1147
 malignant 1259
 nasopharyngeal 2119
 ultrasound 724
- terfenadine
 allergic rhinitis 1397–8
 drug interactions 411
- terminal deoxynucleotidyl transferase
 (TdT) 61
- terminal duct carcinoma, salivary
 glands 2500
- terminal nerve (CN0) 1662
- tertiary olfactory cortex 3912–3
- Tertroxin (liothyronine sodium) 450
- Tessier classification, craniofacial
 clefts 802 *F*, 997
- testosterone, salivary assay 1867–8
- test sensitivity 822–3
- tetracycline(s) 231
 adverse effects 231
 contraindications 231
 respiratory scleroma 1463
 tooth discolouration 1817
- 3,5,3',5'-tetraiodothyronine *see*
 thyroxine (T₄)
- tetranucleotide 5
- tetrofosmin radionuclide scans
 parathyroid imaging 383
 thyroid cancer 334
- text systems 3669
- tezosentan 113
- Th1 cells
 allergic response 149–50, 151
 interferon-gamma 137
- Th2 cells, allergic response 149–50,
 151, 152 *F*
- thalamic nuclei lesions, eye movement
 defects 3921
- thalamic taste nucleus (TTN) 1842
- thalassaemias 271–2
 causes 271
 HbH disease 271
 iron overload 262, 271–2
- α thalassaemias 271
- β thalassaemias 271–2
- thalidomide
 jugular foramen meningiomas
 4042
 recurrent aphthous stomatitis 242,
 1830–1
- thalidomide tragedy 408
- ²⁰¹thallium radionuclide scans
 parathyroid imaging 383
 thyroid cancer 334

- The clinical use of red cell transfusion* 255–6
- 'the neglected cranial nerve' *see* glossopharyngeal nerve
- Therabite system, dysphagia management 2088
- therapeutic index, drugs 412, 412 *F*
- therapeutic range, drugs 411
- thermal ablation, snoring 2330
- thermal imaging, wound assessment 100
- thermo-tactile stimulation, dysphagia 2087
- Thermus aquaticus* 7
- thioguanine 38
- thionamides 346, 450
‘block and replace’ regimen
Graves’ disease 347
pregnancy 347
side effects 347
- dosage regimen 346
- Graves’ disease 346–7, 347
- hypothyroidism 450
- side effects 450
- thyrotoxicosis 346 *T*
- toxic adenoma 347
- toxic multinodular goitre 347
- third branchial fistulae 1779
- third degree burns 96
- IIIrd nerve *see* oculomotor nerve (III)
- thoracic lymphatic duct 1750
- Thornwaldt’s bursa 2122
- Thornwaldt’s cyst 1074, 2122
- 3D computer-generated models extra-oral prostheses construction 2930
- facial reconstructive methods 2941
- prosthetic reconstruction 2941
- 3D conformal radiotherapy 2759, 2759 *F*
- 3D laser facial scanning, deviated nose 2988
- 3D planning and reconstruction 701–10 CT data 701, 702 *F*
- image data visualization 703–4
- image reconstruction 703 pixels 703
- slices, concepts of 703
- surgical planning 704
- surgical simulation 704–5 voxels 703
- throat infections, mycotic 223–5
- throat lozenges 448
- throat pastilles 448
- throat swabs, diphtheria 2253
- thrombin 279
- thrombin time (TT) 280
- thrombocytopenia autoimmune *see* idiopathic thrombocytopenic purpura causes 259 epistaxis, children 1067 post-blood transfusion 262
- thrombocytosis 275–6, 276 *T*
- thrombophilias acquired 290 inherited 290 investigations 289 perioperative management 289
- thrombosis jugular foramen lesions 4028 pathogenesis 290
- thrombotic disorders 288–90 perioperative management 289 heparin 290
- thrombotic episode management 288–9
- thrombotic microangiopathies 286
- thrombotic thrombocytopaenia purpura (TTP) 286–7
- clinical manifestations 286
- diagnosis 286
- platelet transfusion contraindication 260 treatment 287
- thromboxane A₂ (TXA₂) 278
- ‘thumb sign’ 1131, 1131 *F*, 2250
- thymine 3
- thymoma(s) airway compromise 1147 myasthenia gravis 172
- thymus, ectopic tissue 727
- thyroarytenoid 2136 *T*
- thyroepiglotticus 2136 *T*
- thyroglobulin 327 autoantibodies 335, 343 degradation 323 iodification 322
- thyroglossal duct cysts 1268, 1777–8 clinical features 1268, 1268 *F*, 1778, 1778 *F*
- embryology 314–5, 805, 1268, 1778 investigation 1268 management 1778–9 pathology 1778 sites 806 *F*
- surgical treatment 1778 recurrent cysts 1778 treatment 1268 ultrasound examination 724, 725 *F*
- thyroglossal duct disorders 1268
- thyroglossal duct fistula embryology 1268 presentation 1268, 1268 *F* treatment 1268
- thyrohyoid ligament, lateral 2133–4
- thyrohyoid membrane 2133–4
- laryngeal trauma 2271–2
- thyrohyoid muscle 1803, 2135 *T*
- thyroid ala grafts, laryngeal reconstruction 1156, 1162
- thyroid artery inferior 317, 372 superior 317, 317 *F*, 372
- thyroid autoantibodies, Graves disease 343
- thyroid cancer 2663–701 anaplastic tumours 2673 *T*, 2675 treatment 2688 ultrasound 720 children 1256–7, 2693 classification 719, 2672 *T*, 2679, 2679 *T* systems comparison 2682 *T* WHO 2673 *T*
- clinical assessment 2675–8
- dietary iodine consumption 2671
- differentiated long-term follow-up 2697 recurrence 2696, 2697 *F* risk groups 2684 *T* surgical treatment 2685 *T* treatment failure 2685 *F*
- examination 2675–6, 2676 *T*
- family history 2671
- follicular carcinoma 331, 2673 *T*, 2674 imaging 719–20, 2677 *F* treatment 2686
- follow-up, long-term 2697
- histopathological types 2366
- history 2675
- imaging 2676–8, 2677 *F*, 2678 *F* *see also individual techniques*
- incidence 2663, 2668–9, 2672 *F*, 2683
- laboratory investigations 2678–9 cytology 2678–9, 2679 *F*, 2679 *T*
- literature, problems with 2663–4
- lymphoma *see* thyroid lymphoma
- medullary *see* medullary thyroid carcinoma (MTC)
- molecular genetics 2669–75
- mortality rates 2666, 2694 *F*
- N stage definition 2364, 2364 *T*
- occurrence 330, 719
- outcome measurements 2697–8

- papillary *see* papillary thyroid cancer (PTC)
 pre-existing thyroid disease and 2671
 prognosis 2679, 2679 *T*, 2680 *F*,
 2682 *T*, 2683
 radiation-induced 2670–1
 radiology 2676–8
 radiotherapy 2693–6, 2694 *F*
 external beam 2696
 serum thyroglobulin
 measurements 2695–6
 side effects 2695 *T*
 recurrence 2696–7, 2697 *F*
 research areas 2698–9
 staging 2679–82, 2680 *T*, 2681 *T*,
 2682 *T*
 histological types 2681–2
 surgical pathology 2671–2
 surgical techniques 2688, 2688 *F*,
 2689 *T*
 see also specific operations
 thyroglossal cyst 1778–9
 thyrotoxicosis and 331
 TNM classification 2362 *T*, 2366,
 2368 *T*, 2680 *T*, 2681 *T*
 treatment
 complex problems 2693
 controversies 2683
 failure, incidences and
 patterns 2685 *F*
 guidelines 2685 *T*
 policy 2682–93, 2683 *T*
 tumour suppressor genes 2670
 thyroid cartilage 2132–3, 2137 *F*
 development 2130
 inferior cornu 2132
 laryngeal framework surgery 2241–2,
 2242 *F*
 pubertal changes 2205
 superior cornu 2132
 surface anatomy 1740
 trauma 2272
 thyroid disease
 aetiology 327–8
 apoptosis 62
 developmental disorders 330
 imaging studies 332
 in vitro investigations 332
 diffuse changes 330, 720–1,
 721 *F*
 diffuse goitre with abnormal
 function 331
 diffuse goitre with normal
 function 330
 in vitro investigations 332
- drug therapy 450–1
 dysphagia aetiology 2035
 functional disorders 330, 331–2
 head and neck
 manifestations 399–401
 hormonal preparations 450
 hyperthyroidism *see* hyperthyroidism
 hypothyroidism *see* hypothyroidism
 investigations *see* thyroid gland,
 functional tests/imaging
 malignant *see* thyroid cancer
 pathology 330–2
 pregnancy 358–60
 structural disorders
 with abnormal function 331–2
 diffuse goitre 330
 goitrous *see* goitre
 imaging studies 332–4
 nodular *see* nodular thyroid
 disease
 nodular goitre 330–1
 nodular vs. diffuse 718
 with normal function 330–1
 see also individual diseases; specific conditions
 thyroidea ima artery 372
 thyroidectomy
 complications 351, 2684 *T*, 2692–3
 accessory nerve damage 2808
 haematoma 351
 recurrent laryngeal nerve
 damage 2692
 hypothyroidism induction 356
 indications 349, 349 *T*
 parathyroid gland injury 351
 preparations 349–51
 surgical personnel issues 2693
 surgical preparations 349–51
 technique 2690 *F*
 thyroid cancer treatment 2683,
 2683 *T*, 2691
 hypoparathyroidism
 incidence 2683, 2684 *T*
 vocal fold paralysis incidence 2683,
 2684 *T*
 thyroid hormone replacement 356
 thyroid exophthalmos 344, 3915–6
 thyroid eye disease 343–4, 344 *F*, 345 *F*
 clinical features 344
 colour vision 344
 CT imaging, ‘Coca Cola’ bottle
 sign 1680 *F*
 exophthalmos 344
 imaging 344, 344 *F*
 orbital effects 1679
- phases 344
 radioiodine therapy 349
 signs 344–5
 therapy 1680
 medical 1680
 orbital decompression *see* orbital decompression
 transconjunctival fat excision 3063 *F*
 treatment 345
 visual acuity 344
 thyroid follicles 319
 connective tissue 320
 destruction
 radioiodine therapy 348
 subacute thyroiditis 352
 fibroblasts 320
 thyroid functioning tests (TFTs) *see* thyroid gland, functional tests/imaging
 thyroid gland 314–26
 anatomy 314–21, 327, 2664 *F*, 2665 *F*
 intrathyroidal parathyroid glands 722
 macroscopic 316–9, 316 *F*
 microscopic 319–21
 ultrasound examination 718
 arterial supply 317, 317 *F*, 2664–5,
 2664 *T*
 assessment *see* thyroid gland,
 functional tests/imaging
 benign enlargement 2671
 current knowledge deficiencies 324
 disease *see* thyroid disease
 ectopic tissue 314–5
 embryology 314–5, 327–8, 805
 lateral anlage 315, 316 *F*, 368
 fascia 316–7
 follicular cells 319, 320 *F*, 327
 development 316 *F*
 enlargement 319–20
 microvilli 319–20
 reabsorption lacunae 319–20
 function 327–8
 future research 324
 historical aspects 315 *T*
 hormones *see* thyroid hormones
 innervation 318–9
 autonomic control 319
 iodine deficiency 356–7
 iodine trapping 321–2
 isthmus 316
 lingual *see* lingual thyroid
 lobes 316
 lateral 315, 368, 368 *F*
 lobules 319

thyroid gland (*continued*)
 lymphatic drainage 318, 318 *F*, 2666,
 2666 *T*
 mal descent 314–5, 330, 332
 maldevelopment 330
 median anlage 314–5, 316 *F*
 neuropeptides 319
 nonmalignant disease 338–66
 eurythyroid conditions 360–3
 nuclear medicine
 assessment 1299–300, 1300 *F*
 parafollicular cells *see* parafollicular
 (C) cells, thyroid gland
 physiology 321–4, 321 *F*
 iodine 321
 metabolism regulation 321
 selenium 321
 pyramidal lobe 316, 316 *F*
 surface anatomy 1741
 surgery 349 *T*
 surgical anatomy 2664–6, 2664 *F*,
 2664 *T*, 2665 *F*
 tumours *see* thyroid cancer
 venous drainage 317–8, 2664–5,
 2664 *T*
 thyroid gland, functional tests/
 imaging 327–37, 340 *T*
 imaging 328, 332
 developmental disorders 332
 hypothyroidism 335–6
 structural disorders 332–4
 with abnormal function 335
 nodular changes 332–4
 thyrotoxicosis 335
see also specific imaging techniques
in vitro tests 328, 328 *T*, 332, 334–5
 nodular thyroid disease 361
 palpation *vs.* 330, 332
 patterns 340 *T*
 subacute thyroiditis 352
 subclinical hyperthyroidism 353
 developmental abnormalities 332
 diffuse changes 332
 free T3/T4 levels 328
 Grave's disease 334–5
 nodular changes 332
 thyroid hormones 321
 biosynthesis 322 *F*
 deactivation 324
 intracellular effects 323–4
 metabolism 323–4
 replacement
 administration 357
 monitoring 357
 pharmacology 357

secretion 322–3, 322 *F*
 colloid droplets 322–3
 endosomes 322–3
 serum levels 323, 323 *T*
 transport proteins 323
 functions 323
see also individual hormones
 thyroid hormone suppressive
 therapy 363
 'block and replace' 347
 thyroid incidentalomas 363
 thyroid inferno (storm) *see* thyroid
 storm
 thyroiditis 351–3
 acute suppurative 720
autoimmune *see* autoimmune
 thyroiditis
 chronic lymphocytic *see* Hashimoto's
 thyroiditis
 classification 351, 352 *T*
 De Quervain's *see* subacute thyroiditis
 giant cell *see* subacute thyroiditis
 granulomatous *see* subacute
 thyroiditis
 Hashimoto's *see* Hashimoto's
 thyroiditis
 imaging 335
 radionuclide scans 335
 ultrasound examination 720, 721,
 721 *F*
 painless 352–3
 subacute *see* subacute thyroiditis
see also specific types
 thyroid lobectomy 2688–92
 gland mobilization 2689
 gland removal 2690–1
 incision 2688–9
 parathyroid gland localization and
 preservation 2689, 2690 *F*
 recurrent laryngeal nerve
 identification 2689
 thyroid vein division 2689 *F*
 upper/lower poles
 mobilization 2689–90, 2690 *F*
 thyroid lymphoma 720, 2673 *T*, 2675,
 2687–8
 aetiology 2671
 Hashimoto's thyroiditis and 331–2,
 336
 primary 720
 staging 2687, 2688 *T*
 treatment 2688
 thyroid peroxidase (TPO) 322
 autoantibodies 335, 343
 thyroid releasing hormone (TRH) 327

thyroid stimulating hormone (TSH) 327
 goitre aetiology 2668
 G-protein mediation 2670
in vitro tests 328, 328 *T*, 332, 334–5
 recombinant 2696
 thyrotoxicosis 339–40
 TSHomas *see* TSHomas
 thyroid stimulating hormone receptor
 (TSHR) 341–2
 thyroid stimulating hormone secreting
 adenomas *see* TSHomas
 thyroid storm 335, 339, 349–51
 clinical features 350 *T*
 management 350 *T*
 thyroid veins 317–8, 372–3
 thyromental distance 470, 470 *F*
 thyropharyngeus muscle 1947, 1948 *T*
 pharyngeal pouch 2045
 thyroplasty
 medialization 1171
 type I 2097, 2241–2
 thyrotoxicosis 338–51
aetiology/pathology
 multiple toxic nodules 331
 solitary toxic nodule 331, 335
 toxic nodular goitre 335
 TSHomas 4102
 atrial fibrillation 339
autoimmune (Grave's disease)
see Grave's disease
 cardiovascular manifestations 339
 clinical manifestations 338–9, 400
 definition 338
 epidemiology 338
 Graves' disease *see* Graves' disease
 imaging studies 335
 investigations 339–40, 340 *T*
 iodine-induced 335
 ocular manifestations 400
 prevalence 338
 primary 338
 proximal myopathy 339
 scintigraphy 340, 340 *T*, 341
 secondary 338
 serum TSH levels 340
 signs 339, 339 *T*
 surgery 346 *T*, 349–51
 complications 351
 preparations 349–51
 symptoms 338–9
 thyroxine 338
 transient 331, 351–3
 treatment 346–51, 346 *T*
 drug 346–9
 medical 346

- triiodothyronine 338
 vocal manifestations 400–1
see also specific types/causes
- thyrotrophs 297
 thyrotropin 301
 effects 301
 half-life 301
 hyperthyroidism 301
 hypothyroidism 301
 iodine uptake regulation 321–2
 secretion control 301, 321
 serum levels 301, 323 *T*
 structure 301
- thyrotropin-releasing hormone (TRH) 300, 321
- thyroxine (T_4) 327
 foetal secretion 314
 function 321
 in vitro tests 328, 328 *T*, 334–5
 nose, effects on 1366
 Pendred's syndrome 2667–8
 secretion 322–3
 serum levels 323 *T*
 thyrotoxicosis 338, 340
 transport proteins 323
- thyroxine-binding protein (TBG) 323
- thyroxine (T_4) therapy 450–1
 absorption 357
 cardiac disease 357
 dosage 357
 elderly 357
 pregnancy 357
 half-life 357
 hypoadrenalinism 357
 poor compliance 357
 triiodothyronine therapy *vs.* 357
- tic douloureux of the nervus intermedius *see* geniculate neuralgia
- tidal volume, anaesthesia monitoring 498
- Tietze's syndrome 190
- timbre
 definition 3253–4
 dull 3254
 mellow 3254
 perception 3253–4
 sharp 3254
 sound properties 3253–4
 vocal tract dimensions 2166
 voice perception 2174
- TIMP hypopharyngeal cancer 2637
- tinea interclinoidea 298
- Tinel sign, sural nerve graft 3080
- tinnitus 3594–628
 aetiology 3598–600, 3599 *T*
 age-related sensorineurial hearing impairment 3544, 3545
 animal studies 3600
 auditory assessment 3610
 auditory control areas 3602
 children 3609
 aetiology 3609
 management 3609
 prevalence 3609
 definitions 3595
 depression 3598, 3608
 ‘echoing’ 3604, 3605 *F*
 epidemiology 3597–8
 associated conditions 3598
 demographic features 3598
 socioeconomic status 3598
 typical patients 3598
 functional imaging 3613
 genetics 3606
 grading systems 3613
 habituation 3601–2, 3607–8
 hearing impairment and 3598
 historical aspects 3594–5
 history taking 3609–10
 hyperbaric oxygen therapy 3584
 imaging 3610
 investigations 3609–13
 laterality 3598
 loudness 3612
 masking 3612
 medical evaluation 3610
 melanin pigmentation 3598
 meningioma 4009
 mood disorders 3608
 motor 3606
 nervous system examination 3610
 neural activity recording 3603 *F*, 3612–3
 neurofibromatosis 2 4000
 neurootological evaluation 3610
 noise-induced hearing loss 3552
 objective 3595, 3600–1
 aetiopathophysiology 3600–1
 causes 3595
 diagnosis 3601
 imaging 3601
 physical examination 3601
 treatment 3601
 see also somatosounds
 otitis media with effusion 3390–1
 ototoxic drugs 3599–600
 outcomes research 641
 Paget's disease 3487
- pathophysiology 3601–8, 3604 *F*
 abnormal afferent excitation 3603–5
 abnormal central neural auditory activation 3606
 abnormal peripheral neural auditory activation 3606
 auditory feedback system 3601, 3602 *F*
 calcium channel dysfunction 3605
 central neuronal network 3601–2
 efferent dysfunction 3606
 GABA downregulation 3606
 glutamate neuroexcitotoxicity 3604
 mechanisms underlying 3602–8
 neural hyperactivity 3606–7
 N-methyl-D-aspartate receptor modulation 3604–5
 spontaneous activity alterations 3606–7
 spontaneous neural activity 3601–2
 tonotopic reorganization 3606–7
 presence authentication 3610–3
 psychoacoustical measurements 3612
 prevalence 3597–8, 3599 *T*
 psychological disorders 3607
 psychological model 3608
 psychological profiling 3613
 psychotherapy 3616
 pulsatile *see* pulsatile tinnitus
 residual inhibition 3612
 sensory 3606
 severity authentication 3613
 skull base lesions 3944, 3944 *T*
 ‘spontaneous’ 3597–8, 3605 *F*
 spontaneous cochlear activity 3595
 spontaneous otoacoustic emissions 3600–1, 3603–4
 stapes surgery 3480
 stress 3604 *F*, 3607
 subjective 3595
 sudden sensorineurial hearing loss 3582
 treatment 3613–8, 3615 *T*
 instrumentation 3614–6
 pharmacological 3615 *T*, 3616–8
 psychotherapy 3615 *T*
 surgical 3614
 tuberculous otitis 3447 *T*
 vestibular assessment 3610
 vestibular schwannoma 3944, 3959
 removal 3983

- tinnitus instruments (combination units) 3616
- tinnitus loudness match 3612
- tinnitus maskers 3616
- tinnitus pitch match 3612
- tinnitus retraining therapy (TRT) 3614, 3615 *T*
- tirapazanine 2410
- tissue engineering 118–30, 122 *F*
advantages for use 122
applications 122
blood vessels 126, 126 *F*
bone 124
cartilage 125
cellular sources 122
clinical applications 124–6
nerve 126
scaffolds *see* tissue scaffolds
skin 126
- tissue expanders 2896
- tissue expansion 2896
pinna reconstruction 3031 *F*
scar revision 2896
skin, effects on 2896
skin flap delay 115
- tissue factor 279
- tissue harmonic imaging,
ultrasound 713, 714
- tissue homeostasis 57
- tissue regeneration, stem cells 72
- tissue scaffolds 122–3
bone 124
cartilage repair 125
characteristics 122–3
clinical applications 124–6
fibre 124
function 122
materials 123–4
natural 123
synthetic 123–4
see also individual materials
- skin repair 94
types 124
- tissue-specific committed stem cells 69
- tissue staining, apoptosis 60
- titanium implants 119
biocompatibility 119
craniofacial bone repair 124
osseointegration 119, 2905, 2906
- T lymphocytes *see* T cell(s)
- TNF α receptor 1, apoptosis 57
- T/NK cell lymphoma 1655
clinical features 1656, 1656 *F*
diagnosis 1656
- imaging 1656
treatment 1656–7
- TNM classification/staging
aims 2359–60
certainty factor (C factor) 2361
clinical (pretreatment, cTNM) 2360
components 2360
definition 2359, 2360 *T*
G category definition 2361, 2361 *T*
grouping 2361 *T*
histopathological grading 2361, 2361 *T*
historical aspects 2360
limitations 2368–9
M category definition 2359, 2360 *T*
method 2362–3
N category definition 2359, 2360 *T*
pathological (postsurgical)
histopathological, pTNM)
2360
primary tumours 2360 *T*
recurrent tumour 2361
regional lymph nodes 2360 *T*
related classifications 2362
residual tumour 2361
sinonasal malignancy 2420, 2421
stage grouping 2361–2, 2361 *T*
exceptions 2361
TANIS score 2369
T category definition 2359, 2360 *T*
tumour sites 2360 *T*
see also individual tumours
- tobacco
Asian countries 2351–2
head and neck cancers 2351–2, 2776
laryngeal squamous cell
carcinoma 2351–2
pan chewing 2351–2
sinonasal malignancy 2347
voice disorders 2219
see also smoking
- tobramycin
chronic rhinosinusitis 1471
malignant otitis externa 3339
- α -tocopherol (vitamin E) 3302
- TOF-o-gram 1296
- tongue 1794
anatomy 1794, 1841–2
base 1794
tumours *see* tongue base tumours
- blood supply 1799
bolus formation 1954–5
central papillary atrophy 1826–7
contact endoscopy 767
discoloration, drug-induced 1825
dorsum 1794, 1794 *F*
- embryology 801, 802 *F*, 1812
descent 798
- inferior surface 1793 *F*, 1794
- lymphatic drainage 1799–800
- muscles 1797–8, 1797 *F*
extrinsic 1797
innervation 1803
intrinsic 1798
swallowing 1954–5
see also individual muscles
- paralysis, hypoglossal nerve
lesions 3936, 3937
- pharyngeal (postsulcal) part 1794
- pigmentation, acquired 1825, 1825 *F*
- sensory innervation 1802–3
- squamous cell carcinoma 1762 *F*
- swallowing 1956–7
- venous drainage 1799
- vowel sound production 2166
- tongue, carcinoma of 2552–4
base of tongue *see* tongue base
tumours
clinical presentation 2552 *F*
imaging 2552–3
investigation 2552–3
management 2553–4
stage I-II 2553–4
stage III-IV 2554
tumour thickness 2553 *T*
survival rates 2558, 2558 *T*
- tongue base exercise, dysphagia 2089 *T*
- tongue base tumours 479 *F*, 2554–7
carcinoma 2554–7
diagnostic delay 2809
inoperable 2555
intubation difficulties 479
otalgia 3531
quality of life issues 2775
reconstruction techniques 2555–7
primary closure 2555, 2555 *F*
resection techniques 2555–7
treatment 2589, 2590 *F*
upper respiratory tract
management 2151
- tongue reconstruction 2555–7, 2871,
2871 *F*
- tongue tie (ankyloglossia) 994
- tonsil(s)
anatomy 1793–4, 1944, 1951
asymmetry 1225, 2006
blood supply 1799
diseases 1219–28
inflammatory 1220–5
noninflammatory 1225–6
see also individual diseases/disorders

- flora 1219–20
 function 1220
 histology 1994
 immune function 1220
 obstructive sleep apnoea 1104, 1105 *F*, 1226
 pseudocysts 2005–6
 at puberty 1794
 spontaneous haemorrhage 1225
 structure 1219
 syphilis 1225
 tuberculosis 1225
 tumours *see* tonsillar tumours
 ulceration 2006
 unilateral enlargement 2006
 children 2006
 tonsil biopsy
 indications 1989
 variant Creutzfeld–Jacob disease 1238
 tonsillar tumours
 ICD-10 site codes 2375 *T*
 mandibular nerve damage 3927
 neck irradiation 2589, 2729
 neoplasia 1225, 1226
 treatment 2589
 see also individual types
 tonsillectomy 1988–96
 adjunctive therapy 1994
 airway management 500–1
 anaesthesia 500–1
 extubation 501
 maintenance 501
 recovery 501
 biopsy purposes 1989
 blood transfusions 1994–5
 children *see* paediatric tonsillectomy
 complications 1994–6, 1995 *T*
 corticosteroids 422, 1994
 day case criteria 1993
 drooling 789
 emergency readmissions 1988
 epidemiology 615–6, 618, 622, 622 *T*, 627–8
 FDG uptake 692
 fever, postoperative 1995–6
 haemorrhage 495, 1994–5
 monitoring 1993
 reactionary 1994–5
 secondary 1995
 historical aspects 1229, 1230 *F*
 immune function and 1220
 indications 1988, 1989–90
 infectious mononucleosis 1784
 medical negligence 1308
 otalgia, postoperative 3530, 3530 *F*
 otolaryngological assessment 1989
 outcomes 1996
 pain cessation 1993–4
 peritonsillar abscess 1222–3, 1998
 postoperative care 1993–4
 antiemetic therapy 1994
 diet 1994
 pain/analgesia
 requirements 1993–4
 rates 1988
 recurrent sore throat 1988
 referral 1988–9
 SIGN guidelines 1989
 speech, effects on 993
 techniques 1991–3
 dissection *see* dissection
 tonsillectomy
 nondissection 1991
 variant Creutzfeld–Jakob
 disease 1238, 1990
 ‘tonsillectomy embargo’ 1231
 tonsillitis
 acute 1220–2
 aetiology 1221
 clinical evaluation 1221
 complications 1222–5
 diagnosis 1221
 epidemiology 1221
 flora 1220–1, 1220 *F*
 management, primary 1221
 microbiological investigation
 1221
 presentation 1220–1, 1220 *F*
 treatment 1222
 chronic 1224–5
 dysphagia aetiology 2030
 infectious mononucleosis 208, 1213, 1783–4
 psoriasis association 1224
 recurrent 1224
 subacute 1224
 tonsillolingual sulcus 1951
 tonsillopharyngitis 1220–1, 1220 *F*
 tonsil plugs 2005–6
 tooth *see* teeth
 tooth bud 799–800
 topotecan 39
 topical anaesthesia
 administration routes 480
 children 509
 lower airways 518–9
 topoisomerase(s) 39, 2379
 topoisomerase inhibitors 39–40
 topoisomerase I inhibitors 39
 topoisomerase II inhibitors 39–40, 51
 torsades de pointes 411
 torsional nystagmus 3220
 tort 595
 torticollis 1044
 torus lateralis (lateral bulge) *see* nose, lateral wall
 torus tubarius 2107
 total conservative parotidectomy 2486, 2486 *F*, 2490 *F*
 total IgE tests, allergy 159, 1394
 totally implantable cochlear amplifier (TICA) 3662
 total maxillectomy 2428
 total ossicular replacement prosthesis (TORP) 120 *F*, 121
 Soundbridge device and 3662
 total parenteral nutrition (TPN)
 critical care, adult 531
 intractable aspiration
 management 2097
 tourniquet hypoxia 50
 ‘tower skull’ 2120
 toxic adenoma 345–6
 aetiology 345
 clinical manifestations 345
 drug treatment 347
 epidemiology 345
 genetics 345
 toxic diffuse goitre *see* Graves’ disease
 toxic multinodular goitre 345–6
 cardiovascular effects 345
 clinical manifestations 345
 drug treatment 347
 elderly 345
 epidemiology 345
 in vitro tests 335
 iodine deficiency 345
 pathogenesis 345
 thyrotoxicosis 340 *T*
 toxic shock syndrome
 rhinosinusitis 1540
 Staphylococcus aureus 196
Toxoplasma gondii 246, 1216, 1784, 2009
 toxoplasmic encephalitis 246
 toxoplasmosis 2009–10
 cervical lymphadenopathy 246, 1784
 children 1216
 diagnosis 2010
 HIV and 246
 immunocompromised patients 246, 2009–10
 pregnancy 2009
 symptoms 2009
 treatment 2010

- toy discrimination tests 841
 Toynbee, Joseph 3595
 T-piece breathing systems 510, 510 *F*
 trachea
 agenesis 1142
 anatomy 2140–4
 bifurcation 2140
 blood supply 2142
 cartilages 2141
 development 2130
 children 2140
 congenital cysts 1147
 congenital disorders 1142–7
 embryology 803–5, 1282, 2130
 fibrous membrane 2141–2
 innervation 2142
 juvenile-onset recurrent respiratory papillomatosis 1179, 1180 *F*
 lymphatic drainage 2142
 mucous membrane 2142
 nonstriated muscle fibres 2142
 pressure changes during breathing 2286
 relations 2143–4, 2143 *F*
 infantile 2143
 structure 2141–2
 surface anatomy 1740
 thyroid cancer 2691
 venous drainage 2142
 Wegener's granulomatosis 1651
 tracheal autotransplantation 2614, 2614 *F*
 tracheal carcinoma, FDG-PET imaging 686 *F*
 tracheal compression, nontoxic multinodular goitre 363
 tracheal disease, special needs children 787
 tracheal injury 1771–2
 intubation 1771
 symptoms 1771
 tracheal intubation
 anaesthesia 494–5
 laryngectomy 505
 laser endoscopy 520
 middle ear surgery 514
 paediatric anaesthesia 510–1
 trachealis muscle 2142
 tracheal obstruction, low 483
 tracheal rings, laryngeal stenosis 1152
 tracheal squamous cell carcinoma 2602
 tracheal stenosis 1142–4, 2282–3
 anterior wall collapse 2283
 complete 2283
 congenital 1142–4, 1143 *F*
 respiratory distress 1143
 surgical management 1143–4, 2302
 end-to-end anastomosis 1144
 tracheostomy-induced 2295–6
 tracheal toilet 1196
 tracheal tubes
 anaesthesia 492–3, 493 *F*
 cuffed 492–3
 preformed 493 *F*, 500–1
 uncuffed 492–3
 tracheal veins 2142
 tracheoarterial fistulae 2302
 tracheobronchial diverticulum 803 *F*, 1943–4, 2130, 2131 *F*
 tracheobronchial septum 1943–4
 tracheobronchial stents, laryngeal stenosis 2279
 tracheobronchial tree 2130–44, 2140 *F*
 blood supply 2142
 embryology 2131
 innervation 2142
 lymphatic drainage 2142–3
 relations 2143–4
 vasculature 2142–3
 see also bronchi; trachea
 tracheobronchomalacia 1145
 tracheobronchoscopy, tracheal injury 1771
 tracheocutaneous fistula (TCF), persistent
 children 1206
 closure 1207
 tracheostomy-induced 2302
 tracheogenic cysts 1147
 tracheomalacia 1144–5
 aetiology 2097
 bronchoscopy 1122–3, 1145, 1145 *F*
 classification 1144–5
 investigations 1145
 oesophageal atresia repair 1287
 open surgical tracheostomy 2295–6
 stridor 1145
 tracheo-oesophageal anomalies 1283, 1283 *T*
 see also specific disorders
 tracheo-oesophageal diversion, intractable aspiration 2102–3, 2102 *F*
 tracheo-oesophageal fistula 1145–6, 1146 *F*, 2071
 congenital anomalies associated 1283, 1283 *T*
 development 801–2, 1282–3, 1943–4
 imaging 1296
 incidence 1283 *T*
 laryngeal atresia 1137–8
 laryngeal clefts 1141, 2030
 recurrent, oesophageal atresia repair 1287
 surgical 2625, 2627 *F*, 2628 *F*
 surgical repair 1284–5, 1286 *F*
 complications 1285–7
 tracheostomy 2302
 types 801–2, 805 *F*
 vocal fold palsy 1287
 see also oesophageal atresia
 tracheo-oesophageal prosthesis 2625, 2626 *F*
 mycotic colonization 225
 valve failure 225
 tracheo-oesophageal puncture (TEP) 2227
 free jejunal transfer 2883
 surgical decision-making flowchart 2229 *F*
 voice rehabilitation, post-laryngectomy 2099, 2627, 2629 *F*
 tracheo-oesophageal speech 2227, 2227–8, 2228 *T*
 tracheostomy 2292–304
 adult epiglottitis 2251
 aspiration 1278
 children *see* tracheostomy, children
 complications 2300–2, 2628–9
 early 2301
 intermediate 2301–2
 late 2302
 rates 2301
 congenital subglottic stenosis 1139
 decanulation 2302
 definition 2292–3
 dysphagia aetiology 2035
 effects 2293
 emergency *see* emergency tracheostomy
 extubation 2301
 historical aspects 2292
 humidification 2300
 indications 2293–4
 indwelling, laryngeal stenosis 2277
 intractable aspiration 2097
 juvenile-onset recurrent respiratory papillomatosis 1179
 laryngeal infections 1133
 laryngeal stenosis 2277
 laryngeal trauma 2274–5
 local anaesthesia 482–3
 local damage 2301
 medical negligence 2808
 neck dissection 2731

neurological dysphagia 2081–2
as part of other procedure 2294
permanent 2293
postoperative management 2300
prolonged ventilation 2293–4
secretion removal 2293, 2300
subglottic haemangioma 1140
swallowing 2300
techniques 2294–7
temporary 2292–3
tracheal injury 1771
tracheal stenosis 2302
translaryngeal 2298
tubes *see* tracheostomy tubes
upper airway obstruction 2288, 2291
see also individual types/procedures

tracheostomy, children 1194–209
anaesthesia 521
care 1197–9
 humidification 1197–8, 1198 *F*
 suction 1197
complications 1201–4, 1201 *T*, 1202 *T*
 bleeding 1203
 suprastomal collapse 1204
decannulation 1205–7
 accidental 1202
 decision to 1205–6
 immediate 1206
 scar revision 1207
 staged 1206
 technique 1206
discharge 1204
historical perspective 1194–5
home care 1204–5
 physical requirements 1205, 1205 *T*
home ventilation 1195–6
indications 1195–6
intensive care 546–7
laryngeal reconstruction 1159
laryngeal stenosis 1151, 1156
long-term ventilation 1195–6
medical negligence 1309
prolonged intubation 1195
skin care 1198
special needs children 786–7, 788 *F*
speech development 1171, 1204
techniques 1196–7
 dissection 1196
 positioning 1196, 1196 *F*
 skin incision 1196
 stay sutures 1197, 1197 *F*
 tracheal incision 1196–7
 tube securing 1197, 1197 *F*
tracheal toilet 1196
upper airway obstruction 1195, 1195 *T*

tracheostomy tubes
 adjustable flange 2300
 changes 1198–9
 children 1199–201
 diameter 1199, 1200 *F*
 features 2298–300
 fenestrations 1199, 2299
 flexibility 2299
 inner tube 1199, 2298–9
 length 1199
 material 1199
 obstruction 1202, 2301
 postoperative management 2300
 speaking valve 1199
 types 2298–300, 2298 *T*, 2299 *F*
 variable/custom-fitted tubes 1201

tracheotomy *see* tracheostomy

Trachlight 475

tractus solitarius 3929

tragal pointer 3873

training *see* surgical training

Traité des maladies de l'oreille et l'audition 3607

tramadol, cancer pain
 management 2786, 2787

tramazoline 1470

tranexamic acid 263
 malignant ulcers/fistulae 2792–3
 oral haemorrhage 259

transantral ethmoidectomy 1495
 complications 1495
 contraindications 1495
 indications 1495
 surgical technique 1495

transarterial tumour embolization 734

transblepharoplasty browplexy 3055, 3056 *F*

transcolumellar incision closure 2962–3

transconjunctival lower lid
 blepharoplasty 3058, 3062–4
 postoperative chemosis 3066 *F*

transcription 4, 15, 35 *F*

transcriptional silencing 9

transcription factors 16
 AP-1 2380
 cell signalling 36

transcription silencing 10

transcutaneous electrical nerve stimulation (TENS) 2784

transcutaneous lower lid
 blepharoplasty 3058, 3059–62
 eyelid laxity management 3061–2

transcutaneous oxygen saturation monitoring, stridor 1119

transcytosis 323

transfemoral Seldinger angiography, epistaxis 1604

transferrin
 malnutrition assessment 95
 nasal secretions 1360

transfer RNA (tRNA) 4

transfixation implants 2902, 2902 *T*

transfixion incision, nasal tip
 surgery 3001

transforming growth factor alpha (TGF α)
 cleft lip and palate 999

haemostasis 89

transforming growth factor beta (TGF β)
 haemostasis 89
 keloids 2892

transfusion-associated graft-versus-host disease (TAG-VHD) 262

transfusion reactions 260–2, 261 *T*
 ABO incompatibility 261
 allergic 261
 immunoglobulin A deficiency 261
 immunoglobulin E 261
 anaphylaxis 261
 bacterial infection 261
 delayed haemolytic 261 *T*, 262
 febrile, nonhaemolytic 261
 fluid overload 262
 immediate 261–2, 261 *T*
 immunomodulatory effects 262
 iron overload 262
 large volume transfusion 262
 post-transfusion purpura 262, 287
 transfused red cells, premature destruction 262

transfusion-related acute lung injury (TRALI) 261–2

transglottic carcinoma 2602

transient brainstem ischaemia 3768, 3769

transient cerebellar ischaemia 3768, 3769

transient evoked otoacoustic emissions (TEOAE) 3277–8, 3277 *F*

auditory neuropathy/
 dyssynchrony 3841 *F*, 3842
 contralateral stimulation 3277–8
 neonatal hearing screening 826, 3291
 stimulus 3277
 tinnitus 3605 *F*, 3611 *F*

transient evoked potentials 3280
 steady state responses *vs.* 3288

- transient hypogammaglobulinaemia 175 *T*, 177, 1081
- transient ischaemic attack (TIA) definition 3767 diagnosis 3769
- transient thyrotoxicosis 351–3
- transitional cells, parathyroid gland 373
- transitional meningiomas 4008
- translaryngeal tracheostomy 2298
- translation 4, 15
- transmandibular implants 2904
- transnasal intubation, upper airway obstruction 2289
- transoesophageal echocardiography, perioperative 500
- transoral resection 2555
- transposition flaps 2834–40 design 2838 glabellar 2840 *F* nasal reconstruction 3019 pivot principle 2840 *F* random 2840
- transsexual voice 2226–7 speech therapy 2226
- transsphenoidal hypophysectomy 4106–8, 4108–11 advantages/disadvantages 4109 *T* cerebrospinal fluid rhinorrhoea aetiology 1636–7 closure 4111 factors affecting 4110 optic nerve/optic chiasm and 4108, 4110–1, 4112 *F* transethmoidal route 4106 *F*, 4107–8, 4107 *F* transnasal route 4106 *F*, 4108, 4108 *F* transseptal route 4106–7, 4106 *F*
- transthoracic impedance plethysmography 529
- transthyretin (TTR) 323
- tratracheal cannulation, upper airway obstruction 2290, 2290 *F*
- transtracheal jet ventilation difficult airways 476–7, 477 *F* paediatric anaesthesia 519
- transverse arytenoids 2136 *T*
- transverse muscles, tongue 1798
- transverse sinus 4027
- trap door scarring 3090
- trapezius 1745–6 paralysis 1745–6 shoulder syndrome 2744–5 surface anatomy 1741
- trapezius flap 2863–5, 2864 *F*
- trastuzumab 44
- trauma acoustic trauma *see* acoustic trauma benign paroxysmal positional vertigo 3497, 3812 dental 1098, 1633 dysphagia 2030 ear *see* ear trauma epistaxis 1605 facial nerve *see* facial nerve injury/trauma frontal sinus 1505–7 head *see* head injury/trauma inner ear 3681–2 laryngeal *see* laryngeal trauma method of injury, scarring and 3090 nasal, medical negligence 1310–1 neck *see* neck trauma ossicular chain trauma *see* ossicular chain trauma perichondritis aetiology 3358 septal 1569–72 temporal bone *see* temporal bone trauma vocal folds 2159, 2275
- traumatic (solitary) bone cyst 1926–7
- traumatic hearing loss 824
- trauma wounds 97
- Treacher Collins syndrome 968, 1033–4, 2120 aetiology 1034 bilateral ear canal atresia 3642–3 clinical features 968, 1034, 1034 *F*, 2120 genetics 813 *T*, 1034 management 1034, 2120 nasopharyngeal narrowing 2120 surgery 1034 upper respiratory tract assessment 2151
- treatment withholding/withdrawal, ethical issues 587–8
- tree pollen, skin prick tests 1394
- T regulatory cells, allergic response 145–6, 151
- trematic nerves, branchial arches 1739
- trephination, frontal sinus 1508
- treponemal haemagglutination (TPHA) test 1461, 2008
- treponemal infections, nasal 1703
- Treponema pallidum* 202, 1460, 2007 infectious rhinosinusitis 1381 neonatal rhinitis 1077
- Treponema pallidum* immobilization (TPI) 2008
- Treponema pertenue* 1381
- triamicinolone hypertrophic scarring 2898–9 keloid scars 2893, 2894 *F*, 2898–9, 3090
- mouth ulcers, advanced head and neck cancer 2789
- recurrent aphthous stomatitis 242, 1830–1
- triamterene 3799
- triangles, neck 1741–3, 1742 *F* anterior 1741–2, 1742 *T* posterior 1742–3, 1743 *T*
- triazoles 233–4, 442
- tri-calcium phosphate (TCP), implants 2917
- triceps skinfold thickness 95
- trichloroacetic acid peel blepharoplasty 3058 medical negligence 1310
- trichoepitheliomas, nasal 1708
- Trichophyton rubrum* 214
- tricyclic antidepressants burning mouth syndrome 1848–9 depression, cancer patients 2796 globus 2040 migrainous vertigo 3804 neuropathic pain 2785 salivary flow 1861 tinnitus 3617
- trigeminal nerve (V) 3923 central mechanisms 3926, 3926 *F* clinical disorders 3926–7 corneal reflexes 3946 absence 3923 damage 3926 skull base surgery 4136–7 divisions 3923 epidermoids (primary cholesteatomas) and 4011 facial pain 1718–9 facial sensation loss 3927 meningiomas 4009 motor nucleus 3926 nasal sensation 1364 olfaction 1662 schwannoma 4014 facial pain 3944–5 intracranial 4126–7 sensory nucleus 3926 taste sensation 3929–30 vestibular schwannoma compression 3958–9, 3958 *F*
- vestibular schwannoma removal 3980

trigeminal neuralgia (TN) 1724, 1829–30, 3927
 alternative therapies 1830
 associated conditions 1830
 disease characteristics 1829–30
 epidermoids (primary cholesteatomas) and 4011
 pain 1829–30, 3927
 treatment 1830
 trigeminal sensory neuropathy 3927
 trigonocephaly (metopic synostosis) 1022 *T*, 1025–6
 triiodothyronine (T_3) 321, 327
 intracellular effects 323–4
 intracellular nuclear receptors 323
 secretion 322–3
 serum levels 323 *T*
 thyrotoxicosis 338
 transport proteins 323
in vitro tests 328, 328 *T*, 334–5
 triiodothyronine (T_3) therapy, thyroxine therapy *vs.* 357
 trimethoprim 231
 resistance 235
 tripod fractures *see* zygomatic complex fractures
 tripod mechanism 2996 *F*, 2997
 cephalic element shortening 2997, 2997 *F*
 triptans 3801–2
 trisacryl gelatin microspheres 733, 3952
 trismus
 maxillary resection 2915
 nasopharyngeal carcinoma 2452
 parapharyngeal space
 tumours 2528–9
 trisomy 21 *see* Down syndrome
 trisomy syndromes, craniofacial defects 792
 Trk 2384, 2669–70
 trochlea, orbital anatomy 1678
 trochlear nerve (IV) 3917–8, 3919 *F*, 3920 *F*
 central mechanisms 3919–21
 examination, eye movements 3710–1
 palsy, vestibular schwannoma
 removal 3980
 vascular lesions 3917–8
 trunk posture observation 3731
Trypanosoma cruzi 260
 tryptase, allergy diagnosis 160
 TSHomas 311, 4102
 clinical features 311
 magnetic resonance imaging 311
 medical management 4102

thyroid functioning tests 312
 treatment 311
 T-tubes
 chronic mucosal otitis media 3410
 otitis media with effusion 896
 tubal elevation 2107
 tubal (Gerlach's) tonsil 1094, 2108
 tubercle, lips 1793
 tubercle of Zuckerkandl 316
 tuberculoid leprosy 1464, 2010
 tuberculosis
 cutaneous 1702–3, 1702 *F*
 drug resistance 2009
 dysphagia 2031
 facial paralysis, childhood 1056–7
 HIV infection 2008
 laryngeal 2266, 2267 *F*
 lymph node ultrasound 718 *F*
 management 1783
 mouth ulcers 1833
 nasal 1458–60
 aetiology 1458
 clinical features 1458–9
 diagnosis 1459–60
 lupus vulgaris 1458–9, 1459 *F*
 sinus granuloma 1459, 1460 *F*
 treatment 1460
 ulcerative form 1459
 nasopharyngeal 2121
 diagnosis 2121
 neck manifestations 1783
 management 1783
 pharyngeal 2008–9
 diagnosis 2009
 treatment 2009
 secondary 2008
 specimen handling precautions 201
 temporal bone *see* tuberculous otitis
 tonsil 1225
 tuberculous lymphadenitis 1760–1, 1760 *F*
 tuberculous otitis 3446–52
 clinical findings 3450 *T*
 complications 3448
 definition 3446
 diagnosis 3447–8, 3447 *T*, 3448 *T*
 infection routes 3447
 laboratory findings 3448–9, 3450 *T*
 management 3449, 3450 *T*
 prevalence 3446
 research areas 3451–2
 risk factors 3446–7
 tuberculum sellae 298
 tuberculum sellae meningioma 3915
 tuberose sclerosis 1708
 tufted cells 1663
 tularaemia, children 1216
 Tullio phenomenon 3708
 children 1046–7
 click-evoked vestibular myogenic potentials 3742
 presentation 3709
 superior semicircular canal dehiscence 3763
 Tumarkin crises 3758
 tumour(s)
 apoptotic index, cellular turnover measure 62
 biology 34–6
 cell cycle 34–5, 35 *F*
 cell loss 36
 cellular kinetics 34–6
 embolization *see* tumour embolization
 growth 36, 57
 doubling time 36
 growth curve 36
 growth fraction 36
 hypoxic cells 49
 metastasis 36, 2716–7
 metastatic neck disease 2714–9
 metastatic spread 36
 mitosis 57
 nasal endoscopy 1350–1
 necrosis 63
 oxygenation 49
 potential doubling times, apoptosis and 57
 size, response to drugs 36
 stabilization, anti-angiogenic agents 43
 telomere length 71
 vascularization 2715
 see also specific types/locations
 tumour clonogen proliferation, radiotherapy 49
 tumour embolization 734–5, 735–9
 agents 734
 complications 734, 736, 739
 haemorrhage 3955
 indications 732, 734, 734 *T*, 736
 intraarterial chemotherapy 735
 juvenile angiomyxoma 734, 734–5, 2440, 3954
 meningioma 735–6, 737 *F*
 paraganglioma 736–9, 738 *F*, 739 *F*
 percutaneous 734–5
 skull base 3951–5
 aims 3951
 catheters 3951–2
 complications 3955

- tumour embolization (*continued*)
 embolic materials 3951–2
 indications 3951
 technical considerations 3952–5
 targetting 732
 transarterial 734, 734 *F*
- tumour immunology, cancer marker 2388 *T*
- tumour suppressor genes (TSG) 36, 2380
 function loss 36
 thyroid cancer aetiology 2670
- tuning curves
 auditory nerve fibres 3177 *F*, 3191 *F*, 3197
 bandwidths, frequency selectivity 3198
 basilar membrane 3190, 3191 *F*
see also individual types
- tuning fork tests 3317–8, 3319
 diplacusis 3597
- turbinates
 anatomy 1589, 1590 *F*
 blood supply 1362, 1362 *F*
 development 1318
 enlarged *see* enlarged turbinates
 ethmoidal 1319, 1319 *F*
 function 1589
 inferior *see* inferior turbinate
 inspiratory resistance 1589
 middle 1344–6, 1345 *F*
 rhinoplasty 1590
 second pass endoscopy 1348, 1348 *F*
 septoplasty 1590–1
 supreme 1336
 surgery, medical negligence 1732
 turbulence, blood flow 111
- Turkish saddle *see* sella turcica
- Turner's syndrome 403
 ear involvement 916, 3428
- XII nerve *see* hypoglossal nerve (XII)
- 24-hour ambulatory pH probe
 monitoring, gastro-oesophageal reflux 1274, 2063, 2063 *F*
- TWIST gene mutations 1028
- two-dimensional gel analysis (2-D gel analysis) 10
- two-tone suppression 3198
- tympanic artery, anterior 3907
- tympanic bone 3900
 development 3124
 necrosis and sequestration *see* benign necrotizing otitis externa
- tympanic cavity
 anatomy 3109–14
 anterior wall 3110, 3111 *F*
- blood supply 3116
 contents 3114–6, 3115 *F*
 floor 3110
 lateral wall 3109–10, 3110 *F*
 medial wall 3110–2, 3111 *F*, 3112 *F*
 mucosa 3116
 oval window 3110–1
 posterior wall 3111 *F*, 3112–4, 3112 *F*, 3113 *F*
 roof 3110
 round window 3111
- tympanic cells 3127
- tympanic membrane
 acute otitis media diagnosis 3386
 age-related changes 3317
 anatomy 3109 *F*
 arterial supply 3109
 atrophy 941, 941 *F*
 development 814
 impedance 3181
 sound pressure gains 3178–9, 3179 *F*
 stiffness 3184–5
 structured otoscopy 3315–6, 3315 *F*
 trauma, cholesteatoma
 development 3412
 vibration 3158–9, 3179–80, 3180 *F*
- tympanic membrane grafts
 chronic otitis media 3404–5, 3405 *F*
 granular myringitis induction 3328
- tympanic membrane perforation
 acute otitis media 921–2
 ancillary disease and 940
 anti-infective ear drops 431
 audiology 936
 benign necrotizing otitis externa 3333
 cholesteatoma development 3411–2
 chronic otitis media, childhood 931, 931 *F*, 932, 932–41
 clinical examination 935
 clinical presentation 934–5
 definitions 932
 epidemiology 933, 934 *F*
 investigation 936
 microbiology 934
 obsolete classifications 932–3
 pathology 932
 risk factors 933–4
 treatment 936–41
 clinical presentation 934–5
 ear discharge treatment 936–41
 hearing impairment 939
 middle ear pathology 939
 otomycosis 214
 otoscopy 3315–6, 3316 *F*
 sound transmission loss 3184
- stapes surgery 3473
 surgical closure, children 938–9, 938 *F*, 939 *T*
- temporal bone fracture 3496
- tuberculous otitis 3447, 3448, 3448 *T*
- tympanostomy tubes 933
- tympanic membrane retraction
 classification 942–3
 definition 942–3
 otitis media with effusion 901
 surgical intervention 945–6
- tympanic membrane rupture,
 barotrauma 3502–3, 3503 *F*
- tympanic nerve (Jacobson's nerve) 1751, 3109, 3527, 3910
- tympanic plexus 3116
- tympanic retraction *see* chronic otitis media (COM), inactive squamous tympanic ring 814, 966
- tympanic sulcus 3107
- tympanocentesis, otitis media with effusion 3391
- tympanograms 3289, 3289 *F*
 classification 887 *F*, 887 *T*
 ossicular chain fixation 3289
 otitis media with effusion 887
 peaked vs. flat 887–8, 888 *T*
 type A 3289, 3289 *F*
 pars tensa retractions 3427
 type B 3289, 3289 *F*
 otitis media with effusion 881, 881 *T*, 888
 pars tensa retractions 3427
 type C 3289, 3289 *F*
 otitis media with effusion 887–8
- tympanomastoid fissure 3900
- tympanomastoid suture 3107
- tympanometric acoustic reflex 3288–9
 measurement, hearing aid gain adjustment 3289
- tympanometry 3289
 acute otitis media 914
 audiometry screen 890, 891 *T*
 auditory neuropathy/
 dyssynchrony 3844
 dizzy child 1042
 noise-induced hearing loss 3553
 objective tinnitus 3601
 otitis media with effusion 887–8, 3390, 3391, 3391 *T*
 otoscopy and 888
 otosclerosis 3463–4
 pars tensa retractions 3427
 patulous Eustachian tube 3600

tympanoplasty 938–9, 938 *F*, 939, 939 *T*
 atresia surgery and 3349
 definition 3421
 dry ear, maintenance of 940
 hydroxyapatite devices 120
 extrusion rates 120
 hybrid implants 120
 outcomes 940–1
 results 939
 technique 940
 timing 939–40

tympanosclerosis
 definition 3401
 incidence 3425–6
 ossicular chain immobility 3401, 3401 *F*
 pathogenesis 3401
 pathology 3397 *F*, 3401, 3401 *F*
 surgery 3422–3
 ventilation tubes 892, 892 *T*, 900–1

tympanosclerotic plaques 3315–6, 3316 *F*

tympanoscopes 888

tympanostomy tubes, tympanic
 membrane perforation and 933

type 1 (anaphylactic) drug
 reactions 414

type 2 (cytotoxic) drug reactions 414

type 3 (immune complex) drug
 reactions 414

type 4 (cell-mediated) drug
 reactions 414

type I Isshiki thyroplasty 2097

type IV hypersensitivity reaction,
 nickel 1426

tyramine, food intolerance 1424

tyrosine kinase, chronic myeloid
 leukaemia 275

tyrosine kinase receptor, targeted
 therapies 52

UK Cochlear Implant Study Group
 (UKCISG) 3656

UKHAN 1 Trial 2730

UK National Study of Hearing, chronic
 otitis media prevalence 3408, 3409 *T*

ulcer(s)
 gingival 1820
 leg *see* leg ulcers
 malignant *see* palliative care, head and
 neck cancer
 mouth *see* mouth ulcers
 oral Crohn's disease 1828

ulcerative colitis 1834

ultimobranchial bodies 315, 316 *F*, 368

ultrasonic dissection tonsillectomy 1235

ultrasonic surgical aspirator
 (CUSA) 3972–3

ultrasonographic-guided FNAC
 (US-FNAC)
 metastatic neck disease 2721
 Sjögren syndrome 1882

ultrasound 711–30
 advantages 715
 best clinical practice 727
 B-mode (brightness-mode) 712
 branchial cysts 724, 725 *F*
 carotid body paragangliomas 725–6, 726 *F*
 cervical lymph node
 metastases 1759–60
 children 1297, 1297 *F*
 common abnormalities 715–21
 contrast agents 714
 current knowledge/future
 research 727
 cystic hygroma 726
 cystic lesions 724–5
 definition 711
 disadvantages 715
 Doppler *see* Doppler ultrasound
 dysontogenetic cysts 724
 dysphagia 1976
 ectopic thymus tissue 727
 endoscopic laryngoscopy 2150
 equipment 711, 711–3
 frequencies used 711, 713–4
 transducer design 712–3, 712 *F*
 transducer selection 713–4
 examination technique 715
 foreign bodies 727
 frontal sinus 1501–2
 Graves' disease 335, 720–1, 721 *F*
 history of/evolution 711
 hyperparathyroidism, primary 391
 hypothyroidism 336
 image generation 711–2, 713
 post-processing 713
 laryngeal 2150
 laryngoceles 724
 lipomas 725, 725 *F*
 lymphangiomas 726
 lymph nodes *see* cervical lymphatics
 lymphoma 1759–60
 medullary thyroid carcinoma 720, 720 *F*
 metastatic neck disease 2721
 neck 1755

neurogenic tumours 726

nodular thyroid disease 332–3, 718
 adenomatous 333, 719–20, 719 *F*
 benign *vs.* malignant disease 721–2
 goitrous 334, 719, 719 *F*
 reliability in 721–4
 role 718

oesophageal carcinoma 2068, 2068 *F*

papillary thyroid carcinoma 719, 720 *F*

paragangliomas 725–6, 726 *F*

parathyroid adenoma 722, 722 *F*

parathyroid glands 384, 722, 722 *F*

patient positioning 715

peritonsillar abscess 1997

physics/basic principles 711–3
 acoustic impedance 712, 713
 acoustic interface 713
 acoustic pressure wave
 directions 712
 microbubble contrast agents 714
 propagation velocity 712

ranulas 725, 1882, 1884 *F*

real-time 712, 713

salivary abscess 724

salivary glands 722–4, 1872–5, 1873 *F*
 advantages/disadvantages 1872, 1874 *T*
 calculi 723, 723 *F*, 724 *F*
 children 1886
 cystic lesions 725
 indications 1890 *T*
 inflammatory/immune
 disorders 724
 tumours 723, 723 *F*, 1884

sialadenitis
 acute 1880, 1881 *F*
 chronic 1882

sialolithiasis 723, 723 *F*, 724 *F*, 1879, 1880 *F*

Sjögren syndrome 1882

soft tissue neoplasms 725–7

subclavian steal syndrome 3769

thyroglossal cysts 724, 725 *F*, 1778

thyroid cancer 333, 719–20, 2676
 anaplastic carcinoma 720
 follicular cell carcinoma 719–20

thyroid gland 328, 329 *T*, 718–21
 diffuse disease 720–1
 size/volume estimation 718
 solid *vs.* cystic lesions 328, 332–3

thyroiditis 721, 721 *F*

thyroid lymphoma 720

thyrotoxicosis 335, 720–1, 721 *F*

vascular malformations 726

wound assessment 100

ultraviolet radiation
 benign skin lesions, scarring 3090
 facelifts 3094
 perichondritis management 3360
 umbo retraction 940
 uncinate epilepsy 3913–4
 uncinate process 1344–6, 1345 *F*
 bent 1335 *T*
 development 1318 *F*, 1319
 ethmoidal infundibulum
 configuration and 1331
 third pass endoscopy 1348
 variations 1331 *F*
 uncomfortable loudness level
 (UCL) 3267
 uncuffed tracheal tubes,
 anaesthesia 492–3
 underprojected nasal tip 3002–4
 undifferentiated carcinoma of
 nasopharyngeal type 2580
Unfinished business 553
 unguentum, leprosy 1464
 UNICEF, measles prevention
 campaign 847
 unilateral permanent hearing loss,
 children 824, 848
 unilateral vestibular deafferentation,
 acute
 neuronal changes 3222
 nystagmus 3219–20
 unilateral vestibular dysfunction (uVD)
 syndrome 3749
 United Kingdom Children with Cancer
 Study Group (UK-CCSG)
 centres 1253
 Universal Blood and Body Precautions,
 HIV 239–40
 University of Michigan Head and Neck
 Quality of Life (HNQOL) 2774 *T*
 University of Michigan vestibular
 exercises 3807, 3807 *T*
 University of Pennsylvania Smell
 Identification Test (UPSIT) 1366,
 1665–6, 1665 *F*
 age-related changes 1670 *F*
 Alzheimer's disease 1669
 Parkinson's disease 1669
 University of Washington Quality of
 Life Questionnaire (UW
 QOL) 2773, 2774 *T*
 Unterberger test 3731–2, 3732 *F*
 skull base lesions 3946
 vestibular neuritis 3752
 upper aerodigestive tract (UADT),
 special needs children 786–8

upper aerodigestive tract (UADT)
 tumours
 alcohol 2352
 otalgia 3531
 tobacco 2351–2
 upper airway dilating muscles
 respiratory sleep disorders 2308,
 2308–9
 sleep 2307
 upper airway obstruction *see* airway
 obstruction
 upper airway resistance syndrome 1103,
 2313–4
 upper cheek flap, oral cavity
 tumours 2567–8
 upper eyelid
 anatomy 3048–50
 dermatochalasis *see* dermatochalasis
 excess skin removal 3048–9, 3049 *F*
 eyebrow-lid distance 3048, 3049 *F*
 fat pads 3050
 skin creases 3049–50
 post-blepharoplasty 3066
 racial differences 3050
 surgery *see* blepharoplasty
 upper lateral cartilages, external
 nose 1325, 2960–1
 nasal valve collapse 3011–2, 3012 *F*
 upper lip reconstruction 2547–8,
 2548 *F*
 upper lobe bronchus
 left 2141
 right 2141
 upper motor neurone facial
 weakness 3930
 upper motor tracts 2158
 upper oesophageal sphincter (UOS)
 globus 2038
 normal swallowing 1964
 upper respiratory tract
 assessment 2145–54
 difficult airway 2150–1
 failed intubation 2151–2
 laryngoscopy *see* laryngoscopy
 nasal airway 2146
 preliminary 2145–6
 preoperative 2151
 impairment
 medical negligence issues 2808
 signs/symptoms 2145
 infection *see* upper respiratory tract
 infection (URTI)
 operative management 2151
 relationship with lower tract 1560–8
 epidemiological evidence 1560–1

upper respiratory tract infection
 (URTI)
 acute otitis media 916
 acute rhinosinusitis 1440–1
 chronic otitis media 3410
 olfactory dysfunction 1667
 otitis media with effusion 3389
 paediatric anaesthesia 508,
 509 *T*
 professional voice 2213
 voice disorders 2219
see also specific diseases
 upper sensory tracts 2158
 Upsherscope 473, 474 *F*
 upwards spread of masking 3247
 uraemia 288
 ureteric stones 391
 urinalysis, rhinosinusitis 1543
 urinary output, critical care
 patients 529
 urodele amphibians
 limb amputation 70
 organ regeneration 72, 75
 urticaria, nasal polyposis 1551
 Usher syndrome (USH)
 genetics 15–6, 20, 813 *T*, 3542
 type 1 (USH1) 20
 type 1B (USH1B) 20, 3238
 vertigo, children 1046
 utilitarianism 584
 utility incision, neck dissection 2732 *F*,
 2733
 utility measures, outcomes
 research 639–40
 utricle 3151–2, 3151 *F*
 congenital deformity 3683 *F*
 hair cells 3228–30
 orientation 3210
see also otolith organs
 utriculoendolymphatic valve 3230–1
 uveoparotid fever 3891
 uvula 1792
 development 1812–3
 oedema 2006
 uvular muscle 1946 *T*, 2112
 uvulopalatopharyngoplasty 2329–30
 success rates 2332
 vaccination
 human papilloma virus 209
 influenza *see* influenza vaccination
 mucosal malignant melanoma
 treatment 2410
 mumps 206, 1243
 pertussis 2252

- rhinosinusitis 1084, 1473
 splenectomy patients 276
 vaccinia, head and neck cancer gene therapy 28
 VACTERL complex 1283–4
 vagal nuclei 2075 *F*, 2158
 vagus nerve (X)
 auricular branch (Arnold's nerve) 1751, 3527, 3910
 branches 1751, 3935
 central connections 3933 *F*, 3934–5, 3934 *F*
 clinical disorders 3937–8
 clinical evaluation 3937–40
 dorsal nucleus 3935
 ganglia 3935
 in jugular foramen 3901, 3903 *F*
 laryngeal distribution 2155, 2156 *F*, 2157 *F*
 lesions 3937
 surgery-related 2808, 4094
 vocal fold paralysis 2222
 voice disorders 2222
 in neck 1751
 paragangliomas 2526
 pharyngeal branches 1751, 1950, 2074
 rootlets 3935
 skull base lesions 3946
 taste sensation 1841, 3929–30
 tracheobronchial tree
 innervation 2142
 valaciclovir 208, 232
 validity
 evidence-based medicine, critical appraisal 649–52, 654–5
 face 635
 outcomes research 635
 systematic reviews 662–3
 valleculae, tongue 1803
 vallecula sign 2250
 Valsalva manoeuvre 2159
 laryngeal reconstruction grafts 1154
 laryngopyocele 2255, 2255 *F*
 paradoxical embolism 3767
 superior semicircular canal
 dehiscence 3763
 valve speech 2625
 valvular disease, surgical
 preparation 459, 460
 vanadium pentoxide exposure 1410
 vancomycin 230
 ‘red man’ syndrome 230
 resistant enterococci 198
 variable domains/regions, antibody 135
 variant Creutzfeldt–Jakob disease (vCJD)
 adenotonsillectomy, transmission risk 517, 626
 blood transfusion 260
 nasendoscopy, transmission risk 2147
 prion 1990
 tonsillectomy 1990
 children 1231, 1238
 surgical instruments, transmission and 1990
 variant genes 16
 variant Hallpike manoeuvre 3721 *F*, 3722
Varicella zoster *see* herpes zoster
 varices, vocal folds 2203
 variconazole 233–4
 vascular bud growth, nasal reconstructions 3017–8
 vascular cell adhesion molecule 1 (VCAM-1)
 allergic rhinitis 1391
 nasal polypsis 1552
 vascular compression 1146–7
 vascular endothelial growth factor (VEGF) 43
 goitre aetiology 2668
 juvenile angiofibroma 2437–8
 salivary gland tumours 2495
 skin flap survival 114
 vascular endothelial growth factor receptor 43
 monoclonal antibodies against 43–4
 vascular grafts 126, 126 *F*
 vascular injuries
 neck 1772
 carotid revascularization *vs.* ligation 1772, 1773 *F*
 clinical evaluation 1772
 intimal injury 1772
 investigations 1772
 pseudoaneurysms 1772
 surgery-related 2808
 vascular lesions
 nasal neoplasms 1708
 somatosounds 3600
 vascular loops
 pulsatile tinnitus 3600
 vestibular pathology 3701
 vascular malformations
 epistaxis 739
 ultrasound examination 726
 see also specific malformations
 vascular ring, tracheal 1146
 vascular sling, tracheal 1146–7
 vascular somatosounds 3600
 vasculitides 187–8
 vasculitis
 antineutrophil cytoplasmic antibody test 171
 bleeding patterns 281
 Churg–Strauss syndrome 1653
 granulomatous nasal conditions 1645, 1646 *T*
 management 170–2
 primary 1646 *T*
 septal perforations 1584
 vasculolymphatic malformations 726
 vasoactive intestinal polypeptide (VIP) 1364
 vasoconstriction
 acetyl choline 113
 blood vessel injury 278
 endothelin-1 113
 nasal 1364
 vasoconstrictors
 bleeding malignant ulcers and fistulae 2792–3
 critical care patients 534
 enlarged turbinates 1592
 hypophysectomy 4105
 vasodilation
 compromised skin flaps 113
 nitroglycerin-induced 113
 vasomotor rhinitis *see* rhinitis, idiopathic
 vasopressin *see* anti-diuretic hormone (ADH)
 vasospasm, skin flaps 113
 VATER association 801–2
 Veau flap, hard palate repair 1006–7, 1007 *F*
 Veau–Wardill–Kilner flap, hard palate repair 1006–7, 1007 *F*
 velar consonants 2166–7, 2167 *T*
 Velcade (bortezomib) 44
 velocardiofacial syndrome 180–1, 1000–1
 velocity, definition 3165
 velocity step test 3213, 3729
 semiquantitative assessment 3729
 velocity storage mechanism (VSM) 3213–4
 velopalatine movement, MRI assessment 1298
 velopharyngeal insufficiency (VPI) 1010–3
 assessment 1010–1
 cleft palate 1001
 palate repair 1011–3

- velopharyngeal insufficiency (VPI)
(continued)
 pathophysiology 1010–1
 post-adenoidectomy 1011
 velopharyngeal sphincter 1948 *T*,
 2111–2
 adenoidectomy-related
 dysfunction 1098
 closure mechanism 1008–9
 incompetence 2166
 vocal resonance 2166
 velum muscles 1007–8, 1009 *F*
 Venereal Disease Research Laboratory
 (VDRL) 202, 1461, 2008
 venous haemorrhage, skull base surgery
 complication 4136
 venous leg ulcers 97
 wound dressings 102
 venous sinusoids, nasal 1362–3
 venous thromboembolism
 oral contraceptives 290
 pathogenesis 288
 prophylaxis 463–4
 heparin 290
 risk factors 288 *T*, 289 *T*
 ventilating bronchoscope 1122–3,
 1122 *F*
 ventilation
 failed 476–7
 phonosurgery 2236
 stridor 1116
 weaning off 2293–4
 ventilation tubes 896
 acute otitis media 920
 adenoidectomy and 897, 898 *F*, 902,
 902 *F*
 anaesthesia 513–4
 behaviour 899
 calcium deposition 3315–6, 3316 *F*
 care pathways 577–8
 chronic mucosal otitis media 3410
 classification 896
 cost-benefit analysis 899
 hearing and 897–8
 inactive squamous chronic otitis
 media 3428, 3429
 insertion 896–7
 aspiration 897
 complications 900–2
 permanent perforation 900, 901 *T*
 site 896–7
 language development 899
 otitis media with effusion 896, 3392,
 3429
 outcomes 897–9
- quality of life 899
 reinsertion 898, 902–3
 speech development 899
 tympanic membrane retraction 945–6
 ventilator-induced lung injury
 (VILI) 528
 ventral cochlear nucleus 3140
 ventricular bands (false cords) 757,
 2132
 ventricular cyst 2201
 ventroposteromedial thalamic nucleus
 (TTN) 1842
 Venturi jet ventilation 519
 verapamil 113
 vergence 3227 *T*
 vermillion 1793, 1795
 Vernet's syndrome 2080 *T*, 3938,
 4027–8
 Verocay body 3957
 verruca vulgaris 1701
 verrucous carcinoma, larynx 2604
 vertebral artery, aneurysm, CPA
 lesions 4014–5
 vertebral artery injury 1772–4
 endovascular techniques 1773
 vertical laryngoplasty, intractable
 aspiration 2099–100, 2101 *F*
 vertical muscles, tongue 1798
 vertical nystagmus 3922
 acute unilateral vestibular
 deafferentation 3220
 vertigo 3239–40, 3932–3
 acute unilateral vestibular
 deafferentation 3223
 adjunctive treatment 3814–6
 benign paroxysmal positional *see*
 benign paroxysmal positional
 vertigo (BPPV)
 cerebral air gas embolism 3520
 children 1040–51
 assessment 1041–2
 ataxia 1045
 diagnostic flow chart 1043 *F*
 drug-induced 1047–8
 hearing loss 1042
 history taking 1041–2
 imaging 1042
 infantile reflex responses 1040–1
 infectious causes 1049
 investigations 1042
 motor milestones 1040–1
 neurological history 1042
 physical treatments 1049
 poisoning 1045
 presentation 1041
- surgery 1049
 symptoms 1041
 treatments 1049
 vestibular conditions with
 associated hearing loss 1045–8
 vestibular system
 maturation 1040–1
 vomiting 1042
 clinical management 3791–825
 clinical syndromes
 associated 3748–90;
see also specific disorders
 cochlear implant-related 3654
 definition 3748
 linear 3706–7
 meningioma 4009
 middle fossa surgery 4023
 migraine attacks 3932–3
 migrainous *see* migrainous vertigo
 multiple sclerosis 3754, 3773
 neurofibromatosis 2 4000
 outcomes research instruments 640
 Paget's disease 3488
 pharmacological treatment 433–4,
 3794–805
 symptom suppression 3794–7
 positional *see* positional vertigo
 positional manoeuvres 3720–1
 post-stapes surgery 3476
 presentations 3708–10
 chronic dizziness 3709–10, 3710 *T*
 recurrent/episodic 3709, 3709 *T*
 single, acute episode 3708 *T*, 3709
 progressive supranuclear palsy 3777–8
 provoked *see* provoked vertigo
 syndrome
 rehabilitation 3791–825
 skull base lesions 3944
 spontaneous *see* spontaneous vertigo
 syndrome
 sudden sensorineural hearing
 loss 3582
 symptoms 3706–7, 3707 *T*
 duration 3706
 terminology issues 562
 tuberculous otitis 3447, 3447 *T*
 vestibular schwannoma 3944, 3959
 removal 3983
see also Menière's disease; vestibular
 compensation; *individual types*
 Vertigo Handicap Questionnaire
 (VHQ) 640
 vesicular infectious agents 137–40
 vestibular atelectasis, primary 3697,
 3698 *F*

- vestibular attacks, acute
pharmacological treatment 3796 *T*
 coexisting conditions 3798
symptom suppression 3794–7
- vestibular compensation 3222–4,
 3791–3
 affecting factors 3793
cellular level 3792–3
chronic dizziness 3710
clinical implications 3791–3
clinical syndrome 3791–2
definition 3223
dynamic recovery 3791–2
dynamic symptoms 3791
experimental drug treatments 3805
failure 3710, 3710 *T*
mechanisms 3792
motor response substitution 3792
neurochemical level 3792–3
sensory input substitution 3792
static oculomotor recovery 3791–2
static postural recovery 3791–2
static symptoms 3791
strategy substitution 3792
substitution mechanisms 3792
- vestibular diseases/disorders
 adjunctive treatment 3814–6
 aminoglycoside ototoxicity 3569
 causes 3791
 central 3767–79
 compensatory eye movements 3749,
 3750 *F*
 dysstereoacusis 3597
 genetics 3241
 hearing, normal 1042–5
 medical treatment 3793–4
 peripheral 3751–66
 pharmacological treatment
 3794–805
 categories 3794
 psychiatric disorders and 3814–6
 classification 3814–5
 neurological linkage 3815, 3815 *F*
 treatment 3816
 stapes surgery contraindication 3469
 see also specific disorders
- vestibular-evoked myogenic potential
(VEMP) 3241
- click-evoked, superior semicircular
canal dehiscence 3764
- sternomastoid muscle 3751
- vestibular exercises 3805–9
comparison 3807–8
evidence for 3807–8
incorrect performance 3806
- programmes 3806–8
 customized 3807, 3807 *T*
 problem oriented approach 3807,
 3807 *T*
 systematic preset 3806–7
 see also individual programmes
regimens 3805
- vestibular eye movements 3227 *T*
- vestibular folds 2134
- vestibular habituation training (Norre's
approach) 3806–7, 3806 *T*
efficacy 3807–8
- vestibular hair cells 3228–38
 adaptation 3231–2, 3232 *F*, 3236 *F*
 afferent responses 3237–8
 age-related changes 3239
 amplification 3236 *F*
 bundle 3228, 3229 *F*
 length 3235
 mechanical behaviours 3236 *F*
depolarization 3215
- dysfunction 3238–9
 efferent responses 3237–8
endolymph 3230–1
environmental disturbances 3238
- frequency selectivity 3235
 spatial coding 3235
 temporal coding 3235
- gating compliance 3231, 3233 *F*, 3236 *F*
- hyperpolarization 3215, 3231
- innervation 3236
- ion (transduction channels) 3231
 blockage 3239
- kinocilium 3228, 3229 *F*
- loss, vestibular function
 affecting 3238–9
- mechanotransduction 3231, 3232 *F*
- myosin abnormalities 3238
- neurochemistry 3794
- neurotransmitter release 3237
- orientation 3230
- physiology 3228–38
- potassium channels 3237
- presynaptic zone 3237
- saccule 3228–30
- semicircular canal 3228, 3230 *F*
- sensitivity 3230
- stereocilia 3228, 3229 *F*
 tip links 3228, 3229 *F*
- transduction apparatus 3228–31,
 3229 *F*
- type I 3228, 3228 *F*
 age-related changes 3239
 innervation 3148–9, 3236
 potassium conductance 3236
- type II 3150 *F*, 3228, 3228 *F*
 age-related changes 3239
 Menière's disease 3239
- type I vs. type II 3235–7
- biochemical differences 3237
- electrical differences 3236
- structural differences 3236
- utricle 3228–30
- vestibular labyrinth
loss/destruction
 Bechterew effect 3749
 bilateral 3749
 ocular tilt reaction 3749
 unilateral 3748–9
mechanical stimulation 3749–51
 caloric test 3750–1
- neoplasms 3685–7
 benign tumours 3685–6
 malignant tumours 3686–7
 secondary 3686–7
- nerve supply 3149
- supporting cells 3155
- temporal bone fracture 3681–2, 3682 *F*
- vestibular ligament 2134, 2137 *F*
- vestibular membrane 806–7
- vestibular migraine *see* migrainous
vertigo
- vestibular nerve 3148–50
neoplasms 3687–91
 vestibular function affecting 3691
schwannoma *see* vestibular
schwannoma
- vestibular neurectomy 4021–2
Menière's disease 3759
- vestibular compensation 3793
- vestibular neuritis 3677–8, 3751–7
aetiology 3678, 3751
benign paroxysmal positioning vertigo
 development 3760
- bilateral sequential 3756
- children 1044–5
- clinical manifestations 3678, 3707–8,
 3751–2
- complications 3756–7
- definition 3751
- diagnosis 3752, 3754 *F*, 3756 *F*
 differential 3752–4, 3756 *F*
- management 3756
- outcomes 3756–7
- sudden sensorineural hearing
loss 3582
- vestibular nerve degeneration 3678,
 3678 *F*
- vestibular neuronitis *see* vestibular
neuritis

vestibular neurons 3153 *F*, 3154
 vestibular nuclei 3220, 3220 *F*
 excitatory pathways 3220, 3221 *F*
 inhibitory pathways 3221, 3221 *F*
 lesions, head tilt 3731
 parabrachial nucleus
 connections 3816
 type 1 neurons 3220, 3221
 type 2 neurons 3222
 see also individual nuclei
 vestibular nystagmus, children 1040
 vestibular organ(s) 3147–8, 3148 *F*
 anatomy 3147–57
 maturation 3155
 ultrastructure 3147–57
 vascular supply 3155
 vestibular receptors 3147
 vestibular rehabilitation 3794, 3805–14
 age 3806
 benign paroxysmal positional vertigo 3808
 bilateral vestibular failure 3808–9
 central vestibular disorders 3809
 exercises *see* vestibular exercises
 Menière's disease 3760, 3808
 migrainous vertigo 3808
 ototoxicity management 3573
 outcomes
 factors affecting 3806
 measurement 3806
 repositioning manoeuvres 3809–14
 vestibular disorders, agoraphobia
 and 3816
 vestibular habituation
 exercises 3806–7
 vestibular neuritis 3756
 visual vertigo 3809
 vestibular schwannoma (VS) 3957–66
 aetiology 3957
 audiological tests, misinterpretation of 4143–4
 best clinical practice 3965
 cerebellopontine angle syndrome 3932, 4007–8
 classification by size 3959, 3959 *T*, 3980, 3980 *T*
 current knowledge/future research 3965
 cystic 3960–1, 3961 *F*
 diagnosis 3687–8, 3959
 cystic schwannoma criteria 3960–1
 delays in 4142–3
 Menière's disease *vs.* 3944
 meningiomas *vs.* 4009
 tests, misinterpretation of 4143–4

 facial nerve damage 3930–1
 growth patterns 3963, 3964 *F*
 in cerebellopontine angle 3958–9, 3958 *F*
 dynamics 3964 *F*
 types 3963, 3964 *F*
 growth rate 3963
 annual 3963
 neurofibromatosis 2 4003–4
 variation 3963, 3963 *F*
 ‘wait and scan’ studies 3963
 hearing loss 3687–8, 3837, 3943, 3959, 4007–8
 incidence 3961–3
 asymptomatic/silent tumours 3961
 diagnosed tumours 3961, 3961 *F*, 3962 *T*
 histological estimation 3962–3
 increased 3961
 medial schwannoma 3960
 symptomatic undiagnosed tumours 3961, 3962
 internal acoustic meatus 3957, 3958 *F*
 medial 3960, 3960–1, 3960 *F*
 natural history 3957–66, 3688
 neurofibromatosis 2 3957, 3998, 4000, 4002, 4003
 otalgia 3528–9
 pathology 3687–8, 3688 *F*, 3957–9
 Antoni A/B patterns 3687, 3957, 3960–1
 bone resorption 3957–8
 extra-meatal expansion 3958–9, 3958 *F*, 4007
 histopathological examination 3957–9
 initial growth 3957, 3958 *F*
 nerve compression 3957
 nerve invasion 3957, 3959–60
 size and 3957–9
 peripheral vestibulopathies 3695–701
 postural imbalance syndrome 3776
 radiology, misinterpretation of 4143
 special manifestations 3959–61
 surgery *see* vestibular schwannoma, surgical management
 symptoms 3959
 tinnitus 3944, 3959
 tumour control rates 3992
 unilateral vestibular dysfunction syndrome 3749
 vertigo/dysequilibrium 3776–7, 3777 *F*, 3944

vestibular schwannoma, surgical management 3967–88
 balance, postoperative 3983
 cerebellopontine angle, approaches to 3968–77
 complications 3977–82
 arterial bleeding 3977, 3977 *F*, 4136
 brain injury 3978–9
 cerebrospinal fluid leak 3981, 4138
 cranial neuropathies 3979–81
 CSF otorrhoea 3981
 CSF rhinorrhoea 3981
 intracranial infection 3982
 postoperative haematoma 3978
 stroke 3977–9
 venous bleeding 3977–8
 employment, return to 3983
 gamma knife stereotactic radiosurgery 3992–3, 3992 *T*
 cranial nerve preservation 3992
 hearing preservation 3983–4
 historical aspects 3967–8
 hospital stay 3983
 middle fossa approach 3968 *T*, 3973–5, 4021
 advantages/disadvantages 3968 *T*
 closure 3975
 craniectomy 3974
 incision 3974
 internal auditory meatus location 3974
 nerve identification 3974
 petrous bone exposure 3974
 position 3974
 tumour removal 3975
 mortality 3977–9
 outcomes 3982–5
 prediction 749–50
 quality of life 3984–5
 reanimation 3077
 retrosigmoid (suboccipital)
 approach 3968 *T*, 3975–7, 4021
 advantages/disadvantages 3968 *T*
 auditory brainstem implant 3976–7
 closure 3976
 craniotomy 3975
 incision 3975
 internal auditory meatus, drilling of 3976
 positioning 3975–6
 tumour exposure 3975, 3976 *F*
 tumour removal 3976 *F*

- tinnitus 3983
 translabyrinthine approach 3968–73,
 3968 *T*
 advantages/disadvantages 3968 *T*
 bony labyrinthectomy 3970, 3970 *F*
 closure 3973
 cortical mastoidectomy 3969–70,
 3969 *F*
 facial nerve identification 3971–2,
 3972 *F*
 facial nerve skeletonization 3970
 internal meatus
 skeletonization 3970–1, 3971 *F*
 jugular bulb skeletonization 3970
 musculoperiostial flap 3969
 patient positioning 3969
 posterior cranial fossa
 opening 3971
 skin incision 3969
 tumour removal 3972–3, 3972 *F*
 tumour extirpation 3982
 vertigo 3983
 vestibular sensory cells 3228–31
 type I 3150–1, 3150 *F*
 type II 3150–1, 3150 *F*
 vestibular system 3148–53
 ageing 3697–8, 3699 *F*
 central projections 3220–8
 acute peripheral lesions 3222–4,
 3223 *F*
 to central nuclei 3220–1, 3220 *F*
 commissural pathways 3221 *F*,
 3222, 3222 *F*
 vestibular compensation 3222–4
 congenital disorders 3683
 in darkness 3210–1
 disturbances 3240 *T*
 examination, skull base lesions 3946
 future research areas 3241
 head orientation 3208–10
 infections 3691–5
 inner ear trauma 3681–2
 inputs 3207, 3208 *F*
 investigations
 chronic otitis media 3419
 skull base lesions 3946
 knowledge deficiencies 3241
 motion decomposition 3208–10
 motion sickness 3239–40
 movement detection 3210–3
 neurochemistry 3794
 nystagmus 3946
 orientation 3209, 3209 *F*
 orthostatic intolerance 3227–8
 otoconial layer 3152–3, 3152 *F*
- ototoxicity 3676–7
 outputs 3207, 3208 *F*
 pathology 3675–705
 peripheral vestibulopathies 3695–701
 role of 3207–20
 temporal bone studies 3701
 vascular injury 3698–701, 3700 *F*
 arterial occlusion 3699–700
 velocity storage 3213–5
 vertigo 3239–40
 vestibular tract, medial 3227
 vestibule
 nasal 1322
 oral 1793
 vestibular schwannoma
 invasion 3959–60
 vestibulitis 442–3, 1700
 vestibulocerebellum 3220
 vestibulocochlear nerve (VIII) 3931–3
 injury, skull base surgery 4137
 optokinetic nystagmus 3717
 Paget's disease 3487–8
 vestibulocochlear schwannoma 3598
 vestibulocollic reflex (VCR) 3207
 vestibuloocular reflex (VOR) 3207
 adaptation 3792
 age-related changes 3239, 3239 *F*
 electrical (galvanic) stimulation 3727
 examination 3718
 techniques 3718, 3719 *F*
 see also individual techniques
 foetus 1040
 gaze stabilization 3226–7
 generation 3215–20, 3216 *F*
 head-impulse test 3224
 inputs 3213
 laboratory assessment 3727
 results interpretation 3730
 Menière's disease 3239, 3239 *F*
 peripheral vestibular lesions 3222–3
 post lesion gain 3224
 push–pull principle 3215
 rotational tests 3728 *F*, 3729–30
 testing 3208
 Usher syndrome type 1B
 (USH1B) 3238
 vestibular compensation 3223
 vestibuloocular reflex (VOR)
 suppression 3720, 3720 *F*
 caloric testing 3728
 vestibulopathy, bilateral *see* bilateral
 vestibulopathy
 vestibuloplasty, atrophic rhinitis 1466
 vestibulospinal reflex (VSR) 3207, 3227
 vestibulosympathic reflex 3227–8
- veterans Affairs study, head and neck
 cancer 2757
 Vibrant Soundbridge 3661
 patient benefit 3663–4
 results 3663
 surgical considerations 3662, 3663 *F*
 vibrating ossicular prosthesis
 (VORP) 3661
 vibration(s) 3158–62
 adding (superposition) 3165–7
 amplitude 3159
 angular frequency 3159
 cycles 3158
 damping 3161
 displacement 3160
 forced vibrations 3161
 frequency 2176, 3158
 oscillations *vs.* 3158–9
 period 3158
 phase 3160
 phase angle 3160, 3160 *F*
 root mean square (rms) value 3162
 sinusoidal motion 3159, 3159 *F*
 velocity 3160
 see also sound
 Victorian Hearing Screening
 Programme, paediatric auditory
 neuropathy/dyssynchrony 3845
 video-assisted parathyroidectomy 395
 video endoscopic evaluation of
 swallowing (VEES) *see* fibreoptic
 endoscopic evaluation of
 swallowing (FEES)
 videofluoroscopy
 aspiration 1277
 barium aspiration 1967
 dysphagia investigations 1965, 1965 *T*,
 1966–7, 2076
 advantages 1967
 analysis 1966–7
 contraindications 1967
 equipment 1966
 limitations 1967
 procedure 1966
 risks 1967
 myasthenia gravis 2077
 neurological dysphagia 2076
 stridor 1119
 videofluoroscopy swallowing study
 (VFSS)
 aspiration 2096
 dysphagia 2028, 2087
 videolaryngostroboscopy
 interpretation 2194 *T*
 laryngeal trauma 2273

videolaryngostroboscopy (*continued*)
 vocal folds mucosa 2193–4
 voice disorders 2193–4
 video nystagmography 3213
 basilar migraine, children 1044
 skull base lesions 3946
 technique 3724
 video-oculography (VOG) 3723
 analysis 3724
 routine 3724
 technique 3724
 temporal resolution 3724
 video otoscopy 887
 vidian nerve 3910, 3924, 3928
 Villaret's syndrome 2080 *T*, 3938
 vinblastine
 cycle cell phase specificity 37
 mechanism of action 38–9
 ototoxicity 3571
 vinca alkaloids 38–9
 vincristine
 mechanism of action 38–9
 ototoxicity 3571
 vindesine 38–9
 vinorelbine 38–9
 viral hepatitis, salivary assay 1868
 viral infection
 acute otitis media 211, 914–5
 apoptosis 61
 croup 1128, 2251
 facial paralysis, childhood 1056
 muscle tension dysphonia 2204
 nasal 1700–1
 olfactory dysfunction 1667,
 1673–4
 oral vesicles 1822
 orofacial 1832–3
 respiratory tract *see* respiratory tract
 viral infections
 see also specific diseases
 viral labyrinthitis 3692–3, 3694 *F*
 clinical picture 3692–3
 histopathology 3693
 viral laryngotracheobronchitis *see* croup
 viral oncogenes 208
 viral parotitis *see* mumps
 viral rhinitis, children 1080
 viridans (oral) streptococci 195–6, 198
 virtual (residue) pitch 3252–3
 virtue-based morality 584–5
 virus(es) 204–12
 malignancy associations 208–9
 cell proliferation 208
 cell-suppressor proteins 208
 see also individual types

visceral myopathy, oesophageal
 diseases 2066
 visceral pain, cancer patients 2784
 Visilab study, obstructive sleep
 apnoea 1108
 visor flap 2588
 visor incision 2732 *F*
 visual acuity, thyroid eye disease 344
 visual analogue scale 636
 visual field assessment
 bedside 3915
 hypophysectomy 4105
 pituitary tumours 312
 visual field defects
 bedside examinations 3915
 pituitary tumours 4099
 visual fixation 3227 *T*
 visual impairment
 blepharoplasty 3064–5, 3096
 childhood hearing tests 841
 orbital tumours 3915
 visually guided eye movements,
 oculographic recording 3726
 visually mediated reflexes, gaze
 stabilization 3226–7
 visual pathways 3914 *F*
 visual pursuit 3919
 visual reinforcement audiometry
 (VRA) 838–9
 calibration 838
 cochlear implantation 863
 method 839, 840 *F*
 minimal response levels 839
 orientation response 839
 signal complexity 839
 test arrangement 838–9, 838 *F*
 visual-spatial axis, sign language 566
 visual vertigo
 posturographic assessment 3736
 symptoms 3708
 vestibular rehabilitation 3809
 optokinetic stimulation 3809
 virtual reality environment 3809,
 3809 *F*
 visuo-verticular mismatch *see* visual
 vertigo
 Vitallium 119
 vitamin B₁₂
 absorption 269
 deficiency 269
 investigations 269
 vitamin D 374–5, 388
 calcium homeostasis 451, 451 *F*
 hypoparathyroidism 451
 metabolites 374
 parathyroid hormone assay and
 382–3
 synthesis 388
 transport 374
 vitamin D receptor 374
 vitamin D supplementation,
 parathyroidectomy 395
 vitamin E (α-tocopherol) 3302
 vitamin K deficiency 282
 fresh frozen plasma 258
 vitamin supplementation, olfactory
 dysfunction 1671
 vitiligo 343 *F*
 vocabulary building 991
 vocal cords *see* vocal fold(s)
 vocal creak 2168
 vocal disorders *see* voice disorders
 vocal fold(s)
 abduction 2159
 adduction
 expiration 2159
 incomplete 2165
 phonation 2160
 swallowing 2159
 aerodynamic separation 2160
 ageing 2205
 anatomy 2132, 2134–5, 2235,
 2235 *F*
 arm exertion 2159
 closure speed 2176
 desiccation 2137–8
 development
 elongation 1167–8
 laminar structure changes 1168
 diagnostic problems 755
 function assessment, critical care
 patients 533–4
 hydration 2195
 insufficient approximation 2160
 intercartilaginous portion 2135–7
 intramembranous part 2135–7
 lamina propria imaging 758, 759 *F*
 laryngeal control 2217
 laryngitis 2196
 lymphatic drainage 2140, 2713–4
 microvascular lesions 2203, 2203 *F*
 causes 2203
 manifestations 2203
 treatment 2203
 mucosal bridges 2201–3
 nodules *see* vocal nodules
 oedema/swelling *see* Reinke's oedema
 optical coherence tomography 757,
 758 *F*
 polarization-sensitive 758, 759 *F*

- pubertal changes 2205
 rate of vibration 2165
 recoil 2160
 sound production 2217
 stroboscopy 2193–4
 structure 2217
 children 1151
 swallowing 1957, 2159
 trauma 2159, 2275
 varices 2237
 vibratory cycle 2160–1, 2160 *F*, 2176,
 2177 *F*
 phases 2160, 2161 *T*
 vocal registers 2161
see also phonation
 vocal fold cysts 2201–3, 2220
 hoarseness 2220
 speech therapy 2202, 2220
 surgery 2202, 2237
 vocal fold haemorrhage, aspirin-induced 2213
 vocal fold injection 2195, 2239–40
 general anaesthesia 2240
 local anaesthesia 2240
 materials 2239–40
 operative method selection 2240
 transcutaneous techniques 2240,
 2241 *F*
 vocal fold medialization
 techniques 2097–8
 vocal fold oscillation 2160, 2165
 vocal fold paralysis 2222–4
 bilateral 1138, 2223
 children 1171
 reinnervation 1171
 collagen injections 450, 2240,
 2245 *T*
 congenital 1138–9
 contact quotient measurement 2179
 dysphagia 2030, 2086
 hypopharyngeal carcinoma 2639,
 2639 *F*
 oesophageal atresia repair 1287
 rehabilitation procedures 2245 *T*
 symptoms 2203
 thyroidectomy-related 2683, 2684 *T*
 tracheo-oesophageal fistula 1287
 treatment 450, 2224 *F*
 speech therapy 2223
 surgical 2097–8, 2223
 unilateral 1138, 1171, 2223
 vagus nerve lesions 2222, 3937
 vocal fold medialization
 techniques 2097–8
 voice quality 2223
 vocal fold polyps 2197–8, 2221
 causes 2197–8
 clinical manifestations 2197–8,
 2198 *F*, 2266 *F*
 epidemiology 2265–6
 incidence 2197
 post-intubation 1170, 1171 *F*
 speech therapy 2221
 surgery 2237, 2266
 symptoms 2198
 treatment 2198, 2266
 vocal fry (vocal pulse register) 2161,
 2162 *T*
 vocal hygiene 2195, 2220
 vocal intonation 2168
 vocalis muscle 2134–5, 2136 *T*
 vocal ligament 2134, 2134–5
 vocal loading 2171
 vocal loudness 2165, 2168
 vocal mutational disorders
 2226
 vocal nodules 2198–9, 2199 *F*
 aetiology 2198–9
 children 1169–70
 exacerbating factors 2198–9
 histology 2198
 incidence 2198
 phonosurgery 2236–7
 speech therapy 2220
 symptoms 2199
 treatment 2199
 voice quality 2199
 vocal note 2160
 vocal process granuloma
 see arytenoid granuloma
 vocal registers 2161, 2162 *T*, 2165
 definition 2161
 see also individual types
 vocal resonance 2166
 vocal sulcus 2201–3
 clinical presentation 2202
 phonosurgery 2203, 2238
 vocal tone 2168
 vocal velocity index (VVI) 2181–2
 voice 2170–1
 acoustic signals 2170
 age-related changes (presbylaryngis)
 2205
 components 2180
 definition 2170
 laryngeal role 2217, 2228 *T*
 normal vs. abnormal 2217–8
 objective evaluation *see* voice
 evaluation
 paralinguistic features 2167–8
 parameters 2217
 pitch 2217
 perceptual factors 2174
 physiology 2211–3
 preservation, laryngeal tumours 2614,
 2614 *F*
 production 2164–9
 nose 1366
 source-filter model 2166
 professional *see* professional voice
 pubertal changes 1169–70, 2204–5
 quality 2170–1, 2174
 paralinguistic features 2168
 uniqueness 2170–1
 see also speech
 voice abuse
 professional voice 2211–2
 vocal nodules 2198–9
 voice accumulators 2171, 2183
 voice clinics, performers and 2213
 voiced consonants 2167, 2167 *T*
 voice disorders 2192–210
 aetiology 2193
 assessment 2192–4, 2219, 2234
 children 1167–73
 functional 1169–70
 classification 2218
 definitions 2192, 2217
 dietary advice 2195
 endocrine causes 2201
 examination 2193–4
 history taking 2193
 hyperfunctional 2225
 inflammatory 2196–7
 jitter/shimmer 2179
 lifestyle advice 2195
 medical treatment 2195
 mucosal bridges 2201–3
 neoplastic lesions 2197–203
 neurological origin 2222–5
 neuromuscular causes 2203
 diagnosis 2203
 symptoms 2203
 nonorganic 2219–20
 organic 2220–2
 outcomes research 641
 prevalence 2217–8
 psychogenic 2225–6
 speech therapy *see* speech therapy
 structural abnormalities 2197–203
 surgery *see* phonosurgery
 symptoms/signs 2218
 thyrotoxicosis 400–1
 treatment 2194–6
 see also specific disorders

voice evaluation 2170–91
 acoustic measures 2171, 2176, 2177 *F*
 microphones 2176
 noise ratios 2180–1
 perturbation measures 2179
 sound intensity 2177
 spectral slope 2176, 2177 *F*
 waveform analysis 2176
 aerodynamic measures 2171, 2181–3
 airflow 2181–2
 air pressure 2182–3
 air volume 2181
 children 1168–9
 examination 1168–9
 history 1168–9
 combined measures 2171, 2183–4
 self organizing maps 2184, 2184 *T*
 consonant–vowel sequences 2172–4
 contact quotient measurement 2179
 electrolaryngography/
 electroglottography 2171, 2173 *F*,
 2176–7, 2178 *F*
 future research 2185
 juvenile-onset recurrent respiratory
 papillomatosis 1179
 laryngeal stenosis 1155
 perceptual evaluation 2171, 2174–6
 expert/trained listeners 2175
 process 2175
 reliability/validity 2176
 schemes used 2175, 2175 *T*
 phonetograms 2179
 problems 2171
 purpose 2171
 quality-of-life measures 2171, 2183,
 2183 *T*
 spectrograms 2178 *F*, 2179–80
 visual assessment 2171, 2181
 voice test material 2171–4
 speech 2172–4, 2173 *F*
 sustained vowels 2171, 2172,
 2173 *F*, 2174 *F*, 2177–8
see also specific methods/techniques
 ‘Voice Function Exercise Programme’
 (Stemple’s) 2225
 Voice Handicap Index (VHI) 641, 2183,
 2183 *T*
 voiceless consonants 2167
 voice prostheses 2228
 voice range profiles 2179
 voice rehabilitation, post-laryngectomy
 2227–30, 2228 *T*, 2627
 historical aspects 2624–7
 methods 2624, 2626 *F*, 2627,
 2627 *F*

physiological prerequisites 2227
 technical aspects 2624–7
 voice rest
 laryngeal trauma 2273–4
 phonosurgery 2236
 voice ‘switching’ 2172
 voice therapy *see* speech therapy
 Voiss questionnaire 2183
 volume averaging, 3D imaging 703
 volume conductor 3279
 volume conductor theory 3279
 volume rendering, 3D image data 704,
 705 *F*, 706 *F*
 volume velocity 3168
 vomer 1316–7, 1326
 vomer flap, hard palate repair 1007,
 1008 *F*
 vomeronasal nerve 1575
 vomeronasal organ 1316–7, 1321, 1368,
 1662, 1819
 vomiting *see* nausea and vomiting
 von Hippel–Landau (VHL)
 disease 4067–8, 4072
 von Recklinghausen disease *see*
 neurofibromatosis
 von Willebrand disease (VWD) 280,
 284 *T*
 adenoidectomy 1096
 bleeding patterns 281
 von Willebrand factor (VWF) 278, 279
 voriconazole 218
 vowel sounds 2166
 long 2166
 short 2166
 voice evaluation 2172, 2173 *F*, 2174 *F*,
 2177–8
 jitter/shimmer 2179
 waveform 3177–8
 VPA scheme 2175, 2175 *T*
 VS38 monoclonal antibody 2408
 V to Y advancement 2832, 2834 *F*
 Waardenburg syndrome 813 *T*, 1046
 Waldeyer’s ring of lymphoid
 tissue 1094, 1219, 1793, 2108
 Wallenberg’s syndrome 2077–8, 3938
 Wallerian degeneration, facial
 nerve 3873
 Walsham’s forceps 1613, 1613 *F*
 Walter Reed Staging Classification,
 HIV 239
 warfarin
 bleeding management 283, 283 *T*
 drug interactions 283
 epistaxis 1605

half-life 447
 loading schedule 289 *T*
 mechanism of action 282, 447 *F*
 patient preparation, surgery 460
 perioperative management 283
 resistance 283
 reversal 283
 fresh frozen plasma 258, 259 *T*
 skin necrosis-induction 282
 thyrotoxicosis 347
 warming devices, paediatric
 anaesthesia 513
 WARN, PAUSE, CHECK (WPC) 2782
 Warthin’s tumour 2482–3
 imaging 723, 1883, 1888 *F*
 incidence 2482
 presentation 2479 *F*, 2483
 warts, nasal 1701
 ‘watchful waiting,’ hearing
 surveillance 830
 water
 fluoridation, otosclerosis 3466
 nasal secretions 1360
 wax *see* earwax
 Waxham, Frank 772
 ‘wax keratosis’ 3343
 Weber-Ferguson incision
 facial translocation 4065
 hard palate carcinoma 2562, 2563 *F*
 nasal malignancy 2428, 2428 *F*
 oral cavity tumours 2567–8, 2568 *F*
 Weber’s syndrome 3921
 Weber tuning fork test 3318
 Webster-Bernard flap 2547 *F*
 Webster cheek advancement flap 2547
 Weerda distending diverticuloscope,
 pharyngeal pouch surgery 2050–1,
 2050 *F*, 2051 *F*, 2058
 Wegener’s granulomatosis 188,
 1649–53, 1651, 1713, 2976, 2976 *F*
 aetiology 1649–50
 age at presentation 1649
 classification criteria 1652 *T*
 clinical features 187 *T*, 1650–1
 laryngeal 1651
 ocular 1650, 1651 *F*
 oral 1650
 otologic 1650
 pulmonary 1650
 renal 1650
 septal perforations 1584
 tracheal 1651
 corticosteroids 424
 definition 1649
 diagnosis 1651–2

- facial nerve disorders 3891
 children 1059
imaging 1651 *F*, 1652, 1652 *F*
larynx 2267
medical negligence 1731
nasal crusting 188 *F*
otitis media with effusion 3389
rhinitis 1384
 treatment 1652–3
vestibular vascular injury 3698–9
- The Welfare of Children and Young People in Hospital 507
- Werner's syndrome *see* multiple endocrine neoplasia (MEN)
- Wernicke's syndrome 3775
- Western blotting 6
- westernization procedure,
 blepharoplasty 3053
- Westley Croup score 1128, 1129 *T*
- wheals, skin prick tests 1394
- wheezing, definition 1114
- Whickham survey, iodine-sufficient goitre 2667
- whiplash injuries 3498
 classification 3499, 3499 *T*
 clinical features 3499
 definition 3498
 epidemiology 3499
 treatment 3499
- whispered voice hearing test 3317, 3317 *T*
- whispers 2165
- white blood cells (WBC) 272–5
 benign disorders 273–5
 granulopoiesis 272–3
 malignant disorders 274
 normal adult ranges 267 *T*
 transfusion-related acute lung injury 261–2
 see also individual cell types
- white folded gingivostomatosis 1824
- white lesions, acquired oral 1835–7
- white noise
 Fourier analysis 3177 *F*, 3178
 hyperacusis therapy 3596
- white-sponge naevus 1824
- Whitnall's ligament 3050, 3051 *F*
- WHO *see* World Health Organization (WHO)
- whooping cough *see* pertussis
 (whooping cough)
- Wilde, Sir William 771
- William's syndrome 389, 3596
- Wilson Complaint Procedure 2803
- Wilson's risk sum 471
- wind parotitis 1908
- Wiskott Aldrich syndrome (WAS) 179, 180 *T*
- Wolfe graft 3019
- Wolff's law 2906
- wood dust, nasal malignancy and 2418
- wood manufacturers, occupational rhinitis 1419
- Woodruffs plexus, epistaxis 1597–8, 1597 *F*
- work (definition) 3165
- Working Time Directive 553
- work of breathing (WOB) 527–8
- World Health Organization (WHO)
 Allergic Rhinitis and Its Impact on Asthma 1381, 1386, 1387 *F*
 analgesic ladder, cancer pain management 2785
 chronic otitis media definition 929, 932
 chronic suppurative otitis media definition 929, 932
 goitre definition 2666
 health-related quality of life 2767
 International classification of diseases for oncology 2362
 leprosy, disease parameters 1463–4
 meningioma classification 4032–3, 4033 *T*
 nasopharynx tumour classification 2449 *T*
 palliative care definition 2782
 thyroid cancer classification 2673 *T*
 tumour classification 2362
- wound(s)
 acute 96
 assessment 99–100
 area 99, 100 *F*
 depth 100
 invasive techniques 99
 noninvasive techniques 99–100
 thermal imaging 100
 volume 100
 chronic 97–8
 closure 95–6
 definition 87
 healing *see* wound healing
 irradiation 96, 96 *F*
 irrigation 448
 mechanical 97
 postoperative 96–7
 thermal 96
- wound contraction 91–2, 92 *F*
 deformity 91
- wound dressings 100–3
- wound healing 87–109
 age-related changes 94
 biochemical analysis 99
 biomaterials, response to 119
 categorization
 by aetiology 96–8
 healing stage 98–100
 wound closure 95–6
 chronic conditions 95
 diagnosis 94, 94–103
 drug regimens and 95
 epithelial tissue 98
 fibre scaffolds 124
 fibroblast theory 92
 first intention healing 88, 88 *F*, 95
 epithelial proliferation 88
 future research 105
 histology 99
 infection 95, 98–9
 identification 99
 radical neck dissection complication 2743
 inflammation 98
 matrix formation 93–4
 myofibroblast theory 91–2
 necrotic tissue 98
 nutritional status 94–5
 proliferation 90–3, 90 *F*, 98
 fibroplasia 91
 granulation tissue formation 91–3
 re-epithelialization 90–1, 90 *F*
 stimulation 93
 regeneration 87, 88
 remodelling 93–4, 98–9
 granulation tissue 98
 repair 87
 fibre scaffolds 124
 research deficiencies 105
 retardation, drug-induced 95
 second intention healing 88–94, 88 *F*, 96
 inflammation 88–90
 re-epithelialization 90–1, 90 *F*
 wound contraction 91–2
 slough 98
 stages 98–100
 ‘wound module’ 90
- W-plasty
 lip cancer 2545, 2545 *F*
 scar revision 2896, 2897, 2898 *F*
- WR-2721, ototoxicity prevention and 3302
- Wullstein's classification, middle ear repair 955

- xanthogranulomatous sialadenitis 1904
 xenografts, augmentation
 rhinoplasty 2971
 xeroderma pigmentosum 1705–6, 2396,
 2398
 Xerolube 1847, 1848
 xerostomia
 associated disorders 1908–9
 drug-induced 1847, 1861, 1861 *T*,
 1906 *T*, 1907
 drug therapy 449, 1912 *T*
 hepatitis C salivary gland disease
 1901
 HIV patients 243
 palliative care, advanced head and
 neck cancer 2788, 2788 *T*
 parapharyngeal space tumours 2536
 radiotherapy-associated 1908–9,
 1909 *F*, 2464, 2465 *F*
 salivary flow 1861
 Sjögren syndrome 1911
 X-linked agammaglobulinaemia
 (XLA) 175 *T*, 176
 X-linked hereditary hearing loss 853
 X-linked hyper IgM syndrome
 (XHIM) 175–6, 175 *T*
 X-linked lymphoproliferative syndrome
 (XLP) 181
 X-linked mutations 18
 X-rays *see* plain radiography
 xylitol 919
 Yankauer nasopharyngeal
 speculum 2455
 360 yaw rotation 3813–4, 3813 *F*
 yaws 1703
 yeast artificial chromosome (YAC) 5–6,
 11
 yeast two-hybrid system 10
 yield, definition 823
 Young's syndrome 1381–2, 1551
 Y type (Crile) incision 2731–3
 zamifenacin 3795
 zanamivir 209–10, 232–3
 ZD1839 (gefitinib, Iressa) 43, 52
 Zenker's diverticulum *see* pharyngeal
 pouch
 zidovudine 233
 Ziehl–Nielsen modified stain 3449
 zinc supplements, olfactory
 dysfunction 1671
 Zitelli's flap *see* bilobed flap
 zolmitriptan 3771, 3801–2
 Z-plasty
 scar regularization 2896, 2896–7,
 2897 *F*
 skin advancement 2832, 2835 *F*
 zygomatic complex fractures 1628–30
 classification 1628
 imaging 1629
 management 1629–30, 1629 *T*
 postoperative care 1630
 signs/symptoms 1628, 1629 *F*
 surgical anatomy 1628
 surgical approaches 1629 *T*
 zygomatic nerve 3923–4
 zygomaticofacial nerve 3923–4
 zygomaticotemporal nerve 3923–4
 zygomaticus implants 2904, 2904 *F*
 nasal reconstruction 2909–10
 zylometazoline 439